

BS

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
27 December 2001 (27.12.2001)

PCT

(10) International Publication Number  
WO 01/98526 A2

(51) International Patent Classification<sup>7</sup>: C12Q

(21) International Application Number: PCT/US01/20122

(22) International Filing Date: 22 June 2001 (22.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/213,812 22 June 2000 (22.06.2000) US  
09/804,291 13 March 2001 (13.03.2001) US

(71) Applicant: SENOMYX, INC. [US/US]; Suite 160, 11099 N. Torrey Pines Road, La Jolla, CA 92037 (US).

(72) Inventors: ZOZULYA, Sergey; 3950 Mahaila Avenue #B22, San Diego, CA 92122 (US). STRYER, Lubert; c/o Senomyx, Inc., 11099 N. Torrey Pines Road, Suite 160, La Jolla, CA 92037 (US).

(74) Agents: TESKIN, Robin, L. et al.; Pillsbury Winthrop LLP, 1600 Tysons Boulevard, McLean, VA 22102 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/98526 A2

(54) Title: RECEPTOR FINGERPRINTING, SENSORY PERCEPTION, AND BIOSENSORS OF CHEMICAL SENSANTS

(57) Abstract: The use of sensory G protein-coupled receptors that recognize chemical sensants, particularly those involving olfactory and taste receptors; polypeptide fragments and mutants thereof; classes of such receptors; polynucleotides encoding such receptors, fragments and mutants thereof, and representatives of receptor classes; genetic vectors including such polynucleotides; and cells and non-human organisms engineered to express such receptor complexes, fragments and mutants of an olfactory or taste receptor, and representatives of receptor classes to simulate sensory perception of odorants and tastants is described. The use of such products as a biosensor or a components thereof to detect, identify, measure, or otherwise process the event of binding between the receptor and its cognate ligand (*i.e.*, chemical sensant) is also described. The invention has application, for example, in the design and formulation of odorant and tastant compositions.

# RECEPTOR FINGERPRINTING, SENSORY PERCEPTION, AND BIOSENSORS OF CHEMICAL SENSANTS

5

### **Cross Reference to Related Application**

This application is related to U.S. Provisional Serial No. 60/213,812, filed June 22, 2000, and U.S. Serial No. 09/804,291, filed March 13, 2001, which are incorporated by reference in their entirety.

10

## Background of the Invention

### Field of the Invention

The invention relates to the use of sensory G protein-coupled receptor complexes that recognize chemical sensants, particularly those involving olfactory and taste receptors; polypeptide fragments and mutants thereof; classes of such receptors; 15 polynucleotides encoding such receptors, fragments and mutants thereof, and representatives of receptor classes; genetic vectors including such polynucleotides; and cells and non-human organisms engineered to express such receptor complexes, fragments and mutants of an olfactory or taste receptor, and representatives of receptor classes to simulate sensory perception of odorants and tastants. The invention also 20 relates to the use of such products as a biosensor or component thereof to detect, to identify, to measure, or otherwise process the event of binding between the receptor and its cognate ligand (*i.e.*, chemical sensant). The invention has application, for example, in the design and formulation of odorant and tastant compositions.

## 25 Description of the Related Art

The olfactory and taste systems provide sensory information about the chemical environment. Olfactory receptors and taste receptors recognize, respectively, "odorants" and "tastants," collectively referred to as "sensants" or "sensory receptor ligands" herein. A "primary" sensant is an odorant or tastant ligand that substantially binds to sensory receptors with a ligand-binding site of a single amino acid sequence. Olfactory and taste receptors belong to the superfamily of seven-transmembrane guanyl nucleotide-binding proteins: such receptors are, however, also recognized as distinct families, or sub-genuses, of olfactory or taste

receptors (see Raming *Nature* 361:353, 1993). These receptors control diverse physiological functions such as media-ting signaling from an external chemical stimulus across the membrane containing the receptor into a cell, endocrine function, exocrine function, heart rate, lipolysis, and carbohydrate metabolism. Thus, the

5 dissection of these diverse functions into component signals is needed.

But the complexities of sensory perception of chemical sensants prevent easy translation of the olfaction and taste systems to a machine sensor. For example, U.S. Patent Nos. 5,675,070; 5,918,257; 5,928,609; and 6,085,576 disclose machine sensors that use various chemistries, but they do not take advantage of the specificity of

10 olfactory and taste receptors for their cognate ligands to produce a biosensor.

WO 00/15269 discloses methods and apparatus for odor reproduction. The total affinities of a specific odorant with a group of receptors was called the affinity fingerprint of the odorant. This odorant fingerprint was represented by a vector of affinity values. It was proposed to repro-duce an arbitrary odor by inputting its sensed

15 odorant fingerprint into a device, which has a palate of predetermined odorants and produces a composite odor using predetermined odorant finger-prints by minimizing the difference between vectors representing the sensed odorant fingerprint and the predetermined odorant fingerprints. This reference, however, does not teach or suggest the human olfactory receptors disclosed herein.

20 WO 00/70343 discloses biosensors and sense replication systems using G-protein coupled receptors (GPCR). It was proposed to mimic the response of the G-protein signal transduction system by detecting the affinity of a stimulus to a plurality of GPCR, codifying such information into electronic signals, and reproducing the stimulus by converting the codified information into a combination of stimulant

25 entities. But this reference also does not teach or suggest the human olfactory receptors disclosed herein.

WO 01/27158 discloses olfactory receptors and their use to determine the correspondence between individual odorant receptors and particular odors. It was proposed that the interactions between an odor and olfactory receptors can be used to represent the odor and to re-create it. This reference, however, does not teach or suggest the human olfactory receptors disclosed herein.

Dissecting the function of sensory receptors by binding sensory receptors of a clone of cells expressing a single sensory receptor gene, fragmentation of sensory

receptors to provide ligand-binding or signal-transducing domains thereof, and construction of fusion sensory receptor proteins will separate the diverse physiological functions associated with sensory perception at the level of ligand-receptor binding. Furthermore, novel "primary sensants" that are identified and isolated by the methods described herein may be used to further define the function of the cognate sensory receptor by uniquely enhancing or, in the alternative, blocking stimulation of sensory receptors with a single ligand-binding domain.

5 The present invention addresses the need for better understanding of these ligand-receptor interactions by using a large set of identified sensory receptors. Even 10 if the receptor set used is incomplete (*i.e.*, a partial set of all sensory receptors encoded in the genome), a large number of sensants will be detected. Moreover, redundancy in the chemical structures recognized by the sensory receptors or combinatorial 15 processing of signals from different sensory receptors would allow broad coverage of chemically diverse sensants (*e.g.*, by selection of a representative class of sensory receptors). Also provided are, *inter alia*, methods for utilizing such sensory receptors and biosensors to simulate sensory perception. To analyze ligand-receptor interactions and their effects on cell signaling and the processing of those signals in sensory perception, specific sensants and their cognate receptor complexes are detected, identified, and measured under binding conditions. Fragrances and 20 flavorings can be detected, identified, measured, and/or custom designed by the methods herein described. In addition, drugs that incorporate artificial odors and/or tastes can be formulated.

### Summary of the Invention

25 Large gene families encoding mammalian olfactory G-protein-coupled receptors (OLFR) and mammalian taste G-protein-coupled receptors (TASR) are known in the prior art or are disclosed herein. An object of the invention to provide fragments and variants of such OLFRs and TASRs which retain odorant- or tastant-binding activity, respectively. The large number of sensory receptors that are made 30 available herein and now amendable to manipulation raises the confidence that a substantially complete, or at least functional, repertoire of sensory receptors is provided.

It is an object of the invention to provide nucleic acid sequences or molecules that encode such sensory receptors, or fragments or variants thereof. Another object is to provide expression vectors which include nucleic acid sequences that encode such sensory receptors, or fragments or variants thereof. It is yet another object of the invention to provide human or non-human cells which functionally express at least one of such sensory receptors, or fragments or variants thereof. Still another object is to provide sensory receptor fusion proteins or other polypeptides which include at least a fragment of at least one of such sensory receptors. In particular, fusions with reporter molecules or other heterologous amino acid sequences may maintain the original ligand-properties while changing the signaling properties to allow easier detection of sensant binding to the receptor (e.g., change in fluorescent signal). Moreover, chimeric proteins or other polypeptides with altered ligand-binding and/or signaling properties can be made from two or more different sensory receptors by mixing domains.

15 The invention provides methods for representing the sensory perception of one or more chemicals (e.g., a primary sensant or mixture thereof) and/or for predicting the sensory perception of one or more chemicals in a mammal (e.g., human) using the aforementioned products. Given a known member of a ligand-receptor binding pair, one or both members of the pair (i.e., ligand, receptor, or both) may be detected, 20 identified, and/or measured under binding conditions.

Novel molecules or combinations of molecules which elicit a desired and predetermined sensory perception in a mammal (e.g., human) can be generated by determining a value of sensory perception in a mammal for a known molecule or combination thereof; determining a value of sensory perception in a mammal for one or more unknown molecules or combinations thereof; comparing the value of sensory perception in a mammal for one or more unknown compositions to the value of sensory perception in a mammal for one or more known compositions; selecting a molecule or combination of molecules that elicits a predetermined sensory perception in a mammal; and mixing two or more unknown molecules or combinations thereof to 25 form a molecule or combination thereof that elicits a predetermined sensory perception in a mammal. The combining step yields a single molecule or a combination thereof that elicits a predetermined sensory perception in a mammal. In particular, primary odorants that uniquely bind to olfactory receptors with a single 30

ligand-binding domain may be such novel molecules. Variants thereof may be used (1) to enhance stimulation of a limited response by olfactory receptors with a single ligand-binding domain or (2) to block stimulation of olfactory receptors with a single ligand-binding domain to reduce or inhibit olfactory perception. An alternative 5 method for identifying primary odorants is to identify the mutated receptors in genetic anosmias because that odorant would be expected to be recognized by only one or a few olfactory receptors affected by the mutation.

### **Detailed Description of the Invention**

#### **10 Perception of Chemical Sensants**

U.S. Patent No. 5,691,188 describes how upon binding of ligand to receptor, the receptor presumably undergoes a conformational change leading to activation of the G protein. The G proteins are comprised of three subunits: a guanyl nucleotide binding  $\alpha$  subunit, a  $\beta$  subunit, and a  $\gamma$  subunit. G proteins cycle between two forms, 15 depending on whether GDP or GTP is bound to the  $\alpha$  subunit. When GDP is bound, the G protein exists as a heterotrimer: the  $G\alpha\beta\gamma$  complex. When GTP is bound, the  $\alpha$  subunit dissociates from the heterotrimer, leaving a  $G\beta\gamma$  complex. When a  $G\alpha\beta\gamma$  complex operatively associates with an activated G protein coupled receptor in a cell membrane, the rate of exchange of GTP for bound GDP is increased and the rate of 20 dissociation of the bound  $G\alpha$  subunit from the  $G\alpha\beta\gamma$  complex increases. The free  $G\alpha$  subunit and  $G\beta\gamma$  complex are thus capable of transmitting a signal to downstream elements of a variety of signal transduction pathways. These events form the basis for a multiplicity of different cell signaling phenomena, including for example the 25 signaling phenomena that are identified as neurological sensory perceptions such as taste and/or smell. A high-resolution X-ray crystal structure is available for rhodopsin, a guanyl nucleotide binding protein, has been solved (Palczewski *et al.*, *Science* 289:739, 2000). Using this structure, the portions of the amino acid sequence of sensant receptors that are responsible for ligand binding can be identified.

30

#### **Sensory Perception - Olfaction**

Genes encoding the olfactory receptors are active primarily in olfactory neurons (*Axel Sci. Amer.* 273:154, 1995). Individual olfactory receptor types are expressed in subsets of cells distributed in distinct zones of the olfactory epithelium (*Breer Semin. Cell Biol.* 5:25, 1994). The human genome contains thousands of genes that encode a diverse repertoire of olfactory receptors (*Rouquier Nat. Genet.* 18:243, 1998; *Trask Hum. Mol. Genet.* 7:2007, 1998). An understanding of an animal's ability to detect and discriminate among the thousands of distinct odorants or tastants, and more particularly to distinguish, for example beneficial tastants or odorants from toxic tastants or odorants, is complicated by the fact that sensory receptors belong to a multigene family with over a thousand members, and the odorant receptors number at least 500 to 1,000. Moreover, each sensory receptor neuron may express only one or a few of these receptors. With respect to odorant receptors, any given olfactory neuron can respond to a small set of odorant ligands. In addition, odorant discrimination for a given neuron may depend on the ligand specificity of the one or few receptors it expresses.

#### Sensory Perception - Taste

Mammals are believed to have five basic taste modalities: sweet, bitter, sour, salty, and umami (the taste of monosodium glutamate). *See, e.g., Kawamura et al., Introduction to Umami: A Basic Taste* (1987); *Kinnamon et al., Ann. Rev. Physiol.*, 54:715, 1992; *Lindemann, Physiol. Rev.*, 76:718, 1996; *Stewart et al., Am. J. Physiol.*, 272:1, 1997. Numerous physiological studies in animals have shown that taste receptor cells may selectively respond to different chemical stimuli. *See, e.g., Akabas et al., Science*, 242:1047, 1988; *Gilbertson et al., J. Gen. Physiol.*, 100:803, 1992; *Bernhardt et al., J. Physiol.*, 490:325, 1996; *Cummings et al., J. Neurophysiol.*, 75:1256, 1996.

In mammals, taste receptor cells are assembled into taste buds that are distributed into different papillae in the tongue epithelium. Circumvallate papillae, found at the very back of the tongue, contain hundreds, *e.g.*, mice, to thousands, *e.g.*, human, of taste buds. By contrast, foli-ate papillae, localized to the posterior lateral edge of the tongue, only contain dozens to hundreds of taste buds. Moreover, fungiform papillae contain only a single or a few taste buds, and are at the front of the tongue.

AC010814, AC018700, AC021304, AC008620, AC011537, AC010760, AC027641, AC017103, AC024729, AC024257, AC025115, AP001524, AP000916, AC010814, AL162254, AC025234, AP001521, AC026090, AC019088, AC016856, AC016787, 5 AP001803, AP001804, AL353767, AP001884, AC026083, AC018793, AP000818, AL353894, AL049734, AL355366, AC011464, AC037472, AC036111, AC019093, AC027239, AC027522, AC009545, AC021333, AC036216, AC021935, AC022762, AL356019, AC055861, AC018375, AC072059, AC068339, AC022891, AL357039, AP002345, AC044810, AC073113, AC024399, AC023564, AL390860, AC074365, 10 AP002826, AL359636, AL391534, AC055731, AC076959, AP002826, AC019088, AC009779, AL445307, AP002512, AP000818, AC079190) by virtue of their sequence homology to some of the known human and other mammalian olfactory receptor genes. Similarly, genes encoding five and thirty-six (36) distinct, novel human T1R and T2R taste receptors, respectively, have been identified in genome 15 sequence databases.

Alternatively, nucleic acids encoding the sensory receptors and other related polypeptides can be isolated from a variety of sources, genetically engineered, amplified, synthesized, and/or expressed recombinantly according to the methods disclosed in WO 00/35374, which is herein incorporated by reference in its entirety.

20 These nucleic acids provide probes for the identification of cells expressing sensory receptors, as the nucleic acids are specifically expressed in such cells. They can also serve as tools for the generation of sensory topographical maps that elucidate the relationship between cells expressing sensory receptors and sensory neurons leading to particular regions of the brain. Furthermore, the nucleic acids and the 25 polypeptides they encode can be used as probes to elucidate olfactant- or tastant-induced behaviors.

Nucleic acid molecules encoding a sensory receptor comprising a nucleic acid sequence that is at least 75%, 85%, 90%, 95%, or 99% identical to a nucleic acid sequence selected from those known in the prior art or disclosed herein are considered 30 variants. Other nucleic acid molecules comprising a nucleic acid sequence that encodes a polypeptide having an amino acid sequence at least 75%, 85%, 90%, 95%, or 99% identical to an amino acid sequence selected from those known in the prior art or disclosed herein are also considered variants. Further variants contain amino acid

sequence differences in at most ten, five, four, three, two, or one amino acid residue(s).

Exemplary nucleic acid sequences may be selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 56, SEQ ID NO: 58, SEQ ID NO: 60, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 68, SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO: 74, SEQ ID NO: 76, SEQ ID NO: 78, SEQ ID NO: 80, SEQ ID NO: 82, SEQ ID NO: 84, SEQ ID NO: 86, SEQ ID NO: 88, SEQ ID NO: 90, SEQ ID NO: 92, SEQ ID NO: 94, SEQ ID NO: 96, SEQ ID NO: 98, SEQ ID NO: 100, SEQ ID NO: 102, SEQ ID NO: 104, SEQ ID NO: 106, SEQ ID NO: 108, SEQ ID NO: 110, SEQ ID NO: 112, SEQ ID NO: 114, SEQ ID NO: 116, SEQ ID NO: 118, SEQ ID NO: 120, SEQ ID NO: 122, SEQ ID NO: 124, SEQ ID NO: 126, SEQ ID NO: 128, SEQ ID NO: 130, SEQ ID NO: 132, SEQ ID NO: 134, SEQ ID NO: 136, SEQ ID NO: 138, SEQ ID NO: 140, SEQ ID NO: 142, SEQ ID NO: 144, SEQ ID NO: 146, SEQ ID NO: 148, SEQ ID NO: 150, SEQ ID NO: 152, SEQ ID NO: 154, SEQ ID NO: 156, SEQ ID NO: 158, SEQ ID NO: 160, SEQ ID NO: 162, SEQ ID NO: 164, SEQ ID NO: 166, SEQ ID NO: 168, SEQ ID NO: 170, SEQ ID NO: 172, SEQ ID NO: 174, SEQ ID NO: 176, SEQ ID NO: 178, SEQ ID NO: 180, SEQ ID NO: 182, SEQ ID NO: 184, SEQ ID NO: 186, SEQ ID NO: 188, SEQ ID NO: 190, SEQ ID NO: 192, SEQ ID NO: 194, SEQ ID NO: 196, SEQ ID NO: 198, SEQ ID NO: 200, SEQ ID NO: 202, SEQ ID NO: 204, SEQ ID NO: 206, SEQ ID NO: 208, SEQ ID NO: 210, SEQ ID NO: 212, SEQ ID NO: 214, SEQ ID NO: 216, SEQ ID NO: 218, SEQ ID NO: 220, SEQ ID NO: 222, SEQ ID NO: 224, SEQ ID NO: 226, SEQ ID NO: 228, SEQ ID NO: 230, SEQ ID NO: 232, SEQ ID NO: 234, SEQ ID NO: 236, SEQ ID NO: 238, SEQ ID NO: 240, SEQ ID NO: 242, SEQ ID NO: 244, SEQ ID NO: 246, SEQ ID NO: 248, SEQ ID NO: 250, SEQ ID NO: 252, SEQ ID NO: 254, SEQ ID NO: 256, SEQ ID NO: 258, SEQ ID NO: 260, SEQ ID NO: 262, SEQ ID NO: 264, SEQ ID NO: 266, SEQ ID NO: 268, SEQ ID NO: 270, SEQ ID NO: 272, SEQ ID NO: 274, SEQ ID NO: 276, SEQ ID NO: 278, SEQ ID

WO 01/98526

NO: 280, SEQ ID NO: 282, SEQ ID NO: 284, SEQ ID NO: 286, SEQ ID NO: 288,  
SEQ ID NO: 290, SEQ ID NO: 292, SEQ ID NO: 294, SEQ ID NO: 296, SEQ ID  
NO: 298, SEQ ID NO: 300, SEQ ID NO: 302, SEQ ID NO: 304, SEQ ID NO: 306,  
SEQ ID NO: 308, SEQ ID NO: 310, SEQ ID NO: 312, SEQ ID NO: 314, SEQ ID  
5 NO: 316, SEQ ID NO: 318, SEQ ID NO: 320, SEQ ID NO: 322, SEQ ID NO: 324,  
SEQ ID NO: 326, SEQ ID NO: 328, SEQ ID NO: 330, SEQ ID NO: 332, SEQ ID  
NO: 334, SEQ ID NO: 336, SEQ ID NO: 338, SEQ ID NO: 340, SEQ ID NO: 342,  
SEQ ID NO: 344, SEQ ID NO: 346, SEQ ID NO: 348, SEQ ID NO: 350, SEQ ID  
10 NO: 352, SEQ ID NO: 354, SEQ ID NO: 356, SEQ ID NO: 358, SEQ ID NO: 360,  
SEQ ID NO: 362, SEQ ID NO: 364, SEQ ID NO: 366, SEQ ID NO: 368, SEQ ID  
NO: 370, SEQ ID NO: 372, SEQ ID NO: 374, SEQ ID NO: 376, SEQ ID NO: 378,  
SEQ ID NO: 380, SEQ ID NO: 382, SEQ ID NO: 384, SEQ ID NO: 386, SEQ ID  
15 NO: 388, SEQ ID NO: 390, SEQ ID NO: 392, SEQ ID NO: 394, SEQ ID NO: 396,  
SEQ ID NO: 398, SEQ ID NO: 400, SEQ ID NO: 402, SEQ ID NO: 404, SEQ ID  
NO: 406, SEQ ID NO: 408, SEQ ID NO: 410, SEQ ID NO: 412, SEQ ID NO: 414,  
SEQ ID NO: 416, SEQ ID NO: 418, SEQ ID NO: 420, SEQ ID NO: 422, SEQ ID  
20 NO: 424, SEQ ID NO: 426, SEQ ID NO: 428, SEQ ID NO: 430, SEQ ID NO: 432,  
SEQ ID NO: 434, SEQ ID NO: 436, SEQ ID NO: 438, SEQ ID NO: 440, SEQ ID  
NO: 442, SEQ ID NO: 444, SEQ ID NO: 446, SEQ ID NO: 448, SEQ ID NO: 450,  
SEQ ID NO: 452, SEQ ID NO: 454, SEQ ID NO: 456, SEQ ID NO: 458, SEQ ID  
25 NO: 460, SEQ ID NO: 462, SEQ ID NO: 464, SEQ ID NO: 466, SEQ ID NO: 468,  
SEQ ID NO: 470, SEQ ID NO: 472, SEQ ID NO: 474, SEQ ID NO: 476, SEQ ID  
NO: 478, SEQ ID NO: 480, SEQ ID NO: 482, SEQ ID NO: 484, SEQ ID NO: 486,  
SEQ ID NO: 488, SEQ ID NO: 490, SEQ ID NO: 492, SEQ ID NO: 494, SEQ ID  
30 NO: 496, SEQ ID NO: 498, SEQ ID NO: 500, SEQ ID NO: 502, SEQ ID NO: 504,  
SEQ ID NO: 506, SEQ ID NO: 508, SEQ ID NO: 510; and SEQ ID NO: 512.

Nucleic acid molecule comprising a nucleic acid sequence that encodes a  
fragment of a polypeptide having an amino acid sequence selected from those known  
in the prior art or disclosed herein; wherein the fragment is at least ten, 20, 30, 50, 70,  
100, or 150 amino acid residues in length, are useful as probes, primers, and to  
construct hybrids or chimerae.

Polypeptides comprising an amino acid sequence that is at least 90%, 95%,  
96%, 97%, 98%, or 99% identical to an amino acid sequence selected from those

known in the prior art or disclosed herein are considered variants. Further variants contain amino acid sequence differences in at most ten, five, four, three, two, or one amino acid residue(s). Other polypeptides comprising a fragment of a polypeptide having an amino acid sequence selected from those known in the prior art or disclosed herein; wherein the fragment is at least 40, 60, 80, 100, 150, 200, or 250 amino acid residues in length, are useful as specific binders of sensants, competitive binders, antigens, and to construct hybrids or chimerae.

5 Exemplary amino acid sequences may be selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, SEQ ID NO: 69, SEQ ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 79, SEQ ID NO: 81, SEQ ID NO: 83, SEQ ID NO: 85, SEQ ID NO: 87, SEQ ID NO: 89, SEQ ID NO: 91, SEQ ID NO: 93, SEQ ID NO: 95, SEQ ID NO: 97, SEQ ID NO: 99, SEQ ID NO: 101, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 107, SEQ ID NO: 109, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, SEQ ID NO: 119, SEQ ID NO: 121, SEQ ID NO: 123, SEQ ID NO: 125, SEQ ID NO: 127, SEQ ID NO: 129, SEQ ID NO: 131, SEQ ID NO: 133, SEQ ID NO: 135, SEQ ID NO: 137, SEQ ID NO: 139, SEQ ID NO: 141, SEQ ID NO: 143, SEQ ID NO: 145, SEQ ID NO: 147, SEQ ID NO: 149, SEQ ID NO: 151, SEQ ID NO: 153, SEQ ID NO: 155, SEQ ID NO: 157, SEQ ID NO: 159, SEQ ID NO: 161, SEQ ID NO: 163, SEQ ID NO: 165, SEQ ID NO: 167, SEQ ID NO: 169, SEQ ID NO: 171, SEQ ID NO: 173, SEQ ID NO: 175, SEQ ID NO: 177, SEQ ID NO: 179, SEQ ID NO: 181, SEQ ID NO: 183, SEQ ID NO: 185, SEQ ID NO: 187, SEQ ID NO: 189, SEQ ID NO: 191, SEQ ID NO: 193, SEQ ID NO: 195, SEQ ID NO: 197, SEQ ID NO: 199, SEQ ID NO: 201, SEQ ID NO: 203, SEQ ID NO: 205, SEQ ID NO: 207, SEQ ID NO: 209, SEQ ID NO: 211, SEQ ID NO: 213, SEQ ID NO: 215, SEQ ID NO: 217, SEQ ID NO: 219, SEQ ID NO: 221, SEQ ID NO: 223, SEQ ID NO: 225, SEQ ID NO: 227, SEQ ID NO: 229, SEQ ID NO: 231, SEQ ID NO: 233, SEQ ID NO: 235,

WO 01/98526

SEQ ID NO: 237, SEQ ID NO: 239, SEQ ID NO: 241, SEQ ID NO: 243, SEQ ID NO: 245, SEQ ID NO: 247, SEQ ID NO: 249, SEQ ID NO: 251, SEQ ID NO: 253, SEQ ID NO: 255, SEQ ID NO: 257, SEQ ID NO: 259, SEQ ID NO: 261, SEQ ID NO: 263, SEQ ID NO: 265, SEQ ID NO: 267, SEQ ID NO: 269, SEQ ID NO: 271, 5 SEQ ID NO: 273, SEQ ID NO: 275, SEQ ID NO: 277, SEQ ID NO: 279, SEQ ID NO: 281, SEQ ID NO: 283, SEQ ID NO: 285, SEQ ID NO: 287, SEQ ID NO: 289, SEQ ID NO: 291, SEQ ID NO: 293, SEQ ID NO: 295, SEQ ID NO: 297, SEQ ID NO: 299, SEQ ID NO: 301, SEQ ID NO: 303, SEQ ID NO: 305, SEQ ID NO: 307, 10 SEQ ID NO: 309, SEQ ID NO: 311, SEQ ID NO: 313, SEQ ID NO: 315, SEQ ID NO: 317, SEQ ID NO: 319, SEQ ID NO: 321, SEQ ID NO: 323, SEQ ID NO: 325, SEQ ID NO: 327, SEQ ID NO: 329, SEQ ID NO: 331, SEQ ID NO: 333, SEQ ID NO: 335, SEQ ID NO: 337, SEQ ID NO: 339, SEQ ID NO: 341, SEQ ID NO: 343, SEQ ID NO: 345, SEQ ID NO: 347, SEQ ID NO: 349, SEQ ID NO: 351, SEQ ID NO: 353, SEQ ID NO: 355, SEQ ID NO: 357, SEQ ID NO: 359, SEQ ID NO: 361, 15 SEQ ID NO: 363, SEQ ID NO: 365, SEQ ID NO: 367, SEQ ID NO: 369, SEQ ID NO: 371, SEQ ID NO: 373, SEQ ID NO: 375, SEQ ID NO: 377, SEQ ID NO: 379, SEQ ID NO: 381, SEQ ID NO: 383, SEQ ID NO: 385, SEQ ID NO: 387, SEQ ID NO: 389, SEQ ID NO: 391, SEQ ID NO: 393, SEQ ID NO: 395, SEQ ID NO: 397, 20 SEQ ID NO: 399, SEQ ID NO: 401, SEQ ID NO: 403, SEQ ID NO: 405, SEQ ID NO: 407, SEQ ID NO: 409, SEQ ID NO: 411, SEQ ID NO: 413, SEQ ID NO: 415, SEQ ID NO: 417, SEQ ID NO: 419, SEQ ID NO: 421, SEQ ID NO: 423, SEQ ID NO: 425, SEQ ID NO: 427, SEQ ID NO: 429, SEQ ID NO: 431, SEQ ID NO: 433, SEQ ID NO: 435, SEQ ID NO: 437, SEQ ID NO: 439, SEQ ID NO: 441, SEQ ID NO: 443, SEQ ID NO: 445, SEQ ID NO: 447, SEQ ID NO: 449, SEQ ID NO: 451, 25 SEQ ID NO: 453, SEQ ID NO: 455, SEQ ID NO: 457, SEQ ID NO: 459, SEQ ID NO: 461, SEQ ID NO: 463, SEQ ID NO: 465, SEQ ID NO: 467, SEQ ID NO: 469, SEQ ID NO: 471, SEQ ID NO: 473, SEQ ID NO: 475, SEQ ID NO: 477, SEQ ID NO: 479, SEQ ID NO: 481, SEQ ID NO: 483, SEQ ID NO: 485, SEQ ID NO: 487, SEQ ID NO: 489, SEQ ID NO: 491, SEQ ID NO: 493, SEQ ID NO: 495, SEQ ID 30 NO: 497, SEQ ID NO: 499, SEQ ID NO: 501, SEQ ID NO: 503, SEQ ID NO: 505, SEQ ID NO: 507, SEQ ID NO: 509 and SEQ ID NO: 511.

Also provided are methods of screening for modulators, e.g., activators, inhibitors, stimulators, enhancers, agonists, and antagonists, of the sensory receptors,

or fragments or variants thereof. Such modulators of signal transduction are useful for pharmacological or genetic modulation of signaling pathways. These methods of screening can be used to identify high affinity agonists and antagonists of sensory cell activity. These modulator compounds can then be used in the pharmaceutical, food, and cosmetic industries to customize odorants or tastants.

Thus, the invention provides assays for sensory modulation, where the sensory receptors, or fragments or variants thereof, act as direct or indirect reporter molecules for the effect of modulators on signal transduction. Sensory receptors, or fragments or variants thereof, can be used in assays, *e.g.*, to measure changes in ion concentration, membrane potential, current flow, ion flux, transcription, signal transduction, receptor-ligand interaction, second messenger concentrations, *in vitro*, *in vivo*, and *ex vivo*. In one embodiment, sensory receptors, or fragments or variants thereof, can be used as an indirect reporters via attachment to second reporter molecules, such as green fluorescent protein (*see, e.g.*, Mistili *et al.*, *Nature Biotech.*, 15:961, 1997). In another embodiment, the sensory receptors, or fragments or variants thereof, can be expressed in host cells, and modulation of signal transduction via sensory receptor activity can be assayed by measuring changes in  $\text{Ca}^{2+}$  levels.

Methods of assaying for modulators of signal transduction include *in vitro* ligand binding assays using the sensory receptors, or fragments or variants thereof. More particularly, such assays can use the sensory receptors; portions thereof such as the extracellular or transmembrane domains; chimeric proteins comprising one or more of such domains; oocyte receptor expression; tissue culture cell receptor expression; transcriptional activation of the receptor; G-protein binding to the receptor; ligand binding assays; voltage, membrane potential and conductance changes; ion flux assays; changes in intracellular second messengers such as cAMP and inositol triphosphate; changes in intracellular  $\text{Ca}^{2+}$  levels; and neurotransmitter release.

The invention also provides for methods of detecting sensory receptor nucleic acid and protein expression, allowing for the investigation of taste transduction regulation and specific identification of sensory receptor cells. The sensory receptors, fragments, and variants of the invention can also be used to generate monoclonal and polyclonal antibodies useful for identifying a sensory receptor cells. Sensory receptor cells can be identified using techniques such as reverse transcription and amplification

of mRNA, isolation of total RNA or poly A<sup>+</sup> RNA, Northern blotting, dot blotting, *in situ* hybridization, RNase protection, S1 digestion, probing DNA microchip arrays, Western blots, and the like.

A. Identification and Characterization of Sensory Receptors

5 The amino acid sequences of the sensory receptors and polypeptides of the invention can be identified by putative translation of the coding nucleic acid sequences. These various amino acid sequences and the coding nucleic acid sequences may be compared to one another or to other sequences according to a number of methods.

10 For example, in sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, as 15 described below for the BLASTN and BLASTP programs, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.

20 A "comparison window," as used herein, includes reference to a segment of any one of the number of contiguous positions selected from the group consisting of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of. 25 contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, *e.g.*, by the local homology algorithm of Smith & Waterman, *Adv. Appl. Math.* 2:482, 1981, by the homology alignment algorithm of Needleman & Wunsch, *J. Mol. Biol.* 48:443, 1970, by the search for similarity method of Pearson & Lipman, *Proc. Natl. Acad. Sci. USA* 85:2444, 1988, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and 30 TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (*see, e.g., Current Protocols in Molecular Biology* (Ausubel *et al.*, eds. 1995 supplement)).

A preferred example of an algorithm that is suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul *et al.*, *Nucl. Acids Res.* 25:3389, 1977 and Altschul *et al.*, *J Mol. Biol.* 215:403, 1990, respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul *et al.*, Altschul *et al.*, *Nucl. Acids Res.* 25:3389, 1977 and Altschul *et al.*, *J. Mol. Biol.* 215:403, 1990). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) or 10, M=5, N=-4 and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, *Proc. Natl. Acad. Sci. USA* 89:10915, 1989) alignments (B) of 50, expectation (E) of 10, M=5, N=-4, and a comparison of both strands.

Another example of a useful algorithm is PILEUP. PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pairwise alignments to show relationship and percent sequence identity. It also plots a so-called “tree” or “dendrogram” showing the clustering relationships used to create the alignment (see, e.g., Figure 2). PILEUP uses a simplification of the progressive

alignment method of Feng & Doolittle, *J Mol. Evol.* 35:351, 1987. The method used is similar to the method described by Higgins & Sharp, CABIOS 5:151, 1989. The program can align up to 300 sequences, each of a maximum length of 5,000 nucleotides or amino acids. The multiple alignment procedure begins with the 5 pairwise alignment of the two most similar sequences, producing a cluster of two aligned sequences. This cluster is then aligned to the next most related sequence or cluster of aligned sequences. Two clusters of sequences are aligned by a simple extension of the pairwise alignment of two individual sequences. The final alignment is achieved by a series of progressive, pairwise alignments. The program is run by 10 designating specific sequences and their amino acid or nucleotide coordinates for regions of sequence comparison and by designating the program parameters. Using PILEUP, a reference sequence is compared to other test sequences to determine the percent sequence identity relationship using the following parameters: default gap weight (3.00), default gap length weight (0.10), and weighted end gaps. PILEUP can 15 be obtained from the GCG sequence analysis software package, e.g., version 7.0 (Devereux *et al.*, *Nucl. Acids Res.* 12:387, 1984) encoded by the genes were derived by conceptual translation of the corresponding open reading frames. Comparison of these protein sequences to all known proteins in the public sequence databases using 20 BLASTP algorithm revealed their strong homology to the members of the mammalian olfactory receptor family, each of the olfactory receptor sequences having at least 50%, and preferably at least 55%, at least 60%, at least 65%, and most preferably at 25 least 70%, amino acid identity to at least one known member of the family.

The nucleic acid molecules of the present invention are typically intronless and encode putative sensory receptor proteins generally having lengths of about 300 to 30 about 400 amino acid residues that contain seven transmembrane domains, as predicted by hydrophobicity plotting analysis, indicating that they belong to the G protein-coupled receptor superfamily, which includes the subset of taste and olfactory receptors. In addition to the overall structural similarity, each of the 256 sensory receptors identified herein has a characteristic sequence signature of an olfactory receptor. In particular, all 256 sequences contain very close matches to the following 35 consensus amino acid motifs (Mombaerts, 1999; Pilpel, 1999): LHTPMY in intracellular loop 1, MAYDRYVAIC at the end of transmembrane domain 3 and the beginning of intracellular loop 2, SY at the end of transmembrane domain 5,

FSTCSSH in the beginning of transmembrane domain 6, and PMLNPF in transmembrane domain 7. Combination of all the above mentioned structural features of the 256 genes and encoded proteins strongly suggests that they represent novel members of the human olfactory receptor family.

5 As noted above, complete or partial sequences of numerous human and other eukaryotic sensory receptors are currently known. The novel human receptors have amino acid sequences distinctly different from the previously known human sensory receptors, which suggests their different specificity in sensant recognition. Therefore, these novel sensory receptors and their genes can be used, alone or in combination with known sensory receptors, in developing detection systems and assays for chemically distinct types of sensants not recognized by the known sensory receptors, as well as for diagnostic and research purposes.

B. Definitions

15 The terms "purified," "substantially purified," and "isolated" as used herein refer to the state of being free of other, dissimilar compounds with which the compound of the invention is normally associated in its natural state, so that the "purified," "substantially purified," and "isolated" subject comprises at least 0.5%, 1%, 5%, 10%, or 20%, and most preferably at least 50% or 75% of the mass, by weight, of a given sample. In one preferred embodiment, these terms refer to the compound of the invention comprising at least 95% of the mass, by weight, of a given sample. As used herein, the terms "purified," "substantially purified," and "isolated" "isolated," when referring to a nucleic acid or protein, of nucleic acids or proteins, also refers to a state of purification or concentration different than that which occurs naturally in the mammalian, especially human, body. Any degree of purification or concentration greater than that which occurs naturally in the mammalian, especially human, body, including (1) the purification from other associated structures or compounds or (2) the association with structures or compounds to which it is not normally associated in the mammalian, especially human, body, are within the meaning of "isolated." The nucleic acid or protein or classes of nucleic acids or proteins, described herein, may be isolated, or otherwise associated with structures or compounds to which they are not normally associated in nature, according to a variety of methods and processes known to those of skill in the art.

The terms "amplifying" and "amplification" refer to the use of any suitable amplification methodology for generating or detecting recombinant or naturally expressed nucleic acid, as described in detail, below. For example, the invention provides methods and reagents (e.g., specific degenerate oligonucleotide primer pairs) for amplifying (e.g., by polymerase chain reaction, PCR) naturally expressed (e.g., genomic or mRNA) or recombinant (e.g., cDNA) nucleic acids of the invention (e.g., sensant-binding sequences of the invention) *in vivo* or *in vitro*.

5 The term "7- transmembrane receptor" means a polypeptide belonging to a superfamily of transmembrane proteins that have seven domains that span the plasma membrane seven times (thus, the seven domains are called "transmembrane" or "TM" 10 domains TM I to TM VII). The families of olfactory and taste receptors each belong to this super-family. Seven-transmembrane receptor polypeptides have similar and characteristic primary, secondary and tertiary structures, as discussed in further detail below.

15 The term "expression vector" refers to any recombinant expression system for the purpose of expressing a nucleic acid sequence of the invention *in vitro* or *in vivo*, constitutively or inducibly, in any cell, including prokaryotic, yeast, fungal, plant, insect or mammalian cell. The term includes linear or circular expression systems. The term includes expression systems that remain episomal or integrate into the host 20 cell genome. The expression systems can have the ability to self-replicate or not, i.e., drive only transient expression in a cell. The term includes recombinant expression "cassettes which contain only the minimum elements needed for transcription of the recombinant nucleic acid.

25 The term "library" means a preparation that is a mixture of different nucleic acid or polypeptide molecules, such as the library of recombinantly generated sensory, particularly olfactory or taste, receptor ligand-binding domains generated by amplification of nucleic acid with degenerate primer pairs, or an isolated collection of vectors that incorporate the amplified sensant-binding domains, or a mixture of cells each randomly transfected with at least one vector encoding a sensory receptor.

30 The term "nucleic acid" or "nucleic acid sequence" refers to a deoxy-ribonucleotide or ribonucleotide oligonucleotide in either single- or double-stranded form. The term encompasses nucleic acids, i.e., oligonucleotides, containing known analogs of natural nucleotides. The term also encompasses nucleic-acid-like

structures with synthetic backbones, *see e.g., Oligonucleo-tides and Analogues, a Practical Approach*, ed. F. Eckstein, Oxford Univ. Press (1991); *Anti-sense Strategies*, Annals of the N.Y. Academy of Sciences, Vol. 600, Eds. Baserga *et al.* (NYAS 1992); Milligan (1993) *J. Med. Chem.* 36:1923-1937; *Antisense Research and Applications* (1993, CRC Press), WO 97/03211; WO 96/39154; Mata (1997) *Toxicol. Appl. Pharmacol.* 144:189-197; Strauss-Soukup (1997) *Biochemistry* 36:8692-8698; Samstag (1996) *Antisense Nucleic Acid Drug Dev* 6:153-156.

10 The term sensory receptor “ligand-binding region” refers to sequences derived from a sensory receptor that substantially incorporates transmembrane domains II to VII (TM II to VII). The domain may be capable of binding a sensant.

15 The terms “conservative variant” or “analog” or “mimetic” refer to a polypeptide which has a modified amino acid sequence, such that the change(s) do not substantially alter the poly-peptide’s (the conservative variant’s) structure and/or activity, as defined herein. These include conservatively modified variations of an amino acid sequence, *i.e.*, amino acid substitutions, additions or deletions of those residues that are not critical for protein activity, or substitution of amino acids with residues having similar properties (*e.g.*, acidic, basic, positively or negatively charged, polar or non-polar, etc.) such that the substitutions of even critical amino acids does not substantially alter structure and/or activity. Conservative substitution tables 20 providing function-ally similar amino acids are well known in the art.

25 For example, one exemplary guideline to select conservative substitutions includes (original residue followed by exemplary substitution): Ala/Gly or Ser; Arg/Lys; Asn/Gln or His; Asp/Glu; Cys/Ser; Gln/Asn; Gly/Asp; Gly/Ala or Pro; His/Asn or Gln; Ile/Leu or Val; Leu/Ile or val; Lys/Arg or Gln or Glu; Met/Leu or Tyr or Ile; Phe/Met or Leu or Tyr; Ser/Thr; Thr/Ser; Trp/Tyr; Tyr/Trp or Phe; Val/Ile or Leu. An alternative exemplary guideline uses the following six groups, each containing amino acids that are conservative substitutions for one another: 1) Alanine (A), Serine (S), Threonine (T); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (I); 5) Isoleucine (I), Leucine (L), 30 Methionine (M), Valine (V); and 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); (*see also, e.g., Creighton, Proteins*, W.H. Freeman, 1984; Schultz & Schimer, *Principles of Protein Structure*, Springer-Verlag, 1979). One of skill in the art will appreciate that the above-identified substitutions are not the only possible

WO 01/98526

conservative substitutions. For example, for some purposes, one may regard all charged amino acids as conservative substitutions for each other whether they are positive or negative. In addition, individual substitutions, deletions or additions that alter, add or delete a single amino acid or a small percentage of amino acids in an encoded sequence can also be considered "conservatively modified variations."

5 The terms "mimetic" and "peptidomimetic" refer to a synthetic chemical

compound that has substantially the same structural and/or functional characteristics of the polypeptides, e.g., translocation domains or sensant-binding domains or 10 chimeric receptors of the invention. The mimetic can be either entirely composed of synthetic, non-natural analogs of amino acids, or, is a chimeric molecule of partly natural peptide amino acids and partly non-natural analogs of amino acids. The mimetic can also incorporate any amount of natural amino acid conservative substitutions as long as such substitutions also do not substantially alter the mimetic's 15 structure and/or activity. As with polypeptides of the invention which are conservative variants, routine experimentation will determine whether a mimetic is

20 within the scope of the invention, i.e., that its structure and/or function is not substantially altered. Polypeptide mimetic compositions can contain any combination of non-natural structural components, which are typically from three structural groups:

a) residue linkage groups other than the natural amide bond ("peptide bond") linkages; 25 b) non-natural residues in place of naturally occurring amino acid residues; or c)

residues which induce secondary structural mimicry, i.e., to induce or stabilize a secondary structure, e.g., a beta turn, gamma turn, beta sheet, alpha helix conformation, and the like. A polypeptide can be characterized as a mimetic when all or some of its residues are joined by chemical means other than natural peptide bonds.

30 Individual peptidomimetic residues can be joined by peptide bonds, other chemical bonds or coupling means, such as, e.g., glutaraldehyde, N-hydroxysuccinimide esters, bifunctional maleimides, N,N'-dicyclohexylcarbodiimide (DCC) or N,N'-diisopropylcarbodiimide (DIC). Linking groups that can be an alternative to the

traditional amide bond ("peptide bond") linkages include, e.g., ketomethylene (e.g., -C(=O)-CH<sub>2</sub>- for -C(=O)-NH-), aminomethylene (CH<sub>2</sub>-NH), ethylene, olefin (CH=CH), ether (CH<sub>2</sub>-O), thioether (CH<sub>2</sub>-S), tetrazole (CN<sub>4</sub>), thiazole, retroamide,

thioamide, or ester (see, e.g., Spatola (1983) in *Chemistry and Biochemistry of Amino Acids, Peptides and Proteins*, Vol. 7, pp 267-357, "Peptide Backbone Modifications,"

Marcell Dekker, NY). A polypeptide can also be characterized as a mimetic by containing all or some non-natural residues in place of naturally occurring amino acid residues; non-natural residues are well described in the scientific and patent literature.

As used herein, "recombinant" refers to a polynucleotide synthesized or 5 otherwise manipulated *in vitro* (e.g., "recombinant polynucleotide"), to methods of using recombinant polynucleotides to produce gene products in cells or other biological systems, or to a polypeptide ("recombinant protein") encoded by a recombinant polynucleotide. "Recombinant means" also encompass the ligation of 10 nucleic acids having various coding regions or domains or promoter sequences from different sources into an expression cassette or vector for expression of, e.g., inducible or constitutive expression of a fusion protein comprising a translocation domain of the invention and a nucleic acid sequence amplified using a primer of the invention.

The term "transmembrane domain" means a polypeptide domain that can 15 completely span the plasma membrane. The general secondary and tertiary structure of transmembrane domains, in particular the seven transmembrane domains of 7-transmembrane receptors such as olfactory receptors, are well known in the art. Thus, primary structure sequence can be designed or predicted based on known transmembrane domain sequences, as described in detail below.

C. Isolation and Expression of Olfactory Receptors

20 Isolation and expression of the sensory receptors, or fragments or variants thereof, of the invention can be performed as described below. PCR primers can be used for the amplification of nucleic acids encoding olfactory receptor ligand binding regions and libraries of these nucleic acids can thereby be generated. Libraries of expression vectors can then be used to infect or transfect host cells for the functional 25 expression of these libraries. These genes and vectors can be made and expressed *in vitro* or *in vivo*. One of skill will recognize that desired phenotypes for altering and controlling nucleic acid expression can be obtained by modulating the expression or activity of the genes and nucleic acids (e.g., promoters, enhancers and the like) within the vectors of the invention. Any of the known methods described for increasing or 30 decreasing expression or activity can be used. The invention can be practiced in conjunction with any method or protocol known in the art, which are well described in the scientific and patent literature.

WO 01/98526

The nucleic acid sequences of the invention and other nucleic acids used to practice this invention, whether RNA, cDNA, genomic DNA, vectors, viruses or hybrids thereof, may be isolated from a variety of sources, genetically engineered, amplified, and/or expressed recombinantly. Any recombinant expression system can be used, including, in addition to mammalian cells, e.g., bacterial, yeast, insect or plant systems.

5      Alternatively, these nucleic acids can be synthesized *in vitro* by well-known chemical synthesis techniques, as described in, e.g., Carruthers, *Cold Spring Harbor Symp. Quant. Biol.* 47:411-418 (1982); Adams, *Am. Chem. Soc.* 105:661 (1983);  
10     Belousov, *Nucleic Acids Res.* 25:3440-3444 (1997); Frenkel, *Free Radic. Biol. Med.* 19:373-380 (1995); Blommers, *Biochemistry* 33:7886-7896 (1994); Narang, *Meth. Enzymol.* 68:90 (1979); Brown, *Meth. Enzymol.* 68:109 (1979); Beaucage, *Tetra. Lett.* 22:1859 (1981); U.S. Patent No. 4,458,066. Double-stranded DNA fragments may then be obtained either by synthesizing the complementary strand and annealing the strands together under appropriate conditions, or by adding the complementary strand using DNA polymerase with an appropriate primer sequence..

15     Techniques for the manipulation of nucleic acids, such as, for example, for generating mutations in sequences, subcloning, labeling probes, sequencing, hybridization and the like are well described in the scientific and patent literature. See, e.g., Sambrook, ed., *Molecular Cloning: a Laboratory manual* (2nd ed.), Vols. 1-3, Cold Spring Harbor Laboratory (1989); *Current Protocols in Molecular Biology*, Ausubel, ed. John Wiley & Sons, Inc., New York (1997); *Laboratory Techniques in Biochemistry and Molecular Biology: Hybridization With Nucleic Acid Probes, Part I, Theory and Nucleic Acid Preparation*, Tijssen, ed. Elsevier, N.Y. (1993).

20     Nucleic acids, vectors, capsids, polypeptides, and the like can be analyzed and quantified by any of a number of general means well known to those of skill in the art. These include, e.g., analytical biochemical methods such as NMR, spectrophotometry, radiography, electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), and hyperdiffusion chromatography, various immunological methods, e.g., fluid or gel precipitin reactions, immunodiffusion, immuno-electrophoresis, radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), immunofluorescent assay, Southern analysis, Northern analysis, dot-blot analysis, gel electrophoresis (e.g., SDS-PAGE),

RT-PCR, quantitative PCR, other nucleic acid or target or signal amplification methods, radiolabeling, scintillation counting, and affinity chromatography.

Oligonucleotide primers are used to amplify nucleic acid encoding an olfactory receptor ligand-binding region. The nucleic acids described herein can also be cloned or measured quantitatively using amplification techniques. Using exemplary degenerate primer pair sequences, (see below), the skilled artisan can select and design suitable oligonucleotide amplification primers. Amplification methods are also well known in the art, and include, e.g., polymerase chain reaction, PCR (*PCR Protocols, a Guide to Methods and Applications*, ed. Innis. Academic Press, NY, 1990 and *PCR Strategies*, ed. Innis, Academic Press, NY, 1995), ligase chain reaction (LCR) (see, e.g., Wu, *Genomics* 4:560, 1989; Landegren, *Science* 241:1077, 1988; Barringer, *Gene* 89:117, 1990); transcription amplification (see, e.g., Kwoh, *Proc. Natl. Acad. Sci. USA* 86:1173, 1989); and, self-sustained sequence replication (see, e.g., Guatelli, *Proc. Natl. Acad. Sci. USA* 87:1874, 1990); Q Beta replicase amplification (see, e.g., Smith, *J. Clin. Microbiol.* 35:1477, 1997); automated Q-beta replicase amplification assay (see, e.g., Burg, *Mol. Cell. Probes* 10:257, 1996) and other RNA polymerase mediated techniques (e.g., NASBA, Cangene, Mississauga, Ontario); see also Berger, *Methods Enzymol.* 152:307, 1987; Sambrook; Ausubel; U.S. Patent Nos. 4,683,195 and 4,683,202; Sooknanan, *Biotechnology* 13:563, 1995.

Once amplified, the nucleic acids, either individually or as libraries, may be cloned according to methods known in the art, if desired, into any of a variety of vectors using routine molecular biological methods; methods for cloning *in vitro* amplified nucleic acids are described, e.g., U.S. Patent No. 5,426,039. To facilitate cloning of amplified sequences, restriction enzyme sites can be "built into" the PCR primer pair. For example, Pst I and Bsp E1 sites were designed into the exemplary primer pairs of the invention. These particular restriction sites have a sequence that, when ligated, are "in-frame" with respect to the 7-membrane receptor "donor" coding sequence into which they are spliced (the sensant-binding region-coding sequence is internal to the 7-membrane polypeptide, thus, if it is desired that the construct be translated downstream of a restriction enzyme splice site, out of frame results should be avoided; this may not be necessary if the inserted sensant-binding domain comprises substantially most of the transmembrane VII region). The primers can be designed to retain the original sequence of the "donor" 7-membrane receptor (the Pst I

WO 01/98526

and Bsp E1 sequence in the primers of the invention generate an insert that, when ligated into the Pst I/Bsp E1 cut vector, encode residues found in the "donor" mouse olfactory receptor M4 sequence). Alternatively, the primers can encode amino acid residues that are conservative substitutions (e.g., hydrophobic for hydrophobic residue, see above discussion) or functionally benign substitutions (e.g., do not prevent plasma membrane insertion, cause cleavage by peptidase, cause abnormal folding of receptor, and the like).

5 The primer pairs are designed to selectively amplify sensant-binding regions of olfactory receptor proteins. These domain regions may vary for different sensants, 10 and more particularly odorants; thus, what may be a minimal binding region for one sensant, and more particularly odorants, may be too limiting for a second potential ligand. Thus, domain regions of different sizes comprising different domain structures may be amplified; for example, transmembrane (TM) domains II through VII, III through VII, III through VI or II through VI, or variations thereof (e.g., only a 15 subsequence of a particular domain, mixing the order of the domains, and the like), of a 7-transmembrane sensory receptor.

As domain structures and sequence of many 7-membrane proteins, particularly 20 olfactory receptors, are known, the skilled artisan can readily select domain-flanking and internal domain sequences as model sequences to design degenerate amplification primer pairs. For example, a nucleic acid sequence encoding domain regions II through VII can be generated by PCR amplification using a primer pair. To amplify a 25 nucleic acid comprising transmembrane domain I (TM I) sequence, a degenerate primer can be designed from a nucleic acid that encodes the amino acid sequence LFLLYL. Such a degenerate primer can be used to generate a binding domain incorporating TM I through TM III, TM I through TM IV, TM I through TM V, TM I through TM VI or TM I through TM VII.

To amplify a nucleic acid comprising a transmembrane domain III (TM III) sequence, a degenerate primer (of at least about 17 residues) can be designed from a nucleic acid that encodes the amino acid sequence M(A/G)(Y/F)DRYVAI (encoded 30 by a nucleic acid sequence such as

5'-ATGG(G/C)CT(A/T)TGACCG(C/A/T)T(AT)(C/T)GT-3'). Such a degenerate primer can be used to generate a binding domain incorporating TM III through TM IV, TM III through TM V, TM III through TM VI or TM III through TM VII.

To amplify a transmembrane domain VI (TM VI) sequence, a degenerate primer (of at least about 17 residues) can be designed from nucleic acid encoding an amino acid sequence TC(G/A)SHL, encoded by a sequence such as 5'-AG(G/A)TGN(G/C)(T/A)N(G/C)C(G/A)CA-NGT-3'. Such a degenerate primer can 5 be used to generate a binding domain incorporating TM I through TM VI, TM II through TM VI, TM III through TM VI or TM IV through TM VI).

Paradigms to design degenerate primer pairs are well known in the art. For example, a COnsensus-DEgenerate Hybrid Oligonucleotide Primer (CODEHOP) strategy computer program is accessible as <http://blocks.fhcrc.org/codehop.html>, and 10 is directly linked from the BlockMaker multiple sequence alignment site for hybrid primer prediction beginning with a set of related protein sequences, as known olfactory receptor ligand-binding regions (see, e.g., Rose, *Nucl. Acids Res.* 26:1628, 1998; Singh, *Biotechniques* 24:318, 1998).

Means to synthesize oligonucleotide primer pairs are well known in the art. 15 "Natural" base pairs or synthetic base pairs can be used. For example, use of artificial nucleobases offers a versatile approach to manipulate primer sequence and generate a more complex mixture of amplification products. Various families of artificial nucleobases are capable of assuming multiple hydrogen bonding orientations through internal bond rotations to provide a means for degenerate molecular recognition. 20 Incorporation of these analogs into a single position of a PCR primer allows for generation of a complex library of amplification products. See, e.g., Hoops, *Nucleic Acids Res.* 25:4866, 1997. Nonpolar molecules can also be used to mimic the shape of natural DNA bases. A non-hydrogen-bonding shape mimic for adenine can replicate efficiently and selectively against a nonpolar shape mimic for thymine (see, 25 e.g., Morales, *Nat. Struct. Biol.* 5:950, 1998). For example, two degenerate bases can be the pyrimidine base 6H, 8H-3,4-dihydropyrimido[4,5-c][1,2]oxazin-7-one or the purine base N6-methoxy-2,6-diaminopurine (see, e.g., Hill, *Proc. Natl. Acad. Sci. USA* 95:4258, 1998). Exemplary degenerate primers of the invention incorporate the nucleobase analog 5'-Dimethoxytrityl-N-benzoyl-2'-deoxy-Cytidine, 3'-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite (the term "P" in the sequences, see above). This pyrimidine analog hydrogen bonds with purines, including A and G residues.

Exemplary primer pairs for amplification of olfactory receptor transmembrane domains II through VII include:

(a) 5'-GGGGTCCGGAG(A/G)(C/G)(A/G)TA(A/G/T)AT(A/G/P)A(A/G/P)(A/G/P)GG-  
3' and  
5'-  
GGGGCTGCAGACACC(A/C/G/T)ATGTA(C/T)(C/T)T(A/C/G/T)TT(C/T)(C/T)T-  
3'.  
(b) 5'-GGGGTCCGGAG(A/G)(C/G)T(A/G)A(A/G/T)AT(A/G/P)A(A/G/P)(A/G/P)GG-  
3' and  
5'-  
GGGGCTGCAGACACC(AC/G/T)ATGTA(C/T)(C/T)T(A/C/G/T)TT(C/T)(C/T)T-  
3'.  
(c) 5'-  
GGGGTCCGGAG(A/G)(C/G)T(A/G)A(A/G/T)AT(A/G/C/T)A(A/G/C/T)(A/G/C/T)  
GG-3' and  
5'-GGGGCTGCAGACACC(A/C/G/T)ATGTA(C/T)(C/T)T(A/C/G/T)  
TT(C/T)(C/T)T-3'.

Nucleic acids that encode ligand-binding regions of olfactory receptors are generated by amplification (e.g., PCR) of appropriate nucleic acid sequences using degenerate primer pairs. The amplified nucleic acid can be genomic DNA from any cell or tissue or mRNA or cDNA derived from olfactory receptor-expressing cells, e.g., olfactory neurons or olfactory epithelium.

Isolation from olfactory receptor-expressing cells is well known in the art (cells expressing naturally or inducibly expressing olfactory receptors can be used to express the hybrid olfactory receptors of the invention to screen for potential odorants and odorant effect on cell physiology, as described below). For example, cells can be identified by olfactory marker protein (OMP), an abundant cytoplasmic protein expressed almost exclusively in mature olfactory sensory neurons (see, e.g., Buiakova, *Proc. Natl. Acad. Sci. USA* 93:9858, 1996). Shirley, *Eur. J. Biochem.* 32:485, 1983), describes a rat olfactory preparation suitable for biochemical studies *in vitro* on olfactory mechanisms. Cultures of adult rat olfactory receptor neurons are described by Vargas, *Chem. Senses* 24:211, 1999). Because these cultured neurons exhibit typical voltage-gated currents and are responsive to application of odorants, they can also be used to express the hybrid olfactory receptors of the invention for odorant screening (endogenous olfactory receptor can be initially blocked, if desired, by, e.g.,

antisense, knockout, and the like). U.S. Patent No. 5,869,266 describes culturing human olfactory neurons for neurotoxicity tests and screening. Murrell, *J. Neurosci.* 19:8260, 1999), describes differentiated olfactory receptor-expressing cells in culture that respond to odorants, as measured by an influx of calcium.

5        Hybrid protein-coding sequences comprising nucleic acids sensory receptors fused to the translocation sequences described herein may be constructed. Also provided are hybrid receptors comprising the translocation motifs and ligand-binding domains of sensory receptors. These nucleic acid sequences can be operably linked to transcriptional or translational control elements, *e.g.*, transcription and translation  
10 initiation sequences, promoters and enhancers, transcription and translation terminators, polyadenylation sequences, and other sequences useful for transcribing DNA into RNA. In construction of recombinant expression cassettes, vectors, transgenics, and a promoter fragment can be employed to direct expression of the desired nucleic acid in all tissues. Olfactory cell-specific transcriptional elements can  
15 also be used to express the fusion polypeptide receptor, including, *e.g.*, a 6.7 kb region upstream of the M4 olfactory receptor coding region. This region was sufficient to direct expression in olfactory epithelium with wild type zonal restriction and distributed neuronal expression for endogenous olfactory receptors (Qasba, *J. Neurosci.* 18:227, 1998). Receptor genes are normally expressed in a small subset of  
20 neurons throughout a zonally restricted region of the sensory epithelium. The transcriptional or translational control elements can be isolated from natural sources, obtained from such sources as ATCC or GenBank libraries, or prepared by synthetic or recombinant methods.

25        Fusion proteins, either having C-terminal or, more preferably, N-terminal translocation sequences, may also comprise the translocation motif described herein. However, these fusion proteins can also comprise additional elements for, *e.g.*, protein detection, purification, or other applications. Detection and purification facilitating domains include, *e.g.*, metal chelating peptides such as polyhistidine tracts or histidine-tryptophan modules or other domains that allow purification on immobilized  
30 metals; maltose binding protein; protein A domains that allow purification on immobilized immunoglobulin; or the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp, Seattle WA).

The inclusion of a cleavable linker sequences such as Factor Xa (see, e.g., Ottavi, *Biochi-mie* 80:289, 1998), subtilisin protease recognition motif (see, e.g., Polyak, *Protein Eng.* 10:615, 1997); enterokinase (Invitrogen, San Diego, CA), and the like, between the translocation domain (for efficient plasma membrane expression) and the rest of the newly translated polypeptide may be useful to facilitate 5 purification. For example, one construct can include a nucleic acid sequence encoding a polypeptide linked to six histidine residues followed by a thioredoxin, an enterokinase cleavage site (see, e.g., Williams, *Biochemistry* 34:1787, 1995), and an amino terminal translocation domain. The histidine residues facilitate detection and 10 purification while the enterokinase cleavage site provides a means for purifying the desired protein(s) from the remainder of the fusion protein. Technology pertaining to vectors encoding fusion proteins and application of fusion proteins are well described in the scientific and patent literature, see, e.g., Kroll, *DNA Cell. Biol.* 12:441, 1993).

Expression vectors, either as individual expression vectors or as libraries of 15 expression vectors, comprising the olfactory binding domain-encoding sequences may be introduced into a genome or into the cytoplasm or a nucleus of a cell and expressed by a variety of conventional techniques, well described in the scientific and patent literature. See, e.g., Roberts, *Nature* 328:731, 1987; Berger *supra*; Schneider, *Protein Expr. Purif.* 6435:10, 1995; Sambrook; Tijssen; Ausubel. Product information from 20 manufacturers of biological reagents and experimental equipment also provide information regarding known biological methods. The vectors can be isolated from natural sources, obtained from such sources as ATCC or GenBank libraries, or prepared by synthetic or recombinant methods.

The nucleic acids can be expressed in expression cassettes, vectors or viruses 25 which are stably or transiently expressed in cells (e.g., episomal expression systems). Selection markers can be incorporated into expression cassettes and vectors to confer a selectable phenotype on transformed cells and sequences. For example, selection markers can code for episomal maintenance and replication such that integration into the host genome is not required. For example, the marker may encode antibiotic 30 resistance (e.g., chloramphenicol, kanamycin, G418, bleomycin, hygromycin) or herbicide resistance (e.g., chlorosulfuron or Basta) to permit selection of those cells transformed with the desired DNA sequences (see, e.g., Blondelet-Rouault, *Gene* 190:315, 1997; Aubrecht, *J. Pharmacol. Exp. Ther.* 281:992, 1997). Because

selectable marker genes conferring resistance to substrates like neomycin or hygromycin can only be utilized in tissue culture, chemoresistance genes are also used as selectable markers *in vitro* and *in vivo*.

A chimeric nucleic acid sequence may encode a sensant-binding domain 5 within any 7-transmembrane polypeptide. Seven-transmembrane receptors belong to a superfamily of trans-membrane (TM) proteins having seven domains that traverse a plasma membrane seven times. Each of the seven domains spans the plasma membrane (TM I to TM VII). Because 7-trans-membrane receptor polypeptides have similar primary sequences and secondary and tertiary structures, structural domains 10 (*e.g.*, TM domains) can be readily identified by sequence analysis. For example, homology modeling, Fourier analysis and helical periodicity detection can identify and characterize the seven domains with a 7-transmembrane receptor sequence. Fast Fourier Transform (FFT) algorithms can be used to assess the dominant periods that characterize profiles of the hydrophobicity and variability of analyzed sequences. To 15 predict TM domains and their boundaries and topology, a “neural network algorithm” by “PHD server” can be used, as done by Pilpel, *Protein Science* 8:969, 1999; Rost, *Protein Sci.* 4:521, 1995. Periodicity detection enhancement and alpha helical periodicity index can be done as by, *e.g.*, Donnelly, *Protein Sci.* 2:55-70 (1993). Other alignment and modeling algorithms are well known in the art, *see, e.g.*, Peitsch, 20 *Receptors Channels* 4:161, 1996; Cronet, *Protein Eng.* 6:59, (1993) (homology and “discover modeling”); <http://bioinfo.weizmann.ac.il/>.

The library sequences include receptor sequences that correspond to TM 25 ligand-binding domains, including, *e.g.*, TM II to VII, TM II to VI, TM III to VII, and TM III to VII, that have been amplified (*e.g.*, PCR) from mRNA of or cDNA derived from, *e.g.*, olfactory receptor-expressing neurons or genomic DNA.

Libraries of sensory receptor ligand-binding TM domain sequences can 30 include a various TM domains or variations thereof, as described above. These sequences can be derived from any 7-transmembrane receptor. Because these polypeptides have similar primary sequences and secondary and tertiary structures, the seven domains can be identified by various analyses well known in the art, including, *e.g.*, homology modeling, Fourier analysis and helical periodicity (*see, e.g.*, Pilpel *supra*), as described above. Using this information sequences flanking the seven

WO 01/98526

domains can be identified and used to design degenerate primers for amplification of various combinations of TM regions and subsequences.

The present invention also includes not only the DNA and proteins having the specified amino acid sequences, but also DNA fragments, particularly fragments of, for example, 40, 60, 80, 100, 150, 200, or 250 nucleotides, or more, as well as protein fragments of, for example, 10, 20, 30, 50, 70, 100, or 150 amino acids, or more.

Also contemplated are chimeric proteins, comprising at least 10, 20, 30, 50, 70, 100, or 150 amino acids, or more, of one of at least one of the sensory receptors described herein, coupled to additional amino acids representing all or part of another G protein receptor, preferably a member of the 7-transmembrane superfamily. These chimerae can be made from the instant receptors and a G protein receptor described herein, or they can be made by combining two or more of the present proteins. In one preferred embodiment, one portion of the chimera corresponds to and is derived from one or more of the domains of the 7-transmembrane protein described herein, and the remaining portion or portions come from another G protein-coupled receptor.

Chimeric receptors are well known in the art, and the techniques for creating them and the selection and boundaries of domains or fragments of G protein-coupled receptors for incorporation therein are also well known. Thus, this knowledge of those skilled in the art can readily be used to create such chimeric receptors. The use of such chimeric receptors can provide, for example, an olfactory selectivity characteristic of one of the receptors specifically disclosed herein, coupled with the signal transduction characteristics of another receptor, such as a well known receptor used in prior art assay systems.

For example, a domain such as a ligand binding domain, an extracellular domain, a transmembrane domain (e.g., one comprising seven transmembrane regions and corresponding extracellular and cytosolic loops), the transmembrane domain and a cytoplasmic domain, an active site, a subunit association region, etc., can be covalently linked to a heterologous protein. For instance, an extracellular domain can be linked to a heterologous GPCR transmembrane domain, or a heterologous CGPCR extracellular domain can be linked to a transmembrane domain. Other heterologous proteins of choice can include, e.g., green fluorescent protein,  $\beta$ -gal, glutamate receptor, and the rhodopsin presequence.

Polymorphic variants, alleles, and interspecies homologs that are substantially identical to a sensory receptor disclosed herein can be isolated using the nucleic acid probes described above. Alternatively, expression libraries can be used to isolate sensory receptors and polymorphic variants, alleles, and interspecies homologs thereof, by detecting expressed homologs immunologically with antisera or purified antibodies made against a sensory receptor-derived polypeptide, which also recognize and selectively bind to the sensory receptor homolog.

Also within the scope of the invention are host cells for expressing the sensory receptors, fragments, or variants of the invention. To obtain high levels of expression of a cloned gene or nucleic acid, such as cDNAs encoding the sensory receptors, fragments, or variants thereof, the nucleic acid sequence of interest is subcloned into an expression vector that contains a strong promoter to direct transcription, a transcription/translation terminator, and if for a nucleic acid encoding a protein, a ribosome binding site for translational initiation. Suitable prokaryotic and eukaryotic expression systems are well known in the art and described, e.g., in Sambrook *et al.*

Any of the well known procedures for introducing foreign nucleotide sequences into host cells may be used. These include the use of calcium phosphate transfection, polybrene, protoplast fusion, electroporation, liposomes, microinjection, plasmid vectors, viral vectors and any of the other well known methods for introducing cloned genomic DNA, cDNA, synthetic DNA or other foreign genetic material into a host cell (see, e.g., Sambrook *et al.*). It is only necessary that the particular genetic engineering procedure used be capable of successfully introducing at least one gene into the host cell capable of expressing the olfactory receptor, fragment, or variant of interest.

After the expression vector is introduced into the cells, the transfected cells are cultured under conditions favoring expression of the receptor, fragment, or variant of interest, which is then recovered from the culture using standard techniques. Examples of such techniques are well known in the art. See, e.g., WO 00/06593, which is incorporated by reference in a manner consistent with this disclosure.

30 D. Immunological Detection of Sensory Receptor Polypeptides

In addition to the detection of sensory receptor genes and gene expression using nucleic acid hybridization technology, one can also use immunoassays to detect

sensory receptors, e.g., to identify olfactory receptor cells, and variants of sensory receptor family members. Immunoassays can be used to qualitatively or quantitatively analyze the sensory receptors. A general overview of the applicable technology can be found in Harlow & Lane, *Antibodies: A Laboratory Manual* (1988).

5           1.    Antibodies to sensory receptor family members

Methods of producing polyclonal and monoclonal antibodies that react specifically with a sensory receptor family member are known to those of skill in the art (see, e.g., Coligan, *Current Protocols in Immunology*, 1991; Goding, *Monoclonal Antibodies: Principles and Practice*, 2d ed., 1986; Harlow & Lane, *supra*; and Kohler & Milstein, *Nature*, 256:495, 1975). Such techniques include antibody preparation by 10 selection of antibodies from libraries of recombinant antibodies in phage or similar vectors, as well as preparation of polyclonal and monoclonal antibodies by immunizing rabbits or mice (see, e.g., Huse *et al.*, *Science*, 246:1275, 1989; Ward *et al.*, *Nature*, 341:544, 1989).

15           A number of sensory receptor-comprising immunogens may be used to produce antibody specifically reactive with a sensory receptor family member. For example, a recombinant sensory receptor protein, or an antigenic fragment thereof, can be isolated as described herein. Suitable antigenic regions include, e.g., the conserved motifs that are used to identify members of the sensory receptor family. 20 Recombinant proteins can be expressed in eukaryotic or prokaryotic cells as described above, and purified as generally described above. Recombinant protein is the preferred immunogen for the production of monoclonal or polyclonal antibodies. Alternatively, a synthetic peptide derived from the sequences disclosed herein and conjugated to a carrier protein can be used an immunogen. Naturally occurring protein may also be used either in pure or impure form. The product is then injected 25 into an animal capable of producing antibodies. Either monoclonal or polyclonal antibodies may be generated, for subsequent use in immunoassays to measure the protein.

Methods of production of polyclonal antibodies are known to those of skill in 30 the art. Mice, hamsters, rats, guinea pigs, rabbits, goats, or chickens is immunized with the protein using an adjuvant (e.g., Freund's adjuvant) and a standard immunization protocol with periodic boosts. The animal's immune response to the immunogen preparation is monitored by taking test bleeds and determining the titer of

reactivity to the sensory receptor. When appropriately high titers of antibody to the immunogen are obtained, blood is collected from the animal and antisera are prepared. Further fractionation of the antisera to enrich for antibodies reactive to the protein can be done if desired (see Harlow & Lane, *supra*).

5 Monoclonal antibodies may be obtained by various techniques familiar to those skilled in the art. Briefly, spleen cells from an animal immunized with a desired antigen are immortalized, commonly by fusion with a myeloma cell (see Kohler & Milstein, *Eur. J. Immunol.*, 6:511, 1976). Alternative methods of immortalization include transformation with Epstein Barr Virus, oncogenes, retroviruses, or other 10 methods well known in the art. Colonies arising from single clones of immortalized cells are screened for production of antibodies of the desired specificity and affinity for the antigen, and yield of the monoclonal antibodies produced by such cells may be enhanced by various techniques, including injection into the peritoneal cavity of a vertebrate host. Alternatively, one may isolate DNA sequences which encode a 15 monoclonal antibody or a binding fragment thereof by screening a DNA library from human B cells according to the general protocol outlined by Huse *et al.*, *Science*, 246:1275, 1989.

Monoclonal antibodies or polyclonal sera are collected and titered against 20 antigen in an immunoassay, for example, a solid phase immunoassay with the antigen immobilized on a solid support. Typically, polyclonal antisera with a titer of  $10^4$  or greater are selected and tested for their cross reactivity against non-sensory receptor proteins, or even other sensory receptor family members or other related proteins from other organisms, using a competitive binding immuno-assay. Specific polyclonal antisera and monoclonal antibodies will usually bind with a  $K_d$  of at least about 0.1 25 mM, more usually at least about 1 pM, optionally at least about 0.1 pM or better, and optionally 0.01 pM or better.

Once sensory receptor family member specific antibodies are available, 30 individual sensory receptor proteins can be detected by a variety of immunoassay methods. For a review of immuno-logical and immunoassay procedures, see *Basic and Clinical Immunology* (Stites & Terr eds., 7th ed., 1991). Moreover, the immunoassays of the present invention can be performed in any of several configurations, which are reviewed extensively in *Enzyme Immunoassay* (Maggio, ed., 1980); and Harlow & Lane, *supra*.

2. Immunological binding assays

Sensory receptor proteins can be detected and/or quantified using any of a number of well recognized immunological binding assays (see, e.g., U.S. Patent Nos. 4,366,241; 4,376,110; 4,517,288; and 4,837,168). For a review of the general immunoassays, see also *Methods in Cell Biology: Antibodies in Cell Biology*, volume 53 (Asai, ed. 1993); *Basic and Clinical Immunology* (Stites & Terr, eds., 7th ed., 1991). Immunological binding assays (or immunoassays) typically use an antibody that specifically binds to a protein or antigen of choice (in this case a sensory receptor family member or an antigenic subsequence thereof). The antibody (e.g., anti-sensory receptor) may be produced by any of a number of means well known to those of skill 10 in the art and as described above.

Immunoassays also often use a labeling agent to specifically bind to and label the complex formed by the antibody and antigen. The labeling agent may itself be one of the moieties comprising the antibody/antigen complex. Thus, the labeling agent 15 may be a labeled sensory receptor polypeptide or a labeled anti-sensory receptor antibody. Alternatively, the labeling agent may be a third moiety, such a secondary antibody, that specifically binds to the antibody/sensory receptor complex (a secondary antibody is typically specific to antibodies of the species from which the first antibody is derived). Other proteins capable of specifically binding 20 immunoglobulin constant regions, such as protein A or protein G may also be used as the label agent. These proteins exhibit a strong non-immunogenic reactivity with immunoglobulin constant regions from a variety of species (see, e.g., Kronval *et al.*, *J. Immunol.*, 111:1401, 1973; Akerstrom *et al.*, *J. Immunol.*, 135:2589, 1985). The labeling agent can be modified with a detectable moiety, such as biotin, to which 25 another molecule can specifically bind, such as streptavidin. A variety of detectable moieties are well known to those skilled in the art.

Throughout the assays, incubation and/or washing steps may be required after each combination of reagents. Incubation steps can vary from about 5 seconds to several hours, optionally from about 5 minutes to about 24 hours. However, the 30 incubation time will depend upon the assay format, antigen, volume of solution, concentrations, and the like. Usually, the assays will be carried out at ambient temperature, although they can be conducted over a range of temperatures, such as 10°C to 40°C.

a. Non-competitive assay formats

Immunoassays for detecting a sensory receptor protein in a sample may be either competitive or noncompetitive. Noncompetitive immunoassays directly measure the amount of antigen. In one preferred "sandwich" assay, for example, the 5 anti-sensory receptor antibodies are bound directly to a solid substrate on which they are immobilized. These immobilized antibodies then capture the sensory receptor protein present in the test sample. The sensory receptor protein thus immobilized is then bound by a labeling agent, such as a second anti-sensory receptor antibody bearing a label. Alternatively, the second antibody may lack a label, but it may, in 10 turn, be bound by a labeled third antibody specific to antibodies of the species from which the second antibody is derived. The second or third antibody is typically modified with a detectable moiety, such as biotin, to which another molecule specifically binds, *e.g.*, streptavidin, to provide a detectable moiety.

b. Competitive assay formats

15 In competitive assays, the amount of sensory receptor protein present in the sample is measured indirectly by measuring the amount of a known, added (exogenous) sensory receptor protein displaced (competed away) from an anti-sensory receptor antibody by the unknown sensory receptor protein present in a sample. In one competitive assay, a known amount of sensory receptor protein is added to a 20 sample and the sample is then contacted with an antibody that specifically binds to the sensory receptor. The amount of exogenous sensory receptor protein bound to the antibody is inversely proportional to the concentration of sensory receptor protein present in the sample. In a particularly preferred embodiment, the antibody is immobilized on a solid substrate. The amount of sensory receptor protein bound to 25 the antibody may be determined either by measuring the amount of sensory receptor protein present in a sensory receptor/antibody complex, or alternatively by measuring the amount of remaining uncomplexed protein. The amount of sensory receptor protein may be detected by providing a labeled sensory receptor molecule.

30 A hapten inhibition assay is another preferred competitive assay. In this assay the known sensory receptor protein is immobilized on a solid substrate. A known amount of anti-sensory receptor antibody is added to the sample, and the sample is then contacted with the immobilized sensory receptor. The amount of anti-sensory receptor antibody bound to the known immobilized sensory receptor protein is

inversely proportional to the amount of sensory receptor protein present in the sample. Again, the amount of immobilized antibody may be detected by detecting either the immobilized fraction of antibody or the fraction of the antibody that remains in solution. Detection may be direct where the antibody is labeled or indirect by the 5 subsequent addition of a labeled moiety that specifically binds to the antibody as described above.

c. Cross-reactivity determinations

Immunoassays in the competitive binding format can also be used for cross-reactivity determinations. For example, a protein at least partially encoded by the 10 nucleic acid sequences disclosed herein can be immobilized to a solid support. Proteins (e.g., sensory receptor proteins and homologs) are added to the assay that compete for binding of the antisera to the immobilized antigen. The ability of the added proteins to compete for binding of the antisera to the immobilized protein is compared to the ability of the sensory receptor polypeptide encoded by the nucleic 15 acid sequences disclosed herein to compete with itself. The percentage cross-reactivity for the above proteins is calculated, using standard calculations. Those antisera with less than 10% cross-reactivity with each of the added proteins listed above are selected and pooled. The cross-reacting antibodies are optionally removed 20 from the pooled antisera by immunoabsorption with the added considered proteins, e.g., distantly related homologs. In addition, peptides comprising amino acid sequences representing conserved motifs that are used to identify members of the sensory receptor family can be used in cross-reactivity determinations.

The immunoabsorbed and pooled antisera are then used in a competitive binding immunoassay as described above to compare a second protein, thought to be 25 perhaps an allele or poly-morphic variant of a sensory receptor family member, to the immunogen protein (i.e., sensory receptor protein encoded by the nucleic acid sequences disclosed herein). In order to make this comparison, the two proteins are each assayed at a wide range of concentrations and the amount of each protein required to inhibit 50% of the binding of the antisera to the immobilized protein is 30 determined. If the amount of the second protein required to inhibit 50% of binding is less than 10 times the amount of the protein encoded by nucleic acid sequences disclosed herein required to inhibit 50% of binding, then the second protein is said to

specifically bind to the polyclonal antibodies generated to a sensory receptor immunogen.

Antibodies raised against sensory receptor conserved motifs can also be used to prepare antibodies that specifically bind only to GPCRs of the sensory receptor family, but not to GPCRs from other families. Polyclonal antibodies that specifically bind to a particular member of the sensory receptor family, can be made by subtracting out cross-reactive antibodies using other sensory receptor family members. Species-specific polyclonal antibodies can be made in a similar way. For example, antibodies specific to human T2R01 can be made by, subtracting out antibodies that are cross-reactive with orthologous sequences, e.g., rat OLF1 or mouse OLF1

d. Other assay formats

Western blot (immunoblot) analysis is used to detect and quantify the presence of sensory receptor protein in the sample. The technique generally comprises separating sample proteins by gel electrophoresis on the basis of molecular weight, transferring the separated proteins to a suitable solid support, (such as a nitrocellulose filter, a nylon filter, or derivatized nylon filter), and incubating the sample with the antibodies that specifically bind the sensory receptor protein. The anti-sensory receptor polypeptide antibodies specifically bind to the sensory receptor poly-peptide on the solid support. These antibodies may be directly labeled or alternatively may be subsequently detected using labeled antibodies (e.g., labeled sheep anti-mouse antibodies) that specifically bind to the anti-sensory receptor antibodies.

Other assay formats include liposome immunoassays (LIA) using liposomes designed to bind specific molecules (e.g., antibodies) and release encapsulated reagents or markers. The released chemicals are then detected according to standard techniques (see Monroe *et al.*, *Amer. Clin. Prod. Rev.*, 5:34, 1986).

e. Reduction of non-specific binding

One of skill in the art will appreciate that it is often desirable to minimize non-specific binding in immunoassays. Particularly, where the assay involves an antigen or antibody immobilized on a solid substrate it is desirable to minimize the amount of non-specific binding to the substrate. Means of reducing such non-specific binding are well known to those of skill in the art. Typically, this technique involves coating the substrate with a proteinaceous composition. In particular, protein

WO 01/98526

compositions such as bovine serum albumin (BSA), nonfat powdered milk, and gelatin are widely used with powdered milk being most preferred.

f. Labels

The particular label or detectable group used in the assay is not a critical aspect of the invention, as long as it does not significantly interfere with the specific binding of the antibody used in the assay. The detectable group can be any material having a detectable physical or chemical property. Such detectable labels have been well-developed in the field of immuno-assays and, in general, most any label useful in such methods can be applied to the present invention. Thus, a label is any composition 10 detectable by spectroscopic, photochemical, bio-chemical, immunochemical, electrical, optical or chemical means. Useful labels in the present invention include magnetic beads (e.g., DYNABEADS™, fluorescent dyes (e.g., fluorescein isothiocyanate, Texas red, rhodamine, and the like), radiolabels (e.g., <sup>3</sup>H, <sup>125</sup>I, <sup>35</sup>S, <sup>14</sup>C, or <sup>32</sup>P), enzymes (e.g., horseradish peroxidase, alkaline phosphatase and others 15 commonly used in an ELISA), and colorimetric labels such as colloidal gold or colored glass or plastic beads (e.g., polystyrene, polypropylene, latex, etc.).

The label may be coupled directly or indirectly to the desired component of the assay according to methods well known in the art. As indicated above, a wide variety of labels may be used, with the choice of label depending on sensitivity required, ease 20 of conjugation with the compound, stability requirements, available instrumentation, and disposal provisions.

Non-radioactive labels are often attached by indirect means. Generally, a ligand molecule (e.g., biotin) is covalently bound to the molecule. The ligand then binds to another molecules (e.g., streptavidin) molecule, which is either inherently 25 detectable or covalently bound to a signal system, such as a detectable enzyme, a fluorescent compound, or a chemiluminescent compound. The ligands and their targets can be used in any suitable combination with antibodies that recognize a sensory receptor protein, or secondary antibodies that recognize anti-sensory receptor.

The molecules can also be conjugated directly to signal generating 30 compounds, e.g., by conjugation with an enzyme or fluorophore. Enzymes of interest as labels will primarily be hydrolases, particularly phosphatases, esterases and glycosidases, or oxidases, particularly peroxidases. Fluorescent compounds include fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone,

etc. Chemiluminescent compounds include luciferin, and 2,3-dihydropthalazinediones, e.g., luminol. For a review of various labeling or signal producing systems that may be used, see U.S. Patent No. 4,391,904.

Methods for detecting labels are well known. Thus, for example, where the 5 label is a radioactive label, it may be detected using a scintillation counter or with photographic film as in autoradiography. Where the label is a fluorescent label, it may be detected by exciting the fluoro-chrome with the appropriate wavelength of light and detecting the resulting fluorescence. The fluorescence may be detected visually, with photographic film, or using electronic detectors such as charge coupled devices 10 (CCDs) or photomultipliers. Similarly, enzymatic labels may be detected by providing the appropriate substrates for the enzyme and detecting the resulting reaction product. Finally, simple colorimetric labels may be detected simply by observing the color associated with the label. Thus, in various dipstick assays, conjugated gold often appears pink, while various conjugated beads appear the color 15 of the bead.

Some assay formats do not require the use of labeled components. For instance, agglutination assays can be used to detect the presence of the target 20 antibodies. In this case, antigen-coated particles are agglutinated by samples comprising the target antibodies. In this format, none of the components need be labeled and the presence of the target antibody is detected by simple visual inspection.

#### E. Detection of Olfactory Modulators

Methods and compositions for determining whether a test compound 25 specifically binds to a mammalian sensory, and more particularly, olfactory receptor of the invention, both *in vitro* and *in vivo* are described below, as are methods and compositions for determining whether a test compound is neurotoxic to an olfactory neuron expressing an olfactory transmembrane receptor polypeptide. Any aspect of cell physiology can be monitored to assess the effect of sensant-binding to a naturally-occurring or chimeric olfactory receptor. These assays may be performed on intact 30 cells expressing an olfactory receptor, on permeabilized cells or on membrane fractions produced by standard methods.

Olfactory receptors are normally located on the specialized cilia of olfactory neurons. These receptors bind odorants and initiate the transduction of chemical

stimuli into electrical signals. An activated or inhibited G-protein will in turn alter the properties of target enzymes, channels, and other effector proteins. The classic examples are the activation of cGMP phosphodiesterase by transducin in the visual system, adenylate cyclase by the stimulatory G-protein, phospholipase C by Gq and other cognate G-proteins, and modulation of diverse channels by Gi and other G-proteins. Downstream consequences can also be examined such as generation of diacyl glycerol and IP<sub>3</sub> by phospholipase C, and in turn, for calcium mobilization by IP<sub>3</sub>.

The sensory receptor protein of the assay will typically be selected from a natural poly-peptide or conservatively modified variant thereof. Generally, the amino acid sequence identity will be at least 75%, 85%, 90%, 95%, or 99%. Optionally, the polypeptide of the assays can comprise a domain of a sensory receptor protein, such as an extracellular domain, transmembrane region, transmembrane domain, cytoplasmic domain, ligand binding domain, subunit association domain, active site, and the like.

Either the sensory receptor protein or a domain thereof can be covalently linked to a heterologous protein to create a chimeric protein used in the assays described herein.

Modulators of sensory receptor activity can be tested using sensory receptor polypeptides as described above, either recombinant or naturally occurring. Protein can be isolated, expressed in a cell, expressed in a membrane derived from a cell, expressed in tissue or in an animal, either recombinant or naturally occurring.

Modulation can be tested using one of the *in vitro* or *in vivo* assays described herein.

#### 1. *In vitro* binding assays

Sensory perception can also be examined *in vitro* with soluble or solid state reactions, using a full-length sensory receptor-GPCR or a chimeric molecule such as an extracellular domain or transmembrane region, or combination thereof, of a sensory receptor covalently linked to a heterologous signal transduction domain, or a heterologous extracellular domain and/or transmembrane region covalently linked to the transmembrane and/or cytoplasmic domain of a sensory receptor. Furthermore, ligand-binding domains of the protein of interest can be used *in vitro* in soluble or solid state reactions to assay for ligand binding. In numerous embodiments, a chimeric receptor will be made that comprises all or part of a sensory receptor polypeptide, as well an additional sequence that facilitates the localization of the

sensory receptor to the membrane, such as a rhodopsin, *e.g.*, an N-terminal fragment of a rhodopsin protein.

Ligand binding to a sensory receptor protein, a domain, or chimeric protein can be tested in solution, in a bilayer membrane, attached to a solid phase, in a lipid monolayer, or in vesicles. Binding of a modulator can be tested using, *e.g.*, changes in spectroscopic characteristics (*e.g.*, fluorescence, absorbence, refractive index) hydrodynamic (*e.g.*, shape), chromatographic, or solubility properties. Sensory receptors with large (*e.g.*, approximately 600 amino acid residues) extracellular N-terminal segments. These N-terminal segments are thought to form ligand-binding domains, and are therefore useful in biochemical assays to identify sensory receptor agonists and antagonists. Similar assays have been used with other GPCRs, such as the metabo-tropic glutamate receptors (*e.g.*, Han & Hampson, *J. Biol. Chem.* 274:10008, 1999). These assays might involve displacing a radioactively or fluorescently labeled ligand, and measuring changes in intrinsic fluorescence or changes in proteolytic susceptibility, *etc.*

Receptor-G-protein interactions can also be examined. For example, binding of the G-protein to the receptor or its release from the receptor can be examined. For example, in the absence of GTP, an activator will lead to the formation of a tight complex of a G protein (all three subunits) with the receptor. This complex can be detected in a variety of ways, as noted above. Such an assay can be modified to search for inhibitors, *e.g.*, by adding an activator to the receptor and G protein in the absence of GTP, which form a tight complex, and then screen for inhibitors by looking at dissociation of the receptor-G protein complex. In the presence of GTP, release of the alpha subunit of the G protein from the other two G protein subunits serves as a criterion of activation.

An activated or inhibited G-protein will in turn alter the properties of target enzymes, channels, and other effector proteins. The classic examples are the activation of cGMP phosphodiesterase by transducin in the visual system, adenylate cyclase by the stimulatory G-protein, phospholipase C by Gq and other cognate G proteins, and modulation of diverse channels by Gi and other G proteins. Downstream consequences can also be examined such as generation of diacyl glycerol and IP3 by phospholipase C, and in turn, for calcium mobilization by IP3.

2. Fluorescence Polarization Assays

In another embodiment, Fluorescence Polarization ("FP") based assays may be used to detect and monitor sensant binding. Fluorescence polarization is a versatile laboratory technique for measuring equilibrium binding, nucleic acid hybridization, and enzymatic activity. Fluorescence polarization assays are homogeneous in that they do not require a separation step such as centrifugation, filtration, chromatography, precipitation, or electrophoresis. These assays are done in real time, directly in solution and do not require an immobilized phase. Polarization values can be measured repeatedly and after the addition of reagents since measuring the polarization is rapid and does not destroy the sample. Generally, this technique can be used to measure polarization values of fluorophores from low picomolar to micromolar levels. This section describes how fluorescence polarization can be used in a simple and quantitative way to measure the binding of odorants to the sensory receptors of the invention.

15 When a fluorescently labeled molecule is excited with plane polarized light, it emits light that has a degree of polarization that is inversely proportional to its molecular rotation. Large fluorescently labeled molecules remain relatively stationary during the excited state (4 nano-seconds in the case of fluorescein) and the polarization of the light remains relatively constant between excitation and emission. 20 Small fluorescently labeled molecules rotate rapidly during the excited state and the polarization changes significantly between excitation and emission. Therefore, small molecules have low polarization values and large molecules have high polarization values. For example, a single-stranded fluorescein-labeled oligonucleotide has a relatively low polarization value but when it is hybridized to a complementary strand, 25 it has a higher polarization value. When using FP to detect and monitor odorant binding which may activate or inhibit the sensory receptors of the invention, fluorescence-labeled sensants or auto-fluorescent sensants may be used.

Fluorescence polarization (P) is defined as:

$$P = \frac{Int_{\parallel} - Int_{\perp}}{Int_{\parallel} + Int_{\perp}}$$

30 Where  $\parallel$  is the intensity of the emission light parallel to the excitation light plane and  $Int_{\perp}$  is the intensity of the emission light perpendicular to the excitation light plane. P, being a ratio of light intensities, is a dimensionless number. For

example, the Beacon® and Beacon 2000™ System may be used in connection with these assays. Such systems typically express polarization in millipolarization units (1 Polarization Unit =1000 mP Units).

The relationship between molecular rotation and size is described by the Perrin equation and the reader is referred to Jolley *J. Anal. Toxicol.* 5, 236, 1981 which gives a thorough explanation of this equation. Summarily, the Perrin equation states that polarization is directly proportional to the rotational relaxation time, the time that it takes a molecule to rotate through an angle of approximately 68.5°. Rotational relaxation time is related to viscosity ( $\eta$ ), absolute temperature (T), molecular volume (V), and the gas constant (R) by the following equation:

$$\text{Rotational Relaxation Time} = \frac{3\eta V}{RT}$$

The rotational relaxation time is small ( $\approx$  1 nanosecond) for small molecules (e.g., fluorescein) and large ( $\approx$  100 nanoseconds) for large molecules (e.g., immunoglobulins). If viscosity and temperature are held constant, rotational relaxation time, and therefore polarization, is directly related to the molecular volume. Changes in molecular volume may be due to interactions with other molecules, dissociation, polymerization, degradation, hybridization, or conformational changes of the fluorescently labeled molecule. For example, fluorescence polarization has been used to measure enzymatic cleavage of large fluorescein labeled polymers by proteases, DNases, and RNases. It also has been used to measure equilibrium binding for protein/protein interactions, antibody/antigen binding, and protein/DNA binding.

### 3. Soluble and solid state high throughput assays

In yet another embodiment, the invention provides soluble assays using molecules such as a domain such as ligand binding domain, an extracellular domain, a transmembrane domain (e.g., one comprising seven transmembrane regions and cytosolic loops), the transmembrane domain and a cytoplasmic domain, an active site, a subunit association region, etc.; a domain that is covalently linked to a heterologous protein to create a chimeric molecule; a sensory receptor protein; or a cell or tissue expressing a sensory receptor protein, either naturally occurring or recombinant. In another embodiment, the invention provides solid phase based *in vitro* assays in a high throughput format, where the domain, chimeric molecule, sensory receptor protein, or cell or tissue expressing the sensory receptor is attached to a solid phase substrate.

In the high throughput assays of the invention, it is possible to screen up to several thousand different modulators or ligands in a single day. In particular, each well of a microtiter plate can be used to run a separate assay against a selected potential modulator, or, if concentration or incubation time effects are to be observed, 5 every 5-10 wells can test a single modulator. Thus, a single standard microtiter plate can assay about 100 (e.g., 96) modulators. If 1536 well plates are used, then a single plate can easily assay from about 1000 to about 1500 different compounds. It is possible to assay several different plates per day; assay screens for up to about 10 6,000-20,000 different compounds is possible using the integrated systems of the invention. More recently, microfluidic approaches to reagent manipulation have been developed.

The molecule of interest can be bound to the solid state component, directly or indirectly, via covalent or non covalent linkage, e.g., via a tag. The tag can be any of a variety of components. In general, a molecule which binds the tag (a tag binder) is 15 fixed to a solid support, and the tagged molecule of interest (e.g., the taste transduction molecule of interest) is attached to the solid support by interaction of the tag and the tag binder.

A number of tags and tag binders can be used, based upon known molecular 20 interactions well described in the literature. For example, where a tag has a natural binder, for example, biotin, protein A, or protein G, it can be used in conjunction with appropriate tag binders (avidin, streptavidin, neutravidin, the Fc region of an immunoglobulin, etc.). Antibodies to molecules with natural binders such as biotin are also widely available and appropriate tag binders (see, SIGMA Immunochemicals 1998 catalogue SIGMA, St. Louis MO).

25 Similarly, any haptenic or antigenic compound can be used in combination with an appropriate antibody to form a tag/tag binder pair. Thousands of specific antibodies are commercially available and many additional antibodies are described in the literature. For example, in one common configuration, the tag is a first antibody and the tag binder is a second antibody which recognizes the first antibody. In addition to antibody-antigen interactions, receptor-ligand interactions are also 30 appropriate as tag and tag-binder pairs. For example, agonists and antagonists of cell membrane receptors (e.g., cell receptor-ligand interactions such as transferrin, c-kit, viral receptor ligands, cytokine receptors, chemokine receptors, interleukin receptors,

describing arrays of biopolymers fixed to solid substrates). Non-chemical approaches for fixing tag binders to substrates include other common methods, such as heat, cross-linking by UV radiation, and the like.

4. Computer-based assays

5 Yet another assay for compounds that modulate sensory receptor protein activity involves computer assisted drug design, in which a digital or analog processing system is used to generate a three-dimensional structure of a sensory receptor protein based on the structural information encoded by its amino acid sequence. The input amino acid sequence interacts directly and actively with a 10 preestablished algorithm in a computer program to yield secondary, tertiary, and quaternary structural models of the protein. The models of the protein structure are then examined to identify regions of the structure that have the ability to bind, *e.g.*, ligands. These regions are then used to identify ligands that bind to the protein.

15 The three-dimensional structural model of the protein is generated by entering protein amino acid sequences of at least 10 amino acid residues or corresponding nucleic acid sequences encoding a sensory receptor polypeptide into the computer system. The nucleotide sequence encoding the polypeptide, or the amino acid sequence thereof, can be any of those described herein, or fragments or variants thereof.

20 The amino acid sequence represents the primary sequence or subsequence of the protein, which encodes the structural information of the protein. At least 10 residues of the amino acid sequence (or a nucleotide sequence encoding 10 amino acids) are entered into the computer system from computer keyboards, computer readable substrates that include, but are not limited to, electronic storage media (*e.g.*, 25 magnetic diskettes, tapes, cartridges, and chips), optical media (*e.g.*, CD ROM), information distributed by internet sites, and by RAM. The three-dimensional structural model of the protein is then generated by the interaction of the amino acid sequence and the computer system, using software known to those of skill in the art.

30 The amino acid sequence represents a primary structure that encodes the information necessary to form the secondary, tertiary and quaternary structure of the protein of interest. The software looks at certain parameters encoded by the primary sequence to generate the structural model. These parameters are referred to as "energy terms," and primarily include electrostatic potentials, hydrophobic potentials, solvent

accessible surfaces, and hydrogen bonding. Secondary energy terms include van der Waals potentials. Biological molecules form the structures that minimize the energy terms in a cumulative fashion. The computer program is therefore using these terms encoded by the primary structure or amino acid sequence to create the secondary structural model.

5 The tertiary structure of the protein encoded by the secondary structure is then

formed on the basis of the energy terms of the secondary structure. The user at this point can enter additional variables such as whether the protein is membrane bound or soluble, its location in the body, and its cellular location, e.g., cytoplasmic, surface, 10 or nuclear. These variables along with the energy terms of the secondary structure are used to form the model of the tertiary structure. In modeling the tertiary structure, the computer program matches hydrophobic faces of secondary structure with like, and hydrophilic faces of secondary structure with like.

Once the structure has been generated, potential ligand binding regions are 15 identified by the computer system. Three-dimensional structures for potential ligands are generated by entering amino acid or nucleotide sequences or chemical formulas of compounds, as described above. The three-dimensional structure of the potential ligand is then compared to that of the sensory receptor protein to identify ligands that bind to the protein. Binding affinity between the protein and ligands is determined 20 using energy terms to determine which ligands have an enhanced probability of binding to the protein.

Computer systems are also used to screen for mutations, polymorphic variants, alleles and interspecies homologs of sensory receptor genes. Such mutations can be 25 associated with disease states or genetic traits. As described above, GeneChip™ and related technology can also be used to screen for mutations, polymorphic variants, alleles and interspecies homologs. Once the variants are identified, diagnostic assays can be used to identify patients having such mutated genes. Identification of the mutated sensory receptor genes involves receiving input of a first nucleic acid or amino acid sequence of a sensory receptor gene, or conservatively modified versions 30 thereof. The sequence is entered into the computer system as described above. The first nucleic acid or amino acid sequence is then compared to a second nucleic acid or amino acid sequence that has substantial identity to the first sequence. The second sequence is entered into the computer system in the manner described above. Once

odorant dependent activation monitored. Control samples (untreated with activators or inhibitors) are assigned a relative sensory receptor activity value of 100. Inhibition of a sensory receptor protein is achieved when the sensory receptor activity value relative to the control is about 90%, optionally 50%, optionally 25-0%. Activation of 5 a sensory receptor protein is achieved when the sensory receptor activity value relative to the control is 110%, optionally 150%, 200-500%, or 1000-2000%.

Changes in ion flux may be assessed by determining changes in polarization (*i.e.*, electrical potential) of the cell or membrane expressing a sensory receptor protein. One means to determine changes in cellular polarization is by measuring 10 changes in current, and thereby measuring changes in polarization, with voltage-clamp and patch-clamp techniques, *e.g.*, the “cell-attached” mode, the “inside-out” mode, and the “whole cell” mode (*see, e.g.*, Ackerman *et al.*, *New Engl. J Med.*, 336:1575, 1997). Whole cell currents are conveniently determined using the standard. Other known assays include: assays to measure ion flux using radiolabeled or fluorescent 15 probes such as voltage-sensitive dyes (*see, e.g.*, Vestergaard-Bogind *et al.*, *J. Membrane Biol.*, 88:67, 1988; Gonzales & Tsien, *Chem. Biol.*, 4:269, 1997; Daniel *et al.*, *J. Pharmacol. Meth.*, 25:185, 1991; Holevinsky *et al.*, *J. Membrane Biology*, 137:59, 1994). Generally, the compounds to be tested are present in the range from 1 pM to 100 mM.

20 The effects of the test compounds upon the function of the polypeptides can be measured by examining any of the parameters described above. Any suitable physiological change that affects GPCR activity can be used to assess the influence of a test compound on the polypeptides of this invention. When the functional consequences are determined using intact cells or animals, one can also measure a 25 variety of effects such as transmitter release, hormone release, transcriptional changes to both known and uncharacterized genetic markers (*e.g.*, Northern blots), changes in cell metabolism such as cell growth or pH changes, and changes in intracellular second messengers such as  $\text{Ca}^{2+}$ , IP3, cGMP, or cAMP.

Preferred assays for G-protein coupled receptors include cells that are loaded 30 with ion or voltage sensitive dyes to report receptor activity. Assays for determining activity of such receptors can also use known agonists and antagonists for other G-protein coupled receptors as negative or positive controls to assess activity of tested compounds. In assays for identifying modulatory compounds (*e.g.*, agonists,

WO 01/98526

antagonists), changes in the level of ions in the cytoplasm or membrane voltage will be monitored using an ion sensitive or membrane voltage fluorescent indicator, respectively. Among the ion-sensitive indicators and voltage probes that may be employed are those disclosed in the Molecular Probes 1997 Catalog. For G-protein coupled receptors, promiscuous G-proteins such as G $\alpha$ 15 and G $\alpha$ 16 can be used in the assay of choice (Wilkie *et al.*, *Proc. Natl. Acad. Sci.*, 88:10049, 1991). Such promiscuous G-proteins allow coupling of a wide range of receptors.

5 Receptor activation typically initiates subsequent intracellular events, e.g., increases in second messengers such as IP<sub>3</sub>, which releases intracellular stores of 10 calcium ions. Activation of some G-protein coupled receptors stimulates the formation of inositol triphosphate (IP<sub>3</sub>) through phospholipase C-mediated hydrolysis of phosphatidylinositol (Berridge & Irvine, *Nature* 312:315, 1984). IP<sub>3</sub> in turn stimulates the release of intracellular calcium ion stores. Thus, a change in 15 cytoplasmic calcium ion levels, or a change in second messenger levels such as IP<sub>3</sub> can be used to assess G-protein coupled receptor function. Cells expressing such G-protein coupled receptors may exhibit increased cytoplasmic calcium levels as a 20 result of contribution from both intracellular stores and via activation of ion channels, in which case it may be desirable although not necessary to conduct such assays in calcium-free buffer, optionally supplemented with a chelating agent such as EGTA, to distinguish fluorescence response resulting from calcium release from internal stores.

Other assays can involve determining the activity of receptors which, when activated, result in a change in the level of intracellular cyclic nucleotides, e.g., cAMP or cGMP, by activating or inhibiting enzymes such as adenylate cyclase. There are 25 cyclic nucleotide-gated ion channels, e.g., rod photoreceptor cell channels and olfactory neuron channels that are permeable to cations upon activation by binding of cAMP or cGMP (see, e.g., Altenhofen *et al.*, *Proc. Natl. Acad. Sci.*, 88:9868, 1991 and Dhallan *et al.*, *Nature* 347:184, 1990). In cases where activation of the receptor results in a decrease in cyclic nucleotide levels, it may be preferable to expose the 30 cells to agents that increase intracellular cyclic nucleotide levels, e.g., forskolin, prior to adding a receptor-activating compound to the cells in the assay. Cells for this type of assay can be made by co-transfection of a host cell with DNA encoding a cyclic nucleotide-crated ion channel, GPCR phosphatase and DNA encoding a receptor (e.g., certain glutamate receptors, muscarinic acetylcholine receptors, dopamine receptors,

serotonin receptors, and the like), which, when activated, causes a change in cyclic nucleotide levels in the cytoplasm.

In a preferred embodiment, sensory receptor protein activity is measured by expressing a sensory receptor gene in a heterologous cell with a promiscuous 5 G-protein that links the receptor to a phospholipase C signal transduction pathway (see Offermanns & Simon, *J. Biol. Chem.*, 270:15175, 1995). Optionally the cell line is HEK-293 (which does not naturally express sensory receptor genes) and the promiscuous G-protein is Gal 5 (Offermanns & Simon, *supra*). Modulation of 10 olfactory transduction is assayed by measuring changes in intracellular  $\text{Ca}^{2+}$  levels, which change in response to modulation of the sensory receptor signal transduction pathway via administration of a molecule that associates with a sensory receptor 15 protein. Changes in  $\text{Ca}^{2+}$  levels are optionally measured using fluorescent  $\text{Ca}^{2+}$  indicator dyes and fluorometric imaging.

In one embodiment, the changes in intracellular cAMP or cGMP can be 15 measured using immunoassays. The method described in Offermanns & Simon, *J. Biol. Chem.*, 270:15175, 1995, may be used to determine the level of cAMP. Also, the method described in Felley-Bosco *et al.*, *Am. J. Resp. Cell and Mol. Biol.*, 11:159, 1994, may be used to determine the level of cGMP. Further, an assay kit for 20 measuring cAMP and/or cGMP is described in U.S. Patent No. 4,115,538, herein incorporated by reference.

In another embodiment, phosphatidyl inositol (PI) hydrolysis can be analyzed according to U.S. Patent No. 5,436,128, herein incorporated by reference. Briefly, the assay involves labeling of cells with  $^3\text{H}$ -myoinositol for 48 or more hrs. The labeled cells are treated with a test compound for one hour. The treated cells are lysed and 25 extracted in chloroform-methanol-water after which the inositol phosphates were separated by ion exchange chromatography and quantified by scintillation counting. Fold stimulation is determined by calculating the ratio of cpm in the presence of agonist, to cpm in the presence of buffer control. Likewise, fold inhibition is determined by calculating the ratio of cpm in the presence of antagonist, to cpm in the 30 presence of buffer control (which may or may not contain an agonist).

In another embodiment, transcription levels can be measured to assess the effects of a test compound on signal transduction. A host cell containing a sensory receptor protein of interest is contacted with a test compound for a sufficient time to

WO 01/98526

effect any interactions, and then the level of gene expression is measured. The amount of time to effect such interactions may be empirically determined, such as by running a time course and measuring the level of transcription as a function of time. The amount of transcription may be measured by using any method known to those of skill in the art to be suitable. For example, mRNA expression of the protein of interest may be detected using northern blots or their polypeptide products may be identified using immunoassays. Alternatively, transcription based assays using reporter gene may be used as described in U.S. Patent No. 5,436,128, herein incorporated by reference. The reporter genes can be, e.g., chloramphenicol acetyltransferase, luciferase, '3-galactosidase and alkaline phosphatase. Furthermore, the protein of interest can be used as an indirect reporter via attachment to a second reporter such as green fluorescent protein (see, e.g., Mistili & Spector, *Nature Biotech.* 15:961, 1997).

15 The amount of transcription is then compared to the amount of transcription in either the same cell in the absence of the test compound, or it may be compared with the amount of transcription in a substantially identical cell that lacks the sensory receptor protein of interest. A substantially identical cell may be derived from the same cells from which the recombinant cell was prepared but which had not been modified by introduction of heterologous DNA. Any difference in the amount of transcription indicates that the test compound has in some manner altered the activity 20 of the sensory receptor protein of interest.

#### 6. Transgenic non-human animals expressing sensory receptors

Non-human animals expressing one or more sensory receptor sequences of the invention, particularly human olfactory receptor sequences, can also be used for receptor assays. Such expression can be used to determine whether a test compound 25 specifically binds to a mammalian olfactory transmembrane receptor polypeptide *in vivo* by contacting a non-human animal stably or transiently transfected with a nucleic acid encoding an olfactory receptor or ligand binding region thereof with a test compound and determining whether the animal reacts to the test compound by 30 specifically binding to the receptor polypeptide.

Use of translocation domains in the fusion polypeptides generates a cell expressing high levels of olfactory receptor. Animals transfected or infected with the vectors of the invention are particularly useful for assays to identify and characterize

odorants/ligands that can bind to a specific or sets of receptors. Such vector-infected animals expressing libraries of human olfactory sequences can be used for *in vivo* screening of odorants and their effect on, *e.g.*, cell physiology (*e.g.*, on olfactory neurons), on the CNS (*e.g.*, olfactory bulb activity), or behavior.

5 Means to infect/express the nucleic acids and vectors, either individually or as libraries, are well known in the art. A variety of individual cell, organ or whole animal parameters can be measured by a variety of means. For example, recording of stimulant-induced waves (bulbar responses) from the main olfactory bulb or accessory olfactory bulb is a useful tool for measuring quantitative stable olfactory responses.

10 When electrodes are located on the olfactory bulb surface it is possible to record stable responses over a period of several days (*see, e.g.*, Kashiwayanagi, *Brain Res. Protoc.* 1:287, 1997). In this study, electroolfactogram recordings were made with a four-electrode assembly from the olfactory epithelium overlying the endoturbinate bones facing the nasal septum. Four electrodes were fixed along the dorsal-to-ventral axis of

15 one turbinate bone or were placed in corresponding positions on four turbinate bones and moved together up toward the top of the bone. *See also*, Scott, *J. Neurophysiol.* 77:1950, 1997; Scott, *J. Neuro-physiol.* 75:2036, 1996; Ezeh, *J. Neurophysiol.* 73:2207, 1995. In other systems, fluorescence changes in nasal epithelium can be measured using the dye di-4-ANEPPS, which is applied on the rat's nasal septum and

20 medial surface of the turbinates (*see, e.g.*, Youngentob, *J. Neuro-physiol.* 73:387, 1995). Extracellular potassium activity (aK) measurements can also be carried out in *in vivo*. An increase in aK can be measured in the mucus and the proximal part of the nasal epithelium (*see, e.g.*, Khayari, *Brain Res.* 539:1, 1991).

The sensory receptor sequences of the invention can be for example expressed in animal nasal epithelium by delivery with an infecting agent, *e.g.*, adenovirus expression vector. Recombinant adenovirus-mediated expression of a recombinant gene in olfactory epithelium using green fluorescent protein as a marker is described by, *e.g.*, Touhara, *Proc. Natl. Acad. Sci. USA* 96:4040, 1999.

The endogenous olfactory receptor genes can remain functional and wild-type (native) activity can still be present. In other situations, where it is desirable that all olfactory receptor activity is by the introduced exogenous hybrid receptor, use of a knockout line is preferred. Methods for the construction of non-human transgenic

WO 01/98526

animals, particularly transgenic mice, and the selection and preparation of recombinant constructs for generating transformed cells are well known in the art. Construction of a "knockout" cell and animal is based on the premise that the level of expression of a particular gene in a mammalian cell can be decreased or completely abrogated by introducing into the genome a new DNA sequence that serves to interrupt some portion of the DNA sequence of the gene to be suppressed. Also, "gene trap insertion" can be used to disrupt a host gene, and mouse embryonic stem (ES) cells can be used to produce knockout transgenic animals (see, e.g., Holzschu, *Transgenic Res* 6:97, 1997). The insertion of the exogenous is typically by 5 homologous recombination between complementary nucleic acid sequences. The exogenous sequence is some portion of the target gene to be modified, such as exonic, 10 intronic or transcriptional regulatory sequences, or any genomic sequence which is able to affect the level of the target gene's expression; or a combination thereof. Gene targeting via homologous recombination in pluripotential embryonic stem (ES) cells 15 allows one to modify precisely the genomic sequence of interest. Any technique can be used to create, screen for, propagate, a knockout animal, e.g., see Bijvoet, *Hum. Mol. Genet.* 7:53, 1998); Moreadith, *J. Mol. Med.* 75:208, 1997; Tojo, *Cytotechnology* 19:161, 1995; Mudgett, *Methods Mol. Biol.* 48:167, 1995; Longo, *Transgenic Res.* 6:321, 1997; U.S. Patents Nos. 5,616,491; 5,464,764; 5,631,153; 5,487,992; 20 5,627,059; 5,272,071; WO 91/09955; WO93/09222; WO 96/29411; WO 95/31560; WO 91/12650.

The nucleic acid libraries can also be used as reagents to produce "knockout" human cells and their progeny.

F. Modulators

25 The compounds tested as modulators of a sensory receptor family member can be any small chemical compound, or a biological entity, such as a protein, sugar, nucleic acid or lipid. Alternatively, modulators can be genetically altered versions of a sensory receptor gene. Typically, test compounds will be small chemical molecules and peptides. Essentially any chemical compound can be used as a potential 30 modulator or ligand in the assays of the invention, although most often compounds-can be dissolved in aqueous or organic (especially DMSO-based) solutions are used. The assays are designed to screen large chemical libraries by

automating the assay steps and providing compounds from any convenient source to assays, which are typically run in parallel (e.g., in microtiter formats on microtiter plates in robotic assays). It will be appreciated that there are many suppliers of chemical compounds, including Sigma (St. Louis, MO), Aldrich (St. Louis, MO),  
5 Sigma-Aldrich (St. Louis, MO), Fluka Chemika-Biochemica Analytika (Buchs, Switzerland) and the like.

In one preferred embodiment, high throughput screening methods involve providing a combinatorial chemical or peptide library containing a large number of potential therapeutic compounds (potential modulator or ligand compounds). Such  
10 10 “combinatorial chemical libraries” or “ligand libraries” are then screened in one or more assays, as described herein, to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity. The compounds thus identified can serve as conventional “lead compounds” or can themselves be used as potential or actual therapeutics.

15 A combinatorial chemical library is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis, by combining a number of chemical “building blocks” such as reagents. For example, a linear combinatorial chemical library such as a polypeptide library is formed by combining a set of chemical building blocks (amino acids) in every possible way for a  
20 20 given compound length (i.e., the number of amino acids in a polypeptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing of chemical building blocks.

Preparation and screening of combinatorial chemical libraries is well known to those of skill in the art. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (see, e.g., U.S. Patent No. 5,010,175; Furka, *Int. J. Pept. Prot. Res.* 37:487, 1991; and Houghton *et al.*, *Nature* 354:84, 1991). Other chemistries for generating chemical diversity libraries can also be used. Such chemistries include, but are not limited to: peptoids (e.g., WO 91/19735), encoded peptides (e.g., WO 93/20242), random bio-oligomers (e.g., WO 92/00091),  
25 25 benzodiazepines (e.g., U.S. Patent No. 5,288,514), diversomers such as hydantoins, benzodiazepines and dipeptides (Hobbs *et al.*, *Proc. Nat. Acad. Sci.* 90:6909, 1993), vinylogous polypeptides (Hagihara *et al.*, *J. Amer. Chem. Soc.* 114:6568, 1992), nonpeptidal peptidomimetics with glucose scaffolding (Hirschmann *et al.*, *J. Amer.*

WO 01/98526

Moreover, a method is provided for simulating a fragrance or flavor sensed by a mammal (e.g., human), comprising: for each of a plurality of sensory receptors, or fragments or variants thereof, ascertaining the extent to which the sensory receptor interacts with the fragrance and/or flavor; and combining a plurality of compounds, 5 each having a previously-determined interaction with one or more of the sensory receptors, in amounts that together provide a stimulation profile that mimics the profile for the fragrance and/or flavor. Interaction of a fragrance and/or flavor with a sensory receptor can be determined using any of the binding or reporter assays described herein. The interactions can be aggregated or a profile generated using known signal processing techniques (e.g., a neural network) as described below. The 10 sensory receptor, or fragments or variants thereof (e.g., fusion proteins with reporters, chimeric proteins) may be expressed in cells; otherwise, ligand-binding domain(s) may be fixed to a substrate (e.g., planar, bead, or fiber) that is solid or porous. The plurality of compounds may then be combined to form a mixture. If desired, one or 15 more of the plurality of the compounds can be combined covalently. The combined compounds substantially stimulate at least 50%, 60%, 70%, 75%, 80%, 90%, 95%, 99% or all of the receptors that are substantially stimulated by the fragrance or flavor.

In yet another aspect of the invention, a method is provided in which a plurality of standard compounds are tested against a plurality of sensory receptors, or fragments or variants thereof, to ascertain the extent to which the sensory receptors each interact with each standard compound, thereby generating a receptor stimulation profile for each standard compound. These receptor stimulation profiles may then be stored in a relational database on data storage medium. The method may further comprise providing a desired receptor-stimulation profile for an odor and/or taste; 20 comparing the desired receptor stimulation profile to the relational database; and ascertaining one or more combinations of standard compounds that most closely 25 match the desired receptor-stimulation profile. The method may further comprise combining standard compounds in one or more of the ascertained combinations to simulate the odor and/or taste.

A further aspect of the invention is to provide a method for representing sensory perception of a particular odor and/or taste in a mammal (e.g., human), comprising: providing values  $X_1$  to  $X_n$  representative of the quantitative stimulation of each of  $n$  sensory receptors of the mammal; where  $n$  is greater than or equal to 5,  $n$  is 30

greater than or equal to 10,  $n$  is greater than or equal to 20,  $n$  is greater than or equal to 50,  $n$  is greater than or equal to 75,  $n$  is greater than or equal to 100,  $n$  is greater than or equal to 125,  $n$  is greater than or equal to 150,  $n$  is greater than or equal to 175,  $n$  is greater than or equal to 200,  $n$  is greater than or equal to 225,  $n$  is greater than or equal to 250,  $n$  is greater than or equal to 275,  $n$  is greater than or equal to 300,  $n$  is greater than or equal to 325, or  $n$  is greater than or equal to 350; and generating from the values a quantitative representation of sensory perception. The sensory receptors may be a receptor disclosed herein, or fragments or variants thereof. The representation may constitute a point or a volume in  $n$ -dimensional space, may constitute a graph or a spectrum, or may constitute a matrix of quantitative representations. Also, the providing step may comprise contacting a plurality of recombinantly-produced sensory receptors, or fragments or variants thereof, with a composition and quantitatively measuring the interaction of the composition with the receptors. The maximum number of taste receptors that are needed to mimic the native repertoire (e.g., about 50) may be less than the maximum number of olfactory receptors that are needed (e.g., about 350). But the number of sensory receptors that need to be represented in an assay to provide useful results may be much less.

It is yet another aspect of the invention to provide a method for predicting the sensory perception in a mammal (e.g., human) generated by one or more molecules or combinations of molecules yielding unknown olfactory perception in the mammal, comprising: providing values  $X_1$  to  $X_n$  representative of the quantitative stimulation of each of  $n$  sensory receptors of the mammal; where  $n$  is greater than or equal to 5,  $n$  is greater than or equal to 10,  $n$  is greater than or equal to 20,  $n$  is greater than or equal to 50,  $n$  is greater than or equal to 75,  $n$  is greater than or equal to 100,  $n$  is greater than or equal to 125,  $n$  is greater than or equal to 150,  $n$  is greater than or equal to 175,  $n$  is greater than or equal to 200,  $n$  is greater than or equal to 225,  $n$  is greater than or equal to 250,  $n$  is greater than or equal to 275,  $n$  is greater than or equal to 300,  $n$  is greater than or equal to 325, or  $n$  is greater than or equal to 350; for one or more molecules or combinations of molecules yielding known sensory perception in a mammal; and generating from the values a quantitative representation of sensory perception in a mammal for the one or more molecules or combinations of molecules yielding known sensory perception in a mammal, providing values  $X_1$  to  $X_n$  representative of the quantitative stimulation of each of  $n$  sensory receptors of the mammal; where  $n$  is

WO 01/98526

greater than or equal to 5,  $n$  is greater than or equal to 10,  $n$  is greater than or equal to 20,  $n$  is greater than or equal to 50,  $n$  is greater than or equal to 75,  $n$  is greater than or equal to 100,  $n$  is greater than or equal to 125,  $n$  is greater than or equal to 150,  $n$  is greater than or equal to 175,  $n$  is greater than or equal to 200,  $n$  is greater than or equal to 225,  $n$  is greater than or equal to 250,  $n$  is greater than or equal to 275,  $n$  is greater than or equal to 300,  $n$  is greater than or equal to 325, or  $n$  is greater than or equal to 350; for one or more molecules or combinations of molecules yielding unknown sensory perception in a mammal; and generating from the values a quantitative representation of sensory perception in a mammal for the one or more molecules or combinations of molecules yielding unknown sensory perception in a mammal generated by one or more molecules or combinations of molecules yielding unknown sensory perception in a mammal, and predicting the olfactory perception in a mammal generated by one or more molecules or combinations of molecules yielding unknown sensory perception in a mammal by comparing the quantitative representation of sensory perception in a mammal for the one or more molecules or combinations of molecules yielding unknown sensory perception in a mammal to the quantitative representation of sensory perception in a mammal for the one or more molecules or combinations of molecules yielding known sensory perception in a mammal. The sensory receptors used in this method may include a receptor disclosed herein, or fragment or variant thereof. The maximum number of taste receptors that are needed to mimic the native repertoire (e.g., about 50) may be less than the maximum number of olfactory receptors that are needed (e.g., about 350). But the number of sensory receptors that need to be represented in an assay to provide useful results may be much less.

Assaying for ligand-receptor binding in a large set of sensory receptors is envisioned to mimic the function of the nose or tongue in sensory perception of chemical sensants. For a set of sensory receptors with a redundancy of ligand-binding domains, the resultant signal is a summation of the interactions of all sensory receptors in the set: none, one, or a few of which have ligand-binding domains that are a perfect fit for the sensant; some of which have ligand-binding domains that are only an imperfect fit for the sensant; and most of which do not significantly bind to the sensant. The individual sensory receptor's binding affinity for sensant varies accordingly. Thus, a suitably large set of ligand-binding domains from sensory receptors will be analogous to any ability of the native repertoire of olfactory or taste receptors to tolerate varying degrees of mismatch between ligand and ligand-binding domain.

The complication of desensitization of sensory receptor signaling will also be avoided by using the invention instead of preparations of nasal or tongue epithelium containing native sensory receptors. For example, the event of binding between ligand and receptor can be separated from more complicated downstream signaling events in the epithelial cells. But the latter events can be reconstituted in the invention by transferring the sensory receptor of interest into appropriate host cells containing an intact and functional signaling pathway.

#### H. Administration of Novel Sensant Compositions

Sensory modulators can be administered directly to a mammal (e.g., human) for modulation of sensory perception *in vivo*. Administration is by any of the routes normally used for introducing a modulator compound into ultimate contact with the tissue to be treated (e.g., nose or tongue). The olfactory modulators are administered in any suitable manner, optionally with acceptable carriers. Suitable methods of administering such modulators are available and well known to those of skill in the art, and, although more than one route can be used to administer a particular composition, a particular route can often provide a more immediate and more effective reaction than another route. Acceptable carriers are determined at least in part by the particular components of the composition to be administered (e.g., stabilizing the sensants), as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions of the present invention (see, e.g., *Remington's Pharmaceutical Sciences*, 17th ed. 1985).

The sensory modulators, alone or in combination with other suitable components, can be made into aerosol formulations (i.e., they can be "nebulized") to be administered via inhalation. Aerosol formulations can be placed into pressurized acceptable propellants, such as dichloro-difluoromethane, propane, nitrogen, and the like that may or may not contribute to sensory perception. Other possible formulation include dry or liquid forms, powders or tablets, solutions of polar (e.g., water) or nonpolar (e.g., alcohol) solvents, emulsions or suspensions, creams, gels, lotions, and syrups.

Formulations suitable for administration include aqueous and non-aqueous solutions, isotonic sterile solutions, which can contain antioxidants; buffers,

WO 01/98526

bacteriostats, and solutes that render the formulation isotonic, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. In the practice of this invention, compositions can be administered, for example, by orally, topically, intravenously, 5 intraperitoneally, intravesically, or intrathecally. Optionally, the compositions are administered orally or nasally. The formulations of compounds can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials. Solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described. The modulators can also be administered as part a of prepared 10 drug, food, or cosmetic. In particular, an un-pleasant odor or taste (e.g., sulfur or bitter, respectively) may not be perceived as such and/or its effects reduced by blocking the binding between sensant ligand and sensory receptor by adding a competitor ligand that blocks binding between cognate ligand and receptor, or 15 inhibiting or reducing signal transduction. In contrast, a pleasant odor or taste can be mimicked or enhanced. Primary sensants are preferred because the subset of activated cells is kept small and the effects limited to projection into a specific region of the brain. But novel olfactants or combinations thereof that bind only a few olfactory receptors (e.g., having less than five different ligand-binding domains) would also be 20 useful.

20 The dose administered to a mammal (e.g., human) should be sufficient to effect a bene-ficial response in the subject over time. The dose will be determined by the efficacy of the parti-cular sensory modulators employed and the condition of the subject, as well as the body weight or surface area of the area to be treated. The size 25 of the dose also will be determined by the existence, nature, and extent of any adverse side-effects that accompany the administration of a particular compound or vector in a particular subject. In determining the effective amount of the modulator to be administered a physician may evaluate circulating plasma levels of the sensory modulator, modulator toxicities, and the production of anti-modulator antibodies. In general, the dose equivalent of a modulator is from about 1 ng/kg to 10 mg/kg for the 30 typical mammal. For administration, sensory modulators can be administered at a rate determined by the ED<sub>50</sub> of the modulator, and the side-effects of the inhibitor at various concentrations, as applied to the mass and overall health of the mammal. Administration can be accomplished via single or divided doses.

### I. Kits

Sensory receptor genes, or fragments or variants thereof are useful tools for identifying cells expressing sensory receptors, for forensics and paternity determinations, and for examining signal transduction in isolated cells. Sensory 5 receptor family member-specific reagents that specifically hybridize to sensory receptor nucleic acids, such AOFLF1 probes and primers, and sensory receptor specific reagents that specifically bind to a sensory receptor protein, *e.g.*, anti-sensory receptor antibodies are used to examine expression in cells and regulation of signal transduction. For example, one or more family member-specific reagents may be 10 used to detect poly-morphisms that are linked to genetic anosmia or to detect allelic exclusion.

Nucleic acid assays for the presence of DNA and RNA for a sensory receptor family member in a sample include numerous techniques known to those skilled in the art, such as Southern analysis, Northern analysis, dot blots, RNase protection, S1 15 analysis, amplification techniques such as PCR, and *in situ* hybridization. In *in situ* hybridization, for example, the target nucleic acid is liberated from its cellular surroundings in such as to be available for hybrid-ization within the cell while preserving the cellular morphology for subsequent interpretation and analysis. The following articles provide an overview of the art of *in situ* hybridization: Singer *et al.*, 20 *Biotechniques*, 4:230-250 (1986); Haase *et al.*, *Methods in Virology*, vol. VII, pp. 189-226 (1984); and *Nucleic Acid Hybridization: A Practical Approach* (Names *et al.*, eds. 1987). In addition, a sensory receptor protein can be detected with the various immunoassay techniques described above. The test sample is typically compared to both a positive control (*e.g.*, a sample expressing a recombinant sensory 25 receptor protein) and a negative control.

The present invention also provides for kits for screening for novel modulators of sensory receptor family members. Such kits can be prepared from readily available materials and reagents, as well as any of the aforementioned products. For example, such kits can comprise any one or more of the following materials: sensory receptor 30 nucleic acids or proteins, reaction tubes, and instructions for testing sensory receptor activity. Optionally, the kit contains a biologically active sensory receptor. A wide variety of kits and components can be prepared according to the present invention, depending upon the intended user of the kit and the particular needs of the user.

## Examples

## AOLFR1 sequences:

5 MKTFSSFLQIGRNMHQGNQTTITEFILLGFFQDEHQNLLFVLFLGMYLVTIGNGLIVAI  
 TYLHTPMYFLFLANLSFADISSISNSVPKMLVNIQTKSQSISYESCITQMYFSIVFVVIDNLLGTM  
 AYDHFVAICHPLNYTILMRPREFGILLTVISWFLSNIAHTHTLLIQLLFCNHNTLPHFFCDLAPLL  
 10 KLSCSDTLINEVLFLIVGLSVIIPFTLSFFSYVCIIRAVLRSSTQGKWKAFSTCGSHLTVVLLFY  
 GTIVGVYFFPSSTHPEDTDKIGAVLFTVTPMINPFIYSLRNKDMKGALRKLINRKISSL (SEQ ID  
 NO: 1)

15 10 ATGAAGACITTTAGTCCTTCTTCAGATGGCAGAAATATGCATCAAGGAAACCAAACCA  
 CCATCACTGAATCATTCTCTGGGATTTCAGCAGGATGAGCATCAAAACCTCCTTT  
 GTGCTTCTGGGTATGTACCTGGTCACTGTGATTGGAACGGGCTCATCATTGGCTA  
 TCAGCTTGGATACGTACCTCATACCCCATGTATCTCTCTGGCCAATCTATCCTTGCT  
 GATATTCTCCATTCCAACTCAGTCCCCAAATGCTGGTGAATATTCAAACCAAGAGTC  
 15 15 AATCCATCTTATGAGAGCTGCATCACACAGATGTACTTTCTATTGTGTTGTCGTCA  
 GACAATTGCTTGGGACCATGGCCTATGACCACTTGTGGCATCTGCCACCCCTGA  
 ATTATACAATTCTCATGGGCCAGGTTGGCATTGGCTCACAGTCATCTCATGGTC  
 AGTAATATTATTGCTCTGACACACACCCCTGTGCTATTCAATTGCTCTGTAA  
 20 20 CACTCTCCACACTCTCTGTGACTTGGCCCTGTGCTCAAACGTCTGTCA  
 TGATCAATGAGCTTGTGTTATTGTGGTTATCAGTTATCATCTTCCCTTACACTC  
 AGCTTCTTCATGTGTCATCAGAGCTGCTGAGAGTATCTCCACAGGGAA  
 AGTGGAAAGCCTCTCCACTTGTGGCTCTGACAGTTGATTACTGTTACGGAAC  
 CATTGTAGGCGTGTACTTTCCCTCTCCACTCACCCTGAGGACACTGATAAGATTGG  
 25 25 GCTGCTCTATTCACTGTGGTACACCCATGATAAACCCCTCATCACAGCTTGAGGAATA  
 AGGATATGAAAGGTGCCCTGAGAAAGCTCATCAATAGAAAATTCTCCCTTGA (SEQ  
 ID NO: 2)

## AOLFR2 sequences:

30 30 MMMVRNLSMPTFALLGFTDYPKLQIPLFLVFLMYVITVVGNLGMIIKINPKFHTPMYFFL  
 SHLSFVDFCYSSIVTPKLLNLMADKSIFYFSCMMQYFLSCTAVVTESFLAVMAYDRFVAIC  
 NPLLYTVAMSQRQLCALLVAGSYLWGMGPLVLLCYALRLNFSGPNVINHFFCEYALISVGS  
 DILPHLLLFSFATFNEMCTLLIILTSYVFIFVTKIRSVGRHKAFSTWASHLTAITIFGTLFL  
 YCVPNSKNSRQTVKVASFYTVNPMLNPIYSLRNKDVKA  
 FWKLIHTQVPH (SEQ ID NO:  
 3)

35 35 ATGATGATGGTTTAAGGAATCTGAGCATGGAGCCACCTTGCCTTTAGGTTCACAG  
 ATTACCCAAAGCTTCAGATTCTCTCTTGTGTTCTGCTCATGTATGTTACAGTG  
 GTAGGAAACCTGGATGATCATAATAATCAAGATAACCCAAATTCACACTCTATGT  
 ACTTTCTCTAGTCACCTCTTTGTGATTGTTACTCTCCATTGTCATCTCCAAGC  
 40 40 TGTTGAGAACTTGTAAATGGCAGATAAAGCATCTCTACTTTAGTCATGATGCAGTA  
 CTTCTGTCCTGACTGCTGGTACAGAGTCTTGTGGCAGTGTGATGGCTATGAC  
 CGCTTGTGGCATCTGCACTCTCTGCTTATAACAGTGGCATGTACAGAGGCTCTGTG  
 CCCTGCTGGTGGCTGGTCAATCTCTGGACCTAATGTAATCAACCACTCTTGTGTT  
 45 45 GCTCTCCGGTAAACTCTCTGGACCTAATGTAATCAACCACTCTTGTGAGTACTGC  
 TCTCATCTGTGCTGGCTCTGATATACTCATCCCCACCTGCTCTTGTGACT  
 CCTTCAATGAGATGTGACTACTGATCATCTCATCTTGTGTTGACT  
 GTACTAAAATCCGTCTGTTAGTGGGCCACAAAGCCTCTCCACCTGGCCCTCCAC  
 50 50 TGACTGCTATCACCCTTCATGGGACCATCCTTACTGTGTTACACAGTGTGAC  
 AACTCTGGCAAACAGTCAAAGTGGCTCTGTTTACACAGTGTGACCCAACTCCAA  
 ACCCTCGATCTACAGCCTAAGGAATAAAGACGTGAAGGATGCTTGTGAAGTAA  
 TACACAAGTTCCATTCACTGA (SEQ ID NO: 4)

## AOLFR3 sequences:

55 55 MLLTDRTSGTFTLLGFSDYPELQVPLFLVFLAIYNVTVLGNIGLIVI  
 KINPKLHTPMYFFLSQ  
 LSFVDFCYSSIIAPKMLVNLVVKDRTISFLGCVVQFFFFCTFVVTESFLAVMAYDRFVAICNPL  
 LYTVDMSQKLCVLLVGSYAWGVSCSLELTCALKCFHGNTIHFCFSSLLSLSCSDTYI

NQWLLFFLATFNEISTLLIVLTSYAFIVVTILKMRVSRRKAFSTCASHLTAITFHGTILFLYCV  
PNSKNSRHTVKVASVFYTVVIPMLNPLIYSLRNKDVKDTVTEILDTKVFSY (SEQ ID NO: 5)

5 ATGCTGCTGACAGATAGAAATACAAGTGGGACCACGTTACCCCTCTGGGCTCTCAGATT  
ACCCAGAACTGCAAGTCCCACCTCCCTGGTTCTGGCCATCTACAATGTCAGTGTGCTA  
GGAAATATTGGGTTGATTGTGATCATCAAATCAACCCAAACTGCATACCCCCATGTACT  
TTTCCTCAGCCAACCTCTCTTGTGGATTCTGCTATTCCCATCATTGCTCCAAAGATG  
TTGGTGAACCTTGTCAAAGACAGAACCATTTCTTGTGAGTGCAGTACAATTCT  
TTTCTCTGTACCTTGTGGTCACTGAATCTTTATTAGCTGTGATGGCTATGACCGC  
10 TTCGTGGCCATTGCAACCCCTGCTACACAGTTGACATGTCAGAAACTCTGCGTGC  
TGCTGGTTGTGGGATCCTATGCCTGGGGAGTCATGTTCCITGGAAGTACGTGCTCTGC  
TTAAAGTTATGTTTATGGTTCAACACAATCAATCACTTCTGTGAGTCTCCTCAC  
TACTCTCCCTTCTTGTCTGATACTTACATCAACCAGTGGCTGCTATTCTTCTGCCACC  
TTAATGAAATCAGCACACTACTCATCGTTCTCACATCTTATGCGTTATTGTTGTAACCAT  
15 CCTCAAGATGCGTTCACTGAGTGGCGCCGCAAAGCCTCTCCACCTGTGCCTCCACCTG  
ACTGCCATCACCATCTTCCATGGCACCATCCTCTTACTGTGTGCCAACTCCAAAAAA  
CTCCAGGCACACAGTCAAAGTGGCTCTGTGTTTACACCGTGGTATCCCCATGTTGAAT  
CCCCTGATCTACAGTCTGAGAAATAAGATGTCAAGGATAACAGTCACCGAGATACTGGAC  
ACCAAAGTCTCTTACTGA (SEQ ID NO: 6)

20

**AOLFR4 sequences:**

MENQNNVTEFILLGTENLEWKIFSAVFLVMYVATVLENLLIVVTIITSQSLRSPMYFFLTFLS  
LLDVMFSSVVAPKIVDLSKSTTISLKGCLTQLFVEHFFGGVGILLTVMAYDRYVAICKPLHY  
25 TIIMSPRVCCLMVGGAWVGGFMHAMIQLLFMYQIPFCGPNIIDHFICDLFQLLACTDTHILGL  
LVTLNSGMMCVAIFLILIASYTVILCSLKSYSKGRHKALSTCSSHLLVVVLFVPCIFLYMRPV  
VTHPIDKAMAVSDSIITPMLNPLIYTLRNAEVKSAMKKLWMKWEALAGK (SEQ ID NO: 7)

30 ATGGAAAATCAAACAAATGTGACTGAATTCAATTCTCTGGGCTCACAGAGAACCTGGAGC  
TGTGGAAAATATTTCTGCTGTGTTCTGTCACTGTATGTAGCCACAGTGTGAAAATCT  
ACTTATTGTGGTAACTATTATCACAAGTCAGAGTCTGAGGTCACTATGTATTCTTCTTA  
CCTTCTGTCCCCTTGGATGTCACTGTTCTCATCTGTCGTTGCCCAAGGTGATTGTAGAC  
ACCCTCTCCAAGAGCACTACCATCTCTCAAAGGCTGCCCTACCCAGCTGTTGTGGAGC  
ATTCTTGGGGATCATCTCTTACTGTGATGGCTATGACCGCTACGTGGC  
CATCTGTAAGCCCCCTGCACTACACGATCATCATGAGTCCACGGGTGTGCCTAATGGTA  
35 GGAGGGGCTTGGGTGGGGGATTATGCAACGCAATGATAACAATTCTCTCATGTATCAA  
TACCCCTCTGTGGTCCTAATATCATAGATCACTTATATGTGATTGTTCAAGTTGTGACA  
CTTGCCTGCACGGACACCCACATCCTGGGCCTCTTAGTTACCCCTAACAGTGGGATGATGT  
GTGTGGCCATCTTCTTATCTTAATTGCGTCTACACGGTCACTCTATGCTCCCTGAAGTCT  
TACAGCTCTAAAGGGCGGCACAAAGCCCTCTACCTGCAGCTCCACCTCACGGTGGTTG  
40 TATTGTTCTTGTCCCCTGTATTCTGTACATGAGGGCTGTGGTCACTCACCCCATAGAC  
AAGGCAATGGCTGTGTCAGACTCAATCATCACACCCATGTTAAATCCCTGATCTACAC  
TGAGGAATGCAAGGGTAAAAGTGCCATGAAGAAACTCTGGATGAAATGGGAGGCTTGG  
CTGGGAAATAA (SEQ ID NO: 8)

45

**AOLFR5 sequences:**

MGKENCTVAFILLGLSDVPELRVCLFLFLIIYGVTLANLGMIALIQVSSRLHTPMYFFLHS  
LSSVDFCYSSIIVPKMLANIFNKAISFLGCMVQFYLFCTCVTEVFLAVMAYDRFVAICNPL  
LYTVTMSWVKRVELASCYFCGTVCSLIHLCLALRIPFYRSNVINHFFCDLPPVLSACSDITVN  
ETLLFLVATLNESVTIMIILTSYLLILTTILKMGSAEGRHKAFSTCASHLTAITFHGTVLSIYCRP  
50 SSGNSGDADKVATVFYTVVIPMLNSVIYSLRNKDVKEALRKVMGSKIHS (SEQ ID NO: 9)

55 ATGGGCAAGGAAAATGCACCACTGTGGCTGAGTTCAATTCTCTGGACTATCAGATGTCC  
CTGAGTTGAGAGTCTGCCTCTCCTGCTGTTCTCATCTATGGAGTCACGTTTAGGCC  
AACCTGGGCATGATTGCACTGATTCAAGGTCACTCTGGCTCCACACCCCCATGTACTTTT  
TCCTCAGGCCACTTGTCCCTGTAGATTCTGCTACTCCTCAATAATTGTGCCAAAATGTGTTG  
GCTAATATCTTAACAAGGACAAAGCCATCTCCTCCTAGGGTGCATGGTCAATTCTACT

WO 01/98526

5           TGTTTGCACITGTGTTGGTCACTGAGGTCTTCCGTGGCCGTGATGCCATGACCGCTT  
 GTGGCCATCTGTAACCTTGTCTACACAGTCACCATGTCCTGGAAAGGTGCGTGTGGAGC  
 TGGCTCTGCTGCTACTTGTGGACGGTGTGTCCTGATTCAATTGTGCTTAGCTCTT  
 AGGATCCCCTCATAGATCTAATGTGATTAACCACTTTCTGTGATCTACCTCCGTCTT  
 10           AAGTCTGCTGCTGATATCACTGTGAATGAGACACTGCTGTCCTGGCCACTTTG  
 AATGAGAGTGTACCATCATGATCATCCTCACCTCACCTGCTAATTCTACCAACCATCCT  
 GAAGATGGGCTCTGCAGAGGGCAGGCACAAAGCCTCTCACCTGCTTCCACCTCACA  
 GCTATCACTGTCTCCATGGAACAGTCCTTCCATTATTGCAAGGCCAGTTCAAGGAATA  
 GTGGAGATGCTGACAAAGTGGCCACCGTGTCTACACAGTCGTGATTCTATGCTGAAC  
 15           TGTGATCTACAGCTGAGAAATAAAGATGTGAAAGAAGCTCTAGAAAAGTGA  
 CAAAATTCACTCTAG (SEQ ID NO: 10)

**AOLFR6 sequences:**

15           MMASERNQSSTPTFILLGFSEYPEIQVPLFLVFLFVYTIVVGNLGMIIIRLNSKLHTIMYFFLS  
 HLSLTDFCFSTVVTPLLENLVVEYRTISFSGCIMQFCFACIFGVETFMLAAMAYDRFVAVCK  
 PLYTTIMSQKLCALLVAGSYTWGIVCSLILTYFLLDSFCESTFINNFICDHSVIVSASYSDPYIS  
 QRLCFIIAIFNEVSSLIIILTSYMLIFTIMKMRSAQRQKTFSTCASHLTATIFHGTLFLYCVPNP  
 KTSSLIVTVASFYTVAPIMLNPLIYSLRNKDINNMFEKLVVKLIYH (SEQ ID NO: 11)

20           ATGATGGCATCTGAAAGAAATCAAAGCAGCACACCCACTTTATTCTCTGGGTTTCAG  
 AATAACCCAGAAATCCAGGTCCACTCTCTGGTTCTGTCGCTACACAGTCACTGTA  
 GTGGGAACTGGGATGATAATAATCATCAGACTCAATTCAAACCTCATAATCATGT  
 ACTTTCTTAGTCACTGTCTGACAGACTCTGTTCCACTGTAGTACACCTAAA  
 CTGTTGGAGAACTGGTTGTGAATACAGAACCATCTTCTCTGGTTGCATCATGCAAT  
 25           TTGTTTGCTGCATTTGGAGTGAACAGAAACTTCTAGTTAGCAGCGATGGCTATGAC  
 CGTTTGTGGCAGTTGTAACCCCTGCTGTATACCACTATTATGTCTCGAAAGCTGTG  
 TCTCTGGTGGCTGGCTCTACATGGGGATAGTGTGCTCCCTGATACTCACATATT  
 CTTCTGACTTATCGTTTGTGAATCTACCTCATAAAATAATTCTGTGACCACCTGT  
 AATTGTTCTGCCTCTACTCAGACCCCTATATCAGCCAGGGCTATGCTTATTATTGCA  
 30           TATTCAATGAGGTGAGCAGCTAATTATCATTCTGACATCATATGCTTATTTCAC  
 ATTATGAAGATGCGATCTGCAAGTGGGCCAGAAAACCTTCTCCACCTGTGCCTCCACC  
 TGACAGCCATCACTATCCATGGAACATCCTTCTGTGTTACACAGTGGCGATTCCAATGCTGA  
 ACTTCTAGCCTCATAGTACAGTGGCTCTGTGTTACACAGTGGCGATTCCAATGCTGA  
 ACCCATTGATCTACAGCCTAGGAACAAAGATATCATAACATGTTGAAAATTAGTTGT  
 35           CACCAAATTGATTACCACTGA (SEQ ID NO: 12)

**AOLFR7 sequences:**

40           MSYFYRLKLMKEAVLVKLPFTSLPLLQLTSLRKSRDMEIKNYSSSTSGFILLGSSNPQLQKPLF  
 AFLIMYLLAAVGVLIIIPAIYSDPRLHPTMYFFLSNLSDMDICFTVIVPKMLVNFLSETKVISY  
 VGCLAQMYFFMAFGNTDSYLLASMAIDRLVAICNPLHYDVVMKPRHCLLMLLGSCSISHLHS  
 FRVLLMSRLSFCASHIHKHFFCDTQPVLKLSCSDTSSSQMVMTETLAVIVTPFLCIIFSYLRIMV  
 TVLRIPSAAGKWKAFSTCGSHLTAVALFYGSIIYVYFRPLSMYSVVRDRVATVMYTVTPMLN  
 PFIYSLRNKDMKRGGLKLQDRIYR (SEQ ID NO: 13)

45           ATGAGCTATTTACAGGCTTAAGCTTATGAAAGAAGCTGCTTGGTCAAACCTGCCCTTA  
 CATCTCTCCCACTGCTCTCCAAACCTATCCAGGAAGTCCAGAGACATGGAGATAAGAA  
 CTACAGCAGCAGCACCTCAGGCTCATCTCTCATGTACCTGCTCGCTCGGTGGGAATGTGCTCAT  
 AAACCTCTTTGCCATCTCTCATGTACCTGACCCAGGCTCCACACCCCTATGACTTTCTCAGCACT  
 CATCCCGGCCATCTACTCTGACCCAGGCTCCACACCCCTATGACTTTCTCAGCACT  
 50           TGTCTTCATGGATATCTGCTTCACAACAGTCATGTGCTTAAGATGCTGGTAATTCTCA  
 TCAGAGACAAAGGTTATCTCTATGTGGCTGCTGGCCAGATGTACTTCTTATGGCAT  
 TTGGGAACACTGACAGCTACCTGCTGCCCTCATGGCCATCGACGGCTGGTGGCCATCTG  
 CAACCCCTTACACTATGATGTGGTATGAAACCAACGGCATTGCTGCTCATGCTATTGGGT  
 TCTTGAGCATCTCCACCTACATTCCCTGTTCCCGCTGCTACTTATGCTGCTTGTCTT  
 CTGTGCTCTCACATCATTAAAGCACTTTCTGTGACACCCAGCCTGTGCTAAAGCTCCT  
 55           GCTCTGACACATCCTCCAGCCAGATGGTGGTGTGACTGAGACCTAGCTGTCAATTGTGAC

5 CCCCTCCTGTATCATCTTCTTACCTGCGAATCATGGTCACTGTGTCAGAACTCCCCT  
 CTGCAGCCGGAAAGTGGAAAGGCCCTCTACCTGTGGCTCCACCTCACTGCAGTAGCCCT  
 TTTCTATGGGAGTATTATTTATGTCTATTTAGGCCCTGTCCATGTACTCAGTGGTTAGGG  
 ACCGGGTAGCCACAGTTATGTACACAGTAGTGACACCCATGCTAACCTTTCATCTACAG  
 CCTGAGGAACAAAGATATGAAGAGGGTTGAAGAAATTACAGGACAGAACCTACCGTA  
 A (SEQ ID NO: 14)

**AOLFR8 sequences:**

10 MATSNHSSGAEFILAGLTQRPELQLPLFLLFLGIYVVTVVGNLGMIFLIALSSQLYPPVYYFLSH  
 LSFIDLCYSSVTPKMLVNFVPEENIISFLECITQLYFFLIFVIAEGYLTAMEYDRYVAICRPLLY  
 NIVMSHRVCSIMMAVVYSLGFLWATVHTTRMSVLSFCRSHTVSHYFCDILPLTLSCSSTHINEI  
 LLFIIGGVNLTATTAVLISYAFIFSSILGIHSTEGQSKAFGTCSHLLAVGIFFGSITFMYFKPSS  
 TTMEKEKVSSVYIHIPMLNPLIYSLRNKDVKNALKKMTRGRQSS (SEQ ID NO: 15)

15 ATGGCTACTTCAAACCATTCTCAGGGCTGAGTTATCCTGGCAGGCTTGACACAACGCC  
 CAGAACTTCAACTGCCACTCTCCTCTGGAAATATATGTGGTCACAGTGGTGGG  
 GAACCTGGGATGATCTCTTAATTGCTCTCAGTCTCAACTTACCCCTCAGTGTATTATT  
 TTCTCAGTCATTGTCTTCATTGATCTCTGCTACTCCTCTGTCATTACCCCTAAGATGCTG  
 GTGAACTTGTCCAGAGGAGAACATTATCTCCTCTGGAAATGCATTACTCAACTTATT  
 20 CTTCCATTATTTGTAAATTGAGAAGGCTACCTCTGACAGCCATGGAAATATGACCGTTAT  
 GTTGCATCTGCGCCACTGCTTACAATTGTCAATGCCCCACAGGGCTGTTCCATAAT  
 GATGGCTGTGGTATACTCACTGGTTTCTGTGGGCCACAGTCCATACTACCCGATGTCA  
 GTGTTGTCATTCTGTAGGTCTCATCGGTCACTGTCATTATTGTGATATTCTCCCTATT  
 GACTCTGCTTGTCCAGCACCCACATCAATGAGATTCTGCTGTTCAATTGGAGGAGTT  
 25 AATACCTTAGCAACTACACTGGCGGTCTTATCTCTATGCTTCAATTCTCTAGTATCCT  
 TGGTATTCACTCCACTGAGGGCAATCAAAGCCTTGGCACTTGTAGCTCCATCTCTG  
 GCTGTGGGCATCTTTGGGTCTATAACATTCAATGTTCAAGCCCCCTCCAGCACTAC  
 TATGGAAAAGAGAACAGGTGTCTCTGTGTTCTACATCACAATAATCCCCATGCTGAATCCT  
 CTAATCTATAGCCTGAGGAACAAGGATGTGAAAAATGCACTGAAGAAGATGACTAGGGGA  
 30 AGGCAGTCATCCTGA (SEQ ID NO: 16)

**AOLFR9 sequences:**

35 MLARNNSLVTETFILAGLTDRPEFWQPFPLFLVIYIVTMVGNLGLITLFLGLNSHLHPTMYYFLFN  
 LSFIDLCYSSVTPKMLMNFVSKNIISNVGCMTRLFFLFFVISECYMLTSMAVDYVAICNPL  
 LYKVTMSHQVCMSLTFAAYIMGLAGATAHTGCMFRLTFC SANIINHYLCDILPLQLSCTSTYV  
 NEVVVLIVVGTNITVPSCTILISYFIVTSILHIKSTQGRSKAFSTCSSHVIALSLFFGSAAFMYIKY  
 SSGSMEQGVFSVYTNVVPMLNPLIYSLRNKDVKVALRKALIKIQRRNIF (SEQ ID NO: 17)

40 ATGCTGGCTAGAAACAACCTCTTAGTGAATTTATCTTGCTGGATTAACAGATCGTC  
 CAGAGTTCTGGCAACCCTCTTTCTGTTCTAGTGAATCTACATTGTCACCATGGTAGGC  
 AACCTTGGCTTGTACTCTTCTGGCTAAATTCTCACCTCCACACACCAATGTACTATT  
 CCTCTCAATCTCCTCTATTGATCTCTGTTACTCCTCTGTTCACTCCAAAATGCTAAT  
 GAACTTTGTGTCAAAAAGAATATTATCTCAATGTTGGGTGCATGACTCGGCTGTTTC  
 TTTCTCTTTCTGTCATCTGTGAATGTTACATGTTGACCTCAATGGCATATGATCGCTATGT  
 45 GGCCATCTGTAATCCATTGCTGTATAAGGTACCATGTCCCACAGGTCTGTTCTATGCTCA  
 CTTTGCTGTTACATAATGGGATTGGCTGGAGGCCAGGCCACACCGGGTGCATGTTAG  
 ACTCACCTCTGCAGTGTAAATATCATTAAACCAATTCTGTGACATACTCCCCCTCTCC  
 AGCTTCTGCACCAGCACCTATGTCAACGAGGTGGTTCTCATGTTGTTGGTACTAA  
 TATCACGGTACCCAGTTGTAACATCCTCATTCTTATGTTTCACTGTCAGCATTCTTC  
 50 ATATCAAATCCACTCAAGGAAGATCAAAGCCTCAGTACTTGTAGCTCTCATGTCATTG  
 TCTGTCTCTGTTTTGGGTCAAGCGGCATTCTCATGTATATTAAATATTCTCTGGATCTATGG  
 AGCAGGGAAAAGTTTTCTGTTCTACACTAATGTGGTGCCCATGCTCAATCCCCATC  
 TACAGTTGAGGAACAAGGATGTCAAAGTTGCACTGAGGAAAGCTCTGATTAAAATTCA  
 AGGAGAAATATATTCTAA (SEQ ID NO: 18)

WO 01/98526

## AOLFR10 sequences:

5      MLARNNSLVTEFILAGLTDRPEFRQPLFFLVIYIVTMVGNLGLIILFGLNSHLHTPMYYFLFNL  
       SFIDLCYSSVFTPCKMLMNFSKKNIISYVGCMQLFFFVISECYILTSMAYDRYVAICNPLLY  
       KVTMSHQVCSMLTFAAYIMLAGATAHTGMLRLTFCSANIINHYLCDILPLLQLSCTSTYVN  
       EVVVLIVVGINIMVPSCTILISYFIVTSILHIKSTQGRSKAFSTCSSHVIALSLFFGSAAFMYIKYS  
       SGSMEQGVSSVFTNVVPMNLPIYSLRNKDVKVALRKALIKJQRNNIF (SEQ ID NO: 19)

10     ATGCTGGCTAGAAACAACTCCTAGTGACTGAATTATTCTGCTGGATTAACAGATCGTC  
       CAGAGTTCGGCAACCCCTCTTTCTGTTCTAGTGAATCATTGTCACCATGGTAGGC  
       AACCTGGCTTGTATCATTCTTCATTGATCTCTGTACTCCTCTGTTTCACTCCAAATGCTAAT  
       CCTCTCAATCTCCTTCATTGATCTCTGTACTCCTCTGTTTCACTCCAAATGCTAAT  
       GAACTTTGATCAAAAAAGAATATTATCTCTATGTTGGGTGCATGACTCAGCTGTTTCT  
       TTCTCTTTGTCACTCTGAATGCTACATATTGACCTCAATGGCATATGATCGTATGTG  
       GCCATCTGTAATCCATTGCTATAAGGTACCATGTCCCATCAGGTCTGTCTATGCTCAC  
       TTTGCTGCTACATAATGGGATTGGCTGGAGCCACGGGCCACACGGGGTGCATGCTTAGA  
       CTCACCTCTGAGTGTAAATATCATCAACCATTACTTGTGACATACTCCCCCTCCTCCA  
       GCTTCCTGCACCAGCACCTATGTCACAGAGGTGGTTCTCATTTGTCAGCTCATTCTCA  
       ATCATGGTACCCAGTTGACCATCCTCATTTCTATGTTTCAATTGTCAGCTCATTGCT  
       TATCAAATCCACTCAAGGAAGATCAAAGCCTTCAGTACTITGAGCTCTCATGTATTA  
       CTGTCCTGTTTGGGTCAAGCGGATTCACTGTATTTAAATATTCTGATCTATGGA  
       GCAGGGAAAAGTTCTCTGTTCTACACTAATGTGGGCCATGCTCAATCCTCTCATCT  
       ACAGTTGAGGAACAAGGATGTCAAAGTTGACTGAGGAAAGCTCTGATTAAAATCAGA  
       GAAGAAAATATTCTAA (SEQ ID NO: 20)

## AOLFR11 sequences:

25     MTLRNSSSVTEFILVGLSEQPELQLPLFLGLIYVFTVVGNLGLITLGINPSLHTPMYFFLNLS  
       FIDLCYSCVFTPCKMLNDFVSEIISYVGCMQLFFFVNSECYVLVSMAYDRYVAICNPLLY  
       MVTMSPRVCFLLMFGSYVVGAGAMAHTGSMRLTFCDSNVIDHYLCDVPLLQLSCTSTHV  
       SELVFFIVVGVITMLSSISIVISYALISNLLCIPSAEGRSKAFSTWGSHIIAVALFFGSGTFTYLTTS  
       FPGSMNHGRFASVFTNVVPMNLPSIYSLRNKDDKLALGKTLKRVLF (SEQ ID NO: 21)

30     ATGACTCTGAGAAACAGCTCCTAGTGAETGAGTTATCCTGTTGAGATTATCAGAACAGC  
       CAGAGCTCCAGCTCCCTCTTTCTTCTATTCTAGGGATCTATGTTCACTGTGGGGC  
       AACTGGGCTTGTACCTTAATTGGATAATCTAGCCTCACACCCCCATGCTACTTTT  
       CCTCTCAACTTGTCTTATAGATCTCTGTATTCTGTGTGTTACCCCCAAATGCTGA  
       ATGACTTTGTTCAATTCTGAGTGTATGTGGATGTTCAATGCCCTATGCGTATGTGGC  
       TGTTTCTTGTCAATTCTGAGTGTATGTGGATGTTCAATGCCCTATGCGTATGTGGC  
       CATCTGCAACCCCCCTGCTACATGGTACCATGCCCCAAGGGCTGCTTCTGCTGATGT  
       TTGGTTCTATGTGGTAGGGTTGCTGGGCCATGCCAACACTGGAAGCATGCTGCACT  
       GACCTCTGTGATTCCAACGTATTGACCAATTCTGTGACGTTCTCCCCCTTGCAGC  
       TCTCTGCACCAGCACCATGTCAGTGAAGCTGTTATTCTGTTGAGTAATCACC  
       ATGCTATCCAGCATAAGCATGTCATCTTACGCTTGTGATACTCTCCAACATCCTCTGTAT  
       TCCTCTGCAGAGGGCAGATCCAAGCCTTAGCACATGGGGCTCCACATAATTGCTGTT  
       GCTCTGTTTGGGTCAAGGACATTCACTTAACACATCTTCTGGCTATGAA  
       CCATGGCAGATTGCCTCAGTCTTACACCAATGTGGTCCATGCTTAACCTCGATCT  
       ACAGTTGAGGAATAAGGATGATAAAACTGCCCTGGGCAAAACCTGAAGAGAGTGTCT  
       TCTAA (SEQ ID NO: 22)

## AOLFR12 sequences:

50     MERNHNPDCNVLNFFFADKKNKRRNFGQIVSDVGRICYSVSLSLGEPTTMGRNNLTRPSEFIL  
       LGLSSRPEDQKPLFAVFLPIYLITVIGNLILAIRSDTRLQTPMYYFLSILSFVDICYVTIIPKMLV  
       NFLSETKTISYGECLTQMYFFLAFGNTDSYLLAAMAIDRYVAICNPFHYTIMSHRCVLLVLS  
       FCIPHPHSLLHILLTNQLIFCAVNVIHFFCDDQPVLKLSSSHFVKEITVMTEGLAVIMTPFSCII  
       SYLRILITVLKIPSAAGKRKAFTCGSHLTVVTLFYGSISYVFQPLSNYTVKDQIAIIYTVLTP  
       MLNPFYSLRNKDMQGLAKLMHRMKCQ (SEQ ID NO: 23)

ATGGAAAGAAACCACAATCCAGATAATTGTAATGTTTAAATTTCCTTGCTGATAAGA  
 AGAATAAAAGGAGAAATTGAGACAGATTGATCAGATGTTGGAAGAACTCTGTTACAGTG  
 TTAGTTATCTTAGGTGAAACCCACAACATGGGAAGAAATAACCTAACAAAGACCCCTCTGA  
 ATTCACTCCTCCTGGACTCTCCTCTGACCTGAGGATCAGAACGCCCTCTGCTGTTCC  
 5 TCCCCATCTACCTTATCACAGTGATAGGAAACCTGCTTATCATCCTGGCCATCCGCTCAGA  
 CACTCGTCTCCAGACGCCATGTACTCTTCTAAGCATTCTGCTTGTGACATTGCT  
 ATGTGACAGTCATTATCCCTAACAGATGCTGGTAACCTTATCAGAGACAAAGACCATCTC  
 TTACGGTGAGTGTCTGACCCAGATGTACTTTCTTAGCCTTGGAAACACAGACAGTTAC  
 CTGCTAGCAGCCATGGCCATTGACCGCTATGTGGCCATATGTAATCCCTCCACTACATCA  
 10 CCATTATGAGTCACAGATGCTGTGCTGCTGGTCTCTCCTGCTTCATTCCACATTT  
 CACTCCCTCCTGCACATTCTGACTAACATCAGCTCATCTCTGTCCTCCAAATGTCATCCA  
 TCACTTTCTCGATGATCAACCAGTGTAAAATTGCTCTGTCCTCCCATTTGTCAAAG  
 AAATCACAGTAATGACAGAAGGCTGGCTGTCATAATGACCCGTTTCATGCATCAT  
 CTCTTATTAAAGAACATCCTCATCACTGTTCTGAAGATTCTCAGCTGCTGGAAAGCGTAAA  
 15 GCATTCTACCTGTGGCTCTACTCACAGTGGTACCCCTGTTATGGAAGCATTAGCTA  
 TGTCTATTTCAAGCCCTGTCCAACATACTGTCAAGGATCAAATGCAACAATTATCTAC  
 ACCGTACTGACTCCTATGCTAAATCCATTATCTATAGTCTGAGGAACAAAGACATGAAGC  
 AGGGTTGGCAAAGTTGATGCACAGGATGAAATGTCAGTAA (SEQ ID NO: 24)

20 **AOLFR13 sequences:**

MDQKNGSSFTGFILLGFSDRPQLELVFVLLIFYIFTLLGNKTIIVLSHLDPLHNPYFFFNSL  
 SFLDLCYTTGIVPQLLVNLRGADKSISYGGCVVQLYISLGLGSTEVLLGVMAFDRYAAVCRPL  
 HYTVVMHPCLYVLMASTSWVIGFANSLLQTVLILLTLGRNKLEHFLCEVPLLKLACVDTT  
 MNESEFFVSVIILVPVALIIFSYSQIVRAVRIKSATGQRKVFGTCGSHLTVSLFYGTAIYAY  
 25 LQPGNNYSQDQGXISLFYTIITPMINPLIYTLRNKDVKGALKVLWKNYDSR (SEQ ID NO:  
 25)

ATGGATCAGAAAAATGGAAGTTCTTCACTGGATTATCCTACTGGGTTCTGACAGGC  
 CTCAGCTGGAGCTAGTCCTCTTGTGGTTCTTGATCTCTATCTTCACTTGTGGGG  
 30 AACAAAACCATCATTGTATTATCTCACTTGGACCCACATCTCACAACTCTATGTATTTT  
 CTTCTCAACCTAACGCTTTGGATCTGTGTTACACAACCGGCATTGTCACAGCTCCTGG  
 TTAATCTCAGGGGAGCAGACAAATCAATCTCTATGGTGGTTGTAGTTAGCTGACAT  
 CTCTCTAGGCTGGGATCTACAGAATGCGTTCTTCTAGGAGTGTGGCATTTGACCGCTAT  
 GCAGCTGTTGCAGGCCCTCCACTACACAGTAGTCATGCACCCCTGTCTGATGTGCTGA  
 35 TGGCTCTACTTCATGGTCATTGGTTGCCAACCTCCATTGACAGGGTGTCTCATCTTG  
 CTTTAACACTTGTGGAAAGAAATAATTAGAACACTTCTTGAGGTTCCATTGCT  
 CAAGCTTGCCTGTGTTGACACTACTATGAATGAATCTGAACCTCTTGTCACTGTCATTA  
 TTCTCTTGACCTGTTGCATTATCATATTCTCTATAGTCAGATTGTCAGGGCAGTCGTG  
 AGGATAAAAGTCAGCAACAGGGCAGAGAAAAGTGTGGGACATGTGGCTCCACCTCACA  
 40 GTGGTTCCCTGTTACGGCACAGCTATGCTACCTCCAGCCGGCAACAAACTACTC  
 TCAGGATCAGGGCAAGKTCATCTCTCTACACCACATTACACCCATGATCAACCC  
 CTCATATATACACTGAGGAACAAGGATGTGAAAGGAGCACTTAAGAAGGTGCTCTGGAAG  
 AACTACGACTCCAGATGA(SEQ ID NO: 26)

45 **AOLFR14 sequences:**

MALPLLLSPSCFASSQLSSRMNSENLTRAAVAPAEVLLGITNRWDLRVALFLTCLPVYLVSL  
 LGNMGMALLIRMDARLHTPMYFFLANLSLDACYSSAIGPKMLVDLLPRATIPYTACALQMF  
 VFAGLADTECCLLAAMAYDRYVAIRNPLLYTTAMSQRCLALLGASGLGAVSAFVHTLTF  
 RLSFCRSRKINSFFCDIPPLAISCSDSLNELLFAICGFIQTATVLAITVSYGFIAGAVIHMRSVE  
 50 GSRRRAASTGGSHLTAVAMMYGTLIFMYLRPSSYALTDKMASVFYTLVIPSLNPLIYSLRNKE  
 VKEALRQTWSRFHCPGQGSQ (SEQ ID NO: 27)

ATGGCCTTGCCTATTGCTTTATCTCCCTCCTGCTTGCCCTTCTCAGTCCTGTCAGTAG  
 GATGAACCTCAGAGAACCTCACCCGGCCGCGGTTGCCCTGCTGAATTGTCCTCTGGGC  
 55 ATCACAAATCGCTGGACCTGCGTGTGCCCTCTCCTGACCTGCTGCCGTCTACCTGG  
 TGAGCCTGCTGGAAACATGGCATGGCCTGCTGATCCGCATGGATGCCGGCTCCACA

WO 01/98526

5           CACCTATGTACTCTCTGCCAACCTCCCTGCTGGATGCCTGCTATTCCCTGCCATC  
 GGCCCAAGATGCTAGTGGACCTGCTGCTGCCAGGACCATCCCTACACAGCCTGTG  
 10          CCCTCCAGATGTTGCTTGCAGGTCTGGCTGACTGAGTGTGCTGCTGGCAGCCAT  
 GGCCTATGACCGCTACGTGGCATCAGAAACCCACTTCTATACAAACAGCTATGTCGAG  
 15          CGTCTATGCCCTGGCTTGTGGAGCATCAGGCCGGGGCAGTGAGTGCCTTGTTC  
 ACACAACCCACCTCCGCTGAGCTCTGCCCTCCCGAAGATCAATAGCTCTCTG  
 CGATATCCCTCCACTGCTGCCATCTCGTCAGTGACACCAGCTCAATGAACCTCTCT  
 TCGCCATCTGTGGCTCATCCAGACAGCCACGGTGTAGCTATCACGGTGTCTATGGCTT  
 20          CATCGCTGGGCTGTGATCCACATGCCCTGGGAGACTGACAAGATGCCCTGTGTTA  
 CGGGTTTCCCACCTCACAGCCGTGGCATGATGACGGGACACTCATTTCATGTACCTG  
 CGCCCCAGCTCCAGCTATGCCCTGGGACACTGACAAGATGCCCTGTGTTA  
 TCATCCCGTCTCTCAACCCACTCATCACGCCCTCGCAATAAGGAGGTCAAGGAGGCCCT  
 CAGGCAGACCTGGAGCCGATTCACTGTCCAGGGCAGGGTCCCAGTGA (SEQ ID NO: 28)

15          **AOLFR15 sequences:**

MRENNQSSTLEFILLGVTQQEQEDFYILFLFIYPITLIGNLLIVLAICSDVRLHNPMYFLLANLS  
 LVDIFFSSVTIPKMLANHLLGSKSISFGGCLTQMYFMIALGNTDSYILAAMAYDRAISHPLH  
 YTTIMSPRSCIWILAGSWVIGNANALPHTLLTASLSFCGNQEAVNFYCDITPLKLSCSDIHFHV  
 KMMYLGVGIFSVPLLCIIVSYIRVFSTVFQVPSTKGVLKAFSTCGSHLTVVSLYYGTVMGTYFR  
 20          PLTNYSLKDAVITVMYTAVTPMLNPFYSLRNRMKAALRKLNFNKRSS (SEQ ID NO: 29)

25          ATGAGGGAAAATAACCAGTCTCTACACTGGAATTACCTCTGGAGTTACTGGTCAGC  
 AGGAACAGGAAGATTCTCTACATCCTCTTGTGATTTACCCATCACATTGATTGGA  
 CACTGCTCATGTCTAGCCATTGCTCTGATGTTGCCCTCACAAACCCATGTATTCT  
 30          CTTGCAACCTCTCTGGGTGACATCTTCTCATCGTAACCATCCCTAAGATGCTGG  
 CCAACCATCTCTGGGTAAACAGACAGCTATATTGCTGCAATGGCATATGATCGAGCT  
 CATGATAGCCTGGGTAAACAGACAGCTATACACAACAAATTGAGTCCACGGTCTGTATCTGGC  
 GTGGCCATGCCACCCACTCACTACACAACAAATTGAGTCCACGGTCTGTATCTGGC  
 TTATTGCTGGGTCTGGGTGATTGGAAATGCCATGCCCTCCCCACTCTGCTCACAGC  
 TAGTCTGCTTCTGTGGCAACAGGAAGTGGCAACTTCACTGTGACATTACCCCTG  
 CTGAAGTTATCCTGTTCTGACATCCACTTCACTGTGAAGATGATGTACCTAGGGTGGCA  
 TTTCTGTGCCATTACTATGCACTATTGCTCCTATATTGAGTCTTCCACAGTCTCC  
 AGGTCCTTCCACCAAGGGCGTCAAGGCCTTCCACCTGTGGITCCACCTCACGGT  
 35          TGTCTTTGATTATGGTACAGTCATGGCACGTATTCCGCCCTTGACCAATTAGCC  
 TAAAGACCGAGTGTACACTGTAATGTACACGGCAGTGACCCCAATGTTAAATCCTTCAT  
 CTACAGTCTGAGAAATCGGGACATGAAGGCTGCCCTCGGAAACTCTCAACAAGAGAAT  
 CTCCTCGTAA (SEQ ID NO: 30)

35          **AOLFR16 sequences:**

MRRNCLTVTEFILLGLTSRELQILLFTLAIYMTVAGNLGMVLIQANAWLHMPMYFFLH  
 LSFVDLCFSNVTPKMLEIFLSEKKSISYPACLVQCYLFIALVHVEIYILAVMAFDYMAICNPL  
 YGSRMSKSVCSFLITVYVYGAUTGLMETMWTYNLAFCGPNEHFYCADPPLIKLACSDTYN  
 KELSMFIVAGWNLSFLIICISYLYIFPAILKIRSTEGRQKAFSTCGSHLTAVTIFYATLFFMYLR  
 PPSKESVEQGKMAVFYTTVPMNLIIYSLRNKNVKEALIKELSMKIYFS (SEQ ID NO: 31)

45          ATGAGAAAGAAACTGCACGTGGTACTGAGTTACCTCTGGACTGACCAGTCGCCGG  
 GAATTACAAATTCTCTCTACGCTGTTCTGGCATTACATGGTCAGGGCAGGAGGA  
 ACCTTGGCATGTTGCTCTACCCAGGCCAACGCCCTGGCTCCACATGCCATGTACTTTTC  
 50          CTGAGCCACTTACCTCTGGATCTGTGCTCTTCCAAATGTGACTCCAAGATGCTGG  
 AGATTTCTTCAGAGAAAGAAAAGCATTCATCTGCCCTGTGCTTGTGAGTCTGCTT  
 TTTATCGCTTGGCCATGTGAGATCTACATCTGGCTGTGATGGCTTGTGAGGCTACAT  
 GGCCATCTGCAACCTCTGCTTATGGCAGCAGAATGTCCAAGAGTGCTGCTCCCTC  
 ATCACGGTGCCTTATGTGATGGAGCGCTCACTGGCTGATGGAGACCATGTGGACCTACA  
 55          ACCTAGCCTCTGTGGCCCAATGAAATTAACTACTTCACTGTGCGGACCCACACTGAT  
 TAAGCTGGCTTGTGACACCTACAACAAGGAGTGTCAATGTTATTGTGGCTGGCTGG  
 AACCTTCTTCTCTCATATGTATTCTACCTTACCTTACATTCCCTGCTATTITA

5 AAGATTGCTCTACAGAGGGCAGGCAGGCAAAAGCTTTCTACCTGTGGCTCCATCTGACAG  
 CTGTCACTATATTCTATGCAACCCCTTCTCATGTATCTCAGACCCCCCTCAAAGGAATCT  
 GTTGAACAGGGTAAATGGTAGCTGTATTTATACACAGTAATCCCTATGCTGAACCTTA  
 TAATTATAGCCITAGAAATAAAATGTAAAAGAAGCATTAAATCAAAGAGCTGTCAATGA  
 AGATATACTTTCTTAA (SEQ ID NO: 32)

**AOLFR17 sequences:**

10 MLNFTDVTEFILLGLTSRREWQVLFIFLVVYIITMVGNIGMMVLKVSPQLNNPMYFFLSHLS  
 FVDVWFSSNVTPKMLENLFSDKKITYAGCLVQCFFFLALVHVEFILAAMAFDRYMAIGNPLL  
 YGSKMSRVCVIRCILITFPYIYGLTSLAATLWTYGLYFCGKIEINHFYCADPPLIKMACAGTFVKE  
 YTMIILAGINFTYSLTVIISYLFILIAILRMRSAEGRQKAFSTCGSHLTAVIIFYGTLIFMYLRRPTE  
 ESVEQGKMWAVFYTTVIPMLNPMIYSLRNKDVKKAMMKVISRSC (SEQ ID NO: 33)

15 ATGCTCAATTCAACCGATGTGACAGAGTTCATCTTTGGGCTAACGAGCCGTGAGAAT  
 GGCAAGTTCTCTTCTCATCATCTTCTGTGGTCTACATCATACCATGGTGGGCAATATC  
 GGCATGATGGTGTAAATCAAGGTCAAGTCAGTCCTCAGCTTAACAACCCCATGTA  
 CTCTTCTCA  
 GTCACCTGTCAATTGTTGATGTGTGGTTTCTCAATGTCACCCCTAAATGTTGGAAAAC  
 CTGTTTCAGATAAAAAAAACAATTACTTATGCTGGTTAGTACAGTGTCTTCTCAT  
 TGCTCTGTCCATGTGGAAATTITATTCTGCTGCGATGGCCTTGTAGATAGATA  
 CATGGCAA  
 20 TTGGGAATCCTCTGTTATGGCAGTAAAATGTCAGGTTGTCTGTATTCAGTATTAC  
 TTTCCCTTACATTATGGTTTCTGACGAGTCTGGCAGCAACATTATGGACTTACGGCTTGT  
 ACTTCTGTGGAAAATTGAGATCAACCATTCTACTGTGCAGATCCACCTCTCATAAAAT  
 GGCCTGTGCCGGGACCTTGTAAAAGAATATAACATGATCATACTGCCGGCATTAAC  
 25 ACATATTCCCTGACTGTAATTATCATCTTACTTATTCACTCCTCATTGCCATTCTGCGAAT  
 GCGCTCAGCAGAAGGAAGGCAGAAGGCCTTCCACATGTGGTCCCCTGACAGCTGT  
 CATTATATTCTATGGTACTCTGATCTCATGTATCTCAGACGTCACAGAGGTCTGTG  
 GAGCAGGGGAAGATGGTGGCTGTGTTCTATACCACAGTGTACCCATGTTGAATCC  
 30 35 TCACTACAGTCTGAGGAACAAGGATGTGAAAAGGCCATGATGAAAGTGTACAGCAGATCAT  
 GTTAA (SEQ ID NO: 34)

**AOLFR18 sequences:**

MSNTNGSAITEFILLGLTDCPELQSLLFVLFLVVYLVTLLGNLGMIMLMRLDSRLHTPMYFFLT  
 NLAFVDLCYTSNATPQMSTNIVSEKTISFAGCFTQCYIFIALLTEFYMLAAMAYDRYVAIYDP  
 LRYSVKTSRRVCICLATFPYVYGFSDGLFQAILTFRLTFCRSNVINHFYCADPPLIKLSCSDTYVK  
 EHAMFISAGFNLSLSTIVLVSYAFILAAILRIKSAEGRHKAFSTCGSHMMAVTLFYGTLFCMYI  
 RPPTDKTVEESKIIAVYTFVSPVLNPLIYSLRNKDVKQALKNVLR (SEQ ID NO: 35)

40 ATGTCCAACACAAATGGCAGTGCAATCACAGAATTCAATTACTGGGCTCACAGATTGCC  
 CGGAACCTCCAGTCTGCTTTGTGCTGTTCTGGTTGTTACCTCGTACCCCTGCTAGGC  
 AACCTGGGATGATAATGTTAATGAGACTGGACTCTCGCCTCACAGCCCCATGTA  
 CTCTCACTAACTTAGCCTTGTGGATTGTGCTATACATCAAATGCAACCCCGCAGATGTC  
 GACTAATATCGTATCTGAGAAGACCATTCTCTGCTGGTGTCTTACACAGTGTACATT  
 TCATTGCCCTTCACTCACTGAGTTTACATGCTGGCAGCAATGGCTATGACCGCTATGT  
 GGCCATATATGACCCTCTGCGCTACAGTGTGAAAAGTCCAGGAGAGTTGCATCTGCTTGT  
 45 GCCACATTCCCTATGTCTATGGCTTCTCAGATGGACTCTCCAGGCCATCCTGACCTCCG  
 CCTGACCTTCTGAGATCCAATGTCTACCAACCAACTCTACTGTGCTGACCCGCCGCTCTTA  
 AGCTTCTGTCTGATACTTATGTCAAAGAGCATGCCATGTTCTATCTGCTGGCTTCAAC  
 CTCTCCAGCTCCCTACCCATCGTCTGGTGTCTATGCCCTCATCTTGTGCCATCCTCCG  
 GATCAAATCAGCAGAGGGAAGGCACAAGGCATTCTCCACCTGTGGTCCATATGATGGC  
 50 TGTCACCCCTGTTTATGGGACTCTCTTGTATATAAGACCACCAACAGATAAGACT  
 GTTGAGGAATCTAAAATAATAGCTGTCTTACACCTTGTGAGTCCGGTACTTAATCCAT  
 TGATCTACAGTCTGAGGAATAAGATGTGAAGCAGGCCCTGAAGAATGTCCTGAGATGA  
 (SEQ ID NO: 36)

55

WO 01/98526

## AOLFR19 sequences:

5 METKNYSSSTSGFILLGLSSNPQKPLFAIFLIMYLTAVGNVLIILAIYSDPRLHTPMYFFLSNL  
 SFMDICFTTIVPKMLVNFLSETKISYVGCLIQMYFFMAFGNTDSYLLASMAIDRLVAICNPLH  
 YDVMVMKPWHCLMMLLGCSISHLHSLFRVLLMSRLSFCAHIKHFCDTQPVLKLSCSDTSSSQ  
 MVVMTETLAVITPFLCTIFSYLQIIVTVLRIPSAAGKWAFTCGSHLTVVLFYGSVIYVYFR  
 10 PLSMYSVMKGRVATVMTVVTPLNPFYSLRNKDMKRLKKLRHRIYS (SEQ ID NO: 37)

15 ATGGAGACAAAGAATTATAGCAGCAGCACCTCAGGCTTCATCCTCCTGGGCCTCTTCCA  
 ACCCTAAGCTGCAGAACCTCTTGCATCTCCATCATGTACCTACTCAGCGGTG  
 GGAATGTGCTCATCATCCTGGCCATCTACTCTGACCCCAGGCTCCACACCCCTATGTACT  
 TTTTCTCAGCAACTTGTCTTATGGATATCTGCTTCACAACAGTCATAGTGCCTAAGATG  
 CTGGTAATTCTATCAGAGACAAAGATTATCTTATGTGGGCTGCCTGATCCAGATGT  
 ACTTCTCATGGCATTTGGAACACTGACAGCTACCTGCTGGCCTCATGGCCATCGACCG  
 GCTGGGCCATCTGCAACCCCTACACTATGATGGTTATGAAACCATGGCATTGCCA  
 20 CTCATGCTATTGGGTTCTGAGCATCTCCACCTACATTCCCTGGCGTACTTAT  
 GTCTCGCTTGTCTTCTGCTCTCACATCATTAAGCACTTTCTGTGACACATCCTCCAGCAGATGGTGGTATGACTGAGACCTT  
 TGCTAAAGCTCTCTGCTCTGACACATCCTCCAGCAGATGGTGGTATGACTGAGACCTT  
 AGCTGTCATTGTGACCCCCCTCTGAGCCGGAAAGTGGAGGCCTCTCACCTGTGGCTCCACCT  
 TGCTCAGAACATCCCCTCTGAGCCGGAAAGTGGAGGCCTCTCACCTGTGGCTCCACCT  
 25 CACTGAGTGGCCTGTTCTATGGGAGTGTCACTATGTCTATTAGGCCTGTCCATGT  
 ACTCAGTGATGAAGGGCCGGTAGCCACAGTTATGTACACAGTAGTGAACACCATGCTGA  
 ACCCTTCATCTACAGCTGAGGAACAAAGATATGAAAAGGGTTGAAGAAATTAAGAC  
 ACAGAATTACTCATAG (SEQ ID NO: 38)

## AOLFR20 sequences:

25 MVEENHTMKNEFILTGFDTDPELKLLFVFFAIYLITVGNISLVALIFHCRRLHTPMYIFLG  
 LALVDSCCACAITPKMLENFFSEGKRISLYECAVQFYFLCTVETADCFLAAVAYDRYVAICNP  
 LQYHIMMSKKLCIQMTTGAIFIAGNLHSMIHVGVLVFLVFCGLNHINHFYCDTLPYRLSCVDPF  
 INELVLFISGSVQVFTIGSVLISYLYILLTIFRMSKESGRAKAFSTCASHFSSVSLFYGSIFFLYIRP  
 30 NLLEGGNDIPAAILFTIVVPLNPFYSLRNKEVISVLRKILLKIKSQGSVNK (SEQ ID NO: 39)

35 ATGGTTGAAGAAAATCATACCATGAAAATGAGTTATCCTCACAGGATTACAGATCACC  
 CTGAGCTGAAGACTCTGTTGTGGTTCTTGCATCTATCTGATCACCGTGGGG  
 GAATATTAGTTGGTGGCACTGATATTACACACTGTCGGCTCACACACCAATGTACATC  
 40 TTTCTGGAAATCTGGCTCTGGATTCTGCTGTGCTGTGCTATTACCCCAAATGTT  
 AGAGAACCTCTTCTGAGGGCAAAGGATTCCCTATGAATGTGAGTACAGTTAT  
 TTTCTTGCACTGTGGAAACTGCAGACTGCTTCTGGCAGCAGTGGCTATGACCGCT  
 ATGTGGCCATCTGCAACCACTGCACTGACGATACATGATGTCAAGAAACTCTGCATTCA  
 GATGACCAAGGCGCCTCATAGCTGAAATCTGCATTCCATGATTGATGTAGGGCTTGTA  
 45 TTAGTTAGTTCTGTTGACCTTCAATGAACCTGTGATACTCTCCCTT  
 CAGTTCAAGTCTTACCATAGGTAGTGTCTTAATATCTATATTCTCTTACTATT  
 TTCAGAATGAAATCCAAGGAGGAAGGGCAAAGCTTCTACTGTGCACTCCACCTT  
 CATCAGTTCAATTATCTATGGATCTATTCTTCTATACATTAGACCAAATTGCTTGA  
 GAAGGAGGTAATGATATACCAAGCTGTATTACATTACAATAGTAGTCCCTACTAAATC  
 CTTTCATTATAGTCTGAGAAACAAGGAAGTAATAAGTGTCTAAGAAAATTCTGCTGAA  
 AATAAAATCTCAAGGAAGTGTGAACAAATGA (SEQ ID NO: 40)

## AOLFR21 sequences:

50 MEPRKNVTDFVLLGFTQNPKEQKVLFVMFLLFYILTMVGNLIVVTVTSETLGSPMSFFLAGL  
 TFIDIIYSSSISPRLISDLFFGNNISFQSFMAQLFIEHLFGGSEVFLLVMAYDRYVAICKPLHYLV  
 IMRQWVCVLLVVSVWVGGFLQSVFQLSIIYGLPFCGPVIDHFFCDMYPLLKLAETDTHVIGLL  
 VVANGLSCCTIAFLLLISYGVILHSLKKLSQKGRQKAHSTCSSHTVVVFVPCIFMCARPAR  
 TFSIDKSVSVFYTWTPLNPLIYTLRNSEMTSAMKKL (SEQ ID NO: 41)

5 TCACCCCTCTCCTCTGTAAGGACAATCAAATAAACTTCTTCTGTGACCTCCCACCCCTG  
 CTGAAGCTTGCTGAGTACAGACAGCAAACATCGAGATTGTCATCATCTTGGCAATT  
 TTGTGATTTGCCAATGCCTCCGTATCCTGATTCTATCTGTCATCATCAAGACCATT  
 TTGAAAGTGAAGTCTCAGGTGGCAGGCCAAGACTTCTCACATGTGCCTCTCACATCA  
 10 CTGCTGTGGCCCTTTCTTGGAGCCCTATCTCATGTATCTGCAAAGTGGCTCAGGCAA  
 TCTCTGGAGGAAGACAAAGTCGTCTGTCTTACAGTGGTCATCCCCATGCTGAACC  
 CTCTGATCTACAGCTTAAGAAACAAAGATGAAAAGACGCCCTCAGAAAGGTGCTAGGA  
 GACTCCAGGTGTCCTGAGCATGTAG (SEQ ID NO: 46)

10 **AOLFR25 sequences:**

15 METGNLTWVSDVFLGLSQTRELQRFLFLMFLFYITVMGNILIIITVTSQQLHTPMYFLLRN  
 LAVLDLCFSSVTAPKMLV DLLSEKKTISYQGCMQIFFFHFLGGAMVFLSVMADFRLIAISRPL  
 RYVTVMNTQLWVGLVVATWVGGFVHSIVQLALMLPLPFCGPNI LDNFYCDVPQVRLACTDT  
 SLLEFLKISNSGLLDVVWFLLLMSYLFILVMLRSHPGEARRKAASTCTTHIIVVSMIFVPSIYLY  
 ARPFTPFPMDKLVSIGHTVMTPMLNPIMYTLRNQDMQAAVRRLGRHRLV (SEQ ID NO: 47)

20 ATGGAAACAGGGAACCTCACGTGGTATCAGACTTGTCTTCTGGGCTCTCGCAGACTC  
 GGGAGCTCCAGCAGCTTCTGTTCTAATGTTCTGTTGTCTACATCACCAGTGTATGGGA  
 AACATCCTTATCATCACAGTGA CCTCTGATTCCCAGCTCCACACACCCATGTACTTTCT  
 GCTCCGAAACCTGGCTGTCTAGACCTCTGTTCTCTCAGTCAGTCACTGCTCCAAAATGCTAG  
 TGGACCTCCTCTGAGAAGAAAACCATCTCTACCAGGGCTGCATGGGTAGATCTTCTT  
 CTTCCACTTTGGGAGGTGCCATGGTCTTCTCTCAGTGATGGCCTTGACCACCTCA  
 TTGCCATCTCCGGCCCTCCGCTATGTCACCGTCATGAACACTCAGCTCTGGTGGGCT  
 GGTGGTAGCCACCTGGGTGGGAGGCCTTGCCACTCTATTGTCAGCTGGCTCTGATGCTC  
 25 CCACTGCCCTCTGTGGCCCAACATTGGATAACTTCACTGTGATGTTCCCAAGTACT  
 GAGACTTGCCTGCACTGACACCTCACTGCTGGAGITCCTCAAGATCTCCAAACAGTGGGCTG  
 CTGGATGTCGCTGGTTCTCCTCTCCTGATGTCCTACTTATTCACTGGTATGCTGAG  
 GTCACATCCAGGGAGGCAAGAAGGAAGGCAGCTCCACCTGCACCACCCACATCATCGT  
 30 GGTTCCATGATCTCGTCCAAGCATTACCTCTATGCCGGCCCTCACTCCATTCCCTA  
 TGGACAAGCTTGTGTCCATCGGCCACACAGTCATGACCCCCATGCTCAACCCATGATCTA  
 TACCCCTGAGGAACCAGGACATGCAGGCAGCAGTGAGAAGATTAGGGAGACACCCGGCTGGT  
 TTGA (SEQ ID NO: 48)

**AOLFR26 sequences:**

35 MAAKNSSVTEFILEGLTHQPLRIPLFLFLGFYTVTVGNLGLITLIGLNSHLHTPMYFFLFNLS  
 LIDFCFSTTITPKMLMSFVSRKNIISFTGCMTQLFFFVSESFILSAMAYDRYVAICNPLLYT  
 VTMSCQVCLLLLGAYGMGFAGAMAHTGSIMNLTFCADNLVNHFMCIDLPLLELSCNSSYMN  
 ELVVFIVVAVDVGMPIVTFVFSYALILSSILHNSSTEGRSKAFSTCSSHIVVSLFFSGAFMYLKP  
 LSILPLEQGVSSLFYTIIVPVLNPLIYSLRNKDVKVALRRTLGRKIFS (SEQ ID NO: 49)

40 40 ATGGCAGCCAAAACCTTCTGTGACAGAGTTATCCTCGAAGGCTAACCCACCAGCCGG  
 GACTGCGGATCCCCCTCTTCTGTTCTGGGTTCTACACGGTCACCGTGGTGGGAA  
 CCTGGGCTTGATAACCCCTGATTGGGCTGAACCTCCTGCACACTCCCATGTA CTTCTTCC  
 TTTTAACCTCTTTAATAGATTCTGTTCTCCACTACCATCACTCCAAAATGCTGATG  
 45 AGTTTGTCAGGAAGAACATCATTTCTTACAGGGGTATGACTCAGCTCTTCTTCT  
 CTGCTCTTGTCTGAGTCTGCTCATCTGTCAGCGATGGCTATGACCGCTACGTGG  
 CCATCTGTAACCCACTGTTGACACAGTCACCATGTCCTGCCAGGTGTGTTGCTCTTTG  
 TTGGGTGCCATGGGATGGGTTGCTGGGCCATGCCACACAGGAAGCATAATGAAC  
 CTGACCTCTGTGCTGACAACCTGTCAATCATGTTGACATCCTCTCTCCTGA  
 50 50 GCTCTCCTGCAACAGCTTACATGAATGAGCTGGTGGTCTTATTGTTGCTGTTGAC  
 GTTGGAAATGCCATTGTCAGTGTCTTATTCTTATGCCCTCATCCTCTCCAGCATTCTACA  
 CAACAGTTCTACAGAAGGCAGGTCCAAAGCCTTACTGTCAGTCCACATAATTGTA  
 GTTTCTCTTCTTGGTTCTGGTCTTCTGTTCATGTTACCTCAAACCCCTTCCATCCTGCCCTC  
 GAGCAAGGGAAAGTGTCTCCCTGTTCTACCATTAATAGTCCCCGTGTTAAACCCATTAA  
 55 TCTATAGCTTGAGGAACAAGGATGTCAAAGTGTGCCCTGAGGAGAACTTGGGAGAAAAAA  
 TCTTTCTTAA (SEQ ID NO: 50)

**AOLFR27 sequences:**

5 MPSQNYSIISEFNLGFSAFPQHLLPILFLYLLMFLFTLLGNLLIMATIWEHRLHTPMYLFCLTL  
 SVSEILFTVAITPRMLADLLSTHHSITFVACANQMFSFMFGFTHSFLLVMGYDRYVAICHPLR  
 YNVLMSPRDCAHLVACTWAGGSVMGMVTTIVFHTFCGSNVIIHFFCHVLSLLKACENKT  
 10 SSVIMGVMLVCVTALIGCLFLILSYVFIVAILRIPSAEGRHKTFSTCVSHLTVVVTHYSFASFIY  
 LKPKGLHSMYSDALMATTYVFTPFLSPIFSRNKELKNAINKNFYRKFCPPSS (SEQ ID NO:  
 51)

15 ATGCCTAGTCAGAACTATAGCATCATCTGAATTAACTCTTGGCTTCAGCCTTCCC  
 CCAGCACCTCTGCCATCTTGTCTGCTGTACCTCTGATGTTCTGTTCACATTGCTGG  
 GCAACCTTCTCATGGCACAATCTGGATTGAACACAGACTCCACACACCCATGTACCT  
 CTTCTGTGACCCCTCCCGTCTGAGATTCTGTTACTGTTGCCATCACCCCTCGCATGC  
 TGGCTGATCTGCTTCCACCCATCATCCATCACCTTGTGGCTTGCCAAACAGATGTTC  
 TTCTCTCATGTTGGCTTCACTCACTCTTCTCTGGTATGGGCTATGATCGCTA  
 TGTGGCCATCTGCCACCCACTGCGTACAATGTGCTATGAGCCCCGTGACTGTGCCAT  
 CTTGTGGCTGTACCTGGGCTGGTGGCTGACTCATGGGATGATGGTACAACGATAGTT  
 20 TCCACCTCACTTCTGTGGGTCTAATGTGATCCACCATTTCTGTATGTGCTTCCCTCT  
 TGAAGTTGGCCTGTGAAAACAAGACATCATCTGTCATGGGTGTGATGCTGGTGTGTT  
 CACAGCCCTGATAGGCTGTTATTCTCATCATCTCTCTATGTCTTCAATTGTGGCTGACTGTGCC  
 TCTTGAGGATTCCCTCTGCCGAAGGGCGGACAAGACATTTCTACGTGTATCCACCT  
 CACTGTGGTGGTCACGCACTATAGTTGCCTTATCTACCTCAAGCCAAGGGCCTCC  
 ATTCTATGTACAGTGACGCCCTGATGGCCACACCTATACTGTCTCACCCCTTCTAGC  
 CCAATCATTTCAGCCTAAGGAACAAGGAGCTGAAGAATGCCATAAATAAAACITTTACA  
 25 GAAAATTCTGTCCTCCAAGTCTGA (SEQ ID NO: 52)

**AOLFR28 sequences:**

30 MPNFTDVTEFTLLGLTCRQELQVLFVVFLAVYMITLLGNIGMIIISIQLQSPMYFFLSHLSF  
 ADVCFSSNVTPKMLENLLSETKTISYVGCLVQCYFFIAVHVVEVYILA VMAFDRYMAGCXPLL  
 YGSKMSRTVCVRLISVXXYXGSVSILCTLWTYGLYFCGNFEINHFYCADPPLIQACGRVHIKE  
 ITMIVIAGINFTYSLSVLISYTLIVVAVLRMRSADRRKAFSTCGSHLTAVSMFYGTPIFMYLR  
 RPTEESVEQGKMOVAFYTTVIPMLNPMIYSLRNKDVKAEVNKAITKTYVRQ (SEQ ID NO: 53)

35 ATGCCTAATTTCACGGATGTGACAGAATTACTCTCTGGGCTGACCTGTCGTCAAGGAGC  
 TACAGGTTCTTTTGTGGTGTCTAGCGGTTACATGATCACTCTGTTGGAAATATT  
 GGTATGATCATTGATTAGCATAGTCTCAGCTTCAAGTCCATGACTTTCTGAG  
 TCATCTGTCTTTGCGGACGTGTGCTTCTCTCAACGTTACCCCAAATGCTGGAAACT  
 TATTATCAGAGACAAAAACCATTCCTATGTGGATGCTGGTGCAGTGTACTTTCTAT  
 TGCCGTTGTCACGTGGAGGTCTATATCCTGGCTGTGATGGCTTGAAGGTACATGCC  
 GGCCTGCAANCTCTGCTTATGGCAGTAAATGTCTAGGACTGTGTGTTGGCTCATCT  
 CTGTGNNNTATGNNTATGGATTCTGTCACTCTAATGCAACTATGGACTTATGGCTT  
 ATACTTCTGTGGAAACTTGAATCAATCACTCTAATGTGCACTATGGACTTATGGCTT  
 TTGCTGTGGAGAGTGCACATCAAAGAAATCACAATGATTGTTATGCTGGAAATTAACTT  
 40 CACATATTCCCTCTGGTGTCTCATCTCTACACTCTCATTGTTAGCTGTGCTACGCA  
 TGCGCTCTGCCGATGGCAGGAGGAAGGCGTCTCACCTGTGGTCCCACCTGACGGCTGT  
 TTCTATGTTTATGGGACCCCCATCTCATGTATCTCAGGAGACCCACTGAGGAATCCGA  
 GAGCAGGGAAAATGGTGGCTGTGTTACACCACAGTAATTCTATGTGAATCCATGA  
 TCTACAGTGTGAGAAATAAGGATGTAAAAGAAGCAGTCACAAAGCAATACCAAGACAT  
 ATGTGAGGCAGTAA (SEQ ID NO: 54)

50

**AOLFR29 sequences:**

55 MMSFAPNASHSPVFLLGFSRANISYTLFFLFLAIYLTILGNVTLVLLISWDSRLHSPMYYLLR  
 GLSVIDMGLSTVLPQLLAHLVSHYPTIPARCLAQFFFFYAFGVTDTLVIAMALDRYVAICD  
 PLHYALVMNHQRCACLLALSVVSIHLTMRLVGLVPLCWTGDAGGNVNLPHFFCDHRPLLR  
 ASCSDIHSNELAIFFEGGFLMLGPCALIVLSYRIGAAILRLPSAAGRRAVSTCGSHLTMVGFL

5           TCCTCTGCCATTGGCCTTGTAGACATTGGGTACTCCTCATCAGTCACACCTGTCATGCTC  
 ATGAGCTTCTAAAGGAAAGAACCTCTCCCTGTTGCTGGTTGTGGCCAGCTCTGTT  
 CTGTAGTGACGTTGGTACGGCCAGTGCTCCTGCTGGCTGCCATGGCTATGATCGCTA  
 TGTGGCCATCTGCTACCCCTGCTACTCACCTGCATGTCCTGGAGTCTGCATCATCT  
 10          TAGTGGGCATGTCCTACCTGGTGGATGTGAATGCTTGGACATTCAATTGGCTGCTTATT  
 AAGACTGTCCTCTGTGGGCCAATAAGTCAATCACCTTTCTGTGACTATTCAACCACTT  
 TGAAGCTTGTGTTCCCATGATTACTTTGAAATAATTCCAGCTATCTTCTGGATCT  
 ATCATGTGGCCACTGTGTGTCAAGCCATATCCTACATCTATATCCTCATCACCATCCT  
 15          GAAGATGCACTCCACCAAGGGCCACAAGGCCTCTCCACCTGCACCTCCCACCTCACT  
 GCAGTCACTCTGTTATGGGACCATTACCTCATTATGTGATGCCAAGTCCAGCTACTC  
 AACTGACCAGAACAGGTGGTCTGTGTTACACCGTGGTATTCCATGTTGAACCCCC  
 CTGATCTACAGCCTCAGGAACAAGGAGATTAAGGGGCTCTGAAGAGAGAGCTTGAATA  
 AAAATATTCTTGA (SEQ ID NO: 60)

15          **AOLFR32 sequences:**

MNSLKDGHNHTALTGFILLGLTDDPILRVILFMIILSGNLSIIILIRISSQLHHPMYFFLSHLAFADM  
 AYSSSVTPNMLVNFLVERNTSYLGCAIQLGSAAFFATVECVLAAAMAYDRFVAICSPLLYSTK  
 MSTQSVQLLLVVYIAGFLIAVSYTTSFYFLLFCGPNVNHFCDFAPLLELSCSDISVTVVLSF  
 20          SSGSIIVVTVCVIAVCYIYIILITKMRSTEHHKAFTCTSHLTVVTLYGTITFIYVMPNFSYST  
 DQNKKVSVVLYTVVIPMLNPLIYSLRNKEIKGALKRELVRKILSHDACYFSRTSNNDIT (SEQ ID  
 NO: 61)

25          ATGAATTCCCTGAAGGACGGGAATCACACCGCTCTGACGGGTTCATCCTATTGGGCTTAA  
 CAGATGATCCAATCCTCGAGTCATCCTCTCATGATCATCCTATCTGGTAATCTCAGCATA  
 ATTATTCTTATCAGAATTCTCTCAGCTCCATCATCCTATGTATTCTTCTGAGCCACTT  
 GGCTTTGCTGACATGGCCTATTCTATCTTCTGTCACACCCAACATGCTTGTAAACTCCTGG  
 TGGAGAGAAATACAGTCTCTACCTTGGATGTGCCATCCAGCTTGGTTAGCGGGCTTCTT  
 TGCAACAGTCGAATGCGCCTTCTGGCTGCCATGGCCTATGACCGCTTGTGGCAATTTC  
 30          AGTCCACTGCTTATTCAACCAAAATGTCCACACAAGTCAGTGTCCAGCTACTCTAGTAG  
 TTTACATAGCTGGTTTCTCATTGCTGTCTCTATACTACTTCTTCTATTCTTACTCTTCT  
 GTGGACCAAATCAAGTCATCATTTCTGTGATTGCTCCCTACTTGAACTCTCCTGT  
 TCTGATATCAGTGTCTCACAGTTGTTCTCATTTCTGATCCATCATTGTGGTCAC  
 TGTGTGTGTATGCCGTCTGCTACATCTATATCCTCATCACCATCCTGAAGATGCGCTCCA  
 35          CTGAGGGGCACCACAAGGCCTCTCCACCTGCACCTCCACCTCACTGTGGTTACCTGT  
 CTATGGGACCATTACCTCATTATGTGATGCCAATTAGCTACTCAACTGACCAAGAAC  
 AAGGTGGTGTCTGTGTTGACACAGTGGTATTCCATGTTGAACCCCTGATCTACAGCC  
 TCAGGAACAAGGAGATTAAGGGGCTCTGAAGAGAGAGCTTGTAGAAAAACTTCTC  
 ATGATGCTTGTATTAGTAGAACTTCAAATAATGATATTACATAG (SEQ ID NO: 62)

40          **AOLFR34 sequences:**

MLEGVEHLLLLLTDVNSKELQSGNQTSVSHFILVGLHHPPQLGAPLFLAFLVIYLLTVSGNG  
 LIITVLDIRLHRPMCLFLCHLSFLDMTISCAIVPKMLAGFLLGSRUIFGGCVIQLFSFHFLGCT  
 ECFLYTLMAYDRFLAICKPLHYATIMTHRVCNSLALGTWGGTHSLFQTSFVFLPFCGPNRV  
 45          DYIFCDIPAMLRLACADTAINELVTFADIGFLALTCFMLILTSYGYVAAILRIPSADGRRAFST  
 CAAHLTIVVIVYYVPCFIYLRPCSQEPLDGVVAVFYTIVTPLLNSIYTLCKEMKAALQRLGG  
 HKEVQPH (SEQ ID NO: 63)

50          ATGTTAGAGGGTGTGAGCATCTCCTCTGCTACTCTTTGACAGATGTGAACAGCAAGG  
 AACTGCAAAGTGGAAACCAGACTCTGTGCTCACTCATTGGTGGCCTGCACCAACCC  
 ACCACAGCTGGAGGCCACTCTCTTAGCTTGTACATCTATCTCCTACTGTTCTG  
 GAAATGGGCTCATCATCCTCACTGTCTTAGTGGACATCCGGCTCCATGTCCCAGATGCTT  
 GTTCCGTGTACCTCTCCTTGGACATGACCATTCTGTGCTATTGTCCCCAAGATGCTT  
 TGGCTGGCTTCTCTGGTAGTAGGATTATCTCTTGGGGCTGTGTAATCCAACATT  
 55          TCTTCCATTCTGGCTGTACTGAGTGTCTTACACACTCATGGCTTATGACCGTT  
 CCTGCCATTGTAAGCCTTACACTATGCTACCATGACCCACAGAGTCTGTAACCTCC  
 TGGCTTACGGCACCTGGCTGGGAGGGACTATCCATTCACTTCCAAACAAGTTGTATT

WO 01/98526

5 CGGGCTGCCCTCTGGCCCCAATGGGTCGACTACATCTCTGACATTCCGCCATGC  
 TCGCTAGCCTGCGCGATACGGCCATCAACGAGCTGGTCACCTTGCAGACATTGGCTT  
 CCTGGCCCTCACCTGCTTATGCTCATCCTCACTTCCATTGGCTATATTGTAGCTGCCATCC  
 TCGAATTCCGTACAGCAGATGGGCGCGCAATGCCCTCTCAGCTTGCACCTTACCTGCGGCCACCTCAC  
 10 TGTTGTCATTGTTACTATGTGCCCTGCACCTCATTACCTGCGGCCCTGTTACAGGAGC  
 CCCTGGATGGGGTGGTAGCTGCTTTACACTGTCACTACCCCTGCTTAACCCATCATC  
 TACACACTGTGCAACAAAGAAATGAAGGCAGCATTACAGAGGCTAGGGGCCACAAGGAA  
 GTGCAGCCTCACTGA (SEQ ID NO: 64)

## 10 AOLFR35 sequences:

MEPLNRTEVSEFFLKGFSGYPALEHLLPLCSAMYLVTLLGNTAIMAVSVDIHLHPTVYFFLG  
 NLSTLDICYPTFVPLMLVHLLSSRKTSFAVCIAQMCLSLSTGSTECLLLAITAYDRYLAICQL  
 RYHVLMSHRLCVLLMGAAWVLCLLKSVTMVISMRLPFCGHVVSHFTCKILAVKLACGNT  
 15 SVSEDFLAGSILLPVPLAFICLPSYLLILATILRVPSAARCKAFSTCLAHLAVVLLFYGTIIFMY  
 LKPKSKEAHISDEVFTVLYAMVTTMLNPTIYSLRNKEVKEAARKVWGRSRASR (SEQ ID NO:

20 ATGGAGCCGCTAACAGAACAGAGGTGTCGAGTTCTTCTGAAAGGATTTCTGGCTACC  
 CAGCCCTGGAGCATCTGCTCTTCCCTGTGCTCAGCCATGTACCTGGTGACCCCTCTGGG  
 25 GAACACAGCCATCATGGCGGTAGCGTCTAGATATCACCTGCACACGCCGTGACTTC  
 TTCCCTGGCAACCTCTTACCCCTGGACATCTGCTACAGCCCACCTTGTGCTCTGATGCT  
 GGTCCACCTCTGTATCCCGGAAGACCATCTCCTTGTGCTGTGCTGCCATCCAGATGTGTC  
 TGAGCCTGTCACGGGCTCACGGAGTGCTACTGGCCATCACGGCTATGACCGCTA  
 CCTGGCCATCTGCCAGCCACTCAGGTACCGTACAGTGGCTCATGAGCACGGCTCTGCGTGTG  
 30 CTGATGGGAGCTGCCCTGGGTCTGCCTCTGCTCAAGTCGGTACTGAGATGGTCATCTCCA  
 TGAGGCTGCCCTCTGTGGCACCGTGGTACGTACTCACCTGCAAGATCCTGGCAGT  
 GCTGAAGCTGCATGGCAACACGTCGGTACGGAGACTTCTGCTGGGGCTCCAT  
 CCTGCTGTCCTGTACCCCTGGCATTCTGCTGCTACTTGCTCATCTGGCAGT  
 35 TCCTGAGGGTGCCTCGGCCAGGTGCTGCAAGCCTCTCACCTGCTGGCACACCT  
 GGCTGTAGTGTGCTTTCTACGGCACCATCATCTCATGACTGAAGCCAAGAGTAAG  
 GAAGCCCACATCTGTATGAGGTCTCACAGTCCTATGCCATGGTCAGGACCATGCTGA  
 ACCCCACCATCTACAGCCTGAGGAACAAGGAGGTGAAGGAGGCCAGGAAGGTGTGGG  
 GCAGGAGTCGGGCCTCCAGGTGA (SEQ ID NO: 66)

## 35 AOLFR36 sequences:

MYLVTVLNLLSILAVSSDSHPTPMYFFLSNLWADIGTLATVPKIVDMGSHSKVISYGG  
 CLTQMSFLVLFACIVDMFLTVMAYDCFVAICRPLHYPVIVNPHLCVFFVLSFFLSQLHS  
 WIVLQFTFFKNVEISNFVCEPSQLKLASYDSVINSIFYFDNTMFGFLPISGILLSYYKIVPSILRIS  
 SSDGKYKAFSACGCHLAVVCLFYGTGIGVYLTSAVAPLRLNGMVASVMYAVVTPMLNPFIYS  
 40 LRNRDIQSALWRVCNKTVESHLFHPFSCVVEKGQPHSIPTSANPAP (SEQ ID NO: 67)

45 ATGTATCTGGTCACGGTGTGAGGAACCTGCTCAGCATCTGGCTGTCAGCTCTGACTCCC  
 ACCCCCCACACACCCATGTACTTCTCCTCTCCACCTGTGCTGGCTGACATCGGTTTCACC  
 TTGGCCACGGTCTCCAAAATGATTGTGACATGGGGTCGATAGCAAAGTCATCTCTTATG  
 GGGGCTGCTGACACAGATGTCTTCTGGTACTTTGCATGTATAGTAGACATGTTCT  
 50 GACTGTATGGCTTATGACTGTCTTCTCGTTGGTACACCTCAGCTTGCCTCTGCACTACCCAGTCATC  
 GTGAATCTCACCTCTGTGCTCTTCTCGTTGGTACACCTCAGCTTGCCTCTGCACTACCCAGTCATC  
 CAGCTGCACAGTGGATTGTGTTACAATTCAAGCTTGCCTCTGCACTACCCAGTCATC  
 TTGTCTGTGAGCCATCTCAACTCTCAAGCTTGCCTCTGCACTACCCAGTCATC  
 55 TTCATATATTTGATAACTATGTTGGTTTCTCCCATTCAGGGATCCTTGTCTTAC  
 TATAAAATTGTCCCCCTCCATTCAAGGATTCTCATCAGATGGGAAGTACAAGCCTTCT  
 CAGCCTGTGGCTGTCACCTGGCAGTTGCTTATTTATGGAACAGGCATGGCGTGA  
 CCTGACTTCAGCTGTGGCACCACCCCTCAGGAATGGTATGGTGGCGTCACTGATGTACGCT  
 GTGGTCACCCCATGCTGAACCTTCACTACAGCCTGAGAAACAGGGACATCAAAGTG  
 CCCTGTGGAGGGTGTGCAACAAACAGTCGAATCTCATGATCTGTCATCCTTCTTCTG

TGTGGTTGAGAAAGGGCAACCACATTCAATCCCTACATCTGCAAATCCTGCCCTAG  
(SEQ ID NO: 68)

**AOLFR37 sequences:**

5 MEKANETSPVMGFVLLRLSAHPELEKTFVLILLMYLVILLGNGVLILVTILDSRLHTPMYFFLG  
NLSFLDICFTTSSVPLVLDSDLTPQETISFSACAVQMALSFAMAGTECLLSMMAFDRYVAICNP  
LRYSVIMSKAAYMPMAASSWAIGGAASVVHTSLAIQLPFCGDNVNINHTCEILAVLKLACADIS  
INVISMEVTNVIFLGVPLFISFSYVIITILRIPSAEGRKKVFSTCSAHTVVIVFYGTLFFMYG  
10 KPKSKDSMGADKEDLSKLIPLFYGVVTPMLNPIYSLRNKDVKAAVRRLLRPKGFTQ (SEQ ID  
NO: 69)

ATGGAAAAAGCCAATGAGACCTCCCTGTGATGGGGTTCTGCTGAGGCTCTGCC  
ACCCAGAGCTGGAAAAGACATTCTCGTCTGCTCATCCTGCTGATGTACCTCGTATCCTGCT  
15 GGGCAATGGGGTCTCATCCTGGTACCATCCTGACTCCGCCTGCACACGCCATGTAC  
TTCTCCTAGGAACCTCTCCTCCTGGACATCTGCTTCACTACCTCCTCAGTCCCCTGGT  
CCTGGACAGCTTTGACTCCCCAGAAACCATCTCCTCAGCCTGTGCTGTGCAGATG  
GCACTCTCCTTGCATGGCAGGAACAGAGTCTGCTCTGAGCATGATGGCATTGATC  
GCTATGTGGCCATCTGCAACCCCCCTAGGTACTCCGTATCATGAGCAAGGCTGCTACAT  
20 GCCCATGGCTGCCAGCTCCTGGGCTATTGGTGGTCTGCTTCCGTGGTACACACATCCTG  
GCAATTCACTGGCCTCTGTGGAGACAATGTCATCAACCACTCACCTGTGAGATTCTGG  
CTGTTCTAAAGTTGGCCTGTGCTGACATTTCATCAATGTGATCAGCATGGAGGTGACGAA  
TGTGATCTCCTAGGAGTCCCCTGTTCTGTTATCTCTTCTCCTATGTCTTATCATCACCA  
25 CCATCCTGAGGATCCCCCTAGCTGAGGGGGAGGAAAAGGTCTCTCCACCTGCTCTGCCA  
CCTCACCGTGGTATCGTCTTACGGGACCTTATTCTTATGATGGGAAGCCTAAGTCT  
AAGGACTCCATGGAGCAGACAAGAGGATCTTCAGACAAACTCATCCCCCTTTCTATG  
GGGTGGTACCCGATGCTCAACCCATCATCTATAGCCTGAGGAACAAGGATGTGAAGG  
CTGCTGTGAGGAGACTGCTGAGACCAAAAGGCTTCACTCAGTGA (SEQ ID NO: 70)

**AOLFR38 sequences:**

30 MYLVTVRNLLIILAVSSDSHLHTPMCFPSNLWADIGFTSAMVPKIVDMQSHSRVISYAGC  
LTQMSFFVLFACIEDMLLTVMAYDRFVAICHPLHYPVIMNPHLGVFLVLSFFSLSQLHSW  
IVLQFTFFKNVEISNFVCDPSQLNLACSDSVINSIFIYLDSIMFGFLPISGILLSYANNVPSILRISS  
SDRKSKAFSTCGSHLAVVCLFYGTGIGVYLTAVSPPPRNGVVASVMYAVVTPMLNPFYSLR  
NRDIQSQLWRLRSRTVESHDLLSQDLLHPFSCVGEKGQPH (SEQ ID NO: 71)

35 ATGTACCTGGTCACGGTGCTGAGGAACCTGTCATCATCCTGGCTGTCAAGCTCTGACTCCC  
ACCTCCACACCCCCATGTGCTTCTCCTCTCCAACCTGTGCTGGCTGACATCGTTTCACC  
TCGGCCATGGTCCCAAGATGATTGTGGACATGCAGTCGATAGCAGAGTCATCTCTTATG  
40 CGGGCTGCTGACACAGATGTCTTCTTGTCTTGCATGTATAGAAGACATGCTCCTG  
ACAGTGATGGCCTATGACCGATTGTGGCCATCTGTCAACCCCTGCACTACCCAGTCATCA  
TGAATCCTCACCTGGTGTCTTCTAGTTGGTGTCTTCTCAGCCTGTTGGATTCC  
CAGCTGCACAGTTGGATTGTTACAATTCACTTCTCAAGAATGTGAAATCTCAATT  
55 TTGTCTGTGACCCATCTCAACTCTCACCTTGCCTGTCTGACAGTGTATCAATAGCATA  
TTCATATTTAGATAGTATTATGTTGGTTCTTCCCATTCAGGGATCCTTGTCTTAC  
GCTAACAAATGCCCCCTCATTCAAGAATTCACTCAGATAGGAAGTCATAAGCCTCT  
CCACCTGTGGCTCTCACCTGGCAGTTGTTGCTATTATGGAACAGGCATTGGCTGTA  
CCTGACTTCAGCTGTGTCAACCACCCCCAGGAATGGTGTGGCATCAGTGTACGCT  
GTGGTCACCCCATGCTGAACCTTCACTCAGCCTGAGAAATAGGACATTCAAAGTG  
CCCTGTGGAGGCTGCGCAGCAGAACAGTCGAATCTCATGATCTGTTATCTCAAGATCTGCT  
50 CCATCCTTTCTGTGTGGGTGAGAAAGGTCAACCACATTAA (SEQ ID NO: 72)

**AOLFR39 sequences:**

MGVKNHSTVTEFLLSGLTEQAEQLPLFCLFLGIYTVVGNLSMISIIRLNRLHTPMYFLSS  
LSFLDFCYSSVTPKMLSGFLCRDRSISYSGCMIQLFFFVCVVISECYMLAAMACDRYVAICSP  
55 LYRVIMSPRVCSSLVAAVFVGFTDAVIHGGCILRLSFCGSNIKHYFCDIVPLIKLSCSSTYIDEL

WO 01/98526

LIFVIGGFNMVATSLTIIISYAFILTSILRIHSKKGRCKAFSTCSSHLTAVLMFYGSLMSMYLKPS  
 SSSLTQEKVSSVFYTTVILMLNPLIYSLRNNEVRNALMKLRRKISLSPG (SEQ ID NO: 73)

5 ATGGGTGTAAAAACCATTCCACAGTGACTGAGTTCTCTTCAGGATTAACGTAAAG  
 CAGAGCTTCAGCTGCCCTCTGCCTCTTAGAATTACACAGTTACTGTGGTGGG  
 AACCTCAGCATGATCTCAATTATTAGGCTGAATCGTCAACTCATACCCCCATGTACTAT  
 10 TTCTGAGTAGTTGTCTTTAGATTCTGCTATTCTGTCTATTCTGGATGCATGATTCACTGTTT  
 ATCAGGGTTTATGCAGAGATAGATCCATCTCTATTCTGGATGCATGATTCACTGTTT  
 TTTCTGTGTTGTATTCTGAATGCTACATGCTGGCAGCCATGGCTGCGATCGCTAC  
 GTGCCATCTCAGCCCAGTCTACAGGGTACATGCTGGCAGCCATGGCTGCGATCGCTAC  
 15 TGGTGGCTGCTGCTCTCAGTAGGTTACTGATGCTGTGATCCATGGAGGTGTATACT  
 CAGGTTGTCTTCTGTGGATCAAACATCAAAACATTATTCTGTGACATTGCCCCTTA  
 TTAAACTCTCTGCTCCAGCACTTATATTGATGAGCTTTGATTTCATATGCTTTATCCTCACAGCATCT  
 AACATGGTGGCCACAAGCTAACAACTATTTCATATGCTTTAGCACCTGTAGCTCCACCTGACA  
 GCGCATCCACTCTAAAAGGGCAGGTGCAAAGCGTTAGCACCTGTAGCTCCACCTGACA  
 GCTGTTCTATGTTTATGGGCTCTGATGTCATGTATCTCAAACCTGCTTAGCAGTTC  
 20 ACTCACCCAGGAGAAAGTATCCTCAGTATTATACCACIGTGAATTCTCATGTTGAATCCC  
 TTGATATAGTCTGAGGAACAATGAAGTAAGAAATGCTCTGATGAAACTTAAAGAAGA  
 AAAATATCTTATCTCCAGGATAA (SEQ ID NO: 74)

20 AOLFR40 sequences:  
 MSNATLTAFILETGLPHAPGLDAPLFGIFLVVYVLTVLGNLLILLVIRVDSHLHTPMYYFLTNLS  
 FIDMWSTVTVPKMLMTLVSPLSGRTISFHSCVAQLYFFHFLGSTECLYTVMSYDRYLAISYPL  
 25 RYTNMMTGRSCALLATGTWLSGSLHSAVQTLTFHLPYCGPNQIQHYFCDAPIKLACADTS  
 ANEMVIFVNIGLVASGCFVLIVLVSYSIVCSILRIRTSEGRHRAFQTCAASHCIVLICFFGPGLIYL  
 30 RPGRDALHGVVAVFYTTLPLFNPVYTLRNKEVKKALLKLKNGSVFAQGE (SEQ ID NO:  
 75)

30 ATGTCCAACGCCACCCACTGACAGCGTTACCTCACGGGCCTCCCCATGCCAGGGC  
 TGGACGCCCTCTTGAATCTCCTGGTGGATTACGTGCTACTGTGCTGGGAAACCT  
 CCTCATCTGCTGGTGATCAGGGGATTCTCACCTCACCCCCATGTACTACTTCTCA  
 35 CCAACCTGTCTTCATTGACATGTGGTCTCCACTGTACGGTCCCCAAATGCTGATGAC  
 CTTGGTGTCCCCAAGCGCAGGACTATCTCTTCCACAGCTGCGTGGCTCAGCTCTATT  
 TCCACTTCTGGGGACCGAGTGTCTCTACACAGTACATGACTGGGCGCTGTGCCCCCTG  
 40 GCCACCGGACTTGGCTCAGTGGCTCTGACTCTGACTCTGCTGTGACGCAACGGCCATCT  
 GGCCATCAGTTACCCGCTCAGGTACACCAACATGATGACTGGGCGCTGTGCCCCCTG  
 ATTGCCCCTACTGTGGACCCAACCAGACACCTCAGCCAACGAGATGGTCACTTGTGA  
 45 GAAACTGGGCTGTGACACCTCAGCCAACGAGATGGTCACTTGTGAACGGCCATCT  
 GTGGCCTCGGGCTGTTGCTGATAGTGTCTCTGACGCACTACTCTGCTGTGACGCA  
 50 GCGGATCCGACCTCAGAGGGAGGCACAGAGCCTTCAGACCTGTGCTGTGCCCCATCCT  
 GTGGTCCTTGTCTTGGCCCTGGTCTTCACTTACCTGAGGCCAGGCTCCACTGTATC  
 CTTGCATGGGTTGTGGCGTTCTACACCACGCTGACTCCTCTTCAACCCCTGTTGT  
 ACACCCCTGAGAAACAAGGAGGTAAGAAAGCTCTGTTGAAGCTGAAAAATGGGTAGTAT  
 TTGCTCAGGGTGAATAG (SEQ ID NO: 76)

45 AOLFR41 sequences:  
 MNPENWTQVTSFVLLGFPSSHIIQFLVFLGLMVTYIVTATGKLIIVLSDWIDQRLHIQMYFFLRN  
 FSFLELLLVTVVVPKMLVVILTGDHTISFVSCIIQSILYFFLGTIDFLLAVMSLDRYLAICRPLR  
 YETLMNGHVCSQLVLASLAGFLWVLCPVLMASLPFCGPNGIDHFFRDSPWLLRLSCGDTH  
 50 LLKLVAFMLSTLVLLGSLALTGSYACILATVLRAPTAERRKAFSTCASHLTVVVIIYGSIFLY  
 IRMSEAQSLLNKGASVLSCTPPLNPFIFTLRNDKVQQALREALGWPRITAVMKLRVTSQRK  
 (SEQ ID NO: 77)

55 ATGAACCTGAAAACGGACTCAGGTAACAAGCTTGTCTTGGGTTCCCCAGTAGCC  
 ACCTCATACAGTCTCTGGTGTCTGGGTTAATGGTGACTACATTGTAACAGCCACAGG  
 CAAGCTGCTAATTATTGTGCTCAGCTGGATAGACCAACGCCATCACAGATGTACTTC

5           TTCTCGGAAATTCTCCTTCCCTGGAGCTGTTGCTGGTAACCTGTTGTTCCCAAGATGCT  
 TGCGTCATCCTCACGGGGATCACACCATCTCATTGTCAGCTGCATCATCCAGTCCTACC  
 TCTACTTCTTCTAGGCACCACTGACTCTTCCCTTGGCCGTATGTCCTGGATCGTTAC  
 CTGGCAAATCTGCCGACCACTCCGCTATGAGACCCGTATGAAATGGCCATGTCCTGGCCAC  
 10          5   TAGTGCCTGGCCTCCCTGGTAGCTGGATTCCCTGGGCTTGGCCCACTGTCCTCATGGCC  
 AGCTGCCTTCTGTGGCCCAATGGTATTGACCACTTCTTCGTGACAGTGGCCCTTGCT  
 CAGGCTTCTGTGGGACACCCACCTGCTGAAACTGGTGGCTTCATGTCCTACGTG  
 GTGTTACTGGGCTACTGGCTCTGACCTCAGTTCCATGCCGCATTCTGCCACTGTTCT  
 CAGGGCCCTACAGCTGCTGAGCGAAGGAAAGCGTTCCACTGCGCCTCGCATCTTACA  
 15          10   GTGGTGGTCATCATCTATGGCAGTCCATCTTCTACATTGCTATGTCAGAGGGCTAGTC  
 CAAACTGCTCAACAAAGGTGCCTCCGTCTGAGCTGCATCATCACACCCCTTGAACCCA  
 TTCATCTCACTCTCCGCAATGACAAGGTGAGCAAGCACTGAGAGAAGCCTGGGTGGC  
 CCAGGCTCACTGCTGTGATGAAACTGAGGGTCACAAGTCAAAGGAAATGA (SEQ ID NO:  
 78)

15

**AOLFR42 sequences:**

20          MNPANHSQVAGFVLLGLSQVWELRFVFFTFSAVYFMTVVGNLIVVIVTSDPHLHTTMYFLL  
 GNLSFLDFCYSSITAPRMLVDLSSGNPTISFGGCLTQLFFFHFIGGIKIFLLTVMAHYDRYAIQPL  
 HYTLIMNQTVCALLMAASWVGGFIHSIVQIALTIQLPFCGPDKLDNFYCDVPQLIKLACTDTFV  
 25          20   LELLMVSNNGLVTLMCFLVLLGSYTALLVMLRSHSREGRSKALSTCASHIAVTLIFVPCIVY  
 TRPFRTFPMDKAVSVLYTIVTPMLNPAYTLRNKEVIMAMKKLWRRKKDPIGPLEHRPLH  
 (SEQ ID NO: 79)

25

30          ATGAATCCAGCAAATCATCCCAGGTGGCAGGATTGTTACTGGGGCTCTCAGGTTT  
 GGGAGCTTCGGTTGTTCTCACTGTTCTGCTGTATTTATGACTGAGTGGGA  
 AACCTCTTATTGTTGCTCATAGTGCACCTCCGACCCACACCTGCACACAACCATGTATTTCT  
 CTTGGCAATCTTCTTGGACTTTGCTACTCTTCATCACAGCACCTAGGATGCTGG  
 TTGACTTGCTCTCAGGCAACCCCTACCAATTCCCTGGATGCCGACTCAACTCTTCTC  
 TTCCACTTCATTGGAGGCATCAAGATCTTCTGCTGACTGTCATGGGTATGACCGCTACA  
 35          30   TTGCCATTCCCAGCCCCCTGCACTACACGCTCATTATGAATCAGACTGTCGTGCACTCC  
 ATGGCAGCCTCTGGGTGGGGGCTCATCCACTCCATAGTACAGATTGCAATTGACTATCC  
 AGCTGCCATTCTGTGGGCTGACAAGCTGGACAACCTTATTGTGATGTCCTCAGCTGAT  
 CAAATTGGCCTGCACAGATAACCTTGTCTAGAGCTTTAATGGTGTCTAACATGGCTG  
 GTGACCTGATGTGTTCTGGTGCCTCTGGGATCGTACACAGCACTGCTAGTCATGCTCC  
 40          35   GAAGCCACTACGGGAGGGCCGAGCAAGGCCGTCTACCTGTCCTCACATTGCTGT  
 GGTGACCTTAATCTTGTGCCTTGATCTACGTCTATACAAGGCCCTTCGGACATTCCCCA  
 TGGACAAGGCCGTCTGTGCTATACACAATTGTCACCCCATGCTGAATCCTGCCATCTA  
 TACCTGAGAAACAAGGAAGTGTATGGCATGAAGAAGCTGTGGAGGAGGAAAAGG  
 ACCCTATTGGTCCCTGGAGCACAGACCCCTACATTAG (SEQ ID NO: 80)

40

**AOLFR43 sequences:**

45          MQKPQLLVPIIATSGNLVHAAYFLVGIPGLGPTIHFWLAFPLCFMYALA  
 RRLHEPMYFLAMLSTIDLVLSSITMPKMASLFLMGIQIEFNICLAQMFLIHALSAVESAVLLA  
 MAFDRFVAICHPLRHASVLTGCTVAKIGSLTRGFVFFFPLFILKWLSCQHTVTHSFCLHQ  
 DIMKLSCTDTRVNVYGLFIILSVMGVDSLFIGFSYIILWAVLELSSRRAALKAFNTCISHLC  
 LVFYVPLIGLSVHRLGGPTSLLHVVMANLYLLPPVNPLVYGAKTKEICSRVLCMFSQGGK  
 (SEQ ID NO: 81)

50

55          50   ATGCAGAAGCCCCAGCTTGGTCCCTATCATGCCACTTCAAATGGAAATCTGGTCCACG  
 CAGCATACTTCTTGGGGTATCCCTGGCCTGGGGCTACCATACACTTTGGCTGGCT  
 TCCCACGTGTTTATGATGCCTGGCCACCCCTGGGTAACCTGACCATGGCTCATCAT  
 TCGTGTGGAGAGGCGACTGCATGAGCCCAGTGTACCTCTTGGCCATGCTTCCACTATT  
 GACCTAGTCCTCTCTATCACCATGCCAAGATGCCAGTCTTCTGATGGCATCCA  
 GGAGATCGAGTTCAACATTGCTGGCCAGATGTTCTTATCCATGCTCTGTCAGCCGTG  
 GAGTCAGCTGCTGCTGGCCATGGCTTGTGACCGCTTGTGGCCATTGCCACCCATTGC  
 GCCATGCTTGTGCTGACAGGGTGTACTGTGGCAAGATTGGACTATCTGCCCTGACCAG

WO 01/98526

NO 01/98526  
5 GGGGTTGTATTCTTCTCCCCACTGCCCTCATCCTCAAGTGGTGTCTACTGCCAACAC  
ATACTGTCACACACTCCTCTGTCACCAAGATATTGAAGCTGTCTGTACTGACAC  
CAGGGTCAATGTGGTTATGGACTCTTCATCATCCTCTCAGTCATGGGTGTGGACTCTCT  
TCATTGGCTTCTCATATATCCTCATCCTGTGGGCTGTTGGAGCTGTCTCTCGGAGGGCA  
GCACCTCAAGGCTTCAACACACTGCATCTCCACCTCTGTGCTGTTCTGGTCTTATGTACC  
CCTCATTGGGCTCTCGTGGGCATAGGCTGGGTGGTCCCACCTCCCTCCATGTGGTT  
ATGGCTAACCTACTGCTGCTACCACCTGTAGTCACCCCCCTGTCTATGGAGCCAAGA  
CCAAGAGATCTGTTCAAGGTCTCTGTATGTTCTACAAGGTGGCAAGTGA (SEQ ID  
NO: 82)

10

### AOLFR44 sequences:

10 AOLFR44 sequences:  
 MSSCNFTHATFVLIGIPGLEKAHFWVGFPPLSMYVVAMFGNCIVFIVRTERSLHAPMYLFLC  
 MLAADILALSTTMPKILALFWFDSREISFEACLTQMFFIHLSAIESTILLAMAEDRYVAICHPL  
 RHAAVLNNTVTAQIGIVAVVRGSLFFFPLPLIKRLAFCHSNVLSHSYCVHQDVMKLAYADTLP  
 NVYGLTAILLVMGVDMFISLSYFLIIRTVLQLPSKSERAKAGTCVSHIGVVLAFYVPLIGLS  
 VVHRFGNSLHPIVRVVMGDIYLLPPVINPIIYGAKTKQIRTRVLAMFKISCDKDLQAVGGK  
 (SEQ ID NO: 83)

(SEQ ID NO: 83)  
20 ATGAGTCTCTGCAACTCACACATGCCACCTTGTGCTTATTGGTATCCAGGATTAGAGA  
AAGCCCATTTCTGGGTGGCTTCCCCCTCCTTCCATGTATGTAGTGGCAATGTTGGAAAC  
TGCATGTGGTCTTCATCGAAGGACGGAACGCAAGCTGCACGGCTCGATGTACCTCTTC  
TCTGCATGTTGCAGCATTGACCTGGCTTATCCACATCCACCATGCCTAAGATCCTTGCC  
CTTTCTGGTTGATCCCAGAGAGATTAGCTTGAGGCCTGTCTACCCAGATGTTCTTAT  
TCATGCCCTCTCAGCATTGAATCCACCATCCTGCTGGCATGGCTTGGCGTATGTTG  
25 CCATCTGCCACCCACTGCGCCATGCTGCAGTGCCTCAACAATACAGTAACAGCCCAGATTGG  
CATCGTGGCTGTGGTCCCGGATCCCTCTTTTTTCCACTGCCTCTGCTGATCAAGCGGC  
TGGCCTCTGCACTCCAATGCTCTCGCACTCCTATTGTGTCACCCAGGATGTAATGAA  
GTGGCCTATGCAGACACTTGGCCAAATGTGGTATATGGTCTACTGCCATTCTGCTGGTC  
ATGGCGTGGACGTAATGTTCATCTCTGCTTATTTCTGATAATACGAACGGTTCTGC  
30 AACTGCCTTCCAAGTCAGAGCGGGCAAGGCTTGGAACCTGTGTACACATGGTGT  
GGTACTGCCCTCATGTGCCACTTATTGGCCTCTCAGTGGTACACCGCTTGGAAACAGC  
CTTCATCCCATTGTCGTGTTGTCATGGGTGACATCTACCTGCTGCTGCCCTGTGTCATCAA  
TCCCATCATCTATGGTGCCTAAACAGATCAGAACACGGGTGCTGGCTATGTTCAAG  
ATCAGCTGTGACAAGGACTTGCAGGCTGTTGGAGGCAAGTGA (SEQ ID NO: 84)

35

### AOLFR45 sequences:

35 AOLFR45 sequences:  
 MLPSNITSTHPAVFLLVGIPGLEHLHAWISIPFCFAYTLALLGNCTLLFIIQADAALHEPMYLFAL  
 MLATIDLVLSSSTLPKMLAIFWFRDQEINFFACLVQMFLHSFSIMESAVLLAMAFDRYVAICKP  
 LHYTTLTGSLITKIGMAAVARAVTLMTPLPFLRRFHCRGPVIAHCYCEHMAVVRLACGDT  
 SFNNIYGIAVAMFSVVLDDLTVILSYVFILQAVLQLASQEARYKAFTCVSHIGAILSTYTPVVIS  
 SVMHRVARHAAPRVHILLAIYLLFPPMVNPITYGVTKQIREYVLSFQRKNM (SEQ ID NO:  
 40 85)  
 -TCAACTCTAATCATATATA

45 TGGAAACAAGAGGTAAATCTTGCAGGTGGGATAGCACAGGTTGAACTCTAATCATATATA  
CTGTAGAAGGTATATAGAAGGTGAAGAACGCCCTGAAAAATTGACAAGGAGATTCCA  
GGAGCCATGCTTCCCTTAATATCACCTAACACATCCAGCTGTCTTTGTTGGTAGGAAT  
50 TCCTGGTTTGGAACACCTGCATGCCGGATCTCCATCCCCTCTGCTTGCCTATACTCTGG  
CCCTGCTAGGCAACTGTACCCCTCTTCAATTATCCAGGCTGATGCAGGCCATGAACCC  
ATGTACCTCTTCTGCCATGTGGCAACCATTGACTGGTTCTTCTTACAACGCTGCC  
CAAATGCTTGCCATTCTGGTCAGGGATCAGGAGATCAACTCTTGCCTGTCGGTC  
55 CAGATGTTCTCCTTCACTCCTCTCCATCATGGACTCAGCAGTGTGGCCATGGCCT  
TGACCGCTATGTGGCATCTGCAAGGCCATTGCACTACACGACGGTCTGACTGGGCCCC  
ATCACCAAGATTGGCATGGCTGCTGTGGCCGGGTGTGACACTAACATGACTCCACTCCCC  
TCCTGCTCAGACGCTTCAACTACTGCCGAGGCCAGTGATTGCCATTGCTACTGTGAACA  
CATGGCTGTGGTAAGGCTGGCGTGTGGGACACTAGCTTCAACAATATCTATGGCATTGCT  
60 GTGGCCATGTTAGTGGTGTGGACCTGCTTTGTTATCCTGCTATGTCTTCACTCCT

5           TCAGGCAGTTCTCCAGCTTGCCTCTCAGGAGGCCGCTACAAAGCATTTGGGACATGTGTG  
TCTCACATAGGTGCCATCCTGTCCACCTACACTCCAGTAGTCATCTCTTCAGTCATGCACCG  
TGTAGCCCAGCATGCTGCCCTCGTCCACATACTCCTGCTATTTCTATCTCCTTTCC  
CACCCATGGTCAATCCTATCATATATGGAGTCAAGACCAAGCAGATTGGTGAATGTGCT  
10          5          CAGTCATTCCAGAGAAAAGAACATGTAGATGGATAGTCTCTTTTATCCCACTGCCA  
AGTAATGAGAATGCTGGATTGGGGTTGAGGGGAAAAATCTAAATAGGAAAATTGAGACT  
ATCTTGACAATTCTCTAGTATGATAAGGAAAATGAGGTTCATTCCCTCACAGATCTACGA  
GTCAGGTCAAACCAGGAGTGCACCTATAGTCTGGTCTGATAGTAGAGGTTGACCTTCCCA  
TTGTCAAGACTCATCACATGGCTAAGGAAGACAAACCTCTCAAAGTGGTATTGTAATCTG  
10          10        GGTAAAAGACAGTAGGACCTTATTGGCTGAGATTGGCCAAACAGCTGAGTC (SEQ ID  
NO: 86)

**AOLFR46 sequences:**

15          MNIKHCWHMIHTWLNIREDDDSDFKNFIGQIQLSGNPHSTSRMYFLCFCTSLLGFKVHWV  
SRLIXKLYMASPNNDSTAPVSEFLLICFPNFQSWQHLSLPLSLLFLLAMGANTLLITIQLEAS  
LHQPLYYLLSLLSLLDIVLCLTVIPKVLAlFWFDLRSISFACFLQMFIMNSFLTMESCTFMVMA  
YDRYVAICHPLRYPsiTDQFVARAVVFIARNAFVSLPVPMLSARLRYCAGNIIKNCICNSLVS  
KLSCDFITFNQLYQFVAGWTLLGSDLILIVISYSFILKVLRIKAEGAVAKALSTCGSHFILILFFS  
20          20        TVLLVLVITNLARKRIPPDVILLNILHHLIPPALNPIVYGVRTKEIKQGIQNLLKRL (SEQ ID NO:  
87)

25          ATGAATATAAACATTGGCTGGCATATGATACATACTGGTAAATATAAGGGAGGAT  
GATGACAGTGATTTAAAAACTTATTGGACAGATAACAGGGCTCTAGTGGAAACCCACACT  
CTACTACGTCTAGAATGACTTTTATGTTCTGACTTCTACTAGGTTAACGGTACAC  
TGGGCTCCAGATTGATCANGAAACTTACATGGCATCTCCAAACAATGACTCCACTGCC  
25          25        CAGTCTCTGAATTCCCTCCATCTGCTTCCCCAACITCCAGAGCTGGCAGCACTGGTTGTCT  
CTGCCCTCAGCCTTCTCTCCTGGCCATGGGAGCTAACACCCACCCCTGATCACC  
CCAGCTGGAGGCCTCTCGCACCAAGCCCCTGTACTACCTGCTCAGCCTCTCCCTGCTGG  
ACATCGTCTGCCTCACCGTCATCCCCAAGGTCTGGCATCTCTGTTGACCTCAGG  
30          30        TCGATCAGCTTCCAGCCTGCTTCCAGATGTTCATCATGAACAGTTTGACCATGGA  
GTCCTGCACGTTCATGGTCATGGCCTATGACCGTTGTGGCATCTGCCATCCATTGAGA  
TACCCGTCTATCATCACTGACCAAGTGTGGCTAGGCCGTTGCTTGTATAGCCCGGA  
ATGCCCTTGTCTCTCTGTTCCATGCTTCTGCCAGGCTCAGATACTGTGCAGGAAAC  
35          35        ATAATCAAGAACTGCATCTGCAGTAACCTGTCTGTGCCAAACTCTCTGTGATGACATCA  
CTTCAATCAGCTTACCAAGTTGGCAGGCTGGACTCTGTTGGCTCTGATCTTATCCTT  
ATTGTTATCTCTATTCTTTATATTGAAAGTTGTGCTTAGGATCAAGGCCGAGGGTGTGT  
GGCCAAGGCCTTGAGCACGTGTGGTCCCACITCATCCTCATCCTCTTCAGCACAGTCC  
TGCTGGTTCTGGTCATCACTAACCTGGCCAGGAAGAGAAATTCTCCAGATGTCCCCATCCT  
40          40        GCTCAACATCCTGCACCACCTCATCCCCAGCTCTGAACCCATTGTTATGGTGAGA  
ACCAAGGAGATCAAGCAGGGAATCCAAAACCTGCTGAAGAGGTTGTAA (SEQ ID NO: 88)

**AOLFR47 sequences:**

45          MSASNITLTHPTAFLLVGIPGLEHLHIWISIPFCLAYTLALLGNCTLLIIQADAALHEPMYLFLA  
MLAAIDLVLSSSALPKMLAIFWFRDREINFFACLAQMFFLHSFSIMESA VLLAMAFDRYVAICK  
PLHYTKVLTGSLITKIGMAAVARAVTLMTPPLRRCFHYCRGPVIAHCYCEHMAVVRLACGD  
TSFNNIYGIAVAMFIVVLDLLVILSYIFILQAVLLASQEARYKAFTGCVSHIGAILAFYTTVVIS  
SVMHRVARHAAPHVHILLANFYLLFPPMVNPPIYGVTKQIRESILGVFPRKDM (SEQ ID NO:  
89)

50          50        ATGTCAGCCTCAATATCACCTAACACATCCAAC TGCCCTTGTGGGGATTCCAG  
GCCTGGAACACCTGCACATCTGGATCTCCATCCCTTCTGCTTAGCATATACACTGCCCTG  
CTTGGAAACTGCACCTCCTCTCATCATCCAGGCTGATGCAGCCCTCATGAACCCATGT  
ACCTCTTCTGCCATGTTGGCAGCCATCGACCTGGCTTCTCCTCCTCAGCACTGCCAAA  
ATGCTTGCCTATTCTGGTTAGGGATGGGAGATAAAACTCTTGCCTGTCTGGCCAGA  
55          55        TGTTCTCCTTCACTCCTCTCATGGAGTCAGCAGTGTGCTGGCCATGCCCTTGAC  
CGCTATGTGGCTATCTGCAAGCCACTGCACACCAAGGTCTGACTGGTCCCTCATCA

WO 01/98526

5           CCAAGATTGGCATGGCTGCTGTGGCCGGGCTGTGACACTAATGACTCCACTCCCCTTCCT  
 GCTGAGATGTTCACTACTGCCAGGCCAGTGATCGCTACTGCTACTGTGAACACATG  
 GCTGTGGTGAGGCTGGCGTGTGGGGACACTAGCTTCAACAATATCTATGGCATCGCTGTGG  
 CCATGTTATTGTGGTGTGGACCTGCTCCTTGTATCCTGCTTATATCTTATTCTTCAG  
 GCAGTTCTACTGCTTGCCTCTCAGGAGGCCGCTACAAGGCATTGGACATGTGTCTCTC  
 ATATAGGTGCCATCTTAGCCTCTACACAACGTGGTCATCTCTCAGTCATGCACCGTGT  
 GCCGCCATGTCGCCCTCATGCCACATCCTCTGCCAATTCTATGCTCTCCACC  
 CATGGTCAATCCATAATCTATGGTGCAAGACCAAGCAAATCCGTGAGAGCATTTGGGA  
 GTATTCCAAGAAAGGATATGTAG (SEQ ID NO: 90)

10           **AOLFR48 sequences:**  
 MMVDPNGESSATYFILIGPLEEAQFWLAFPLCSLYIAVGNLTIIYIVRTEHSLHEPMYIFL  
 CMLSGIDILISTSSMPKMLAIFWFNSTIQFDACLLQMFAIHSLSGMESTVLLAMAFDRYVAICH  
 PLRHATVLTLPRTVKIGVAAVVRGAALMAPLPVFIKQLPFCRSNLSHSYCLHQDVMKLA  
 RVNVVYGLIVIISAIGLDSLLISFSYLLILKTVLGLTREAQAKAFGTCVSHVC  
 VHRFSKRRDSPLPVILANIYLLVPPVLPNIVYGVKTKEIRQRLFHVATHASEP (SEQ ID NO:  
 91)

15           ATGATGGTGGATCCAATGGCAATGAATCCAGTGCTACATACTTCATCCTAATAGGCCTCC  
 CTGGTTAGAAGAGGCTCAGTTCTGGTTGGCCTTCCATTGTGCTCCCTCTACCTATTGCT  
 GTGCTAGGTAACTTGACAATCATCTACATTGTGCGGACTGAGCACAGCCTGCATGAGCCA  
 TGTATATATTCTTGTGATGCTTCAGGCATTGACATCCTCATCTCCACCTCATCCATGCC  
 AAAATGCTGGCATCTCTGGTTCAATTCCACTACCATCCAGTTGATGCTGTGGCATGGCTT  
 GATGTTGCCATCCACTCTTATCTGGCATGGAATCCACAGTGTGCTGGCATGGCTT  
 GACCGCTATGTGGCATCTGTACCCACTGGCCATGCCACAGTACTTACGGTGCCTCGT  
 TCACCAAAATGGTGTGGCTGTGTGGCGGGGGCTGACTGATGGCACCCCTTCCTGT  
 CTTCATCAAGCAGCTGCCCTCTGCCGCTCCAATATCCTTCCATTCTACTGCCTACACC  
 AAGATGTCAAGCTGGCTGTGATGATATCGGGTCAATGTCGTCTATGGCCTTATCGT  
 CATCATCTCCGCCATTGGCTGGACTCACTCTCATCTCTCATATCTGCTTATTCTTA  
 AGACTGTGTGGCTTGACACGTGAAGCCCAGGCCAGGCATTGGCATTGCGTCTCTCA  
 TGTGTGTGCTGTGTCATTCTATGTACCTTCAATTGGATTGTCATGGTCATCGCTT  
 GCAAGCGGGCTGACTCTCGCTGCCGTCACTTGGCCAATATCTATGCTGGTCTCTC  
 GTGCTCAACCAATTGTCTATGGAGTGAAGACAAAGGAGATTGACAGCGCATTGCG  
 CTTTCATGTGGCCACACGCTTCAGAGCCCTAG (SEQ ID NO: 92)

20           **AOLFR49 sequences:**  
 MLTFHNCSVPSFWLTGIPGLESLHVWLSPFGSMYLVAVGNTILAVVKIERSLHQPMYFF  
 LCMLAAIDLVLSTSTIPKLLGIFWFGACDIGLDACLQMFLIHCFAVESGIFLAMAFDRYVAIC  
 NPLRHSMVLTYTVVGRGLVLSSLRGVLYIGPLPLMIRLRLPLYKTHVISHSYCEHMAV  
 40           VALTC  
 GDSRVNNVYGLSIGFLVILDSVIAASYVMI  
 FRAVMGLATPEARLKT  
 LGCASHLC  
 IAVSSLIHRFGQCVP  
 PPVHTLLANFYLLIP  
 LNPIVYAVRTK  
 QIRESL  
 LQIPRIEMKIR (SEQ ID  
 NO: 93)

25           ATGCTCACTTTCATATGTCTGCTCAGTACCCAGCTCCCTGGCTACTGGCATCCCAGG  
 GCTGGAGTCCTACACGTCTGGCTCTCCATCCCCTTGGCTCATGTACCTGGTGGCTGTG  
 GTGGGAATGTGACCATCCTGGCTGTGTAAGATAGAACCGCAGCCTGCACCAGCCATG  
 TACTTTCTGTGATGTTGGCTGCCATTGACCTGGTTCTGCTACTTCCACTATACCCAA  
 ACTTCTGGAAATCTCTGGCTGGTGCCTTGACATTGGCTGGACGCTGGCTTCTGCT  
 ATGTTCTTATCCACTGCTTGCCTGAGTCAGGCATCTCCCTGGCATGGCTTCTGGCAA  
 50           TCGCTACGTGGCCATCTGCAACCCACTACGTACAGCATGGTGTCACTTACAGTGGT  
 GGTGCTTGGGCTTGTTCCTCCTCCGGGTTCTACATTGGACCTCTGCCTCTGAT  
 GATCCGCTGCGGCTGCCCTTATAAAACCATGTTATCTCCACTCTACTGTGAGC  
 ATGGCTGAGTTGCCATTGACATGTGGGACAGCAGGGTCAATAATGTCTATGGCTGAGC  
 ATCGGCTTCTGGTGTGATCCTGGACTCAGTGGCTATTGCTGATCCTATGTGAT  
 55           CAGGGCCGTGATGGGTTAGCCACTCTGAGGGTAGGCTAAACCTGGGACATGCG  
 TTCTCACCTCTGTGCCATCTGATCTTATGTTCCATTGCTGTTCTCCCTGATTCA  
 CCG

ATTTGGTCAGTGTGCTCCCTCCAGTCCACACTCTGCTGCCAATTCTATCTCCTCATTC  
CTCCAATCCTCAATCCCATTGTCTATGCTGTCGACCAAGCAGATCCGAGAGAGCCTCT  
CCAATACCAAGGATAGAAATGAAGATTAGATGA (SEQ ID NO: 94)

5 **AOLFR50 sequences:**

MNLDSFFSFLKSLIMALSNSWRLPQPSFLVGIPGLEESQHWIALPLGILYLLALVGNVTILFII  
WMDPSLHQSMYLFLSMLAAIDLVVASSTAPKALAVLLVRAQEIGYTVCLIQMFFTHAFSSMES  
GVLVAMALDRYVAICHPLHHSTILHPGVIGHIGMVVLVRGLLLIPFLILLRKLIFCQATIIGHAY  
CEHMAVVKLACSETTVNRAYGLTVALLVVGLDVLALIGVSYAHILQAVLKVPGNEARLKAFST  
10 CGSHVCVILVFYIPGMFSFLTHRFGHHVPHVHIVLLAILYRLVPPALNPLVYRVKTQKIHQ  
(SEQ ID NO: 95)

15 ATGAATTGGATTCTTTCTCTTCCCTCAAGTCATTGATAATGGCACTTAGCAATT  
CAGCTGGAGGCTACCCCCAGCCTTCTTTCTGGTAGGAATTCCGGTTAGAGGAAAGC  
CAGCACTGGATCGCACTGCCCTGGGCATCCTTACCTCCTGCTTAGTGGGCAATGTTA  
CCATTCTCTTCATCATCTGGATGGACCCATCCTGCACCAATCTATGTACCTCTCCTGTC  
ATGCTAGCTGCCATCGACCTGGTGTGGCCTCCACTGCACCCAAAGCCCTGAGTGC  
TCCTGGTTCGTGCCAAGAGATTGGTTACACTGTCTGCCTGATCCAGATGTTCTCACCCAT  
GCATTCTCCTCCATGGAGTCAGGGTACTTGTGGCATGGCTCTGGATCGCTATGTAGCCA  
20 TTTGTCAACCCCTTGACCAATTCCACAATCCTGCATCCAGGGTCAAGGGCACATCGGAAT  
GGTGGTGTGGTGGGGATTACTACTCCTCATCCCCCTCCTCATTCTGTTGCGAAAACCT  
ATCTTCTGCCAAGCCACCATCATAGGCCATGCCATTGTGAACATATGGCTGTTGAAAC  
TTGCCTGCTCAGAAACACAGTCATCGAGCTTATGGGCTGACTGTGGCCTGCTTGTGGT  
TGGGCTGGATGTCTGGCATTGGTGTTCCTATGCCACATTCTCAGGCAGTGCTGAAG  
25 GTACCAAGGAAATGAGGCCGACTTAAGGCCTTAGCACATGTGGCTCTCATGTTGTGTCA  
TCCTGGCTTCTATATCCCGGAATGTTCTCCTCCTCACTCACCGCTTGGTCATCATGTA  
CCCCATCACGTCCATGTTCTCTGGCATACTGTATGCCCTGTGCCACCTGCACTCAATCC  
TCTTGCTATAGGGTGAAGACCCAGAAGATCCACCACTGTA (SEQ ID NO: 96)

30 **AOLFR51 sequences:**

MCQQILRDCILLIHLICNRKKVSLVMLGPAYNHTMETPASFLVGIPGLQSSHWLAIISAM  
YIIALLGNTIITAIWMDSTRHEPMYCFCLVLAADVIMASSVVPKMSIFCSGDSSISFACFTQ  
MFFVHLATAVETGLLLTMAFDRYVAICKPLHYKRILTPQVMLGMSMAITIRAIIAITPLSWMVS  
35 HLPFCGSNVVVHSYCEHIALARLACADPVPSSLYSLIGSSLMVGSDVAFIAASYILILKAVFGLSS  
KTAQLKALSTCGSHVGVMALYYLPGMASIYAAWLQDVPPLHTQVLLADLYVIIPATLNPIIY  
GMRTKQLRERIWSYLMHVLFDHSNLGS (SEQ ID NO: 97)

40 ATGTGTCAACAAATCTACGGGATTGCATTCTCTCATACATCATTTGTGATTAACAGGA  
AAAAAGTCTCACTTGTGATGCTGGGTCCAGCTTATAACCACACAAATGGAAACCCCTGCCTC  
CTTCCTCTGTGGGTATCCCAGGACTGCAATCTCACATCTTGGCTGGCTATCTCACTGA  
GTGCCATGTACATCATAGCCCTGTTAGGAAACACCATCATGTGACTGCAATCTGGATGGA  
TTCCACTCGGCATGAGCCCATGTATTGCTTCTGTGTTCTGGCTGCTGGACATTGTTA  
TGGCCTCTCGGTGGTACCAAGATGGTGAGCATCTCTGCTCAGGAGACAGCTCAATCAG  
CTTTAGTGTCTGTTCACTCAGATGTTTGTCCACTAGCCACAGCTGTGGAGACGGGG  
45 CTGCTGCTGACCATGGCTTGTGACCGCTATGTAGCCATCTGCAAGCCTCTACACTACAAGA  
GAATTCTCACGCTCAAGTGATGCTGGGAATGAGTATGCCATCACCACAGAGCTATCAT  
AGCCATAACTCCACTGAGTTGGATGGTGAGTCATCACCTTCTGTGGCTCCAATGTGGTT  
GTCCACTCCTACTGTGAGCACATAGCTTGGCCAGGTAGCATGTGCTGACCCGTGCCA  
GCAGTCTCTACAGTCTGATTGGTCTCTCTTATGGTGGGCTGTGATGTGGCCTCATGCT  
50 GCCTCCTATATCTTAATTCTAAGGCAGTATTGGTCTCTCCTCAAAGACTGCTCAGTGAA  
AGCATTAAGCACATGTGGCTCCCAGTGGGGTTATGGCTTGTACTATCACCTGGATG  
GCATCCATCTATGGGGCTGGTTGGGGCAGGATGTAGTGCCTTGCACACCCAAGTCTGC  
TAGCTGACCTGTACGTGATCACCCAGCCACCTAAATCCCACATCTATGGCATGAGGAC  
CAAACAACTGCAGGGAGAGAATATGGAGTTATCTGATGCTGATGTCCCTTTGACCATTCCAAC  
55 CTGGGTTCATGA (SEQ ID NO: 98)

WO 01/98526

**AOLFR52 sequences:**

MLGPAYNHTMETPASFLLVGIPGLQSSHWLAIISAMYITALLGNTLIVTAIWMDSTRHEPMY  
 CFLCVLAAVDIVMASSVVPKMSIFCSGDSSISFSACFTQMFFVHLATAVETGLLTMAFDRYV  
 5 AICKPLHYKRILTPQVMLGMSMAVTIRAVTFMTPLSWMMNHLPPCGSNNVVHSYCKHIALAR  
 LACADPVSSLYSLGSSLMVGSDVAFIAASYILILRAVFDLSSATAQLKALSTCGSHVGVMALY  
 YLPGMASIYAAWLQGDIVPLHTQVLLADLYVIPIATLNPIIYGMRTKQLLEGIWSYLMHFLFDH  
 SNLGS (SEQ ID NO: 99)

10 ATGCTGGGTCCAGCTTACAACCACACAATGGAAACCCCTGCCTCCTTCCTTGTGGGTA  
 TCCCAGGACTGCAATCTTCACATCTTGGCTGGTATCTCACTGAGTGCATGTACATCAC  
 AGCCCTGTTAGGAAACACCCATCGTGAATGCAATCTGGATGGATTCCACTCGGATGAG  
 CCCATGATTGCTTCTGTGTTCTGGCTGCTGGACATTGTTATGCCCTCCGTGGT  
 ACCCAAGATGGTGGCATCTCTGCTCGGGAGACAGCTCATCAGCTTAGTGTGTTTC  
 ACTCAGATGTTTTGTCACCTAGCACAGCTGTGGAGACGGGGCTGCTGCTGACCATGG  
 15 CTTTGACCGCTATGTAGCCATCTGCAAGCCTACACTACAAGAGAATTCTCACGCCCTCA  
 AGTGTGCTGGGAATGAGATGGCCGTACCATCAGAGCTGTACATTGACTCCACTG  
 AGTTGGATGATGAATCATCACCTTCTGTGGCTCAATGTGGTTGTCACACTCTACTGTAA  
 GCACATAGCTTGGCCAGGTTAGCATGTGCTGACCCCGTGCCTCAGCAGTCTACAGTCTG  
 ATTGGTCTCTCTATGGGGCTCTGATGTGGCTTCATTGCTGCCCTATCTTAAT  
 20 TCTCAGGGCAGTATTIGATCTCTCTCAAAGACTGCTCAGTTGAAAGCATTAAGCACATGT  
 GGCTCCCATGTGGGGTTATGGCTTGTACTATCACCTGGATGGCATCCATCTATGCCG  
 CCTGGTGGGGCAGGATATAGTGCCTTGCACACCCAAAGTGTGCTAGTGTACCTGTACGT  
 GATCATCCCAGCCACTTAAATCCATCATCTATGGCATGAGGACAAACAATTGCTGGAG  
 25 GGAATATGGAGTTATCTGATGCACTCCTCTTGACCACCTCAACCTGGITCATGA (SEQ ID NO: 100)

**AOLFR54 sequences:**

MSDSNLSNDNLPDTFFLTGIPGLEAAHFWIAIPFCAMYLVALVGNAALIVIAMDNALHAPMY  
 LFLCLLSLTDLALSSTVPKMLAILWLHAGEISFGGCLAQMFCVHSIYALESSILLAMAFCRVA  
 30 ICNPLRYTTILNHAVIDRIGFVGLFRSVAIVSPFILLRLPYCGHRRVMHTYCEHMGIAIRLACA  
 NITVNIVYGLTALLAMGLDSILIAISYGFILHAFHLPShDAQHKALSTCGSHIGILVFYIPAFF  
 SFLTHRFGHHEVPKHVHIFLANLYLVPPVLPILYGARTKEIRSLLKLLHLGKTSI (SEQ ID NO: 101)

35 ATGTCAGATTCCAACCTCAGTGATAACCACCTTCAGACACCTTCTTAAAGGGATCC  
 CAGGGCTGGAGGCTGCCACTCTGGATTGCCATCCCTTCTGTGCCATGTATCTGTAGC  
 ACTGGITGGAAATGTCGCCCTCATCTGGTCAATTGCCATGGACAATGCTCTCATGCCACCT  
 ATGTACCTCTCCTCTGCCCTCTCACTCACAGACCTGGCTCTAGTTCTACCATGTGCC  
 CAAGATGTCGCCATTITGTGGCTCATGCTGGTGGAGATTCTCTGGATGCCCTGGCC  
 40 CAGATGTTTGTGTCATTCTATCTATGCTCTGGAGTCTCGATCTACTTGCCATGCCCT  
 TGATAGGTATGTGGTATCTGTAACCCATTAGGTATACAACCATCTCAACCATGCTGTC  
 ATAGGCAGAATTGGCTTGTGGTATTCCGTAGTGTGGTATTGTCTCCCCCTCATCTT  
 CTTGCTGAGGCAGTCCCTACTGTGGTCAACGTGACACACACATACTGTGAGCAT  
 45 ATGGGCATGCCCGACTGGCTGTGCCAACATCACTGTCAATTGTCTATGGCTAACTG  
 TGGCTCTGCTGGCATGGACTGGATTCCATTCTCATGCCATTCTATGCCATTCTCCT  
 CATGCAGTCTTCACCTCCATCTCATGATGCCAGACAAAGCTCTGAGTACCTGTGGCT  
 CCCACATTGGCATCATCCTGGTTCTACATCCCTGCCCTCTCTCCTCCTCACCCACCGC  
 TTTGGTCACCACGAAGTCCCCAAGCATGTGCACATCTTCTGGCTAATCTCTATGTGCTGG  
 50 TGCCTCTGTACTCAATCTATTCTATGGAGCTAGAACCAAGGAGATCGGAGTCGACT  
 TCTAAAATGCTTCACCTGGGAAGACTCAATATGA (SEQ ID NO: 102)

**AOLFR57 sequences:**

MSFQVTYMFYLHWTMEKSNNSTLFILLGFSQNKNIEVLCFVLFCYIAIWGNLLIMISITCTQ  
 LIHQPQMYFFLNYLSLSDLCYTSTVTPKLMV DLLAERKTISYNMCIQLFTTHFFGGIEIFLTGM  
 55 AYDRYVAICKPLHYTIIMSRQKCNIIIVCCTGGFIHSASQFLTIFVPPCGPNEIDHYFCDVYPLL  
 KLACSNIHMIGLLVIANSGLIALVTFVVLSSYVFILYIRAYAERRSKALATCSSHVIVVLF

APALFIYIRPVTTFSEDKVFAFYIIAPMFNPLIYTLRNTEMKNAMRKVWCCQILLKRNQLF  
(SEQ ID NO: 103)

5 ATGTCATITCAGGTGACTTATGTTCTATCTACACTGGACCATGGAAAAAGCAATAATA  
GCACTTGTATTCTCTGGGTTTCCAAAATAAGAACATTGAAGTCTGCTTGTA  
TTATTTGTTGCTACATTGCTATTGGATGGAAACTACTCATAATGATTCTATCAC  
10 GTGCACCCAGCTCATTACCAACCCATGTATTCTCCTCAATTACCTCTCACTCTCGACC  
TTGCTACACATCCACAGTGACCCCAAATTATGGTGACTTACTGGCAGAAAGAAAGAC  
CATTCTATAATAACTGTATGATACAACCTTACCAACCCATTGGAGGCATAGAGA  
15 TCTCATTCTCACAGGGATGGCTATGACCGCTATGTGGCATTGCAAGCCCCTGCACTA  
CACCATTATTAGCAGGCAAAAGTGAACACAATCATCATAGTTGTTACTGGGGA  
TTATACATTCTGCCAGTCAGTTCTCACCATTGTAACATTGTCCTGAAATTGGCCTTCTAATATACACA  
GATAGATCACTACTCTGTGATGTATCCTTGTCAAATTGCTTGGTACATTGTTGCTTGT  
20 TGATAGGTCTCTAGTCATTGCTAATTGCTTGGTACATTGTTGCTTGTCTGCTTGT  
TTGTTGCTTATGTTTATATTGTATACCATCAGAGCATACTTCAGAGAGACGCAGCA  
AAGCTCTGCCATTGTAAGTCTCATGTAATTGTTGTCCTGTTTGTCTGCTTGTCTGCTTGT  
TTCAATTACATTAGACCGGTACAACATTCTCAGAAGATAAAAGTGTGTTGCCCTTTTATAC  
CATCATTGCTCCATGTTCAACCTCTCATATACACGCTGAGAAACACAGAGATGAAGAAC  
GCCATGAGGAAAGTGTGGTGTCAAATACTCCTGAAAAGAAATCAACTTTCTGA (SEQ  
ID NO: 104)

**AOLFR58 sequences:**

25 MFSMTTEALNNFALGCTNLLMTMIPQIDLKQIFLCNCRLYMPVGAFIFSLGNMQNSFVTEF  
VLLGLSQNPNVQEIVFVVFLFYIATVGGNMLIVVTILSSPALLVSPMYFFLGFLSFLACFSSVI  
TPKMIVDSLIVTKTISFEGCMMQLFAEHFFAGVEVILTAMAYDRYVAICKPLHYSSIMNRRL  
CGILMGVAWTGGLLHSMIQLFTFQLPFCGPNVINHFMCDLYPLLEACTDTHIFGLMVINS  
FICIINFSLLVSYAVILLSLRTHSSEGRWKALSTCGSHIAVILFFVPCIFVYTRPPSAFSLDKMA  
AIFYIILNPLNPLIYTFRNKEVKQAMRRIWNRLMVVSDEKENIKL (SEQ ID NO: 105)

30 ATGTTCTCAATGACAACAGAAGCACTCAATAATTGCACTTGGATGTACCAACTTGTAA  
TGACTATGATACCAACAAATTGATCTGAAGCAAATTCTTGTCTTAATTGCAAGACTATA  
CATGATCCCTGTTGGAGCTTCATCTTCTGGAAACATGCAAAACCAAGCTTGTAA  
ACTGAGTTGTCCTCTGGACTTACAGAAATCCAATGTTCAAGGAAATAGTATTGTTG  
TATTGTTGTTGTCATATTGCAACTGTTGGGGCAACATGCTAATTGTAACCATTCTC  
35 AGCAGCCCTGCTCTGGTCTCTATGTAATTCTCTGGCTTCTGCTTGGCTTCTGCTTCTGGA  
TGCCTGCTTCTCATCTGTCACTACCCAAAGATGATTGTAAGACTCCCTCTATGTGACAAAA  
ACCATCTCTTGAAGGCTGCATGATGCAGCTTTGCTGAACACACTTCTTGCTGGGTGG  
AGGTGATTGTCCTCACAGCCATGGCTATGATGTTATGTGGCAATTGCAAGCCCTGCA  
TTACTCTCTATCATGAACAGGAGGCTCTGGCATTGATGGGGTAGCCTGGACAGGG  
40 GGCCTCTGCAATTGATACAAATTCTTACTTCCAGCTTCCCTTGTGGCCCTGGACAGGG  
TGTCAATCACTTATGTTGACTTGTACCCGTTACTGGAGCTTGCCTGCACTGATACTC  
ACATCTTGGCCTCATGGTGGTCAACACAGTGGTTATCTGCACTATAAACTTCTCCTG  
TTGCTTGCTCTCATGCTGTCATCTGCTCTGAGAACACACAGTCTGAAGGGCGCTG  
GAAAGCTCTCTCCACCTGTGGACTCACATTGCTGTTGATTTGTTCTTGTCCCAGCAG  
45 TATTGTTATACACGACCTCCATGCTTTCCCTGACAAAATGGCGCAATATTAT  
ATCATCTTAAATCCCTGCTCAATCTTGATTACACTTCAGGAATAAGGAAGTAAAC  
AGGCCATGAGGAGAATATGGAACAGACTGATGGTGGTTCTGATGAGAAAGAAAATATTA  
AACTTTAA (SEQ ID NO: 106)

50 **AOLFR59 sequences:**

MGDWNNSDAVEPIFILRGFPGLEVHSWLSILFCLAYLVAFMGNVILSVIWISSLHQPMYYFI  
SILA VNDLGMSSLTLPMLAVLWLDAPEIQASACYAQLFFIHTFTFLESSVLLAMA FDRFVAICH  
PLHYPTILTSVIGKIGLACLLRSLGVVLPTPLLRYHYCHGNALSHAFCLHQDVLRLSCTDA  
RTNSIYGLCVVIATLGVD SIFILLSYVLLNTVLDIASREEQLKALNTCVSHICVVLIFFFVPIGVS  
55 MVH RFGKHLSPIVHILMADIYLLLPPVLPNPIVYSVRTKQIRLGILHKFVLRRRF (SEQ ID NO:  
107)

WO 01/98526

ATGGGAGACTGGAATAACAGTGATGCTGTGGAGGCCATATTATCCTGAGGGGTTTCTG  
 5 GACTGGAGTATGTCATTCTGGCTCTCCATCCTCTGTCTGCATATTGGTAGCATTT  
 ATGGGTAATGTTACCATCCTGTCATTTGGATAGAATCCTCTCCATCAGCCATGTA  
 10 TTACTTATTCATCTAGCAGTGAATGACCTGGGATGCCCTGTCTACACTCCCACCA  
 TGCTTGCTGTGTTATGGTGATGCTCCAGAGATCCAGGCAAGTGCTGCTATGTCAGCT  
 GTTCTCATCCACACATTACATTCTGGAGTCCTCAGTGTGCTGCCATGCCCTTGACC  
 15 GTTTGTGCTATCTGCCATCCACTGCACTACCCACCATCCTACCAACAGTGAATTGGC  
 AAAATTGGTTGGCTGTTGCTACGAAGCTTGGGAGTTGACTTCCACACCTTGCTACT  
 GAGACACTATCACTGCAATGCCCTCTCACGCCCTCTGTTGACCAAGGAT  
 GTTCTAAGATTATCCTGTACAGATGCCAGGACCAACAGTATTATGGCTTGATGTC  
 TTGCCACACTAGGTGTGGATTCAATCTCATACTTCTTATGTTGATTCTTAATACT  
 GTGCTGGATATTGCACTCGTGAAGAGCAGCTAAAGGCACTCAACACATGTTGATCCCATA  
 TCTGTGTTGCTTATCTCTTGCCAGTTTGGGTTGCAATGGCCATGCCCTTGGG  
 20 AAGCATCTGTCTCCATAGTCCACATCCTCATGGCAGACATCACCTTCTTCCCCAGT  
 CCTTAACCTATTGCTATAGTGTAGAACAAGCAGATTGCTAGGAATTCTCCACAAG  
 TTTGTCTAAGGAGGAGGTTTAA (SEQ ID NO: 108)

## AOLFR60 sequences:

20 MFLPNNDTQFHPSFLLLGIPGLETLHIWIGFPFCAVYMLIGNFTILLVIKTDSSLHQPMFYFLA  
 MLATTDVGLSTATIPKMLGIFWINLRGIIFEAQTLQMFHNFNTLMEAVLVAMAYDSYVAICN  
 PLQYSAILTNKVVSVIGLVFVRALIFVIPSILLRLPFCGNHVIPHTYCEHMLAHLSCASIKINI  
 IYGLCAICNLVFDITVIALSYVHILCAVFRPLPHEPRLKSLSLTCGSHVCVILAFYTPALFSFMTHC  
 FGRNVPRYIHILLANLYVVVPPMLNPVIYGVRTKQIYKCVKKILLQEQQMEKEEYLIHTRF  
 25 (SEQ ID NO: 109)

ATGTTCTTCCAATGACACCCAGTTCACCCCTCCTCTGTTGCTGGGATCCAGG  
 ACTAGAAACACTCACATCTGGATCGGTTTCCCTCTGTCATGATCGCACTC  
 30 ATAGGAACTCACTATTCTACTTGTGATCAAGACTGACAGCAGCTACACCAGCCATGT  
 TCTACTTCTGGCATGTTGCCACACTGATGTTGCTCTAACAGCTACCCCTAA  
 GATGCTTGGATCTCTGGATCACACCTCAGAGGGATCATCTTGAAGCCTGCCCTACCCAG  
 ATGTTTTTATCCACAACCTCACACTTATGGAGTCAGCAGTCTTGTGGCAATGGCTTATG  
 35 ACAGCTATGTGGCCATCTGAATCCACTCCAATATAGGCCATCTCACCACAAAGGTTGT  
 TTCTGTATTGGCTTGGTGTGTTGTAGGGCTTAATTTCGTCACTCCCTATACTTC  
 TTATATTGCCGTATCTATCTGTGCCAGCATAAAATCAATATTATGGTTATGTGCCA  
 GGGCTTGCTCATCTATCTGTGCCAGCATAAAATCAATATTATGGTTATGTGCCA  
 TTTGTAATCTGGTGTGACATCACAGTCATTGCCCTCTTATGTGCATATTCTTGCT  
 40 GTTTCCGCTTCCCTACTCATGAGCCCCGACTCAAGTCCCTCAGCACATGTGGTCACATGT  
 GTGTGTAATCTTGCCCTATACACCAGCCCTTTCTTATGACTCATGGCTTGGCC  
 GAAATGTGCCCGCTATATCCATACTCTAGCCAATCTCTATGTGTGGCCACCAAT  
 GCTCAATCTGTATATGGAGTCAGAACCAAGCAGATCTATAATGTGAAAGAAAAT  
 ATTATTGCAGGAACAAGGAATGGAAAAGGAAGAGTACCTAATACAGGAGGTTCTGA  
 (SEQ ID NO: 110)

## AOLFR61 sequences:

45 MSIINTSYVEITFFLVGMPGLEYAHIWISIPCSMYLIALGNGTILFIKTEPSLHGPMYYFLSML  
 AMSDLGLSLSLPTVLSIFLNAPETSSACFAQEFFFHGSVLESSVLLIMSFDRFLAIHNPRLYT  
 SILTTVRVAQIIVFSFKSMLLVLPPFPFLRSRLRYCKNQLSHSYCLHQDVMLACSDNRIDVIY  
 GFFGALCLMVDLILIAVSYTLILKTVPGIAKKEELKALNTCVSHICAIIYLPINLA VVHRFAG  
 HVSPLINVLMANVLLVPPLMKPIVYCVTKQIRVRVVAKLCQWKI (SEQ ID NO: 111)

50 ATGTCCATTATCAACACATCATATGTTGAAATCACCTTCTTGGGATGCCAG  
 GGCTAGAATATGCACACATCTGGATCTCATCCCCATCTGCAGCATGTATCTTATTGCTATT  
 CTAGGAATGGCACCATTCTTATCATCAAGACAGAGGCCCTCTGCATGGGCCATGT  
 55 ACTATTCTTCCATGTGGTATGTCAGACTTGGGTTGCTTATCATCTCTGCCACT  
 GTGTTAACATCTCTGTTCAATGCCCTGAAACTCTCTAGTGCCTGCTTGGCCAGGA

ATTCTTCATTGATTCTCAGTACTGGAGTCCTCAGTCCTCTGATCATGTCATTGATA  
 GATTCCATGCCACAACTCTGAGATACACCTCAATCCTGACAACAGTCAGAGTTGC  
 CCAAATAGGGATAGTATTCTCCTTAAGAGCATGCTCTGGTTCTCCCTCCCTTCACTT  
 5 TAAGAAGCTTGGAGATATTGCAAGAAAAACCAATTATCCCATTCTACTGTCTCCACCAAGGA  
 TGTCATGAAGTTGGCCTGTTCTGACAACAGAATTGATGTTATCTATGGCTTTGGAGCA  
 CTCTGCCTTATGGTAGACTTATTCTCATTGCTGTCTACACCCCTGATCCTCAAGACTGT  
 ACCGGGAATTGCATCCAAAAGGGAGGAGCTTAAGGCTCTCAATAACTTGTGTTCACACATC  
 10 TGTGCAGTGATCATCTTCTACCTGCCATCATCAACCTGGCCGTTGTCACCGCTTGCCGG  
 GCATGTCCTCTCCCTCATTAATGTTCTCATGGCAAATGTTCTACTTGTACCTCCGCTGA  
 TGAAACCAATTGTTATTGTGAAAAACTAAACAGATTAGAGTGAGAGTTGTAGCAAATT  
 GTGTCAATGGAAGATTAA (SEQ ID NO: 112)

**AOLFR62 sequences:**

MFYHNKSIFHPVTFFLIGIPGLEDFHMWISGPFCVYLVALLGNATILLVIKVEQTLREPMFYFL  
 15 AILSTIDLALSATSVPRMLGIFWFDAHEINYGACVAQMFLIHAFTGMEAEVLLAMAFDRYVAIC  
 APLHYATILTSVLVGISMCIIRPVLLTLPMVYLIYRLPFCQAHIIAHSYCEHMGIAKLSGNIRI  
 NGIYGLFVVSFFVNLVLIGISYVYILRAVFRLPSHDAQLKALSTCGAHVGVICVFYIPSVFSFLT  
 HRFGHQIPGYIHLVANLYLIIPPSLNPIIYGVRTKQIRERVLYVFTKK (SEQ ID NO: 113)

20 ATGTTTATCACAAACAAGAGCATATTCACCCAGTCACATTTCTCATTGGAATCCAGG  
 TCTGGAAGACTTCCACATGTGGATCTCGGCTTCTGCTCTGTTACCTGTGGCTTGC  
 TGGCAATGCCACCATTCTGCTAGTCATCAAGGTAGAACAGACTCTCGGGAGCCATGTT  
 CTACTTCTGGCCATTCTTCCACTATTGATTGGCCCTTCTGCAACCTCTGTGCCTCGCA  
 TGCTGGTATCTTCTGGTTGATGTCACGAGATAACTATGGAGCTGTGTGGCCAGAT  
 25 GTTCTGATCCATGCCCTACTGGCATGGAGGCTGAGGTCTACTGGCTATGGCTTTGAC  
 CGTTATGTGGCATCTGTGCTCCACTACATTACGCAACCATTGACATCCCTAGTGTGGT  
 GGGCATTAGCATGTGCAATTGAACTCGTCCGTTACTACACTCCATGGCTATCTTA  
 TCTACCGCCTACCCCTTGTCAAGGCTCACATAATAGCCATTCTACTGTGAGCACATGGG  
 CATTGCAAAATTGCTCTGTGAAACATTGTATCAATGGTATCTATGGCTTTGTAGTT  
 30 CTTTCTTGTCTGAACCTGGTCTATTGGCATCTCGATGTTACATTCTCCGTGTC  
 TTCCGCCTCCCATCACATGATGCTCAGCTAAAGCCCTAACGACGTGTGGCGCTATGTTG  
 GAGTCATCTGTGTTCTATATCCCTCAGTCITCTCTTACTCATCGATTGGACAC  
 CAAATACCAGGTTACATTCACATTCTGTTGCCAATCTCTATTGATTATCCCACCCCTCT  
 CAACCCCATCATATTGGGTGAGGACCAACAGATTGAGAGCGAGTGCTATGTTT  
 35 ACTAAAAATAA (SEQ ID NO: 114)

**AOLFR63 sequences:**

MSIINTSYVEITTFVLVMPGLEYAHIWISIPCSMYLIALGNGTILFIKTEPSLHEPMYYFLSML  
 AMSDLGLSLSLPTVLSIFLNAPEISSNACFAQEFFFHGSVLESSVLLIMSFDRFLAIHNPLRYTS  
 40 ILTVRVAQIGIVFSFKSMLLVLPPFTLRLNRYCKKNQLSHSYCLHQDVMLACSDNRIDVIY  
 GFFGALCLMVDFILIAVSYTILKTVLGIASKKEQLKALNTCVSHICAVIIFYLPINLAVVHRFAR  
 HVSPLINVLMANVLLVPPLTNPIIVCVTKQIRRVVAKLCQRKI (SEQ ID NO: 115)

ATGCCATTATCACACACATCATATGTTGAAATCACCACTTCTTGGTTGGATGCCAG  
 45 GGCTAGAAATATGCACACATCTGGATCTCTATCCCCATCTGCAGCATGTATCTTATTGCTATT  
 CTAGGAAATGGCACCATTCTTATCATCAAGACAGAGGCCCTCTGATGAGCCATGT  
 ACTATTCTTCCATGTTGGCTATGTCAGACTGGGTTGTCTTATCATCTGCCACT  
 GTGTTAAGCATCTCCTGTTCAATGCTCTGAAATTCTACCAATGCCCTGTTGCCAGGA  
 ATTCTTCATTGATTCTCAGTACTGGAGTCCTCAGTCCTCTGATCATGTCATTGATA  
 GATTCCCTAGCCATCCACAAACCTCTGAGATACACCTCAATCCTGACAACAGTCAGAGTTGC  
 50 CCAAATAGGGATAGTATTCTCTTAAGAGCATGCTCTGGTTCTCCCTCCCTTCACTT  
 TAAGAAACTTGAGATATTGCAAGAAAAACCAATTATCCCATTCTACTGTCTCCACCAAGGA  
 TGTCAATGAGTTGGCCTGTTGACAACAGAATTGATGTTATCTATGGCTTTGGAGCA  
 CTCTGCCTTATGGTAGACTTATTCTCATTGCTGTCTACACCCCTGATCCTCAAGACTGT  
 55 ACTGGGAATTGCATCCAAAAGGAGCAGCTTAAGGCTCTCAATACTTGTGTTCACACATC  
 TGTGCAGTGATCATCTTCTACCTGCCATCATCAACCTGGCCGTTGTCACCGCTTGCCG

WO 01/98526

GCATGTCTCTCCCTCATTAATGTTCTCATGGCAAATGTTCTCTACTTGTACCTCCACTGA  
 CGAACCCAATTGTTATTGTGAAAAACTAAACAGATTAGAGTGAAGTTGAGCAAAATT  
 GTGTCAACGGAAGATTAA (SEQ ID NO: 116)

## 5 AOLFR64 sequences:

MTILLNSSLQRATFFLTGFQGLEGLHWISIPFCFIYLTILGNLTILHVICTDATLHGPMYYFLG  
 MLAVTDLGLCLSTLPTVLGIFWFDTREIGIPACFTQLFFIHTLSSMESSVLLSMSIDRSVAVCNPL  
 HDSTVLPACIVKMGSLVRSALLLPLPFLLKRFQYCHSHVLAHYCLHLEIMKLACSSIIVN  
 HIYGLFVVACTVGVDSSLIFLSYALIRTVLSIASHQERLRALNTCVSHICA VLLFYIPMIGLSLV  
 10 HRFGEHLPRVVHLFMSYVYLLVPPPLMNPPIYSIKTKQIRQRIKKFQFIKSLRCFWKD (SEQ ID  
 NO: 117)

ATGACAATTCTCTTAATAGCAGCCTCAAAGAGCCACTTCTCTGACGGGCTTCCAAG  
 GTCTAGAAGGTCTCCATGGCTGGATCTCATTCCTCTGCTTCATCTACCTGACAGTTATC  
 15 TTGGGAACCTCACCATTCTCCACGTCAATTGTACTGATGCCACTCTCCATGGACCCATGT  
 ACTATTCTGGCATGCTAGCTGACAGACTTAGGCCTTGCCCTTCCACACTGCCACT  
 GTGCTGGCATTCTGGTTGATACCAGAGAGATTGGCATCCCTGCCGTGTTACTCAGC  
 TCTTCTCATCCACACCTGTCTCAATGGAGTCATCAGTTCTGTTATCCATGCCATTGAC  
 CGCTCCGTGGCGTCTGCAACCCACTGCATGACTCCACCGTCTGACACCTGCATGTATTG  
 20 TCAAGATGGGCTAACACTGCCACTCCATGCTAGCTAGTCTAGAAGTGTCTCCATCCTCCCTGCCATTCTC  
 CTGAAGCGCTTCAATACTGCCACTCCATGCTAGCATATTGTCATCACATCTATGGGCTTTGTTGTG  
 GATCATGAAGCTGGCTGCTCTAGCATATTGTCATCACATCTATGGGCTTTGTTGTG  
 25 GCCTGCACCGTGGGTGGACTCCCTGCTCATCTTCTCATACGCCCTCATCCITCGCAC  
 CGTGCCTAGCATGCCCTCACAGGAGCGACTCCGAGCCCTAACACCTGTCTCAT  
 ATCTGTGCTGACTGCTCTACATCCCAGTATTGGCTGTCTTGTGCATCGCTTGG  
 TGAACATCTGCCCGCTGTACACCTCTCATGTCCTATGTATCTGCTGGTACCA  
 TTATGAACCCCATCATCACAGCATCAAGACCAAGCAAATCGCCAGCGCATATTAAAGAA  
 GTTCAAGTTATAAGTCACTTAGGTGTTTGGAGGATTAA (SEQ ID NO: 118)

## 30 AOLFR65 sequences:

MAGRMSTSNTQFHPSSFLLGIPGLEDVHIWIGVPFFFVYLALLGNTALLFVIQTEQSLHEPM  
 YYFLAMLDSDILGLSTATIPKMLGIFWFNTKEISFGGCLSHMFFIHFTAMESIVLVAMAFDRYI  
 AICKPLRYTMILTSKIISLIAGIAVRLSLYMVVPLVFLLLRPFCGHRIIPHTYCEHMGIA  
 LACASIKVNIRFLGNISLLLDVILILSYVRILYAVFCLPSWEARLKALNTCGSHIGVIAFFTPAFSFL  
 35 THRFGHNIPQYIHLANLYVVVPPALNPVIYGVRTKQIRERVLRIFLKNH (SEQ ID NO: 119)

ATGGCAGGAAGAATGTCACGCTAATCACACCCAGTTCCATCCTCTCATCCACTGCT  
 GGGTATCCCAGGGCTAGAACAGATGTGCACATTGGATTGGAGTCCCTTTCTTGTGTT  
 40 CTGTTGCACCTCTGGAAACACTGCTCTTGTGTTGTGATCCAGACTGAGCAGACTCTCC  
 ATGAGCCTATGTTACTACTTCTGGCATCTCTGGTTCAATACCAAAAGAAATCTTTGGAGGC  
 CACCATCCCCAAATGTTGGCATCTCATCCATTCTCACTGCTATGGAGAGCATTGTGTTGG  
 TGCTTCTCACATGTTCTCATCCATTCTCACTGCTATGGAGAGCATTGTGTTGG  
 45 CATGCCCTTGACCGTACATTGCCATTGCAAACCTCTCGGTACACCAGTACCTCACC  
 GAAAATCATCAGCCTATTGCAAGGCTATTGCTGTCTGAGGCTGCCATTGTGTTGG  
 ACTGGTGTCTCTCTGAGGCTGCCATTGTGAGGCTGCCATTGTGTTGG  
 50 CTTGGCAACATATCTCTGAGGCTGCCATTGTGAGGCTGCCATTGTGTTGG  
 TCCTGTATGCTGCTCTGCTGCCCTCTGGCTGCCCCATGCTGAGGAGCCTGTACATGG  
 GGTTCTCATATTGGTGTATCTAGCTTACCCAGTATACATATTAGCCAAAGCTCAACACCTGT  
 TCGTTTGGCCATAATATCCCACAGTATACATATTAGCCAAACCTGTATGG  
 TCCCACCAAGCCCTCAATCCTGTAATCTAGGAGTCAGGACAAAGCAGATTGAGAGAG  
 TGCTGAGGATTCTCAAGACCAACTAA (SEQ ID NO: 120)

## 55 AOLFR66 sequences:

MSFLNGTSLTPASFLNGIPGLEDVHLWISFPLCTMYSIAITGNFGLMYLIYCDEALHRPMYVFL  
 ALLSFTDVLMLCTSLPNTLFLWFLNLKEIDFKACLAQMFFVHTFTGMESGVLMALDHCVAI

CFPLRYATILTNSVIAKAGFLTFLRGVMLVIPSTFLTKRLPYCKGNVIPHTYCDHMSVAKISCGN  
VRVNAIYGLIVALLIGGFDLICITISYTMILQAVVSLSSADARQKAFSTCTAHFCAIVLTYPAFF  
TFFTHFGGHTIPLHIIMANLYLLMPPTMNPIVYGVKTRQVRESIRFFLKGKDMSHNF (SEQ  
ID NO: 121)

5

ATGTCATTCTAAATGGCACCGCCTAACTCCAGCTTCATTCCATCCTAAATGGCATCCCTG  
GTTGGAAAGATGTGCATTGTGGATCTCCTCCACTGTGTACCATGTACAGCATTGCTATT  
ACAGGGAACTTCGGCCTTATGTACCTCATCTACTGTGTGATGAGGCCTACACAGACCTATGT  
ATGTCTCCTGCCCTCTTCCTCACAGATGTGCTCATGTGCACCAGCACCCCTCCAAC  
10 ACTCTCTCATATTGTGGTTAACATCTCAAGGGAGATTGATTAAAGCCTGCCCTGCCAGAT  
GTTCTTGTGCACACCTCACAGGGATGGAGTCTGGGGTGCTCATGCTCATGGCCCTGGAC  
CACTGTGTGGCCATCTGCTCCCTCGCTTATGCCACCATCTCACTAATTCACTGATTGC  
TAAAGCTGGGTTCTCACTTTCTTAGGGGTGTGATGCTTATCCCTCCACTTCTCA  
CCAAGGCCCTCCATACTGCAAGGGCAACGTACATACCCCACACCTACTGTGACCACATGTC  
15 TGTGGCCAAGATATCTTGTGGTAATGTCAAGGGTAACGCCATCTATGGTTGATAGTTGCC  
CTGCTGATTGGGGCTTGTGATATCCTGTGCATTACAATCTCCTACACTATGATTCTCAAGC  
AGTTGTGAGTCTATCATCAGCAGATGCTGACAGAAGGCCTCAGCACCTGCACTGCCAC  
TTCTGTGCCATAGCCTCACCTATGTCAGCCTTCTTACCTTACACACCATTG  
GGGACACACCATTCTCACACATACATATTATGCTAATCTCTACCTACTAACGCTC  
20 CCACAATGAACCTATTGTGTATGGGGAAAACCAGGCAGGTACGAGAAAGTGTCTTA  
GGTTCTTCTTAAGGGAAAGGACAATTCTCATAACTTTAA (SEQ ID NO: 122)

**AOLFR67 sequences:**

MSGDNSSLTPGFFILNGVPGLEATHIWISLPFCFMYIIAVVNCGLICLISHEEALHRPMYYFLA  
25 LLSFTDVTLCCTMVPNMLCIFWFNLKEIDFNACLAQMFFVHMLTGMEGVLMALDRYVAI  
CYPLRYATILTNPVIKAGLATFLRNVMLIIPFTLLTKRLPYCRGNFIPHTYCDHMSVAKVSCGN  
FKVNAIYGLMVALIGVFDICCISVSYTMILQA VMSLSSADARHKAFSTCTSHMCISIVITYVAAF  
FTFFTHRFGHNPNIHIIIVANLYLLPPTMNPIVYGVTKQIPEGVIKFLLGDKVSFTYDK  
(SEQ ID NO: 123)

30

ATGCTGGGGACAACAGCTCCAGCCTGACCCCAGGATTCTTATCTGAATGGCGTCTCTG  
GGCTGGAAAGCCACACACATCTGGATCTCCCTGCCATTCTGCTTATGTACATCATTGCTGTC  
GTGGGGAACTGTGGGCTCATCTGCCCTCATGCCATGAGGAGGCCCTGCACCGGCCATGT  
ACTACTCCTGCCCTGCTCTCCTCACTGATGTCACCTTGTGCACCACCATGGTACCTAAT  
35 ATGCTGTGCATATTCTGGTTCAACCTCAAGGGAGATTGACTTAAACGCCCTGCCCTGGCCAGA  
TGTTTTTGTCCATATGCTGACAGGGATGGAGTCTGGGGTGCTCATGCTCATGGCCCTGGA  
CCGCTATGTGCCATCTGCTACCCCTACGCTATGCCACCATCCTTACCAACCCGTCTCATCG  
CCAAGGGCTGGTCTGCCACCTCTGAGGAATGTGATGCTCATCCCATCACTCTCCTC  
ACCAAGGCCCTGCCCTATTGCCGGGGAACTTCATCCCCACACCTACTGTGACCATATGT  
40 CTGTGGCCAAGGTATCCTGTGGCAATTCAAGGTCAATGCTATTATGGCTGATGGTTGC  
TCTCTGATTGGGTGTTGATATGCTGTATCTCTGATCTTACACTATGATTTCAGG  
CTGTTATGAGCCTGTCATCAGCAGATGCTGTCACAAAGCCTCAGCACCTGCACATCTCA  
CATGTGTTCCATTGTGATCACCTATGTTGCTGCTTTTCACTTTTCACTCATCGTTTGT  
AGGACACAAATATCCAAACACACATACACATCATCGTGGCCAACCTTATCTGCTACTGCCT  
45 CCTACCATGAACCAATTGTTATGGAGTCAAGACCAAGCAGATTCAAGGAAGGTGAATT  
AATTTCATTGGAGACAAGGTTAGTTTACCTATGACAAATGA (SEQ ID NO: 124)

**AOLFR68 sequences:**

MTTHRNDTLSTEASDFLLNCFVRSPSWQHWLSPLSLLAVGANTLLMTIWLEASLHQPL  
50 YYLLSLLSLLDIVLCLTVIPKVLTIFWFDLRPISPACFLQMYIMNCFLAMESCTFMVMAYDRY  
VAICHPLRYPSIITDHFVVKAAMFILTRNVLMTLPIPILSAQLRYCGRNVIENCICANMSVSRSLC  
DDVTINHLYQFAGGWTLGSDLILIFLSYTFILRAVRLKAEGAVAKALSTCGSHFMLILFFSTL  
LVFVLTHVAKKKVSPDVPVLLNVLHHVIPAALNPIIYGVRTQEIKQGMQRLLKKGC (SEQ ID  
NO: 125)

55

WO 01/98526

ATGACAAACACACCGAAATGACACCCCTCCACTGAAGCTCAGACTTCTCTGAATTGTT  
 5 TTGTCAGATCCCCAGCTGGCAGCACTGGCTGTCCCTGCCCTCAGCCTCTTCTG  
 GCCGTAGGGGCAACACCACCCCTGTATGACCCTCTGGCTGGAGGCCTCTGACCAGC  
 CCCTGTACTACCTGCTCAGCTCTCCCTGTCAGACATCGTCTGCCTCACTGTCATC  
 10 CCCAAGGTCTGACCATCTTGGTTGACCTCAGGCCATCAGCTCCCTGCCTGCTCCT  
 CCAGATGTACATCATGAATTGTTCTAGCCATGGAGTCTGCACATTGATGGTCATGGCC  
 TATGATCGTTATGTTAGCCATCTGCCACCCACTGAGATATCCATCAATCATCACTGATCACTT  
 TGTAGTCAAGGCTGCCATGTTATTGACAGAAAATGTGCTTATGACTCTGCCATCCCC  
 ATCCTTCAGCACAACCTCGTTATTGAGAAGAAAATGTCATTGAGAAGTGCATCTG  
 15 ATATGTCGTTCTCAGACTCTCTGCGATGATGTCACCATCAATCACCTTACCAATTGCT  
 GGAGGCTGGACTCTGCTAGGATCTGACCTCATCCTTATCTCCTCTACACCTTCATTCT  
 GCGAGCTGTGCTGAGACTCAAGGCAGAGGGTGGCAGAACGCCCTAACGACATGTGG  
 CTCCCACCTCATGTCATCCTCTTCAGCACCACCTCTGGTTTTGCTCACACATGT  
 GGCTAAGAAGAAGTCTCCCTGATGTGCCAGTCTGCTCAATGTTCTCCACCATGTCATT  
 CCTGCAGCCCTAACCCCATCATTACGGGTGAGAACCAAGAAATTAAAGCAGGAAATG  
 CAGAGGTTGTTGAAGAAAGGGTGTAA (SEQ ID NO: 126)

**AOLFR69 sequences:**

MSYSIYKSTVNIPLSHGVVHSFCHNMNCNFMHIFKFVLDNMKNVTEVTLFVLKGFTDNLELQ  
 20 TIFFFLFLAIYLFTLMGNLGLILVIVRDSQLHKPMLYYFLSMLSSVDACYSSVITPNMLVDFTTKN  
 KVISFLGCVAQVFLACSFGTTECFLLAAMAYDRYVAIYNPLLYSVMSPRVYMLINASVYVAGI  
 LHTAHTVATFSLSGCANEIRRVFCDIPPLAISYSDHTNQLLFFYFVGSIELVTILVLSYGLIL  
 LAILKMYSAEGRKVFSTCGAHLTGSIVYYGTLFMYVRPSSSYASDHDMIVSIFYTIVIPLNPV  
 IYSLRNKDVKDSMKGKNQVINKVYFHTKK (SEQ ID NO: 127)

25 ATGTCGTACAGTATATAAGAGCACAGTTAACATCCCCITGAGTCATGGTTGTTCAATT  
 CTTTTGTATAATATGAACTGTAACCTTATGCAATCTCAAGTTGTTCAAGATTCAAC  
 ATGAAGAATGTCACTGAAGTTACCTTATTGACTGAAGGGCTTCACAGACAATCTGAAC  
 30 TGCAGACTATCTCTTCTCTGTTCTAGCAATCTACCTCTTCACTCTCATGGAAATTAA  
 GGACTGATTTAGTGGTCATTAGGGATCCCAGCTCCACAAACCCATGTAATTTCTGA  
 GTATGTTGTCCTGTGGATGCCTGCTATTCTCAGTTATTACCCAAATATGTTAGTAGAT  
 TTTACGACAAAGAATAAAGTCATTCACTTCTGGATGTTGTCAGCACAGGTGTTCTGCTT  
 GTAGTTTGGAACACACAGAATGCTTCTTGGCTGCAATGGCTATGATCGCTATGTC  
 35 CATCTACAACCTCTCTGTATTCACTGAGCATGTCACCCAGAGTCTACATGCCACTCATC  
 AATGCTTCCTATGTTGCTGGATTACATGCTACTATACATACAGTGGCTACATTAGCCT  
 ATCCTCTGGAGCCAATGAAATTAGCGTGTCTTGATATCCCTCTCTCTGCTA  
 40 TTTCTTATTCTGACACTCACACAAACAGCTTACTCTTCTACTCTTCTACTCTGAG  
 CTGGTCACTATCCTGATTGTTCTGATCTCTTCTGTTGATTCTGTTGGCCATTCTGAAGAT  
 GTATTCTGCTGAAGGGAGGAGAAAAGTCCTCCACATGTGGAGCTACCTAACTGGAGT  
 GTCAATTATTATGGACAATCTCTTCTGATGTGAGACCAAGTCCAGCTATGCTCG  
 GACCATGACATGATGTCAATTTCACACCATTGTGATTCTTGTGAATCCGTCAT  
 CTACAGTTGAGGAACAAAGATGAAAAGACTCAATGAAAAAAATGTTGGAAAAATCA  
 GTTATCAATAAGTATTTCTACTAAAAATAA (SEQ ID NO: 128)

**AOLFR70 sequences:**

45 MDSTFTGYNLYNLQVKTEMDKLSSGLDIYRNPLKNKTEVTMFILTGFTDDFELQVFLFLFFAI  
 YLFTLIGNLGLVVLVIEDSWLHNPMYYFLSFLDACYSTVTPKMLVNFLAKNKSISFIGCA  
 TQMLLFVTGTTCTCFLAAMAYDHVVAIYNPLLYSVMSPRVYVPLITASVYVAGILHATIHLVA  
 TFSLSFCGSNEIRHVFCDMPPLLAISCSDTHTNQLLFFYFVGSIEVTLVLSIISDFILLSILKMHSA  
 KGRQKAFSTCGSHLTGVTIYHGTILVSYMRPSSSYASDHDIIVSIFYTIVIPKLNPIYSLRNEVK  
 50 KAVKKMLKLVYK (SEQ ID NO: 129)

55 ATGGACTCCACTTCACAGGCTATAACCTTATAACCTGCAAGTAAAAGTGAATGGACA  
 ATGTTGTCATCAGGTTGGATATATACAGGAATCCACTGAAAGAACAGACTGAAGTCACCA  
 TGTTTATTCAGGCTTCACAGATGTTGAGCTGCAAGTCTCCTATTTCATT  
 TTGCAATCTATCTCTTACCTGATAGGCAATTAGGGCTGGTTGTGGTATTGAGG

ATTCCCTGGCTCCACAACCCCATGTATTATTTCTAGTGTATCATTCTGGATGCTTGC  
 TATTCTACAGTTGCACTCCAAAAATGTTGGTCAATTCTGGCAAAAAATAATCCATT  
 CATTATCGGATGTGCAACACAGATGCTTCTTGTACTTTGGAACACAGAAATGTTT  
 5 CTCTGGCTGCAATGGCTATGATCACTATGAGCCATCTACAACCCCTCTCTGTATTAGT  
 GAGCATGTCACCCAGAGTCTATGTCACACTCATCACTGCTTCTACGTTGCTGGCATTTAC  
 ATGCTACTATACATATAGTGGCTACATTAGCCTGCTCTGTTGATCCAATGAAATTAG  
 GCATGTCTTTGTGATATGCCTCCTCCTGCTATTCTTGTCTGACACTCACACAAACC  
 AGCTTCACTCTACTTGTGGGTTCTATTGAGATAGTCACTATCCTGATTGTCCTCATT  
 10 TCCTGTGATTTCATTCTGTGTCATTCTGAAGATGCAATTGCTAAGGGAGGAAAAGG  
 CCTTCTACATGTGGCTCTCACCTAACGGAGTGACAATTATCATGGAACAATTCTCGTC  
 AGTTATATGAGACCAAGTCCAGCTATGCTCAGACCATGACATCATAGTGTCAATT  
 ACACAATTGTGATTCCAAGTTGAATCCATCATCTATAGTTGAGGAACAAAGAAGTAAA  
 AAAGGCAGTGAAGAAAATGTTGAAATTGGTTACAAATGA (SEQ ID NO: 130)

15 **AOLFR71 sequences:**

MGRRNNTNVPDFILTGLSDSEEVQMALFILFLIYLITMLGNVGMILIIRLDLQLHTPMYFFLTH  
 LSFIDLSYSTVTPKTLANLLTSNYISFMGCFAQMFFFVFLGAAECFLSSMAYDRYVAICSPRLY  
 PVIMSKRLCCALVTGPYVISFINSFNVVWMSRLHFCDSNVVRHFFCDTSPILALSCMDTYDIEI  
 MIHILAGSTLMVSLITISASYVSILSTILKINSTSGKQKALSTCASHLLGVTIFYGTMIFTYKPRK  
 20 SYSLGRDQVASVFYTIVIPMLNPLIYSLRNKEVKNALIRVMQRQRQDSR (SEQ ID NO: 131)

ATGGGTAGAAGAAAATAACACAAATGTGCCTGACTTCATCCTTACGGGACTGTCAGATTCTG  
 AAGAGGTCCAGATGCCCTTCTTACTATTCTCTGATAACCTAATTACTATGCTGGC  
 AATGTGGGGATGATATTGATAATCCGCCTGGACCTCCAGCTTACACTCCATGTATT  
 25 TCCTTACTCACTGTCATTATTGACCTCAGTTACTCAACTGTCATCACACCTAAACCTTA  
 GCGAACTTACTGACTTCAACTATATTCTCATGGGCTGCTTGCCTGAGATGTTCTT  
 TGTCTCTGGGAGCTGTAATGTTCTCTCATCAATGCCCTATGATGCTACGTAG  
 CTATCTGCACTCCTACGTTACCCAGTTATTGTCACACTCCTTGCAATGTCGGTTGGATGAGCAGAC  
 30 ACTGGGCCCTATGTGATTAGCTTATCAACTCCTTGCAATGTCGGTTGGATGAGCAGAC  
 TGCATTCTGCGACTCAAATGTAGTTGTCACCTTCTGCGACACGTCTCCAATTAGCT  
 CTGCTCTGCATGGACACATACGACATTGAAATCATGATAACACATTAGCTGGTCCACCC  
 TGATGGTGTCCCTATACAATATCTGCATCCTATGTCCTATTCTCTCATCCTGAAA  
 ATTAATTCCACTCAGGAAAGCAGAAAGCTTGTCTACTTGTGCTCTCATCTTGGGAG  
 TCACCATTTATGGAACTATGATTCTATTAAAACCAAGAAAGCTTATTCTTG  
 35 GGAAGGGATCAAGTGGCTCTGTTTATACTATTGTGATTCCATGCTGAATCCACTCAT  
 TTATAGTCTAGAAACAAAGAAGTAAAAATGCTCTCATTAGAGTCATGCAGAGAACACA  
 GGACTCCAGGTAA (SEQ ID NO: 132)

**AOLFR72 sequences:**

40 MAPENFTRVTEFILTGVSSCPLEQIPLFLVFLVLYGLTMAGNLGIITLTSVDSRLQTPMYFFLQHL  
 ALINLGNSTVIAPKMLINFLVKKKTSFYECATQLGGFLFFIVSEVIMLALMACDRYVAICNPLL  
 YMVVVSRRLLCLLVSLTYLYGFSTAIVSSYVFSVSYCSSNIINHFYCDNVPLLALSCSDTYLPE  
 TVVFISAATNVVGSLIIVLVSYFNIVLSILKICSEGRKKAFSTCASHMMAVTIFYGTLFMYVQP  
 RSNHSLDTDDKMASVFYTLVIPMLNPLIYSLRNKDVKTALQRFMTNLCSFKTM (SEQ ID NO:  
 45 133)

ATGGCTCCTGAAAATTCAACCAGGGTCACTGAGTTATTCTTACAGGTGCTCTAGCTGTC  
 CAGAGCTCCAGATTCCCTCTTCTGGTCTTCTGGTCTATGGCTGACCATGGCAGG  
 50 GAACCTGGGCATCATCACCTCACCAAGTGTGACTCTGACTTCACAAACCCCATGTACTTT  
 TCCTGCAACATCTGGCTCTCATTAACTTGGTAACCTACTGTCATTGCCCTAAATGCTG  
 ATTAACCTTTAGTAAAGAAGAAAACCTACCTCATTCTATGAATGTCGCAACCCACTGGGAG  
 GGTCTTGTCTTATTGTATCGGAGGTAATCATGTCGGCTTGTATGGCTGTGACCGCTAT  
 GTGGCTATTGTAAACCTCTGCTGTACATGGGGTGTCTGGCGGCTCTGCCCTCTGCT  
 55 GGTCTCCCTCACATACCTCTATGGCTTCTACAGCTATTGTGGTTCATCTTATGTATTCT  
 CTGTGTCTTATTGCTCTTAATATAATCAATCATTACTGTGATAATGTCCTCTGTTA  
 GCATTATCTGCTCTGATACTTACTTACAGAAACAGTTGTCATTATCTGCAGAACAA

WO 01/98526

ATGTGGTGGTCCTGATTATAGTCTAGTATCTTCAATATTGTTGTCTATTITA  
 AAAATATGTTCATCAGAAGGAAGGAAAAAGCCTTTCTACCTGTGCTTCACATATGATGG  
 CAGTCACAATTCTATGGACATTGCTATTCTATGTATGTGAGCCCCGAAGTAACCATTC  
 ATTGGATACTGATGATAAGATGGCTCTGTGTTTACACGTTGGTAATTCTATGCTGAAT  
 5 CCCTTGATCTACAGCCTGAGAATAAGGATGTGAAGACTGCTACAGAGATTGACA  
 AATCTGTGCTATTCTTAAAACAATGTAA (SEQ ID NO: 134)

**AOLFR73 sequences:**

10 MNHVVKHNTAVTKVTEFILMGITDNPGLQAPLFGLFLIYLTVIGNLGMVILTYLDSKLHTP  
 MYFFLRHLSITDLCYSTVIAPKMLVNFIHKNTISYNWYATQLAFFEIFISELFSAMAYDRYV  
 AICKPLLVIIMAEKVLWVLVIVPYLYSTFVSLFLTIKLFKLSFCGSNIISYFYCDCIPLMSILCSDT  
 NELELILIFSGCNLLFSLSIVLISYMFILVAILRMNSRKGRYKAFSTCSSHLTVVIMFYGTLLFIYL  
 QPKSSHTLAIDKMASVFYTLIPMLNPLIYSLRNKEVKDALKRLTNRFKIP (SEQ ID NO: 135)

15 ATGAATCATGTGGTAAAACACAATCACACGGCAGTGACCAAGGTGACTGAATTATTCTCA  
 TGGGGATTACAGACAACCTGGCTGCAGGCTCCACTGTTGGACTCTCCTCATCATATA  
 TCTGGTCACAGTGATAGGAATCTGGCATGGTTATCTTGACCTACTGGACTCCAAGCTA  
 20 CACACCCCCATGTACTTTCTTAGACATTGTCAATCACTGATCTGGTTACTCCACTGT  
 CATTGCCCGAAGATGTTAGTAAACCTCATAGTGACAAAAACACAATTCTACAATTGG  
 TATGCCACTCAGCTAGCATTGAGATTTCATCATCTTGAGCTCTTATTCTATCAGC  
 AATGCCATATGATCGCTACGTAGCCATCTGTAACCTCTCTGTACGTGATCATCATGGCA  
 GAGAAAGTACTTGGGTGCTGGTAATTGTCCTATCTCTAGCACGTTGTGACTATT  
 TCTCACAATTAAAGTTATTAAACTGCTCTGTGCTGACACAAATGAATTAGAATTAAAT  
 25 GTGACTGTATCCTCTGTGTCATACTCTGTTCTGACACAAATGAATTAGAATTAAAT  
 TTTGATCTCTCAGGCTGTAATTGCTCTCTCCCTCTCAATTGTCATATCCTACATGTT  
 TATTCTAGTGGCATTCTCAGAATGAACCTCAAGGAAGGGAGGTACAAAGCCTCTCACC  
 TGTAGCTCTCATGACAGTGGTGATCATGTTCTATGGACATTGTTATTATTTACTGCA  
 ACCCAAGTCCAGTCATACTTGGCTATTGATAAAATGCCCTAGTGTGTTATACCCTGTG  
 ATTCCATGCTGAATCCGGTATCACGCTAAGGAACAAAGAAGTAAAGATGCTCTAA  
 30 AGAGAACTTAAACCAATCGATTCAAAATTCCATTAA (SEQ ID NO: 136)

**AOLFR74 sequences:**

35 MEQHNLTIVNEILTGTIDIAELQAPLFAELMIYVISVMGNLGMIVLTKLDSRLQTPMYFFLRH  
 LAFMDLGYSTVGPKMLVNFDVKNIISYYFCATQLAFLVFIGSELFILSAMSYDLYVAICNPL  
 LYTVIMSRRVCQVLVAIPYLYCTFISLLVTIKIFLTSFCGYNISHFYCDSLPLLLCSNTHEIELI  
 ILIFAAIDLISLLIVLLSYLLILVAILRMNSAGRQKAFSTCGAHLTVVIVFYGTLLFMYVQPKSSH  
 SFDTDKVASIFYTLVIPMLNPLIYSLRNKDVKYALRRTWNNLCNIFV (SEQ ID NO: 137)

40 ATGGAACACACAATCTAACACGGTGAATGAATTCTTACGGGAATCACAGATATC  
 GCTGAGCTGCAGGCACCATTATTGCTATTGCTCATGATCTATGTGATCTCAGTGATGG  
 GCAATTGGCATGATTGCTCCTACCAAGTTGGACTCCAGGTGCAAACCCCTATGTACTT  
 TTTCTCAGACATCTGGCTTCTGGATCTGGTTATTCAACAATGTGGGACCCAAATG  
 TTAGTAAATTGTTGTGATAAGAATATAATTCTTATTATTGTGCAACACAGCTAGC  
 45 TTCTTCTGTGTTCTGGTAGTGAATTCTCTACACAGTAATCATGTCAGGAAGGGTATGTAGGT  
 GCTGGTAGCAATCCCTAACCTCTATTGACATTCTTCTAGTCACTGTGACAGTCTCCCTTG  
 TTACTTATCCTCTGTGGCTAACACGTCTAGTCAATTCTCTAGTCACCATAAGATT  
 TGATTGATTCTCTGTGATAGTTCTTACCTGCTCATCCTGTCAGTCTCCCTTG  
 50 CAGGATGAATTCTGTGGCAGACAAAAGGTTTCTACCTGTGAGCCACCTGACAGTG  
 GTCATAGTGTCTATGGGACTTGTCTTCTACGTGTCAGCCAAAGTCCAGTCATTCT  
 TGACACTGATAAAAGTGGCTTCATATTACACCTGGTATCCCCATGTGAATCCCTG  
 TCTATAGTTACGAAACAAAGATGTAAAATGCCCTACGAAGGACATGGAATAACTTATG  
 TAATATTGTAA (SEQ ID NO: 138)

**AOLFR75 sequences:**

MEGKNQTNISEFLLGFSSWQQQVLLFALFLCLYLTLGNLLILLAIGSDHCLHTPMYFFLA  
 NLSLVDLCLPSATVPKMLNIQTQTISYPGCLAQMYFCMMFANMDNFLLTVMAYDRYVAI  
 5 CHPLHYSTIMALRLCASLVAAPWVIAILNPLLHTLMMALHFCSDNVIHFFCDINSLLPLSCSD  
 TSLNQLSVLATVGLIFVVPSCILVSYLIVSAVMKVPSAQGKLKAFSTCGSHLALVILFYGANT  
 GVYMSPLSNHSTEKDSAASVIFMVVAPVLPFIYSLRNNELKGLKTLRPGAVAHACNPSTL  
 GGRGGWIMRSGDRDHPG (SEQ ID NO: 139)

10 ATGGAAGGGAAAAATCAAACCAATATCTCTGAATTCTCCTCCTGGGCTTCTCAAGTTGGC  
 AACAAACAGCAGGTGCTACTCTTGCACCTTCTGTGTCTATTTAACAGGGCTTTGGGA  
 AACTTACTCATCTTGCCTGCCATTGGCTGGATCACTGCCTCACACACCCATGTATTCTT  
 CCTTGCCAATCTGCTCTGGTAGACCTCTGCCTCCCTCAGCCACAGTCCCCAAGATGCTAC  
 15 TGAACATCCAACCCAAACCCAAACCATCTCCTATCCCGCTGCCTGGCTCAGATGTATT  
 CTGTATGATGTTGCCAATATGGACAATTCTTCTCACAGTGATGGCATATGACCGTTAC  
 GTGGCCATCTGTACCCTTACATTACTCCACCATATTGGCCCTGCGCTCTGTGCCTCTCT  
 GGTAGCTGCACCTTGGTCATTGCCATTGAAACCCCTCTTGACACTCTTATGATGGCCC  
 ATCTGCACTTCTGCTCTGATAATGTTATCCACCATTCCTCTGTGATATCAACTCTCCCTC  
 CCTCTGTCCCTGTCGACACCAAGTCTTAATCAGTTGAGTGTCTGGCTACGGTGGGCTGA  
 TCTTGTTGGTACCTTCAGTGTGATCTGGTATCCTATATCCTCATTGTTCTGCTGTGATG  
 20 AAAGTCCCTCTGCCAAGGAAAACCTCAAGGCTTCTCACCTGTGGATCTCACCTGCCTT  
 GGTCAATTCTTCTATGGAGCAAACACAGGGCTATATGAGCCCCATTCCAATCACTCT  
 ACTGAAAAAGACTCAGCCGATCAGTCATTGTTATGGTTGAGCACCTGTGTTGAATCCAT  
 TCATTTACAGTTAAGAAAACAATGAACACTGAAGGGACTTAAAAAGACCCCTAACCGGGC  
 CGGGCGCGGTGGCTCACGCCGTAAATCCCAGCACTTGGGAGGCCGAGGCCGGTGGATCA  
 25 TGAGGTCAGGAGATCGAGACCATCCTGGCTAA (SEQ ID NO: 140)

**AOLFR76 sequences:**

MENNTVEFILLGLTNAPELQVPLFIMFTLIYLITLTGNLGMILILLDSHLHTPMYFFLSNLSA  
 GIGYSSAVTPKVLGLLIEDKAISYSACAAQMFFCAVFATVENYLLSSMAYDRYAAVCNPLHY  
 30 TTMMTTRVCACLAIGCYVIGFLNASIQIGDTFRLSFCMSNVIIHFFCDKPAVITLTCSEKHISELIL  
 VLISSFNVFFALLVTLISYLFILEILKRHTGKGYQKPLSTCGSHLIAIFLFYITVIIMYIRPSSSHSM  
 DTDKIASVFYTMIPMLSPIVYTLRNKDVKNAFMKVVEKAKYSLDSVF (SEQ ID NO: 141)

35 ATGGAGAATAATACAGAGGTGAGTGAATTCATCCTGCTTGGCTAACCAATGCCAGAA  
 CTACAGGTTCCCTCTTATCATGTTACCCATCACCTCATCACTCTGACTGGAAACCT  
 GGGGATGATCATATTAAATCCTGCTGGACTCTCATCTCCACACTCCCATGTACTTTCTCA  
 GTAACCTGTCTTGCAGGCATTGGTACTCCTCAGCTGTCACTCCAAAGTTAACTGG  
 GTTGCTTATAGAAGACAAAGCCATCTCCTACAGTGCCTGTGCTCAGATGTTCTTGT  
 GCAGTCTTGCACGTGAAATTACCTCTGCTCAATGGCTATGACCGCTACGCAG  
 40 CAGTGTGTAACCCCTACATTATACCAACCATGACAACACAGTGTGCTGCTGCTGTGCTGGC  
 TATAGGCTGTTATGTCATTGGTTCTGAATGCTTCTATCCAAATTGGAGATACTTCGCC  
 TCTCTTCTGCATGTCCAATGTGATTCACTTTCTGTGACAAACAGCAGTCATTACT  
 CTGACCTGCTCTGAGAAACACATTAGTGAGTTGATTCTGTTCTTATATCAAGTTAAATGT  
 CTTTTGCACTCTGTTACCTGATTCTCATATTGATCACCATCTTAAGAG  
 45 GCACACAGGTAAGGGATACCAGAAGCCTTATCTACCTGTGGTCTCACCTCATGCCATT  
 TTCTTATTTATATAACTGTCATCATGTACATACGACCAAGTCCAGTCATTCCATGG  
 CACAGACAAAATTGATCTGTTCTACACTATGATCATCCCCATGTCAGTCCTATAGTCT  
 ATACCCCTGAGGAACAAAGACGTGAAGAATGATTGAGTTGAGAAGGCAAAT  
 ATTCTCTAGATTGACTCTTAA (SEQ ID NO: 142)

50

**AOLFR77 sequences:**

MGDVNQSVASDFILVGLFSHGSRQLLFSLVAVMFVIGLLGNTVLLFLIRVDSRLHTPMYFLLS  
 QLSLFDIGCPMVTPKMASDFLRGEGATSYGGAAQIFFLTMGVAEGVLLVMSYDRYVAVC  
 55 QPLQYPVLMRRQVCLLMMGSSWVVGVLNASIQTTSITLHFPYCASRIVDHFFCEVPALLKLSA  
 DTCAYEMALSTSGVLILMLPLSLIATSYGHVLQAVLSMRSEEARHKAVTTCSSHITVVGLFYGA

WO 01/98526

AVFMYMVP CAYHSPQQDNVVS F YSLV TPTLNPLI YSLRNPEVWMALVKVLSRAGL RQMC  
(SEQ ID NO: 143)

5 ATGGGGATGTGAATCAGTCGGTGGCCTCAGACTCATTCTGGTGGCCCTTCAGTCACT  
CAGGATCACGCCAGCTCCTCTCCCTGGCTGTATGTTGTCTAGGCCTCTGGC  
AACACCGTCTCTCTTGTGACATGGCTGCCACACACCCATGACTTCCT  
GCTCAGCCAGCTCCCTGTTGACATGGCTGCCACATGGCACCACCCAAAGATGGCA  
TCAGACTTCTGGGGAGAAGGTGCCACCTCTATGGAGGTGGTGCAGCTCAAATATTCT  
10 TCCTCACACTGATGGGTGGCTGAGGGCTCTGTTGGTCTCATGTCCTATGACCGTTA  
TGTTGCTGTGTCAGCCCTGCAGTACCTGTACTTATGAGACGCCAGGTATGCTGCTG  
ATGATGGCTCCTGGGGTAGGTGTGCTCAAGCCTCCATCCAGACCTCCATCACCC  
TGCAAGCTCTCTGTGAGATAACCTGTGCCACAGATGGCCTGCCACCTCAGGGTGC  
15 TGATCTTAATGCTCCCTCTTCCCTATGCCACCTCCTACGCCACGTGTTGCAGGCTTT  
CTAACGATGCGCTCAGAGGAGGCCACACAAGGCTGTCACCACCTGCTCCTGCACATCA  
CGGTAGTGGGGCTTTATGGTGGCCCGTGTGATGACATGGTGCCTTGCGCCTACCA  
CAGTCACAGCAGGATAACGTGGTTCCTCTATAGCTTGTCAACCCCTACACTCAAC  
CCCCTATCTACAGTCTGAGGAATCCGAGGTGTGGATGGCTTGGTCAAAGTGCTTAGCA  
GAGCTGGACTCAGGAAATGTGCTGA (SEQ ID NO: 144)

20 AOLFR78 sequences:  
MSPDGNHSSDPTEFVLAGLPNLNSARVELFSVFLVYLLNLGNVLIVGVVRADTRLQTPMYF  
FLGNLSCLEILLTSVIPKMLSNFLSRQHTISFAACITQFYFFLGASEFLLAVMSADRYLAICH  
PLRYPLMSGAVCFRVALACWVGGLPVLGPTAVALLPCKQGAVVQHFFCDSGPLLRLAC  
25 TNTKLEETDFVLASLVIVSSLLITAVSYGLIVLAVLSIPSASGRQKAFSTCTSHLIVVTLFYGSAI  
FLYVRPSQSGSVDTNWAVTVITTFVTPLLNPFIYALRNEQVKEALKDMFRKVAGVGNLLD  
KCLSEKAVK (SEQ ID NO: 145)

30 ATGAGTCCTGATGGGAACCACAGTAGTGATCCAACAGAGTTCTGGCAGGGCTCCA  
AATCTCAACAGCGCAAGAGTGGATTCTGGGGGGTGTAAGGGCTGATACTCGACTACAGACCCCTAT  
GACAGGCAATGTGTTGATTCTGGGGGGTGTAAGGGCTGATACTCGACTACAGACCCCTAT  
GTACTCTCTGGTAACCTGTCTGCCAGAGATACTGCTACTCTGTCTCATCATTCAA  
AGATGCTGAGCAATTCTCTCAAGGAAACACACTATTCTCTGGCATGTATCACCA  
ATTCTATTCTACTCTCTGGGGCTCCGAGTTCTACTGTTGGCTGTCTGCGG  
35 ATCGTACCTGGCCATCTGTCTGCTACCTCTGCCCTGCTCATGAGTGGGCTGTG  
CTTCTGTGGCCCTGGCTGCTGGGTGGGGACTCGTCCCTGTGCTGGTCCACAGTG  
GCTGTGGCCCTGCTCTCTCTGTAAGCAGGGTGTGCTGAGTGGGCTGTG  
GTGGCCCACTGCTCCGCCCTGGCTGACCAACACCAAGAAGCTGGAGGAGACTGACTTTGT  
CCTGGCCCTCTCGTCACTGTATCTCTGCTGATCACTGCTGTGCTACGGCCTCATG  
40 TGCTGGCAGTCTGAGCATCCCTCTGCTCAGGCCCTGAGAAGGCCCTCTACCTGTAC  
CTCCCACITGATAGTGGTGAACCTCTATGGAAGTGCCATTCTCTATGTGCGCCAT  
CGCAGAGTGGTCTGGAACACTAAGTGGCAGTGAAGTAATAACGACATTGTGACAC  
CACTGTTGAATCCATTCTATGCTTACGTAATGAGCAAGTCAAGGAAGCTTGAAGGA  
CATGTTAGGAAGGTAGTGGCAGGCCTTAGGAATCTTACTGATAATGTCTCAGT  
45 GAGAAAGCAGTAAAGTAA (SEQ ID NO: 146)

AOLFR79 sequences:  
MTPGELALASGNHPTVKFILQGSNYPDLQELLFGAIIYAITVGNLGMMALIFTDSHLQSP  
MYFFLNVLSDLICSYSSVTPKLLVNFLVSDKSISFEGCVVQLAFFVVHVTAESFLASMYDR  
50 FLAICQPLHYGSIMTRGTCLQLVAWSYAFGGANSAIQTNVFALPFCGPQLTHYYCDIPPLH  
LACANTATARVVLVFSALVLLPAAVILTSYCLVLAIGRMRSVAGREKDLSTCASHFLAIAI  
FYGTVVFTYVQPHGSTNNNTNGQVSVFTIIIPMLNPFIYSLRNKEVKGALQRKLQVNIFPG  
(SEQ ID NO: 147)

55 ATGACACCTGGAGAACTAGCCCTGCCAGTGGCAACCACACCCAGTCACCAAGTTCT  
TGCAGGGATTCTCCAATTATCCAGACCTCCAGGAGCTTCTCGGAGGCCATCCTGCTCAT

5 CTATGCCATAACAGTGGTGGCAACTTGGGAATGATGGCACTCATCTTCACAGACTCCAT  
 CTCCAAAGCCCAATGTATTCTCCTCAATGTCCTCTCGTTCTGATATTGTTACTCTCT  
 GTGGTCACACCTAAGCTCTGGTCAACTTCCCTGGTCTCTGACAAGTCCATCTCTTGAGG  
 GCTGTGGTCCAGCTCGCTTCTTGTAGTGCATGTGACAGCTGAGAGCTCCTGCTGGC  
 10 CTCCATGGCCTATGACCGCTTCTAGCCATCTGTCAACCCCTCCATTATGGTTATCATGA  
 CCAGGGGACCTGTCTCCAGCTGGTAGCTGTGCTATGCATTGGTGGAGCCAACCTCCGC  
 TATCCAGACTGGAATGTCTTGCCTGCCTTCTGTGGGCCAACAGCTAACACACTAC  
 TACTGTGACATACCAACCCCTCTCCACCTGGCTGTGCCAACACAGCCACAGCAAGAGTGG  
 TCCTCTATGTCTTCTGCTCTGGTACCCCTGCGCTGAGTCATTCTCACCTCCTACT  
 15 GCTTGGTCTTGGGCCATTGGGAGGATGCGCTCAGTAGCAGGGAGGGAGAAGGACCTCT  
 CCACITGTGCCTCCACTTCTGGCATTGCCATTCTATGGCACTGTGGTTTCACCTAT  
 GTTCAGCCCCATGGATCTACTAACAAATGCCAACAGTAGTGTCCGTCTCACACCA  
 TCATAATTCCCATGCTCAATCCCTCATCTATAGCCTCCGAACAAGGAGGTGAAGGGCGC  
 TCTGCAGAGGAAGCTCAGGTCAACATCTTCCGGCTGA (SEQ ID NO: 148)

15 **AOLFR80 sequences:**  
 MEGINKTAKMQFFRPFSPDPEVQMLIFVVFLMMYLTSGGNATIAVIVQINHSLHTPMYFFLA  
 NLAVLEIFYTSSITPLALANLISMGKTPVSITGCGTQMFFVFLGGADCVLLVVMAYDRFIAICH  
 20 PLRYRLMSWSLCVELLVGSVLVLGFLSLPLTILFHLFCHNDEIYHFYCDMPAVMRLACADTR  
 VHKTALYIISFIVLSIPLSLISIYVFIVVAILRIRSAEGRQQAYSTCSSHILVVLQYGCTSFYLSPS  
 SSYSPEMGRVVSVAYTFITPILNPLIYSLRNKELKDALRKALRKF (SEQ ID NO: 149)

25 ATGGAAGGAATAAATAAAACTGCAAAGATGCAGTTTCTTCGTCCATTCTCACCTGACC  
 CTGAGGTCCAGATGCTGATTTGTGGTCTTCTGATGATGTATCTGACCAGCCTCGGTGG  
 AAATGCTACAATTGCACTGCTATTGTCAGATCAATCATTCCCTCACACCCCCATGTACTTT  
 30 TCCTGGCTAATCTGGCAGTTCTAGAAATCTTCTATACATCTTCCATCACCCCATGGCCTTG  
 GCAAACCTCCTTCAATGGGCAAACCTCTGTTCCATCACGGGATGTGGCACCCAGATGT  
 TTTCTTGTCTTGGTGGGCTGATTGTGCTCTGCTGGTAGTCATGGCTTATGACCGG  
 TTTATAGCGATCTGTACCCCTCTGCATAACAGGCTCATCATGAGCTGGTCTTGTGTGG  
 35 AGCTGCTGGTAGGCTCTGGTCTGGGTTCTGTTCTGACTGCCACTCACCATTAACT  
 TTCCATCTCCATTCTGCCACAATGATGAGACTACCAACTCTACTGTGACATGCCTGCAGT  
 CATGCGCTGGCTTGTGCAGACACACCGCTTACAAGACTGCTCTGTATATCATCAGCTTC  
 ATCGTCTTAGCATCCCCCTCTATTGATCTCCATCTCTATGCTTCTACGTGGTAGCCAT  
 TTTACGGATCCGGTCAGCAGAAGGGGCCAGCAAGCTACTCTACCTGCTTCTCACATC  
 40 TTAGTGGCTCTCTGCACTATGGCTGCACCACTTATATACTTGTCCCCCAGTCCAGCTA  
 CTCTCTGAGATGGGCCGGGTGGTATCTGTGGCTACACATTACTCACTCCCATTAAAC  
 CCCTTGATCTATAGTTGAGGAACAAGGAACTGAAAGATGCCCTAAGGAAAGCATTGAGA  
 AAATTCTAG (SEQ ID NO: 150)

40 **AOLFR81 sequences:**  
 MGVKNHSTVTEFLSGLTEQAEQLPLFCLFLGIYTVVGNLSMISIIRLNRLQHHTPMYYFLSS  
 LSFLDFCYSSVTPKMMKLWMESHLLIVPETRSPRMMMSNQTLVTEFILQGFSEHPEYRVFLFSCF  
 LFLYSGALTGNVLITLAITFNPGHLAPMYFFLLNATMDIICCTSSIMPKALASLVSEESSISYGGC  
 45 MAQLYFLTWAASSELLLTVMAIDRYAAICHPLHYSSSMSKVFCSGLATAVWLCAVNTAIH  
 TGLMLRLDFCGPNVIIHFFCEVPPLLLSCSSTYVNGVMVLADAFYGINFLMTIASYGFIVSSI  
 LKVKTAWGRQKAFSTCSSHLLTVVCMYYTAVFYAYISPVSGYSAGSKLAGLLYTVLSPTLNPL  
 IYTLRNKEVKAALRKLFPFFRN (SEQ ID NO: 151)

50 ATGAAGCTGTGGATGGAGAGTCACCTGATACTCCAGAAACCCGTCCCAGCCAAAGGATG  
 ATGAGTAACCAGACGTTGTAACCGAGTTCATCTGCAGGGCTTTCGGAGCACCCAGAAT  
 ACCGGGTGTTCTTATTCACTGTTCTCTCCCTACTCTGGGGCCCTCACAGGTAAATGTC  
 CTCATCACCTGCCATCACGTTCAACCCCTGGCTCCAGCTCCATGTACTTTCTTACT  
 CAACTTGGCTACTATGGACATTATCTGCACCTCTCCATCATGCCCAAGGGCGTGGCCAGT  
 CTGGTGTGGAAAGAGAGCTCCATCTCTACGGGGGCTGCATGGCCAGCTATTTCTCA  
 55 CGTGGGCTGCATCTCAGAGCTGCTGCTCTCACGGTCATGGCTATGACCGTACGCAGC  
 CATCTGCCACCCGCTGCATTACAGCAGCATGAGCAAGGTGTTCTGCAGCGGGCTGGCC

WO 01/98526

5 ACAGCCGTGTGGCTCTGCGCCGTCAACACGGCCATCCACACGGGCTGATGCTGCGCT  
 TGGATTCTGTGGCCCCAATGTCATTATCCATTCTCTGCGAGGTCCCTCCCTGCTGCTT  
 CTCTCCTGCAGCTCACCTACGTCAACGGTGTATGATTGCTCTGGCGATGCTTCTACG  
 GCATAGTAACCTCTGATGACCATCGCGTCTATGGCTTACATCGTCTCCAGCATCTGAA  
 10 GGTGAAGACTGCCTGGGGAGGCAGAAAGCCTCTCCACCTGCTCTCCACCTCACCGTG  
 GTGTGCATGTATTACACCGCTGTCTACGCCTACATAAGCCGGTCTGGCTACAGCG  
 CAGGGAAAGAGCAAGTTGGCTGGCTGTACACTGTGCTGAGTCCTACCCCTAACCCCT  
 CATCTATACTTGAGAAACAAGGAGGTCAAAGCAGCCCTAGGAAGCTTCCCTTC  
 AGAAATTAA (SEQ ID NO: 152)

15 10 AOLFR82 sequences:  
 MQLNNNVTEFILLGLTQDPFWKKIVFVFLRLYLGLLGNLIIISVKASQALKNPFFFFLYSL  
 SDTCLSTSIAPRMIVDALLKKTTISFECMIQVFSSHVFGCLEFILILTAVDRYVDICKPLHYMTII  
 SQWVGVLMAAVWVGSCVHSLVQIFLALSPFCGPNVINHCFCDLQPLKQACSETYVNLLL  
 VSNSGAICAVSYVMLIFSYVIFLHSLRNHSAEVIKALSTCVSHIIVVILFFGPCIYTCPATVFP  
 15 MDKMAIVFYTGVTSFLNPVIYTLKNTEVKSAMRKLWSKKLITDDKR (SEQ ID NO: 153)

20 20 ATGCAACTGAATAATAATGTGACTGAGTTCATCTGCTGGATTGACACAGGATCCTTTT  
 GGAAGAAAATAGTGTGTTATTCTTGCCTCTACTTGGGAACACTGTTGGTAATT  
 GCTAACATTATTAGTGTCAAGGCCAGGCAGGCCTTAAGAACCCAAATGTTCTTCTCCTT  
 TTCTACTTATCTTATCTGATACTTGCCTCTACTCCATAGCCCTAGAATGATTGTGGA  
 TGCCCTTTGAAGAAGACAACATATCCTCAGCGAGTGCATGATCCAAGTCTTCTACCC  
 CATGTCTTGGCTGCCCTGGAGATCTCATCCTCAGCGAGTGCATGATCCAAGTCTTCTACCC  
 25 CATCTGTAAGCCCTGCACTACATGACCACATAGCCAGTGGGCTGTGGTGTGACCGCTATGTGGA  
 GCTGTGGCTGGGTGGGATCTGTGTGCAATTAGTCAGATTCTTCTGCTGACTTCAGCCCTGGTGTGAA  
 GCCATTCTGTGGCCCAATGTGATCAATCACTGTTCTGTGACTTCAGCCCTGGTGTGAA  
 CAAGCCTGTCAGAAACCTATGTGTTAACCTACTCCTGGTTCTCAATGAGGGCCATT  
 GTGCAGTGAGTTATGTGATGCTAAATTCTCTATGTGATCTCTGCAATTCTGAGAAC  
 CACAGTGTGAAGTGATAAAAGAACACTTCCACATGTGCTCCACATCATTGGTCA  
 30 TCTGTTCTTGGACCTGCATATTATGACACATGCCCTGCAACCGTATCCCCATGGAT  
 AAGATGATAGCTGTATTATACAGTTGGAACATCTTCTAACCTGTGATTACACGCT  
 GAAGAATACAGAAGTGGCATGAGGAAGCTTGGAGCAAGAAATTGATCACAGA  
 TGACAAAAGATAA (SEQ ID NO: 154)

35 35 AOLFR83 sequences:  
 MGNWTAATVTEFVLLGFLSREVELLVLVLLPTFLTLGNLIIISTVLSCSRLHTPMYFFLCNL  
 SILDILFTSVISPKVLANLGSRDKTISFAGCTQCYFYFLGTVEFLLLTVMFYDRYATICCPLRYT  
 TIMRPSVCIGTVVFSWVGGFLSVLFPILISQLPFCGSNIHFFCDSGPLLALACADTTAIELMDF  
 MLLSMVILCCIVLVAYSYTIILITVIRIPSASGRKKAFNTCASHLTIVIIPSGITVFIYVTPSKEYL  
 40 EINKIPLVLSSVVTPLNPFIYTLRNDTVQGVLRDVWVVRVRGVFEKMRRAVLRSRLSSNKHQ  
 GRACSSPPCVYSVKLQC (SEQ ID NO: 155)

45 45 ATGGGTAACTGGACTGCAGCGGTGACTGAGTTGTTCTGCTGGGTTTCCCTGAGCAGGG  
 AGGTGGAGCTGCTGCTCCTGGTCTGCTGCCACGTTCTGCTGACTCTCTGGGAA  
 CCTGCTCATCTCACTGTGCTGCTCTGCTCCCGCTCCACACCCCATGTACITCTCT  
 TGTGCAACCTCTATCCTGGACATCCTCTCACCTCAGTCATCTCCAAAAGTGTGGCC  
 AACTTAGGATCTAGGGATAAAACCATCTCTTGCCTGCTGACGGTCATGTCTATGACCGTATTCT  
 ACTTTTCTGGGACAGTTGAGTTCTCTGCTGACGGTCATGTCTATGACCGTATTCT  
 ACCATCTGCTGCCCTGCGGTACACCACATGAGACCTCTGTGCTGACCGTATTGCC  
 50 TTGTATTCTTGGGGAGGCTTCTGTGCTTCTGCTGACAGTGGACCCCTGGTGC  
 CTGCCCTCTGTGGCTCCAATATCATTAAACCATCTCTGTGACAGTGGACCCCTGGTGC  
 CCTGGCCTGTGCAGACACCACGCCATCGAGCTGAGTGGATTATGCTTCTCCATGGTC  
 ATCCTCTGCTGCATAGTCCTCTGCTGGCTATTCTATACGTACATCTGACCATAGTGC  
 CATTCTCTGCAAGTGGAGGAAGAAGGCTTAATACCTGTGCTTCCACCTGACCA  
 55 GTCATATTCTAGGGCATCACTGTGTTATCTATGTGACTCCCTCCCAGAAAGAATATCT  
 GGAGATCAACAAGATCCCTTGGTCTGAGCAGTGTGGTACTCCATTCTCAACCCCTT

ATATATACTCTGAGGAATGACACAGTCAGGGAGTCCTCAGGGATGTGTGGGTAGGGTT  
 CGAGGAGTTTGAAAAGAGGATGAGGGAGTGCTGAGAAGCAGATTATCCTCAAACAAA  
 GACCACCAAGGAAGGGCTGCTCTCTCCACCATGTGTCTATTCTGTAAGCTCCAGTGT  
 AG (SEQ ID NO: 156)

5

**AOLFR85 sequences:**

MGAKNNVTEFLGLFESREMQHTCFVVFFLFHVLTVLGNLLVIITINARKTLKSPMYFFLSQL  
 SFADICYPSTTIPKMIADTFVEHKIISFNGCMTQLFSAHFFGGTEIFLLTAMA YDRYVAICRPLHY  
 TAIMDCRKCGLLAGASWLAGFLHSILQTLTVQLPCGPNEIDNFFCDVHPLLKACADTYMV  
 10 GLIVVANSGMISLASFFILISYVIILLNRSQSSEDRRKAVSTCGSHVITVLLVLMPPMFMYIRPS  
 TTLAADKLIILFNIVMPPLLNP LIYTLRNDVKNAMRKLFRVKRSLGEK (SEQ ID NO: 157)

ATGGGTGCCAAGAACAAATGTGACTGAGTTGTTTATTGGCCTTTGAGAGCAGAGAGA  
 15 TGCAGCATAACATGCTTGTGGTATTCTCCTCTTATGTGCTCACTGTCCTGGGAACCTT  
 CTGGTCATCATCACCATCAATGCTAGAAAGACCCCTGAAGTCTCCATGTATTCTCCTGA  
 GCCAGTTGTCTTTGCTGACATATGTTATCCATCCACTACCATACCCAAAGATGATTGCTGAC  
 ACTTTGTGGAGCATAAGATCATCTCCTCAATGGCTGATGACCCAGCTTTCTGCCA  
 CTTCTTGGTGGCACTGAGATCTCCTCTACAGCCATGGCTATGACCGCTATGTGGCC  
 20 ATCTGTAGGCCCTGCACTACACAGCCATCATGGATTGCCGAAGTGTGGCCTGCTAGCGG  
 GGGCCTCCTGGTTAGCTGGCTTCTGCATTCCATCCTGCAGACCCCTCCTCACGGTTAGCTG  
 CCTTTGTGGGCCAATGAGATAGACAACCTCTCTGTGATGTTCATCCCTGCTCAAGTT  
 GGCCTGTGCA GACACCTACATGGTAGGTCTATCGTGGTGGCCAACAGCGGTATGATTCT  
 TTAGCATCCTTTTATCCTTATCATTCTATGTTATCATCTTACTGAACCTAAAGAACCA  
 25 GTCATCTGAGGAGCCGGCTAAGGCTGTCACATGTGGCTCACAGTAATCACTGTCCTT  
 TTGGTTCTCATGCCCTCATGTTATGTACATTGTCCTCCACCAACCCCTGGCTGCTGACAA  
 ACTTATCATCCTTTAACATTGTGATGCCACCTTGTGAACCCCTTGATCTATACACTAA  
 GGAACAACGATGTGAAAATGCCATGAGGAAGCTGTTAGGGTCAAGAGGAGCTAGGGG  
 AGAAGTGA (SEQ ID NO: 158)

30

**AOLFR86 sequences:**

MQLVLLMFLLVFIGNTAPAFSVTLESMDIPQNITEFFMLGLSQNSEVQRVLFVVFLIYVVTV  
 GNMLIVVTITSSPTLASPVYFFLANLSFIDTFYSSSMAPKLIADSLYEGRTISYECCMAQLFGA  
 LGGVEIILTVMA YDRYVAICKPLHNTTIMTRHLICMLVGVAWLGGFLHSVLQLLLVLWLPFC  
 GPNVINHFACDLYPLLEVACTNTYVIGLLV VANSGLICLLNFLMLAASYVILYSLRSHSADGR  
 35 KALSTCGAHFIVVALFFVPCIFTYVHPFSTLPIDKNMALFYGILTPMLNPLIYTLRNEEVKNAMR  
 KLFTW (SEQ ID NO: 159)

ATGCAATTAGTTCTATTACTTATGTTCTCCTGTCTTATAGGCAAACTGCACCTGCATT  
 40 CTCAGTGACCTTGAATCTATGGACATACCAACAAATACACAGAAATTTCATGCTGGGG  
 CTCTCACAGAACTCAGAGGTACAGAGAGTTCTCTTGTGGTCTTTGCTGATCTATGTGG  
 TCACGGTTGTGGCAACATGCTCATTGTGGTCACTATCACCTCAGCCCCACGCTGGCTTC  
 CCCTGTGTATTCTCCTGGCCAACCTATCCTTATTGACACCTTTATTCTCTATGGC  
 TCCTAAACTCATTGCTGACTCATTGTATGAGGGGAGAACCATCTCTTATGAGTGCTGCATG  
 GCTCAGCTCTTGGAGCTCATTGGAGGTGTGAGATCATTGCTCACAGTGATGG  
 45 CTTATGACCGCTATGTGGCCATCTGTAAGCCCTGCACAATACCAATCATGACCAAGGCA  
 TCTCTGTGCCATGCTTGTAGGGGTGGCTGGCTGGGGCTCCTGCATTGCTTGTGA  
 CTCCTCCTGGTCTTGGTGCCTCTGTGGGCCAATGTGATCAATCACCTTGCCTGTGA  
 CTTGTACCCCTTGCTGGAAAGTTGCCTGCACCAATACGTATGTCATTGGTCTGGTGGTT  
 50 GCCAACAGTGGTTAATCTGCCTGTTGAACCTCCTCATGCTGGCTGCCTCACATTGTCAT  
 CCTGTA CTCCTGAGGTCCCACAGTGCAGATGGGAGATGCAAAGCCCTCTCCACCTGTGGA  
 GCCCACTTCATTGTTGCTGCTTGTGCCCCGTATATTACTTATGTCATCCATT  
 TCTACTTACCTATAGACAAAATGGCATTATTGTTGGTATTCTGACACCTATGTTGAA  
 TCCACTCATTATACCCCTGAGAAATGAAGAGGTAAAAAATGCCATGAGAAAGCTCTTACA  
 TGGTAA (SEQ ID NO: 160)

55

WO 01/98526

## AOLFR87 sequences:

5 MNNIAQLSLGFIDLGLIPSVLQKIIITKJILLFKMYVSNCPCAIHKINYPNTKLDFEQVNNITEF  
 LLGLTQNAAEQKLLFAVFTLIVFLTMVDNLIVVTITSPALDSPVYFFLSFFSFIDGCSSSTMAP  
 KMIFDLLTEKKTISFSGCMTQLFVEHFFGVEIILLVVMAYDCYVAICKPLYYLITMNRQVCGL  
 10 LVAMAWVGGFLHALIQMILLIVWLPFCGPVIDHFCIDLFLKLSCTDTHVFLGFLVAANSGLM  
 CMLIFSILTSYVLILCSQRKALSTCAFHTVVLFVPCILVYLRPMITFPIDKAVSVFYTVVTPM  
 LNPLIYTLRNTEVKNAMKQLWSQIWGNNLCD (SEQ ID NO: 161)

15 10 ATGAATAACATAGCTCAACTAGTCTGGTTTATAGATTAGGGATTCCATCAGTGTAC  
 AGAAAATAATCCTGACCAAAATTATTATTGTCAAAATGTATGTGCAAATTGCAATCC  
 TTGTGCTATTACAGAAAAATCAATTATCCAATACCAAACCTGGATTTCGAGCAAGTGAA  
 AACATAACCGAATTATCTGCTGGCTGACACAGAACGGCAGAGGCACAGAAACTCTGT  
 TTGCTGTGTTACACTCATCTACTTCTACCATGGTAGACAACCTAATCATTGTGGTGACA  
 ATCACCACCAGCCCAGCCCTGGACTCCCCGTGTATTTTCTGTCTTCTTCCTCAT  
 15 AGATGGCTGCTCCTCTTACCATGGCCCCAAATGATATTGACTTACTCACTGAAAAG  
 AAAACTATTCCITCAGTGGGTGATGACCCAGCTCTTGAGAACATTCTTGGGGAG  
 TTGAGATCATTCTGCTCGGGTATGGCCTATGACTGCTATGTGGCCATCTGCAAGCCCC  
 GTACTACCTGATACAATGAACAGGGAGGTATGTGGCCTCTGGTGGCCATGGCATGGC  
 GGGGATTCTTCACGCTGTGATTCAAATGCTTTAATAGTCTGGCTGCCCTCTGTGGCC  
 20 CAATGTCATTGACCAATTCTATCTGACCTTTCCCTCTGCTAAAACCTCCTGCACTGACA  
 CTCACGTCTTGACTCTTGTGCCCAACAGTGGGTGATGTGTATGCTCATTTTCT  
 ATTCTTATTACCTCTACGTCTTAATCTCTGCTCACAGCGGAAGGCTCTCTACCTGCG  
 CTTCCATATCACTGTAGTCGCTCTTGTCCCTGTATATTGGTGTACCTTCGACCCA  
 TGATCACCTCCCTATTGATAAAGCTGTCTGTGTTTATACTGTGGTAACACCCATGTIA  
 25 AACCCTTAATCTACACCTCAGAAACACAGAGGTGAAAATGCCATGAAGCAGCTGG  
 AGCCAAATAATCTGGGTAACAATTGTGTGATTAG (SEQ ID NO: 162)

## AOLFR88 sequences:

30 MWQKNQTSLADFILEGLFDDSLTHLFLSLTMVVFLIAVSGNTLTILLICIDPQLHTPMYFLLSQ  
 LSLMDLMHVSTIILKMATNYLSGKKSISFVGCAHQFLYLCLGGAECFLLAVMSYDRYVAICH  
 PLRYAVLMNKVKGLMMAVMSWLGASVNSLIHMAILMHFPFCGPRKVYHFYCEFPAAVVKLVC  
 GDITVYEITVYISSLLLPIFLISTSYVFLQSVIQMRSSGSKRNAFTCGSHLTVSLWFGACIFS  
 YMRRPSQCTLQNKVGSVFYSIITPTLNSLIYTLRNKDVAKALRRVLRRDVITQCIQLQLWLP  
 RV (SEQ ID NO: 163)

35 35 ATGTGGCAGAAGAACATGACCTCTGGCAGACTTCATCCTTGAGGGCTCTCGATGACT  
 CCCTTACCCACCTTTCTTTCTCTGACATGGTGGCTTCTTATTGCGGTGAGTGGC  
 AACACCCCTCACCATTCTCCTCATCTGCATTGATCCCCAGCTTCATACACCAATGTATTCT  
 GCTCAGCCAGCTCCCTCATGGATCTGATGCTCCACAATCATCTGAAGATGGCT  
 40 ACCAACTACCTATCTGCAAGAAATCTATCTCCTTGTTGGCTGTGCAACCCAGCACTTCC  
 TCTATTGTGTCTAGGTGGTGTGAATGTTCTTAGCTGTCTATGTCATGCTCTATGACCGCTAT  
 GTGCCATCTGTCTACACTGCGCTATGCTGTCTATGAACAAAGAAGTGGGACTGATGA  
 TGGCTGTCTAGTGGTGGGCTCGGAAAGTCTACCACTCTACTGTGAGACGAGTGTACATCAGCAGATTCT  
 GCACTCCCTTCTGTGGGCTCGGAAAGTCTACCACTCTACTGTGAGACGAGTGTACATCAGCAGATTCT  
 45 TGAAGITGGTATGTGGCAGACATCACTGTGATGAGACCAAGTGTACATCAGCAGATTCT  
 CCTCCTCCTCCCCATCTCCTGATTCTACATCCTATGTCTCATCCTCAAAGTGTATTCA  
 GATGCGCTCATCTGGAGCAAGAGAAATGCCITGCCACTTGTGGCTCCACCTCACGGTG  
 GTTCTCTTGGTTGGTGTCTGATCTCTCTACATGAGACCCAGGTCCCAGTGCACCTCT  
 ATTGCAGAACAAAGTGGTCTGTGTTACAGCATCATTACGCCACATTGAATTCTGT  
 50 ATTATACCTCCGAATAAAAGATGTAGCTAAGGCTGTGAGAAGAGTGTGAGGAGAGAT  
 GTTATCACCCAGTGCATTCAACGACTGCAATTGTGGTGGCCAGTGTAG (SEQ ID NO:  
 164)

## AOLFR89 sequences:

55 MLDPSISSHTLYLHSLFQGLRKGTMWQKNQTSLADFILEGLFDDSLTHLFLSLTMVVFLIAVS  
 GNTLTILLICIDPQLHTPMYFLLSQLSLMDLMHVSTIILKMATNYLSGKKSISFVGCAHQFLYL

CLGGAECFLLAVMSYDRYVAICHPLRYAVLMNKKVGLMMAVMSWLGASVNSLIHMAILMHF  
 PFCGPRKVYHFYCEFPVVKLVCGDITVYETTVYISSILLLPILISTSYVILQSVIQMRSRGSK  
 RNAFATCGSHLTVVSLWFGACIFSYMRPRSQCTLLQNKGVSFVSIITPTLNSLIYTLRNKDVA  
 KALRRVLRDVITQCIQRLQLWLPRV (SEQ ID NO: 165)

5 ATGCTGGACCCCAGTATTCCAGTCACACTCTTATCTCCACTCTCTGTTCCCTCAGGGATT  
 GAGAAAGGGGACAATGTGGCAGAAGAATCAGACCTCTGGCAGACTTCATCCTTGAGGG  
 GCTCTCGATGACTCCCTTACCCACCTTTCCCTTCTCCTGACCATGGTGGTCTCCTTAT  
 10 TCGGGTGAGTGGCAACACCCCTACCATTCTCCTCATCTGCATTGATCCCCAGCTTCATACA  
 CCAATGTATTCTGCTCAGCCAGCTCCCTCATGGATCTGATGCATGTCTCCACAACCCT  
 CCTGAAGATGGCTACCAACTACCTATCTGGCAAGAAATCTATCTCCTTGTTGGGCTGTGCA  
 ACCCAGCACTTCCTCTATTGTGTCTAGGTGGTGTGAATGTTCTCTAGCTGTATGTC  
 CTATGACCGCTATGTTGCCATCTGCATCCACTGCCTATGCTGTGCTCATGAACAAGAAG  
 15 GTGGGACTGATGATGGCTGTATGTCATGGTTGGGGCATCCGTGAACCTCCCTAATTACA  
 TGGCGATCTTGTGACTTCCCTTCTGTGGGCGTCGAAAGTCTACCAACTCTACTGTGA  
 GTTCCCAGCTGTGTGAAGTTGGTATGTGGCACATCACTGTGTATGAGACCACAGTGTAC  
 ATCAGCAGCATTCTCCTCCCTCCCTACATCTCCTGATTTCTACATCCTATGTCATCCTT  
 CAAAGTGTCAATTAGCAGATGCGCTCATCTGGGAGCAAGAGAAATGCCCTTGCCACTTGTGGCT  
 20 CCCACCTCACGGTGGTTCTCTTGGTGTGCATCTTCTCCTACATGAGACCCAGG  
 TCCCAGTGCACTCTATTGAGAACAAAGTTGGTCTGTGTTCTACAGCATCATTACGCCCA  
 CATTGAATTCTCTGATTATACTCTCCGAAATAAGATGTAGCTAAGGCTCTGAGAAGAGT  
 GCTGAGGAGAGATGTTATCACCCAGTGCATTCAACGACTGCAATTGTGGTTGCCCGAGTG  
 TAG (SEQ ID NO: 166)

25 **AOLFR90 sequences:**

MFSMTTEALNNFALGCTNLLMTMIPQIDLKQIFLCPNCRLYMIPVGAFIFSLGNMQNQSFVTEF  
 VLLGLSQNPNVQEIVFVVFVYIATVGGNMLIVVTILSSPALLVSPMYFFLGFLSFLACFSSVI  
 TPKMIVDSLTVTKTISFEGCMMQLFAEHFFAGVEVIVLTAMAYDRYVAICKPLHYSSIMNRRL  
 30 CGILMGVAWTGGLLHSMIQILFTFQLPFCGPNVINHFMCDLYPLLEACTDTHIFGLMVINS  
 FICIINFSLLVSYAVILLSLRTHSSEGRWKALSTCGSHIAVVLFFVPCIFVYTRPPSAFSLDKMA  
 AIFYIILNPLLNPLIYTFRNKEVKQAMRRIWNRLMVSDEKENIKL (SEQ ID NO: 167)

ATGTTCTCAATGACAACAGAACGACTCAATAATTTCGACTTGGATGTACCAACTTGTAA  
 TGACTATGATACCAACAAATTGATCTGAAGCAAATTTCCTTGTCTTAATTGCAGACTATA  
 35 CATGATCCCTGTGGAGCTTCATCTTCTGGAAACATGCAAAACCAAAGCTTGTAA  
 ACTGAGTTGTCTCTGGACTTTCACAGAAATCCAAATGTTAGGAAATAGTATTGTGTT  
 TATTTTGTCTACATTGCAACTGTTGGGGCAACATGCTAATTGTAAGTAAACCATTCTC  
 AGCAGCCCTGCTCTGGTGTCTCATGTACTTCTTCTGGCTCTGCTCTCTGG  
 TCGTGCTTCTCATGTACACCCAAAGATGATTGTAGACTCCCTCTATGTGACAAAA  
 40 ACCATCTCTTGAAGGCTGCATGATGCAGCTTGTCTGAACACACTTCTGCTGGGTGG  
 AGGTGATTGTCTCACAGCCATGGCCTATGATCGTTATGTGCCATTGCAAGCCCTGCA  
 TTACTCTTCTATCATGAACAGGAGGCTGTGGCATTCTGATGGGGTAGCCCTGGACAGGG  
 GGCCTCTGCATCCATGATACAAATTCTTACTTCCAGCTTCCCTTGTGGCCCAA  
 TGTATCAATCAACTTATGTGACTTGTACCCGTACTGGAGCTGCTGCACGTGATACTC  
 45 ACATCTTGGCCTCATGGTGGTCATCAACAGTGGTTATCTGCATCATAAACCTCTCCTG  
 TTGCTGTCTCCTATGCTGTCATCTGCTCTCTGAGAACACACAGCTGAAGGGCCTG  
 GAAAGCTCTCTCACCTGTGGATCTCACATTGCTGTTGTGATTGTCTTGTCCATGCA  
 TATTGTATATACAGACCTCCATCTGCTTTCCCTGACAAAATGGCGCAATATTAT  
 ATCATCTTAAATCCCTGCTCAATCCTTGATTTACACTTCAGGAATAAGGAAGTAAAC  
 50 AGGCCATGAGGAGAATATGGAACAGACTGATGGTGGTTCTGATGAGAAAGAAAATATTA  
 AACTTAA (SEQ ID NO: 168)

**AOLFR91 sequences:**

MGNWSTVTEITLIAFPALLEIRISLFVVLVVTYTLTATGNITIISLIWIDHRLQTPMYFFLSNLSFL  
 55 DILYTTVITPKLLACLLGEEKTISFAGCMIQTYFYFFLGTVEFILLA VMSFDRYMAICDPLHYTVI  
 MNSRACLLVLGCWVGAFLSVLFPITVVTRLPYCRKEINHFFCDIAPLLQVACINTHLIEKINFL

WO 01/98526

SALVILSSLAFTTGSYVYIISTILRIPSTQGRQKAFSTCASHITVVSIAHGSNIFVYVRPNQNSLD  
YDKVAAVLITVVTPLNPFYSLRNEKVQEVLRETNRIMTLIQRKT (SEQ ID NO: 169)

5 ATGGGAAACTGGAGCACTGTGACTGAAATCACCTAATTGCCCTCCAGCTCTGGAGA  
TTCGAATATCTCTCTCGTGGTCTGTGGTAATTACACATTAACAGCAACAGGAAACAT  
10 CACCATCATCTCCCTGATATGGATTGATCATGCCGCAAACCTCAATGTACTCTCCCTCA  
GTAATTGCTTCTGGATATCTTACACACTGTCAATTACCCAAAGTTGCTGGCTGC  
CTCCTAGGAGAAGAGAAAACCATATCTTGTGGGTGATGTCCTTGACCGCTACATGGC  
TCTTCTGGGGACGGTGGAGTTATCCTCTGGGGTGTGGTGCATGTCACATTTCTACT  
15 TATCTCGGACCCACTGCACTACACGGTCACTGAACAGCAGGGCCTGCCCTGCTGGT  
CTGGGATGCTGGGTGGAGCCTCTGTGTGTTCCAACCATTGTAGTGACAAGGC  
TACCTTACTGTAGGAAAGAAATTAAATCATTTCTGTGACATTGCCCTCTCAGGTG  
GCCTGTATAAAATCACCTCATTGAGAAGATAAACTTCTCCTCTGCCCTGTACATCC  
GAGCTCCCTGGCATTCACTACTGGGTCTACGTGTACATAATTCTACCATCCTGCGTATCC  
20 CCTCCACCCAGGGCCGTAGAAAGCTTTCTACCTGTGCTTCACATCACTGTGTCTCC  
ATTGCCACGGGAGCAACATCTTGTGTATGTGAGACCCAATCAGAACTCCTCACTGGATT  
ATGACAAGGTGGCGCTGCTCATCACAGTGGTACCCCTCTCTGAACCCTTATCTA  
CAGCTTGAGGAATGAGAAGGTACAGGAAGTGTGAGAGAGACAGTGAACAGAATCATGAC  
CTTGATACAAAGGAAAATTGA (SEQ ID NO: 170)

20

**AOLFR92 sequences:**

MRNGTVITEFILLGFPVIQGLQTPLFIAIFLTYILTLAGNGLIATVWAEPRLQIPMYFFLNLNSFLE  
IWYTTVIPKLLGTFVVAARTVICMSCLLQAFFHFFVGTTFLITIMSFDRYLTICNPLHPTIM  
25 TSKLCLQLALSSWVVGFTIVFCQTMILLQLPFCGNNVISHFYCDVGPSLKAACIDTSILELLGVIA  
TILVIPGSLLFNMSIYIYIISAILRIPSATGHQKTFSTCASHLTVSLLYGAVLFMYLRPTAHSSFK  
INKVVSVLNTILTPLNPFYIIRNKEVKGALRKAMTCPKTGHAK (SEQ ID NO: 171)

25

30 ATGAGAAATGGCACAGTAATCACAGAATTACCTGCTAGGCTTCTGTATCCAAGGCC  
TACAAACACCTCTTATTGCAATCTTCTCACCATATAACCCCTGCAGGCAATGGG  
CTTATTATTGCCACTGTGGCTGAGGCCAGGCTACAAATTCCAATGTACTCTCCTTG  
TAACCTGTCTTCTAGAAAATCTGGTACACCACACCAGTCATCCCCAAACTGCTAGGAACC  
35 TITGTAGTGGCAAGAACAGTAATCGCATGTCCTGCTGCTGCAGGCCCTCTCCACT  
TCTTCGTGGGACCACCGAGTTCTGATCCTCACTATGTCCTTGTGACCGCTACCTCACC  
ATCTGCAATCCCCITCACCAACCCACCATCATGACCAGCAAACCTGCCTGCAGCTGCC  
TGAGCTCTGGGTGGCTTCACTATTGCTTTGTGACGACGATGCTGCTCATCCAGIT  
40 GCCATTCTGTGGCAATAATGTTACAGTCATTCTACTGTGATGTTGGGCCAGTTGAAA  
GCCGCCTGCATAGACACCAGCATTTGAACTCCTGGCGTCATAGCAACCATCCTGTGA  
TCCCAGGGTCACTCTCTTAAATGATTCTTATATCTACATTCTGTCCGCACTGACAGITGT  
CTCCCTGCTCACGGGGCTGTTCTGTCATGTAACCTAACAGCACACTCCTCTTA  
AGATTAATAAGGTGGTGTGTCAAATACTATCCTACCCCCCTCTGAATCCCTTATT  
TATACTATTAGAAACAAGGAGGTGAAGGGAGCCTAAGAAAGGCAATGACTTGCCCAAAG  
ACTGGTCATGCAAAGTAA (SEQ ID NO: 172)

45

**AOLFR93 sequences:**

MLMNYSSATEFYLLGFPSEELHHILFAIFFFYLVLMGNTVIIMIVCVDKRLQSPMYFFLGLH  
SALEILVTTIVPVMLWGLLPGMQTIYLSACVVLQLFLYAVGTTFALLGAMAVDRYAVCN  
PLRYNIIMRHTCNFVVLVSWVFGFLQIWPVYVMFQLTYCKSNVNNFFCDRGQLLKLSCN  
NTLFTEFILFLMAVFVLFGLIPTIVSNAYIISTILKIPSSGRRKSFTCASHFTCVVIGYGSCLFLY  
50 VKPKQTQAADYNWVVSMLVSVTPFLNPIFTLRNDKVIEALRDGVKRCCQLFRN (SEQ ID  
NO: 173)

50

55 ATGTTGATGAATTACTCTAGTGCACGTGAATTCTCCTGGCTTCCCTGGCTCTGAAGA  
ACTACATCATATCCTTTGCTATATTCTCTTCTACTTGTTGACATTAATGGGAAACA  
CAGTCATCATCATGATTGTGTGGATAAACGTCTGCAGTCCCCATGTAATTCTCCTC  
GGCCACCTCTGCCCTGGAGATCCTGGTCACAACCATAATCGTCCCCGTGATGCTTGGG

5 GATTGCTGCTCCCTGGGATGCAGACAATATTTGTCTGCCTGTGTTGTCAGCTCTCTTG  
 TACCTTGCTGTGGGGACAACAGAGTCGCATTACTGGAGCAATGGCTGTGGACCGTTATG  
 TGGCTGCTGTAAACCCCTGAGGTACAACATCATTATGAACAGACACACCTGCAACTTGT  
 10 GGTTCTTGTGTATGGGTGTTGGGTTCTTTCAAATCTGGCCGGCTATGTCTATGTTG  
 AGCTTACTTACTGCAAATCAAATGTGGTGAACAATTTTTGACCGAGGGCAATTGCT  
 CAAACTATCCTGCAATAATACTCTTACGGAGTTATCCTCTCTTAATGGCTTTTG  
 TTCTCTTGGTTCTTGATCCCTACAATTGTCTCCAAACGCCATCATCTCCACCATCTC  
 AAGATCCCGTCATCCTCTGGCCGGAGGAAATCTTCTCCACTGTGCTCCACTCACCTG  
 15 TGTTGTGATTGGCTACGGCAGCTGCTGTTCTACGTGAAACCCAAGCAAACGCCAGGCA  
 GCTGATTACAATTGGTAGITTCCTGATGGTTCACTAGTAACCTTCTCAATCCTT  
 CATCTCACCCCTCCGGAATGATAAAGTCATAGAGGCCCTCGGGATGGGTGAAACGCC  
 TGTCAACTATTCAAGGAATTAG (SEQ ID NO: 174)

**AOLFR94 sequences:**

15 METWVNQSYTDFLLGIFSHSTADLVFSVMAVFTVALGNVLLFLYMDPHLHTPMYFF  
 LSQSLMDLMLVCTNPKMAANFLSGRKSIISFVGCGIQIGLFVCLVGSEGLLGLMAYDRYVA  
 ISHPLHYPILMNQRVCLQITGSSWAIFIIDGLIQMVMVNFVYCGLRKVNHFFCEMLSLKLAC  
 20 VDTSLFEKVIIFACCVFMLLFPFSIVASYAHILGTVLQMHSQAQAWKKALATSSHATAVLFY  
 AAMFIYLRPRHYRAPSHDKVASIFYTVLTPMLNPLIYSLRNREVMGALRKGLDRCRIGSQH  
 (SEQ ID NO: 175)

25 ATGGAGACGTGGGTGAACCAGTCTACACAGATGGCTTCTCCTCTAGGCATCTCTCC  
 ACAGTACTGCTGACCTTGTCCCTCTCTCGTGGTTATGGCGGTCTCACAGTGGCCCTCTGT  
 GGGAAATGTCTCCTCATCTTCTCATCTACATGGACCTCACCTTCACACCCCCATGTACTT  
 CTTCTCAGCAGCTCCCTCATGGACCTCATGTGGTCTGTACCAATGTGCCAAAGATG  
 GCAGCCAACCTCCTGTCTGGCAGGAAGTCCATCTCTTGTGGCTGTGGCATACAATTG  
 GCCTCTTGTCTGTCTGTGGGACTCATGGCTATGGCTTATGACCG  
 CTATGTGGCATTAGCACCACCTCACTATCCATCCTCATGAATCAGAGGGCTGTCTCC  
 AGATTACTGGAGCTCTGGCCTTGGATAATCGATGGCTGATGCCAGATGGTGGTAGT  
 30 AATGAATTCCCTACTGTGGCTGTAGACACATCCCTGTGAGAAGGTGATATTGCTGCTGT  
 TTGTTGAAGCTGGCCTGTAGACACATCCCTGTGAGAAGGTGATATTGCTGCTGT  
 TCTTCATGCTCTCTCCATTCTCCATCATGTGGCTCCTATGCTCACATTCTAGGGACT  
 GTGCTGCAAATGCACTCTGCTCAGGCCCTGGAAAAAGGCCCTGGCACCTGCTCCTCCACC  
 35 TGACAGCTGTCAACCTCTCATGGGCAGCCATGTCACTACCTGAGGCCTAGGCACTA  
 CCGGGCCCCCAGCCATGACAAGGTGGCCTCTACCTACACGGCTCTACTCCATGCTC  
 AACCCCTCATTTACAGCTTGAGGAACAGGGAGGTGATGGGGACTGAGGAAGGGCTG  
 GACCGCTGCAGGATCGGCAGCCAGCACTGA (SEQ ID NO: 176)

**AOLFR95 sequences:**

40 MLGSKPRVHLYILPCASQQVSTMGRGTSNHSEMTDFILAGFRVRPELHILLFLFVYAMILL  
 GNVGMMTIUMTDPLRLNTPMYYFLGNLSFIDLFYSSVIEPKAMINFSENKSISFAGCVAQLFLFA  
 LLIVTEGFLLAAMAYDRFIAICNPLLYSVQMSTRLCTQLVAGSYFCGCISSVIQTSMFTLSFCAS  
 RAVDHFYCDRPLQLRSCSDLFIRHMISFLSCHIILPTIIVIVSYMYIVSTVLKIHSTEGHKKAEST  
 45 CSSHLGVVSVLYGAVFFMYLTPDRFPELSKVASLCYSLVTPMLNPLIYSLRNKDQEAALKFLE  
 KKNIL (SEQ ID NO: 177)

50 ATGCTAGGATCCAAACCAAGAGTCATTGTATATTTGCCCTGTGCCCTCTCAACAGGTT  
 TACCATGGGTGACAGGGAAACAAGCAATCACTCAGAAATGACTGACTTCATTCTGCAGG  
 CTTCAGGGTACGCCAGAGCTCCACATTCTCTCTCCTGCTATTITGTTGTTATGCCA  
 TGATCCTCTAGGAATGTGGGATGATGACCAATTATGACTGATCCTCGGCTGAACAC  
 ACCAATGTATTCTCTAGGAATCTCTCTCATTGATCTTCTATTCACTGTATTGA  
 ACCCAAGGCTATGATCAACTCTGGTCTGAAAACAAGTCTATCTCTTGCAGGCTGTG  
 55 GCCCAGCTTTCTCTTGCCTCTCATTGTGACTGAGGGATTCTCTGGCGGCCATGGC  
 TTATGACCGTTATTGCCATCTGCAACCCCTGCTCTACTCTGTCAAATGTCCACACGTC  
 TGTGTACTCAGTTGGTGGCTGGTCTATTGTGGCTGCATTAGCTCAGTTATTCA  
 AGCATGACATTTACTTATCTTTGCGCTCTCGGGCTGTTGACCACTTTACTGTGATT

WO 01/98526

5 TCGCCCACCTCAGAGACTGTCTGTTGATCTCTTATCCATAGAATGATATCTTTCCCT  
 TATCATGTATTATTATCTGCCTACTATCATAGTCATTATAGTATCTTACATGTATTGTG  
 TCCACAGTTCTAAAGATACATTCTACTGAGGGACATAAGAAGGCCCTCTCCACCTGCAGCT  
 10 CTCACCTGGGAGTTGTGAGTGTGCTGTATGGTGTCTTTTATGTATCTCACTCCTGAC  
 AGATTTCTGAGCTGAGTAAAGTGGCATCCTATGTTACTCCCTAGTCACTCCCAGTTGA  
 ATCCTTGTATTACTCTGAGGAACAAAGATGTCCAAGAGGCTCTAAAAAAATTCTAGA  
 15 GAAGAAAAATATTATTCTTGA (SEQ ID NO: 178)

**AOLFR96 sequences:**

10 MICENHTRVTEFILLGFTNNPEMQVSLFIFLAIYTVLLGNFLIVTVTSVLDALQTPMYFFLQN  
 LSLLEVCFILVMVPKMLVLDLSPRKIISFVCGTQMYFFFFGSSECFLSSMMAYDRFVAICNP  
 LHYSVIMNRSLCLWMAIGSWMSGVPVSMQLTAWMALPFCGPNAVDFFCDGPPVVKLVTV  
 DTTMYEMQALASTLLFIMFPFCLILVSYTRIILRMSSATGRQKAFSTCSSHLIVVSLFYGTASL  
 15 TYLRPKSNQSPESKKLVSLSYTVITPMLNPIYGLRNNEVKGAVKRTITQVQLQKLDVF (SEQ  
 ID NO: 179)

20 ATGATCTGTAAAATCACACCAGAGTCACTGAATTATTCTCTGGTTTACAAACAACC  
 CCGAGATGCAAGTTCCCTTTATTCTGGCCATTATACAGTCACTTGTTGGGC  
 AACTTTCTATTGTACAGTACCTGGAATCTCGCACTCAAAACACCCATGACTCTT  
 TCTTCAAAATCTGTCACTCTGAAGTATGTTCACCTGGTTATGGTGCCAAAATGCTTG  
 TAGATCTAGTGTCCCCAAGGAAAATTATCTTTGTGGCTGTGGTACCCAGATGTACTT  
 CTTCTCTTGTGGAGTTCTGAATGTTCCCTCTCCATGATGGCTTATGATCGCTTGT  
 25 GCCATCTGTAAACCTCTCATTATTCACTGATAATGAAACAGGTCCATGCTTGTGGATG  
 GCCATAGGCTTGTGGATGTCGGTGTCTGTCTACAGACAGCTGGATGATGGTCCACAGTGT  
 CCCTCCCTTGTGGACCAATGCCGTGGACACTTTCTGTGATGGTCCCCAGTGTAA  
 30 AAACATGTACAGTGGATACAACCATGATGAAATGCAAGCAGTGCCTCCACACTCTGT  
 TTATCATGTTCCCTTTGTCTCATTGGTTCTACACCCGCATTATCATAACAATTCTG  
 AGGATGTCCTGCACTGGCCAGAAGGCATTCTACTTGTCTCACACCTCATGTT  
 GGTGTCCTCTACGGAACAGCAGCTGTGACCTACCTGCGGCCAAATCAAACCAAGTCC  
 CCTGAGAGCAAGAAGCTAGTGTCAATTGTCTACACTGTCAACACCTATGTAACCCCCA  
 TCATCTACGGCTGAGGAACAAATGAAGTGAAGGGCTGTCAAGAGGACAATCACTCAA  
 AAGTCTACAGAAGTTAGATGTGTTGA (SEQ ID NO: 180)

**AOLFR97 sequences:**

35 MTEFHLQSQMPSPRLIFRRLSLGRIKPSQSPRCSTSFMVVPFSIAEHWRMKGANLSQGMFEL  
 LGLTTDPQLQRLLFVVFGLMYTATLLGNLVMFLLIHVSATLHTPMYSLLSFLDFCYSTVV  
 PQLVNFLAKRKVISYFGCMTQMFFYAGFATSECYLIAAMAYDRYAAICNPLLYSTIMSPEVC  
 ASLIVGSYSAGFLNSLIHTGCFISLKFCAHVVTHFFCDGPPILSLCVDTLCEILLFIFAGFNLLS  
 CTLTILISYFLILNTILKMSAQGRFKAFSTCASHLTAICLFFGTTLFMYLPRRSSYLTQDRTVA  
 40 VIYTVPVIPNPLMYSLRNKDVKALIKVWGRKTME (SEQ ID NO: 181)

45 ATGACAGAGTTCATCTGCAAAGCAAATGCCCTAATAAGACTCATCTCAGAAGGCTGT  
 CCTIAGGCAGAATTAAACCCAGTCAGAGCCCCAGGTGTTCAACCTCATTATGGTGGTGC  
 TTCTTCTCCATGCAAGAGCACTGGAGAAGGATGAAAGGGCAAACCTGAGCCAAGGGAT  
 GGAGTTGAGCTTGGGCTACCAACTGACCCCCAGCTCCAGGGCTGCTCTGGTGC  
 50 TTCCCTGGCATGTACACAGCCACTCTGCTGGGAACCTGGTCAAGAGCCTCTCTGATTC  
 TGAGTGCCACCTGCACACACCCATGACTCCCTCTGAAGAGCCTCTCTGATTC  
 TGCTACTCCACGGTTGTGCCCATGACATGAGTTCTATGCGGGTTTGCCACCAAGTGA  
 TCTCTTATTTGGCTGATGACTCAGATGTTCTATGCGGGTTTGCCACCAAGTGA  
 55 TATCTCATCGCTGCCATGGCTATGACCGCTATGCCGCTATTGTAACCCCTGCTACTC  
 AACCATCATGTCCTGAGGTCTGCGCTCGTATTGTTGGCTCCTACAGTGCAGGATT  
 CTCATTCTCTTACACACTGGCTGATGGCCACCCATCCTGCTCTGTTGAGACACCTCACTGT  
 CACTCACTCTCTGATGGCCACCCATCCTGCTCTGTTGAGCTGCAACCTCCTG  
 GTGAGATCCTGCTCTCATTTGCTGGTTCAACCTTTGAGCTGCAACCTCCTG  
 ATCTCCTACTCTTAATTCTAACACCCATCCTGAAAATGAGCTGGCCAGGGCAGGTTA  
 AGGCATTTCACCTGTGCATCCCACCTCACTGCCATCTGCCTCTTGGCACAACACTT

TTTATGTACCTGCGCCCCAGGTCCAGCTACTCCTGACCCAGGACCGCACAGTTGCTGTCA  
TCTACACAGTGGTATCCAGTGCTGAACCCCTCATGTACTCTTGAGAAAACAAGGATGT  
GAAGAAAGCTTAATAAAGGTTGGGTAGGAAAACAATGGAATGA (SEQ ID NO: 182)

5 **AOLFR98 sequences:**

MRGFNKTTVVTQFILVGSSLGELQLLFVIFLLLYLTLIVANVTIMAVIRFSWTLHTPMYGLFI  
LSFSESCYTFVIIPQLLVHLLSDTKTISFMACATQLFFLGFACTNCLIAVMGYDRYVAICHPLR  
YTLIINKRLGLELISLSGATGFFIALVATNLICDMRFCGPNRVNHYFCDFMAPVIKLAETDTHVKE  
LALFSLSLVIMVPFLLILISYGFIVNTILKIPSAEGKKAFVTCASHLTVVFHYGCASIYLRPKSK  
10 SASDKDQLVAVTYTVVTPLLNPLVYSLRNKEVKTALKRVLGMPVATKMS (SEQ ID NO: 183)

ATCGGAGGTTCAACAAAACACTGTGGTTACACAGTTACATCCTGGTGGGTTCTCCAGCC  
TGGGGGAGCTCCAGCTGCTGCTTTGTATCTTCTCCTATACTTGACAATCCTGGTG  
15 GCCAATGTGACCACATGCCGTTATCGCTTCAGCTGGACTCTCCACACTCCATGTATG  
GCTTCTATTCACTCCTTCATTTCTGAGTCCTGCTACACTTTGTATCATCCCTCAGCTG  
TGGTCCACCTGCTCTAGACACCAAGACCATCTCCTCATGGCTGTGCCACCCAGCTGTT  
CTTTTCCCTGGCITTGCTGCACCAACTGCCCTCATGGCTGTGATGGGATATGATCGCT  
ATGTAGCAATTGTCACCCCTGAGGTACACACTCATCATAAACAAAAGGCTGGGTTGGA  
20 GTTGATTCTCTCAGGAGCCACAGGTTCTTATTGCTTGGCCACCAACCTCATT  
GTGACATGCGTTTGTGGCCCAACAGGTTAACCACTATTCTGTGACATGGCACCTGT  
TATCAAGTTAGCCTGCACTGACACCCATGTGAAAGAGCTGGTTATTAGCCTAGC  
CTGGTAATTATGGTGCCTTCTGTTAATTCTCATATCCTATGGCTCATAGTAACACCAT  
CCTGAAGATCCCTCAGCTGAGGGCAAGAAGGCCTTGTACCTGTGCCTCACATCTCACT  
25 GTGGCTTTGTCCACTATGGCTGTGCCCTATCATCTATCTGCAGGCCAAGTCCAAGTCTG  
CTCAGACAAGGATCAGTTGGCGAGTACACAGTGGTTACTCCCTACTTAATCCT  
CTTGTCTACAGTCTGAGGAACAAAGAGGTAAGACTGCATTGAAAAGAGTTCTGGAATG  
CCTGTGGCAACCAAGATGAGCTAA (SEQ ID NO: 184)

**AOLFR99 sequences:**

MERVNETVREVIFLGSSLARLQQLLFVIFLLLYLFTLGTNAIIISTIVLDRALHIPMYFFLAILSC  
SEICYTFIIVPKMLVDLLSQKKTISFLGCAIQMFSFLFLGCSHSFLAVMGYDRYIAICNPLRYSV  
LMGHGVCMGLVAAACACGFTVAQIITSVFHLPFYSSNQLHHFFCDIAPVLKLA  
SHHNHSQIVIFMLCTLVLAIPLLLILVSYVHILSAILQFPSTLGRCKAFSTCVSHLIVTVHYGCASFIYLRPQS  
30 SSSQDALISVSYTIITPLFNPMIYSLRNKEFKSALCKIVRRTISLL (SEQ ID NO: 185)

35 ATGGAGCGGGTCAATGAGACTGTGGTGAGAGAGGTCATCTCCTCGGCTTCTCATCCCTGG  
CCAGGCTGCAGCAGCTGCTTTGTTATCTCCTGCTCCTACCTGTCATCTGGCACC  
AATGCAATCATCATTCCACCATGGCTCTGGACAGGGCCCTCATATCCCCATGTA  
CTTCTGCCTCCTCTGCTGAGATTGCTACACCTCATATTGACCCAAGATGCTGG  
40 TTGACCTGCTGTCCCAGAAGAAAGACCATTTCTTCTGGCTGTGCTCACTCC  
TTCTCTTCTGCTGCTCTCACTCCCTTCTGCTGCTGGCAGTCATGGTTATGATCGTACAT  
AGCCATCTGTAACCCACTGCGCTACTCAGTGTAAATGGGACATGGGGTGTG  
GTGGCTGCTGCCTGTGCTGGCTTCACTGTTGACAGATCATCACATCCTGGTATT  
CCTGCCTTTTATTCTCAACTACATCACTCTCTGTGACATTGCTCTGTCTCA  
45 AGCTGGCATCTCACCATAACCACTTAGTCAGATTGTCATCTCATGCTCTGTACATGGTC  
CTGGCTATCCCTTATTGTTGATCTGGTGTCTATGTTCACATCCTCTGCTGCC  
GTTTCCTCCACACTGGGTAGGTGCAAAGCTTCTACCTGTGATCTCACCTCATT  
TCACTGTCCACTATGGCTGTGCCCTTATCTACTTAAGGCTCAGTCCA  
AGCCAGGATGCTTAATATCAGTACCTACATTATAACTCCATTGTTCAACCC  
50 AGAATTTATAGCTTGAGAAATAAAGAGTTCAAATCAGCTCTTGTAAAATTGTGAGAAGAAC  
ATTCCCTGTTGAA (SEQ ID NO: 186)

**AOLFR101 sequences:**

MDTGNWSQVAEFIGFPHLQGVQIYLFLLLLIYLMTVLGNLLIFLVVCLDSRLHTPMYHFVSI  
55 LSFSELGYTAATIPKMLANLLSEKKTISFSGCLLQIYFFHSLGATECYLLTAMAYDRYLAICRPL  
HYPTLMPTLCAELAIGCWLGGLAGPVVEISLISRLPFCGPNRIQHVFCDFPPVLSACTDTSINV

WO 01/98526

LVDFVINSCKILATFLILCSYVQIICTVLRIPSAAGKRKAISTCASHFTVVLIFYGSILSMYVQLK  
KSYSLDYDQALAVVSVLTPFLNPFIYSLRNKEIKEAVRQLKRIGILA (SEQ ID NO: 187)

5 ATGGACACAGGAACTGGAGCCAGGTAGCAGAATTACATCTTGGGTTCCCCATCTCC  
AGGGTGTCCAGATTATCTCTCCTTGTGCTTCATTAACCTCATGACTGTGTTGGGA  
AACCTGCTGATATTCTCTGGTCTGCTGGACTCCGGCTCACACACCCATGTACCACT  
10 TTGTCAGCATTCTCCTTCTCAGAGCTTGGCTATACAGCTGCCACCATCCCTAAGATGCTG  
GCAAACCTGCTAGTGAGAAAAAGACCATTCATTCTCTGGGTCTCCTGCAGATCTATT  
TCTTCACTCCCTGGAGCGACTGAGTGCTATCTCTGACAGCTATGCCCTACGATAGGTA  
15 TTAGCCATCTGCCGGCCCTCCACTACCCAACCCATGACCCAACACTTGTGAGAG  
ATTGCCATTGGCTGGTGGAGGCTGGCTGGCTGGCCAGTAGTTGAAATTCCCTGATT  
CACGCCCTCCATTCTGTGGCCCAATCGCATTGACGCTTTGTGACTTCCCTCTGTG  
CTGAGTTGGCTGACTGATACTGCTATAAATGCTCTAGATGATTTGTTATAAAATTCTG  
CAAGATCCTAGCCACCTTCTGCTGATCCTCTGCTATGTCAGATCATCTGCACAGTGC  
15 TCAGAATTCCCTCAGCTGCCGGCAAGAGGAAGGCCATCCACGTGCTCCACTTCAC  
TGTGGTCTCATTTCTATGGGAGCATCTTCCATGTATGTGAGCTGCTCACACCCTCCTCAACC  
TCACTGGACTATGACCAGGCCCTGGCAGTGGCTACTCAGTGTCAACACCCTCCTCAACC  
CCTTCATCTACAGCTTGCCTAACAGGAGATCAAGGAGGCTGTGAGGAGGAGCTAAAGA  
GAATTGGGATATTGGCATGA (SEQ ID NO: 188)

20

## AOLFR102 sequences:

MPVGLVFNQSEPTEFVRAFTTATEFQVLLFLFLLYLMLCGNTAIWWVCTHSLRTPMF  
FLSNLFLCYYTUVVPLMSNILGAQKPIISLAGCGAQMFVTLGSTDCFLAIMAYDRYVAI  
25 CHPLHYTLIMTRELCTQMLGGALFPLSQLTALIFTLPFCGHHQEINHFLCDVPPVRLACA  
DIRVHQAVLYVVSILVLTIPFLICVSYVFITCAILSIRSAEGRRAFSTCSFHLTVULLQYGCCSL  
VYLRPRSSSTSEDEDSQIALVYTFVTPLLNPILYSLRNKDVKGALRSAIRKAASDAN (SEQ ID  
NO: 189)

30

ATGCCGTGGGAAACTGTCTCAACCAGTCTGAGCCACTGAGTTGTGTTCCGTGCGT  
TCACCACAGCACTGAATTCCAGGTTCTCTCCCTCTCTCCCTCCTACTTGTAG  
ATCCTCTGTGCAACACAGCCATCATCTGGGTGGTGTGACACACAGCACCCCTCCGACCC  
CGATGTTATTCTCTGTCCAACCTGTCTTCTGGAAACTCTGCTACACCACCGTGGTAGTA  
CCCTTGATGCTTCTTCAACATTGGGGCCAGAACGCCATTCTGGCTGGATGTGGGG  
35 CCCAAATGTTCTTCTTGTCAACCTCGGACGGACTGTTCTCTGGCGATCATGGCC  
TATGACCGCTATGTGGTATCTGCCACCCGCTGCACTACACCCTCATGACCCGCGAGC  
TGTGACCGAGATGCTGGGTGGGGCCCTGGGCTGGCCCTTCCCTCCCTGAGCTCAC  
CGCCTTAATCTCACCTGCCCTTGGGCCACCAAGGAAATCAACCACTTCTCTGCG  
40 ATGTGCCTCCGCTCTGCGCTGGCTGACATCCGCGTGCACAGGCTGTCTCA  
TGTGCGTGCAGCATCTCGTGCAGCATCCGTTCTGCCAGGGCCGCCGGCTTCTCCACCTG  
TCACCTGTGCCATCCTGAGCATCCGTTCTGCCAGGGCCGCCGGCTTCTCCACCTG  
CTCCTCCACCTCACCGTGGCTGCTGCAGTATGGCTGCTGCAGCTCGTGTACCTGCGTCA  
CTCGGTCCAGCACCTCAGAGGATGAGGACAGCCAATCGCTGGCTACACCTTGTCA  
50 CCCCTACTCAACCCCTTGCTTACAGCCTAGGAACAAGGATGTCAAAGGTGCTTGAGG  
AGTGCCATTATCCGTAAGCAGCCTGACGCCACTGA (SEQ ID NO: 190)

45

## AOLFR103 sequences:

MAEMNLTVTEFLIAFTEYPEWALPLFLFLFMYLITVLGNLEMILILMDHQLHAPMYFLLSH  
LAFMDVCYSSITVPQMLAVLLEHGAALSYTRCAAQFFLFTFFGSIDCYLLALMAYDRYLAVCQ  
PLLYVTILTQQARLSLVAGAYVAGLISALVRTVSATLSCFGTSEIDFIFCDLPLLKLTGESYT  
50 QEVLIIMFAIFVIPASMVVLVSYLFIIVAIMGIPAGSQAKTFSTCTSHLTAVSLFFGTLIFMYLRG  
NSDQSSEKNRVSVSLYTEVPMLNPLIYSLRNKEVKEALRKILNRAKLS (SEQ ID NO: 191)

55

ATGGCAGAGATGAACCTCACCTGGTACCGAGTTCCCTTATTGCAATTCACTGAATATC  
CTGAATGGCACTCCCTCTTCTCTTGTATTATTTATGTATCTCATCACCGTATTGGGG  
AACTTAGAGATGATTATCTGATCCTCATGGATCACAGCTCCACGCTCAATGTATTCC  
TCTGAGTCACCTCGCTTCTGGACGCTGCTACTCATCTACTGTCCCCCAGATGCTGG

CAGTGCTGCTGGAGCATGGGGCAGCTTATCTTACACACGCTGTGCTGCTCAGTTCTTCT  
 GTTCACCTTCTTGGTCCATCGACTGCTACCTCTGGCCCTATGGCTATGACCGCTACT  
 TGGCTGTGCTGCCAGCCCCGCTTATGTCACCATCCTGACACAGCAGGCCCCGCTTGAGTCT  
 5 TGTGGCTGGGCTTACGTGCTGGTCTCATCAGTGCCTGGTGCAGACAGTCTCAGCCTTC  
 ACTCTCCTCTGTGGAACAGTGAGATTGACTTATTTCTGTGACCTCCCTCCTGTGTT  
 AAAGTTGACCTGTGGGAGAGCTACACTCAAGAAGTGTGATTATTATGTTGCCATT  
 10 GTCATCCCCTGCTTCCATGGTGGTGTACCTGGTCTACCTGTTATCATCGTGGCCATCAT  
 GGGGATCCCTGCTGGAAGGCCAGGCCAGACCTCTCCACCTGCACCTCCCACCTCACTGCT  
 GTGTCACTCTTGTGACCTCATCTCATGTACTTGAGAGGTAACTCAGATCAGTCITC  
 GGAGAAGAATCGGGTAGTGTCTGTGTTACACAGAGGTCATCCCATGTTGAATCCCCTC  
 15 ATCTACAGCCTGAGGAACAAGGAAGTGAAGGAGGCCCTGAGAAAAATTCTCAATAGAGCC  
 AAGTTGTCCTAA (SEQ ID NO: 192)

**AOLFR105 sequences:**

15 MQGLNHTSVSEFILVGFSAFPHLQLMLFLLMYLFTLLGNLLIMATVWSERSLHMPMYLFLC  
 ALSITEILYTVAIIPRMLADILLSTQRSLAFLACASQMFSSFSFGFTHSFLTVMDYDRYVAICHPL  
 RYNVLMSLRGCTCRVGC SWAGGLVMGMVVTSAIFHLAFCGHKEIHHFFCHVPPPLLKACGDD  
 VLVVAKGVGLVCITALLGCFLILLSSYAFIVAAILKIPSAEGRNKAFTCASHLTVVVHYGFAS  
 20 VIYLPKGPQSPEGDTLMGITYTVLTPFLSPIIFSLRNKELK VAMKKTCFTKLPQNC (SEQ ID  
 NO: 193)

ATGCAGGGGCTAAACCACACCTCCGTGTGAATTCATCCTCGTTGGCTTCTCTGCCTTCCC  
 CCACCTCCAGCTGATGCTCTCCTGCTGTTCTGCTGATGTACCTGTTACGCTGCTGGGCA  
 25 ACCTGCTCATCATGCCACTGTCTGGAGCGAGCGCAGCCTCCACATGCCATGCTACCTCTT  
 CCTGTGTGCCCTCTCCATACCGAGATCCTACACCGTGGCCATCATCCCGCGATGCTG  
 GCCGACCTGCTGTCCACCCAGCGCTCCATGCCCTGGCCTGTGCCAGTCAGATGTTCTT  
 CTCCCTCAGCTTCGGCTTACCCACTCCTCCTGCTACTGTATGGGCTACGACCGCTACG  
 TGGCCATCTGCCACCCCTCGTTACAACGTGCTATGAGCCTGCGGGCTGCACCTGCCG  
 30 GGTGGGCTGCTCTGGGCTGGTGGTGTGGCATGGGATGGTGGTGAACCTGGCCATTTC  
 CACCTCGCCTCTGTGGACACAAGGAGATCCACCATTTCTCTGCCACGTGCCACCTCTGTT  
 GAAGTTGGCCTGTGGAGATGATGTGCTGGTGGCCAAGGGCTGGGCTTGGTGTGTAT  
 CACGGCCCTGCTGGCTGTTCTCTCATCCTCCCTCCTATGCCCTCATCGTGGCCCA  
 TCTTGAAGATCCCTCTGCTGAAGGTCGAAACAAGGCCCTCTCCACCTGTGCCCTCACCT  
 35 CACTGTGGTGGTCGTGCACATGGCTTGCCTCCGTCAATTACCTGAAGGCCAAAGGTCCC  
 CAGTCTCCGGAAAGGAGACACCTGATGGGATCACCTACACGGCCTCACACCCCTCCTCA  
 GCCCCATCATCTCAGCCTCAGGAACAAGGAGCTGAAGGTGCCATGAAGAAGACTTGCTT  
 CACCAAACCTTCCACAGAACTGCTGA (SEQ ID NO: 194)

**AOLFR106 sequences:**

40 METANYTKVTEFVLTGLSQTPPEVQLVLFVIFLSYFLFILPGNILIICTISLDPHLTSPMYFLLANLA  
 FLDIWYSSITAPEMLIDFFVERKIISFDGCIAQLFFLHFAGASEMFLLTVMAFDLYTAICRPLHYA  
 TIMNQRLCCILVALSWRGGFIHSIIQVALIVRLPFCGPNELDYFCIDITQVVRACANTFPEELVM  
 ICSSGLISVVCLIAALLMSYAFLLALFKKLKGSGENTNRAMSTCYSHITIVVLMFGPSIYIYARPF  
 SFSLDKVVSVFNTLIFPLRNPIIYTLRNKEVKAAMRKLVTKYILCKEK (SEQ ID NO: 195)

45 ATGGAAACTGCAAATTACACCAAGGTGACAGAATTGTTCTCACTGGCCTATCCCAGACTC  
 CAGAGGTCCAACCTAGTCCTATTGTTATATTCTATCCTCTATTGTCATCCTACCCAGGA  
 AATATCCTTATCATTCGACCATCAGTCTAGACCCCTCATCTGACCTCTCCTATGTATTCT  
 GTGGCTAATCTGGCCTTCTGATATTGGTACTCTCCATTACAGCCCTGAAATGCTCA  
 50 TAGACTCTTTGTGGAGAGGAAGATAATTCTTTGATGGGATGCATTGCACAGCTCTCTT  
 CTTACACTTGTGGGCTTGGAGATGTTCTGCTCACAGTGTGATGGCCTTGACCTCTACA  
 CTGCTATCTGCCACCCCTCCACTATGCTACCATCATGAATCACGTCTGCTGTATCCTG  
 GTGGCTCTCTCCTGGAGGGGGGCTTCATTCTATCATAACAGGTGGCTCTATTGTT  
 GACTTCCTTCTGTGGGCCAATGAGTTAGACAGTTACTCTGTGACATCACACAGGTGT  
 55 CGGGATTGCCTGTGCCAACACCTCCCAGAGGAGTTAGTGTGATGATCTGTAGTAGTGGTCTG  
 ATCTCTGTGGTGTGTTGATTGCTCTGTTAATGTCCTATGCCCTCTGGCCTGTTCAA

WO 01/98526  
GAAACTTCAGGCTCAGGTGAGAATACCAACAGGGCATGTCCACCTGCTATTCCACATT  
ACCATTTGTGGTCTAATGTTGGCCATCCATCTACATTATGCTGCCATTGACTCGTT  
TTCCCTAGATAAAAGTGGTGTCTGTGTTCAAACTTTAATATTCCCTTACGTAATCCATTAA  
TTTACACATTGAGAAACAAGGAAGTAAAGGCAGCCATGAGGAAGTTGGTCACCAAATATA  
5 TTTGTGTAAAGAGAAGTGA (SEQ ID NO: 196)

5

AOLFR107 sequences:

**AOLFR107 sequences:**  
10 MELWNFTLGGSGFILVGILNDSGSPELLCATITILYLLALISNGLLLAITMEARLHMPMYLLLQ  
LSLMDLLFTSVTPKALADFLRRENTISFGGCALQMFLALTMGGAEDLLLAFMAYDRYVAICH  
PLTYMTLMSRACWLMVATSWILASLSALIYTVTMHPFCRAQEIRHLLCEIPHLLKVACAD  
TSRYELMVYVMGVTFLIPSLAIALASYTQILLTVLHMPSENKRKKALVTCSSHLTVVGMFYGA  
ATFMYVLPSFHSTRQDNIISVFYTIVTPALNPLIYSLRNKEVMRALRRVLGKYMLPAHSTL  
(SEQ ID NO: 197)

(SEQ ID NO: 197)  
15 ATGGAGCTCTGGAACCTCACCTGGGAAGTGGCTCATTTGGGGATTCTGAATGACA  
GTGGGTCTCTGAACCTGCTCTGTGCTACAATTACAATCCTATCTGTTGCCCTGATCAG  
CAATGGCTACTGCTCTGGCTATCACCATGGAAGCCGGCTCCACATGCCATGTACCTC  
CTGCTTGGGCAGCTCTCTCATGGACCTCTGTTCACATCTGTTGACTCCAAAGGCCCT  
TGCAGCTTCTGCCAGAGAAAACACCATCTCCTTGGAGGCTGTGCCCTCAGATGTT  
20 CTGGCACTGACAATGGTGGTGTGAGGACCTCATGGCCTCATGGCCTATGACAGGT  
ATGTGGCCATTGTACATCCTGACATACATGACCATGAGCTCAAGAGCCTGCTGGCT  
CATGGTGGCACGTCTGGATCCTGGCATCCCTAAGTGCCTAATATATACCGTGTATACC  
ATGCACTATCCCTCTGCAGGGCCAGGAGATCAGGCATCTCTGTGAGATCCCACACT  
TGCTGAAGGTGGCTGTGCTGATACCTCCAGATATGAGCTATGGTATATGTGATGGGTG  
25 GACCTCCTGATCCCTCTTGCTGCTATACTGCCCTCATACAAATTCTACTCACTG  
TGCTCCATATGCCATCAAATGAGGGAGGAAGAAAGCCCTGTACCTGCTTCCACCT  
GACTGTGGTGGGATGTTCTATGGAGCTGCCACATTCTGTTGACTCCAGTTCCCTG  
ACAGCACCAGACAAGACAACATCATCTGTTTCTACACAATTGTCACTCCAGCCCTGA  
TCCACTCATCACAGCCTGAGGAATAAGGAGGTCATGGGGCCTGAGGAGGGCCTGG  
30 AAAATACATGCTGCCAGCACACTCCACGCTCTAG (SEQ ID NO: 198)

30

### 40 LFR108 sequences:

**AOLFR108 sequences:**  
 MCSFFLCQTGKQAKISMGEENQTFVSKFIFLGLSQDLQTQILLFILFLITYLLTVLGQNQIILIFLD  
 SRLHTPMYFFLRLNLSFADLCFSTSIVPQVLVHFLVKRKTISFYGCMTQIVFLLVGCTECALLAV  
 MSYDRYVAVCKPLYYSTIMTQRVCLWLSFRSWASGALVSLVDTSFTFHLPPYGQNIINHYFCE  
 PPALLKLASIDTYSTEMAIFSMGVVILLAPVSLILGSYWNISTVIQMGSQEGRLKAFSTCGSHLI  
 VVVLFYGSGIFTYMRPNSKTTKELDKMISVFTAVTPMLNPIIYSLRNKDVKGALRKLVGRKC  
 FSHRQ (SEQ ID NO: 199)

40 ATGTGTTCTTTCTGTGCCAACAGGAAAC  
 ACCAACCTTGTGTCAGTTATCTTCTGGCTTTCACAGGACTTGAGACCCCT  
 CCTGCTATTATCCTTCTCATCATTATCTGCTGACCGTCTGGAAACAGCTCATCA  
 TCATTCTCATCTCCTGGATTCTGCCCTCACACTCCATGTATTCTTAGAAATCTCT  
 CCTTGCAGATCTCTGTCTACTAGCATTGTCCTCAAGTGTGGTCACTCTGGTA  
 45 AAGAGGAAAACCATTCTTTATGGGTATGACACAGATAATTGTCTTCTGGTTG  
 GGTGTACAGAGTGTGCGCTGTCAGTGTGCTATGACCGGTATGGCTGTGCAA  
 GCCCTGTACTACTTACCATGACACAACGGGTGTCTGGCTGTCCCTCAGGTCT  
 GGGCCAGGGGGCACTAGTGTCTTAGTAGATACCAGCTTACTTCCATCTCCCTACTG  
 GGGACAGAATATAATCAATCACTACTTTGTGAACCTCCTGCCCTGAAGCTGGCTCC  
 50 ATAGACACTTACAGCACAGAAATGCCATCTTCAATGGCGTGGTAATCCTCTGGCCC  
 CTGTCCTCTGATTCTGGTTTATTGAATATTATCTCACTGTATCCAGATGCACTCT  
 GGGGAAGGGAGACTCAAGGCTTTCCACCTGTGGCTCCATCTTATTGTGTGCTCTT  
 CTATGGGTAGGAATATTCACTACATGCGACCAACTCCAAGACTACAAAAGAACGTGGA  
 TAAAATGATACTGTGTTCTACAGCGGTGACTCCAATGTGAACCCATAATTATAGC  
 55 TTGAGGAACAAAGATGTCAAAGGGCTCTCAGGAAACTAGTGGGAGAAAGTGTCTCT  
 CATAGGCAGTGA (SEQ ID NO: 200)

**AOLFR109 sequences:**

5 MLRNNSIVTEFILVGFQQSSTSTRALLFALFLALYSLTMAMNGLIIFITSWTDPKLNNSPMYFFLG  
 HLSLLDVCFITTIPQMLIHLVVRDHIVSFVCCMTQMYFVFCVGVAECILLAFCMAYDRYVAICY  
 PLNYVPIISQKVCVRLVGTAWFFGLINGIFLEYISFREPFRNDHIESFFCEAPIVIGLSCGDPQFSL  
 WAIFADAIVVILSPMVLTVTSYVHILATILSKASSSGRGKTFSTCASHLTVVIFLYTSAMFSYMN  
 PHSTHGPDKDKPFSLLYTIITPMCNPIIYSFRNKEIKEAMVRALGRTRLAQPSV (SEQ ID NO:  
 201)

10 ATGCTAAGGAATGGCAGCATAGTGACGGAATTATCCTCGTGGGCTTCAGCAGAGCTCCA  
 CTTCCACACGAGCATTGCTCTTGCCTCTTGGCCCTACAGCCTACCATGCCATG  
 AATGGCCTCATCATCTTATCACCTCTGGACAGACCCAAGCTAACAGCCCCATGACT  
 TCTTCCTCGGCCATCTGTCCTCTGGATGTCGTTACCACTACCATCCCACAGATG  
 TTGATCCACCTCGTGGTCAGGGACACATTGTCCTCTGTATGTCATGACATGACCCAGATG  
 15 ACTTTGTCCTCTGTGTTGGTGTGGCCAGTGATGCATCCTCTGGCTTCATGCCATGACCGT  
 TATGTTGCTATCTGCTACCCACTTAACATATGCCCCATCAAGCCAGAAAGGTCTGTC  
 GGCTTGTTGGAACTGCCTGGTTCTTGGGCTGATCAATGGCATTTCTCGAGTATTT  
 ATTCCGAGAGGCCCTCCGAGAGACAACCACATAGAAAGCTTCTCTGTGAGGCC  
 20 GTGATTGGCCTCTTGTGGGACCCCTCAGTTAGTCTGTGGCAATCTTGCCATGCCA  
 TCGTGGTAATTCTCAGCCCCATGGTGCCTACTGTCACCTCTATGTCACATCCTGCCACC  
 ATCCTCAGCAAAGCCTCCTCAGGTGGGGAAAGACTTCTACTTGTGCCCTCACC  
 TGACTGTGGTCATCTTCTACACTTCAGCTATGTTCTTACATGAACCCCCACAGCACA  
 CATGGCCTGACAAAGACAAACCTTCTCCCTCTGTACACCACATTACCCCCATGTGCA  
 25 ACCCCATCATTTATAGTTCCGCAACAAGGAATTAGGAGGCATGGTGAGGGCACTTG  
 GAAGAACCAAGGCTGGCCAGCCACAGTCTGTCTAG (SEQ ID NO: 202)

**AOLFR110 sequences:**

30 MKIANNTVVTEFILLGLTQSQDIQLLVFVLILIFYLILPGNFLIIFTIRSDPGLTAPLYLFLGNLAFL  
 DASYSFIVAPRMLVDFLSEKKVISYRCITQLFFLHFLGGGEGLLVVMAFDRYIAICRPLHCST  
 VMNPRACYAMMLALWLGGFVHSIQQVVLILRLPFCGPNQLDNFFCDVRQVIKACTDMFVVEL  
 LMVFNSGLMMLLLCFLGLLLASYAVILCHVRRAASEGKNKAMSTCTRVIILMFGPAIFYMCPL  
 RALPADKMVSLFHTVIFPLMNPMIYTLRNQEVKTSKRLLSRHVVCQVDFIIRN (SEQ ID NO:  
 203)

35 ATGAAGATAGCAAACAACACAGTAGTGACAGAATTATCCTCCTGGTCTGACTCAGTCTC  
 AAGATATTAGCTCTTGGCTTTGTGATCTTAATTCTACCTTATCCTCCCTGGA  
 AATTCTCATTATTTACCATAAGGTAGCAGACCCCTGGCTCACAGCCCCCTTATT  
 TCTGGCAACTTGGCCTCCTGGATGTCATCCTACTCCTCATTGTGGCTCCAGGATGTTGG  
 TGGACTTCCTCTGAGAAAAGGTAAATCTCCTACAGAGGCTGATCACTCAGCTTTT  
 40 CTTGCACCTCCTGGAGGGAGGGAGGGATTACTCCTGTTGTGATGGCCTTGACCGCTAC  
 ATCGCCATCTGCCGGCCTCTGCACTGTTCAACTGTCATGAACCCTAGAGCCTGCTATGCAA  
 TGATGTTGGCTCTGTTGGCTGGGGTTTGTCCACTCATTATCAGGTGGCTCATCCTC  
 CGCTTGCCCTTTGTGGCCAAACCAGCTGGACAACCTCTGTGATGTCGACAGGTCA  
 TCAAGCTGGCTTGACCATGTTGTGGTGAGCTCTAATGGCTTCAACAGTGGCCT  
 45 GATGACACTCTGTGTTCTGGGGCTTCTGGCTTCTGAGTCATCCTCTGCCATGTT  
 GTAGGGCAGCTCTGAAGGGAAAGAACAGGCCATGTCACGTGACCAACTCGTGTCTTAA  
 TTATACCTCTATGTTGGACCTGCTATCTCATCTACATGTGCCCTTCAGGGCTTACCA  
 GCTGACAAGATGGTTCTCTTACACAGTGATCTTCCATTGATGAATCCTATGATT  
 TACCTCGCAACCAGGAAGTGAAAACCTCCATGAAGAGGTATTGAGTCGACATGTAGTC  
 50 TGTCAAGTGGATTATAAGAAACTGA (SEQ ID NO: 204)

**AOLFR111 sequences:**

55 MCYIYLIFKEWTLIFYFSLLLQLITPAIMANLTIVTEFILMGFSTNKNMCILHSILFLYLALM  
 GNVLIIMITLDHHLHTPVYFFLKNLSFLDLCISVTAPKSIANSLIHNNISFLGCVSQVFL  
 ASAELLLLTVMSFDRYTAICHPLHYDVMRDRSTCVQRATVSWLYGGIAVMHTAGTFSLSYCG  
 SNMVHQFFCDIPQLLAISCSENLIREIALILINVVLDCCFIVIITYVHVFSTVKIPSTEGQSKAY

WO 01/98526

SICLPHLLVVLFLSTGFIAYLKPAESPSILDAVISVFYMLPPTFNPIIYSLRNKAIKVALGMLIKG  
KLTKK (SEQ ID NO: 205)

5 ATGTGTATATATTTAATTTAAAGAGTGGACATTGATATTTACTTCAGTCTTCTCCT  
TTCTGCAGATTACTCCTGCAATAATGCAAATCTACAATCGTACTGAATTATCCTTA  
10 TGGGTTTCTACCAATAAAATATGCAATTTCGATTCTGATTCTCTTGTGATTAT  
TTGTGTGCCCTGATGGGAATGCTCTCATTATCATGATCACAACCTTGGACCATCATCTCC  
ACACCCCCGTGATTCTCTGAAGAATCTATCTTCTGATCTGCTGCCATTTCAGTC  
ACGGCTCCAAATCTATGCAATTCTTGATACACAACACTCCATTCTACCTGGCTG  
15 TGTTCCAGGTCTTGTGCTTCTCAGCATCTGCAGAGCTGCTCCTCACGGTGA  
TGTCTTGACCGTATACTGCTATATGTCACCCCTGCACTATGATGTCATCTGAGCAGG  
AGCACCTGTGTCAGGAAAGAGCCACTGCTGGCTATGGGGCTGATTGCTGTGATGC  
ACACAGCTGGCACCTCTCTTATCCTACTGTGGTCCAACATGGTCATCAGTCTCTGT  
GACATCCCCAGTTATTAGCTATTCTGCTCAGAAAATTAAATAAGAGAAATTGCACTCA  
20 TCCTTAAATGTAGTTGGATTCTGCTGTTATTGTCATCATCATTACCTATGTCCAC  
GTCTCTACAGTCAAGAAGATCCCTCACAGAAGGCCAGTCAGCTAAAGCCTACTCTATT  
GCCTCCACACTGCTGGTGTGTTATTCTTCCACTGGATTCTGTTATCTGAAGCCA  
GCTTCAGAGTCTCTCTATTGGATGCTGTAATTCTGTTACACTATGCTGCC  
AACCTTAATCCATTATACAGTTGAGAAACAAGGCCATAAGGTGGCTGGGATG  
TTGATAAAGGAAAGCTCACCAAAAGTAA (SEQ ID NO: 206)

## AOLFR113 sequences:

MKFHWGFSHLNPMFSSFLYLSLPWINTTIQAWLNLCSLALPVWAMSGAGFLSCCYWHTCSP  
SVTCSSSQSSDWMLQLCTHLCTLSVFFPSWCGIQLPLSLRCLIFSVRRKPFLQDASFRPTSS  
25 TPWGACECYLLTAMAYDRYLAICRPLHPIIMTTLCAKMAAACWTGFLCPISEVILASQLPF  
CAYNEIQHIFCDFPPLSACKDTSANILVDFAINAFIILITFFFIMISYARIIGAVLKITASGRKK  
AFSTCASHLAVVLIFFGSIIFMYVRLKSKSystLDRTLAIIVSVLTPMVNPiIYSLRNKEIKAIR  
TIFQKGDKASLAHL (SEQ ID NO: 207)

30 ATGTGTCAACAAATCTACGGGATGCAATTCTCTCATACATCATTGTCATTAACAGGA  
AAAAAGTCTCACTTGTGATGCTGGTCCAGCTTAAACCACACAATGGAAACCCCTGCCTC  
CTTCCCTCTGGTATCCCAGGACTGCAATCTCACATCTTGGCTGGCTATCTCACTGA  
GTGCCATGTACATCATAGCCCTGTTAGGAAACACCATCATCGTACTGCAATCTGGATGGA  
35 TTCCACTCGGCATGAGCCATGTATTGTTCTGTTCTGGTGTGCTGGTGTGACATTGTTA  
TGGCCTCCTCGGTGGTACCAAGATGGTAGCATCTGTCAGGAGACAGCTCAATCAG  
CTTATGTGCTGTTCACTCAGATGTTTGTCCACTAGCCACAGCTGGAGACGGGG  
CTGCTGTCACCATGGCTTGTACAGTGTGAGCATGAGTGGCATCTGCAAGCTCTACACTACAAGA  
40 GAATTCTACGCCTCAAGTGTGAGTGGATGGTAGTCATCTGCAAGCTCTACAGCTATCAT  
AGCCATAACTCCACTGAGTGGATGGTAGTCATCTGCAAGCTCTACACTACAAGA  
GTCCACTCCTACTGTGAGCACATAGCTTGGCAGGTAGCATGTGTCAGCTGGCTTCAATGTGGTT  
GCAGTCTCTACAGTGTGATTGGTCTCTTATGGTGGCTGTGATGTGTCAGTGGT  
45 GCCTCTATCTTAACTCAAGGCAGTATTGGTCTCTCTCAAAGACTGCTCAGTGGAA  
AGCATTAAGCACATGTGGCTCCATGTGGGGTTATGGCTTGTACTATCTACCTGGATG  
GCATCCATCTATGCGGCCTGGTGGGGCAGGATGTAGTGCCTTGACACCCAAAGTCTGC  
TAGCTGACCTGTACGTGATCATCCAGCCACCTAAATCCATCATCTATGGCATGAGGAC  
CAAACAATGCGGGAGAGAATATGGAGTTATCTGATGTCATGCTCTTGGCATTCAAC  
CTGGGTTCATGA (SEQ ID NO: 208)

## AOLFR114 sequences:

50 MERINHTSSVSEFILLGLSSRPEDQKTLFVLFLIVYLVTITGNLLAIRFNPHLQTPMFFLSFLS  
LTDICFTTSVVPKMLMNFLSEKKTISYAGCLTQMYFLYALGNSDSCLLAVMAFDRYVAVCDPF  
HYVTTMSHHCVLLVAFSCSFPHLHSLLHLLNRLTFCDSNVHHFLCDLSPVLSKLSCSSIFVN  
EIVQMTEAPIVLVTRFLCIAFSYIRLTTVLKIPSTSGRKAFSTCGFYLTIVTLYGSIFCVYLQP  
PSTYAVKDHVATIVYTVLSSMLNPFIYSLRNKDLQGLRKLM SKRS (SEQ ID NO: 209)

ATGGAAAGAACATCAACCACACCAGCAGTGTCTCGAGTTATCCTCCTGGGACTCTCCTCCC  
 5 GGCCTGAGGACCAAAAGACACTCTTGTCTCTCATCGTGTACCTGGTACCCATAAC  
 AGGGAACCTGCTCATCATCCTGGCATTGCTCAACCCCCATCTCAGACCCCTATGTATT  
 TCTTCTGAGTTCTGTCTCACTGATATTGCTTACAACAAGCGTTGTCCCAAGATG  
 CTGATGAACCTCCTGTCAAGAAAAGAACGACCATCTCCTATGCTGGGTGTGACACAGATG  
 10 ATTTCTCTATGCCTTGGCAACAGTGACAGCTGCCTCTGGCAGTCATGGCCTTGACCG  
 CTATGTGGCCGTCTGTGACCCCTTCACTATGTCACCACCATGAGCCACCACACTGTGTCC  
 TGCTGGTGGCCTCTCCTGCTCATTCCTCACCTCCACTCCTGCACACACACTCTGCTG  
 AATCGTCTCACCTCTGTGACTCCAATGTTATCCACCACTTCTGTGACCTCAGCCCTGT  
 15 GCTGAAATTGTCTGCTCTCCATATTGTCAATGAAATTGTGACAGTGACAGAACCT  
 ATTGTTTGGTGAACCGTTCTGCATTGCTTCTTTATACGAATCCTCACTACAGT  
 TCTCAAGAGTCCCTACTTCTGGAAACGCAAAGCCTCTCCACCTGTGGTTTACCTCA  
 CCGTGGTACGCTCTTATGAAAGCATCTCTGTGTATTACAGCCCCATCCACCTAC  
 GCTGTCAAGGACACGTGGCAACAATTGTTACACAGTTGTGATCCATGCTCAATCCTT  
 20 TTATCTACAGCCTGAGAAACAAAGACCTGAAACAGGGCCTGAGGAAGCTTATGAGCAAGA  
 GATCCTAG (SEQ ID NO: 210)

**AOLFR115 sequences:**

MEGFYLRRSHELQGMGKPGRVNQTTVSDFLLGLSEWPEEQPLLFGIFLGMYLVTMVGVL  
 20 LAIISDPHLHTPMYFFLANLSLTDACFTSASIPKMLANIHTQSQIISYSGCLAQLYFLLMF  
 NCLLAVALMAYDRYVAICQPLHYSTSMPQLCALMLGVCVWLTNCPALMHTLLL  
 AIPHFYCDPSALLKLACSDTHVNELMIITMGLLFTVPLLIVFSYVRIFWAVFVISSP  
 GGRWKA FSTCGSHLTVVLLFYGSLMGVYLLPPSTYSTERESRAAVLYMVIPTLN  
 KLFVSGKTF (SEQ ID NO: 211)

25 ATGGAAGGTTTATCTGCGCAGATCACAGAACATACAAGGGATGGGAAAACCAGGCAGA  
 GTGAACCAAACCACTGTTCAAGACTTCCTCCTCTAGGACTCTGAGTGGCAGAGGAGC  
 AGCCTCTCTGTTGGCATCTCCTGGCATGTACCTGGTACCATGGTGGGAACCTGCTC  
 ATTATCCTGCCATCAGCTGACCCACACCTCCATACTCCATGTTACTCTTCTGCCAA  
 30 CCTGTCATTAACGTGCTGTTCACTCTGCTTCTGACAGCTATGCTGGCAACATTC  
 ATACCCAGAGTCAGATCATCTGTTACTCTGGGTGTCTTGACAGCTATATTCTCCTTATG  
 TTTGGTGGCCTTGACAACACTGCTGCTGGCTGTGATGGCATATGACCGCTATGTGGC  
 35 ATCTGCCAACACTCATTACAGCACATCTGAGTCCCCAGCTCTGTGCACTATGCTGG  
 GTGCTGGGTGCTAACCAACTGCTGCTGCCCTGATGCACACACTGTTGCTGACCCGCG  
 TTCTGTGCCAGAAAGCCATCCCTCACTCTGATCTGCTCTCTGAAAGCTTGC  
 CTGCTCAGATAACCATGTAACAGAGCTGATGATCATCACCATGGGCTGCTGTT  
 40 GTCCTCCCTGCTGATCGTCTCTCTATGTCGCTTCTGATCTCACGGTGGTCTG  
 ATCTCCTGGAGGGAGATGGAAGGCCTCTACCTGTGGTTCTCATCTCACGGTGGTCTG  
 CTCTCTATGGGTCTTATGGGTGTATTACTCCTCCATCAACTTACTCTACAGAGAG  
 GGAAAGTAGGGCTGCTGTTCTATATGGTGATTATTCCACGCTAAACCCATTCA  
 45 AGCTTGAGGAACAGAGACATGAAGGAGGCTTGGTAAACTTTGTGAGTGGAAAAACA  
 TTCTTTATGA (SEQ ID NO: 212)

**AOLFR116 sequences:**

50 MDEANHSVSEVFVFLGLSDSRKIQLLLFLFFSVFYVSSLMGNLIVLTVTSDPRLQSP  
 MYFLLAN LSIINLVFCSSAPKMIYDLFRKHKTISFGGCVVQIFFIHAVGGTEM  
 VLLIAMAFDRYVAICKPLHYLTIMNPQRCILFLVISWIIGHSVIQLAFV  
 VDLLFCGPNELEDSFFCDLPRFIKLACIETYTLGFMV  
 TANSGFISLASFLIIISYIFILTVQKKSSGGIFKAFS  
 MLSA  
 HVI  
 VV  
 LVFGPLIFFYIFPFPTSHLD  
 KFLAIFDAVITPV  
 LNP  
 VIY  
 TFRN  
 KEM  
 MVAMRR  
 RCSQF  
 VNY  
 SKIF (SEQ ID NO: 213)

55 ATGGATGAAGCCAATCACTCTGTTGCTCTGAGTTGTGTTCTGGACTCTCTGACTCGC  
 GGAAGATCCAGCTCCTCCTCTTCTCAGTGTCTATGTTACAGCCTGATGGGA  
 AATCTCCTCATGGTCTGACTGTGACCTCTGACCCCTGTTACAGTCCCCATGTA  
 CTCTGCTGGCCAACCTTCCATCATCAATTGGTATTGTTCTCTCACAGCT  
 CCCAAGATGATT  
 ATGACCTTITCAGGAAGCACAAGACCATCTCTTGGGGCTGTGAGTT  
 TATCCATGCAGTTGGGGAACTGAGATGGTGTGCTCATGCC  
 ATGGCTTTGACCGATAT

WO 01/98526

GTGGCCATATGTAAGCCTCTCCACTACCTGACCACATGAACCCACAAAGGTGCATTTGT  
 5 TTTAGTCATTCCTGGATTATGGTATTACACTCAGTGAATCAGTTGGCTTTGGTGTAA  
 GACCTGCTGTTCTGGCCCTAATGAATTAGATAGTTCTTGTGATCTCCTCGATTAT  
 10 ATTCCTGGCTCTTTTAATTCTCATATCTTACATCTTATTTGGTACTGTCAGCTCATGTGG  
 AAAAAATCTTCAGGGTGTATTCAAGGCTTCTATGTCAGCTCATGTGGATT  
 TGGTTTGGCTTGGCCATTATCTTCTATATTTCCATTCCCACATCACATCTG  
 ATAAATCCTGCCATCTTGATGCAGTTACTCCGTTGAATCCAGTCATCTACT  
 TTAGAAATAAAGAGATGATGGTGGCAATGAGAAGACGATGCTCTCAGTTGTGAATTAC  
 15 AGTAAAATCTTAA (SEQ ID NO: 214)

## AOLFRI17 sequences:

MNNTIVFVIKIQIEKSDLKYRAISLQEISKISLLFWVLLVISRLLAMTLGNSTEVFYLLGFGA  
 QHEFWCILFIVFLIYVTSIMNSGILLINTDSRFQTLTYFFLQHLAFVDICYTSAITPKMLQSFT  
 15 EEKNLILFQGCVIQFLVYATFATSDCYLLAMMAVDPYVAICKPLHYTVMSRTVCIRLVAGSYI  
 MGSINASVQTGFTCSLSFCKNSINHFFCDVPPILALCSNVNDINIMLLVVFGSNLIFTGLVVIFS  
 YIYIMATILKMSSAGRKKSFSTCASHLTAVTIFYGTLQSYMLQSHSNSQENMKVAFIFYGTVI  
 PMLNPLIYSLRNKEVKEALKVIGKKLF (SEQ ID NO: 215)

20 ATGAATAACACTATTGTATTGTCAAAAATACAATAGAAAAAGTGAATTGAAATATA  
 GAGCCATTTCATTGCAAGAAATCTCAAAGATTCCCTCTGGTCTCTGGTC  
 ATTCTAGACCTTACTAGCCATGACACTAGGAAACAGCACTGAAGTCATGAATTCTATC  
 TTCTGGGATTGGTCCCAGCATGAGTTGGTGTATCTCTCATGTATTCTCTCATC  
 25 TATGTGACCTCCATAATGGTAATAGTGAATAATCTACTCATCAACACAGATTCCAGAT  
 TTCAACACACTCACGTACTTTCTACAACATTGGCTTGTGATATCTGTACACTCT  
 GCTATCACTCCAAAGATGCTCAAAGCTCACAGAAGAAAAGAATTGATATTTCAGG  
 GCTGTGTGATACAATTCTAGTTATGCAACATTGCAACCAGTGACTGTTATCTCTGGCT  
 ATGATGGCAGTGGATCCTATGTTGCCATCTGAAGCCCTCACTACTGAAATCATG  
 30 CCCGAACAGTCTGCATCCGTTGGTAGCTGGTCATACATCATGGCTCAATAATGCC  
 TGTCACAAACAGGTTTACATGTTACTGTCTCTGCAAGTCAAAGCATCAATCACTT  
 TCTGTGATGTCCTCCATTCTGCTCTCATGCTCAAATGTTGACATCAACATCATGTA  
 CTTGTTGCTTGTGGATCTAACCTGATATTCACTGGGTTGGTCATCTTCTACAT  
 35 CTACATCATGGCCACCATCTGAAAATGTCCTAGTCAGGAAGGAAAATCCTCTCA  
 ACATGTGTCCTCCACCTGACCGCAGTCACCATTTCTATGGGACACTCTTACATGTATT  
 GCAGTCTCATCTAAATAATCCAGGAAAATGAAAGTGGCTTATATTATGGCACA  
 GTTATTCCCATGTTAAATCTTAACTATAGCTGAGAAATAAGGAAGTAAAGCTT  
 TAAAAGTGTAGGGAAAAGTTATTAA (SEQ ID NO: 216)

## AOLFRI18 sequences:

40 MNHMSASLKIISNSKQFQVSEFILLGFPGIHSWQHWLSPLALLYLSALAANTLILIIWQNPQLQQ  
 PMYIFLGILCMVDMGLATTIPKILAFWFDAKVISLPEFAQIYIAHFFVGMESGILLCMADFDRY  
 VAICHPLRYPISIVTSSLILKATLFMVLRNLGVTPVPLAQRDYSCKNEIEHCLCSNLGVTSIA  
 CDDRRPNSICQLVLAWLMGSDLSLILSYLILYSVRLNSAEAAAKALSTCSSHLTLILFFYTIV  
 VVISVTHLTEMKATLIPVLLNVLHNIPPSLNPTVYALQTKELRAAFQKVLFALTKEIRS (SEQ ID  
 45 NO: 217)

ATGAATCATATGTCATCTCAAAATCTCAAATGCTCAAATTCCAGGTCTGAGTT  
 CATCCTGCTGGATTCCGGCATTCACAGCTGGCAACACTGGCTATCTCTGCCCTGGCA  
 50 CTACTGTATCTCTCAGCACTGCTGCAAACACCCATCCTCATCATCTGGCAGAACCC  
 TTCTTACAGCAGCCATGTATATTCTCTGGCATCCTCTGTATGGTAGACATGGCTGG  
 CCACACTATCATCCTAAGATCCTGGCATTCTCTGGTTGATGCCAAGGTATTAGCCTC  
 CCTGAGTGCTTGCTCAGATTATGCCATTCACTCTTGTGGCATGGAGTCTGGTATCCT  
 ACTCTGCATGGCTTGATAGATATGTGGCTATTGTCACCCCTTCGCTATCCATCAATTG  
 55 TCACCAAGTCCCTAATCTAAAAGTACCCCTTCGCTATGGTGTGAGAAATGGCTTATTGTC  
 ACTCCAGTGCCTGTGCTGCAAGCACAGCGTGATTATGCTCCAAGAATGAAATGAACACT  
 GCCTGTGCTCAACCTGGGGTCACAAGCCTGGCTGTGATGACAGGAGGCCAACAGCAT

TTGCCAGTTGGTCTGGCATGGCTTGAATGGGAGTGATCTAAGTCTTATTATACTGTCA  
 TATATTGATTCTGACTCTGACTTAGCTGAACCTAGCTGAAGCTGCAGCCAAGGCC  
 TGAGCACTTGAGTTCACATCTCACCCCTCATCTTACACTATTGTTGAGTGATT  
 5 TCAGTGACTCATCTGACAGAGATGAAGGCTACTTGATTCCAGTCTACTTAATGTGTTGC  
 ACAACATCATCCCCCTCCCTCAACCCCTACAGTTATGCACTTCAGACCAAAGAACCTAG  
 GGCAGCCTCCAAAAGGTGCTTTGCCCTACAAAAGAAATAAGATCTTAG (SEQ ID NO:  
 218)

**AOLFR119 sequences:**

10 MPLFNSLCWFPTIHVTPPSFILNGIPGLERVHVWISLPLCTMYIIFLVGNLGLVYLIYYEESLHHP  
 MYFFFGHALSLIDLTLTCTTLPNALCIFWFSLKEINFNACLAQMFFVHGFTGVESGVLMALMD  
 RYIAICYPLRYATTLPNIKAELATFLRGVLLMIPFPFLVKRLPFCQSNIISHTYCDHMSVVKL  
 SCASIKVNVIYGLMVALLIGVFDICCISLSYTLKAAISLSSDARQKAFSTCTAHISAIITYVPA  
 15 FFTFFAHRFGGHTIPPSLHIVANLYLLPPTLNPIVYGVTKQIRKSVIKFFQGDKGAG (SEQ ID  
 NO: 219)

ATGCCTCTATTAATTCAATTGCTGGTTCCAACAATTATGACTCCTCCATCTTAT  
 TCTTAATGGAATACCTGGCTGGAAAGAGTACATGTATGGATCCCTCCACTCTGCACA  
 20 ATGTACATCATCTTCTTGTGGGAATCTTGGTCTTGTACCTCATTTATTATGAGGGAGTC  
 CTTACATCATCCGATGTATTTTTGGCCATGCTCTCCCTCATGACCTCCTTACCTG  
 CACCACCACTCTACCCAATGCACTCGCATCTCTGGTCAGTCTCAAAGAAATTAACTTCA  
 ATGCTTGGCTGGCCAGATGTTCTTGTATGGGTCACAGGGTGTGGAGTCTGGGGTGC  
 CATGCTCATGGCTCTAGACCGCTATAGCCATTGCTACCCTTGCCTATGCTACCAACAC  
 25 TCACCAACCTATCATGCCAAGGGTGTGAGCTGCCACCTCCTGAGGGGTGTATTGCTGAT  
 GATTCCCTTCCCATTCTGGITAAGCGITTGCCCTTCTGCCAAGCAATTATCTCCATA  
 CGTACTGCGACCACATGCTGTAGTAAAGCTATCTTGTGCCAGCATCAAGGTCAATGTAAT  
 CTATGGCTAAATGGTTGCTCTGTATTGGAGTGTGACATTGTTGATATCTTGTCTT  
 30 ACACTTGATCTCAAGGCAGCGATGCCCTCTTGTACAGATGCTGCCAGAAGGCTT  
 CAGCACCTGCACTGCCATATATCTGCCATCATCACCTATGTTCCAGCATTCTCACTT  
 TCTTGGCCACCGTTTGGGGACACACAATTCCCTCTTGTACATCATTGTGGCTAAT  
 CTTATCTTCTTCCCAACTCTAAACCTATTGTTATGGAGTAAAGACAAAACAGAT  
 ACGCAAGAGTGTCAAAAGTTCTCCAGGGTGATAAGGGTGAGGTGA (SEQ ID NO: 220)

**AOLFR120 sequences:**

35 MQPYTKNWTQVTEFVMMGFAGIHEAHLLFFILFTMYLFTLVENLAIILVVGLDHRLRPMYF  
 FLTHLSCLEIWYTSVTVPKMLAGFIGVDGGKNISYAGCLSQLFIFTFLGATECFLLAAMAYDRY  
 VAICMPLHYGAFVSWGTCIRLAAACWLGVFLPILPIYLLSQLTFCGPVIDHFSCDASPLLALS  
 CSDVTWKETVDFLVSIAVLLASSMVIASYGNIVWTLLHIRSAAERWKAFSTCAAHLTVVSLF  
 40 YGTLFFMYVQTKVTSSINFNVVSVFVSVTPMLNPLIYSLRNKEVKGALGRVFSLNFWKGQ  
 (SEQ ID NO: 221)

ATGCAACCATATACCAAAAAACTGGACCCAGGTACTGAATTGTCATGATGGGCTTGCTG  
 GCATCCATGAAGCACACCTCCTCTTCTCATACTCTTCTCACCATGTACCTGTTACCTTG  
 GTGGAGAATTGGCCATCATTAGTGGGGTTGGACCAACCGACTACGGAGACCCATGT  
 45 ATTCTTCTGACACACTTGTCTGCCATTGAAATCTGGTACACTCTGTTACAGTGCCAAG  
 ATGCTGGCTGGTTTATTGGGGTGGATGGTGGCAAGAATATCTCTTATGCTGGTTGCCAT  
 CCCAGCTCTCATCTCACCTTCTGGGGCAACTGAGGTGTTCTACTGGCTGCCATGGCC  
 TATGATCGTTATGTGCCATTGTTATGCTCTCCACTATGGGCTTGTGCTCTGGGCAC  
 CTGCATCCGTCTGGCAGCTGCCATTGGCTGGTAGGTTCTCACACCCATCTGCCAATCT  
 50 ACCTCTTGTCTCAGCTAACATTGTGGCCAAATGTCATTGACCATTTCTCTGTGATGCC  
 TCACCCCTGCTAGCCTTGTGCTCAGATGTCACCTGGAAGGAGACTGTGGATTCTGG  
 TGTCTCTGGCTGTGCTACTGGCCTCTCATGGTACCTGCTGTGCTCTATGGCAACATCGTC  
 TGGACACTGCTGCACATCCGCTCAGCTGCTGAGCGCTGGAAGGCCCTCTACCTGTGCA  
 CTCACCTGACTGTGGTGAGCCTCTATGGCACTCTTATGTTATGTATGCCAGACCAAG  
 55 GTGACCTCCTCCATCAACTCAACAAGGTGGTATCTGTCTACTCTGTTACGCCAT

WO 01/98526

GCTCAATCCTCTCATCTACAGTCTTAGGAACAAGGAAGTGAAGGGAGCTGGGTCGAGTC  
 TTTCTCTCAACTTGGAAAGGGACAGTGA (SEQ ID NO: 222)

## AOLFR121 sequences:

5 MKRKNFTEVSEFIFLGFFSGKHQITLFWVFLTVYILTVANIIIVIICIDHHLHTPMYFFLSMLA  
 SSETVYTLVIVPRMILSILFHNQPISLAGCATQMFFFVILATNNCFLLTAMGYDRYVAICRPLRY  
 TVIMSKGLCAQLVCGSGIGLTMALVHTAMFNLPFCGTVVDFHFCDIYPVMKLSCIDTTINEII  
 NYGVSSFVIFVPIGLIFISYVLVISSILQIASAEGRKTFATVSHLTVVIVHCGASIAYLKPSES  
 SIEKDLVLSVTYIITPLNPVYSLRNKEVKDALCRVGRNIS (SEQ ID NO: 223)

10 ATGAAGAGAAAAGAACCTCACAGAACAGTGTAGAATTCACTTTCTGGGATTTCTAGCTTG  
 GAAAGCATCAGATAACCCCTTTGTGGTTTCTTAACGTCTACATTAACTCTGGTTGCT  
 AACATCATCATTGTGACTATCATCTGCATTGACCATCATCTCCACACTCCCATGTATTCTT  
 CCTAAGCATGCTGGCTAGTCAGAGACGGTGTACACACTGGTCACTGGCTATTGCCACGAATGCTT  
 TTGAGCCTCATTTCTACAACCAACCTATCTCCTGGCAGGCTGTGCTACACAAATGTTCTT  
 TTTGTTATCTGGCCACTAATAATTGCTCCTGCTTACTGCAATGGGTATGACCGCTATG  
 TGGCCATCTGCAGACCCCTGAGATAACTGTCATCATGAGCAAGGGACTATGCCCCAGCT  
 GGTGTGGGTCTTGGCATTGGTGTGACTATGGCAGTTCCATGTGACAGCCATGTT  
 AATTGCCCTGTGGCACAGTGGTAGACCACTTGTGACATTACCCAGTCATGA  
 AACTTCTGCATTGATACCACTATCAATGAGATAATAATTGGTGAAGTTCATTG  
 GATTGCTCAGCTGAGGGCGGAAGAAGACCTTGCACCTGTGCTCCACCTCACTG  
 GGTTATTGTCACGTGGCTGTGCCTCCATTGCCACCTCAAGCCGAAGTCAGAAAGTTCA  
 ATAGAAAAAGACCTTGTCTCTCAGTGACGTACACCATCATCACTCCCTGCTGAACCTG  
 25 TTGTTTACAGTCTGAGAAACAAGGAGTAAAGGATGCCCTATGCAGAGTTGTGGCAGAA  
 ATATTCTTAA (SEQ ID NO: 224)

## AOLFR122 sequences:

30 MEWENQTLVEFFLKGSVHPRLLELFFVLIFIMYVVILLGNGLLILISLDPHLHTPMYFFLGNL  
 SFLDICYTTSPSTLVSFLSERKTISFGCAVQMFLGLAMGTTECVLGMMAFDRYVAICNPLR  
 YPIIMSKNAVPMAGWSWFAGIVNSAVQTTFVQLPFCRKNVINHFSCEILAVMKLACADISGN  
 EFLMLVATILFTLMPLLLIVISYSLISSLKIHSSEGRSKAFSTCSAHLTVIIFYGTILFMYMKPKS  
 KETLNSDDLDATDKIISMFYGVMTPMNNPLIYSLRNKDVKAEVKHLPNRRFFSK (SEQ ID NO:  
 225)

35 ATGGAATGGAAAACCAACCATTCTGGGAATTCTGCTAACTTCATAATGTATGTTGCTACCTCTGGG  
 CAAGGCTGAGTTACTCTTAACTCAGCATCTGGACCTCACCTTACACCCCTATGACTCTT  
 AATGGTACTCTCATTTAACTCAGCATCTGGACATCTGCTACACCACCCCTATCCCTACACTAG  
 TCTGGGAACTCTCTTCTGGACATCTGGCTTCTGGCATGATGCCCTTGACCGCTATG  
 40 TGAGCTTCTTCAGAAAAGAAAGACCAACAGAGTGTGCTCTGGCATGAGCAAAATGCTT  
 GGCTTGGCCATGGGACAACAGAGTGTGCTCTGGCATGATGCCCTTGACCGCTATG  
 TGGCTATCTGCAACCCCTGAGATATCCCATCATGAGCAAAATGCTT  
 GGCTTGGGCTGTGCTGAGATCTGCAACTCTGCAAGTACAACATTTGAGTA  
 CAATTGCCCTCTGAGGAAGAATGTCAATCATGAGTCTGAAATTCTAGCTGT  
 45 GAAGTTGCCCTGTGACATCTCAGGCAATGAGTCTCTGAGTCTGAAATTCTAGCTGT  
 TTCACATTGATGCCACTGCTCTGAGTCTGAGTCTCTGAGTCTGAAATTCTAGCTGT  
 CAAGATTCACTCTGAGGGAGAAGCAAAGCTTCTCATGAGTCTGAAATTCTAGCTGT  
 GTGGTCAATATTCTATGGGACCATCTCTCATGAGTATATGAAGCCCAAGTCAAAGAGA  
 CACTTAATTCAAGATGACTGGATGCTACCGACAAATTATCATGAGTCTGAAATTCTAGCTGT  
 50 GACTCCCATGATGAATCTTAAATCACAGTCTAGAAACAAGGATGTGAAAGAGGCAGT  
 AAAACACCTACCGAACAGAACAGGTTCTTAGCAAGTGA (SEQ ID NO: 226)

## AOLFR123 sequences:

55 MYRFTDFDVSNISIYLNHVLFYTTQQAGDLEHMETRNSAMTEFFLVGLSQYPELQLFLFLCL  
 IMYMIILGNSLIITILDRLHTPMYFFLGNLSFLDICYTSSSIPPMLIIFMSERKSISFIGCALQM  
 VVSLGLGSTEVCVLLAVMAYDHYVAICNPLRYSIIMNGVLYVQMAAWSWIIGCLTSLLQTVLT

MMLPFCGNVIDHITCEILALLKLVCSGITINVILMTVTNIVSLVILLLIFISYVFILSSILRINCAE  
GRKKAFSTCSAHSIVVILFYGSALFMYMKPNSKNTNTSDEIIGLSYGVVSPMLNPIIYSLRNKEV  
KEAVKKVLSRHLHLLKM (SEQ ID NO: 227)

5 ATGTACAGATTACAGATTGATGTATCAAACATTCAATTACCTGAATCATGTCCTTT  
CTATACTACCCAGCAGGCAGGTGACCTAGAACACATGGAGACAAGAAATTACTGCCAT  
GACTGAATTCTTCTGGTGGGCTTCCAAATATCCAGAGCTCCAGCTTTCTGTCCTGC  
TCTGCCTCATCATGTACATGATAATCCTCCTGGAAATAGCCTCCTCATTATCATCACCAC  
TTGGATTCTGCCTCCATACTCCATGTATTCTTCTGGAAACCTCTCATTCTGGACAT  
10 CTGTTACACATCCTCATCCATTCTCAATGCTTATTATATTATGTCTGAGAGAAAATCCA  
TCTCCTCATTGGCTGTGCTCTGCAGATGGTTGTGTCCTTGGCTTGGCTCCACTGAGTGT  
GTCCTCCTGGCTGTGATGCCATGACCACTATGTGGCCATCTGCAACCCACTGAGGTACT  
CCATCATCATGAACGGAGTGCTGTATGTGCAAATGGCTGCATGGCCTGGATCATAGGCTG  
TCTGACCTCCATTGCAAACAGTCTGACAATGATGTTGCCTTCTGTGAGGAAATAATGTC  
15 ATTGATCATATTACCTGTGAAATTGGCCCTCTAAAACCTGTTGTCAGATATCACCAC  
CAATGTGCTTATCATGACAGTGCACAAATATTGTTCACTGGTATTCTTCACTGTTAATT  
TCATCTCCTATGTGTTATTCTCTCCATCCTGAGAATTAAATTGTGCTGAGGAAAGAAAG  
AAAGCCTCTCTACCTGTCAGCGCACTGATTGTGGCATCTTATTCTACGGTCAGCCCT  
20 TTTTATGTACATGAAACCCAAGTCAAAGAACACTAATACATCTGATGAGATTATTGGGCTG  
TCTTATGGAGTGTAAAGCCAATGTTAAATCCATCATCTAGCCTCAGGAATAAAGAGG  
TCAAAGAGGCTGTAAAGAAAAGTCCTGAGCAGACATCTGCATTATTGAAAATGTGA (SEQ  
ID NO: 228)

**AOLFR124 sequences:**

25 MNHSVVTTEFIILGLTKPELQGIFLFFLIVYLVAFLGNMLIIAKIYNNTLHTPMYVFLTLAVV  
DIICTSIIPKMLGMLTSENTISYAGCMYSQLFLFTWSLGAEMVLFTTMAYDRYVAICFPLHYST  
VMNHHCVCALLSMVMAIAVTNSWVHTALIMRLTFCGPNTIDHFFCEIPPLLALSCSPVRINEV  
MIVVADITLAIGDFILTCISYGFIVAILRIRTVEGKRKAFTCSSHLTVVTLYYSPVIYTYIRPASS  
YTFERDKVVAALYTLVTPTLNPMVYSFQNREMQAGIRKVFAFLKH (SEQ ID NO: 229)

30 ATGAATCACAGCGTTGTAACTGAGTTCAATTCTGGCCTCACCAAAAAGCCTGAACCTCC  
AGGAATTATCTCCTCTTTCTATTGTCTATCTGCTATCTGGCTTCTCGGCAACATGCTC  
ATCATCATTGCCAAATCTATAACACACCTGACATGCCATGTATGTTCTCTGAC  
ACTGGCTGTGTGGACATCATCTGCACAACAAGCATCATACCGAAGATGCTGGGACCAT

35 GCTAACATCAGAAAATACCATTTCATATGCAGGCTGCATGTCAGCTCTTCTGTCACA  
TGGTCTCTGGAGCTGAGATGGTTCTCTCACCACCATGGCCTATGACCGCTATGTGGCCA  
TTTGTCTCTCTTCACTACAGTACTGTTATGAACCACCATATGTGTGACCTGCTCAGC  
ATGGTCATGGCTATTGCACTGACCAATTCTGGTGACACAGCTTATCATGAGGGTGA  
CTTCTGTGGGCAAACACCATTGACCACTCTCTGTGAGATAACCCCATTGCTGGCTTG

40 TCCTGTAGCCCTGTAAGAATCAATGAGGTGATGGTGTATGTTGCTGATATTACCTGGCCA  
TAGGGGACTTTATTCTTACCTGCATCTCTATGGTTTATCATTGCTATTCTCCGTATC  
CGCACAGTAGAAGGCAAGAGGAAGGCCTCTCAACATGCTCATCTCACAGGGTG  
ACCCTTACTATTCTCTGTAATCTACACCTATATCCGCTCTCCAGCTACATTTGA  
AAGAGACAAGGTGGTAGCTGCACTCTACTCTGTGACTCCCACATTAAACCCGATGGTG

45 TACAGCTTCCAGAATAGGGAGATGCAGGCAGGAATTAGGAAGGTGTTGCATTCTGAAA  
CACTAG (SEQ ID NO: 230)

**AOLFR125 sequences:**

50 MTNQTQMMEFLVRFTEWVLLRLHALLFSIYLTAVLMLVIIILMILDHRLHMAMYFFLRH  
LSFLDLCISATVPKSILNSVASTDSISFLGCVLQLFLVVLLAGSEIGILTAMSYDRYAAICCPLHC  
EAVMSRGLCVQLMALSWLNRGALGLYTAGTFSLNFYGSDELHQFFCDVPALLKLTCSKEHAI  
ISVSVAIGVCYAFSCLVCIVVSYVYIFSAVLRISQRQRQSKAFSNCVPHLIVVTFLVTGAVAYL  
KPGSDAPSILDLLVSFVSYVAPPTLNPTVYCLKNKDIKSALSKVLWNVRSSGVMKDD (SEQ ID  
NO: 231)

WO 01/98526

ATGACCAATCAGACACAGATGATGGAATTCTGCTGTGAGATTACTGAGAATTGGGTGC  
 5 TCCTGAGGCTGCATGTTGCTCTCACTGATCTACCTCACGGCTGTGATGAATTAA  
 ACATTGTCCCTCTAGACCTGTGCTCATTCTGCCACAGTCCCAATCCATCTCCG  
 CTGCGCTCCACTGACTCCATCTCCTGGGGTGTGCTGAGCTCTTCTGGTA  
 10 TCTGCTGCCCCCTACACTGTGAGGCTGTGATGAGCAGAGGGCTGTGCTGAGCTTCTG  
 TCTGTCTGGCTAACAGAGGGCTGGACTCTGTACACAGCTGAAACATTCTCTG  
 AATTATGGCTGTGAGCTACATCAGTTCTGCGATGTCCTGCCACTAAAGCT  
 CACTGTTCTAAAGAACATGCCATCATTAGTGTGAGCTTCTGCTGTTAAGGAT  
 15 TTTCATGTTAGTTGCAATTGAGTTCTATGTGTACATTCTGCTGTTAAGGAT  
 ATCACAGAGACAGAGACAATCCAAGCCTTCAACTGTGTGCTCACCTCATGTTG  
 ACTGTGTTCTGTAACAGGTGCTGTGCTATTAAAGCAGGGCTGATGACCTCTAT  
 TCTAGACTTGTGGTGTGTTCTATTCTGTCACCTAACCTGAACCTGTATCT  
 ACTGTCGAAGAACAGGACATTAAATCCGCTGAGTAAGTCCTGGAATGTTAGAA  
 15 GCAGTGGGTAATGAAAGATGACTAA (SEQ ID NO: 232)

**AOLFR126 sequences:**

20 MFLYLCFIFQRTCEEMEEENATLLTEFVLTGFLHQPDCKIPLFLAFLVIYLITIMGNLGLIVLIW  
 KDPHLHPMLFLGSLAFVDAISSTVTPKMLNFLAKSKMISLSECMVQFFSLVTVCFL  
 ATMAYDRYVAICKALLYPVIMTNELCIQLLVLFIGGLLHALIHEAFSFRLTCNSNIIQHFYCDII  
 PLLKISCTDSSINFLMVFIFAGSVQVFTIGTILISYHILFTILEKKSIKGIRKA  
 25 VSTCGAHLLSVSLY YGPLTFKYLGSASPQADDQDMMESLFYTVVPLNPMIYSLRNKQVIASFTKMFKSNV (SEQ ID  
 NO: 233)

25 ATGTTCTTTACCTTGCTTACAGAGGACATGCAGTGAGGAGATGGAAGAGAAA  
 ATGCAACATTGCTGACAGAGTTGTTCTCACAGGATTTACATCACCTGACTGTA  
 30 ACCGCTCTCTGGATTCTGGTAATATATCTCATCACCATATGGGAATCTGGCTAA  
 TTGTTCTCATGGAAAGACCTCACCTCATATCCAATGTACTATTCTGGAGTTA  
 GCCTTGTGGATGCTCGTTATCATCCACAGTGACTCCAGATGCTGATCAACTTCTTAG  
 CTAAGAGTAAGATGATACTCTCTGAATGCTGATGGTACAATTCTCCCTGTA  
 35 GTAACCACAGAATGTTCTCTGGCAACAATGGCATATGCTGATGCTGATG  
 AAGCTTACTTATCCAGTCATTATGACCAATGAACTATGCATTGCTATTAGTCTGCA  
 TTTATAGGTGGCTTCTCATGTTAAATCCATGAAGCTTTCTCAGATAACCTCTG  
 TAATTCCAACATAATACAACACTTACTGTGACATTATCCATTGTTAAAGATTCTGTA  
 40 CTGATTCTCTATTAAACTTCTAAATGGTTTATTTCCAGGTTCTGTCAGTTTACCA  
 TTGGAACTATTCTATATCTTACAATTATCCCTTACAATCTTACAGAAAAGTCTAC  
 AAAGGGATACGAAAAGCTGTCTCACCTGTGGGCTATCTCTATCTGTATCTTACT  
 ATGGCCCCCTCACCTCAAATATCTGGCTCTGCATCTCGCAAGCAGATGACCAAGATAT  
 GATGGAGTCTCTATTACACTGTGATGCTTATTAAATCCATGATCTACAGCCTGA  
 45 GAAACAAGCAAGTAATAGCTTCAACAAAATGTCACAAAGCAATGTTAG (SEQ ID  
 NO: 234)

**AOLFR127 sequences:**

45 MSNEDMEQDNTLLTEFVLTGLTYQPEWKMPFLVFLVYLITVWNGLIALIWNPDQLHIPM  
 YFFLGLSLAFVDAISSTVTPKMLNFLAKNRMISLSECMVQFFSFAGGGTECFL  
 VAICKPLLYPVIMNNNSLCIRLLAFSFLGGFLHALIHEVLFRLTCNSNIIHFYCDIPLFMISCTD  
 PSINFLMVFILSGSIQVFTIVTVLNSYTFALFTILKKSVRGVRKAFSTCGAHLLSVSLY  
 50 YGPLRASPQADDQDMIDSVFYIIPLNPIYSLRNKQVIDSFTKMKVRNV (SEQ ID NO: 235)

50 ATGTCGAATGAGGACATGGAACAGGATAATACAACATTGCTGACAGAGTTGTCACA  
 GGACTTACATATGCCAGAGTGGAAAATGCCCTGTTCTGGTGTCTGGTATCTAC  
 TCATCACTATTGTGGAACCTTGGCTGATTGCTTATCTGGAAATGACCCACA  
 55 ATCCCCATGACTTTCTGGAGTTAGCCTTGTGATGCTTGGATATCTCTGTCAGT  
 AACTCCAAAATGTTGGTAATTCTGGCAAAACAGGATGATATCTCTGTCAGT  
 ATGATTCAATTCTCTGATTGGGAACACAGAAATGTTCTGGCAACAAT

5           GGCATATGATCGCTATGTAGCCATATGCAAACCTTACTATATCCAGTGATTAGAACAAAT  
 TCACTATGCATACGGCTGTTAGCCTCTCATTTAGGTGGCTTCCTCCATGCCTTAATTCA  
 TGAAGTCCTTATATTCAAGATTAACCTCTGCAATTCAACATAAACATCATTTACTGTG  
 ATATTATACCACTGTTATGATTCCTGTACTGACCCCTCTATTAAATTCTAATGGTTTTA  
 10           TTTGTCTGGCTCAATTCAAGGATTACCACTGTGACAGTCTTAATTCTACACATTGCT  
 CTTTCACAATCTAAAAAGAAGTCTGTTAGAGCGTAAGGAAAGCCTTCCACCTGTG  
 GAGCCCATCTCTTATCTGCTCTTATATTATGGCCCACTTATCTCATGTATTGCGCCCT  
 GCATCTCCACAAGCAGATGACCAAGATATGATAGACTCTGCTTTATACAATCATAATT  
 CTTGCTAAATCCCATTATCTACAGTCTGAGAAATAAACAGTAATAGATTCAACACAAA  
 15           AATGGTAAAAAGAAATGTTAG (SEQ ID NO: 236)

**AOLFR128 sequences:**

15           METQNLTUVTEFILLGLTQSQDAQLLVFVLVLIFYLILPGNFLIIFTIKSDPGLTAPLYFFLGNL  
 LLDASYSFIVVPRMLVDFLSEKKVISYRSCITQLFFLHFLGAGEMFLVVMADFDRYIACRPLHY  
 STIMNPRACYALSLVLWLGGFIHSIVQVALILHLPFCGPQLDNFFCDVPQVIKACTNTFVVEL  
 LMVSNSGLSLLCFLGLLASYAVILCIREHSSEGSKAISTCTTHIIIIFLMFGPAIFIYTCPFQAFP  
 ADKVVSLFHTVIFPLMNPVIYTLRNQEVKASMRKLLSQHMFC (SEQ ID NO: 237)

20           ATGGAAACACAGAACCTCACAGTGGTACAGAACATTCTTCTGGTCTGACCCAGTCTC  
 AAGATGCTCAACTCTGGCTTTGTGCTAGTCTTAATTCTACCTTATCCTCCCTGGA  
 AATTCTCATCTTACCATAAAGTCAGACCCCTGGGCTCACAGCCCCCTTATCTT  
 TCTGGCAACTTGGCCTTACTGGATGCATCCTACTCCTTATTGTGGTCCAGGATGTTG  
 GTGGACTTCTCTCTGAGAAGAAGTAATCTCCTATAGAACGTCATCACTCAGCTCTT  
 TCTTGCTATTCTTCTGGAGCGGGAGAGAGATGTTCTCTCGTTGTGATGGCTTGCACCGCTAC  
 25           ATCGCCATCTGCCGCCCTTACACTATTCAACCATCATGAACCTAGAGCCTGCTATGCAT  
 TATCGTTGGTCTGTGGCTTGGGGCTTATCCATTCCATTGTACAAGTAGCCCTTATCTG  
 CACTTGCCTTCTGTGGCCAAACCCAGCTCGATAACTCTCTGTGATGTTCCACAGGTCT  
 CAAGCTGGCCTGCACCAATACCTTGTGGAGCTCTGATGGTCTCCAACAGTGGCTG  
 CTCAGCCTCCTGTGCTTCTGGGCCCTCTGGCCTCCTATGCACTCCTCTGCGTATAAG  
 30           GGAGCACTCCTCTGAAGGAAAGAGCAAGGCATTTCCACATGCACCAACCATATTACATT  
 ATATTCTCATGTTGGACCTGCTATTCTACACTGTCATCTTCCAGGCTTCCAGGCTTCCAGC  
 TGACAAGGTAGTTCTCTTCCATACTGTCATCTTCCAGGCTTCCAGGCTTCCAGGCTTCCAGC  
 CGCTTCGCAACCAGGAGGTGAAAGCTTCCATGAGGAAGTTGTTAAGTCACATATGTTG  
 CTGA (SEQ ID NO: 238)

35

**AOLFR129 sequences:**

40           MALYFSLILHGMSDFFLSTGHPRASCRMEAMKLLNQSQVSEFILLGLTSSQDVEFLLALFSVI  
 YVVTVLGNLLIIIVTVFNTPNLNTPMYFLGNLSFVDMTLASFATPKVILNLLKKQKVISAGCFT  
 QIFLLHLLGGVEMVLLVSMAFDRYVAICKPLHYMTIMNKKVCVLLVVTWLGLLHSQFQIPF  
 AVNLPFCGPNVVDSIFCDLPLVTKLACIDIYFVQVVIVANSGIISLSCFIILLISYLILITKHNHSPT  
 QOSKARSTLTAHITVVLFFGPCIFIYTWPGNHSVDKFLAVFYTIITPILNPIIYTLRNKEMKISMK  
 KLWRAFVNSREDT (SEQ ID NO: 239)

45           ATGGCTCTTATTTCACACTCATCCATGGTATGAGTGTCTTTCTCTCTACAGG  
 TCATCCAAGAGCGAGCTGTAGGATGGAGGCCATGAAACTATTAAATCAATCTCAAGTGTCT  
 AGAATTCAATTGCTGGACTGACCAGCTCCAGGATGTAGAGTTCTCTCTTGCCTCT  
 TCTCGGTTATCTATGTGGTCACAGTTGGTAACCTCTTATTATAGTCACAGTGTAAAC  
 ACCCCTAACCTGAATACTCCCATGTATTCTCCTGGTAATCTCTCTTTGTAGATATGAC  
 CCTTGCTTCTTGCACCCCTAACGGTGAATTCTGAACCTGTTAAAAAGCAGAACAGGAATT  
 50           TCTTTGCTGGGTCTTCACTCAGATATTCTCCTTCACCTACTGGGTGGGGTTGAAATGGT  
 ACTGTTGGTCTCCATGGCTTGACAGATATGTGGCCATTGTAAGCCCTACACTACATG  
 ACCATCATGAACAAGAAGGTATGTGTTTGCTGTAGTGACCTCATGGCTCTGGGTCTCC  
 TTCACTCAGGGTTTCAGATACCATTGCTGTGAACCTGCCCTTGTGGTCCAAATGTGGTA  
 GACAGCATTGGTGAACCTCCCTGGTTACTAAGCTTGCCTGTATAGACATATATTGTT  
 55           ACAGGTAGTCATTGTTGCCAACAGTGGCATAATCTCCCTGAGCTGTTCATTATTGCTTA  
 TCTCCTACAGTCTGATCCTCATAACCATTAAAGAACCAACTCTCCTACTGGCAATCTAAAGC

WO 01/98526

CCGGTCCACTTGACTGCTCACATCACAGTGGTATTCTCTTGGCCCATGCATCTTTA  
 TCTACATTGGCCCTCGGCAACCACTCTGTAGATAAGTCTCTGCTGTGTTTATACCATC  
 ATCACTCTATCTGAATCCAATTATCTATACTCTGAGAAACAAAGAAATGAAGATATCCA  
 TGAAAAAACTCTGGAGAGCTTTGTGAATTCTAGAGAAGATACTTAG (SEQ ID NO: 240)

5

**AOLFR131 sequences:**

10

MASTSNVTELIFTGLFQDPAVQSVCVFVFLPVYATVVGNGLIVLTVSISKSLDSPMYFFLSCLS  
 LVEISYSSTIAPKFIIDLAKIKTISLEGCLTQIFFFHFFGVAEILLIVVMAYDCYVAICKPLHYMNI  
 ISRQLCHLLVAGSWLGGFCHSIIQILVIIQLPFCGPVIDHYFCDLQPLFKLACTDTFMEGVIVLA  
 NSGLFSVFSFLILVSSYIVILVNLRNHSAEGRHKALSTCASHITVILFFGPAlFLYMRPSSTFTED  
 KLVAVFYTVPMLNPIYTLRNAEVKIAIRRLWSKKENPGRE (SEQ ID NO: 241)

15

20

25

ATGGCCAGTACAAGTAATGTGACTGAGTTGATTTCAGTGGCCTTTCCAGGATCCAGCTG  
 TGAGAGTGTATGCTTGTGGTCTTCTCCCGTGTAACCTGCCACGGTGGTGGCAATGG  
 CCTCATCGTTCTGACGGTCAGTACAGCAAGAGTCTGGATTCTCCATGTACTCTTCCTTA  
 GCTGCTGTCTGGTGGAGATCAGTTATTCTCCACTATGCCCTAAATTCATAGAC  
 TTACTGCCAAGATTAAAACCCTCTCTGGAAAGGCTGTGACTCAGATATTCTTC  
 CTCTTGGGGTGTGAGATCCTTGTGATTGTGGTATGCCATGATTGCTACGTGGCC  
 ATTGCAAGCCTCTTCAATTATGAACTTACAGTCGTACTGTGACCTCTGGTGC  
 TGGTCTGGCTGGGGCTTGTCACTCCATAATTCAAGATTCTCGTTATCCTCAATTGC  
 CCTCTGTGGTCCAAATGTGATTGACCACTATTCTGTGACCTCCAGCCTTATTCAAGCTT  
 GCCTGCACTGACACCTCATGGAGGGGTTATTGTGTTGGCAACAGTGGATTATTCTCG  
 TCTTCCTCCATCTGGTCTCTTATATTGTCATCTGGTCAACTTGAGGAACCAT  
 TCTGAGAGGGAGGCACAAAGCCCTCTCCACCTGTGCTTCTCACATCACAGTGGTCATCT  
 TGTTTTGGACCTGCTATCTCCTACATGCGACCTCTCCACTTCACTGAAGATAAA  
 CTTGTGGCTGTATTCTACACGGTCATCCCCATGTAACCCCATCTTACACACTCAG  
 GAATGCAGAGGTGAAATGCCATAAGAAGATTGTGGAGCAAAAGGAGAATCCAGGG  
 GGGAGTGA (SEQ ID NO: 242)

30

**AOLFR132 sequences:**

35

MVATNNVTEIFVGFSQNWSERVISVMFLMLYTAVVLGNGLIVVILASKVLTSPMYFFLSYL  
 SFVEICYCSVMAPKLIFDSFIKRKVISLGCLTQMFSLHFVGGTEAFLLMVMAYDRYVAICKPL  
 HYMAIMNQRMCGLLVRIAWGGLLHSVGQTFLIFQLPFCGPIMDHYFCDVHPVLELACADT  
 FFISLLIITNGGSISVVSFFVLMASYLILHFLRSNLEQHKALSTCASHVTVDLFFIPCSLVYIR  
 PCVTLPADKIVAVFYTVPPLNPVYFSRNAEVKNAMRRFIGGKVI (SEQ ID NO: 243)

40

45

50

ATGGTTGCTACAAACAATGTGACTGAAATAATTCTGGGATTTCCAGAATTGGAGTG  
 AGCAGAGGGTCATTCTGTGATGTTCTCTCATGTACACAGCTGTGCTGGCAATGG  
 CCTCATGGGTGACCATCCTGCCAGCAAAGTGTACCTCCCCATGTATTCTTC  
 GCTACTTATCCTTGTGGAGATCTGCTACTGTTCTGTATGCCCTAACAGATGTTCTCC  
 TCCTTATCAAGAGGAAAGTCATTCTCTCAAGGGCTGCCACACAGATGTTCTCC  
 ATTCTTGTGGCACTGAGGCCCTCTCTGATGGTATGCCCTATGACCGCTATGTGG  
 CATCTGCAAGCCCTGCACATGCCATCATGGACCAACTCTGTGATGTCCACCCAGTGT  
 AGGATAGCATGGGGGGGGCTGCTGCAATTCTGTGGCAAAACCTCTGATTTCC  
 TCCCGTTCTGTGGCCCCAACATCATGGACCAACTCTGTGATGTCCACCCAGTGT  
 GCTGGCTGCGCAGACACCTCTCATTAGCCTGCTGATGGCTTACCTGATCAT  
 CCACAATTGGAGGGGAGCACAAGGCCCTCCACCTGTGCTCTCATGTGACCTCT  
 GACCTGTCTCATACCTGCTCTGGTCTATATTAGGCCCTGTGTCACCCCTGCAGA  
 CAAGATAGTGCTGTATTATACAGTGGTCACACCTCTTAAACCTGTGATTACTC  
 TCAGGAATGCTGAAGTGAAAATGCCATGAGGAGATTATTGGGGAAAAGTAATTGA  
 (SEQ ID NO: 244)

**AOLFR133 sequences:**

55

MTEFIFLVSPNQEVRVCFVFLFLYTAIVLGNFLIVLTVMTSRLGSPMYFFLSYLSFMEICYS  
 SATAPKLISDLLAERKVISWWGCMAQLFFLHFVGGTEIFLLTVMAJDHYVAICKPLSYTTIMN

WQVCTVLVGLAWVGGFMHSFAQILILFHLLFCGPNVINHYFCDLVPLLKLACSDTFLIGLLIVAN  
GGTLSVISFGVLLASYMVILLHLRTWSSEGWCALSTCGSHFAVVILFFGPCVFNSLRPSTTLPI  
DKMVAVFYTITAILNPVIYSLRNAEMRKAMKRLWIRTLRLNEK (SEQ ID NO: 245)

5 ATGACTGAATTCACTTCTGGTACTTCTCCAACCAGGAGGTGCAGAGGGTTGCTTG  
TGATATTCTGTTCTGTACACAGCAATTGTGCTGGGAATTCTCATTGTGCTACTGTC  
ATGACCAGCAGAACGCCCTGGTCCCCATGTACTTCTCCTCAGCTACCTCTCCTCATGGA  
GATCTGCTACTCCTCCGCTACAGCCCCAAACTCATCTCAGATCTGCTGGCTGAAAGGAAA  
GTCATATCTTGGTGGGCTGCATGGCACAGCTTCTTGCACCTCTTGGTGGACTGA  
10 GATTTCTGCTCACTGTGATGGCCTATGACCACTATGTGGCCATCTGCAAGCCCCTCAGC  
TACACCACCATCATGAACCTGGCAGGTGTACTGTCCTGTAGGAATAGCATGGTGGGA  
GGCTTCATGCATTCCCTGCACAAATCCTCTCATCTTCCACCTGCTCTCTGTGGCCCCAA  
TGTGATCAATCACTATTCTGTGACCTAGITCCCCTCTCAAACCTGCCTGCTGACACCT  
15 TCCTCATGGTCTGCTGATTGTCATGGCAGGACCCCTGTGTGATCAGTTGGGGT  
CCTCTAGCATCTATGGTCATCTGCTCCATCTGAGAACCTGGAGCTCTGAAGGGTGG  
TGCAAAGCCCTTCCACCTGTGGTCCCATTGCTGTGGTTATCTGTTCTTGGGCCCTG  
CGTCTCAACTCTCTGAGGCCTTCTACCAACTCTGCCATAGACAAGATGGTGGCTGTTCT  
ACACAGTGATAACCGCGATCCTGAACCTGTACACTCTCTGAGAAATGCTGAAATGAG  
GAAGGCCATGAAGAGGCTGTGGATTAGGACATTGAGACTAAATGAGAAATAG (SEQ ID  
20 NO: 246)

**AOLFR134 sequences:**

MTTILEVDNHTVTRFILLGFPTRPAFQLLFFSIFLATYLLTLENLLIILAIHSDGQLHKPMYFFL  
SHLSFLEMWYVTVISPKMLVDFLSDHKISFNGCMTQLYFFVTVCHEYILLAIAFDYVAIC  
25 NPLRYPVIMTNQLCGTLAGGCWFGLMTAMIKMVFLAQHLHYCGMPQINHYFCDISPLNVSC  
DASQAEMVDFFLALMVIAPLCVVVASYAILATILRIPSAQGRQKAFSTCASHLTVVILFYSMT  
LFTYARPKLMYAYNSNKVVSVLYTVIVPLLNPIIYCLRNHEVKAALRKTIHCRGSGPQNGAFS  
S (SEQ ID NO: 247)

30 ATGACCACCAATTCTGGAAGTAGATAATCATACTGACAACACGTTCTATTCTCTGG  
GGTTTCCAACACGACCAGCCCTCCAGCTCTTCTCCATTCTGCACCTATCTG  
CTGACACTGCTGGAGAACCTTCTATCATCTAGCTATCCACAGTGTGGCAGCTGCATA  
AGCCCCATGTACTTCTTGAGCCACCTCTCCCTGGAGATGTGGTATGTCACAGTCATC  
AGCCCCAAGATGCTGTTGACTCTCAGTCATGACAAGAGTATTCTCAATGGCTGCA  
35 TGACTCAACTTACTTTTGTGACCTTGTCTGCACTGAGTACATCCTCTGCTATCATG  
GCCTTGACCGCTATGTAGCCATTGTAATCCACTACGCTACCCAGTCATGACCAACC  
AGCTCTGTGGCACACTGGCTGGAGGATGCTGGTCTGTGGACTCATGACTGCCATGATTAA  
GATGGTTTTATAGCACAACCTCACTACTGTGGCATGCCAGTCAGATCAATCACTACTTTGTG  
ATATCTCTCCACTCCTAACGTCTCTGTGAGGATGCCACAGGCTGAGATGGTGGACTT  
40 CTTCTTGGCCCTCATGGTCATTGCTATTCTCTTGTGTTGTCATCCTACGCTGCTA  
TCCTTGGCCACCATCCTCAGGATCCCTCTGCTCAGGGCCCAAAGGCATTCTCACCTG  
TGCCTCCCACCTGACCGTCGTAATTCTCTTCTACACTTTCACCTATGCCGTC  
CCAAACTCATGTATGCCACAATTCCAACAAAGTGGTATCTGTTCTACACTGTCATTGTT  
45 CCACTCCTCAACCCCATCATTACTGTCTGAGGAACCATGAAGTAAAGGCAGCCCTCAGAA  
AGACCACATTCAGAGGAAGTGGGCCAGGGAAATGGGCTTCAGTAGTTAA (SEQ  
ID NO: 248)

**AOLFR135 sequences:**

MIFPSHDSQAFTSVDMEVGNCTILTEFILLGFSADSQWQPIFGVFLMLYLITLSGNMTLVILIRT  
50 DSHLHTPMYFFIGNLSFLDFWYTSVYTPKILASCVSEDKRISLAGCGAQLFFSCVVAYTECYLL  
AAMAYDRHAAICNPLLYSGTMSTAALCTGLVAGSYIGGFLNIAHTANTFRLHFCGKNIIDHFFC  
DAPPLVKMSCTNTRVYEKVLLGVVGFTVLSSILAILISYVNILLAILRIHSASGRHKAFSTCASHL  
ISVMLFYGSLLFMYSRPSSTYSLERDKVAALFYTVINPLLNPLIYSLRNKDIKEAFRKATQTIQPQ  
T (SEQ ID NO: 249)

WO 01/98526

ATGATTTCCCTCTCATGATAGTCAGGTTCACCTCCGTGGACATGGAAGTGGGAAATT  
 GCACCATCTGACTGAATTCATCTTGTGGGTTCTCAGCAGATTCCAGTGGCAGCCGAT  
 TCTATTGGAGTGTCTGATGCTCTATTGATAACCTGTCAAGAAACATGACCTGGTTA  
 5 TCTTAATCCGAAGTATTCCCACCTGCATACACCTATGACTTTTCACTGGCAATCTGTCT  
 TTTTGGATTCTGGTATACCTCTGTGTATACCCCCAAATCTGGCCAGTTGTCTCAGA  
 AGATAAGCGATTCTGGCTGGATGTGGGCTCAGCTGTTTCTGTGTCTCAGA  
 ACAGTGAATGCTATCTCCTGGCAGCCATGGCATATGACGCCATGCAGCAATTGTAAACC  
 10 ATTGCTTATTCAAGGTACCATGTCCACCCCTCTGTACTGGCTGTGCTGGCTCTACA  
 TAGGAGGATTITGAATGCCATAGCCCATACTGCCAATACATTCCGCTGCATTGTGG  
 TAAAAATATCAITGACCACTTTCTGTGATGCACCACATTGGTAAAAATGTCTGTACA  
 AACACCAGGGTCTACGAAAAGTCTGCTGGTGTGGCTCACAGTACTCTCCAGCA  
 15 TCTCTGCTATCTGATTCTCTATGTCAACATCCTCTGGCTATCTGAGAATCCACTCAGCT  
 TCAGGAAGACACAAGGCATCTCACCCTGTGCTCCACCTCATCTCAGTCATGCTCTCTA  
 TGGATCATTGTGTTATGATTCAAGGCCTAGTTCCACCTACTCCCTAGAGAGGGACAAA  
 GTAGCTGCTCTGTTACACCGTGTCAACCCACTGCTCAACCCCTCATCTATAGCCTGAG  
 AAACAAAGATATCAAAGAGGCCCTCAGGAAGCAACACAGACTATACAACCACAAACATG  
 A (SEQ ID NO: 250)

## AOLFR136 sequences:

20 MTMENYSMAAQFVLGLTQQAEQLPLFLFLGIYVVTVVGNLGMILLIASPLLHTPMYYFL  
 SSLSFVDFCYSSVTPKMLVNFLGKNTILYSECMVQLFFFVVAEGYLTAMA YDRYVAIC  
 SPLLYNAIMSSWVCSLLVLAFFLGFLSALHTSAMMKLSFCKSHIINHYFCDVPLLNLSCSNT  
 HLNELLFIAGFNTLVPTLAVAVSYAFLYSILHRSSEGRSKAFGTCSHLMMAVVIFFGSITFMY  
 FKPPSSNSLDQEKVSSVFTTVPMLNPLIYSLRNKDVKKALRKVLVGK (SEQ ID NO: 251)

25 ATGACCATGGAAAATTATCTATGGCAGCTCAGTTGCTTAGATGGTTAACACAGCAAG  
 CAGAGCTCCAGCTGCCCTCTCCTCTGGAAATCTATGTGGTCACAGTAGTGGG  
 30 CAACCTGGGCATGATTCTCTGATTGAGTCAGCTGCCCTACTTCACACCCCATGTACTATT  
 TCCTCAGCAGCTGCTCTCGTCGATTCTGCTATTCTCTGTCTATTACTCCAAAATGCTG  
 GTGAACCTCTAGGAAAGAAGAACATAATCTTACTCTGAGTGCATGGTCAGCTTTT  
 TCTTGTGGCTTTGTGGCTGAGGTTACCTCTGACTGCCATGGCATATGATCGCTA  
 TGTGCCATCTGAGCCACTGCTTAATGCGATCTGCCATGGCTGCTACTGC  
 35 TAGTGCTGGCTGCCCTCTGGCTTCTCTGACTCATACAAAGTGCATGATG  
 AAACGTCTCTGCTCAACACACACCTCAATGAGCTCTACTTTTATCATTGCGGGTTTA  
 CAATCTCTGCTCCACACACACCTCAATGAGCTCTACTTTTATCATTGCGGGTTTA  
 ACACCTGGTGCCTCACCTAGCTGCTGCTCTCTGCTTCACTCCTCTACAGCATCCT  
 CACATCCGCTCTCAGAGGGCCGGTCCAAAGCTTGGAACATGCAGCTCTCATCTG  
 40 CTGTGGTGTCTCTGGTCCATTACCTCATGTATTCAAGCCCCCTCAAGTAACCTC  
 CTGGACCAGGAGAAGGTGTCTGTGTCTACACCACGGTGTCCCCATGCTGAACCCCT  
 TAATATACAGTCTGAGGAATAAGGATGTGAAGAAGCATTAGGAAGGTCTAGTAGGAA  
 AATGA (SEQ ID NO: 252)

## AOLFR137 sequences:

45 MSPENQSSVEFLLLGLPIRPEQQAVFFALFLGMYLTTVLGNLLIMLIQLDSHLHTPMYFFLSH  
 LALTDISFSSVTPKMLMMNMQTQHLAVFYKGICSYFFIFFADLDSFLITSMAYDRYVAICHPL  
 HYATIMTQSQCVMVLAGSWVIACACALLHTLLAQLSFCADHIIHYFCDLGALLKLSCSDTSL  
 NQLAIFTAALTAIMLPFLCILVSYGHIGVTILQIPSTKGICKALSTCGSHLSVVIYRTIIGLYFLP  
 PSSNTNDKNIASVIYTAVTPMLNPIYSLRNKDIKGALRKLLSRSGAVAHAACNLSTLGG (SEQ  
 ID NO: 253)

50 ATGAGCCCTGAGAACCAAGAGCAGCGTGTCCGAGTTCTCTCTGGGCCTCCCCATCCGGC  
 CAGAGCAGCAGGCCGTGTTCTGCCCTGTTCTGGCATGTACCTGACCACGGTGTGGG  
 55 GAACCTGCTCATCATGCTGCTCATCCAGCTAGACTCTCACCTCACACCCCATGTACTCT  
 TCCTTAGCCACTTGGCCCTCACTGACATCTCTTTCATCTGCACTGCTCCCTAAGATGCTG  
 ATGAACATGCAGACTCAGCACCTAGCCGTCTTTACAAGGGATGCATTACAGACATATT  
 TTTCATATTTTGCTGACTAGACAGTTCTTATCACTCAATGGCATATGACAGGTAT

5                    GTGGCCATCTGCATCCTCTACATTATGCCACCATCATGACTCAGAGCCAGTGTGTCATGC  
 TGGTGGCTGGGCTGGTCATCGCTGTGCGTGTGCTCTTGCATACCCCTCCTGGCC  
 CAGCTTCCCTCTGTGCTGACCACATCATCCCTCACTACTTCTGTGACCTTGGTGCCCTGCT  
 CAAGTTGTCCCTGCTCAGACACCTCCCTCAATCAGTTAGCAATCTTACAGCAGCATTGACA  
 10                GCCATTATGCTTCATTCCATTCTGTGCATCCTGGTTCTTATGGTCACATTGGGTCACCACCT  
 CCAGATTCCCTCTACCAAGGGCATATGCAAAGCCTTGTCCACTTGTGGATCCCACCTCTCA  
 GTGGTGA CTTACTATTATCGGACAATTATTGGTCTCTATTCTCCCCATCCAGCAACAC  
 CAATGACAAGAACATAATTGCTTCAGTGATATAACACAGCAGTCACTCCATGTTGAACCCA  
 TTCATTACAGTCTGAGAAATAAGACATTAAGGGAGCCCTAAGAAAACCTTGAGTAGG  
 15                TCAGGCGCAGTGGCTCATGCCTGTAATCTCAGCACTTGGGAGGCTGA (SEQ ID NO: 254)

**AOLFR138 sequences:**

15                MLNFTDVTEFILLGLTSRREWQVLFFIVFLVVIITVVGNI GMMLIKVSPQLNSPMYFFLSHLS  
 FVDVWFSSNVTPKMLENLFSDKKTISYADCLAQCFFFIALVHVEIFILAAIAFDRYTVIGNPLLY  
 GSKMSRGVCIRLITFPYIYGLTSLTATLWTYGLYFCGKIEINHFYCADPPLIKMACAGTFVKEY  
 TMLILAGINFTYSLTVIISYLFILIAILRMRSAEGRQKAFSTCGSHPTAVIIFYGTLIFMYLRRPTE  
 ESVEQGK MVAVFYTTVIPMLNPIMYSLRNKDVKAMMKVISRSC (SEQ ID NO: 255)

20                ATGCTCAATTCAACCGATGTGACAGAGTTCAATTCTTGGGCTAACGAGGCCGTCGGGAAT  
 GGCAAGTTCTCTTCTCATCGTTTCTTGTGGTCTACATTATCACCGTGGTGGCAATATC  
 GGATGATGTTGTAATCAAGGTCACTCAGCTTAACAGCCCCATGTACTTTTCTCA  
 GTCACTTGTCAATTGTTGATGTGTGGTTCTCCAATGTCACCCCTAAATGTTGGA AAAT  
 CTGTTATCAGATAAAAAAAACAATTCTTATGCTGGCTTTAGCACAGTGTTCTTCTCAT  
 TGCTCTGTCCATGTGGAAATTTTATTCTGCTGCGATTGCCATTGATAGATAACAGTGA  
 25                TTGGAAATCCTTGCCTTATGGCAGCAAATGTCAAGGGATGTCGTATTGACTGATTAC  
 TTTCCCTTACATTATGGTTCTGACGAGTCTGACAGCAACATTATGGACTTATGGCTTGT  
 ACTTCTGTGGAAAATTGAGATCAACCATTCTACTGTGCA GATCCACCTCTCATCAAAAT  
 GGCCTGTGCCGGGACCTTGTAAAAGAATATACAATGCTCATACTGCCGGCATCAACTTC  
 30                ACATATTCCCTGACTGTAATTATCATCTTACTTATTCTCATCCTCATTGCCATTGCGAAT  
 GCGCTCAGCAGAAGGAAGGCAGAAGGCCTTCCACATGTGGTCCCCTGACAGCTGT  
 CATCATATTCTATGGTACTCTGATCTCATGTACTCAGACGTCCCACAGAGGAGTCTGT  
 GAGCAGGGGAAGATGGTGGCTGTGTTCTATACCACAGTGATCCCCATGTTGAATCCCATGA  
 TCTACAGTCTGAGGAACAAGGATGTGAAAAGGCCATGATGAAAGTGATCAGCAGATCAT  
 GTTAA (SEQ ID NO: 256)

35

**AOLFR139 sequences:**

40                MGFPGIHSWQHWSLPLALLYLLALSANILILIINKEAALHQPMYYFLGILAMADIGLATTIMP  
 KILAILWFNAKTI SLLCFAQMYAIHCVAMESSTFVCMAIDRYVAICRPLR YPSIITESFVFKAN  
 GFMALRNSLCLISVPLLAQRHYCSQNQIEHCLCSNLGVTSLSDDRRINSINQVLLAWTLMGS  
 DLGLIILSYALILYSVLKLN SPEAASKALSTCTSHLILFFYTVIIVISITRSTGMRVPLIPVLLNVL  
 HNVIPPALNP MVYALKNKELRQGLYKVLRLGVKGT (SEQ ID NO: 257)

45                ATGGGATTCCCTGGCATTACACAGTTGGCAGCACTGGCTCTCCCTGCCCTGGCTCTGCTCT  
 ACCTCTTAGCTCTCAGTGCCAACATCCTTATCCTGATCATCAACAAAGAGGCAGCACT  
 GCACCA GCCTATGTA CTTGGGCATCTTGGCTATGGCAGACATAGGCCTGGCTACC  
 ACCATCATGCCTAAGATTGGCCATCTATGGTCAATGCTAAGACCATCAGTCTCCTGG  
 AGTGCTTGCTCAGATGTATGCCATACATTGCTTGTGGCCATGGAATCAAGTACCTTGT  
 CTGCATGGCTATTGATAGATATGTAGCCATTGTCGACCGCTACGATATCCATCAATCATC  
 ACTGAATCTTTGTTTCAAAGCAAATGGGTCA TGGCACTGAGAAACAGCCTGTGCTCA  
 50                TCTCAGTGCCTCTGTTGGCTGCCAGAGGCATTACTGCTCCAGAACATTGAGCACTG  
 TCTTGTCTAACCTTGGAGTCACTAGCCTATCTGTGATGATCGAAGAACATAGCATT  
 AACCAAGGTCCCTTGGCTTGGACACTCATGGGAAGTGACCTGGTTGATTATTTATCAT  
 ATGCTCTAACACTTACTCTGCTCTGAAGCTGAACCTCCAGAACAGCTGCATCCAAGGCCTT  
 AAGTACCTGCACCTCCCACCTCATCTTAATCTTCTACACAGTCATCTGATTT  
 55                CCATTACTCGTAGTACAGGAATGAGAGTTCCCTTATTCCAGTTACTTAATGTGCTACA

WO 01/98526

CAATGTCATTCCCCCTGCCCTGAACCCCATGGTATATGCACTCAAGAACAGGAACCTCAGG  
 CAAGGCTTATACAAGGTACTAGACTGGGAGTGAAGGCACCTGA (SEQ ID NO: 258)

## AOLFR140 sequences:

5      MLTLNKTDLIPASFILENVPGLEDTQLWISFPFCSMYVVAMVGNCGLYLHYEDALHKPMYY  
 FLAMLSFTDLMCSSTIPKALCIFWFHLKDGFDECLVQMFIIHTGMESGVIMLMALDRYV  
 AICYPLRYSTILTPVIAKVGTATFLRGVLLIIPFTFLTKRLPYCRGNILPHTYCDHMSVAKLSCG  
 NVKVNAYGLMVALLIGGFIDLCITISYTMILRAVVSLSADARQAFNTCAHICAIVFSYTPAF  
 FSFFSHRFGEHIIPPSCHIVANIYLLPPTMNPIVGVKTKQIRDGVIRILSGSKDTKSYSM (SEQ  
 10     ID NO: 259)

ATGCTAACACTGAATAAACAGACCTAACACAGCTTCAATTCTGAATGGAGTCCCAG  
 GACTGGAAGACACACAACACTGGATTCCCTCATTCTGCTCTATGTATGTTGGCTAT  
 15     GGTAGGAAATTGGACTCCTCACCTCATTCACTATGAGGATGCCCTGCACAAACCCATG  
 TACTACTTCTGGCCATGTTCTTACTGACCTTGTATGTGCTCTAGTACAATCCCTAA  
 AGCCCTCTGCATCTCTGGTTCATCTCAAGGACATTGGATTGTATGAATGCCTGTCCAG  
 ATGTTCTCATCCACACCTCACAGGGATGGAGTCTGGGTCTATGCTTATGGCCCTGG  
 20     ATCGCTATGTGGCCATCTGCTACCCCTACGCTATTCAACTATCCTACCAATCCCTGAATT  
 GCAAAGGTTGGGACTGCCACCTCTGAGAGGGTATTACTCATTATCCCTTACTTCT  
 TCTGTAGCCAATTGCTCTGTGGAATGTCAAGGTCAATGCCATCTATGGTCTATGGTTG  
 CCCTCCTGATTGGGGCTTGCACATACTGTGATACCACTCTCCTATACCATGATTCTCCGG  
 25     GCAGTGGTCAGCCTCTCCAGCAGATGCTGGCAGAAGGCCTTAATACCTGACCATG  
 ACATTGTGCCATTGTTCTCCTATACTCCAGCTTCTCCTTACCTGACATGCTTACCTG  
 GGGAACACATAATCCCCCTCTGCCACATCATTGAGCCAATTATCTGCTTACCA  
 CCCACTATGAACCCATTGCTATGGGTGAAAACCAACAGATACTGAGACTGTGTCAA  
 GGATCCTTCAGGTCTAAGGATACCAATCCTACAGCATGTGA (SEQ ID NO: 260)

## AOLFR141 sequences:

30     MSSTLGHNMESPNTDVPDVFFLGPGLQFHLWLSLPVCGLTATIVGNITLVVVATEPVL  
 HKPVYFLCMLSTIDLAASVTPKLLAIFWCGAGHISASACLAQMFFIHAFCMMESTVLLAM  
 AFDRYVAICHPLRYATLTDIIAHIGVAAVVRGSLMLPCFLIGRLNFCQSHVILHTYCEHMA  
 VVKLAGDTRPNRVYGLTAALLVIGVDLFCIGLSYALSAQAVRLSSHEARSKALGTCGSHVC  
 VILISYTPALFSFFTHRGHHVPHILLANVYLLPPALNPVYGVKTKQIRKRVVRFQSGQ  
 35     GMGIKASE (SEQ ID NO: 261)

ATGTCAGCACTTGGCACAACATGGAATCTCTAACACACTGATGTTGACCCCTCTG  
 TCTTCTCCTCTGGCATCCAGGTCTGGAACATTCAATTGTTGGCTCTCACCTCTG  
 40     TGTGGCTTAGGCACAGCCACAATTGTGGCAATAACTATTCTGGTGTGTTGCCACTG  
 AACAGTCTGCACAAGCCTGTGACCTTCTGCTCATGCTCTCACCATCGACTGGCT  
 GCCTCTGCTCCACAGTCCCAAGCTACTGGCTATCTCTGGTGTGGAGCCGGACATATAT  
 CTGCCCTGCTGCCCTGGCACAGATGTTCTCATTGATGCCACTGCCACCCACTCCGCTATGCCA  
 GTGCTACTGGCATGCCCTTGATCGCTACGTGGCATCTGCCACCCACTCCGCTATGCCA  
 CAATCCTCACTGACACCACATGCCACATAGGGTGGCAGCTGATGGAGTCCACT  
 45     GCTCATGCTCCCATGCCCTCTTATTGGCGTTGAACCTCTGCCAAAGCCATGTGATCC  
 TACACACGTAATGTGAGCACATGGCTGGTGAAGCTGGCTGTGGCATGGAGGCTCCCT  
 ACCGTGTATGGGTGACAGCTGCACTGTGCTGGTCACTGGTCTGGTCACTGGGTTGACTGTTG  
 TCTCTCCTATGCCCTAAGTGACAAGCTGCTCTGCCCTCTCATGGGGTTGACTGTTG  
 50     AGGCCCTAGGGACCTGTGGTCCCATGCTGTGCTCATCTCTATACACCAGCCCTC  
 TTCTCTTACACACCCTGGCCATACGTTCCAGTCCATATTCAACATTCTTGGCATTGG  
 CAATGTTATCTGCTTITGCCACCTGCTTAAATCTGTGGTATATGGAGTTAACCAAC  
 AGATCCGTAAGAGGTGTCAGGGTGTCAAAGTGGCAGGGATGGCATCAAGGCAT  
 CTGAGTGA (SEQ ID NO: 262)

**AOLFR143 sequences:**

5 MLGLNGTPQPATLQLTGIPGIQTGLTWVALIFCILYMISIVGNLSILTVFWEPALHQPMYYFL  
 SMLALNDLGVSFSTLPTVISTFCFNYNHVAFNACLVQMFFIHTFSFMESGILLAMSLDRFVAICY  
 HVNNIYGLLVIIFTYGMDSTFILLSYALILRAMLVIISQEQRLKALNTCMSHICAVLAFYVPIIAVS  
 10 MIHRFWKSAPPVHVMMMSNVYLFVPPMLNPIIYSVKTKEIRKGILKFFHKSQA (SEQ ID NO:  
 263)

15 ATGCTGGTCTCAATGGCACCCCTCCAGCCAGCAACACTCCAGCTGACAGGCATTCCTG  
 GGATACAAACAGGCCTCACCTGGGTTGCCCTGATTCTGCATCCTCATGATCTCCATT  
 GTAGGTAACCTCAGCATTCTCACTCTGGTTGGGAGCCTGCTGCATCAGCCCATGT  
 ACTACTCCCTCTATGCTCGCTCAATGATCTGGAGGTGTCCTTCTACACTTCCACT  
 GTGATTCTACTTCTGCTCAACTACAACCATGTTGCGTTAATGCTGCCTGGTCCAGAT  
 20 GCTTGTGGCTATTGTTATCCATTACGCTATGTCAGTGTGCTCACTCACAAACCGTATATTG  
 GCTATGGGTCTGGGCATCCTTACCAAGAGTTTACCAACTCTCTCCCTTCCCTTGTGGT  
 GAAACGACTGCCCTCTGCAAAGGCAATGTTGATCACTCCTACTGTCTCCATCCAGAT  
 CTCATGAAAGTAGCATGTGGAGACATCCATGTTAACACATTTATGGGCTTGGTGATCA  
 TTTTACCTATGGTATGGACTCAACTTCATCCTGCTTCCATCGCATTGATCCTGAGAGCC  
 25 ATGCTGGTCATCATATCCCAGGAACAGCGGCTCAAGGCACTCAACACCTGCATGTCACACA  
 TCTGTGCAGTGCTGGCTTTATGTGCCATAATTGCTGTCCATGATTACCGCTCTGG  
 AAAAGTGTCCACCTGTTGTTCATGTCATGATGTCCAATGTCTACCTGTTGTACCAACCAT  
 GCTCAACCCATCATCTACAGTGTGAAAACCAAGGAGATCCGCAAAGGGATTCTCAAGTTC  
 TTCCATAAAATCCCAGGCCTGA (SEQ ID NO: 264)

**AOLFR144 sequences:**

30 MGLFNVTHPAFFLLTGIPGLESSHSWLSGPLCVMYAVALGGNTVILQAVRVEPSLHEPMYYFL  
 SMLSFSDVAISMATLPTVLRFCLNARNITFDACLIQMFLIHFFSMMESGILLAMSFDRYVAICD  
 PLRYATVLTTEVIAAMGLGAAARSFITLFPLPFLIKRLPICRSNVLSHSYCLHPDMMRACADISI  
 NSIYGLFVLVSTFGMDLFFIFLSYVLILRSVMATASREERLKALNTCVSHILA  
 VLAFYVPMIGVS  
 TVHRGKHVPCYHVLMNSNVYLFVPPVLNPLIYSAKTKEIRRAIFRMFHIIKI (SEQ ID NO: 265)

35 ATGGGGTTGTTCAATGTCACTCACCCCTGCATTCTCCTCCGTACTGGTATCCCTGGTCTGG  
 GAGCTCTCACTCCTGGCTGTCAGGGCCCTCTGCGTGTGATGTTGCTGTGGCCCTGGGG  
 AATACAGTGATCCTGCAGGCTGTGCGAGTGGAGGCCAGCCTCATGAGCCCATGTACTACT  
 TCCGTCCATGTTGCTTCAGTGATGTTGCCCCATATCCATGGCCACACTGCCACTGTACTC  
 CGAACCTCTGCCTCAATGCCGAAACATCACTTTGATGCCTGCTAATTCAAGATGTTCT  
 TATTCACTCTCCATGATGGAATCAGGTATTCTGCTGGCCATGAGTTTGACCGCTATG  
 40 TGGCCATTGACCCCTTGCCTATGCAACTGTGCTCACCCTGAAGTCATTGCTGCAAT  
 GGGTTAGGTGCACTGCTCGAAGCTCATCACCCCTTCCCTCCCTTCTATTAAAGA  
 GGCTGCCTATCTGCAGATCCAATGTTCTCACTCCTACTGCCTGCACCCAGACATGATG  
 AGGCTTGCCGTGCTGATCAGTATCAACAGCATCTATGGACTCTTGTCTTGTATCCAC  
 CTTGGCATGGACCTGTTTATCTCCTCTCATGTCATTCTGCCTGTCTCATGG  
 45 CCACTGCTCCCGTGAAGAACGCCCTCAAAGCTCTCAACACATGTGTGTCACATATCCTGG  
 TGACTTGCATTGCAATTGATGCAACTGATGGGTCTCCACAGTGCACCGCTTGGAAAGCAT  
 GTCCCATGCTACATACATGCTCATGTCAAATGTGTACCTATTGTCCTGTGCTCAA  
 CCCTCTCATTTAGCGCCAAGACAAAGGAATCCGCCAGCCATTCCGATGTTCAC  
 CACATCAAAATATGA (SEQ ID NO: 266)

WO 01/98526

## AOLFR145 sequences:

5 MSVQYSLSPQFMLSNTQFSPIFYLTSFPGLEGIKHWIFIPFFFMYMVAISGNCFILIIKTNPRLH  
 TPMYYLLSLLALTDLGLCVSTLPTTMGIFWFNSQSIFYGACQIQMFCIHSFSFMESSVLLMMSFD  
 RFVAICHPLRYSVIITGQQVVRAGLIVIFRGPVATIPVLLKAFPYCGSVVLSHSFCLHQEVQLA  
 10 CTDTTFNNLYGLMVVVFTVMLDLVLIALSYGLILHTVAGLASQEEQRRAFQTCAHLCAVLVP  
 FVPMMGLSLVHRFGKHAPPAIHLMANVLFVPPMLNPIIYSIKTKEIHRAIKLLGLKKASK  
 (SEQ ID NO: 267)

15 ATGTCAGTCCAATATCGCTCAGTCCTCAATTAGTCAGTCATCCAACATTACTCAGTTAG  
 CCCCATATTCTATCTCACCACTTCTGGATTGGAGGCATCAAACACTGGATTTCATCC  
 CCTTTTCTTATGTACATGGTGCACACACCCATGACTATCTACTATCCTGCTGGCCCTACTGACCT  
 ACCAACCTCGTCTGCACACACCCATGACTATCTACTATCCTGCTGGCCCTACTGACCT  
 20 GGGGCTGTGTGTCCACGTTGCCACCCTATGGGATCTCTGGTTAACCTCCAGAGT  
 ATCTACTTTGGAGCGTGTCAAATCCAGATGTTCTGCATCCACTCTTTCTCATGGAGTC  
 CTCAGTGCCTCATGATGTCCTTGACCGCTTGTGGCATCTGCCACCCCTGAGGTATT  
 CGGTCAATTACTGCCAGCAAGTGGTCAAGCAGGCCAATTGTCATCTCCGGGACC  
 TGTGGCACTATCCCTATTGTCCTCTCTGAAGGCTTTCCCTACTGTGGATCTGGTCC  
 25 TCTCCCACTCATTTGCCTGCACCAGGAAGTGATACAGCTGGCCTGCACAGATACCACCT  
 CAATAATCTGTATGGACTGATGGTGTAGTTTCACTGTGATGCTGGACCTGGTCTCATC  
 GCACTGTCCATGGACTCATCTGCACACAGTAGCAGGCCCTGCCAACAGAGGAGCAGC  
 GCGTGCCTTTCAGACATGCACCGCTCATCTGTGCTGTGCTAGTATTCTGTGCCATG  
 ATGGGGCTGTCCCTGGTGCACCGTTGGAAAGCATGCCCACTGCTATTCACTCTCTAT  
 GGCAATGTCTACCTTTGTGCCTCCATGCTTAACCAATCATATACAGCATTAAGACC  
 AAGGAGATCCACCGTGCCTATTCAAACCTCTAGGTCTAAAAGGCCAGTAAATGA (SEQ  
 25 ID NO: 268)

## AOLFR146 sequences:

30 MSQVTNTTQEGLYFILTDIPGFEASHIWISIPVCCLYTISIMGNTTILT VIRTEPSVHQRMYLFLSM  
 LALTDLGLTTLPTVMQLLWFNVRRISEACFAQFFFHLGFSFMESSVLLAMSVDCYVAICCP  
 LHYASILTNEVIGRTGLAIICCVLAVLPSLFLKRLPFCHSHLRSYCLHQDMIRLVCADRLN  
 SWYGFALALLIIVDPLLIVISYTLILKNILGTAWERLRAALNNCLSHILAVLVIYPMVGVSMT  
 HRFAKHASPLVHVIMANIYLLAPPVMNPIIYSVKNQIQWGMLNFLSLKNMHSR (SEQ ID NO:  
 269)

35 ATGTCAGGTGACTAACACCACACAAGAAGGCATCTACTTCATCCTCACGGACATCCCTG  
 GATITGAGGCCCTCCACATCTGGATCTCCATCCCCCTGCTGCTCTACACCATCTCCATC  
 ATGGGCAATACCACTCCACTGTCACTGCACAGAGCCATCTGCCACCCAGCGCATGT  
 ATCTGTTCTCTCCATGCTGGCCCTGACGGACCTGGCTCACCCCTACCCACCA  
 GTCATGCAGCTCTCTGGTCAACGTTCTGAGAATCAGCTCTGAGGCCCTTTGCTCAGTT  
 40 TTTCTCTCATGGATTCTCTTATGGAGTCTCTGCTCTCTGGCTATGTCCTGACT  
 GCTATGTGGCCATCTGCTGCTCCCTCATTATGCCTCCATCTCACCAATGAAGTCATTGGT  
 AGAACTGGGTAGCCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT  
 CAAGCGACTGCCCTCTGCCACTCCCACCTTCTCTCGCTCTTATGCTCCACCCAGGATA  
 TGATCCGCTGGTCTGCTGACATCAGGCTAACAGCTGGTATGGATTGCTCTGCCT  
 45 GCTCATTATTATCGTGGATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT  
 TCTGGCACGCCACTGGCTGAGCGACTCCGTCCTCAATAACTGCCCTGCTCCACAT  
 TCTAGCTGCTGGTCTCTACATCCCCTGGTGTATCTATGACTCATGCTGGCCT  
 AGCATGCCCTCCACTGGTCCATGTTATCATGGCAATATCACCTGCTGGCACCCGGT  
 GATGAACCCCATCATITACAGTGTAAAGAACAAAGCAGATCCAATGGGAATGTTAAATT  
 50 CTTCCCTCAAAATATGCATTCAAGATGA (SEQ ID NO: 270)

## AOLFR147 sequences:

55 MPSASAMIIIFNLSSYNPGPFLVGIPGLEQFHVWIGIPFCIYIVAVVGNCLILYLVVEHSLHEPMF  
 FFLSMLAMTDLILSTAGVPKALSIFWLGAIREITPGCLTQMFFLHYNFVLDSDLAMAFDHYV  
 AICSPLRYTTILTPKTIKSAMGISFRSFCILPDVFLTCLPFCRTIIPHTYCEHIGVAQLACADISI  
 NFWYGFVPIMTVISDVILIAVSYAHILCAVGLPSQDACQKALGTCGSHVCILMFYTPAFFSI

LAHRFGNVSRTFHIMFANLYIVIPPAALNPMVYGVTKQIRDKVILLFSKG TG (SEQ ID NO: 271)

5 ATGCCATCTGCCTCTGCCATGATCACTTCAACCTGAGCAGTTACAATCCAGGACCCCTCAT  
TCTGGTAGGGATCCCAGGCCTGGAGCAATTCCATGTGTGGATTGAAATTCCCTCTGTATC  
ATCTACATTGTAGCTGTGGAAACTGCATCCTCTACCTCATTGTGGTGGAGCATA  
GTCTCATGAACCCATGTTCTCTCCATGCTGCCATGACTGACCTCATCTGTCC  
ACAGCTGGTGTGCCTAAAGCACTCAGTATCTTGGCTAGGGCTCGCGAAATCACATTCC  
CAGGATGCCCTACACAAATGTTCTCCTCACTATAACTTGTCTGGATTGCCATTCTG  
10 ATGGCCATGGCATTGATCACTATGTAGCTATCTGTTCTCCCTGAGATATACCACCATCTT  
GACTCCAAGACCATCATCAAGAGTGCTATGGGCATCTCCTTCGAAGCTCTGCATCATC  
CTGCCAGATGTATTCTGCTGACATGCCCTGCCTTCTGCAGGACACGCATCATACCCACA  
CATACTGTGAGCATATAGGTGTTGCCAGCTGCCGTGCTGATATCTCCATCAACTTCTG  
GTATGGCTTTGTGTTCCATCATGACGGTCATCTCAGATGTGATTCTCATTGCTGTTCCCT  
15 ACGCACACATCCTCTGTGCTGCTTGGCCTCCCAAGATGCCGCCAGAAAGCCCT  
CGGCACCTGTGGTCTCATGTCGTGTCATCCTCATGTTTATACACCTGCCCTTCTCCA  
TCCTGCCCATCGCTTGGACACAAATGTCCTCGCACCTCCACATCATGTTGCCAATCTC  
TACATTGTTATCCCACCTGCACTCAACCCATGGTTACGGAGTGAAGACCAAGCAGATCA  
GAGATAAGGTTATACTTTGTTCTAAGGGTACAGGATGA (SEQ ID NO: 272)

20

**AOLFR148 sequences:**

MPTVNHSCTSHTVFHLLGIPGLQDQHMWISIPFFISYVTALLGNSLLIFIILTKRSLHEPMYLFLC  
MLAGADIVLSTCTIPQALAIFWFRAGDISLDRCTQLFFIHSTFISESGILLVMAFDHYIAICYPLR  
YTTILTNALIKKICVTVSLRSYGTIFPIIFLLKRLTFCQNNIIPHTFCHEIGLAKYACNDIRINIWYG  
25 FSILMSTVVLVVLIFISYMLILHAVFHMPSPDACHKALNTFGSHVCIILFYGGIFTILTQRFGR  
HIPPCIHPLANVCILAPPMLNPITYGIKTQIQEQQVQFLFIKQKITLV (SEQ ID NO: 273)

30

ATGCCTACTGTAAACCACAGTGGCACTAGCCACACAGTCTTCCACTTGCTGGGCATCCCTG  
GCCTACAGGACCAGCACATGTGGATTCTATCCATTCTCATTCCTATGTCACCGCCCTT  
CTTGGGAACAGCCTGCTCATCTTCAATTATCCTCACAAAGCGCAGCCTCCATGAACCCATGT  
ACCTCTCCTCTGCATGCTGGCTGGAGCAGACATTGTCCTCTCCACGTGCACCATTCTCAG  
GCCTTAGCTATCTCTGGTCCGTGCTGGGACATCTCCCTGGATCGTTGCATCACTCAGCT  
CTTCATCCATCCACCTTCATCTGAGTCAGGGATCTGCTGGTGATGGCCTTGACC  
ACTATATTGCCATATGCTACCCACTGAGGTACACCACATTCTACAAATGCTGATCAA  
35 GAAAATTGTGACTGTCTCTGAGAAGTTATGGTACAATTTCCTATCATATTCTTT  
AAAAAGATTGACTTCTGCCAGAATAATTATTCCACACACCTTTGTGAACACATTGG  
CCTAGCCAAATATGCATGTAATGACATTGAATAAACATTGGTATGGGTTCCATTCTA  
ATGTCGACGGTGGCTTAGATGTTACTAATTCTATTCCTATATGCTGATTCTCCATGC  
TGTCTCCACATGCCCTCTCCAGATGCTGCCACAAAGCTCTCAACACATTGGCTCCCATG  
40 TCTGCATCATCATCCTCTTTATGGGCTGGCATCTCACAAATCCTACCCAGAGGTTGG  
CGCCACATTCCACCTTGTATCCACATCCGGTGGCTAATGTCGTGCAATTGGCTCCACCTAT  
GCTGAATCCCATTATTATGGGATAAAACCAAGCAAATCCAGGAACAGGTGGTTCAAGTT  
TTGTTATAAAACAGAAAATACTTGGTTAA (SEQ ID NO: 274)

45

**AOLFR149 sequences:**

MSNASLLTAFILMGLPHAPALDAPLFGVFLVVYVLTVLGNLLILLVIRVDSHLHTTMYYFLTNL  
SFIDMWSTVTVPKLLMTLVFPSGRAISFHSCMAQLYFFHFLGGTECFLYRVMSCDRYLAISYP  
LRYTSMMTGRSCTLLATSTWLSGSLHSAVQAILTFHLPYCGPNWIQHYLCDAPPILKACADTS  
50 AIETVIFVTVGIVASGCFVLIVLSYVSIVCSIRIRTSEGKHRAFQTCASHCIVVLCFFPGPLFIYLR  
PGSRKAVDGVVAVFYTVLTPLLNPVYTLRNKEVKALLKLKDVAHSQSK (SEQ ID NO:  
275)

55

ATGTCCAACGCCAGCCTACTGACAGCGTTCATCCTCATGGGCCTCCCATGCCAGCGC  
TGGACGCCCTCTTGGAGTCTTCTGGTGGTTACGTGCTACTGTGCTGGGGAACT  
CCTCATCCTGCTGGTGTACAGGGTGGATTCTCACCTCCACACCACCATGTTACTACTCCTCA  
CCAACCTGTCGTTCATGACATGTGGTCTCCACTGTCACGGTGCCAAATTGCTGATGAC

WO 01/98526

5           TTGGTGTCCAAAGTGGCAGGGCTATCCTTCCACAGCTGCATGGCTCAGCTCTTTCT  
 TTCACCTCTAGGGGACCGAGTGTCTCTACAGGGTATGCTGTGATCGTACCT  
 10           GGCCATCAGTACCGCTCAGGTACACAGCATGATGACTGGCGCTCGTACTCTG  
 15           GCCACGACTGGCTCAGGGCTCTGACTCTGTCAGGCCATATTGACTTCC  
 20           ATTCGCTACTGGACCCACTGGATCCAGCACTATTGATGCACGCCATCCT  
 25           GAAACTGGCTGTGAGACACCTCAGCCATAGAGACTGTCACTTGTGACTGTTGAATA  
 30           GTGGCTCGGGCTGTTGCTGATAGTGTCTATGTGTCATCGTGTCCATCT  
 35           GCGGATCCGACCTCAGAGGGAAAGCACAGGCCCTCAGACCTGTGCCCTCCACTGTATC  
 40           GTGGCTTTGCTCTTGGCCCTGGTCTTCACTGTGCTGACGCCCTCTCAACCCGTGTTGT  
 45           TGTGGATGGAGTTGTGGCCCTTCACTGTGCTGACGCCCTCTCAACCCGTGTTGT  
 50           ACACCTGAGGAACAAGGAGGTGAAGAAAGCTCTGTTGAAGACAAAGTAGCAC  
 55           ATTCTCAGAGCAAATAG (SEQ ID NO: 276)

**AOLFR150 sequences:**

15           MELGNVTRVKEFIFLGLTQSQDSLVLFLCLVYMTLLGNLLIMVTCTESRLHPTMYFLRL  
 20           NLAILDICFSSTTAPKVLLLSKKKTISYTSCMTQIFLHLLGGADIFSLVMAFDCYMAISKPL  
 25           HYVTIMSRGQCTALISASWMGGFVHSIVQISLLPLPFCGPNVLDTFYCDVPQLKLTCTDTFA  
 30           LEFLMISNGLVTTLWFIFLVLVSYTIVLMLRSQAGGRRKAISTCTSPHHCBDPAFCALHCLC  
 35           PALHCPPHRKGHLCHLHCLPSAEPFDLHSEEPGNEVSHEKTEEKTRAF (SEQ ID NO: 277)

20           ATGGAGTTGGGAAATGTACCAGAGTAAAGAATTATTTCTGGACTTACTCAATCCC  
 25           AAGACCAAGAGTTGGTCTGTTCTTTATGTCTGTGACATGACGACTCTGCTGGGA  
 30           AACCTCCTCATGGTACCGTACCTGTGAGTCTGCCCTCACACCCCCATGTACTCCT  
 35           GCTCCGCAATCTAGCCATCCTGACATCTGCTCTCCACAACTGCTCTAAAGTCTGC  
 40           TGGACCTCTGCAAAGAAAAAGACCATATCCTATACAAGCTGCATGACACAGATATTCT  
 45           CTTCCACCTCCTGGTGGGGCAGACATTCTCTCTCTGTGATGGCGTTGACTGCTACA  
 50           TGGCCATCTCCAAGCCCTGACTATGTGACCATCATGAGTAGAGGGCAATGCACTGCCCT  
 55           CATCTCTGCTCTGGATGGGGCTTGTCCACTCCATCGTCAGATCTCCCTGTTGCTGC  
 60           CTCTCCCTTCTGTGGACCAATGTTCTGACACTTCTACTGCGATGTCCCCCAGGTCTC  
 65           AAACTCACITGCACTGACACTTTGCTCTGAGTTCTGATGATTCCAACAATGGCCTGGT  
 70           CACTACCTGTGGTTATCTCCTGCTGTGCTCACAGTCATCTAACAGCTGAGGT  
 75           CTCAGGAGGGGGCAGGAGGAAGCCATCTCACCTGACCTCCCCACACTGTG  
 80           GTGACCCCTGCATTTGTCCTGCATCTATGTCTATGCCGGCCCTCACTGCCCTCCCCAC  
 85           AGAAAAGGCCATCTGTCACCTCACTGTCATCTCCCTCTGCTGAACCTTGATCTACA  
 90           CTCTGAGGAACCAGGAATGAAGTCAGCCATGAGAAGACTGAAGAGAAGACTCGTGCCTT  
 95           CTGA (SEQ ID NO: 278)

**AOLFR151 sequences:**

40           MFSPNHTIVTEFILLGLTDDPVLEKILFGVFLAIYLITLAGNLCMILLRTNSHLQTPMYFFLGHLS  
 45           FVDICYSSNVTNPMLHNFLSEQKTISYAGCFTQCLLFIATVITEFYILASMALDRYVAICSPHLHS  
 50           SRMSKNICVCLVTIPYMGFLSGFSQSLTFHLSFCGSLEINHFYCADPPLIMLACSDTRVKKMA  
 55           MFVVAGFNLSLFIILSYLFIAIFRIRSAEGRHKAFSTCASHLTIVTLFYGTLFCMYVRPPSE  
 60           KSVEESKITAVFYTFLSPMLNPLIYSLRNTDVILAMQQMIRGKSFHKIAV (SEQ ID NO: 279)

45           ATGTTCTCCCCAACACACCATAGTGACAGAATTCTCTGGACTGACAGACGACC  
 50           CAGTGCTAGAGAAGATCCTGTTGGGTATCCTTGCGATCACCTAACACTGGCAGG  
 55           CAACCTGTGCATGATCCTGCTGATCAGGACCAATTCCACCTGCAAACACCCATGTATTTC  
 60           TTCCTGGCCACCTCTCTTGTAGACATTGCTATTCTCAATGTTACTCCAATATGCT  
 65           GCACAATTCTCTCAGAACAGAAGACCATCTCCTACGCTGGATGCTCACACAGTGTCTT  
 70           CTCTTCATGCCCTGGTGCATCTGAGTTACATCCTGCTCAATGGCATTGGATCGCTA  
 75           TGTAGCCATTGAGCCCTTGCAATTACAGTCCAGGATGTCCAAGAACATCTGTC  
 80           CTGGTCATATCCCTACATGTATGGGTTCTAGGGTTCTCAGTCAGTCACTGCTAACCTT  
 85           TCACATTCTCTGTCCTGAAATCAATTTCTACTGCGCTGATCCTCTCTTA  
 90           TCATGCTGGCCTGCTGACACCCGTGCAAAAGATGGCAATGTTGAGTTGCAGGCTT  
 95           TAATCTCTCAAGCTCTCTTCACTATTCTCTGCTTATCTTCAATTGTCAGGCTT  
 CAGGATCCGTTCTGCTGAAGGCAGGCACAAAGCCTTCTACGTGCTGCCACCTGACA

ATAGTCACTTGTATGGAACCTCTCTGCATGTACGTAAGGCCTCCATCAGAGAAGT  
 CTGTAGAGGAGTCCAAAATACTGCAGTCTTATACTTTGAGCCAATGCTGAACCC  
 ATTGATCTATAGCCTACGGAACACAGATGTAATCCTGCCATGCAACAAATGATTAGGGGA  
 AAATCCTTCATAAAATTGAGTTAG (SEQ ID NO: 280)

5

**AOLFR152 sequences:**

MDQINHTNVKEFFFLELTRSRELEFFLFVVFAVYVATVLGNALIVVTITCESRLHTPMYFLRN  
 KSVLDIVFSSITVPKFLVDLLSDRKTISYNDMAQIFFFHAGGADIFFLSVMAYDRYLAIKPL  
 HYVTMMRKEVWVALVVASWVSGGLHSIIQVILMLPFPFCGPNTLDAFYCYVLQVVKLAETDT  
 10 FALELFMISNNGLVTLLWFLLLGSYTVILVMLRSHSGEGRNKALSTCTSHMLVVTLHFVPCV  
 YIYCRPFMTLPMDTTISINNTVITPMILNPIIYSLRNQEMKSAMQRLQRLGPSESRKWG (SEQ ID  
 NO: 281)

15 ATGGACCAGATCAACCACACTAATGTGAAGGAGTTTCTCCTGGAACCTACACGGTCCC  
 GAGAGCTGGAGTTTCTGTTGTTGCTTCTTGCTGTATGTAGCAACAGTCTGGG  
 AAATGCACTCATTGTTGACTATTACCTGTGAGTCCCGCCTACACACTCCTATGACTTT  
 TCCTGCGGAACAAATCAGCCTGGACATCGTTTTCTCATCTATCACCGTCCCCAAGTTCTG  
 GTGGATCTTATCAGACAGGAAACCATCTCTACAAATGACTGCATGGCACAGATCTTT  
 20 TCTTCCACTTGTGGTGGGGCAGATATTCTCTCTCTGTGATGGCCTATGACAGATAC  
 CTTGCAATCGCCAAGCCCTGCACTATGTGACCATGATGAGGAAAGAGGTGTGGTGGCC  
 TTGGTGGTGGCTTCTGGGTGAGTGGTGGTTGCATTCATCAGGTAATTCTGATGC  
 TTCCATTCCCTCTGTGGCCCCAACACACTGGATGCCCTACTGTTATGTGCTCCAGGTG  
 GTAAAACGTGGCTGCAGTACACCTTGCTTGGAGCTTCTATGATCTAACAACGGAC  
 25 TGGTGACCTGCTCTGGTCCCTCTGCTCTGGCTCCTACACTGTCATTCTGGTATGCTG  
 AGATCCCACCTGGGGAGGGCGGAACAAGGCCCTCTCACGTGCACGTCCCACATGCTG  
 GTGGTGAACCTCTGGGGAGGGCGGAACAAGGCCCTCTCACGTGCACGTCCCACATGCTG  
 CATGGACACAACCATATCCATTAATAACACGGTCATTACCCCATGCTGAACCCCACATC  
 TATTCCCTGAGAAATCAAGAGATGAAGTCAGCCATGCAGAGGCTGCAGAGGAGACTGGG  
 30 CCTTCCGAGAGCAGAAAATGGGGGTGA (SEQ ID NO: 282)

30

**AOLFR153 sequences:**

MSKTSLVTAFLTGLPHAPGLDAPLFGIFLVVYVLTVLGNLLILLVIRVDSHLHTPMYFLTNLS  
 FIDMWFSTVTPKMLMTLVSPSGRAISFHSCVAQLYFFHFLGSTEFLYTVMSYDRYLAIYPL  
 35 RYTSMSMSGSRCALLATSTWLSGLHSAVQTLTFHLPYCGPNQIQHYLCDAPPILKACADTSA  
 NEMVIFVDIGLVASGCFLIVLVSIVCSILRIHTSEGRHRAFQTCA SHCIVVLCFFVXCVFIYLR  
 PGSRDVVVDGVVAIFYTVLTPLLNPVYTLRNKEVKKAVLRLDKVAHSQGE (SEQ ID NO:  
 283)

40 ATGTCCAAGACCAGCCTCGTACAGCGTCATCCTCACGGGCCTCCCCATGCCAGGGC  
 TGGACGCCCACTCTTGAATCTCCTGGTGGTTACGTGCTACTGTGCTGGGAACCT  
 CCTCATCCTGCTGGTATCAGGGGGATTCTCACCTCCACACCCCCATGTA CACTCTCCTCA  
 CCAACCTGTCCCTCATTGACATGTGGTCTCCACTGTCACGGTGCCAAAATGCTGATGAC  
 CTTGGTGTCCCCAAGCGGCAGGGCTATCTCCTCCACAGCTGCGTGGCTCAGCTCTATT  
 TCCACTCCTGGGGAGCACCAGTGTTCTACACAGTCATGTCCTATGATCGTACTTG  
 45 GCCATCAGTTACCGCTCAGGTACACCAAGCATGATGAGTGGGAGCAGATGTGCCCTCTGG  
 CCACCAAGCACTGGCTCAGTGGCTCTGCACTCTGCTGTCCAGACCATATTGACTTTCCAT  
 TTGCCCTACTGTGGACCCAACCAGATCCAGCACTATTGTGATGCACCCCATCCTGA  
 AACTGGCCTGTGCAGACACCTCAGCCAACGAGATGGTCACTTGTGGACATTGGCTAGT  
 GGCCTGGGCTGCTTCTCTGATAGTGTGCTTATGTGTCATCGTCTGTTCCATCCTGC  
 50 GGATCCACACCTCAGAGGGGAGGCACAGAGCCTTCAGACCTGTGCCTCCACTGCATCGT  
 GGTCTTGTCTTTGTNNCCTGTGTTCTACCTGAGACCAAGGCTCCAGGGACGTGCG  
 TGGATGGAGTTGTGGCCATTCTACACTGTGCTGACACCCCTCTCAACCTGTTGAC  
 ACCCTGAGAAACAAGGAGGTGAAGAAAGCTGTGTTGAAACTGAGAGACAAAGTAGCACAT  
 TCTCAGGGAGAATAA (SEQ ID NO: 284)

55

WO 01/98526

## AOLFR156 sequences:

5 MCWAMPSPFTGSSTRNMESRNQSTVTEFIFTGFPQLQDGSLYFFPLLFIYTFIIDNLISAVRL  
 DTHLGNPMYNFISIFSLEIWYTTATIPKMLSNLISEKKAISMTGCLQMYFFHSLENSEGILLIT  
 MAIDRYVAICNPLRYQMIMTPRLCAHLSAGSCLFGFLILLPEIVMISTLPFCGPNIHQIFCDLVP  
 10 VSLACTDTSMILIEDVIHAVTIITFLIILSYVRIVTILRIPSSEGQRQAXSTCAGHLMVFLIFFG  
 15 SVSLMYLRFNSNTYPPVLDTAIALMFTVLAPFFNPIYSLRNKDMNNAIKKLFCCLQKVLPNGG  
 (SEQ ID NO: 285)

10 ATGTGCTGGCTATGCCCTCTCATTACAGGTAGCTACTAGAAATATGGAGAGCAGAA  
 ACCAACATCAACAGTACTGAATTATCTCACTGGATTCCCTCAGCTTCAGGATGGTAGTCT  
 CCTGTACTCTTCCTTACTTTCATCTATACTTTATTATCATTGATAACTTATTAACTT  
 15 CCTCTGGTGAAGGCTGGACACCCATCTGGCAACCCATGTATAATTATCAGTATATT  
 TGAAAAGAAGGCCATCTCAATGACTGGCTGCATCTGCAGATGTATTCTCCACTCAG  
 GAAAACTCAGAGGGATCTGCTGACCACCATGGCATTGACAGATACTGGCCATCTGCA  
 ACCCTCTCGCTATCAAATGATCATGACCCCCGGCTGTGCTCACCTCTGCAGGTTCC  
 TGCCTCTCGGTTCTTATCTGCTTCCCAGATTGTGATTTCCACACTGCCCTCTG  
 TGGGCCAACCAAATCCATCAGATCTGTGACTTGGTCCCTGTGCTAAGCCTGGCTGT  
 20 ACAGACACGTCCATGATTGTGAGGATGTGATTGACATGCTGTGACCACATCATTACCT  
 TCCTAATCATTGCCCTGTCTATGTAAGAATTGTCAGTGTGATATTGAGGATTCCCTTCT  
 GAAGGGAGGAAAAGGCTNTTCTACCTGTGCAAGGCCACCTCATGGCTTCCGTGATATTCT  
 TTGGCAGTGTACTCATGTACTTGCCTTCAAGAACACTTCCACCAAGTTGGACAC  
 AGCCATTGCACTGATGTTACTGACTTGCCTCATTCTCAATCCACATTTAGCCTGA  
 25 GAAACAAGGACATGAACAATGCAATTAAAAACTGTTCTGCTTCAAAAGTGTGAACA  
 AGCTGGAGGTTAA (SEQ ID NO: 286)

## AOLFR157 sequences:

30 MAMDNVTAVFQFLIGISNYPQRDTFFTLVLIYLSTLLNGFMIFLHFDPNLHTPIYFFLSNL  
 SFLDLCYGTASMPQALVHCFSTHPYLSYPRCLAQTSVSLALATAECLLLAAMAYDRVVAISNP  
 LRYSVVMNGPVCVCLVATSWGTSVLTAMLISLRLHFCGANVINHFACEIILSLIKLTCSDTSL  
 NEFMILITSIFTLLPFGFVLLSYIRIAMAIIRSLQGRLKAFTCGSHLTVVTIFYGSAISMYMKT  
 QSKSSPDQDKFISVFYGAATPMLNPLIYSLRKDKVRAIRKVMLKRT (SEQ ID NO: 287)

35 ATGGCCATGGACAATGTCACAGCAGTITCAGTTCTCTTATTGGCATTCTAACTATCC  
 TCAATGGAGAGACACGTTTACATTAGTGTGATAATTACCTCAGCACATTGTTGGGG  
 AATGGATTATGATCTTCTTATTCACTTTGACCTTGTATGGACAGCTCCACACTCCAATCTACTTCTT  
 CCTTAGTAACCTGTCTTCTAGACCTTGTATGGACAGCTCCATGCCAGGCTTGG  
 40 TGCAATTGTTCTACCCATCCCTACCTCTCTTATCCCCATGGCTTGGCTCAAACGAGTGTG  
 TCCTGGTTGGCCACAGCAGAGTGCCTCTACTGGCTGCCATGGCTATGACCGTGTGG  
 TTGCTATGCAATCCCCGCGTTATTCACTGGTTATGAATGGCCCAGTGTGTCTGCTT  
 GGTTGCTACCTCATGGGGACATCACTTGTGCTACTGCCATGCTCATCTATCCCTGAGG  
 45 CTTCACTCTGTGGGCTAATGTCATCAACCATTGCTGAGATTCTCCCTCATCACCAGTATCTCACCC  
 GCTGACCTGTTCTGATACCAGCCTCAATGAATTATGATCCTCATCACCAGTATCTCACCC  
 TGCTGCTACCATGGGTTGTTCTCTCTCCATACGAATTGCTATGGCTATCATAAGG  
 ATTGCGTCACTCCAGGGCAGGCTCAAGGCTTACACATGTGGCTCTCACCTGACCGTGG  
 TGACAATCTCTATGGTCAGCCATCTCATGATATGAAAACTCAGTCCAAGTCCCTCCCC  
 TGACCAAGGACAAGTTATCTCACTGGTTATGGAGCTTACACCCATGTTGAACCCCTG  
 ATATATAGCCTGAGAAAAAAAGATGTTAACGGCAATAAGAAAAGTATGTTGAACCCCTG  
 ACATGA (SEQ ID NO: 288)

50

## AOLFR158 sequences:

55 MKAGNFSDTPEFFLGLSGDPEQPLFMLFLSMYLATMLGNLLILAVNSDSHLHTPMYFLSI  
 LSLVDICFTSTTMPKMLVNQQAQSQNSINTGCLTQICFVLVFVGLENGILVMMAYDRFVAICH  
 LRYNVIMNPKLCGLLLLSSFIVSVDALLHTLMVLQLTFCIDLEIPHFFCELAHILKLA  
 CSDVLLIN  
 NILVYLVTSLLGVVPLSGIIFSYTRIVSSVMKIPSAGGKYKAFSICGSHLIVVSLFYGTGFVYLS  
 GATHSSRKGAIASVMYTVVTPMLNPLIYSLRNKDMILKALRKLIISRIPSFH (SEQ ID NO: 289)

5 ATGAAAGCAGGAAACTCTCAGACACTCCAGAATTCTTCTCTGGGATTGTCAGGGGATC  
 CGGAGCTGCAGCCCACCTCTCATGCTGTCCTGTCATGTACCTGGCCACAATGCTGGG  
 GAACCTGCTCATCATCTGGCCGTCAACTCTGACTCCCACCTCCACACCCCCATGTACTTCC  
 10 5 TCCTCTCATCTGGTCCTGGTCACATCTGTTCACCTCCACACAGGATGCCAAGATGCTG  
 GTGAACATCCAGGCACAGGCTCAATCCATCAATTACACAGGCTGCCTCACCCAAATCTGCT  
 TTGTCCTGGTTTGTGGATTGGAAAATGGAATTCTGGTCATGATGGCTATGATCGATT  
 TGTGGCCATCTGTCACCCACTGAGGTACAATGTCATCATGAACCCCCAACTCTGTGGGCTG  
 CTGCTCTGCTGTCCTCATCGTTAGTGTGTCCTGGATGCTCTGTCACACGTTGATGGTGC  
 15 10 ACAGCTGACCTTCTGCATAGACCTGAAATTCCCCACTTTCTGTGAACACTGCTCATATT  
 TCAAGCTCGCCTGTTCTGATGTCCTCATCAAATACATCCTGGTGTATTGGTGACCAGCCT  
 GTTAGGGTGTGTTCTCTGGGATCATTCTCTACACACGAATTGTCCTCTGTCA  
 TGAAAATTCCATCAGCTGGTGGAAAGTATAAAGCTTTCCATCTGCGGGTCACATTAAT  
 CGTTGTTCTGTTATGGAACAGGGTTGGGTGACCTTAGTCTGGGCTACCCACT  
 15 15 CCTCCAGGAAGGGTGCAATAGCATCAGTGATGATACCGTGGTCACCCCATGCTGAACCC  
 ACTCATTTACAGCCTGAGAAAACAAGGACATGTTGAAGGCTTGAGGAAACTAATATCTAG  
 GATACCATCTTCCATTGA (SEQ ID NO: 290)

**AOLFR159 sequences:**

20 20 MGPRNQTAVSEFLMKVTEDPELKLIPFSLFLSMYLVTILGNLLILLAISDSHLHPTMYFLFN  
 LSFTDICLTTTVPKILVNIQAQNQSITYTGCLTQICLVLVFAGLESCFLAVMAYDRYVAICHPL  
 RYTVMNVHFGLLILLSMFMSTM DALVQSLMVLQLSFCKNVEIPLFFCEVVQVIKLA  
 CSDTLINNILIYFASSVFGAIPLSGIIFSYSQIVTSVRMPSARGKYKAFSTCGCHLSV  
 FSLFYGTAFGVYISAVAE  
 25 25 SSSRITAVASVMYTVPQMMNPFIYSLRNKEMKKALRKLIGRLFPF (SEQ ID NO: 291)

25 ATGGGACCCAGAAACCAAACAGCTTTCAGAATTCTTCTCATGAAAGTGACAGAGGAC  
 CCAGAACTGAAGTTAACATCCTTCAAGCTGTCATCTGACTCCCACCTCCACACCCCCATGTACTTC  
 GGAACCTGCTCATTCTCCTGGCTGTCACTCTGTTAACACACAGTCCAAAGATCCT  
 30 30 CTTCTCTTAATCTCCTTACTGACATCTGTTAACACACAGTCCAAAGATCCT  
 AGTGAACATCCAAGCTCAGAACATCAGAGTATCACTTACACAGGCTGCCTCACCA  
 GAGATCTGTTGCTGGCTGGAAAGTTGCTTTCTGCAGTCATGGCTACAGTCTGATGGTATT  
 TGTCAGTCTGCTGGCTGGCTGGAAAGTTGCTTTCTGCAGTCATGGCTACAGTCTGATGGTATT  
 35 35 GCAGCTGCTCTGCAAAAACGTTGAAATCCCATTGTTCTGTGAAGTCGTTCA  
 ATCAAGCTGCCTGTTCTGACACCCATCAACAAACATCCTCATATATTGCAAGTAGTGT  
 ATTGGTCAATTCTCTGGAATAATTCTTCTTATTCTCAAATAGTCACCTCTGTT  
 TGAGAATGCCATCAGCAAGAGGAAAGTATAAAGCGTTTCCACCTGTGGCTGT  
 CACCTCTCTGTTCTGTTCTATGGACAGCTTTGGGTGTA  
 40 40 CATTAGTCTGCTGTTGCTGAGTGAAGAAAGCTTGAAGGAAACTTATTGGTAG  
 CTTCATCTACAGCCTGAGAAAATAAGGAGATGAAGAAAGCTTGAAGGAAACTTATTGGTAG  
 GCTGTTCTTTAG (SEQ ID NO: 292)

**AOLFR160 sequences:**

45 45 MPMQLLTDIIFSIRFIINSMEARNQTAISKFLLGLIEDPELQPVLFLFLSMYLVTILGNLLILLA  
 AVISDSHLHPTMYFFLSNLSDICLSTTIPKMLVNIQAQNRSITYSGCLTQICFVLFAGLENC  
 LLAAMAYDRYVAICHPLRYTVIMNPRLCGLLILSLTSV  
 VNALLSLMVLRLSFCTDLEIPLFFCELAQVIQLTCS  
 CSDTLINNILIYFAACIFGGVPLSGIILSYTQITC  
 VLRMPSASGKHKA  
 VSTCGSHLSIVLLFYGAGLGVYISSV  
 VTDSPRKTAVASV  
 MYSVFPQM  
 VNPFIYSLRNKDMKGTLRKFIGRIP  
 SLLWCAICFGFRFLE (SEQ ID NO: 293)

50 50 ATGCCGATGCAGCTGCTGTTACAGATTATTATCTTCCATCAGATT  
 CATCAACAGCATGGAAAGCGAGAAAACCAAACAGCTATT  
 CAAATTCCTCTCCTGGACTGATAGAGGAT  
 CCGGAAC  
 TGCAGCCGTC  
 TTTCA  
 GCGCTGTC  
 TGTCCATG  
 TACTGGT  
 CACCATC  
 CTGGG  
 GAACCTGCTCAT  
 CCTCTTG  
 GCTGT  
 CATCTG  
 ACTCT  
 CACCT  
 CCACAC  
 CCCCC  
 ATGTACT  
 TCT  
 55 55 TCCTCTCCAATCTCTCCTTTGGACATTGTTA  
 AGCACA  
 ACCAC  
 GAT  
 CCCC  
 AAAGATG  
 CTG  
 GTGAACAT  
 CCAAG  
 CT  
 CAGA  
 AT  
 CGGAG  
 CAT  
 CACG  
 TACT  
 CAGG  
 CT  
 GCCT  
 CACCC  
 AGATCTGCT

WO 01/98526

TTGTCTTGTGCTGGCTGGAAAATTGTCCTTGCAGCAATGGCTATGACCGCTAT  
 GTGGCCATTGTCACCCCCTAGATACACAGTCATCATGAACCCCGCCTCTGTGGCCTGC  
 TGATTCTCTCTCTGTGACTAGTGTGTGAATGCCCTCTCTGTGACTGGCTGATGGTGTG  
 5 AGGCTGCCCTCTGCACAGACCTGGAAATCCGCTCTCTGTGAACCTGGCTCAGGTCA  
 TCCAACTCACCTGTCAGACACCCCTCATCAATAACATCCTGATATATTTCAGCTGCATA  
 TTTGGTGGTGTCTCTGTGGAATCATTTGCTTACACTCAGATCACCTCCTGTGTTT  
 GAGAATGCCATAGCAAGTGGAAAGCACAAGCAGTTCCACCTGTGGGTCTACCTCTCC  
 ATTGTTCTCTGTATGGGGCAGGTTGGGGTGTACATTAGTTCTGTGGTTACTGACTC  
 10 ACCTAGGAAGACTGCAGTGGCTTCAGTGATGATTCTGTGTCCTCAAATGGTAACCCC  
 TTTATCTATAGTCGAGGAATAAGGACATGAAAGGAACCTGAGGAAGTTCATAGGGAGG  
 ATACCTCTCTGTGGTGTGCCATTGCTTGATTCAAGGTTCTAGAGTAA (SEQ ID  
 NO: 294)

**AOLFR161 sequences:**

15 MEPRNQTSASQFILLSEKPEQETLLSLFFCMYLMVVGNLILAIISIDSHLHTPMYFFLANL  
 SLVDFCLATNTIPKMLVSLQTGSKAISYPCCLIQMYYFFFGIVDSVIAMMAYDRFVAICHPLH  
 YAKIMSLRLCRLLVGALWAFSCFISLTHILLMARLVFCGSHEVPHYFCDLTPIRLSCTDSVNR  
 IFILIVAGMVIATPFVCILASYARILVAIMKVPAGGRKAFSTCSSHLVVVALFYTTIGVYLC  
 SSVLTIVKEKASAVMYTAVTPMLNPFYSLRNRLKGALRKLVNRKITSSS (SEQ ID NO: 295)

20 ATGGAACCAAGAAAACCAAACCAAGTCATCTCAATTCTCCTGGACTCTCAGAAAAGC  
 CAGAGCAGGAGACGCTCTCTTCCCTGTTCTGATGTACCTGGTATGGCGTGG  
 25 GAACCTGCTCATCATCTGGCCATCAGCATAGACTCCACCTCCACACCCCATGTACTCT  
 TCCTGCCAACCTGTCCCTGGTTGATTCTGCTGGCCACCAACACCATCCCTAAGATGCT  
 GGTAGCCTCAAACCGGGAGCAAGGCCATCTTATCCCTGCTGCCTGATCCAGATGTC  
 TTCTCCATTCTCTGGCATCGTGGACAGCGTCATAATGCCATGATGGCTTATGACCGGTT  
 CGTGGCCATCTGCCACCCATTGCACTACGCCAAGATCATGAGCCTACGCCCTGTCGCTG  
 30 CTGGTCGGCGCCCTCTGGCGTTCTCTGCTCATCTCACTCACTACTCTGCGACCTCACTCCATCC  
 CCGTCTCGTTCTCGGGCAGCCATGAGGTGCTCACTACTCTGCGACCTCACTCCATCC  
 TCCGACTTCGTGCACGGACACCTCTGTGAATAGGATCTCATCCTCATGTGGCAGGGAT  
 GGTGATGCCACGCCCTTGTCTGCATCCTGGCTCTATGCTGCATCCTGTGGCCATCA  
 TGAAGGTCCCCCTTGCTGCAGGGCAGGAAGAAAGCCTCTCCACCTGCAGCTCCACCTGTC  
 35 TGTGGTGTCTCTATGGGACCACATTGGCGTCTATCTGTGTCCTCTCGGTCTCA  
 CCACTGTGAAGGAGAAAGCTCTCGGGTGTACACAGCAGTCACCCCCATGCTGAATCC  
 CTCATCTACAGCTGAGGAACAGAGACCTGAAAGGGCTCTAGGAAGCTGGTCAACAG  
 AAAAGATCACCTCATCTCCTGA (SEQ ID NO: 296)

**AOLFR162 sequences:**

40 MMRLMKEVRGRNQTEVTEFLLLGLSDNPDLQGVLFALFLIYMANMVGNLGMIVLIKIDLCLH  
 TPMYFFLSSLSFVDASYSSVTPKMLVNLMAENKAISFHGCAAQFYFFGSFLGTECFLLAMMA  
 YDRYAAIWNPLLVPVLVSGRICFLIATSLAGCGNAIHTGMTFRLSFCGSNRINHFYCDTPPL  
 LKLSCSDTHFNGIVIMAFSSFIVISCVMVLISYLCIFIAVLKMPSELGRHKAFSTCASYLMAVTIF  
 FGTLFMYLRPTSSYSMEQDKVVSFVYTVIPVLNPLIYSLKNKDVKKALKKILWKHIL (SEQ ID  
 NO: 297)

45 ATGATGAGACTTATGAAAGAGGTTGAGGCAGAAATCAAACAGAACAGAACATTCTC  
 CTCTTAGGACTTCCGACAATCCAGATCTACAAGGAGTCCTCTTGCAATTGTTCTGTGAT  
 CTATATGGCAAACATGGTGGCAATTGGGGATGATTGTATTGATTAAGATTGATCTCTG  
 50 CTCCACACCCCATGTATTCTCTCAGTAGCCTCTCTTGAGATGCCCTACTCTCT  
 TCCGTCACTCCAAAGATGCTGGTGAACCTCATGGCTGAGAATAAGGCCATTCTTCTCATG  
 GATGTGCTGCCAGTTCTACTCTTGGCTCTCTGGGACTGAGTGCTTCTGTGGCC  
 ATGATGGCATATGACCGCTATGCAGCCATTGGAACCCCTGCTCACCCAGTTCTCGTGT  
 55 CTGGGAGAATTGCTTTGCTAATAGCTACCTCTTGTGAGGTTGTTAATAGGATCAACCATTCT  
 CATAACATACAGGGATGACTTTAGGTTGCTCTTGTGGTTAATAGGATCAACCATTCT  
 ACTGTGACACCCGCCACTGCTAAACTCTTGTCTGATACCCACTCAATGGCATTGTG  
 ATCATGGCATTCTCAAGTTATTGTCATCAGCTGTGTTATGTCCTCATTCCTACCT

5 GTGTATCTCATTGCCGCTTGAAGATGCCCTCGTTAGAGGGCAGGCACAAAGCCTCTCC  
 ACCTGTGCCTCTACCTCATGGCTGCACCATATTCTTGGAACAAATCCTCTCATGTACTT  
 GCGCCCTACATCTAGCTACTCAATGGAGCAAGACAAGGTTGTCTGTCTTATAACAGTA  
 ATAATCCCTGTGCTAAATCCCTCATCTATAGTTAAAAAATAAGGATGTAAAAAAGGCC  
 5 TAAAGAAGATCTTATGGAAAACACATCTTGTAG (SEQ ID NO: 298)

**AOLFR163 sequences:**

10 MQRSNHTVTEILLGFTTDPGMQLGLFVVFLGVYSLTVVGNSTLIVLICNDSCLHTPMYFFTGN  
 LSFLDLWYSSVYTPKILVTCISEDKSISFAGCLCQFFFASAGLAYSECYLLAAVAYDRYVAISKPL  
 LYAQAMSIKLCALLVAWSYCGGFINSSIITKKTFSNFCRENIIDDFCDLLPLVELACGEKGGYK  
 IMMYFLASNVICPAVLASYLFIITSVLRISSSKGYLKAFSTCSSHLTSVTLYYGSILYIYALPRS  
 SYSFDMDKIVSTFYTVVFPMNLMIYSLRNKDVKEALKLLP (SEQ ID NO: 299)

15 ATGCAGAGGAGCAATCATACAGTACTGAGTTATACTGCTGGCTTACACAGACCCA  
 GGAATGCAGCTGGGCCTCTCGTGGTGTCTGGTACTCTCTCACTGTGGTAGGAA  
 ATAGCACCTCATCGTGTGATCTGTAATGACTCCTGCCTCACACACCCATGTATTTTC  
 ACTGGAAATCTGCGTTCTGGATCTCTGGTATTCTCTGTCTACACCCAAAGATCCTAGT  
 GACCTGCATCTCTGAAGACAAAAGCATCTCCCTTGCTGGCTGCCGTGGCTTATGACCGCTACGT  
 20 CTGCAGGGCTGGCCTATAAGTGAAGTGTACCTGCTGGCTGCCGTGGCTTATGACCGCTACGT  
 GGCCATCTCCAAGCCCCCTGCTTATGCCAGGCCATGCCATAAAGCTGTGCTATTGCTG  
 GTAGCAGTCTCATATTGTGGTGGCTTTATTAACTCTCAATCATCACCAAGAAAAGCTTTTC  
 CTTAACCTCTGCCGTGAAAACATCATTGATGACTTTCTGTGATTGCTTCCCTGGTGG  
 AGCTGGCCTGTGGCGAGAAGGGCGGCTATAAAATTATGATGTACTCCTGCTGGCCTCAA  
 25 TGTATCTGCCCGCAGTGTCTACCTGGCCTCACCTCTTATCATCACCAAGTGTCTGA  
 GGATCTCCCTCCAAGGGCTACCTCAAAGCCTCTCCACATGCTCCTCCACCTGACCTCT  
 GTCACTTTATACTATGGCTCCATTCTACATCTACGCTCTCCCAGATCTAGCTATTCTT  
 TGATATGGACAAAATAGTTCTACATTTACACTGTGGTATTCCCCATGTTGAATCTCATG  
 ATCTACAGCCTAAGGAATAAGGATGTGAAAGAGGCTGAAAAAAACTCTCCCATAA (SEQ  
 ID NO: 300)

30 **AOLFR164 sequences:**

MFLTERNTTSEATFTLLGFSDYLELQIPLFFVFLAVYGFSSVGNLGMIVIINKINPKLHTPMYFFLN  
 HLSFVDFCYSSIIAPMMLVNLVEDRTISFSGCLVQFFFFCTFVVTTELIFAVMAYDHFVAICNP  
 35 LLYTVAISQKLCAMLVVLYAWGVACSLTLACSAKLSFHGFNTIHFFCELSSLISLSPDSYL  
 SQLLFTVATFNEISTLLIILTSYAFIIVTTLKMPASGHRKVFSTCASHLTAITFHGTILFLYCVP  
 NSKNSRHTVKVASVFYTVVPLLNPLIYSLRNKDVKDAIRKIINTKYFHIKHRHWYPFNFVIEQ  
 (SEQ ID NO: 301)

40 ATGTTCTGACAGAGAGAAATCGACATCTGAGGCCACATTCACTCTCTGGCTTCTCAG  
 ATTACCTGGAACTGCAAATCCCCCTCTCTTGTATTCTGGCAGTCTACGGCTCAGTGTG  
 GTAGGGAATCTGGGATGATAGTGTACATCAAAATTAAACCCAAAATTGACATACCCCATGT  
 ATTTTTCTCAACCACCTCCTTGTGGATTCTGCTATTCTCCATCATTGCTCCCATGA  
 TGCTGGTGAACCTGGTTGAGAAGATAGAACCATTCATTCTCAGGATGTTGGTGCATT  
 45 CTTTTCTTTGCACCTTGACTGAATTAAATTCTATTGCGGTGATGGCTATGACC  
 ACTTTGTGGCCATTGCAATCCTCTGCTCTACACAGTTGCCATCTCCAGAAACTCTGTGCC  
 ATGCTGGTGGTTGATTGTATGCACTGGGAGTCGCATGTTCCCTGACACTCGCGTGTCTG  
 CTTAAAGTTATCTTCTATGGTTCAACACAATCAATCATTCTCTGTGAGTTATCTCC  
 CTGATATCACTCTTACCCCTGACTCTTATCTCAGCCAGTTGCTCTTTCACTGTTGCCAC  
 50 TTTAATGAGATAAGCACACTACTCATCTTGACATCTTATGCAATTCTCATCATTGTCACCA  
 CCTTGAAGATGCCCTCAGCCAGTGGGCACCGCAAAGTCTCTCCACCTGTGCCTCCACCT  
 GACTGCCATCACCCTTCCATGGCACCATCCTCTTCACTGTGACCCAATCCTAA  
 ACTCCAGGCACACAGTCAAAGTGGCCTCTGTGTTTACACCGTGGTATCCCCTGTTGAA  
 TCCCTGATCTACAGTCTGAGAAATAAGATGTTAAGGATGCAATCCGAAAAATAATCAAT  
 55 ACAAAATATTTCTATTTAAACATAGGCATTGGTATCCATTAAATTGTTATTGAACAAATA  
 A (SEQ ID NO: 302)

WO 01/98526

## AOLFR165 sequences:

5 MAVGRNNTIVTKFILLGLSDHPQMKIFLFLGLYLLTLAWNLSLIALIKMDSHLHMPMYFFL  
 SNLSFLDICYSSTAPKMLSDITEQKTISFVGATQYFVFCMGLTECFLAAMAYDRYAAICN  
 PLLYTVLISHTLCLKMVVGAYVGGFLSSFIETYSVYQHDFCGPYMINHFFCDLPPVLALSCSDTF  
 TSEVVTFIVSVVVGIVSVLVLLISYGYIVAAVKISSATGRTKAFSTCASHLTAVTLYGSGFFM  
 YMRPSSSYSLNRDKVVSIFYALVIPVNPIIYSFRNKEIKNAMRKAMERDPGISHGGPFIFMTLG  
 (SEQ ID NO: 303)

10 ATGGCTGTAGGAAGGAACAACACAATTGTGACAAAATTCTCTGGACTTCAGACC  
 ATCCTCAAATGAAGATTTCTTTCTATGTTATTCTGGGCTCTACCTCTGACGTTGGCC  
 TGGAACTTAAGCCTATTGCCCTATTAAAGATGGACTCTACCTGCACATGCCCATGTACT  
 TCTTCCTCAGTAACCTGCTTCTGGACATCTGCTATGTCTCCACGCCCTAAGATG  
 CTGTCGACATCATCACAGAGCAGAAAACCATTCTTGTGGCTGTGCCACTCAGTACT  
 TTGTCCTCTGTGGATGGGCTGACTGAATGCTTCTCTGGCAGCTATGCCCTATGACCG  
 GTATGCTGCAACTGCAACCCCTTGTTCACACAGTCTCATATCCCATACACTTGTAA  
 AGATGGTGGTTGGCCTATGTGGTGGATTCTTAGTTCTATGAAACATACTCTGT  
 CTATCAGCATGATTCTGTGGCCCTATATGATCAACCACTTTCTGTGACCTCCCTCAG  
 TCCTGGCTCTGCTCTGCTGATACCTCACAGCGAGGGTGCACCTCATAGTCAGTGT  
 GTCGTGGAATAGTGTCTGTGCTAGTGGCCTCATCTTATGGTACATTGTTGCTGCTG  
 20 TGTGAAGATCAGCTCAGCTACAGTAGGACAAAGGCCCTCAGCACTTGTGCCCTCACCTG  
 ACTGCTGTGACCCCTTCTATGGTTCTGGATTCTCATGTACATGCGACCCAGTCCAGCTA  
 CTCCCTAAACAGGGACAAGGGTGTCCATATTCTATGCCCTGGTATCCCCGGTGAAT  
 CCCATCATCTACAGTTTAGGAAATAAGGAGATTAAAATGCCATGAGGAAAGCCATGGAA  
 AGGGACCCGGGATTCTCACGGTGGACCATTCTATGACCTGGCTAA (SEQ ID  
 25 NO: 304)

## AOLFR166 sequences:

30 MEMENCTRKEFIFLGLTQNREVSLVLFLLLVYVTLLGNLLIMVTCTESRLHTPMYFLH  
 NLSIADICFSSITVPKVLVDLLSERKTISFNHCFTQMFLFHIGGVDFVLSVMALDRYVAISKPL  
 HYATIMSRDHICLTVAAWLGGFVHSIVQISLLLPLFCGPNVLDTFYCDVHRLVLAHTDIFIL  
 ELLMISNNGLLTLWFFLLVSYIVLSPKSQAGEGRRKAISTCTSHTVVTLHFVPCIVYVYARP  
 FTALPMDKAISVTFTVISPLLNPLIYTLRNHEMKSAMRRLKRLVPSDRK (SEQ ID NO: 305)

35 ATGGAGATGGAAAATGCACCAGGGTAAAAGAATTATTCCTGGCCTGACCCAGAAC  
 GGGAAAGTGAAGCTTAGCTTATTCTTCTACTCTGGTGTATGTGACAACATTGCTGGGA  
 AACCTCCTCATCATGGCACTGTACCTGTGAATCTGCCCTCACAGGCCATGTATT  
 GCTCCATAATTATCTATTGCCGATACTGCTCTCTCCATCACAGTGCCCAAGGTTCTGG  
 TGACCTCTGCTGAAAGAAAGACCATCTCCATCAATTGCTCACTCAGATGTTCTA  
 TTCCACCTATTGGAGGGGTGGATGTATTCTCTTCGGTGTGGATTGGATCGATATG  
 40 TGGCCATCTCAAGCCCCTGCACTATGCAGTATCATGAGTAGAGACCATTCGATTGGC  
 CACAGTGGCTGCCTGGTGGGGCTTGTCCACTCCATCGCAGATTCCCTGTGCTC  
 CCACTCCCTCTCGGGACCAATGTTCTGACACTTCTACTGTGATGCCACGGTCT  
 CAAACTGGCCCATACAGACATTCTACATTGAACTACTAATGATTCCAACAATGACTG  
 CTCACCACTGTGGTTCTCTGCTCTGGTGTACATAGTCATATTACATTACCCAA  
 45 GTCTCAGGCAAGGAGAGGGCAGGAGGAAAGCCATCTCCACCTGCACCTCCACAT  
 GGTGACCCCTGCATTCTGTCACCTTCACTGTGATGCCGGCCCTACTGCCCTCCCCA  
 TGGATAAGGCCATCTCTGTACCTTCACTGTGATGCCGGCCCTACTGCCCTGATCTAC  
 ACTCTGAGGAACCATGAGATGAAGTCAGCCATGAGGAGACTGAAGAGAAGACTGTG  
 TCTGATAGAAAATAG \*SEQ ID NO: 306)

50

## AOLFR167 sequences:

55 MSITKAWNSSVTMFILLGFTDHPPELQALLFVTFLGIYLTTLAWNLAFLIRGDTHLHTPMYFF  
 LSNLSDICYSSTAPKMLSDITEQKTISFVGCAAQFFFVGMGLSECLLTAMAYDRYAAI  
 SSPLLYPTIMTQGLCTRMVVGAYVGGFLSSLIQASSIFRLHFCGPNIINHFFCDLPPVLALSCSDT  
 FLSQVNVFLVVVTVGTSFLQLLISYGYIVSAVLKIPSAEGRWKACNTCASHLMVVTLLFGTAL

FVYLRPSSYLLGRDKVSVFYSVIPMLNPLIYSLRNKEIKDALWKVLERKKVFS (SEQ ID NO: 307)

5 ATGTCCATAACCAAAGCTGGAACAGCTCATCAGTGACCATGTTCATCCTCCTGGGATTCA  
 CAGACCATCCAGAACTCCAGGCCCTCCTTTGTGACCTCCTGGCATCTATCTTACCA  
 CTGGCCTGGAACCTGGCCCTCATTTCATGATCAGAGGTGACACCCATCTGCACACACCA  
 TGTACTCTTCTTAAGCAACTTATCTTCATTGACATCTGCTACTCTCTGCTGTGGCTCC  
 AATATGCTCACTGACTTCTGGGAGCAGAAGACCATATCATTGTGGCTGTGCTGCTC  
 AGTTTTTTCTTGTGGCATGGGTCTGCTGAGTGCCTCCTGACTGCTATGGCATA  
 10 GACCGATATGCAGCCATCTCCAGCCCCCTCTACCCACTATCATGACCCAGGGCTCT  
 GTACACGCATGGTGGTGGGCATATGTTGGTGGCTCTGAGCTCCCTGATCCAGGCCAG  
 CTCCATATTTAGGCCTCACTTTGCGGACCCAAACATCATCAACCAACTCTCTGCGACCTCC  
 CACCAAGTCCTGGCTCTGCTTGCTGACACCTCCTCAGTCAAGTGGTGAATTCTCTG  
 GTGGTCACTGTCGGAGGAACATGTTCTCAAACCTCTTATCTCCTATGGTACATAGTGT  
 15 CTGCGGTCTGAAGATCCCTCAGCAGAGGGCCGATGGAAAGCCTGCAACACGTGCGCT  
 CGCATCTGATGGTGGTGAECTGCTGTTGGACAGCCCTTCTGACTTGCAGCCAG  
 CTCCAGCTACTTGCTAGGCAGGGACAAGGTGGTGTCTGTTCTATTGATGGTACATGG  
 ATGCTGAACCCTCTCATTACAGTTGAGGAACAAAGAGATCAAGGATGCCCTGTGGAAG  
 GTGTTGGAAAGGAAGAAAGTGTGTTCTAG (SEQ ID NO: 308)

20

**AOLFR168 sequences:**

MEKINNVTEFIFWGLSQSPEIEKVCVVFSFFYIILLGNLLIMLTVCVLSNLFKSPMYFFLSFLSFV  
 DICYSSVTAPKMIVDLLAKDKTISYVGMLQLLGVHFFGCTEIFLTVMAVDRYVAICKPLHYM  
 25 TIMNRETCNKMLLGTWVGGFLHSIIQVALVVQLPFCGPNEIDHYFCDVHPVLLACTETYIVG  
 VVVTANSGTIALGSFVILLISYIILVSLRKQSAEGRRKALSTCGSHIAMVVIFGPCTFMYMRPD  
 TTFSEDKMVAVFYTIITPMLNPLIYTLRNAEVKNAMKKLWGRNVFLEAKGK (SEQ ID NO: 309)

30

ATGGAAAAAATAAACACGTAACTGAATTCACTTCTGGGTCTTCTAGAGCCCAGAGA  
 TTGAGAAAGTTGTTTGTGGTGTCTTCTTCTACATAATCATCTCTGGAAATCTC  
 CTCATCATGCTGACAGTTGCCTGAGCAACCTGTTAACGTACCCATGTATTCTTCTCAG  
 CTTCTTGTCTTGTGGACATTGTTACTCTTCAGTCACAGCTCCAAGATGATTGTTGACC  
 TGTTAGCAAAGGACAAAACCATCTCT1ATGTTGGGTGCATGTTGCAACTGCTGGAGTAC  
 ATTTCTTGGTTGCACTGAGATCTCATCCTACTGTAATGCCATGATCGTTATGGCT  
 35 ATCTGTAACCCCTACATTATGACCATCATGAACCGGGAGACATGCAATAAAATGTTAT  
 TAGGGACGTGGTAGGTGGTTCTACACTCCATTATCCAAGTGGCTCTGGTAGTCCA  
 ACCCTTTGTGGACCCAAATGAGATAGATCACTACTTTGTGATGTTCACCTGTGTTGAAA  
 CTTGCCTGCACAGAAACATACATTGTTGGTGTGACAGCCAACAGTGGTACCTTG  
 CTCTGGGGAGTTGTTACTCTGCTAATCTCCTACAGCATCATCCTAGTTCCCTGAGAAAG  
 40 CAGTCAGCAGAAGGCAGGCGCAAAGCCCTCTCACCTGTGGCTCCCACATTGCCATGGTC  
 TTATCTTTCTGCCCTGTACTTTATGTACATGCGCCCTGATACGACCTTCAGAGGAT  
 AAGATGGTGGCTGTATTACACCAATTACACTCCCATGTTAAATCCTGATTATACACT  
 GAGAAATGCAGAAGTAAAGAATGCAATGAAGAAACTGTGGGGAGAAATGTTCTTGG  
 GGCTAAAGGGAAATAG (SEQ ID NO: 310)

45

**AOLFR169 sequences:**

MMDNHSSATEFHLLGFPGSQGLHHILFAIFFFYLVLMGNTVIIVVCVDKRLQSPMYFFLSHL  
 STLEILVTTIIPMMWLGLFLGCRQYLSLHVSLNFSCGTMEALLGVMAVDRYVAVCNPLRY  
 50 NIIMNSSTCIWVVIVSWVFGFLSEIWPIYATFQFTFRKSNSLDHFYCDRGQLLKLSCDNTLTFI  
 LFLMAVFILIGSLIPTIVSYTYIISTILKIPSASGRRKAFSTFASHFTCVVIGYGSCLFLYVVKPKQTQ  
 GVEYNKIVSLLSVLTPFLNPFI TLRNDKVKEALRDGMKRCCQLLKD (SEQ ID NO: 311)

55

ATGATGGACAACCACTCTAGTGCCACTGAATTCCACCTCTAGGCTCCCTGGGTCCAAG  
 GACTACACCACATTCTTTGCTATATTCTTCTTCTATTAGTACATTAATGGGAAAC  
 ACGGTACATCATTGTGATTGTCTGTGGATAAACGTCTGCAGTCCCCCATGTATTCTCCT  
 CAGCCACCTCTACCCCTGGAGATCCTGGTACAACCATATTGCCCCATGATGCTTGG

WO 01/98526

GGATTGCTCTTCTGGGATGCAGACAGTATCTTCTACATGTATCGCTCAACTTTCTG  
 5 TGGGACCATGGAGTTGCATTACTGGAGTGATGGCTGTGGACCGTTATGGCTGTGTG  
 AACCCCTTGAGGTACAACATCATTATGAACAGCAGTACCTGTATTGGTGGTAATAGTGT  
 CATGGGTGTTGGATTCTTCTGAAATCTGGCCCATCTATGCCACATTCAAGTTACCTTC  
 CGCAAATCAAATTAGACCATTTACTGTGACCGAGGGCAATTGCTCAAACAGTCCT  
 10 GCGATAACACTCTTCACAGAGTTATCCTTCTTAATGGCTGTTTATTCTCATTGGT  
 TCTTGTACCCCTACGATTGTCTCTACACCTACATTATCTCACCACCTCAAGATCCCGTC  
 AGCCTCTGCCGGAGGAAGCCTCTCCACTTTGCCTCCACTTCACCTGTGTTGATTG  
 GCTATGGCAGCTGTTCTACGTGAAACCCAAGCAAACACAGGGAGTTGAGTACAA  
 TAAGATAGTTCCCTGTTGGTTCTGTGTTAACCCCCCTCTGAATCCTTCATCTTACTCT  
 15 TCGGAATGACAAAGTCAAAGAGGCCCTCGAGATGGGATGAAACGCTGCTCAACTCCT  
 GAAAGATTAG (SEQ ID NO: 312)

## AOLFR170 sequences:

15 MSFTSLIPSLCSLTLPLFCYLSLLPFLSAFLITRWLLAFLSLFSVSPVSSVSSSMVLCLYLSVS  
 ASPSVFCFSCMQGPILWIMANLSQPSEFVLLGFSFGELQALLYGPFLMLYLLAFMGNTIIVMVI  
 ADTHLHTPMYFFLGNFSLLEILVTMTAVPRMLSDLVPHKVTFTGCMVQFYFHFSLGSTSFLIL  
 20 TDMALDRFVAICHPLRYGTLMSRAMCVQLAGAAWAAPFLAMVPTVLSRAHLDYCHGDVNH  
 FFCDNEPLQLSCLSDTRLLEFWDFLMLTFVLSSFLVTLISYGYIVTTVLRIPSASSCQKAFSTCG  
 SHLTLVFIGSSTIFLYVRPGKAHSVQVRKVVALVTSVLTPLNPFILTFCNQTVKTVLQGQMQ  
 25 RLKGLCKAQ (SEQ ID NO: 313)

ATGTCTTCACTCTCATACCCCTACTCTGTTCTCCTGACTCTCCATTCTGTTTGT  
 TATCTTCTTATTGCCGTTCTTCTGCTTTCTGTTTACTCGCTGGCTACTGCCCTT  
 25 CTCTCTCATCTCTGCTCTGCTCTGCCGTTCTGCTTTCTGTTCTTGCATGCAGGGCCCATACTG  
 TATCTCTGTTCTGCCCTCCGCTGTCTTCTGTTCTTGCATGCAGGGCCCATACTG  
 TGGATCATGGCAAATCTGAGCCAGCCCTCCGAATTGCTCTTCTGTTCTTGCATGCAGGGCCCATACTG  
 TGAGCTGCAGGCCCTCTGTATGGCCCTTCTCATGCTTATCTCTGCCCTCATGGGAA  
 30 ACACCATCATAGTTAGCTGACACCCACCATACACCCATGACTCTTCTC  
 CTGGGCAATTTCCTGCTGGAGATCTGGTAAACATGACTGCAGTGCCTCAGGATGCTCT  
 CAGACCTGTTGGTCCCCACAAAGTCATTACCTCACTGGCTGCATGGCCAGTTCTACTTC  
 CACTTTCCCTGGGTCCACCTCCCTCATGACAGACATGGCCCTGATCGCTTGT  
 35 GGCCATCTGCCACCACTGCGCTATGGCACTCTGATGAGCCGGCTATGTGTGTCAGCTG  
 GCTGGGGCTGCCTGGCAGCTCCTCTAGCCATGGTACCCACTGTCCTCTCCGAGCTC  
 ATCTTGATTACTGCCATGGCAGCTCATCAACCCTTCTGTGACAATGAACCTCTCTG  
 CAGTTGTCATGCTGACACTCGCCTGTTGAATTCTGGACTTCTGATGCCCTGACCTT  
 40 TGTCTCAGCTCTCTGGTACCCCTCATCCTATGGCTACATAGTGACCATGTC  
 GGATCCCTCTGCCAGCTGCAGAAGGCTTCTCCACTTGGCTCAGGCTGGTACCTCACA  
 GGTCTTCATGGCTACAGTAGTACCATCTTCTGTATGTCAGGCTGGCAAAGCTCACTCT  
 GTGCAAGTCAGGAAGGTCGTGGCTGGTACCTGAGTCTCAGTTCTCACCCCCCTCTCAATCCCT  
 TTATCCTTACCTCTGCAATCAGACAGTTAACAGTGCTACAGGGCAGATGCAGAGGCT  
 45 GAAAGGCCCTTGCAAGGCACAATGA (SEQ ID NO: 314)

## AOLFR171 sequences:

45 MVGNLLIWTTIGSPSLGSLMYFFLAYLSMDAIYSTAMSPKLMIDLLCDKIAISLACMGQLFI  
 EHLLGGAEVFLLVVMAFDYVAISKPLHYLNIMNRLVCILLVVAMIGGFVHSVVQIVFLYSLP  
 ICPNVIDHSVCDMYPLLELLCLDTYFIGLTVVANGGIICMVIFTLLISCGVILNFLKTYSQEER  
 HKALPTCISHIIVVALVFVPCIFMYVRPVSNPFDKLMTVFSIITLMLNPLIYSLRQSEMKNAM  
 KNLWCEKLSIVRKRVSPTLNIFIPSSKATNRR (SEQ ID NO: 315)

50 ATGGTGGAAACCTCTCATTTGGTACTACTATGGCAGCCCTCTGGCTCCCTAA  
 TGTACTCTTCTCTGCCTACTTGTCACTTATGGATGCCATATATTCCACTGCCATGTCACCC  
 AAATTGATGATAGACTACTCTGTATAAAATCGTATTCTCTGTCACTTGTCACTGGTC  
 AGCTCTCATAGAACACTTACTGGTGGTGCAGAGGTCTCTTGGTGGTATGGCTA  
 55 TGATCGCTATGTGGCTATCTCAAGCCGCTGCACTATTGAACATCATGAATGACTGGT  
 TGCATCTCTGTTGGTGGCCATGATTGGAGGTTTGTGCACTCTGTGGTCAAATTGT

CTTTCTGTACAGTCTACCAATCTGTGGCCCCAATGTTATTGACCACTCTGTCTGTGACATGT  
 ACCCATTGTTGGAACTGTTGTGCCTGACACCTACTTTATAGGACTCACTGTGGTTGCCAA  
 TGGTGGAAATAATTGTATGGTCATCTTACCTTCTGCTAATCTCTGTGGAGTCATCCTAA  
 5 ACTTCCTTAAAACCTACAGTCAGGAAGAGAGGGCATAAAGCCCTGCCTACCTGCATCTCCA  
 CATCATTGTTGCTGCCCTGTTTGTCCCTGTATTGTTATGTTAGACCCGTTCCA  
 ACTTTCCCTTGTATAAATTAAATGACTGTGTTTATTCAATTATCACACTCATGTTGAATCCT  
 TTAATATACTCGTGGAGACAATCAGAGATGAAAAATGCTATGAAAATCTCTGGTGTGAA  
 AAGTTAAGTATAGTTAGAAAAAGAGTATCTCCACACTGAACATATTATTCTAGTTCTA  
 AGGCAACAAATAGGCGGTAA (SEQ ID NO: 316)

10

**AOLFR172 sequences:**

MAETLQLNSTFLHPNFFILTGFPGGLGSAQTWLTLVFGPIYLLALLGNGALPAVVWIDSTLHQPM  
 FLLLAAILAATDGLATSIAPGLLAVLWLGPNSVPYAVCLVQMFFVHALTAMESGVLLAMACDR  
 15 AAAIGRPLHYPVLTVKACVGYAALALALKAVAIVVPFPLVAKFHFQAKTIGHTYCAHMAV  
 VELVVGNTQATNLYGLALSLAISGMDILGITGSYGLIAHVLQLPTREAHAKAFGTCSHICVIL  
 AFYIPGLFSYLAHRRFGHHTVPKPVHILLSNIYLLPPLNPLIYGARTKQIRDRLLETFTFRKSPL  
 (SEQ ID NO: 317)

20

ATGGCAGAAACTCTACAACTCAATTCCACCTCCTACACCCAAACTTCTTCATACTGACTG  
 GCTTTCCAGGGCTAGGAAGTGCCAGACTTGGCTGACACTGGTCTTGGGCCATTATCT  
 GCTGGCCCTGCTGGCAATGGAGCACTGCCGGCAGTGGTGTGGATAGACTCCACACTGCA  
 CCAGCCCATGTTCTACTGTTGCCATCCTGGCAGCCACAGACCTGGCTTAGCCACATCT  
 25 ATAGCCCCAGGGTTGCTGGCTGTGGCTTGGGCCCCGATCTGTGCCATATGCTGTGT  
 GCCTGGTCCAGATGTTCTTGACATGCACTGACTGCCATGGAATCAGGTGTGCTTTGGC  
 CATGGCCTGTGATCGTGCCTGGCAATAGGGCGTCCACTGCACTACCCGTCTGGTCACC  
 AAAGCCTGTGTGGTTATGCAGCCTGGCCCTGGCACTGAAAGCTGTGGCTATTGTTGTAC  
 CTTTCCCACTGCTGGTGGCAAAGTTGAGCACTTCAAGCCAAGACCATAGGCCATACCTA  
 TTGTGACACATGGCAGTGGTAGAAGTGGTGGGTAACACACAGGCCACCAACTTATA  
 30 TGGTCTGGCACTTCACTGGCCATCTCAGGTATGGATATTCTGGGTACTGGTCTCTCCTAT  
 GGACTCATTGCCATGCTGTGCTGCAGCTACCTACCCGGAGGCCATGCCAAGGCCITTG  
 GTACATGTAGTTCTCACATCTGTGTCATTCTGGCCTCTACATACTGGTCTCTCCTAC  
 CTCGCACACCGCTTGGTCATCACACTGTCCAAAGCCTGTGCACATCCTCTCCTACAT  
 CTACTGCTGCTGCCACCTGCCCTCAACCCCCCATCTATGGGGCCCGACCAAGCAGATC  
 AGAGACCGACTCCTGGAAACCTTCACATTAGAAAAGCCGTGTAA (SEQ ID NO: 318)

35

**AOLFR173 sequences:**

MSHTNVTFHPAVFVLPGIPGLEAYHIWLSIPLCLIYITAVLGNISILIVVIVMERNLHVPMYFFLS  
 MLA VMDILLSTTVPKALAIFWLQAHNIAFDACVTQGFFVHMMFVGESAILLAMA FDRFVAIC  
 40 APLRYTTVLTWPVVGRIALAVITRSFCIIFPVIFLLKRLPFCLTNIVPHSYCEHIGVARLACADITV  
 NIWYGFSPIVMVILDVILIAVSYSILRAVFRLPSQDARHKALSTCGSHLCVILMFYVPSFTLL  
 THHFGRNIPQHVHILLANLYVAVPPMLNPIVYGVTKQIREGVAHRRFDIKTWCCSTSPLGS  
 (SEQ ID NO: 319)

45

ATGAGTCACACCAATGTTACCATCTTCCATCCTGCAGTTTGTCCCTGGCATCCCTGG  
 GTTGGAGGCTTACACATTGGCTGTCATAACCTCTTGCTCATTTACATCACTGCAGTCC  
 TGGGAAACAGCATCCTGATAGTGGTTATTGTCATGGAACGTAACCTTCATGTGCCCATGTA  
 TTTCTCCTCTCAATGCTGCCGTATGGACATCCTGCTGTACCACTGTGCCCAAGG  
 CCCTAGCCATCTTGGCTCAAGCACATAACATTGCTTGTGCCTGTGCACCCAGGC  
 TTCTTGTCCATATGATGTTGTGGGGAGTCAGCTACCTGTTAGCCATGGCCTTGATCG  
 50 CTTTGTGCCATTGTGCCCACTGAGATATAACACAGTGTCAACATGGCCTGTGGGG  
 AGGATTGCTCTGCCGTATCACCCGAAGCTCTGCATCATCTCCAGTCATATTCTGCT  
 GAAGCGGCTGCCCTCTGCCCTAACCAACATTGTCCTACTCCTACTGTGAGCATATTGGA  
 GTGGCTCGTTAGCCTGTGACATCACTGTTAACATTGGTATGGCTTCTCAGTGCCCAT  
 TGTCACTGGTCATCTGGATGTTATCCTCATCGCTGTGCTTACTCACTGATCCTCCGAGCAG  
 55 TGTTTCGTTGCCCTCCAGGATGCTCGGCACAAGGCCCTCAGCACTTGTGGCTCCACCT  
 CTGTGTCATCCTTATGTTATGTTCCATCCTCTTACCTTATTGACCCATCATTTGGCG

WO 01/98526

TAATATTCTAACATGTCCATCTTGTGGCCAATCTTATGTGGAGTGCACCAATGC  
 TGAACCCATTGCTATGGTGTGAAGACTAACAGAGATACGTGAGGGTAGCCCACCGGTT  
 CTTGACATCAAGACTTGGTGTACCTCCCTGGGCTCATGA (SEQ ID NO: 320)

## 5 AOLFR175 sequences:

MHFLSQNDLNINLIPHLCRHRHSVIAGAFTIHRHMKIFNSPSNSSTGFILLGFPCPREGQILLFV  
 LFTVVYLLTLMNGNSIICAVHWDQRLHAPMYILLANFSFLEICYVTVPMLANFLSDTKIISF  
 SGCFQFYFFFSLGSTECCFLAVMAFDRLAICRPLRYPTIMTRLCTNLVNCWVLGFIWFLIPI  
 VNISQMSFCGSRIIDHFLCDPAPLLTCKKGPIVELVFSVSLPVLFIVGSYALVRAVL  
 10 RVPSAAGRRKAFSTCGSHLAVVSLFYGSVLVMSPPSKNEAGKQKTVTLFYSVVTPLNPVI  
 YSLRNKDMRKALKFWGT (SEQ ID NO: 321)

15 ATGCATTTCTTCCAAAATGATTAAATATAATCTGATTCCCCATCTATGTTGCACCG  
 TCATTCACTGCTGGTCTTTACAATTACAGGCACATGAAAATCTCAACAGCCCC  
 AGCAACTCCAGCACCTCACTGGCTCATCCTCTGGGCTCCCTGCCAGGGAGGGGC  
 AGATCTCCTCTTGTGCTTCACTGTTACCTCTGACCCCTATGGCAATGGTCC  
 ATCATCTGTGCTGTGACTGGGATCAGAGACTCCACGCCCCATGTACATCTGCTGCCA  
 ACTTCTCCTCTGGAGATATGTTATGTCACCTCCACAGTCCCCAGCATGCTGCCA  
 CTCTGACACCAAGATCATCTGTTCTGGCTCTCCAGTTACTCTTCTCC  
 20 TTGGGCTCTACAGAATGCTTTCTGGAGTATGGCATTGATGACATCTGCTGCCA  
 TCGGCCTCTACGCTATCCAACCATTATGACCAAGACGTCTGTACCAATCTGTTCTCC  
 GCTGGGTACTGGTTCTGGTTCTGATTCTATGTCACATCTCCAAATGCTCC  
 TGTGGATCTAGGATTATTGACCACTCCATGTGACCCAGCTCTCTTAAGTCC  
 25 CAAAAAGGCCCTGTGATAGAGCTGTTCTGCTCTGGCTCACCTGGCTGTGGTTCA  
 TCTTCTCTTCAATTGGGGCTCATGCTCTGGCTGAGAGCTGTTGAGGGTCCCTCA  
 GCAGCTGGGAGAAGAAAGGCTTCTCCACCTGTGGGCTCACCTGGCTGTGGTTCA  
 TCTACGGCTCAGTACTGGTCATGTATGGGAGCCACATCTAAGAATGAAGCTGGAAAGC  
 AGAAGACTGTGACTCTGTTATTCTGTTACCCACTGCTTAACCTGTGATATAAGT  
 30 CTTAGGAACAAAGATATGAGAAAGCTCTGAAGAAATTGGGGAACATAA (SEQ ID NO:  
 322)

## AOLFR176 sequences:

MFFIIHSLVTSVFLTALGPQNRTMHFVTEFVLLGFHGQREMQSCKFSFILVLYLLLLNGAIVC  
 AVKLDRLRHTPMYILLGNFAFLIEWYISSTVPNMLVNILSEIKTISFGCFLQFYFFFSLGTTECFF  
 35 LSVMAYDRYLAICRPLHYPSIMTGFCHLVCVCWGGFLCYPVPIVLISQLPFCGPNIIDHLVCD  
 PGPLFALACISAPSTELICYTFNSMIFGPFLSILGSYTLVIRAVLCIPSGAGRKAFSTCGSHLMV  
 VSLFYGTLVMVYSPSGNPAGMVKIITLVYTAMTPFLNPLIYSLRNKDMKDALKVGLTVS  
 QN (SEQ ID NO: 323)

40 ATGTTCTTATTATTCAATTCTTGGTACTCTGTTCTAACAGCTTGGGACCCAGAA  
 CAGAACATGCATTGGTACTGAGTTGCTCTGGTTCTCATGGTCAAAGGGAGATG  
 CAGAGCTGCTCTCTCATTCACTCTGGTTCTATCTCTGACACTGCTAGGAATGGAGC  
 TATTGTCTGTGAGTAAATTGGACAGGGGGCTCCACACACCCATGTACATCTGGGA  
 45 AACTTGCCTTCTAGAGATCTGGTACATTCTCCACTGTCCAAACATGCTAGTCAATAT  
 CCTCTGAGATAAAACCATCTCTCTGGTCTCTGGTCAATTCTATTCTTTTC  
 ACTGGGTACAACAGAGTGTCTTTTATCAGTTATGGCTTATGATGGTACCTGGCCATC  
 TGTCGTCCATTACACTACCCCTCATCATGACTGGGAAGTTCTGTATAATTCTGGTCTGT  
 ATGCTGGTAGGGGATTCTGTCTGATCCAGTCCATTGTCTTATCTCCAACTCCCT  
 50 TCTGTGGGCCAACATCATTGACCACTGGTGTGACCCAGGCCATTGTTGACTGGC  
 CTGCATCTGCTCCCTCCACTGAGCTTATCTGTTACACCTCAACTCGATGATTCTTG  
 GGCCCTTCTCTCCATCTGGATCTAACACTCTGGTACTCAGAGCTGCTTGTATTCCC  
 TCTGGTCTGGTCAACTAAAGCTTCTCCACATGTGGTCCACCTAATGGTGGTCTC  
 TATTCTATGGAACCTTATGGTATGTGAGCCACATCAGGGAACCCAGCAGGAAT  
 55 GCAGAAGATCATCACTCTGGTATACACAGCAATGACTCCATTAAATCCCCTATCTAT  
 AGTCTCGAAACAAAGACATGAAAGATGCTAAAGAGAGTCTGGGTTAACAGTTAGC  
 CAAAATG (SEQ ID NO: 324)

**AOLFR177 sequences:**

5 MSFFFVDLRPMNRSATHIVTEFILLGFPGCWKIQIFLFLVVIYVLTLLNGNAAIIYAVRCNPLLH  
 TPMYFLLGNFAFLEIWYVSSTIPNMLVNILSHTKAISFSGCFLQFYFFFSLGTTECLFLAVMAYD  
 RYLAICHPLQYPAIMTVRFCGKLVSCWLIGFLGYPIPIFYISQLPFCGPNIIDHFLCDMDPLMAL  
 SCAPAPITECIFYTQSSLVLFITSMYILRSYILLTAVFQVPSAAGRRAFSTCGSHLVVVSFYG  
 TVMVVMYVSPTYGIPITLLQKILTLVYSVTTPLFNPLIYTLRNKDMKLALRNVLFGMIRQNS  
 (SEQ ID NO: 325)

10 ATGTCTTCTTCTTGTAGACTTAAGACCCATGAACAGGTAGCAACACACATCGTGACAG  
 AGTTTATTCTCCTGGGATCCCTGGTGTGGAAAGATTCAAGATTTCCTCTTCATTGTTT  
 TTGGTGTGATTTATGTCTTGACCTTGCTGGAAATGGAGCCATCATCTATGCAGTGAGATGCA  
 ACCCACTACTACACACCCCCATGTACTTCTGCTGGAAATTTCCTCCTTGAGATCTGG  
 TATGTGTCCTCCACTATTCTAACATGCTAGCAACATTCTCTCCAAGACCAAGGCCATCTC  
 15 ATTTCTGGGTGCTCCTCCAGTTCTATTCTCTTTCACTGGAAACAACATGAATGTCCT  
 TTCTGGCAGTAATGGCTTATGATCGATACCTGGCCATCTGCCACCCACTGCAGTACCCCTGC  
 CATCATGACTGTAAGGTTCTGTGGTAAGCTGGTGTCTTCTGTTGGCTTATTGGATTCCCTG  
 GATACCCATTCCCATTCTACATCTCCAACTCCCCCTCTGTTGGCTTAATATCATTGAT  
 CACTTCCTGTGACATGGACCCATTGATGGCTCATCTGTGCCAGCTCCATAACTG  
 20 AATGTATTTCTATACTCAGAGCTCCCTGTCTCTTTCACTAGTATGTACATTCTCGA  
 TCCTATACTCTGTTACTAACAGCTGTTTCAAGTCCCTCTGCAGCTGGTCGGAGAAAAG  
 CCTTCTCTACCTGTGGTCTCATTTGGTGTGGTATCTCTTTCTATGGGACAGTCATGGTA  
 ATGTATGTAAGTCCATATGGATCCAACTTATTGAGAAGATCCTCACACTGGTAT  
 ATTCACTGAGAAATGTCCTGTTGGATGAGAATTGTCAAAATTGTC (SEQ ID NO:  
 25 326)

**AOLFR178 sequences:**

30 MVGANHSVVSEFVFLGLTNSWEIRLLLLVFSSMFYMASMMGNSLILLTVTSDFHLHSPMYFLL  
 ANLSFIDLGVSSVTSPKMIYDLFRKHEVISFGGIAQIFFIIVIGGVEVLLIAMAFDRYVAICKP  
 LQYLTIMSPRMCMFLVAAWVTGLIHSVQVLVFFVNLPCGPNSDSFYCDLPRFIKLACTDSY  
 RLEFMVTANSGFISLGSFFILISYVVIILTVLKHSSAGLSKALSTLSAHSVVVLFFGPLIFVYTW  
 PSPSTHLDKFLAIFDAVLTPVLPNPIIYTFRN (SEQ ID NO: 327)

35 ATGGTTGGGCAAATCACTCCGTGGTGTAGAGTTGTGTTCTGGGACTCACCAATTCC  
 GGGAGATCCGACTTCTCCTCTGTGTTCTCCATGTTTACATGGCCAGTATGATGGGA  
 AACTCTCTCATTTGCTCACTGTGACTTCTGACCCCTCACTTGCACTCCCCATGTATTTCT  
 GTTAGCCAACCTCTCCTCATTGACCTGGGTGTTCTCTGTCACTCTCCAAAATGATT  
 40 ATGACCTGTTAGAAAGCACGAAGTCATCTCCTTGAGGCTGCATCGCTCAAATCTCTT  
 CATCCACGTCATTGGCGGTGTGGAGATGGTGTGCTCATAGCCATGGCCTTGACAGATAT  
 GTGGCCATATGTAAGCCCCCTCCAGTACCTGACCATTATGAGCCAAAGAATGTGCATGTTCT  
 TCTTAGGGCTGCTGGGTGACCGGCCTATCCACTCTGTAGTTCAATTGGTTTGTAGTA  
 AACTTGCCTCTGTGGTCTTAATGTATCGGACAGCTTTACTGTGACCTTCCTCGGTTCAT  
 CAAACTTGCCTGCACAGACAGCTACCGACTGGAGTTACGGTACAGCCAAACAGTGGATT  
 45 ATCTCTGGGCTCCTCTCATACTGATCATTTCTATGTGGTCTCATCTCACTGTTCT  
 GAAACACTCTCAGCTGGTTATCCAAGGCTCTGTCCACCCCTTCAGCTCACGTAGTGTG  
 GTAGTTTGTCTTGGTCTTGTATACGTGGCCATCTCCCTCCACACACCT  
 GGATAAGTTCTGGCCATTTGATGCAGTTCTCACTCCTGTTAAATCCTATCATCTACA  
 CATTAGGAATTGA (SEQ ID NO: 328)

50

**AOLFR179 sequences:**

55 MNGMNHSVVSEFVFMGLTNSREIQLLFVFSLLFYFASMMGNLVIVFTVTMDAHLHSPMYFLL  
 ANLSIIDMAFCISIAPKMICDIFKKHKAISFRGCITQIFFSHALGGTEMVLLIAMAFDRYMAICKP  
 LHYLTIMSPRMCLYFLATSSIIGLIHSVLQVFVVDLPCGPNSDSFYCDLPRLLRACNTQEL  
 EFMVTVNSGLISVGSFVLLVISYIFILFTVWVKHSSGGAKALSTLSAHTVVIIFFGPLMFFYTW  
 PSPTSHLDKYLAIIFDAFITPFLNPVIYTFRNKDMKVAMRRLCSRLAHFTKIL (SEQ ID NO: 329)

WO 01/98526

5 ATGAAATGGAATGAATCACTCTGGTATCAGAATTGTATTCAATGGGACTCACCAACTCAC  
 GGGAGATTCACTCTACTTTGTTCTTGTGTTACTTGCAGCATGGGAA  
 AACCTTGTCAATTGATTCACTGTAACCATGGATGCTCATCGCACTCCCCATGTATTCC  
 CCTGGCTAACCTCTCAATCATTGATATGGCATTTGCTCAATTACAGCCCCTAACAGATGATT  
 10 GTGATATTTCAGAACAGCACAAGGCCATCTCCTGGGGATGTATTACTCAGATCTTCTT  
 TAGCCATGCTCTGGGGACTGAGATGGTGTGCTCATGCCATGGCTTACAGATAAC  
 ATGGCATATGTAACCTCTCAACTACCTGACCACATGAGCCAAAGAATGTGTCTATACT  
 TTTAGCCACTTCCTATCATTGGCTTATCCACTATTGGTCCAATTAGTTTGTGGTA  
 GATTACCTTTGTGGTCTAATATCTTGACAGTTTACTGTGATCTCCCTCGGCTCCT  
 CAGACTGCCTGTACCAACACCCAAAGAACCTGGAGTTATGGTCACTGTCAATAGGACTC  
 ATTTCTGTGGGCTCCTTGCTTGTGCTGGTAATTCTACATCTTCTTGTCACTGTTG  
 GAAACATTCTCTGGTGTAGCCAAGGCCCTCTACCCCTGTCAGCTCATGTCAGTGT  
 GTCATCTGTCTTGGGCACTGATGTTTCTACACATGCCCTCTCCACATCACACCT  
 15 GGATAAAATATCTGCTATTGATGCAATTACTCCTTCTGAATCCAGTTATCTACA  
 CATTAGGAACAAAGACATGAAAGTGGCAATGAGGAGACTGTGCAGTCGCTTGCCTT  
 TTACAAAGATTGTAA (SEQ ID NO: 330)

**AOLFR180 sequences:**

20 MTNKMAYIYIKNLNYFSFLIVQCLQPTMAIFNNNTSSSNFLTAFFGLECAHVWISIPVCCLYTI  
 ALLGNSMIFLVITKRLHKPMMYFLSMLAAVDLCLTITLPTVLGVLFHAREISFKACFIQMF  
 FVHAFSLLESSVLAAMFDRFVAICNPLNYATILTDRLMVLIGLVICIRPAVFLPLLVAINTVSF  
 HGGHELSPFCYHPEVIKYTSKPWISSFWGLFLQLYLNGLTDVLFILESYVLRLTVLGIVARKK  
 25 QOKALSTCVCHICAVTIFYVPLISLSLAHRLFHSTPRVLCSTLANYLLPPVLPNPIIYSLKTKTIR  
 QAMFQLLQSKGSWGFNVRLRGRWD (SEQ ID NO: 331)

25 ATGACTAATAAAATGTATGCTATATATAAAGAATCTAATTATTTCTTCTCATAGT  
 TCAGTGTCTCAACCAACCATGGCAATTCAATAACACCACTTCGCTTCTCTAAACTCC  
 30 TCCTCACTGCATTCCCTGGGCTGGAAATGTGCTCATGTCATGGATCTCCATTCCAGTCTGCTGT  
 CTCTACACCATGGCCCTTGGGAAACAGTATGATCTTCTGTATCATTACTAACGGGA  
 GACTCCACAAACCCATGTATTATTCCTCTCATGCTGGCAGCTGTGATCTATGTCAGC  
 ATTACGACCCCTCCACTGTGCTTGGTCTCTGGTTATGCCGGAGATCAGCTTAA  
 AGCTTGTCTCATCAAATGTCTTGTGATGCTTCTGGAGTCTCGTGGAGTCTCGGTGTGG  
 35 TAGCCATGCCCTTGACCGCTTGTGCTATCTGAACCCACTGAACATGCTACTATCCTC  
 ACAGACAGGATGGTCTGGTGTAGGGCTGGTATCTGATTAGCCAGCAGTTTCTAC  
 TTCCCTTCTGTAGCCATAAACACTGTGCTTCTCATGGGGTCAGGAGTTCCATCCA  
 TTTGCTACCAACCCAGAAGTGTCAAATACACATATTCAAACCTTGGATCAGCAGTTT  
 40 GGGGACTGTTCTCAGCTCTACCTGAATGGCACTGACGTATTGTTATCTTCTCTAT  
 GTCTGATCTCCGTACTGTCTGGCATTGTGGCCAAAGAAGCAACAAAAGCTCTCA  
 GCACCTGTGTCTGTACATCTGCACTGCACTATTCTATGTGCCACTGATCAGCTCT  
 TTGGCACACCGCCTTCCACTCCACCCAAAGGGTGTCTGTAGCACTTGGCAATATT  
 TCTGCTTACCACTGTGCTGAACCCATCATTAACAGCTTGAAGACCAAGACAATCCGC  
 CAGGCTATGTTCCAGCTGTCCAATCAAAGGGTCACTGGGTTATGTGAGGGTCTTA  
 GGGGAAGATGGGATTGA (SEQ ID NO: 332)

45

**AOLFR181 sequences:**

MSVLNNSEVKFLILLGIPGLEHAIWFSIPICLMLYLLAIMGNCTILFIKTEPSLHEPMYYFLAML  
 AVSDMGLSLLPTMLRVFLNAMGISPNAFAQEFFIHGFTVMESSVLLMSLDRFLAIHNPLR  
 YSSILTSNRVAKMGLILAIRSILLVIPFPFTLRLKYCQKNLLSHSYCLHQDTMKLACSDNKTNV  
 50 YVGFIALCTMLDLALIVLSVILKTIILSIALAERLKALNTCVSHICAVLTFYVPIITLAAMHHF  
 AKHKSPLVVVILIADMFLVPPLMNPIVYCVKTRQIWEKILGKLLNVCGR (SEQ ID NO: 333)

55 ATGTCTGTTCTCAATAACTCCGAAGTCAAGCTTCTCTGATTGGGATCCCAGGACTGG  
 AACATGCCACATTGGTCTCCATCCCCATTGCTCATGTACCTGCTGCCATCATGGGC  
 AACTGCACCACTCTTATTATAAAGACAGAGGCCCTGCTCATGAGCCCATGTATTATT  
 CCTTGCCATGTTGGCTCTGACATGGGCTGTCCCTCTCCCTACCATGTTGA

5 GGGTCTTGTCAATGCCATGGAAATTACCTAATGCCGCTTGCTCAAGAATTCTTC  
 ATT CATGGATTCACTGTCAATGGAAATCCTCAGTACTTCTAATTATGCTTGGACCGCTTCT  
 TGCCATTACAATCCCTTAAGATAACAGTTCTACCTCACTAGAACAGGGTTGCTAAAATG  
 GGACTTATTAGCATTAGGAGCATTCTTCTAGTATTCCATTCCCCTACCTAACCTAAGGAG  
 10 ATTAAAATATTGTCAAAAGAACATCTCTTCTCACTCATACTGTCTCATCAGGATACCATGA  
 AGCTGCCCTGCTCTGACAACAAGACCAATGTCATCTATGGCTTCTCATGCTCTGTACT  
 ATGCTGGACTTGGCACTGATTGTTGCTTATGTGCTGATCTGAAAGACTATACTCAGCAT  
 TGCATCTTGGCAGAGAGGCTAAGGCCCTAAATACCTGTCTCCCACATCTGTGCTGTG  
 CTCACCTCTATGTGCCCATCATCACCCGGCTGCCATGCATCACTTGCCAAGCACAAAA  
 15 GCCCTCTGTTGTGATCCTATTGAGATATGTTCTGTTGGCCGCCCCCTATGAACCCC  
 ATTGTGTAAGACTCGACAAATCTGGGAGAAGATCTGGGAAGTTGCTTAAT  
 GTATGTGGGAGATAA (SEQ ID NO: 334)

**AOLFR182 sequences:**

20 15 MTLGSLGNSSSVSATFLSGIPGLERMHIWISIPLCFMYLVSIPGNCTILFIKTERSLHEPMYLF  
 I SMLALIDLGLSLCTLPTVLGIFWVGAREISHDACFAQLFFIHCFSFLESSVLLSMAFDRFVAICHPL  
 LHYVSILTNTVIGRIGLVSLGRSVALIFPLPFMLKRFPYCGSPVLSHYCLHQEVMKLACADMK  
 ANSIYGMFVIVSTVGDLSLLILFSYALILRTVLSIASRAERFKALNTCVSHICAVLLFYTPMIGLSV  
 IHRFGKQAPHLVQVMGFMYLLFPPVMNPIVYSVTKQIRDRTVHAFCY (SEQ ID NO: 335)

25 20 ATGACCCCTGGGATCCCTGGGAAACAGCAGCAGCAGCGTTCTGCTACCTCCCTGCTGAGTG  
 GCATCCCTGGGCTGGAGCGCATGCACATCTGGATCTCCATCCACTGTGCTTCATGTATCT  
 GGTTCCTACCCGGCAACTGCACAATTCTTTATCATTAAAACAGAGCGCTCACTTCAT  
 GAACCTATGTATCTCTTCTGTCCATGCTGGCTCTGATTGACCTGGCTCTCCCTTGAC  
 30 25 TCTCCCTACAGTCTGGCATCTTTGGGCTCTGCTCTGGCTAGTGTAGCACTCATTTCATTA  
 TTTGCTCAGCTCTTTCTTCATTCACTGCTCTCCCTCGAGTCCCTGTGCTACTGTCTATG  
 GCCTTGACCGCTTGCTATCTGCCACCCCTTGCACTATGTTCCATTCTCACCAACAC  
 AGTCATTGGCAGGATTGGCTGGCTCTGGCTAGTGTAGCACTCATTTCATTA  
 CCTTTATGCTAAAAGATTCCCTATTGTGGCTCCCGACATGAAGGCCAACAGCATCTACGGC  
 35 30 ATCGCTTGGAAAGCAGGCACCCACCTGGTCCAGGTGGCTATGGTTCTATGTATCT  
 CCACCAAGAAGTGTGAAATTGGCTGTGCCACATGAAGGCCAACAGCATCTACGGC  
 GTTTGTCATGTCCTACAGTGGGTATAGACTCACTGCTCATCCTCTCTTATGCTCTGA  
 TCCTGCGCACCGTGTCCATGCCCTCCAGGGCTGAGAGATTCAAGGCCCTAACACCTG  
 TGTTTCCCACATCTGTGCTGTGCTCTACACTCCATGATTGGCCTCTGTGTCATCC  
 ATCGCTTGGAAAGCAGGCACCCACCTGGTCCAGGTGGCTATGGTTCTATGTATCT  
 CTTCCCTGTGATGAATCCCATTGCTACAGTGTGAAGACCAACAGATCCGGATCGA  
 GTGACGCATGCCCTTGTTACTAA (SEQ ID NO: 336)

**AOLFR183 sequences:**

40 40 MTNLNASQANHRNFILTGPDPDKNPWLAFPLGFLYTLTLLNGNTILAVIKVEPSLHEPTYYFL  
 SILALTDVLSMSTLPSMLSIYWFNAPQIVFDACIMQMFFIHVFGIVESGVLVSMAFDRFVAIRN  
 PLHYVSILTHDVIRKTGIVSLTRAVCVVFPVPFLIKCLPFCHSNVLHSYCLHQNMMLACASTR  
 INSLYGLIVVIFTLGLDVLTLSSYVLTALKTVLGIVSRGERLKLSTCLSHMSTVLLFYVPFMGA  
 ASMIHRFWEHLSPVVMVMAIDIYLLPPVLPNPIVYSVTKQI (SEQ ID NO: 337)

45 45 ATGACGAACCTGAATGCATCACAGGCCAACCAACCGTAACCTCATTCTGACAGGTATCCCAG  
 GAACGCCAGACAAGAACCCATGGTGGCTTCCCTGGATTCTCTACACACTCACACT  
 CCTGGGAAATGGTACCATCTAGCTGTCACTCAAGGTGGAGCCAAGTCTCCATGAGGCCACG  
 TATTACTCTTCTATCTGGCTCTCACTGACGTTAGTCTCTCCATGTCCACCTGCCCTCC  
 50 50 ATGCTCAGCATCTACTGGTTAATGCCCTCAGATTGTTTGATGCATGCATCATGCAGAT  
 GTTCTTCATCCATGTATTGGAATAGTGAATCAGGAGTCCCTAGTGTCCATGGCCTTGAC  
 AGATTGTCGGCCATCCGAAACCCATTACACTATGTTCCATCCTCACTCACGATGTTATTG  
 AAAGACTGGAATATCTGTCTCACCCGGGAGTCTGTGGTATTCCCTGTGCCCTCC  
 ATAAAGTGCCTACCCCTCTGCCATTCAATGCTTGTCTATTCAACTGTCTCACCAAAA  
 55 55 CATGATGCGGCTAGCTGTGCCAGCACCCGCATCAACAGCCTCACGGCCTCATCGTC  
 ATCTCACACTGGGCTCGATGTTCTCCTCACTCACTGTCTTATGTACTCACCTGAAGAC  
 TGTGCTGGCATTGTCTCCAGAGGTGAAAGGCTGAAAACCTCAGCACATGCCCTCTCAC

WO 01/98526

ATGTCTACCGTGCCTCTTCTATGTCCTTATGGGTGCTGCCCATGATCCACAGATT  
 TTGGGAGCATTATCACCACTAGTAGCAGATGGTCACTGGCTGATATACCTACTGCTCCG  
 CCTGTCTAAACCCATTGTCTACAGTGTGAAGACCAAGCAAATTG (SEQ ID NO: 338)

## 5 AOLFR184 sequences:

MSTLPTQIAPNSSTSMAPTFLVGMPGLSGAPSWWTLPLIAVYLLSALGNGTILWIALQPALHR  
 PMHFFLFLLSVSDIGLVTALMPTLLGIALAGAHTVVASACLLQMVFIHVFSVMESSVLLAMSID  
 RALAICRPLHYPALLTNGVISKISLAISFRCLGLHLPLFLLAYMPYCLPQVLTHSYCLHPDVARL  
 ACPEAWGAAYSLFVVLSAMGLDPPLLIFSYGLIGKVLQGVESREDRWKAGQTCAAHLSAVLLF  
 YIPMILLALINHPELPIQHTHTLLSYVHFLLPLINPILYSVKMKEIRKRILNRLQPRKVGGAQ  
 (SEQ ID NO: 339)

10 ATGTCAACATTACCAACTCAGATAGCCCCAATAGCAGCACTCAATGGCCCCCACCTCT  
 TGCTGGTGGCATGCCAGGCCATCAGGTGCACCCCTCTGGGACATTGCCCTCATTGC  
 15 TGTCTACCTCTCTGCACTGGAAATGGCACCCTCTCTGGATATTGCCCTCAGGCC  
 GCCCTGCACGCCAATGCACCTCTCTCTGGCTTAGTGTCTGATATTGGATTGGT  
 CACTGCCCTGATGCCACACTGCTGGCATGCCCTGCTGGTCTCACACTGCCCTGCC  
 TCAGCCTGCCCTACAGATGGTTTATCCATGTCTTCTGTATGGAGTCTCTGTCTT  
 GCTGCCATGTCCATTGATCGGGACTGCCATCTGCCACCTCTCCACTACCGCGCTC  
 20 CTCACCAATGGTGAATTAGAAAATCAGCTGGCCATTCTGGGCTACTGCCCTCCACAGGTCTTAACCCAT  
 ATCTGCCCTGCCATTCTGCTGGCTACATGCCCTACTGCCCTCCACAGGTCTTAACCCAT  
 TCTTATTGCTGCATCCAGATGTGGCTGTTGGCTGCCAGAAGCTGGGTGCAGCCT  
 ACAGCCTATTGTGGTTTCAGCCATGGGTTGGACCCCTGCTTATTCTCTCCAT  
 25 GGCCTGATTGCAAGGTGTTGCAAGGTGTTGGAGTCCAGAGAGGATCGCTGGAAAGGCTGT  
 CAAACCTGTGCTGCCACCTCTGCAGTGCCTCTCTGAGTCCACTCAGCATACTCTCTATGTCC  
 ACTGATTAACCATCCTGAGCTGCCATCAGCATACTCAGCATACTCTCTATGTCC  
 ATTTCTCTCTCCATTGATAAACCTATTCTCTATAGTGTCAAGATGAAGGAGATTAGA  
 AAGAGAAACTCAACAGGTGCAAGCCAGGAAGGTGGTGGCTCAGTGA (SEQ ID NO:  
 340)

30

## AOLFR185 sequences:

MFYPILDISTKNNSNIMSCCNILFIKTVIILVYNQTOQPWYPIVPSKLVYNNNTCFDCYHLQR  
 VDCVPSRDHINQSMVLASGNSSHPVSFILLGIPGLESFQLWIAFPFCATYAVAVGNITLLHIVR  
 35 IDHTLHEPMYFLAMLAITDVLSSSTQPKMLAIFWFHAHEIQYHACLIQVFFIHFSSVESGVL  
 MAMALDCYVATCFPLRHSSILTPSVVILGTIVMLRGLLWVSPFCFMVSRMPCQHQAPIQSYC  
 EHMVLKLVCADTSISRGYGLFVAFSVAGFDIVIGMSYVMILRAVLQLPSGEARLKAFSTRA  
 SHICVILALYPAFLSFLTYRGHDVPRVVFILFANLYLLIPMLNPIIYGVRTQIGDRVIQGCCG  
 NIP (SEQ ID NO: 341)

40 ATGTTCTACCCATTGAAATGACATAAGTACGAAAAACAACAGTAACATCATGTCATGTT  
 GTAAACATATTATTTAAACAGTTGAATTATTCTAGTTATAATCAAACCAATCACC  
 CTGGTATCCAATAGTCCCATCCAAAAGCCTTGTATATAATAATAACACTGTTTGATTGTT  
 ATCATCTGCAGAGAGTAGATTGCGTCCCAGCAGAGACCATATAACCAGTCCATGGTCTG  
 GGCTTCAGGAACAGCTCTCTCATCCTGTCCTCATCCTGTTCTGCCCCGCTG  
 45 GAGAGTTCCAGTTGGATTGCTTCTGCCCCGCTGCCCCGCTGATGCTGTGGCTGTTG  
 AAATATCCTCTCCATGTAATCAGAATTGACCACACCCTGCATGAGCCCATGTACCTC  
 TTTCTGGCCATGCTGGCCATCAGTGCACCTGGCTCTCCTCCACTCAACCTAACATGTT  
 GGCCATATTCTGGTTCATGCTCATGAGATTCACTGACCTGGCTCTGCTGCTG  
 50 TCATCCATGCCTTCTCTGTCAGTACAGCATGCTGACCTGGCTCTGCTGCTG  
 GTGGCTACCTGCTTCCACTCCGACACTAGCATCTGACCTGGCTCTGCTGCTG  
 TGGGACCATGTCATGCTGAGAGGGCTGCTGTGGGTGAGGCCCTGCTGCTG  
 TAGGATGCCCTCTGCCAACACCAAGCCATTCCCCAGTCATACTGTGAGCACATGGCTG  
 CTGAAGTTGGTGTGCTGATACAAGCATAAGTGTGGGTGCTGCTGCTGCTG  
 55 CTGTGGCTGGTTGATATGATTGCTTGTGATGCTACAGTGTGATGATTGAGAGCTG  
 GCTTCAGTTGCCCTCAGGTGAAGCCGCTCAAAGCTTTAGCACACGTGCCTCCATAC  
 TGTGTCATCTGGCTTTATCCAGCCCTTTCTCCTCACCTACCGCTTGGCCAT

GATGTCCCCGAGTTGTACACATCCTGTTGCTAATCTCTATCTACTGATACCTCCATGCT  
CAACCCCATCATTATGGAGTTAGAACCAAACAGATCGGGACAGGGTTATCCAAGGATG  
TTGTGGAAACATCCCTGA (SEQ ID NO: 342)

5 AOLFR186 sequences:

MSNASLVTAFILTGLPHAPGLDALLFGIFLVVYVLTVLGNLLILLVIRVDSHLHTPMYYFLTNLS  
FIDMWFSTVTVPKMLMTLSPSGRAISFHSCVAQLYFFHFLGSTECLFLYTVMSYDRYLAISYPL  
RYTSMMSGSRCALLATGTWLSGSLHSAVQTILTFHLPYCGPNQIQHYFCDAPPILKACADTSA  
NVMVIFVDIGIVASGCFVLIVLSYVSIVCSILRIRTSRGRRRAFQTCASHCIVVLCFFVPCVVIYLR  
10 PGSMAMDGVVAIFYVLTPLLNPVVYTLRNKEVKKAVLKL RDKVAHPQRK (SEQ ID NO:  
343)

ATGTCCAACGCCAGCCTCGTACAGCATTACCTCACAGGCCTCCCCATGCCAGGGC  
TGGACGCCCTCCTCTTGAATCTTCTGGTTACGTGCTACTGTGCTGGGGACCT  
15 CCTCATCCTGCTGGTATCAGGGTGGATTCTCACCTCACACACCCCATGTTACTACTTCCTCA  
CCAACCTGTCCTCATTGACATGTGGTCTCCACTGTCACGGTGCCAAATGCTGATGAC  
CTTGGTGTCCCCAAGCGGCAGGGCTATCTCCCTCACAGCTGGTGGCTCAGCTCTATT  
TCCACTTCCTGGGGAGCACCAGTGTGTTCTACACAGTCATGCTCTATGATCGCTACTTG  
20 GCCATCAGTTACCCGCTCAGGTACACCAGCATGATGAGTGGGAGCAGGTGTGCCCTCCTGG  
CCACCGGACTTGGCTCAGTGGCTCTGCACCTGCTGTCCAGACCATAATTGACTTTCCAT  
TTGCCCTACTGTGGACCCAACCAGATCCAGCACTACTTCTGTGACGCACCGCCATCCTGA  
AACTGGCCTGTGCAGACACCTCAGCCAACGTGATGGTCATTTGTGGACATTGGGATAGT  
25 GGCCTCAGGCTGCTTGTCTGATAGTGTGTCCTATGTGTCCATCGTCTGTTCCATCCTGC  
GGATCCGCACCTCAGATGGGAGGCGCAGAGCCTTTCAGACCTGTGCCTCCACTGTATTGT  
GGTCCTTGCTTGTGTTCCCTGTGTTGTCATTATCTGAGGCCAGGCTCCATGGATGCCA  
TGGATGGAGTTGTGGCCATTTCACACTGTGCTGACGCCCTCTCAACCTGTTGAC  
30 ACCCTGAGAAACAAGGAGGTGAAGAAAGCTGTGTTGAAACTAGAGACAAAGTAGCACAT  
CCTCAGAGGAATAA (SEQ ID NO: 344)

30 AOLFR187 sequences:

MAQVRALHKIMALFSANSIGAMNNSDTRIAGCFLTGIPGLEQLHIWLSIPFCIMYIAALENGNILI  
CVILSQAILHEPMYIFLSMLASADVLLSTTTPKALANWLGYSHISFDGCLTQKFFIHFLFIHSA  
VLLAMAFDRYVAICSPRLYVTLTSKVGKIVTATLSRSFIIMFPSIFLLEHLHYCQINIIAHTFCEH  
MGIAHLSCSDISINVWYGLAAALLSTGLDILITVSYIHLQAVFRLSQDARSKALSTCGSHICV  
35 ILLFYVPALFSVFAYRGGRSIPCYVHILLASLYVVIIPMLNPVIYGVRTKPILEAKQMFSNLAK  
GSK (SEQ ID NO: 345)

ATGGCACAGGTGAGGGCGCTGCTAAAATCATGGCCCTTTCTGCTAACAGCATAGGTG  
CTATGAACAACACTGACACTCGCATAGCAGGGCTTCTCACTGGCATCCCTGGCTGGA  
40 GCAACTACATATCTGGCTGTCCATCCCTCTGCATCATGTACATCGCTGCCCTGGAAAGGC  
AATGGCATTCTAATTGTGTCATCCTCTCCAGGCAATCCTGCATGAGCCATGTACATAT  
TCTTATCTATGCTGGCCAGTGTGATGTCTGCTCTACCAACACATGCCCTAAGGCCCTG  
GCCAATTGTGGCTAGGTTATGCCACATTCTTGTGATGGCTGCCTCACTCAAAGTTCTT  
45 CATTCACTTCCTCTTCATTCACTCTGCTGTCCTGCTGGCCATGGCTTGTGACCGCTATGTGG  
CCATCTGCTCCCCCTGCGATATGTCACAATCCTCACAAAGCAAGGTCACTGGGAAGATCGT  
CACTGCCACCCCTGAGCCGAGCTTCATCATTATGTTCCATCCATCTTCTCCTGAGCACC  
TGCACATTGCCAGATCAACATCATTGCACACACATTGTGAGCACATGGCATTGCCA  
TCTGTCTGTTGATATCTCATCAATGTCTGGTATGGGTTGGCAGCTGCTCTCTCCA  
50 CAGGCCTGGACATCATGCTTATTACTGTTCTACATCCACATCCTCCAAGCAGTCTTCCGC  
CTCCCTTCTCAAGATGCCGCTCCAAGGCCCTGAGTACCTGTGGATCCCATCTGTGTCAT  
CCTACTCTTCTATGTCCCTGCCCTTTCTGCTTGTCTTGCCTACAGGTTGGGGAGAAGCA  
TCCCATGCTATGTCCAATTCTCTGGCCAGCCTCACGTTGTCAATTCTCTATGCTCAAT  
CCCCTTATTATGGAGTGAGGACTAAGCCAATCTGGAAGGGCTAAGCAGATGTTTCA  
AATCTGCCAAGGATCTAAATAA (SEQ ID NO: 346)

55

WO 01/98526

**AOLFR188 sequences:**

5 MFPSLCPCVLLVQLPLMNENMQCFVFCSCDSLLRMMVSFIFHVPFKMKRIIVGGYSKHFSSN  
 ELLCVRPWSGKTSIRHHIFDMELLNNLKFITDPFVCRRLRHSPTPSEEHMKNKNVTEFILL  
 GLTQNPEGQKVLFVTFLLIYMTIMGNLLIVTIMASQSLGSPMYFFLASLSPIDTVYSTAFAPK  
 10 MIVDLLSEKKTISFQGCMQLFMDHLFAGAEVILLVVMAYDRYMAICKPLHELTMRRCV  
 MLLAAWIGGFLHSLVQFLFIYQLPFCGPVNIDNFLCDLYPLLKLA  
 CTNTYVTGLSMIANGGAIC  
 15 AVTFFTILLSYGVILHSLKTQSLEGKRKAFTCASHVTVILFFVPCIFLYARPNSTFPIDKSMTV  
 VLTFTPMNLNPLIYTLKNAEMKSAMRKLWSKKVSLAGKWLHYS (SEQ ID NO: 347)

10 ATGTTCCCTCCCTGTGTCCATGTGTTCTCTTGTCAACTCCACTTATGAATGAGAACAT  
 GCAGTGTGTTCTGTTCTGTGATAGTTGCTGAGAATGATGGTTCCCGCTTCATCC  
 ATGTCCTATGTAAAAATGAAAAGGATAATTGTGGGAGGATATTCTAAACACTCTTTC  
 TAATGAGCTGCTGTGAGGCCCTGGTCAGGGAAACGTGGTCGATAAGGCATCACAT  
 15 TTTGACATGGAGCTCTGACAATACTCAAATTATCACTGACCCTTTGTAGGC  
 TCCGACACCTGAGTCCAACACCTCAGAAGAACACATGAAAATAAGAACATGTACTG  
 AATTATCCTCTAGGGCTCACACAGAACCCGTAGGGGAAAAGGTTTATTTGTCACATT  
 CTTACTAATCTACATGGTACGATAATGGCAACCTGCTATCATAGTACCATGATGGCC  
 AGCCAGTCCCTGGGTTCCCCATGTACTTTCTGGCTTCTTATCATTGATAGAACATGGC  
 20 CTATTCTACTGCATTGCTCCAAAATGATTGTGACTTGCTCTGAGAAAAGACCATTT  
 CCTTCTAGGGTTGATGGCTCAACTTTATGGATCATTATTGCTGGTGTGAAGTCATT  
 TCACCATGAATCGTCGAGCTGTCTTATGCTGTTGGCCCTGGATTGGAGGCTTCT  
 25 ACAACTTCTGTGATTGTATCCCTTATTGAAACTTGCTGACCCAATACCTATGTCACT  
 GGGCTTCTATGATAGCTAATGGAGGAGCATTGTGCTGACCTCTTCACTATCCTGC  
 TTTCTACACCTGTGATCCCACGTCACTGTGGTCATTATTCTTGTCCCCTGATCTCTT  
 GTATGCAAGGCCAATTCTACTTTCCATTGATAAATCCATGACTGTAGTTCAACTTTA  
 30 TAACTCCATGCTGAACCCACTAATCTATACCTGAAGAACATGAGAAATGAAAGTCAT  
 GAGGAAACTTGGAGTAAAAAGTAAGCTAGCTGGAAATGGCTGTACTCATG  
 (SEQ ID NO: 348)

**AOLFR189 sequences:**

35 MQQNSVPEFILLGLTDPLRQKIVFVILIFYMGTVGNGMLIIVTIKSSRTLGSPMYFFLYLSF  
 ADSCFSTSTAPRLIVDALSEKKIITYNECMTQVFALHLFCMEIFVILMAVDRYVAICKPLRYP  
 TIMSQVCIILIVLAWIGSLIHTAQILALRLPFCGPYLIDHYCCDLQPLLKACMDTYMINLL  
 VSNSGAICSSSFMLIISYIVLHSLRNHSAGKKKALSACTSHIIVVILFFGPCIFIYTRPPTTFPM  
 KMVAVFYTIGTPFLNPLIYTSEECRSEKCHEK (SEQ ID NO: 349)

40 ATGCAGAAAATAACAGTGTGCTGAATTCTACTGTTAGGATAACACAGGATCCCTGA  
 GGCAGAAAATAGTGTGTAATCTTAAATTCTATATGGAACTGTGGTGGGGAAATAT  
 GCTCATTATGTGACCATCAAGTCCAGCCGACACTAGGAAGCCCCATGTACTCTTCTA  
 TTTATTGCTCTTGAGATTCTGCTTCAACTTCCACAGCCCTAGATTAATTGTGA  
 45 TGCTCTCTGAAAAGAAAATTAAACCTACAATGAGTGCATGACACAAGTCTTGCACTA  
 CATTATTGCTGCATGGAGATCTTGTCTCATTCTCATGGCTGTGATCGCTATGTGGC  
 CATCTGTAAGCCCTGCGTTACCAACCACATGAGCCAGCAGGTCTGCATCATCTGATT  
 GTCTTGCTGGATAGGGCTTTAACACTACAGCTCAGATTATCTGGCCTTAAGATT  
 50 GCCTTCTGTGGACCCATTGATTGATCATTGTGATTTGCTGTTGGTCTAACAGTGGGCAATTG  
 TTGCTGCATGGACACTTACATGATCACCTGCTGTTGGTCTAACAGTGGGCAATTG  
 CTCAGTAGTTCATGATTGATAATTCTATATTGCTCATCTGCATTCACTGAGAAC  
 ACAGTGCCAAAGGGAGAAAAGGCTCTCCGCTTGACGTCACATAATTGTAGTCAT  
 CTTATTCTTGCCCCATGTATATTCTATATACAGCCCCCGACCACTTCCCCATGGACA  
 AGATGGGGCAGTATTCTACTATTGGAACACCCCTTCTCAATCCACTCATCACATCT  
 GAGGAATGCAGAAGTGAAGATGCCATGAGAAAG (SEQ ID NO: 350)

**AOLFR190 sequences:**

5           MQRSNHTVTEFILLGFTTDPGMQLGLFVVFLGVYCLTVVGSSLIVLICNDSRLHTPMYFVIGN  
 LSFLDLWYSSVHTPKILVTCISEDKSISFAGCLCQFFSARLAYSECYLLAAMAYDHYVAISKPLL  
 YAQTMRRRLCICLVLYSYTGGFVNAILTSNTFLDFCGDNVIDDFCDVPLVKLACSVRESYQ  
 5           AVLHFLLASNVISPTVLILASYLSIITLRIHSTQGRIKVFSTCSSHLISVTLYYGSILYNYSRPSSS  
 YSLKRDKMKVSTFYTMLFPMLNPMIYSLRSKDMKDALKFFKSA (SEQ ID NO: 351)

10           ATGCAGAGGAGCAATCACACAGTGACTGAGTTCATCCTGCTGGGCTTACCCACAGATCCAG  
 GGATGCAACTGGGCCTTTGTGGTCTGGGTGTACTGTCTGACTGTGGTAGGAAG  
 10           TAGCACCCCTCATCGTGTGATCTGTAATGACTCCCCGCTACACACACCCATGTATTTGTCA  
 TTGGAAATCTGTCAATTCTGGATCTCTGGTATTCTCTGTCCACACCCAAAGATCCTAGTG  
 ACCTGCATCTCTGAAGACAAAAGCATCTCCTTGCTGGCTGCCTGTGTCAGTTCTCTCTGC  
 CAGGCTGGCCTATAGTGAGTGCTACCTACTGGCTGCCATGGCTATGACCAACTACGTGGCC  
 15           ATCTCCAAGCCCCCTGCTTATGCTCAGACCATGCCAAGGAGATTGTGCATCTGTTGGTTT  
 ATATTCCCTATACTGGGGGTTTGTCATGCAATAATATTAACCAGCAACACATTACATTG  
 GATTTTGTTGTGGTGACAATGTCATTGATGACTTTCTGTGATGTTCCACCCCTCGTGAAGCT  
 GGCATGCAGTGTGAGAGAGAGCTACCAGGCTGTGCTGCACTTCCTCTGGCCTCCAATGTC  
 ATCTCCCTACTGTGCTCATCCTGCCCTAACCTCTCCATCATACCACCATCCTGAGGAT  
 CCACCTACCCAGGGCCGCATCAAAGTCTCTCCACATGCTCCTCCCACCTGATCTCCGTTA  
 20           CCTTATACTATGGCTCCATTCTACAACATACCTCCGGCCAAGTCCAGCTACTCCCTCAAG  
 AGGGACAAAATGGTTCTACCTTATACTATGCTGTTCCCAGTGTGAATCCCATGATCTA  
 CAGTCTGAGGAGTAAAGACATGAAAGACGCTCTGAAAAAAATTCTTCAAGTCAGCATAA  
 (SEQ ID NO: 352)

WO 01/98526

**AOLFR191 sequences:**

5 MTGGGNITEITYFILLGFSDFPRIKVLFTIFVYITSLAWNLSLIVLIRMDSHLHTPMYFFLSNLS  
 FIDVCYISSTPKMLSNLQEQQTITFVGCIQYFIFSTMGLSESCLMTAMAYDRYAAICNPLLYS  
 SIMSPTLCVWMVLGAYMTGLTASLFQIGALLQLHFCGSNVIRHFFCDMPQLLILSCTDTFFVQV  
 5 MTAILTMFYIASALVIMISYGYIGISIMKITSAKGSPKAFNTCASHLTAVSLFYTSGIFVYLRSSS  
 GGSSSFDRFASVFYTVVIPMLNPLIYSLRNKEIKDALKRLQKRKCC (SEQ ID NO: 353)

10 ATGACTGGGGAGGAAATTACAGAAATCACCTATTCTCCTGCTGGATTCTCAGATT  
 TTCCCAGGATCATAAAAGTGTCTTCACTATATTCTGGTGTACATTACATCTGGCC  
 15 TGGAACTCTCCCTCATTGTTAATAAGGATGGATTCCACCTCCATACACCCATGTATT  
 CTTCCCTAGTAACCTGTCTTCAAGATGTCTGCTATATCAGCTCCACAGTCCCCAAGATGC  
 TCTCCAACCTCTTACAGGAACAGCAAACATCACTTTGTTGGTGTATTATTCACTACTTT  
 ATCTTCAACGATGGGACTGAGTGAGTCTTGTCTATGACAGCCATGGCTTATGATCGTT  
 ATGCTGCCATTGTAACCCCTGCTCTTCACTCATGTCACCCACCCCTGTGTTGG  
 15 ATGGTACTGGGAGCCTACATGACTGGCTCACTGCTTATTCCAATTGGTGTCTTGCT  
 TCAACTCCACTCTGTGGGCTAATGTCATCAGACATTCTCTGTGACATGCCCAACTGT  
 TAATCTTGTCTGTACTGACACTTCTTGACAGGTATGACTGCTATAATTAAACATGTC  
 TTTGGGATAGCAAGTGCCTAGTTATCATGATATCCTATGGCTATAATTGGCATCTCCATCA  
 TGAAGATCACTTCAGCTAAAGGCAGTCCAAGGCATTCAACACCTGTGCTTCTCATCAAC  
 20 AGCTGTTCCCTCTCTATACATCAGGAATCTTGTCTATTGAGGTCAGCTCTGGAGGT  
 CTTCAAGCTTGACAGATTGCATCTGTTCTACACTGTGGTCTTCCATGTTAAATCCC  
 TTGATTTACAGTTGAGGAACAAAGAAATTAAAGATGCCTAAAGAGGTGCAAAGAGA  
 AAGTGCTGCTGA (SEQ ID NO: 354)

**AOLFR192 sequences:**

25 MENNTEVTEFILVGLTDDPELQIPLFIVFLIYLITLVGNLGMIELILDSCLHTPMYFFLSNLSV  
 DFGYSSAVTPKVMVGFGLDKFILYNACATQFFFFVAFITAESFLLASMAYDRYAAALKPLHY  
 TTTMTTNCACLAIGSYICGFLNASIHTGNTFRSLCRSNVVEHFFCDAPPLTLSCSDNYISEM  
 VIFFVVGNDLFSILVILISYLFIFITIMKMRSPGRQKAFSTCASHLTAVSIFYGTGIFMYLRPNSS  
 30 HFMGTDKMASVFYAIVIPMLNPLVYSLRNKEVSAFKKTVGAKASIGFIF (SEQ ID NO: 355)

35 ATGGAGAACACACAGAGGTGACTGAATTCATCCTGTTAACTGATGACCCAGAA  
 CTGCAGATCCCACTCTCATAGTCTTCCATTCTACCTCATCACTCTGGTGGAAACCT  
 GGGGATGATTGAATTGATTCTACTGGACTCTGTCTCCACACCCCATGTACTCTCCTCA  
 GTAACCTCTCCCTGGGACTTTGGTATTCTCAGCTGTCACTCCAAGGTGATGGTGG  
 40 GTTTCTCACAGGAGAAAATTCAATTATAATGCTGTGCCACACAATTCTCTTCTG  
 TAGCCTTATCACTGCAGAAAGTTCTCTGGCATCAATGGCTATGACCGCTATGCAGC  
 ATTGTGTAACCCCTGCATTACACCACCATGACAACAAATGTATGTGCTTGCCTGGCC  
 ATAGGCTCTACATCTGTGGTTCTGAATGCATCCATTCAACTGGAACACTTCAAGGC  
 45 TCTCCTCTGTAGATCCAATGTTGAACACTTTCTGTGATGCTCTCTCTGTACT  
 CTCTCATGTCAGACAACATCACTGAGATGGTTATTTTGTGGGGATTCAATG  
 ACCTCTTCTATCTGGTAATCTGATCTCTACTTATTATTTATCACCACATGAAG  
 ATGCGCTCACCTGAAGGACGCCAGAAGGCCCTTACTTGTGCTTCCCACCTACTGCAG  
 TTTCCATTTATGGGACAGGAATCTTATGTAATTACGACCTAACCTCAGGCCATTCA  
 GGCACAGACAAAATGGCATCTGTGTTCTATGCCATAGTCATTCCATGTGAATCCACTGG  
 TCTACAGCCTGAGGAACAAAGAGGTTAAGAGTGCCTTAAAAGACTGTAGGGAGGCAA  
 AGGCCTCTATAGGATTCAATTAA (SEQ ID NO: 356)

**AOLFR193 sequences:**

50 MENKTEVTQFILLGLTNDSLQVPLFITFPFIYIITLVGNLGIIVLIFWDSCLNPMYFFLSNLSV  
 DFCYSSAVTPIVMAGFLIEDKVISYNACAAQMYIFVAFATVENYLLASMAYDRYAAVKPLHY  
 TTTMTTVCARLAIGSYLCGFLNASIHTGDTFSLSFCKSNEVHFFCDIPAVMVLSCSDRHISEL  
 VLIYVVSFNIFIALLVILISYTFIFITILKMHSAVYQKPLSTCASHFIAVGIFYGTIIFMYLQPSSSH  
 SMDTDKMAPVFYTMVIPMLNPLVYSLRNKEVSAFKKVEAKLSVGWSV (SEQ ID NO:

ATGGAAAATAAGACAGAAGTAACACAATTCTTCTAGGACTAACCAATGACTCAGAA  
 CTGCAGGTTCCCTCTTATAACGTTCCCTCATCTATATTACACTCTGGTGGAAACCT  
 GGGATTATTGTATTGATATTCTGGGATTCCTGTCTCCACAATCCCATGTACTTTCTCA  
 5 GTAACTTGTCTCTAGTGGACTTTGCTACTCTCAGCTGCACTCCATCGTCATGGCTGGA  
 TTCTTATAGAACAGACAAGGTCACTCTTACAATGCATGTGCTGCTCAAATGTATATCTTGT  
 AGCTTTGCCACTGTGGAAAATTACCTCTTGGCCTCAATGGCCTATGACCGCTATGCAGCA  
 GTGTGCAAACCCCTACATTACACCACAACCAGACAACAACACTGTGTGCTCGTCTGGCCA  
 TAGGCTCCTACCTCTGTGGTTCTGAATGCCTCCATCCACACTGGGGACACATTTAGTCTC  
 10 TCTTCTGTAAGTCCAATGAAGTCCATCACTTTCTGTGATATCCAGCAGTCATGGTCT  
 CTCTGCTCTGATAGACATATTAGCGAGCTTGTCTTATTATGTTGAGCTTCATATCT  
 TTATAGCTCTCGTTATCTGATATCCTACACATTCTACCTTATCACCATCCTAAAGATG  
 CACTCAGCTCAGTATACAGAACGCTTGTCCACCTGTGCCTCTCATTCATTGCACTCGG  
 CATCTCTATGGGACTATTATCTCATGTACTTACAACCCAGCTCCAGTCACTCCATGGACA  
 15 CAGACAAAATGGCACCTGTGTTCTATACAATGGTACCCCCATGCTGAACCCCTGGTCTA  
 TAGTCTGAGGAACAAAGGAAGTGAAGAGTCATTCAAGAAAGTTGTTGAGAAGGAAAATT  
 GTCTGTAGGATGGTCAGTTAA (SEQ ID NO: 358)

**AOLFR194 sequences:**

20 MERQNQSCVVEFILLGFSNYPELQGQLFVAFLVIYLVTLIGNAIIVSLDQSLHVPMYLFLLNL  
 SVVDLSFSAVIMPEMLVVLSTEKTTISFGGCFAQMYFILLFGGAECFLGAMAYDRFAAICHPL  
 NYQMIMNKGVFMKLIIFSWALGFMLGTQTSWVSSFPFCGLNEINHISCTPAVLELACADTFL  
 FEIYAFGTFLIILVPFLLILSYIRVLFAILKMPSTTGRQKAFSTCAAHLSVTLYGTASMTYLQ  
 PKSGYSPETKKVMSLSYSLLTPLLNLISLRNSEMKRALMKLWRRRVVLHTI (SEQ ID NO:  
 359)  
 25  
 ATGGAAAGACAAAATCAAAGCTGTGTTGAATTACATCCTCTGGCTTTCTAACTATC  
 CTGAGCTCCAGGGGCAGCTTTGTGGCTTCTGGTATTATCTGGTGACCCGTAGAG  
 AAATGCCATTATTATAGTCATCGTCTCCCTAGACCAGAGCCTCCACGTTCCATGTACCTGT  
 30 TTCTCCTGAACTTATCTGTGGTGGACCTGAGTTTCAGTGCAGTTATTATGCCTGAAATGCT  
 GGTGGTCCTCTACTGAAAAAAACTACAATTCTTTGGGGCTGTTGACAGATGTAT  
 TTCATCCTCTTTGGTGGGCTGAATGTTCTCTGGGAGCAATGGCTATGACCGATT  
 TGCTGCAATTGCCATCCTCTCAACTACCAAAATGATTATGAATAAAGGAGTTTATGAAA  
 TTAATTATATTCATGGCCTTAGGTTATGTTAGGTACTGTTCAAACATCATGGGTATC  
 TAGTTTCCCTTTGTGGCCTTAATGAAATTACCATATATCTGTGAAACCCAGCAGTGT  
 35 TAGAACTTGCATGTGCAGACACGTTTGTGAAATCTATGCATTACAGGCACCTTTG  
 ATTATTTGGTCTTCTGTGATACTCTTGTCTTACATTGAGTTCTGCCATCTG  
 AAGATGCCATCAACCACTGGAGACAAAAGGCCCTTCCACCTGTGCCGCTCACCTCACAT  
 CTGTGACCCATTCTATGGCACAGCCAGTATGACTTATTACAACCCAAATCTGGCTACTC  
 40 ACCGGAAACCAAGAAAGTGTGATGTCTACTCACTCTGACACCAGTGTGAATCTG  
 CTTATCTACAGTTGCGAAATAGTGAGATGAAGAGGGCTTGATGAAATTATGGCGAAGG  
 CGAGTGGTTTACACACAATCTGA (SEQ ID NO: 360)

**AOLFR195 sequences:**

45 MIVQLICTVCFLAVNTFHVRSSEDFLKADDMGEINQLVSEFLLGLSGYPKIEIVYFALILVMY  
 LVILIGNGVLIASIFDSHFHTPMYFFLGNLSFLDICYTSSVPSTLVSLSKKRNISFSGCAVQMFF  
 GFAMGSTECLLLGMMAFDRLYVAICNPLRYPILSKVAYVLMASVWSLSGGINSAVQTLLAMRL  
 PFCGNNIINHFACEILAVLKLACADISLNIITMVISNMAFLVPLMVIFPSYMFYTLQMSATG  
 RRKAFSTCSAHLTVVIIFYGIFTMYAKPKSQDLIGEELQALDKLISLYGVVTPMLNPILYSLR  
 NKDVKAALKYLLNKKPIH (SEQ ID NO: 361)  
 50  
 ATGATTGTTCACTTAATTGTACTGTTCTTGGCAGTAAATACATTCTATGTAGATC  
 TTCTTGTATTCTGAAAGCAGATGACATGGGTGAGATTAACCCAGACACTGTGTCA  
 55 AGTTATGTACCTAGTGAATTCTAATTGGCAATGGTGTCTAATCATAGCCAGCATCTTGATT  
 CTCATTTCACACACCAATGTACTCTCTGGCAACCTCTCTTCTGGATATCTGCTAT  
 ACATCCTCCTCTGTTCCCTAACATTGGTGAGCTTAATCTCAAAGAAAAGAACATTCCCT

WO 01/98526

5           TCTCTGGATGTGCA GTGCAGATGTTGGTTGCAATGGGTCAACAGAACATGCTGCT  
 TCTTGGCATGATGGCATTGATCGTTATGTGGCCATCTGCAACCCACTGAGAACATCCATC  
 ATCCTGAGCAAGGTGGCGTATGTATTGATGGCTCTGTGTCTGGCTGCCGTGGAATAA  
 ATTCACTGTGCAAACATTACTGCCATGAGACTGCCCTCTGTGGGAATAATATTATCAA  
 10          TCATTTGGCATGTGAAATATTAGCTGCTCTCAAGCTGGCCTGTGCTGATATATCCCTCAATA  
 TTATCACCATGGTATCAAATATGGCTCTGGTCTTCAACTGATGGTCATTITTC  
 TCCTATATGTTCATCCTACACCCTGCAAATGAATTGCCACAGGAAGACGCAAGG  
 CATTTCACGTGCTCAGCTCACCTGACTGTGGTATCATATTACGGTACCATCTTCTT  
 ATGTATGCGAAACCGAAGTCTCAAGAACCTGATTGGGAAGAAAATTGCAAGCATTAGAC  
 15          AAGCTCATTCTGTTATGGGTAGTGACACCCATGCTGAATCTATACTCTAGCTT  
 GAGAAATAAGGAAGTGTAAAAGCTGCTGAAATATTGCTGAACAAAAACCAATTCACTA  
 A (SEQ ID NO: 362)

**AOLFR196 sequences:**

15          MLESNYTMAPTEFLFVGFTDYLPLRVTLFLVFLVYTLTMVNILLIILVNINSSLQIPMYYFLSNL  
 SFLDISCSTAIPKMLANFLASRKSIISPYGCALQMFFFASFADAELAAMAYDRYAAICNPLL  
 YTTLMRRVCVCFIVLAYFSGSTTSLVHVCLTRLSFCGSIVNHFCDIPPLLALSTDTQINQL  
 LLFALCSFIQTSFVVFISYFCILITVLSIKSSGRSKTFSTCASHLIAVTLYGALLFMYLQPTTS  
 20          YSLDTDKVVAVFYTVVFPFMNPYISFRNKDVKNALKKLERIGYSNEWYNRLRIVNI (SEQ  
 ID NO: 363)

25          ATGTTGGAGAGTAATTACACCATGCCACTGAGTTCTATTGTTGGATTACAGATTATC  
 TACCTCTCAGAGTCACACTGTTCTGGTATTCTCTGGTATATACATTAACATGGTGG  
 AATATACTCTTAATAATTCTAGTTAATTAATTCAAGCCCTCAAATTCCCATGTATTATT  
 30          TCTTAGCAACTATCTCTAGACATCAGCTGTTCTACAGCAATCACTCCTAAATGCTGG  
 CAAACTCTTGGCATCCAGGAAAAGCATCTCTCTTATGGGTGTGCACTACAAATGTTT  
 CTTCGCTTCTTGTGATGCTGAGTGCTTATCTGGCAGCAATGGCTTATGACCGCTATG  
 CAGCCATCTGCAACCCACTGCTCTACTACACTGATGCTAGGAGAGTCTGTCTGCTT  
 CATTGTGTTGGCATATTCACTGGAAAGTACAACATCACTGGTCCATGTGTGCCACATTC  
 35          AGGCTGTCACTTGCTCCAATATCGTCAATCATTTTCTGTGATATCCACCTCTCT  
 GGCTTATCATGTACAGACACTCAGATCAACCAGCTCTGCTCTTGCTTGTGAGCTCA  
 TCCAGACCAGCACTTGTGGAATATTCTTACTCTGCATCCTCATACTGTGTTG  
 AGCATCAAGTCTCAGGTGGCAGAAGCAAACATTCTCCACTTGTGCTTCCACCTCATAG  
 CAGTCACCTTATTCTATGGAGCGCTCTGTTATGACTTACAGCCCACCACTAGCTATTCC  
 40          CTAGACACTGATAAGGTGGTGGCAGTGTATTACTGTTGATTCCCATGTTAATCAA  
 TAATTATAGTTCAAAACAGATGTAAAAATGCTCTAAAAAGCTATTAGAAAGAA  
 TTGGATATTCAAATGAATGGTATTAAATGTTAAGAATAGTCATATCTAA (SEQ ID NO:  
 364)

**AOLFR197 sequences:**

40          MCYLSQLCLSLGEHTLHMGMVRIHTNESNLAGFILLGFSDYQLQKVLFVLILYL  
 ILVSRLEPKLHMPMYFFLHSFLYRCFTSSVIPQLLVNLWEPMKTIAYGGLVHLYNSHALGS  
 TECVLLALMSCDRYVAVRPLHYTLMHIICMALASMAWLSGIATTLVQSTLTLQPFCH  
 RQVDHFICEVPVLKLAvgTTFNEAELFVASILFLIVPVSFILVSSGYIAHAVRIKSATRQKAF  
 45          GTCFSHLTVTIFYGTIIFMYLQPAKSRSRDQGKFVSLFYTVVTRMLNPLIYTLRIKEVKGALKK  
 VLAKALGVNIL (SEQ ID NO: 365)

50          ATGTGTTATCTTCTCAGCTATGCCAGCCTGGGAACACACTTACATATGGGATGG  
 TGAGACATACCAATGAGAGCAACCTAGCAGGTTCATCCTTCTGATTCTGATTATCC  
 TCAGTTACAGAAGGTCTATTGTGCTCATATTGATTCTGATTACTAATTTGGGA  
 ATACCACCATCATTGGTTCTCGTCTGGAACCCAGCTCATATGCCATGTATTCTC  
 CTTCTCATCTCCTCTGTACCGCTGCTCACCAGCAGTGTATTCCCACTGCTCTGGT  
 AACACCTGTGGGAACCATGAAAATATGCCATGGTGGCTTGGTCACTTACAAC  
 TCCCAGCCCTGGGATCCACTGAGTGCCTCTGGCTCTGATGTCCTGTGACCGCTATGT  
 55          GGCTGTCGCCGTCCTCTCATTACACTGCTTAATGCATATCCATCTGCATGGCCTTGG  
 CATCTATGGCATGGCTCAGTGGAAAGCCACCACTGGTACAGTCCACCCCTGCA

5 GCTGCCCTCTGTGGCATGCCAAGTGGATCATTCATCTGCAGGGCTCTGTGCTCATC  
AAGCTGGCTTGTGGCACCACTTAAACGAGGCTGAGCTTTGTGGCTAGTATCCTT  
TCCTTATAGTCCTGCTCATTCATCCTGGCTCTGGTACATTGCCACCGAGTGGT  
AGGATTAAGTCAGCTACCAGGAGACAGAAAGCATCGGGACCTGCTCTCCACCTGACA  
GTGGTCACCATCTTTATGGAACCATCATCTTCATGTATCTGCAGCCAGCCAAGAGTAGAT  
CCAGGGACCAGGGCAAGTTGTTCTCTTCAACTGTGGTAACCCGCATGCTTAACCC  
TCTTATTATACCTTGAGGATCAAGGAGGTGAAAGGGCATTAAAGAAAGTCTAGCAAA  
GGCTCTGGGAGTAAATTTATGA (SEQ ID NO: 366)

## 10 AOLFR198 sequences:

15 MENCTEVTKFILLGLTSVPELQIPLFILFTFIYLLTLCGNLGMMLLILMDSCLHTPMYFFLSNLSL  
VDFGYSSAVTPKVMAGFLRGDKVISYNACAVQMFFFVALATVENYLLASMAYDRYAAVCKP  
LHYTTTMTASVGACALGSYVCGLNASFHIGGIFSLSFCKSNLVHHFFCDVPAVMALSCSDKH  
TSEVILVFMFSSFNIFVFVLLVIFISYLFIFITILKMHSAKGHQKALSTCASHFTA  
PSSSHSMDTDKMASVFYAMIPMLNPVYSLRNREVQNAFKKVLRRQKFL (SEQ ID NO: 367)

20 ATGGAGAATTGTACCGAAGTGACAAAGTCTATTCTCTAGGACTAACAGTGTCCCCAGAAC  
TACAGATCCCCCTCTTATCTTGTACCTCATCTACCTCCTCACTCTGTGGAAACCTG  
GGGATGATGTTGCTGATCCTGATGGACTCTGTCTCCACACCCCCATGTAACCTTCTCAG  
TAACCTGTCTGGTGGACTTGGATACTCCTCAGCTGTCACTCCAAAGGTATGGCTGGG  
TTCCCTAGAGGAGACAAGGTCACTCCTACAATGCATGTGCTGTTCAAGATGTTCTTCTTGT  
AGCCTTGGCCACGGTGGAAAATTACTTGTGGCTCAATGGCCTATGACCGCTATGCAGCA  
GTGTGCAAACCCCTACACTACACCAACCCATGACGGCCAGTGTAGGTGCTGTGGCCC  
TAGGCTCATATGTCTGTGGCTTCTAAATGCCTCATTCCACATTGGGGGATATTCAAGTCTC  
25 TCTTTCTGTAAATCCAATCTGGTACATCACTTTCTGTGATGTTCCAGCAGTCATGGCTCT  
GTCTTGCTCTGATAAACACACTAGTGAGGTGATTCTGGTTTTATGTCAAGCTTAATATCT  
TTTTGTTCTCTAGTTATCTTATCTCTACTTGTTCATATTCAACCATCTGAAGATGC  
ATTCAAGGGACACCAAAAGCATTGTCCACCTGTGCCTCTACTTCAGTCAGTC  
CGTCTCTATGGGACAGTAATCTCATCTACTTGCAAGCCCAGCTCCAGCCACTCCATGGAC  
30 ACAGACAAAATGGCATCTGTGTTCTATGCTATGATCATCCCCATGCTGAACCTGTGGTCT  
ACAGCCTGAGGAACAGAGAAGTCCAGAATGCATTCAAGAAAGTGTGAGAAGGCAAAAT  
TTCTATAA (SEQ ID NO: 368)

### AOLFR199 sequences:

35 MDTGNKTLQPQDFLLGFPGSQLQLSFLMLFLVMYILTVSGNVAILMLVSTSHQLHTPMYFFLS  
NLSFLEIWYTTAAVPKALAILLGRSQTISFTSCLLQMYFVFSLGCTEYFLAAMA YDRCLAICYP  
LHYGAIMSSLLSAQLALGSGWVCGFVAIAVPTALISGLSFCGPRAINHFFCDIAPWIALACTNTQA  
VELVAFVIAVVVILSSCLITFVSYVYIISTILRIPSASGRSKAFSTCSSHTVVLIWYGSTVFLHVR  
TSIKDADDLIKAHVVLNTVVTPVLPNPFIYTLRNKEVRETLLKKWKGK (SEQ ID NO: 369)

40 ATGGACACAGGCAACAAAACCTGCCCCAGGACTTCTTACTGGGCTTCCTGGTCTC  
AAACTCTCAGCTCTCTCTTATGCTTTCTGGTGATGTACATCCTCACAGTTAGGGT  
AATGTGGCTATCTTGTGATGTGGTGAGCACCTCCATCAGTGCATACCCCCATGTACTCTT  
TCTGAGCAACCTCTCCTCTGGAGATTGGTATACCACAGCAGCAGTGCCAAAGCACTG  
45 GCCATCCTACTGGGGAGAAGTCAGACCATATCAATTACAAGCTGCTTTGCAGATGTACT  
TTGTTTCTCATTAGGCTGCACAGAGTACTTCCCTGGCAGCCATGGCTATGACCGCTGT  
CTTGCACATCTGCTATCCTTACACTACGGAGCCATCATGAGTAGCCTGCTCAGCGCAGC  
TGGCCCTGGGCTCTGGGTGTGGTTCTGTGCCATTGCACTGCCACAGCCCTCATCAG  
50 TGGCCCTGTCTTCTGTGGCCCCGTGCCATCAACCACTTCTGTGACATTGCACCCCTGGA  
TTGCCCTGGCTGCACCAACACACAGGCACTAGAGCTTGTGGCTTGTGATTGCTGTTGT  
GGTATCCTGAGTTCATGCCTCATCACCTTGTCTCTATGTGTACATCATCAGCACCATCC  
TCAGGATCCCCCTGTGCCAGTGGCCGGAGCAAAGCCTCTCCACGTGCTCCTCGCATCTCAC  
CGTGGTGTCTATTGGTATGGGTCCACAGTTCTTACGTCCGCACCTCTATCAAAGAT  
55 GCCTTGGATCTGATCAAAGCTGTCCACGTCTGAACACTGTGGTGACTCCAGTTAAACC  
CCTTCATCTATACGCTTCGTAATAAGGAAGTAAGAGAGACTCTGCTGAAGAAATGGAAGG  
GAAAATAA (SEQ ID NO: 370)

WO 01/98526

## AOLFR200 sequences:

5 MTRKNYTSLTEFVLLGLADTLELQIILFLFLVIYTLTVLGNLGMILLRIDSQQLHTPMYFFLANL  
 SFVDVCNSTTIPKMLADLSEKKTISFAGCFLQMYFFISLATTECILFGLMAYDRAAICRPLL  
 YSLIMSRVTYVLKMAAGAFAAGLNFVNTHVSSLSFCDSNVIIHFFCDSPPLFKLSCSDTILKE  
 SISSILAGVNIVGTLVILSSYVLFISIFSMHSGEGRHRAFSTCASHLTAIILFYATCIYTLYRPSS  
 10 SYSLNQDKVASVFTVVPMLNPLIYSLRSKEVKKALANVISRKRTSSFL (SEQ ID NO: 371)

15 ATGACCAGAAAAATTATACTCACTGACTGAGTTGTCCTATTGGGATTAGCAGACACGC  
 TGGAGCTACAGATTATCCTCTTTGTTTCTTGATTATACACTACAGTACTGGGA  
 AATCTCGGGATGATCCTCTTAATCAGGATCGATTCCAGCTCACACACCCATGTATTCTT  
 CCTGGCTAACCTGCTCTTGAGCTTGTAACTCAACTACCATACCCCCAAAGATGCTG  
 GCAGATTATTATCAGAGAAGAAAACATCTCTTGCTGGCTGCTTACAGATGTACT  
 20 TCTTATCTCCCTGGCACAACCGAATGCATCCTCTTGCTTAATGGCTATGACAGGTA  
 TGCGGCCATATGCGCCCGTGTACTCCITGATCATGTCAGGACCGTACCTAAAA  
 ATGGCAGCCGGGCTTGCTGCAGGGTTGCTGAACCTCATGGTCAACACAAGCCATGTCA  
 GCAGCTTGTCAATTGTGACTCCAATGTCATCCATCACTCTCTGTGACAGTCCCCCATT  
 TTCAAGCTCTTGTCTGACACAATCCTGAAAGAAAGCATAAGTTCTATTGGCTGGTG  
 25 TGAATATTGTGGGGACTCTGCTGTATCCTCTCCTACTCCTACGTTCTCTCCATT  
 TTTCTATGCAATGGGGAGGGCACAGAGCTTCCACGTGTGCCCTCACCTGA  
 CAGCCATAATTCTGTTATGCCACCTGCATCTACTTACCTGAGACCTAGTCCAGCTAC  
 TCCCTGAATCAGGACAAAGTGGCTCTGTCTACACAGTGGTGAATCCCATGTTGAATC  
 CTCTGATCTACAGCCTCAGGAGTAAGGAAGTAAAGAAGGCTTAGCGAATGTAATTAGCA  
 GGAAAAGGACCTTCTCTGTGA (SEQ ID NO: 372)

25

## AOLFR201 sequences:

MEWENHTILVEFFLKGSLGHPRLELLFFVLIFIMYVILLGNGLLISILDPLHHTPMYFFLGNL  
 SFLDICYYTSIPSTLVSFLSERKTISLSGCAVQMFLGLAMGTTECVLLGMMAFDRYVAICNPLR  
 YPIIMSKDAYVPMAAGSWIIGAVNSAVQSVFVQLPFCRNNIINHFTCEILAVMKLACADISDN  
 30 EFIMLVATTLFILTPLLILIVSYTLIIVSIFKISSSEGRSKASSTCSAHLTVIIFYGTILFMYMKPKS  
 KETLNSDDLDATDKIISMFYGVMPMMNPLIYSLRNKDVKAEVKHLLNRRFFSK (SEQ ID NO:  
 373)

35 ATGGAATGGAAAACCACACCATTCTGGGAATTCTGAAGGGACTTCTGGTCACC  
 CAAGACTTGAGTTACTCTTTCTGCTCATCTTCATAATGTATGTGGTCATCCTCTGGGG  
 AATGGTACTCTCATTTAATCAGCATCTGGACATCTGTCACACCCCTATGTTACTCTT  
 TCTGGGGACCTCTCCTCTGGACATCTGTCACACCCACCTCTATTCCCTCACGCTAG  
 TGAGCTTCTTCAGAAAGAAAGACCATTCCTCTGGCTGTGCAGTGAGATGTCT  
 CGGCTTGGCCATGGGACAACAGAGTGTGCTCTGGCATGATGGCCTTGACCGCTAT  
 40 GTGGCTATCTGCAACCTCTGAGATATCCCATCATGAGTAAGGATGCCATGTACCA  
 TGCGAGCTGGCTCTGGATCATAGGAGCTGCAATTCTGCAGTACAATCAGTGTGGT  
 ACAATTGCCCTCTGCAAGGAAACATCATCAATCATTCACTGTTGAAATTCTGGCTGTC  
 ATGAAACTGGCTGTGCTGACATCTCAGACAATGAGTTCATGCTTGCCACAACAT  
 45 TGTCATATTGACACCTTGTATTAAATCATTGTCTTACACGTTAATCATTGTGAGCATC  
 TTCAAAATTAGCTCTCCAGGGGAGAAGCAAAGCTTCTACCTGTCAGCCATCTGA  
 CTGTGGTCATAATATTCTATGGGACCATCCTCTCATGTCAGATGAAGCCAAGTCAAAGA  
 GACACTTAATCGGATGACTGGATGCTACCGACAAAATTATCCATGTTCTATGGGTG  
 ATGACTCCCATGATGAATCTTAAATCTACAGTCTAGAAACAGGATGTGAAAGAGGCA  
 GTAAAACACCTACTGAACAGAAGGTTCTTAGCAAGTGA (SEQ ID NO: 374)

50

## AOLFR202 sequences:

MEWENHTILVEFFLKGSLGHPRLELLFFVLIFIMYVILLGNGLLISILDPLHHTPMYFFLGNL  
 SFLDICYYTSIPSTLVSFLSERKTISLSGCAVQMFLSLAMGTTECVLLGVMAFDRYVAICNPLR  
 YPIIMSKDAYVPMAAGSWIIGAVNSAVQSVFVQLPFCRNNIINHFTCEILAVMKLACADISGN  
 55 EFILLVTTLFLLTPLLILIVSYTLIILSIFKISSSEGRSKPSSTCSARLTVVITFCGTIFLMMYMKPKSQ

ETLNSDDLDATDKLIFIFYRVMTPMMNPLIYSLRNKDVKEAVKHLLRRKNFNK (SEQ ID NO: 375)

5 ATGGAATGGGAAAACCACACCATTCTGGTCCAATTCTGAAGGGACTTCTGGTCACC  
 CAAGACTTGAGTTACTCTTTTGTGCTCATCTCATAATGTATGGTCATCCTCTGGGG  
 AATGGTACTCTCATTAACTCAGCATCTGGACCCTCACCTCACACCCCTATGACTTCTT  
 TCTGGGAAACCTCTCCTCTGGACATCTGCTACACCACCTCTATTCCCTCACGCTAG  
 TGAGCTCCTTCAGAAAGAAAGACCATTCCCTCTGGCTGTGCAGTCAGATGTTCT  
 CAGCTGGCCATGGGGACAACAGAGTGTGTGCTCTGGCGTGATGGCCTTGACCGCTAT  
 10 GTGGCTATCTGCAACCCTCTGAGATATCCCATCATCATGAGTAAGGATGCCATGTACCCA  
 TGGCAGCTGGGCTCTGGATCATAGGAGCTGCAATTCTGCAGTACAAACAGTGTGGT  
 ACAATTGCCTTCTGCAGGAATAACATCATCAATCATTCACCTGTGAAATTCTAGCTGTC  
 ATGAAAATGGCCTGTGCTGACATCTCAGGCAATGAGTTCATCCTGCTTGACCAACAT  
 TGTTCTATTGACACCTTGTATTAAATTATTGTCTTACACGTTAATCATTGAGCATE  
 15 TTCAAAATTAGCTCTCGAGGGGAGAAGCAAACCTTCTCACCTGCTCAGCTCGTCTGA  
 CTGTGGTGATAACATTCTGTGGGACCCTTCCTCATGTACATGAAGCCCAAGTCTAAGA  
 GACACTTAATTCAAGATGACTTGGATGCCACTGACAAACTATATTATTCACAGGGTG  
 ATGACTCCATGATGAATCTTTAATCTACAGTCTAGAAACAAGGATGTGAAGGAGGCA  
 GTAAAACACCTACTGAGAAGAAAAATTAAACAAGTAA (SEQ ID NO: 376)

20

**AOLFR203 sequences:**

MKRQNQSCVVEFILLGFSNPELQVQLFGVFLVIYVVTLMGNAIITVIISLNQLHVPMLFLLN  
 LSVVEVSFSAVTPEMLVVLSTEKTMISFVGCFQMYFILLFGGTECFLLGAMAYDRFAAICHPL  
 25 NYPVIMNRGVFMKLVIFSWISGMVATQTTWVFSPPFCGPNEINHLCETPPVLELVCADTFLF  
 EIYAFGTILIVMVPFLILLSYIRVLFAILKMPSTTGRQKAFSTCASHLTSVTLFYGTANMTYLQ  
 PKSGYSPETKKLISLAYTLLPPLLNPYSLRNSEMKTLLKWRKVLHTF (SEQ ID NO: 377)

30

ATGAAAAGACAAAATCAAAGCTGTGGTGAATTCATCCTCTGGCTTTCTAACTTTC  
 CTGAGCTCCAGGTGCAGCTTTGGGTTTCTAGTTATTATGTGGTGACCTGATGGG  
 AAATGCCATCATTACAGTCATCATCCTTAAACCAGAGCCTCACGTTCCATGACCTGT  
 TCCTCTGAACCTATCTGTGGGAGGTGAGTTCACTGAGTCATTACGCCCTGAAATGCT  
 GGTGGTCTCTACTGAGAAAATATGATTCTTGTGGCTGTTGACAGATGTAT  
 TTCATCCTCTTTGGTGGACTGAATGTTCTCCTGGAGCGATGGCTATGACCGATT  
 TGCTGCAATTGCCATCCTCTGAACTACCCAGTGATTATGAACAGAGGGTTTATGAAA  
 35 TTAGTAATATTCTCATGGATCTCAGGGATCATGGTGGCTACTGTGCAGACCACTGGGTAT  
 TTAGTTTCCATTGTGGCCCCAATGAAATTATCATCTCTGTGAGACTCCCCGGTA  
 CTAGAGCTTGTGTGCAGACACCTCTTATTTGAAATCTATGCCCTCACAGGCACCATTT  
 GATTGTTATGGTCCCTTCTGTGATCCTCTGTCTACATTGGAGTTCTGTTGCCATCCT  
 GAAGATGCCATCAACTACTGGAGACAAAAGGCCTTCCACCTGTGCCTCACCTCACA  
 40 TCTGTGACCTGTTCTATGGCACAGCCAATATGACTTATTACAACCCAAATCTGGCTACTC  
 ACCCGAAACCAAGAAACTGATCTCATTGGCTTACACGTTGCTTACCCCTGCTCAATCCG  
 CTCATCTATAGCTTACGAAACAGTGAGATGAAGAGGACTTGATAAAACTATGGCGAAGA  
 AAAGTGATTTCACACACATTCTGA (SEQ ID NO: 378)

45

**AOLFR204 sequences:**

MEKKNVTEFILIGLTQNPIEKVTFVVFLVLYMITLSGNLLIVVTITTSQALSSPMYFFLTHLSL  
 IDTVYSSSSAPKLVDSFQEKKIISFNGCMAQAYAEHIFGATEIILTVMACDCYVAICKPLNYTT  
 IMSHSLCILLVAVA WVGGFLHATIQILFTVWLPFCGPNVIGHFMCMDLYPLLKLVCIDTHTLGLFV  
 AVNSGFICLLNFLILVVSYVIIRLSLKNNLEGRCKALSTCISHIIVVLFVPCIFVYLRVTTLPI  
 50 DKA VAVFYTMVVPMLNPVYTLRNAEVKSARKLWRKKVTSND (SEQ ID NO: 379)

55

ATGGAGAAGAAAAAGAATGTGACTGAATTCTTAAAGGTCTTACACAGAACCCATA  
 ATGGAGAAAGTCACGTTGTAGTATTCTGGTCTTACATGATAACACTTCAGGCAACC  
 TGCTCATTGTGGTACCATACCACCAAGCCAGGCTCTGAGCTCCCCATGACTTCTCCTG  
 ACCCACCTTCTTGTAGACACAGTTATTCTCTTCTCAGCTCTAACAGTTGATTGTGGA  
 TTCCCTTCAAGAGAAGAAAATCATCTCCTTAATGGGTGATGGCTCAAGCCTATGCAGAA

WO 01/98526

5           CACATTTGGTGTACTGAGATCATCTGCTGACAGTGATGGCCTGTGACTGCTATGTGG  
 CCATCTGCAAACCTCTGAACATACACAACCATTAGGCCACAGCCTGTGCATTCTCTGGT  
 GGCAGTGGCCTGGTGGGAGGATTCTCATGCAACTATTCAAGATTCTTACAGTATGG  
 CTGCCCTCTGTGGCCCAATGTCATAGGCCACTCATGTGTGACTTGTACCCATTGTTAAA  
 10          ACTTGTGGCATAGACACTCATACCCCTGGTCTTGTGTGAACAGTGGTTATCT  
 GCTTATTAAACTCCTATCTGGGTATCCTATGTGATCATCTGAGATCTTAAAGAAC  
 AATAGCTTGGAGGGAGGTGAAAGCCTCTCCACCTGTATTCTCACATAGTAGTTG  
 TCTTATTCTTGTGCCCTGTATATTGTGATCTGGCTCAGTGACCACTGTGCCATTGAT  
 15          AAAGCTTGTGCTGTATTATACTATGGTGGTCCAATGTTAAATCCCGTGGTACACAC  
 TCAGAAATGCTGAGGTAAGTCAATAAGGAAGCTTGGAGAAAAAAAGTGAATTCAAG  
 ATAATGATTAA (SEQ ID NO: 380)

**AOLFR205 sequences:**

15          MESENRTVIREFILLGTQSQDIQLLVFVLVLIFYFILPGNLIIFTIKSDPGLTAPLYFFLGNLAFI  
 DASYSFTVAPRMLVDFLSAKKIISYRCITQLFLHLFLGGGEGLLVVMAFDRYIAICRPLHYPT  
 VMNPRTCYAMMLALWLGFVHSIIQVVLRLPFCGPQNLDNFFCDVPQVIKLAQDTFVVEL  
 LMVFNSGLMTLLCFLGLLASYAVILCIRGSSEAKNKAMSTCITHIIVFFMFPGFIFIYTRPFRA  
 FPADKVVSLFHTVIFPLLNPIYTLRNQEVKASMVKVFNKHIA (SEQ ID NO: 381)

20          ATGGAAAAGCGAGAACAGAACAGTGATAAGAGAATTCACTCCCTGGTCTGACCCAGTCT  
 CAAGATATTCACTCCTGGTCTTGTGCTAGTTAATATTCACTCATCATCCCTGG  
 AAATTTCTCATTATTTACCATAAAGTCAGACCCCTGGCTCACAGCCCCCTCTATTCT  
 TTCTGGCAACTTGGCCTCCTGGATGCATCTACTCCTCACTGTGGCTCCCCGGATGTTG  
 25          GTGGACTTCCTCTCGCAAGAACAGATAATCCTACAGAGGCTGCATCACTCAGCTTT  
 TCTTGACTTCCTGGAGGAGGGAGGGATTACTCCTGGTGTGATGGCTTGACCGCTA  
 CATCGCCATCTGCCGCCCTGCACATCCTACTGTCACTGAACCTAGAACCTGCTATGCA  
 ATGATTTGGCTCTGTGGCTGGGGTTTGCCACTCATTATCAGGTGGCCTCATCCT  
 30          CCGTTGCCCTTTGTGGCCAACCAGCTGGACAACACTCTCTGTGATGGCTTCACAGGTC  
 ATCAAGCTGGCTGCACGACACATTGTGGAGCTCTGCTCATGCAGTCATTGTGCGATA  
 TGATGACACTCCTGTGCTTCTGGGCTTCTGGCCTCATGCACTTCACACGGC  
 35          CGAGGGCTCTCTGAGGCCAAAAAACAGGCCATGCCACGTGCATACCCATATCATTG  
 TTATATTCTCATGTTGGACCTGGCATCTCATCACCGCCTTCAGGGCTTCCCA  
 GCTGACAAGGTGGTTCTCTTCCACACAGTGATTCTTGTGAATCCTGTCAATT  
 TACCCCTCGAACAGAACAGTGAAAGCTCCATGAAAAGGTGTTAATAAGCACATAGC  
 CTGA (SEQ ID NO: 382)

**AOLFR206 sequences:**

40          MANRNNVTEFILLGLTENPKMQKIIFFVVFVSIYINAMIGNVLIVVTIASPLSRSPMYFFLA  
 DACYSSVNTPLITDSLYENKTLFNGCMTQVFGEHFFRGVEVILLTVMA  
 45          DHYVAICKPLHYT  
 TIMKQHVCSSLGVGVSWVGGFLHATIQILFICQLPFCGPNVIDHFMCDLYTLIN  
 IAANSGFICLLNCLLLVSCVVLVSLKTHSLEARHEALSTVSHITV  
 VILSFIPCIFVYMRPPATL  
 PIDKAVAVFYTMTSMLNPLIYTLRNAQMKN  
 AIRKLCRKA  
 ISSVK (SEQ ID NO: 383)

45          ATGGCGAATAGAACAAATGTGACAGAGTTATTCTATTGGGCTTACAGAGAAC  
 ATGCAGAAAATCATATTGTGTTCTGTCTACATCAACGCCATGATAGGAAATG  
 TGCTCATTGTGGTCACCATCACTGCCAGCCATCACTGAGATCCCCCATGACTTTCTG  
 GCCTATCTCTCTTATTGATGCCCTGATTCTCTGTCAATACCCCTAACGCTGATCACAGA  
 TTCACTCATGAAAACAAGACTATCTTATTCAATGGATGTACTCAAGTCTTGGAGAA  
 CATTTCAGAGGTGTTGAGGTACATCTACTGTAAATGCCATGACCACTATGTGG  
 50          CCATCTGCAAGCCCTGCACTATACCCATCATGAAGCAGCATGTTGTAGCCTGCTAGT  
 GGGAGTGTCTGTGGCTTAATGTCATAGATCACTTATGTGATCTCTACACTTGATCAA  
 TTACCTTCTGTGGCTTAATGTCATAGATCACTTATGTGATCTCTACACTTGATCAA  
 TCTTGCTGCACTAATACCCACACTCTAGGACTCTTCTGCTGCAACAGTGGGTT  
 GCCTGTTAAACTGTCTTGTCTGGTCTCTGGTCTCGTGGTCAACTGTACTCCTAAAGACC  
 55          CACAGCTTAGAGGCAAGGCATGAAGCCTCTACCTGTCTCCCACATCACAGTGTCA  
 TCTTATCCTTATACCCATGATATTGTGACATGAGACCTCCAGCTACTTACCCATTGAT

AAAGCAGTTGCTGTATTCTACACTATGATAACTCTATGTTAAACCCCTTAATCTACACCTT  
GAGGAATGCTCAAATGAAAAATGCCATTAGGAAATTGTGTAGTAGGAAAGCTATTCAAG  
TGTCAAATAA (SEQ ID NO: 384)

5 **AOLFR207 sequences:**

MERTNDSTSTEFFLVGLSAHPKLQTVFFVILWMYLMILLGNGVLISVIIFDSHLHTPMYFFLCN  
LSFLDV CYTSSSVPLILASFLAVKKVFSGCMVQMFISFAMGATECMILGTMALDRYVAICYP  
LRYPVIMSKGAYVAMAAGSWVTGLVDSVVTQAFAMQLFCANNVHKFVCEILAILKLACADI  
10 SINVISMTGSNLIVLVIPLLVISIYIFIVATILRIPSTEKGHKAFSTCSAHLTVVIIFYGTIFFMYAKP  
ESKASVDSGNEDIEALISLFYGVMTPLNPLIYSLRNKDVKAAVKNILCRKNFSDGK (SEQ ID  
NO: 385)

ATGGAAAGGACCAACGATTCCACGTCGACAGAAATTTCTGGTAGGGCTTCTGCCACC  
CAAAGCTCCAGACAGTTCTCGTCTAATTTGTGGATGTACCTGATGATCCTGTTGGA  
15 AATGGAGTCCTTATCTCAGTTATCATCTTGATTCTCACCTGCACACCCCCATGTATTCTT  
CCTCTGTAATCTTCCTCCTCGACGTTGCTACACAAGTTCTGTCCCCTAATTCTG  
CCAGCTTCTGGCAGTAAAGAAAAAGGTTCTCTGGGTGTATGGTCAAATGTTAT  
TTCTTTGCCATGGGGCACGGAGTGCATGATCTTAGGCACGATGGCACTGGACCGCTAT  
20 GTGGCCATCTGCTACCCACTGAGATACCCGTACATGAGCAAGGGTGCCTATGTGGCCA  
TGGCAGCTGGGTCTGGGTCACTGGGCTTGTGGACTCAGTAGTGCAGACAGCTTTGCAAT  
GCAGTTACCATTCTGTGCTAATAATGTCATTAACATTGGCTGTGAAATTCTGGCTATCT  
TGAAACTGGCCTGTGCTGATATTCAATCAATGTTAGTATGACAGGGTCGAATCTGAT  
TGTTCTGGTTATTCCATTGTTAGTAATTCCATCTTACATATTATTGTGCCACTATTCT  
25 GAGGATTCCITCCACTGAAGGAAACATAAGGCCTCTCACCTGCTCAGCCCACCTGACA  
GTGGTATTATATTCTATGGAACCATCTCTCATGTCAGCAAAGCCTGAGTCTAAAGCCT  
CTGTTGATTCAAGGTAATGAAGACATCATTGAGGCCCTCATCTCCCTTCTATGGAGTGT  
GACTCCATGCTTAATCCTCTCATCTAAGTCTGCGAAACAAGGATGTAAGGCTGTC  
AAAAACATACTGTGTAGGAAAAACTTCTGATGGAAAATGA (SEQ ID NO: 386)

30 **AOLFR208 sequences:**

MFPANWTSVKVFFFLGFFHYPKVQVIIAVCLLMYLITLLGNIFLISITILDSHLHTPMYFLSNL  
SFLDIWYSSSALSPMLANFVSGRNTISFSGCATQMYLSLAMGSTEVLPPMAYDRYVAICNP  
LRYPVIMNRRTCVQIAAGSWMTGCLTAMVEMMSVLPLSLCGNSINHFTCEILAILKLCVDTS  
35 LVQLIMLVISVLLPMPMLLICISYAFILASILRISSVEGRSKAFSTCTAHLMVVVLFYGTALSMH  
LKPSAVDSQEIDKFMALVYAGQTPMLNPIYSLRNKEVKVALKLLIRNHNTAFISILK (SEQ  
ID NO: 387)

ATGTTCCCGCAAATTGGACATCTGAAAAGTATTCTTCTGGATTTTTCACTACCC  
CAAAGTTCAAGTCATCATATTGCGGTGTGCTGATGTACCTGATCACCTGCTGGGC  
40 AACATTCTGATCTCCATCACCAATTCTAGATTCCCACCTGCACACCCCTATGTACCTCTT  
CCTCAGCAATCTCTCCTTCTGGACATCTGGTACTCCTCTCTGCCCTCTCCAATGCTGG  
CAAACTTGTTCAAGGGAGAACACTATTCAATTCTCAGGGTGCGCCACTCAGATGTACCT  
CTCCCTGCCATGGGCTCCACTGAGTGTGCTCTGCCATGATGGCATATGACGGGTAT  
GTGGCCATCTGCAACCCCTGAGATACCCGTACATGAATAGGAGAACCTGTGTCAGA  
45 TTGCAAGCTGGCTCTGGATGACAGGCTGTCTCACTGCCATGGTGGAAATGATGTCTGTGCT  
GCCACTGTCTCTGTGGTAATAGCATCATCAATCATTTCACTTGTGAAATTCTGGCCATCT  
TGAAATTGGTTGTGGACACCTCCCTGGTGCAGTTAATCATGCTGGTGTAGTGTACT  
TCTTCTCCCCATGCCAATGCTACTCATTGTATCTTATGCATTATCCTGCCAGTATCC  
TGAGAACAGCTCAGTGGAGGGTGAAGTAAAGCCTTCAACGTGCACAGCCCACCTGA  
50 TGGTGGTAGTTGTCTATGGGACGGCTCTCCATGCACCTGAAGCCCTCGCTGTAGA  
TTCACAGGAAATAGACAATTATGGCTTGGTGTATGCCGGACAAACCCCATGTTGAAT  
CCTATCATCTAAGTCTACGGAACAAAGAGGGTGAAGTGGCCTGAAAAAAATTGCTGATTA  
GAAATCATTTAATACTGCCTCATTCCATCCTCAAATAA (SEQ ID NO: 388)

## AOLFR209 sequences:

MDKINQTFRFILLGLSGYPKLEIIFALLVMYVVILIGNGVLIASILDSRLHMPMYFFLGNLS  
 FLDICYTSSIPSTLVSLSKRNISFSGCAVQMFFGAMGSTECLLGMMAFDRYVAICNPLRY  
 5 PIIMNKVVYVLLTSVSLSGGINSTVQTSLMRWPFCGNNIINHFLCEILAVLKLACSDISVNIV  
 TLAVSNTAFLVLPPLLIVFSYMFILYILRTNSATGRHKAFSTCSAHLTVIIFYGTIFFMYAKPKS  
 10 QDLLGKDNLQATEGLVSMFYGVVTPMLNPIIYSLRNKDVKAIAKYLLSRKAINQ (SEQ ID NO:  
 389)

ATGGACAAGATAAACAGACATTGTGAGAGAATTCAATTCTGGACTCTCTGGTACCC  
 CCAAACCTGAGATCATTCTTGCTCTGATTCTAGTTATGTACGTAGTATTCTAATTGGC  
 AATGGTGTCTGATCATAGCAAGCATCTGGATCTCGTCTCACATGCCATGACTTCTT  
 15 CCTGGCAACCTCTCTTGATATCTGCTATACAACCTCCATTCCCTCAACACTGG  
 TGAGCTTAATCTCAAAGAAAAGAAACATTCTCTCTGGATGTGCAGTGCAGATGTTCTT  
 TGGGTTTCAATGGGTCAACAGAATGTTCTCTGGCATGATGGCATTGATCGTTAT  
 GTGGCCATCTGAACCCCTGAGATAACCCATCATGAACAAGGTGGTGTATGACTGC  
 TGACTCTGTATCATGGCTTCTGGTGAATCAATTCAACTGTGCAAACATCACTGCCAT  
 GCGATGGCCTTCTGTGGGAACAATTATTAAATCATTTCTATGCGAGATCTAGCTG  
 20 TAAAATTAGCTTCTGTGATATATCTGTCAATTGTTACCTAGCAGTGTCAAATTGCT  
 TTCTAGTTCTCCTCTGCTGATTCTCTGATTTCTCTATATGTTCATCCTCACACCCTTG  
 CGAACGAACTCGGCCACAGGAAGACACAAGGCATTCTCTGATTTCTACATGCTCAGTCACCTGACTG  
 TGGTGTATATTATGTTACCATCTCTTATGTTATGCAAACCTAACGTCAGGACCTC  
 CTTGGAAAGACAACCTGCAAGCTACAGAGGGCTTCCATGTTATGGGGTGTGA  
 25 CCCCATGTTAAACCCATAATCTATAGCTTGAAGAAATAAGATGTAAGCTATAAA  
 ATATTGCTGAGCAGGAAAGCTATTAAACAGTAA (SEQ ID NO: 390)

## AOLFR210 sequences:

MMGRRNDTNVADFLTGSDSEEVQMALFMLLIIYLITMLGNVGMLIIRLDLQLHTPMYFFL  
 THLSFIDLSYSTVTPKTLANLLTSNYISFTGCFQAQMFCVFLGTAECYLLSSMAYDRYAAICSP  
 30 LHYTVIMPKRLCLALITGPYVIGFMDSFVNVSMSRLHFCDNSVIIHFFCDTSPILSCTDN  
 TEMLIFIAGSTLMVSLITISASYVSILSTILKINSTSGKQAFSTCVSHLLGVTIFYGTMIFTYK  
 RKSLSGRDQVAPVFYTVIPMLNPLIYSLRNREVKNALRVMQRQDSR (SEQ ID NO: 391)

ATGATGGGTAGAAGGAATGACACAAATGTGGCTGACTTCATCCTACGGGACTGTCAGAC  
 35 TCTGAAGAGGTCCAGATGGCTGTTATGCTATTCTCTCATATACTAATTACTATGCT  
 GGGGAATGTGGGATGCTATTGATAATCCGCTGGACCTCCAGCTTCACACTCCATGTAT  
 TTTTCCTTACTCACCTGTCATTATTGACCTCAGTTACTCAACTGTGTCGTACACCTAAAC  
 CTTAGCGAACTTACTGACTTCAACTATTTCTTACGGGCTGTTGCCAGATGTTCT  
 GTTTGTCTCTGGTACTGCTGAATGTTATCTCTCTCAATGCCATTGATCGCTAT  
 40 GCAGCGATCTGAGCTCTACACTACACAGTTATTATGCCAAAGGCTCTGCCCGTC  
 TCATCACTGGCCTATGTGATTGGCTTATGGACTCCTTGTCAATGTGTTCCATGAGC  
 AGATTGCAATTCTGTGACTCAAACATAATTCACTTTCTGTGACACTTCCCAATT  
 AGCTCTGCTCTGACTGACACAGACAACACTGAAATGCTGATATTCAATTGCTGTTCC  
 45 ACCCTGATGGTGTCCATTACAATATGCACTTGTGTCATTCTCTACCATCTCT  
 GAAAATTAAATTCACTTCAGGAAAGCAGAAAGCTTCTCTACTTGTGCTCTCATCTT  
 GGAGTCACCATCTCTATGGAACATGATTCTACTTAAAGCCAAGAAAGCTTATT  
 CTTGGGAAGAGATCAAGTGGCTCTGTGTTTACTATTGTGATTCCATGCTGAATCC  
 ACTCATTTATAGTCTAGAAACAGAGAAGTGAAGAAATGCTCTCATTAGAGTCATGAGAG  
 AAGACAGGACTCCAGGTAG (SEQ ID NO: 392)

50

## AOLFR211 sequences:

MMGRRNNNTVADFLMGLTSEEIQMALFMLLIIYLITMLGNVGMLIIRLDLQLHTPMYFFL  
 THLSFIDLSYSTVTPKTLANLLTSNYISFTGCFQAQMFFAFLGTAECYLLSSMAYDRYAAICSP  
 LHYTVIMSKRLCLALITGPYVIGFDSFVNVSMSRLHFYDSVIIHFFCDTSPILSCTDTYNT  
 55 EILIFIIVGSTLMVSLITISASYVILSTILKINSTSGKQAFSTCVSHLLGVTIFYSTLIFTYKPRK  
 SYSLGRDQVASVFYTVIPVLPNPLIYSLRNKEVKNAIRVMQRQDSR (SEQ ID NO: 393)

5 ATGATGGGTAGAAGGAATAACACAAATGTGGCTGACTTCATCCTATGGGACTGACACTT  
 CTGAAGAGATCCAGATGGCTCTGTTATGCTATTCTCCTGATATACTAATTACTATGCTG  
 GGGATGTGGGATGATATTGATAATCCGCCGGACCTCCAGCTCACACTCCCATGTATT  
 TTTCCCTACTCACCTGTCAATTATTGACCTCAGTTACTCAACTGTGTCACACCTAAAACC  
 10 TTAGCGAACTTACTGACTTCAACTATATTCTTACGGGCTGCTTGCCCAGATGTTCTT  
 TTTGCTTCTGGTACTGCTGAATGTTACCTCTCCTCAATGGCCCATGATCGCTATG  
 CAGCGATCTGCAGTCCTACACTACACAGTTATTATGTCAAAAGGCTGCTCGCTCT  
 CATCACTGGGCCTTATGTGATTGGCTTATAGACTCCTTGTCAACGTGGTTCCATGAGCA  
 15 GATTGCATTCTACGACTCAAACGTAATTCACTCACTTTCTGTGACACTCCCCAATTAA  
 GCTCTGCTGCAGTACATACACACCGAAATCCTGATATTCAATTATTGTTGGTCCAC  
 CCTGATGGTGTCCCTTTCAAAATATCTGCATCCTATGTGTTATTCTCTTACCATCCTGA  
 AAATTAATTCACTTCAGGAAAGCAGAAAGCTTCTACTTGCCTCTCATCTCTGGG  
 AGTCACCACATTTTATAGCACTCTGATTTTACTTATTAAAACCAAGAAAGTCITATTCT  
 20 TGGGAAGAGATCAAGTGGCTCTGTTTTATACTATTGTGATTCCGTGCTGAATCCACT  
 CATTATAGTCTAGAAACAAAGAGGTGAAAAATGCTGTACAGAGTCATGCAGAGAAG  
 ACAGGACTCCAGGTAA (SEQ ID NO: 394)

**AOLFR212 sequences:**

20 MAGNNFTEVTVFILSGFANHPELQVSLFLMFLIYLFTVLGNLGLITLIRMDSQLHTPMYFFLSN  
 LAFIDIFYSSVTVPKALVNFSNRRSISFVGCFVQMYFFVGLVCCECFLLGSMAYNRYIAICNPL  
 LYSVVMSQKVSNWLGVMPYVIGFTSSLISVWVISSLAFCDSINHFFCDTTALLALSCVDTFGT  
 EMVSFVLAGFTLLSSLLITVTYIIISAILRIQSAAGRQKAFSTCASHLMAVTIFYGSLIFTYLQPD  
 NTSSLTQAQVASVFYTIVIPMLNPLIYSLRNKDVKNALLRVIHRKLFP (SEQ ID NO: 395)  
 25 ATGGCTGGCAACAATTCACTGAGGTTACCGTCTTCATCCTCTGGATTGCAAATCACC  
 CTGAATTACAAGTCAGTCTTCTGATGTTCTCTCATTATCTATTCACTGTTGGGA  
 AACCTGGGACTGATCACGTTAACAGAAATGGATTCTCAGCTCACACCCCTATGACTTT  
 TCCTAGCAATTAGCATTATTGACATATTTACTCCTACTGTAACACCTAACGGCATTG  
 30 GTGAATTCCAATCCAATCGGAGATCCATCTCCATTGTTGGCTGCTTGTCAAATGTA  
 TTTGTTGGATTGGTGTGAGTGTGTTCTCTGGGATCAATGGCCTACAATCGCTACA  
 TAGCAATCTGCAATCCCTACTGTATTCACTAGTCATGTCCAAAAGTGTCCAAGTGGCT  
 GGGAGTAATGCCATATGTGATAGGCTCACAGCTCGCTGATATCTGCTGGGTGATAAGC  
 AGTTTGGCGTTCTGTGATTCCAGCATCAATCATTGTTGTGACACACCAGCTTTAGC  
 35 ACTCTCTGTGAGATACATTGGCACAGAAATGGTAGCTTGTCTAGCTGGATTCACT  
 CTTCTTAGCTCTCCTTATCATCACAGTCACCTATATCATCATCTCAGCCATCCTGAG  
 GATCCAGTCAGCAGCAGGCAGGAGGCTTCTCCACCTCGCGATCCACCTCATGGCT  
 GTAACATCTTATGGGCTCTGATTTCACCTATTGCAACCTGATAACACATCATCGCT  
 GACCCAGGCGCAGGTGGCATCTGTATTCTATACGATTGTCACTCCATGCTGAATCCACTC  
 40 ATCTACAGTCTGAGGAACAAAGATGTGAAAAATGCTCTGAGAGTCATACATAGAAAA  
 CTTTTCCATGA (SEQ ID NO: 396)

**AOLFR213 sequences:**

45 MNSLGKLVSMILSAHVFCYSKFNCFGCTHSIPALGADPPGMGLGNESSLMDILLGFSDHPR  
 EA VLFVFLFFYLTLVGNTIIISYLDPLHTPMYFFLSNLSLLDICFTTSLAPQTLVNLQRPKK  
 TITYGGCVAQLYISLALGSTECELLADMALDRYIAVCKPLHYVVIMNPRLCQLASISWLSGLA  
 SSLIATFTLQLPLCGNHRLDHFICEVPALLKACVDTTVNELVLFVSVLFVVI  
 PPALISIYGFI  
 TQAVLRIKSVEARHKAFSTCSSHLTVIIFYGTIIYVYLQPSDSYAQDQGKFISLFY  
 TMVPTLNP  
 IIYTLRNKDMKEALRKLLSGKL (SEQ ID NO: 397)  
 50 ATGAATAGTTGGAAAGTTGGCTCCATGATCCTCTCAGCTCATGTGTTCTGTTATTCTAA  
 ATTTAATTGTTGGATGTACCCATTCCATTCTGCCTAGGTGCGGATCCCCCTGGAGGG  
 ATGGGATTGGCAATGAGAGTCCCTAATGGATTCTCCTTAGGCTTCTCAGACCACC  
 CTCGCTGGAGGTGTTCTCTTGTATTGTCCTTCTACCTCCTGACCCTGTGGGA  
 55 AACTTCACCATAATCATCATCTCATATCTGGATCCCCCTCTCATACCCCAATGTACTTTT  
 TCTCAGCAACCTCTTTACTGGACATCTGCTTCACTACTAGCCTGCTCCTCAGACCTTAG

5 TTAACTTGCAAAGACCAAAGAAGACGATCACTACGGTGGTGTGGCGCAACTCTATA  
TTCTCTGGCACTGGGCTCCACTGAATGTATCCTCTGGCTGACATGGCCTTGGATCGGTAC  
ATTGCTGTCTGCAAACCCCTCCACTATGTAGTCATCATGAACCCACGGCTTGGCAACAGC  
TGGCATCTATCTCCTGGCTCAGTGGTTGGCTAGTCCCTAATCCATGCAACTTTACCTG  
CAATTGGCCTCTGTGGCAACCATAGGCTGGACCATTATTGCGAAGTACCACTCTTCT  
CAAGTTGGCTTGTGGACACCACTGTCAATGAATTGGTGTGCTTTTGTGTTAGTGTCTGT  
TTGTTGTCAATTCCACCAAGCACTCATCTCCATCTCCTATGGCTCATAACTCAAGCTGTGCTG  
AGGATCAAATCAGTAGAGGCAAGGCATAAAGCCTCAGCACCTGCTCTCCACCTTACAG  
TGGTGATTATATTCTATGGCACCATAATCTACGTGTACCTGCAACCTAGTACAGCTATGC  
10 CCAGGACCAAGGGAAAGTTATCTCCCTCTACACCATGGTGACCCCACTTTAAATCCT  
ATCATCTATACTTAAGGAACAAGGATATGAAAGAGGCTGTAGGAAACTCTCGGGA  
AAATTGTGA (SEQ ID NO: 398)

### AOI LFR214 sequences:

15 AOLFR214 sequences:  
MDKSNSSVVSEFVLLGLCSSQKLQLFYFCFFSVLYTVIVLGNLLIILTTSLSLHSPMYFLLGN  
LSFVDICQASFATPKMIADFLSAHETISFSGCIAQIFFIHLFTGGEMVLLVSMAYDRYVAICKPLY  
YVVIMSRRTCTVLVMSWAVSLVHTLSQLSFTVNLPCGPNVVDSFFCDLPRVTKLACLDSYIIIE  
ILIVVNSGILSLSLTSFSLLVSSYIIILVTWVLKSSAAMAKAFSTLASHIAVVILFGPCIFIVVWPFTIS  
PLDKFLAIFYTVFTPVLNPPIYTLRNRDMKAAVRKIVNHYLRPRRISEMSLVVRTSFH (SEQ ID  
20 NO: 399)

20 NO: 399) ATGGATAAGTCCAATTCTCAGGGTGTGAATTGTACTGTGGGACTCTGTAGTCTC  
 AAAAACTCCAGCTTCTATTTTGTCTCTGTGTATACAGTCATTGTGCTGGAA  
 25 AATCTCTCATTATCCTCACAGTGACTCTGATACCAGCCTGACTCCCTATGTACTTTCT  
 CTTGGGAAACCTTCCTTGTGACATTGTCAAGGCTCTTTGCTACCCCTAAATGATTG  
 CAGATTTCTGAGTGACACAGAGACCATATCTTCAGTGGCTGCATAGCCAAATTCTT  
 ATTACCTTTACTGGAGGGAGATGGTGTACTGTGATGGCCTATGACAGGTATG  
 TAGCCATATGCAAACCTTATACTATGTGGTCATCATGAGCGAAGGACATGCACTGTCT  
 30 GTAAATGATCTCCTGGCTGTGAGCTGGTCACACATTAAGCCAGTATCATTTACTGTG  
 AACCTGCCCTTTGTGGACCTAATGTAGTAGACAGCAGCTTTTGTGATCTCCCGAGTCAC  
 CAAACTGCCCTGGACTCTTACATCATTGAAATACTAATTGTGGTCATAGTGGAAATT  
 CTTCCCTAAGCACTTCTCTCTGGTCAGCTCCACATCATTATTCTGTACAGTCA  
 GCTCAAGTCTCAGTGAATGGCAAGGCATTTCTACGCTGGCTCCATATTGCAGTA  
 35 GTAATATTATTCTTGTGGACCTTGCATCTCATCTATGTGTGGCCCTTACCATCTCCCTT  
 GGATAATTCTGCCATATTACACTGTGTTTCACCCCGTCCTAAACCCATTATTATA  
 CACTAAGGAATAGGGATATGAAGGCTGCCGTAAAGGAAAATTGTGAACCAATTCTGAGGC  
 CAAGGAGAATTCTGAAATGTCAGTAGTAGTGAGAACTCCTTCATTAA (SEQ ID NO:  
 400)

#### 40 AOLFR215 sequences:

40 AOLFR215 sequences:  
MAHTNESMVSEFVLLGLSNWGLQLFFFQAFSIVYVTSLGNVLIVIISFDSHLNSPMYFLLSNL  
SFIDICQSNFATPKMLVDFFIERKTISFEGCMAQIFVLHSFVGSEMMLLVAMAYDRFIAICKPLH  
YSTIMNRRLCVIFVSISWAVGVLHSVSHLAFTVDPFCGPNEVDSFFCDLPLVIELACMDTYEM  
EIMTLTNSGLISLSCFLALIISYTIILIGVRCRSSGSSKALSTLTAHTVVILFFGPCIYFYIWPFSL  
45 PVDKFLSVFYTVCTPLLNPIIYSLRNEDVKAAMWKLRNHHVNSWKN (SEQ ID NO: 401)

45 PVDKFLSVFYTCIPLNTRYSEI  
ATGGCTCACACAAATGAATCGATGGTGTCTGAGTTGTACTTTGGGACTCTCTAACTCCT  
GGGGACTCTAACCTTTCTCGCCATCTCTCTATAGTCTATGTGACATCAGTGTAGGC  
50 AATGTCTTAATTATTGTCTTCTTCTTGTACTCCATTGAACCTCCTATGTACTCTTG  
CTCAGTAATCTTCTTCTTGTACTGATATCTGTCACTTGTCCACCCCCAAGATGCTTGT  
AGACTTTTATTGAGCGCAAGACTATCTCCTTGAGGGTGTGATGGCCAGATATTCGTT  
CTTCACAGTTGTGGGAGTGAGATGATGTTGCTGTAGCTATGGCATATGACAGATTTA  
55 TAGCCATATGTAAGCCTCTGCACTACAGTACAATTATGAACCGGAGGCTCTGTAAATT  
TGTGTCTATTCTGGCGGTGGCGTTCTCATTGTGAGCCACTGGCTTACAGTGG  
ACCTGCCATCTGGTCCCATTGAGGTGGATAGCTTGTGACCTCCCTGGTGATA  
GAGCTGGCTGATGGATACATATGAAATGGAAATTATGACCTAACGAAACAGTGGCTG

5 ATATCATTGAGCTGTTCTGGCTTAATTATTCCTACACCATCATTGATCGGTGTCG  
 ATGCAGGTCCCTCCAGTGGTCATCTAAGGCTCTACATTAACAGCCCACATCACAGTG  
 GTCATTCTTCTCGGGCCTGCACTTATTCCTATATGGCCTTTAGCAGACTCCTGT  
 GGACAAATTCTTCTGTGTTACACTGTTGACTCCCTGTTGAACCCATCATCTACT  
 CTTGAGGAATGAAGATGTTAAAGCAGCCATGTGGAAGCTGAGAAACCATCATGTGA  
 CCTGGAAAAACTAG (SEQ ID NO: 402)

**AOLFR216 sequences:**

10 MDVGNKSTMSEFVLLGLSNSWELQMFFFVFSLLYVATMVGNSLIVITVIVDPHLHSPMYFLL  
 TNLSIIDMSLASFATPKMIDYLTGHKTISFDGCLTQIFFLHLFTGTEIILLMAMSFDRYIAICKPL  
 HYASVISPVQCVALVVASWIMGVMHMSMSQVIFALTLPFCGPYEVDSFFCDLPVVFQLACVDTY  
 VLGLFMISTSGIIALSCFIVLFSYVIVLTVKHSSRGSSKALSTCTAHFIVVFLFFGPCIFYMW  
 PLSSFLTDKILSVFYTIFTPTLNPIIYTLRNQEVKIAMRKLKNRFLNFNKAMPS (SEQ ID NO: 403)

15 ATGGATGTGGGCAATAAGTCTACCATGTCTGAATTGTTGCTGGGCTCTCTAATTCT  
 GGGAACTACAGATGTTTCTTATGGTGTGTTCTTGCCTTATGCTTATGTCACAAATGGTGGG  
 TAACAGCCTCATAGTCATCACAGTTAGTGGACCCCTACCTACACTCTCTATGTATTCC  
 TGCTTACCAATCTTCAATCATTGATATGTCTCTGCTCTCGCCACCCAAAGATGATT  
 ACAGATTACCTAACAGGTACAAAACCATCTCTTGTGAGGCTGCCTTACCCAGATATTCT  
 TTCTCCACCTTTCACTGGAACGTGAGATCATCTTACTCATGGCCATGTCCTTGATAGGTAT  
 ATTGCAATATGCAAGCCCTGCACTATGCTTCTGTCAATTAGTCCCAGGTGTGTTGCTCT  
 CGTGGTGGCTTCCCTGGATTATGGGAGTTATGCAATTGAGTCAGGTCAATTGCCCTC  
 ACGTTACCATTCTGTGGTCCCTATGAGGTAGACAGCTTTCTGTGACCTCCTGTGGTGT  
 CCAGTTGGCTTGTGGATACCTATGTTCTGGGCTCTTATGATCTAACAAAGTGGCATA  
 25 ATTGCGTTGCTCTGTTTATTGTTTATTAAATTCAATATGTTATTGCTCTGGTTACTGTGAA  
 GCATCATTCTCCAGAGGATCATCTAAGGCCCTTCTACTTGTACAGCTCATTCAATTGTTG  
 TCTCTTGTCTTGGGCCATGCATCTCATCTACATGTGGCCACTAACAGCTTCTCACA  
 GACAAGATTCTGTCTGTGTTTATACCATCTTACTCCACTCTGAACCCAATAATCTATAC  
 TTGAGGAATCAAGAAGTAAAGATAGCCATGAGGAAACTGAAAAATAGGTTCTAAATT  
 30 TAATAAGGCAATGCCTTCATAG (SEQ ID NO: 404)

**AOLFR217 sequences:**

35 MLESFQKSEQMAWSNQSAVTEFILRGLSSLELQIFYFLFFSIVYATVGNLLIVVTIASEPHLH  
 SPTYFLLGNLSFIDMSLASFATPKMIAFLREHKAISFEGCMTQMFLHLLGAEIVLLISMFD  
 RYVAICKPLHYLTIMSRMCMVGLVILSWIVGIFHALSQLAFTVNLPCGPNEVDSFFCDLPLVIK  
 LACVDTYILGVFMISTSGMIALVCFILLVISYIILTVRQRSSGGSSKALSTCSAHFTVVTLFFGP  
 CTFIYVWPFTNFPIDKVLVFYIYTPLLNPVIYTVRNKDVKYSMRKLSSHIFKSRKTDHTP  
 (SEQ ID NO: 405)

40 ATGCTAGAGTCCTCCAGAAATCAGAGCAAATGGCCTGGAGCAATCAGTCTGCGGTAAACC  
 GAATTCTACTACGGGGCTGTCCAGTTCTAGAACCTCCAGATTCTACTTCCTGTTTT  
 CTCCATAGTCTATGCAGCCACTGTGCTGGGAACCTCTTATTGTTGTCACCATTGCATCA  
 GAGCCACACCTTCATTCCCTACGTACTTCTGCTGGCAATCTCTCCTCATTGACATGTC  
 CCTGGCCTCATTTGCCACCCCAAATGATTGAGACTCTCTAGAGAACACAAAGCCATC  
 45 TCTTTGAAGGCTGCATGACCCAGATGTCTCTACATCTTCTAGGGGTGCTGAGATTG  
 TACTGCTGATCTCCATGTCTTGTAGGTACGTGGCTATCTGTAAGCCTCTACATTACCTA  
 ACAATCATGAGCCGAAGAATGTGTGTTGGCTGTGATACTTCTGGATTGTCGGCATCT  
 TCCATGCTCTGAGTCAGTTAGCATTACAGTGAATCTGCCCTCTGTGGACCCAATGAAGT  
 AGACAGTTCTTGTGACCTCCCTTGGTATTAAACTGCTTGTGCGACACATATATT  
 50 TGGGGGTGTCATGATCTCAACCAGTGGCATGATTGCCCTGGTGTGCTTCATCCTCTGGT  
 GATCTCTTACACTATCATCTGGTCACCGTTGGCAGCGTCTCTGGTGGATCCTCCAAA  
 GCCCTCTCCACGTGCAGTGGCCACTTACTGTTGTGACCCCTTCTTGGCCATGCACTT  
 CATTATGTTGTCAGTGGCTTCAAAATTCCAAATAGACAAAGTACTCTCAGTATTATACCA  
 TATACACTCCCTCTGAATCCAGTGAATCTACCGTTAGGAATAAGATGTCAAGTATT  
 55 CATGAGGAAACTAAGCAGCCATATCTTAAATCTAGGAAGACTGATCATACTCCTTAA  
 (SEQ ID NO: 406)

### AOLFR218 sequences:

5 AOLFR218 sequences:  
 METANYTKVTEFVLTGLSQTREVQLVLFVIFLSFYLFILPGNIICTIRLDPHLTSPMYFLLANLA  
 LLDIWYSSITAPKMLIDFVERKIISFGCIAQLFFLHFVGASEMFLIVMAYDRYAAICRPLHYA  
 TIMNRRLCCILVALSWMGGFIHSIIQVALIVRLPFCGPNELDSYFCDTQVVRIACANTFPEELVM  
 ICSSGLISVVCFIALLMSYAFLLALLKKHSGSDENTNRAMSTCYSHITIVLVMFGPSIYIYARPF  
 SFSLDKVVSFVHTVIFPLNPIIYTLRNKEVKAAMRKVVTKYILCEEK (SEQ ID NO: 407)

10 SFSLDKVVSVHIVVTC  
ATGGAAACTGCAAATTACACCAAGGTGACAGAATTGTTCTACTGGCCTATCCCAGACTC  
GGGAGGTCCAACTAGCCTATTGTTATATTCTATCCTTCTATTGTCATCCTACCAAGGA  
AATATCCTTATCATITGACCACATCAGGCTAGACCCCTATCTGACTCTCCATTGATTTCCT  
GTGGCTAACCTGGCCCTCCTGATATTGGTACTCTCATTACAGCCCTAAATGCTCA  
TAGACTTCTTGTGGAGAGGAAGATAATTCCATTGGTGGATGCATTGACAGCTCTCTT  
CTTACACTTTGTGGGGCTCGAGATGTTCTGCTCATAGTGTGGCCTATGACCGCTAT  
GCTGCTATCTGCCGACCCCTCCACTATGCTACCACATGAATGACGCTCTGCTGTATCCT  
GGTGGCTCTCTGGATGGGGGCTTCATTCTATAATACAGGTGGCTCTATTGTT  
CGACTTCCTTCTGTGGGCCAATGAGTTAGACAGGTTACTCTGTGACATCACACAGGTTG  
TCCGGATTGCCTGTGCCAACACCTTCCAGAGGAGTTAGTGTGATCTGTTAGTGGCT  
GATCTCTGTTGCTGTTATTGCTCTGTTAATGTCCTATGCCCTCTGGCTTGCTCA  
20 AGAAACATTCAAGGCTCAGATGAGAATACCAACAGGGCCATGTCACCTGCTATTCCACAT  
TACCAATTGTTGGTCTAATGTTGGGCCATCCATCTACATTATGTCGCCATTGACTCAT  
TTTCCCTAGATAAAAGTGGTCTGTGTTCAACTGTAATTCCCTTACTTAATCCCAT  
ATTACACATTGAGAAAACAAGGAAGTAAAGGCAGCCATGAGGAAGGTGGTACCAAATAT  
ATTGTGTGAAGAGAAGTGA (SEQ ID NO: 408).

25

### AOLFR219 sequences:

25 AOLFR219 sequences:  
 MLTS LTDLCFSPIQVAEIKSLPKSMNETNHSRVTEFVLLGLSSRELQPFLFLTSLLYLAILLGNF  
 LIILT VTVTSDSRLLHTPMYFLLANLSFIDVCVASFATPKMIAFLVERKTISFDACLAQIFFVHLFTGS  
 30 EMVLLVSMAYDRYVAICKPLHYMTVMSRRVCVVLVLISWFVGFIIHTTSQLAFTVNLPFCGPN  
 KVDSFFCDPLPLVTKLACIDTYVVSSLIVADSGFLSLSFLLLVSYTIVLTVTRNRSSASMAKAR  
 STLT AHTIVVTLFFGPGCIFIYVWPSSSYSDVKVLAVFTIFTLILNPVIYTLRNKEVKAAMSKLKS  
 RYLKPSQVSVVIRNVLFLETK (SEQ ID NO: 409).

35 RYLPKPSQVS VVIRNVE... ATGCTCACTCATTAACTGATCTGTTCTCTCCTATTAGGTAGCTGAAATTAGTCCCT  
TCAAAATCGATGAATGAGACAAATCATTCTGGGTGACAGAATTGTGTTGCTGGGACTG  
TCTAGTTCAAGGGAGCTCAACCTTCTTCTTACATTTCACACTTATCTAGCAAT  
TCTGTTGGCAACTTCTCATCATCCTCACTGTGACCTCAGATCCCGCTTCACACCCCCA  
TGTACTTTCTGCTTCAAACCTGTCATTATAGACGTATGTGTTGCCCTTTGCTACCCCT  
AAAATGATTGAGACTTCTGGTTGAGCGCAAGACTATTCTTTGATGCCCTGGCCC  
40 AGATTTCTTGTGCTATATGCAAACCTCTTCACTGGCAGTGAATGGTGCCTAGTTCCATGCCCTAT  
GACCGTTATGTTGCTATATGCAAACCTCTTCACTACATGACAGTCATGAGCCGTCGTAT  
GTGTTGTGCTCGTCCCTATTATGGTTGTGGCTTCATCCACTACCAAGCCAGTTGGCA  
TTCACTGTTAATCTGCCATTGGTGTGCTTAATAAGGTAGACAGTTCTGTGACCTTCC  
TCTAGTGACCAAGTAGCCTGCATAGACACTTATGGTGTGCTAGCTACTAATAGTTGCA  
45 AGTGGCTTCTTCTGAGTTCTTCTCTCTTGGTTGTCTCTTACACTGTAATACTTGT  
ACAGTTAGGAATCGCTCTCTGCAAGCATGGCGAAGGCCGCTCCACATTGACTGCTCACA  
TCACTGTGGTCACCTTATTCTTGGACCATGCATTTCATCTATGTGTTGCCCTCAGCAGT  
TACTCAGTTGACAAGTCCTGTGTATTCTACACCATCTCACGCTATTAAACCCCTGT  
AATCTACACGCTAAGAAACAAAGAAGTGAAGGCAGCTATGTCAAAACTGAAGAGTCGGTA  
50 TCTGAAGCCTAGTCAGGTTCTGTAGTCATAAGAAATGTTCTTCTAGAAACAAAGTAA  
(SEQ ID NO: 410).

### AOLFR220 sequences:

55 AOLFR220 sequences:  
MKQYSVGNQHSNYSRSLFPFLCSQMTQLTASGNQTMTEFLFSMFPHAHRGGLLFIPLLIYG  
FILTGNLIMFIVIQVGMALHTPLYFFISVLSFLEICYTTTIPKMLSLISEQKSISVAGCLLQMYFF  
HSI GITESCVLTAMAIDRYIAICNPLRYPTIMPKLCIQLTVGSCFCGFLLVLPTEIAWISTLPFCGS

NQIHQIFCDFTPVLSLACTDTFLVVIVDAIHAEEIVASFLVIALSYIRIIIVILGMHSAEGHHKAFST  
CAAHLAVFLLFFGSVAVMYLRFSAVSVFWDTIAVTFVILAPFFNPIIYSLKNKDMKEAIGRLF  
HYQKRAWGAGK (SEQ ID NO: 411).

5 ATGAAGCAATATTCACTGGTAATCAACATTCCAATTATAGGAGTCTCTGTTCCCTTTCT  
GTGTTCACAGATGACACAGTTGACGGCCAGTGGGAATCAGACAATGGTACTGAGTCCT  
CTTCTCTATGTTCCCGCATGCGCACAGAGGTGGCCTTTATTCTTATTCCCTGCTCTCA  
TCTACGGATTATCCTAATGGAAACCTAATAATGTTATTGTCTCCAGGTGGCATGGC  
CCTGCACACCCCTTGTATTCTTATCAGTGTCTCTCCCTGGAGATCTGCTATACCA  
10 CAACCACCATCCCCAAGATGCTGTCTGCCTAATCAGTGAGCAGAAGAGCATTCCGTGGC  
TGGCTGCCCTCTGCAGATGTACTTTTCACTCACTTGGTATCACAGAAAGCTGTGCTG  
ACAGCAATGGCCATTGACAGGTACATAGCTATCTGCAATCCACTCCGTTACCCAAACATCA  
TGATTCCCAAACCTTGTATCCAGCTGACAGTGGATCTGCTTTGTGGCTTCCCTGTG  
CTTCCCTGAGATTGCATGGATTCCACCTGCTTCTGTGGCTCCAACCAGATCCACCAAGAT  
15 ATTCTGTGATTTCACACCTGTGCTGAGCTTGCCTGCACAGATACTACATTCTAGTGGTCATT  
GTGGATGCCATCCATGCAGCGGAATTGTAGCCTCCTCTGGTCATTGCTCTATCCTACA  
TCCGGATTATTAGTGTACTGGGAATGCACTCAGCTGAAGGTATCACAAGGCCCTTTC  
CACCTGTGCTGCTCACCTGCTGTTCTGCTATTGGCAGTGTGGCTGTCATGTATT  
TGAGATTCTCAGCCACCTACTCAGTGTGGACACAGCAATTGCTGTCACTTTGTATTAC  
20 CTTGCTCCCTTTCAACCCATCATCTATAGCCTGAAAAACAAGGACATGAAAGAGGCTA  
TTGGAAGGCTTCCACTATCAGAAGAGGGCTGGTTGGCTGGAAATAG (SEQ ID NO:  
412).

**AOLFR221 sequences:**

25 MRNLSGGHVEEFVLVGPTPPLQLLLFVLFFAIYLLTLENALIVFTIWLAPSLHRPMYFFLGH  
LSFLELWYINVTPRLLAALFTQDGRVSYVGCMQLYFFIALACTECVLLAVMAYDRYLAICGP  
LLYPSLMPSSLATRLAAASWGSFFSSMMKLLFISQLSYCGPNIINFFCDISPLLNLTCSDKEQ  
ELVDFLLALVMILLPLLAVVSSYTAIIAAILRIPTSRGRHKAFSTCAAHЛАVVVIYSSTLFTYAR  
PRAMYTFNHNKIISVLYTIIVPFFNPAYCLRNEVKEAFRKTVMGRCHYPRDVQD (SEQ ID  
30 NO: 413).

ATGAGAAAATTGAGTGGAGGCCATGTCGAGGAGTTGTCTGGGGTTCCCTACCACGC  
CTCCCTCCAGCTGCTCCTTTGTCTTGTCAATTACCTTCTGACATTGTGGAGA  
ATGCACTTATTGTCTTACAATATGGCTGCTCAAGCCTTACATGTCCCAGTACTTTTC  
35 CTTGGCCATCTCTTCTGGAGCTATGGTACATCAATGTACCATTCCTCGGCTCTGGC  
AGCCTTCTTACCCAGGATGGTAGAGTCTCCTACGTAGGTTGCATGACCCAACTGTACTTC  
TTTATTGCCTTAGCCTGTACTGAATGTGTGCTTGGCAGTTATGGCTATGATCGCTACCT  
GGCCATCTGTGGACCCCTCTTACCTAGTCTCATGCCTCCAGTCTGGCCACTCGCCTG  
CTGCTGCCTCTGGGGCAGTGGCTCTTCAGTCCATGATGAAGCTTCTTTATTCCCAA  
40 TTGTCTACTGTGGACCCAAACATTATCAACCACTTTCTGTGATATTCCCCACTACTCAA  
CCTCACCTGCTCTGACAAGGAGCAAGCAGAGCTAGTAGACTTCTTCTGGCCCTGGTGTAG  
ATTCTACTCCCTTATTGGCTGTGGTTCATACACTGCCATATTGCAGCCATCTGAG  
GATCCCTACGTCCAGGGACGCCACAAAGCCTTCCACTGTGCGCTCATGGCAGTG  
GTTGTTATCTACTACTCCTCCACTCTTACCTATGCACGGCCCCGGGCATGTACACCTT  
45 CAACCACACAAGATTATCTCTGTGCTCTACACTATCATTGTACCATCTCAACCCAGCCA  
TCTACTGCCTGAGGAACAAGGAGGTGAAGGAGGCCTCAGGAAGACAGTGTAGGGCAGAT  
GTCACTATCCTAGGGATGTTAGGACTGA (SEQ ID NO: 414).

**AOLFR222 sequences:**

50 MGQTNVTSWRDFVFLGFSSSGELQLLFALFLSYLVTLTSNVFIIIAIRLDSHLHTPMYFLSFL  
SFSETCYTLGIIPRMLSGLAGGDQAISYVGCAAQMFFSASWACTNCFLLAAMGFDYVAICAPL  
HYASHMNPTLCAQLVITSFLTGYLFLGMTLVIFHLSFCSSHEIQHFFCDTPPVSLACGDTGPS  
ELRIFILSLLVLLVSFFFITISYAYILAIRIPSAEGQKKAFTCASHLTVVIHYGCASFVYLRPK  
ASYSLERDQLIAMTYTVVTPLNPIVYSLRTRAIQTLRNAFRGRLLGKG (SEQ ID NO: 415).

WO 01/98526

ATGGGGCAGACCAACGTAACCTCCTGGAGGGATTGTCTTCCCTGGGCTTCTCCAGTTCTG  
 5 GGGAGTTGCAGCTCCTCTCTTGCCTGTTCTCTGTATCTAGTCACCTGACCAGC  
 CCTTCCTCCTATCCTCTGTAGACCTGCTACACTTGGGATCATCCCTAGAATGCTCT  
 CTGGCCTGGCTGGGGGACCAAGGCTATCTCTATGTGGGCTGTGCCAGATGTTCTT  
 TTCTGCCTCATGGGCTGTACTAAGTGCCTCTGGCTGCCATGGCTTACAGATATG  
 10 TGGCCATCTGTGCTCCACTCCACTATGCCAGCCACATGAATCCTACCCCTGTGCCAGCT  
 GGTCAATTACTCCTCTGTACTGGATAACCTCTTGGACTGGAAATGACACTAGTTATTITCC  
 ACCTCTCATTCAGCTCCCATGAAATCCAGCACTTTTGACACGCCACCTGTGCTG  
 AGCCTAGCCTGTGGAGATAAGGCCAGTGGAGCTGAGGATCTTACAGATCTTCC  
 15 TCCTCTGGCTCCTCTTCTCATCACCATCTCCTACGCCTACATCTGGCAGCAACTG  
 AGGATCCCCTCTGTGAGGGCAGAAGAAGGCCCTCTCCACTTGTGCCACCTACAG  
 TGGTCATTATTCAATTGGCTGTCTCCTCGTGTACCTGAGGCCAAAGCCAGCTACTCT  
 CTTGAGAGAGATCAGCTATTGCCATGACCTATACTGTAGTGACCCCCCTCTTAATCCCA  
 TTGTTTATAGTCTAAGGACTAGGGCTATACAGACAGCTGAGGAATGCTTCAGAGGGAG  
 ATTGCTGGTAAAGGATGA (SEQ ID NO: 416).

## AOLFR223 sequences:

MEAANESSEGISFVLLGLTSPGQQRPLFVLFLLYVASLLNGNIVAAIQASPALHAPMYFLLA  
 20 HLSFADLCFASVTPKMLANLLAHDHSISLAGCLQMYFFFALGVTDSCLLAAMAYDCYVAIR  
 HPLPYATRMSRAMCAALVGMAWLVSHVHSLLYILLMARLSFCASHQVPHFFCDHQPLRLSC  
 SDTHHIQLLIFTEGAAVVVTPLFLILASYGAIAAAVLQLPSASGRRAVSTCGSHLAVVSLFYGT  
 VIAVYQATSRREAEWGRVATVMYTVTPMLNPIYSLWNRDVQGALRALLIGRRIASDS  
 (SEQ ID NO: 417).

25 ATGGAGGCTGCAATGAGTCTCAGAGGAATCTCATTGTTTATTGGACTGACAACAA  
 GTCCCTGGACAGCAGCGGCCCTCTTGTGCTTGTCTGCTCTGTATGTGGCCAGCCTCTG  
 GGTAAATGGACTCATTGTGGCTGCCATCCAGGCCAGTCCAGCCCTCATGCACCCATGTACT  
 30 TCCTGCTGGCCACCTGTCCTTGTGACCTCTGTTGCCCTCGTCACTGTGCCAAGATG  
 TTGGCCAACCTGTTGGCCATGACCACTCCATCTCGCTGGCTGGCTGCCATGGCAATGACTG  
 ACTTCTTCTTGCCTGGGGTAACCTGATAGTGTCTCTGGCGGCCATGGCTATGACTG  
 CTACGTGGCCATCCGGCACCCCTCCCTATGCCACGAGATGTCCACCTCTCTGTATATCCTGCTCA  
 35 GCCCTGGTGGGAATGGCATGGCTGGTGTCCACGTCACCTCTCTGTATATCCTGCTCA  
 TGGCTCGCTTGTCTCTGTGCTCTGACACCCACCATCCAGTGTCTATCTCACCAGGGCG  
 CTCTTAAGGCTCTCGTGTCTGACACCCACCATCCAGTGTCTATCTCACCAGGGCG  
 CCGCAGTGGGGTCACTCCCTCTGCTCATCTCGCCCTCATGGGCCATCGCAGCTGC  
 CGTGCCTCAGCTGCCCTCAGCCTGGAGGCTCCGGCTGTCCACCTGTGGCTCCAC  
 40 CTGGCTGTGGTAGCCTCTATGGGACAGTCATTGAGCTACTTCAGGCCACATCCC  
 GACCGCAGGGCAGAGTGGGGCGTGTGGCCACTGTGATGACTGTAGTCACCCCCATGC  
 TGAACCCCATCTACAGCCTGGAAATCGCATGTACAGGGGACTCCGAGGCCCTCT  
 CATTGGCGAAGGATCTCAGCTAGTGAACCTCTGA (SEQ ID NO: 418).

## AOLFR224 sequences:

MGSFNTSFEDGFLVGFSDWPQLEPLFVIFIFYSLTLFGNTIIIALSWLDLRLHPTMYFFLHLSL  
 45 LDLCFTTSTVQPLLNLGVDRITRGGCVAQLFIYLALGSTECLVVMAFDYAAVCRPLHY  
 MAIMHPHLCQTLAIASWAGFVNLSIQTGLAMAMPLCGHRLNHFCEMPVFLKLACADTEGT  
 EAKMFVARVIVVAVPAALILGSYVHIAHVLRVKSTAGRRAFGTCGSHLUVFLFYGSAYT  
 YLQSIHNYSEREGKFVALFYTIITPILNPLIYTLRNKDVKGALWKVLWRGRDSDG (SEQ ID NO:  
 419).

50 ATGGGAAGTTCAACACCAAGTTGAAGATGGCTCATTTGGGGATTCTCAGATTGGC  
 CGCAACTGGAGCCCATCTGTTGTCTTACTCCCTAATCTCTTGGC  
 AACACCATCATCATCGCTCTCCTGGCTAGACCTCGGCTGCACACACCTATGTACTTCTT  
 TCTCTCTCATCTGTCCTCTGGACCTCTGCTTACCCACCCAGCAGCTCCAT  
 55 TCAACCTTGCAGGGTGGACCGCACCACCCGGTGTGGCTAGCTCTGGTATGGCCTTGCAT  
 CTACCTAGCCCTGGCTCCACAGAGTGTGTGCTCTGGTATGGCCTTGCACCGCTAT

5                   GCTGCTGTCTGTCGTCCACTCCACTACATGGCCATCATGCACCCCCATCTGCCAGACCC  
 GGCTATCGCCTCTGGGGTGCAGGTTCTGTAACCTCTGATCCAGACAGGTCTCGAATG  
 GCCATGCCTCTGTGGCCATCGACTGAATCACTCTCTGTGAGATGCCGTATTCCTGAA  
 GTTGGCTTGTGCGGACACAGAACAGAGGCCAAGATGTTGTGGCCGAGTCATAGT  
 10                CGTGGCTGTTCTGCAGCACTTATTCTAGGCTCTATGTGCACATTGCTCATGCAGTGCTG  
 AGGGTGAAGTCAACGGCTGGCGCAGAAAGGTTTGGACTTGTGGTCCCACCTCTA  
 GTAGTTTCTTTTATGGCTCAGCCATCTACACATATCTCAATCCATCCACAATTATTC  
 TGAGCGTGGAGGAAAATTGTTGCCCTTTTATACTATAATTACCCCCATTCTCAATCCTC  
 TCATTTATACACTAAGAAACAAGGACGTGAAGGGGCTGTGGAAAGTACTATGGAGGG  
 15                GCAGGGACTCAGGGTAG (SEQ ID NO: 420).

**AOLFR225 sequences:**

20                MENYNQTSTDILLGLFPPSIIDLFFFILIVFIFLMALIGNLSMILLFLDTHLHTPMYFLLSQLSLID  
 LNYISTIVPKMASDFLHGDKSISFTGCGIQSFFFALGGAELLASMAYDRYIAICFPLHYLIRM  
 15                SKRVCVLMITGSWIISINACAHTVYVLHIPYCRSRAINHFFCDVPAMVTLACMDTWVYEGTV  
 FLSATIFLVFPFIGSCSYGQVLFAVYHMKSAEGRKKAYLTCSTHVTFFYAPFVYTYLRPRS  
 LRSPTEDKVLAVFYTILTPMLNPIIYSLRNKEVMGALTRVSQRICSVKM (SEQ ID NO: 421).

20                ATGGAAAATTACAATCAAACATCAACTGATTCTATGGGGCTGTTCCACCATCAA  
 TAATTGACCTTTCTTCTTCTATTCTCATTGTTCTGATGGCTCTAATTGGAAACC  
 TGTCCATGATTCTCTCATCTCTGGACACCCATCTCACACACCCATGTATTCTACTG  
 AGTCAGCTCTCCCTCATTGACCTAAATTACATCTCACCATTGTTCTAAGATGGCATCTGA  
 TTTTCTGCACTGAAACAAGTCTATCTCCTTCACTGGGTGTGGGATTCAAGAGTTCTCTTCT  
 TGGCATTAGGAGGGTGCAGAAGCACTACTTTGGCATCTATGGCCTATGATCGTTACATTGC  
 25                TATTGCTTCTCCACTATCTATCCGATGAGCAAAGAGTGTGTGCTGATGATA  
 ACAGGGCTTGGATCATAGGCTCGATCAATGCTTGTGCTCACACTGTATATGACTCCATA  
 TTCCATTATTGCCATCCAGGGCCATCAATCTTCTGATGTCAGTCCCAGCAATGGTACT  
 CTGGCCTGATGGACACCTGGTCTATGAGGGCACAGTGTGAGTGCCACCATTITC  
 TCGTGTCTCCCTCATGGTATTTCTGATGTCAGTCCCAGCAATGGTACT  
 30                ATGAAATCTGAGAAGGGAGGAAGAAAGCCTATITGACCTGAGCACCCACCTCACTGTA  
 GTAACCTTCTACTATGCACCTTTGCTACACTATCTACGTCCAAGATCCCTGCGATCTCC  
 AACAGAGGACAAGGTTCTGGCTGCTCTACACCCTCACCCAAATGCTCAACCCATC  
 ATCTATAGCCTGAGGAACAAGGAGGTGATGGGGCCCTGACACGAGTGAGTCAGAGAATC  
 TGCTCTGTGAAATGTAG (SEQ ID NO: 422).

35

**AOLFR226 sequences:**

40                MEWRNHSGRVSEFVLLGFPAPAPLQVLLFALLLAYVLVLTENTLIIMAIRNHSTLHKPMYFFL  
 ANMSFLEIWIYVTVTIPKMLAGFVGSKQDHGQLISFEGCMQLYFFLGLGCTECVLLAVMAYD  
 RYMAICYPLHYPVIVSGRLCVQMAAGSWAGGGFISMVKVFLISGLSYCGPNIINHFFCDVSPLL  
 NLSCTDMSTAELTDFILAIFILLGPLSVTGAASYVAITGAVMHISAAGRYKAFSTCASHLTVVIIIF  
 YAASIFIYARPKALSAFDTNKLVSVLYAVIVPLLNPIIYCLRNQEVKRALCCTLHYQHQPDPD  
 KKASRNV (SEQ ID NO: 423).

45                ATGGAGTGGCGGAACCATACTGGGAGAGTGAGTTGTGTTGCTGGCTTCCCTGCT  
 CCTGCCACTACAGGTACTATTGTTGCCCTTGTGCTGGCTATGTGTTGGTGTGAC  
 TGAGAACACACTCATATTGGCAATTAGGAACCATCTACCCCTCACAAACCCATGTAC  
 TTTTCTAGCTAATATGTCCTTCTGGAGATCTGGTATGTCAGTCACTATTCCAAAGAT  
 GCTGCTGGCTTGTGGATCCAAACAGGATCATGGACAGCTAATCTCCTTGAGGGATGC  
 ATGACACAGCTACTTTCTGGCTTGTGGCTGCACTGAGTGTCCTCGCTTAT  
 50                GGCCTATGATCGTATATGCCATCTGCTATCCTCTCCACTACCCAGTCATTGTCAGTGGCC  
 GGCTGTGTGCAAGATGGCTGCTGGCTTGGCTGGAGGTTGGCATCTCCATGGCAA  
 AGTTTCTTATTCTGGCTCTTACTGTGGCCCCACATCATCAACCACCTTCTGTG  
 ATGTCCTCCATTGCTCAACCTCTCATGCACTGATATGTCACAGCAGAGCTTACAGATTTC  
 ATCCTGCCATTATTCTTAGGGCACTCTCTGTCAGTGGGCCCTATGTGCCAT  
 55                TAATGGTGCTGTGATGCACATATCTCGGCTGCTGGACGCTATAAGGCCTTCCACCTGT  
 GCCTCTCATCTCACTGTTGATAATCTTCTATGCAGCCAGTATCTCATATGCTCGGCC

WO 01/98526

AAAGGCACCTCTCAGCTTGCACCAACAAGTTGGCTCTGTACTGTATGCTGTATTGTA  
 CCATTGCTCAATCCCATCATTACTGCCTGCGCAATCAAGAGGTCAAGAGAGGCCATTGCT  
 GTACTCTGCACCTGTACCAGCACCAGGATCCTGACCCCAAGAAAGCTAGCAGAAATGTATA  
 G (SEQ ID NO: 424).

5

## AOLFR227 sequences:

10

MEPQNTSTVNFQLGFQNLLWEQALLFVIFLLIYCLTIGNVVIITVVSQGLRLHSPMYMFLQH  
 LSFLEVWYTSTTVPLLNLNLSWGQAIASFACMAQLYFFVFLGATECFLLAFMAYDRYLAICSP  
 LYRPFMLHRLCARLVVSWCTGVSTGFLHSMMISRLDFCRNQINHFFCDLPLMQLSCSRV  
 YITEVTIFILSIAVLCICFFLTGPYVFIVSSILRIPSTSGRRKTFSTCGSHLA VVTLYYGTMISMVV  
 CPSPHLLEPIKIIISVFYTVVTPLNPVIYSLRNKDFKEAVRKVMRRKCGILWSTSKRKF  
 LY (SEQ ID NO: 425).

15

ATGGAGCCCCAAAATACCTCCACTGTGACTAACCTCAGCTGTAGGATTCCAGAACCTTC  
 TTGAATGGCAGGCCCTGCTTTGTCACTTCTGCTCATCTACTGCCTGACCATTATAGGG  
 AATGTTGTCACTCATCACCGTGGTGAGCCAGGGCCTGCGACTGCACCTCCCTATGTACATGT  
 TCCTCCAGCATCTCTCCTTCTGGAGGTCTGGTACACGTCCACACTGTGCCCTCTCCTA  
 GCCAACCTGCTGCTGGGCCAACCGACATCTCCTCTGCCTGCATGGCACAGCTACT  
 TCTTCGTATTCTCGGCCACCGAGTGCTTCTCTGGCCTCATGGCCTATGGCCTATGACCGTTAC  
 CTGGCCATCTGCAGCCCACCTCGTACCCCTTCTCATGCATCGTGGGCTATGTGCCAGGTT  
 GGTGGTGGTCTCATGGTGACAGGGTCAGCACAGGCTTCTGCATTCCATGATGATTCC  
 AGGTGGACTCTGTGGGCCAATCAGATTAAACCATTCTCTGCACCTCCGCACTCA  
 TGCAGCTCTCTGTCCAGAGTTATATCACCGAGGTGACCATCTCATCCTGTCATTGCC  
 GTGCTGTGCAATTGTTTTCTGACACTGGGCCATGTTTATTGTGTCTCCATATT  
 GAGAATCCCTTCCACCTCTGGCCGGAGAAAGACCTTTCCACATGTGGCTCCACCTGGCT  
 GTTGTCACTCTACTACGGGACCATGATCTCATGTATGTGTGTCCAGTCCCCACCTGGT  
 GCCTGAAATCAACAAGATCATTCTGTCTACACTGTGGTCACACCAACTGCTGAACCCA  
 GTTATCTACAGCTTGAGGAACAAAGACTTCAAAAGAAGCTTAGAAAGGTATGAGAAGG  
 AAATGTGGTATTCTATGGAGTACAAGTAAAGGAAGTCTTTATTAG (SEQ ID NO: 426).

30

## AOLFR229 sequences:

35

MFYVNQIPFQLYHISFVYPTELWSRAIIPCMPLSFWVCSATPVSPGFFALILLVFVTSIASNVVK  
 IIIHIDSRLHTPMYFLLSQLSLRDILYISTIVPKMLVDQVMSQRAISFAGCTAQHFLYLTAGAE  
 FFLLGLMSCDRYVAICNPLHYPDLMRKRICWLIVAAA WLGGSIDGFLTPVTMQFPFCASREIN  
 HFFCEVPALLKSLCTDTSAETAMYVCCIMILLIPFSVISGSYTRILITVYRMSEAEGRRKAVAT  
 CSSHMMVVSVLFYGAAMYTYVLPHSYHTPEQDKAVSAFYTILTPMLNPLIYSLRNKDVTGALQK  
 VVGRCVSSGKVTF (SEQ ID NO: 427).

40

ATGTTTATGTAATCAGACCTTCAACTTATCATATCTCTTGTACCCATACAGA  
 GCTATGGAGCAGAGCAATTATCCGTATGCCGACTTATCCTCTGGTTGTACGA  
 ACGCCCGTTCCCTGGCTCTTGCCTCATTCTCTGGCTTGTGACCTCCATAGCCAG  
 CAACGTGGCAAGATCATTCTCATCCACATAGACTCCGCTCACACCCCCATGTACTTC  
 CTGCTCAGCCAGCTCCCTCAGGGACATCTGTATATTCCACCATGTGCCAAATGCT  
 GGTGACCAAGGTGATGAGCCAGAGGCCATTCTTGTGGATGCACTGCCAACACTTC  
 CTCTACTTGACCTTAGCAGGGCTGAGTTCTCTCTAGGACTCATGCTCTGTGATGCTA  
 CGTAGCCATCTGCAACCCCTCTGCACTATCTGACCTCATGAGCCGAAGATCTGCTGGTTG  
 ATTGTGGCGCAGCTGGCTGGAGGGCTATCGATGGTTCTGCTCACCCCCGTCA  
 TGCAGTCCCCTCTGTGCCTCTGGAGATCAACCACTCTCTGCAGGGTGCCTGCC  
 CTGAAGCTCTCATCCCTCTCTGTGATCTGGCTTACACAAGAATTCTCATTACTGTT  
 TGATGCTCCTCATCCCTCTCTGTGATCTGGCTTACACAAGAATTCTCATTACTGTT  
 TATAGGATGAGCGAGGCAGAGGGAGGGCAAAGGCTGTGGCCACCTGCTCCTCACACATG  
 GTGGTTGTCAAGCCTCTATGGGCTGCCATGTACACATACGTGCTGCCTCATTCTACCA  
 CACCCCTGAGCAGGACAAAGCTGATCTGCCTTACACCATCCTCACTCCATGCTAAT  
 CCACTCATTTACAGCCTAGGAACAAGAGATGTCACGGGGGCCACAGAAGGTGTTGGG  
 AGGTGTGTGCTCAGGAAAGGTAAACCACTTCTAA (SEQ ID NO: 428).

55

**AOLFR230 sequences:**

5           MGMEGLLQNSTNFVLTGLITHPAFPGLLFAIVFSIFVVAITANLVMILLIHMDSLRHTPMYFLLS  
 QLSIMDTIYICITVPKMLQDLSKDKTISFLGCAVQIFLYLTIGEFFLLGLMAYDRYVAVCNP  
 LRYPLLMNRRVCLFMVVGWSVGGSLDGMLTPVTMSFPFCRSREINHFFCEIPAVLKLSCTDTS  
 10          LYETLMYACCVLMLIPLSVSIVSYTHILLTVHRMNSAEGRRKAFATCSSHIMVVSVFYGAAFY  
 TNVLPHSYHTPEDKVVSAFYTILTPMLNPLIYSLRNKDVAALRKVLGRCSSQSIRVATVIR  
 KG (SEQ ID NO: 429).

10          ATGGGCATGGAGGGTCTTCTCCAGAACCTCCACTAACCTCGCCTCACAGGCCTCATCACCC  
 ATCCTGCCTCCCCGGGCTTCTCTTGCAATAGTCTTCCATCTTGTTGGTGGCTATAACA  
 GCCAACTTGGTCATGATTCTGCTCATCCACATGGACTCCGCCTCACACACCCATGTACTT  
 CTTGCTCAGCCAGCTCTCCATCATGGATACCATCTACATCTGTATCACTGTCCCCAAGATGC  
 TCCAGGACCTCCTGTCCAAGGACAAGACCATTCTCTGGCTGTGCAGTTCAGATCTT  
 CCTCTACCTGACCCGTATTGGAGGGAAATTCTCTGCTGGGTCTCATGGCCTATGACCGC  
 15          TATGTGGCTGTGCAACCCCTACGGTACCCCTCTCCTCATGAACCGCAGGGTTGCTTATT  
 CATGGTGGTCGGCTCTGGTTGGTCTCTGGATGGGTTCATGCTGACTCCTGTCACT  
 ATGAGTTCCCCTCTGTAGATCCCAGAGATCAATCACTTTCTGTGAGATCCCAGCCGT  
 GCTGAAGTTGTCTGCACAGACACGTCACTCTATGAGACCCGTATGTATGCCTGTCGCTG  
 CTGATGCTGCTTATCCCTCATCTGTCTCATCTGCTCTACACGCACATCCTCTGACTGT  
 20          CCACAGGATGAACCTCTGCTGAGGGCCGGCGAAAGCCTTGCTACGTGTTCTCCCACATT  
 ATGGTGGTGGCTCTACGGGCGACCTCTACACCAACGTGCTGCCCACTCTACCC  
 ACACTCCAGAGAAAGATAAAAGTGGTCTGCCTCTACACCATCCTCACCCCCATGCTCAA  
 CCCACTCATCTACAGCTTGAGGAATAAGATGTGGCTGCAGCTTGAGGAAAGTACTAGG  
 GAGATGTGGTCTCCAGAGCATCAGGGTGGCGACTGTGATCAGGAAGGGCTAG (SEQ ID  
 25          NO: 430).

**AOLFR231 sequences:**

30          MERANHSVVSEFILLGLSKSQNLQILFFLGFSVVFVGIVLGNLLILVTVTFDSSLHTPMYFLLSNL  
 SCIDMILASFATPKMIVDFLRLERKTISWWGCYSQMFFMHLLGGSEMLLVAMAIDRYVAICKP  
 LHYMTIMSPRVLGLLLSSYAVGFVHSSSQMAFMLTLPCGPVIDSFFCDLPLVIKLACKDTYI  
 LQLLVIADSGLLSVCFLLLVSYGVIIFSVRYRAASRSSKAFSTLSAHITVVTLFAPCVFIYVW  
 PFSRYSVDKILSVFYTIFTPLLNPIIYTLRNQEVKAAIKKRLCI (SEQ ID NO: 431).

35          ATGGAAAGAGCAAACCATTCACTAGTGGTATCGGAATTATTATTGTGGACTTCCAAATCTC  
 AAAATCTTCAGATTATTCTCTGGGATTCTCTGTGGTCTCGTGGGATTGTGTTAGGA  
 AACCTGCTCATCTGGTGAATGTGACCTTGTGATTGCTCCTCACACACCAATGTATTCT  
 GCTTAGCAACCTCTCCTGCATTGATATGATCCTGGCTTCTTGTACCCCTAAGATGATTG  
 TAGATTCCCTCCAGAGAACGTAAGACCATCTCATGGTGGGATGTTATTCCAGATGTTCTT  
 TATGCACCTCTGGTGGAGTGAGATGATGTTGCTTAGCCATGGCAATAGACAGGTAT  
 40          GTTGCCATATGCAAACCCCTCATTACATGACCATCATGAGCCCACGGGTGCTACTGGC  
 TACTGTTATCCTCTATGCAGTTGGATTGTGCACTCATCTAGTCAAATGGCTTCTGTTG  
 ACTTTGCCCTCTGTGGTCCAATGTTATAGACAGCTTTCTGTGACCTCCCTGTGAT  
 TAAACTGCCTGCAAGGACACCTACATCCTACAGCTCTGGTCACTGCTGACAGTGGCTC  
 CTGTCACTGGTCTGCTTCCCTCTTGCTTGTCTCCTATGGAGTCATAATATTCTAGTTAG  
 45          GTACCGTGTGCTAGTCGATCCTCTAAGGTTCTCCACTCTCAGTCACATCACAGTTG  
 TGACTCTGTTCTTGTCCGTGTGTTATCTACGTCTGGCCCTCAGCAGATACTCGGTA  
 GATAAAATTCTTCTGTGTTTACACAATTTCACACCTCTTAAATCCTATTATTATAC  
 ATTAAGAAATCAAGAGGTAAAAGCAGCATTAAAAAAAGACTCTGCATATAA (SEQ ID NO:  
 432).

50

**AOLFR232 sequences:**

55          MDNITWMASHTGWSDFILMGLFRQSKHPMANITWMANHTGWSDFILLGLFRQSKHPALLCV  
 VIFVVFLMALSGNAVLILLIHCDAHLHTPMYFFISQLSMDMAYISVTPKMLLDQVMGVNKIS  
 APECGMQMFFYVTLAGSEFFLLATMAYDRYVAICHPLRYPVLMNHRVCLFLSSGCWFLGSVD  
 GFTFTPITMTPFRGSREIHHFFCEVPAVLNLSCDTSLYEIFMYLCCVLMILLIPVVISSSYLLILL

WO 01/98526

TIHGMNSAEGRKKAFATCSSHLTVVILFYAAIYTMLPSSYHTPEKDMMVSVFYTLTPVVNP  
 LIYSLRNKDVGMALKMLTVEPAFKAME (SEQ ID NO: 433).

5 ATGGACAACATCACCTGGATGCCAGCCACACTGGATGGTCGGATTTCATCCTGATGGAC  
 TCTTCAGACAATCCAACATCCAATGCCAATATCACCTGGATGCCAACACACTGGATG  
 GTCATTTGGTTTCTGATGGCGTGTGAAATGCTGCTGATCCTCTGATACA  
 CTGTGACGCCACCTCCACACCCCCATGTACTTTCATCAGTCAATTGTCATGGACA  
 10 TGGCGTACATTCTGACTGTGCCCAGATGCTCTGGACCAGGTATGGGTGAATAA  
 GATCTCAGCCCTGAGTGTGGATGCAGATGTTCTACGTGACACTAGCAGGGTCA  
 TTTTCCTCTAGGCCACATGGCTATGACCGTACGGCCATCTGCCATCCTCCGTTA  
 CCCTGTCCTCATGAACCATAAGGTGTCTTCTGTATCAGGCTGCTGGTCTCTGGCT  
 CAGTGGATGGCTTCACATTCACTCCCATACCATGACCTTCCCCTCCGTGGATCCGGAA  
 15 GATTCACTATTCTCTGTGAAGTCTGCTGTATTGAATCTCCTGCTCAGACACCTCAC  
 TCTATGAGATTTCATGACTGTGCTGTCTCATGCTCTCATGCTGGTATCATT  
 TCAAGCTCTATTACTCATCCTCTACCATCCACGGATGAACTCAGCAGAGGGCCGGA  
 AAAAGGCCCTGCCACCTGCTCCTCCACCTGACTGTGGTATCCTCTATGGGCTGCC  
 ATCTACACCTACATGCTCCCAGCTCTACCAACCCCTGAGAAGGACATGATGGTATCTG  
 20 TCTCTATACCATCCTCACTCCAGTGGTAACCCCTTAATCTATAGTCTAGGAATAAGGAT  
 GTCAAGGGGCTCTGAAGAAAATGTTAACAGTGGAACCTGCCITCAAAAGCTATGGAG  
 TAG (SEQ ID NO: 434).

**AOLFR233 sequences:**

25 MANITRMANHTGKLD FILMGLFRRSKHPALLSVVIFVVFLKALSGNAVLILLIHDAHLHSPMY  
 FFISQLSLMDMAYISVTVPKMLDQVMGVNKVSAPECGMQMFLYLTLAGSEFFLATMAYDR  
 YVAICHPLRYPVLMNHRVCLFLASGCWFLGSVDGFMLTPITMSFPFCRSWEIHIFCCEVPATI  
 LSCSDTSLYETLMLYLCVLMILLIPVTISSLILLTVHRMNSAEGRKKAFATCSSHLTVVILFY  
 GAAVYTYMLPSSYHTPEKDMMVSVFYTLTPVNLPIYSLRNKDVGMALKMLTVRFV  
 (SEQ ID NO: 435).

30 ATGGCCAACATCACCAAGGATGCCAACCAACTGGAAAGTTGGATTTCATCCTCATGGGAC  
 TCTTCAGACGGATCCAACATCCAGCTACTTAGTGTGGTCATCTTGTGGTTTCTGAAAG  
 GCGTTGTCGAAATGCTGCTGATCCTCTGATACACTGTGACGCCACCTCCACAGCC  
 35 CCATGTACTTTCTCATCAGTCATTGCTCTCATGGACATGGCTACATTCTGACTGTG  
 CCCAAGATGCTCTGGACCAGGTATGGGTGAATAAGGTCTCAGCCCTGAGTGTGG  
 ATGCAGATGTCCTCATCTGACACTAGCAGGTTCGGAATTTCCTCTAGCCACCATGGC  
 CTATGACCGCTACGGCCATCTGCCATCCTCTCGGTACCCCTGCTCATGAACCATAGG  
 GTCTGTCTTCTGGCATGGCTGCTGGTCTGGCTCAGGGATGGCTCATGCTCAC  
 TCCCATCACATGAGCTTCCCTCTGACATGGGAGATTCTACATTCTGTAAG  
 40 TCCCTGCTGTAACGATCCTGCTCAGACACCTACTCTATGAGACCCCTATGTCAC  
 TGCTGTCTCTCATGCTCTCATCCCTGTGACGATCATTCAAGCTCTATTACTCATCCT  
 CCTCACCGTCCACAGGATGAACTCAGCAGAGGGCCGGAAAAGGCCCTGCCACCTGCTC  
 45 CTCCCACCTGACTGTGGTCATCTCTATGGGGCTGCCGTACACCTACATGCTCC  
 GCTCCTACACACCCCTGAGAAGGACATGATGGTATCTGCTCTATACCATCCTACTCC  
 GGTGCTGAACCCCTTAATCTATAGTCTAGGAATAAGGATGTCATGGGGCTCTGAAGAAA  
 ATGTTAACTGTGAGATTGCTCTTAG (SEQ ID NO: 436).

**AOLFR234 sequences:**

50 MPNSTTVMFLLMRFSDVWTLQILHSASFFMLYLVTLMGNILIVTTCDSLLHMPMYFFLRN  
 LSILDACYISVTVPSCVNSLLDSTISKAGCVAQVFLVVFFVYVELLFTIMAHDRYVAVCQPL  
 HYPVIVNSRICIQMLASLLSGLVAGMHTGSTFQLPFCRSNVIIHQFFCDIPSLLKLSCSDTSNE  
 VMIVVSALGVGGGCFIIRSYIHFSTVLFPRGADRTKAFSTCIPHLVVSVFLSSCSSVYLRPP  
 AIPAATQDLILSGFYSIMPPLFNPIIYSLRNKQIKVAIKKIMKRIFYSENV (SEQ ID NO: 437).

55 ATGCCCAATTCAACCACCGTATGGAATTCTCCTCATGAGGTTTCTGATGTGTGGACAC  
 TACAGATTTCACATTCTGCATCCTCTTATGTTGATTTGTAACCTAATGGAAACATC

5 CTCATTGTGACCGTCACCAACCTGTGACAGCAGCCTCACATGCCCATGTACTTCTCCTCAG  
 GAATCTGTCTATCTTGGATGCCTGCTACATTCTGTTACAGTCCTACCTCATGTGTCAATT  
 CCCTACTGGACAGCACCACCAATTCTAAGGGGGATGTGAGCTCAGGTCTCCTCGTGGT  
 TTTTTTGATATGTGGAGCTTCTGTTCTCACCAATTGGCTCATGACCGCTATGTGGCTG  
 10 TCTGCCAGCCACTTCACTACCCCTGTGATCGTAACCTCGAATCTGCATCCAGATGACACT  
 GGCCTCCCTACTCAGTGGCTTGTCTATGCAGGCATGCACACTGGCAGCACATTCCAGCTG  
 CCCTCTGTCGGTCCAACGTTATTCACTAATTCTCTGACATCCCCTCTGCTGGGGTAGGT  
 CTCTGCTCTGACACCTCAGCAATGAGGTATGATTGTTCTGCTCTGCTGGGGTAGGT  
 GGCAGCTGTTCATCTTATCATCAGGTCTACATTACATCTTCGACCGTCTGGGTT  
 15 TCCAAGAGGAGCAGACAGAACAAAGGCCTTCCACCTGCATCCCTCACATCCTGGTGGT  
 TCAGTCTCCTCAGTCATGCTCTTGTGACCTCAGGCCACCTGCGATACCTGCAGCCAC  
 CCAGGATCTGATCCTTCTGGTTTATTCCATAATGCCTCCCCTTTAACCCTATTATTA  
 CAGTCTAGAAATAAGCAAATAAGGTGGCATCAAGAAAATCATGAAGAGAATTTTTA  
 TTCAGAAAATGTGTAA (SEQ ID NO: 438).

15 **AOLFR235 sequences:**

20 MDGVNDSSLQGFVLMGISDHPQLEMIFFIAILFSYLLTLLGNSTIILSRLEARLHTPMYFFLSNL  
 SSSDLAFATSSVPQMLNWLWPGPKTISYGGCITQLYVFLWLGATECILLVVMADFDRYVAVCRPL  
 RYTAJMPNQLCWLLAVIACLGGLGNSVIQSTFTLQLPLCGHRRVEGFLCEVPAMIKLACGDTSL  
 NQAVLNGVCTFFTAVPLSIVISYCLIAQAVLKIRSAEGRRKAFNTCLSHLLVVFLFYGSASYGY  
 25 LLPAKNSKQDQGKFISLFYSLVTPMVNPLIYTLRNMEVKGALRLLGKGREVG (SEQ ID NO:  
 439).

30 ATGGACGGGGTGAATGATAGCTCCTGAGGGCTTGTGATGGCATATCAGACCATC  
 CCCAGCTGGAGATGATCTTTTATAGCCATCCTCTCTCTATTTGCTGACCTACTTGGG  
 AACTCAACCATCATCTGCTTCCCGCTGGAGGCCGGCTCCATACACCCATGTACTTCTT  
 CCTCAGCAACCTCTCCTCTGGACCTGCTTGTACTAGTTAGTCCAGTCCCCAAATGCTGA  
 TCAATTATGGGGACCAGGCAAGACCATCAGCTATGGTGGCTGCATAACCCAGCTATGT  
 35 CTTCTTGGCTGGGGCCACCGAGTGCATCCTGCTGGTGTGATGGCATTGACCGCTAC  
 GTGGCAGTGTGCCGGCCCTCCGCTACACCGCCATCATGAACCCCCAGCTCTGCTGGCTGC  
 TGGCTGTGATTGCCGCCTGGGTGGCTGGCAACTCTGTGATCCAGTCACATTCACTCT  
 GCAGCTCCCATTGTGTGGCACCGGAGGGTGGAGGGATTCTCTGCGAGGTGCCTGCCAT  
 GATCAAACCTGGCCTGTGGCGACACAAGTCTAACCAACAGGCTGTGCTCAATGGTGTCTGCACC  
 TTCTTCACTGCAGTCCCACAAAGCATCATCGTATCTCTACTGCCATTGCTCAGGCAGT  
 40 GCTGAAAATCCGCTCTGCAGAGGGAGGCGAAAGGCCTCAATACGTGCCTCTCCATCT  
 GCTGGTGGTGTCTCTTCTATGGCTCAGCCAGCTATGGGTATCTGCTTCCGGCAAGAAC  
 AGCAAACAGGACCAGGGCAAGTTCATTCCCTGTTACTCGTGGTACACCCATGGTGA  
 ATCCCTCATCTACACGCTGCGGAACATGGAAGTGAAGGGCGACTGAGGAGGTTGCTGG  
 GGAAAGGAAGAGAAGTTGGCTGA (SEQ ID NO: 440).

40 **AOLFR236 sequences:**

45 MTSQERDTAIYSINVSVAKGMTSRVCEKMTMTENPNQTVVSHFFLEGLRYTAKHSSLFFL  
 LFLLIYSITVAGNLLILLTVGSDSHSLPMYHFLGHLSFLDACLSTVTPKVMAGLLLDGKV  
 FECAVQLYCFHFLASTECFLYTVMAYDRYLAICQPLHYPVAMNRRMCAEMAGITWAIGATH  
 AAIHTSLFRLLYCOPCHIAYFFCDIPPVLKLAECTTINELVMLASIGIVAAGCLILIVISYIFIVA  
 AVLRIRTAQGRQRAFPCTAQLTGVLYYVPPVCIYLQPRSSEAGAGAPAVFYTIVTPMLNPFY  
 TLRNKEVKHALQRLCSSFRESTAGSPPP (SEQ ID NO: 441).

50 ATGACATCTCAGGAAAGGGATACAGCTATTATCCATTAATGTCAGTTTGTGCAAAGG  
 GGATGACTAGCCGCTCTGTGTGAGAAGATGACCATGACAACGGAGAACCCCAACCAGA  
 CTGTGGTGGCCACTTCTCTGGAGGGTTGAGGTACACCGCTAAACATCTAGCCTCTT  
 CTTCTCTCTCTCTCATCTACAGCATCACTGTGGCTGGGAATCTCCTCATCCTCTCAA  
 CTGTGGGCTCTGACTCTCACCTCAGCTTACCCATGTACCAACTTCTGGGGACCTCTCTC  
 CTGGATGCCGTGGTCTACAGTGACAGTGCCAAAGGTACGGCAGGCCTGCTGACTCTGG  
 55 ATGGGAAGGTGATCTCCTTGAGGGCTGTGCCGTACAGCTTATTGCTTCCACTTCTGGC  
 CAGCACTGAGTGCTCCTGTACACAGTCATGCCATGACCGCTATCTGGCTATCTGTCAA

5 CCCCTGCACTACCCAGTGGCCATGAACAGAAGGATGTGAGAAATGGCTGGAATCACC  
TGGGCCATAGGTGCCACGCACGCTGCAATCCACACCTCCCTCACCTCCGCTGCTACT  
GTGGCCTTGCACATTGCCACTTCTGCGACATACCCCTGCTCTAAAGCTCGCCTGT  
ACAGACACCACCATTAATGAGCTAGTCATGCTGCCAGCATGGCATCGTGGCTGCAGGGCT  
10 GCCTCATCCTCATCGTTATTCCTACATCTCATCGTGGCAGCTGTGCGCATCCGCACA  
GCCCAGGGCCGGCAGCAGGGCTTCTCCCCCTGCACTGCCCAGCTCACTGGGTGCTCCTGT  
ACTACGTGCCACCTGCTGTATCTACCTGCAGCCTCGCTCCAGTGAGGCAGGAGCTGGGGC  
CCCTGCTGTCTACACAATCGTAACCTCAATGCTCAACCCATTCAATTACACTITGCGGA  
ACAAGGAGGTGAAGCATGCTCTGCAAAGGCTTGTGAGCAGCTCCGAGAGTCTACAG  
CAGGCAGCCCACCCCCATAG (SEQ ID NO: 442).

**AOLFR237 sequences:**

15 MDQRNYTRVKEFTFLGITQSRELSQVLFITFLVYMTTLMGNFLIMVTVCESHLHTPMYFLL  
RNLSILDICFSSITAPKVLIDLLSETKTISFGCVTQMFFFHLLGGADVFSLVMAFDRYIAISKPL  
HYMTIMSRGRCTGLIVGFLGGGLVHSIAQISLLLPLVCGPNVLDTFYCDVPQVLKACTDTFT  
LELLMISNNGLVSWFVFFFLISYTVILMMLRSHTGEGRRKAISTCTSHITVVLHFVPCIYVYA  
RPFTALPTDTAISVTFTVISPLNPIYTLRNQEMKLAMRKLKRLGQSERILIQ (SEQ ID NO:  
443).

20 ATGGATCAGAGAAATTACACCAGAGTGAAAGAATTACCTTCTGGAAATTACTCAGTCCC  
GAGAACTGAGCCAGGTCTATTACCTTCTGTTTTGGTGTACATGACAACCTCTAATGGG  
AAACTCCTCATCATGGTACAGTTACCTGTGAATCTCACCTCATACGCCATGTACTTCC  
TGCTCCGCAACCTGTCTATTCTTGACATCTGCTTTCTCCATCACAGCTCTAACGGTCTG  
ATAGATCTTCTATCAGAGACAAAAACCATCTCTTCAGTGGCTGTGACTCAAATGTTCT  
25 TCTTCCACCTCTGGGGGAGCAGACGTTTTCTCTCTGTGATGGCTTGGCGTACAGCGCTAT  
ATAGCCATCTCCAAGGCCCTGCACTATATGACCATCATGAGTAGGGGGCGATGCACAGGCC  
TCATCGTGGCTCCTGGGTGGGGCTTGCCACTCCATAGCGCAGATTCTCTATTGCT  
CCCACTCCCTGCTGTGGACCCAATGTTCTGACACTTCTACTGCGATGTCCCCAGGTCC  
TCAAACCTGCCTGCACTGACACCTCACTCTGGAGCTCTGTGATGATTCAAATAATGGGTT  
30 AGTCAGTTGGTTGTATTCTTCTCTCATATCTTACACGGTCATCTGATGATGCTGA  
GGTCTCACACTGGGAAGGCAGGAGGAAGCCATCTCACCTGCACCTCCCACATCACCG  
TGGTACCCCTGCATTCTGCCCCCTGCATCTATGTCTATGCCGCCCTCACTGCCCTCCCC  
ACAGACACTGCCATCTCTGTGACCTCACTGTCATCTCCCTTGCTCAATCCTATAATTAA  
CACGCTGAGGAATCAGGAAATGAAGTGGCCATGAGGAAACTGAAGAGACGGCTAGGAC  
35 AATCAGAAAGGATTAAATTCAATAA (SEQ ID NO: 444).

**AOLFR238 sequences:**

40 MAPENFTRVTEFILTGVSSCPELQIPLFLVFLVLYVLTMAGNLGIITLTSVDSRLQTPMYFFLRHL  
AIINLGNSTVIAPKMLMNFLVKKKTTSFYECATQLGGFLFFIVSEVMMALAVMAYDRYVAICNP  
LLYMVVVSRRLLCLLVLSTLYGFSTAIVVSPCIFSVSYCSSNIINHIFYCDIAPLLALSCSDTYIPE  
TIVFISAATNLFFSMITVLVSYFNIVLISLIRSPEGRKKAFSTCASHMIAVTVFYGTMLFMYLQP  
QTNHSLDTDKMASVFYTLVIPMLNPLIYSLRNNNDVNVALKKFMENPCYSFKSM (SEQ ID NO:  
445).

45 ATGGCTCCTGAAAATTACACCAGGGTCACTGAGTTATTCTCACAGGTGCTCTAGCTGTC  
CAGAGCTCCAGATTCCCTCTTCCCTGGTCTTCCCTAGTGTCTATGTGCTGACCATGGCAGG  
GAACCTGGGCATCATCACCCCTCACCAGTGTGACTCTCGACITCAAACCCCCATGTACTTIT  
50 TCCTGAGACATCTAGCTATCATCAATCTTGGCAACTCTACTGTCATTGCCCTAAATGCTG  
ATGAACCTTTAGTAAAGAAAACCTACCTCATCTATGAATGTGCCACCCAACTGGGAG  
GGTCTTGTCTTATTGTATCGGAGGTAATGATGCTGGCTGTGATGGCTATGACCGCTA  
TGTGGCCATTGTAACCCCTGCTACATGGTGGTGTCTCGCGGGCTCTGCCTCCTGC  
TGGTGTCCCTCACGTACCTCTATGGCTTTACAGCTATTGTGGTTACCTGTATATT  
55 TCTGTGCTTATTGCTCTTAATATAATCAATCATTAACTGTGATATTGACACCTCTGTT  
AGCATTATCTGCTCTGATACTTACATACCAAGAAACAATAGTCTTATATCTGAGCAACA  
AATTGTTTTTCCATGATTACAGTTCTAGTATCTTATTCAATATTGTTTGTCCATTCTA  
AGGATACTGTCACCAGAAGGAAGGAAAAAGCCTTCCACCTGCGCTCGCATATGATA

GCAGTCACGGTTTCTATGGACAATGCTATTATGTATTCAGCCCCAACCAACCA  
 CACTGGATACTGATAAGATGGCTCTGTGTTTACACATTGGTATTCTATGCTGAATCC  
 CTTGATCTACAGCCTGAGGAATAATGATGTAATGTTGCCTAAAGAAATTATGGAAAT  
 CCATGTTACTCCTTAAATCAATGTA (SEQ ID NO: 446).

5

**AOLFR239 sequences:**

MDPQNYSLVSEFVLHGLCTSRHLQNFFFIFFFGVYVAIMLGNNLILTVISDPCLHSSPMYFLLG  
 NLAFLDMWLASFATPKMIRDFLSDQKLISFGGCMQAQIFFLHFTGGAEMVLLVSMAYDRYVAIC  
 KPLHYMTLMSWQTCIRLVLASWVVGVFVHSISQVAFTVNLPCGPNEVDSFFCDLPLVIKACM  
 10 DTYVLGIIMISDGLLSLSCFLLLISYTVILLAIRQRAAGSTSKALSTCSAHIMVVTLFFGPIFV  
 YVRPFSRFSVDKLLSVFYTIIFTPLLNPIIYTLRNEEMKAAMKKLQNRRVTQF (SEQ ID NO: 447).

ATGGACCCACAGAACTATCCTGGTGTCAAGAATTGTGTTGCATGGACTCTGCACTTCAC  
 GACATCTCAAAATTCTTCTTATATTCTTCTGGGTCTATGTGCCATTATGCTGGGT  
 15 AACCTTCTCATTGGTCACTGTAATTCTGATCCCTGCCGCACCTCCCTCCATTGTACTT  
 CCTGCTGGGAACCTAGCTTCCCTGGACATGTGGCTGCCCTCATTGCCACTCCAAAGATG  
 ATCAGGGATTCTTAGTGATCAAAAACATCTCCTTGGAGGATGTATGGCTAAATCT  
 TCTCTTGCACTTACTGGTGGGGCTGAGATGGTGTCTGGTTCCATGCCCTATGACAG  
 20 ATATGTGGCCATATGCAAACCCCTGCATTACATGACTTGTGAGTTGGCAGACTTGCATC  
 AGGCTGGTGTGGCTTCATGGGCGTTGGATTGTGCACTCCATCAGTCAAGTGGCTTCA  
 CTGTAATTGCTTACTGTGGCCCCATGAGGTAGACAGCTCTCTGTGACCTCCCTCTG  
 GTGATCAAACCTGCCTGCATGGACACCTATGTCTGGTATAATTATGATCTCAGACAGTG  
 25 GGTTGCTTCTTGAGCTGTTCTGCTCCTCTGATCTCCTACACCGTGATCCTCCTCGCT  
 ATCAGACAGCGTGTGGCGTAGCACATCCAAAGCACTCTCCACTGCTCTGCACATATCA  
 TGGTAGTGACGCTGTTCTTGGCCCTTGCACTTGTGTTATGTGCGGCCCTTCAGTAGGTT  
 TCTGTGGACAAGCTGCTGTGTTTACCACTTACTCCACTCTGAACCCATTAT  
 CTACACATTGAGAAATGAGGAGATGAAAGCAGCTATGAAGAAACTGCAAAACCGACGGGT  
 30 GACTTTCAATGA (SEQ ID NO: 448).

**AOLFR240 sequences:**

MAGENHTTLPEFLLGFSDLKALQGPLFWVLLVLYLVTLLGNSLIILLTQVSPALHSSPMYFFLR  
 QLSVVELFYTTDIVPRTLANLGSHPQAIQMYFIVLGISECCLLTAMAYDRYVAIC  
 QPLRYSTLLSPRACLAMVGSSWLTGIIATTHASLIFSLPFRSHPIIPHFLCDILPVLRLASAGKHR  
 35 SEISVMTATIVFIMIPFSLIVTSYIRILGAILAMASTQSRRKVFSTCSSHLLVVSLLFFGTASITYIRPQ  
 AGSSVTTDRVLSLFYTVITPMNLNPITYTLRNKDVRRALRHLVKRQRPSP (SEQ ID NO: 449).

ATGGCTGGGAAAACCATACTACACTGCCTGAATTCCCTCTGGGATTCTCTGACCTCA  
 AGGCCCTGCAGGGCCCCCTGTTCTGGGTGGTCTCTGGTACCTGGTACCTTGCTGGG  
 TAACCTCCCTGATCATCCTCCTCACACAGGTCAGCCCTGCCCTGCACCCCCATGTACTTCT  
 40 TCCTGCGCCAACTCTCAGTGGTGGAGCTCTTACACCAACTGACATCGTGCCAGGACCT  
 GGCAATCTGGCTCCCCCATCCCCAGGCCATCTCTCCAGGGCTGTGCAGCCCAGATG  
 TACGTCTCATGGCTGGCATCTCGGAGTGTGCTGCCCTCACGGCCATGGCCTATGACC  
 GATATGTTGCCATCTGCCAGCCCTACGCTATTCCACCCCTTGTGAGCCCACGGGCTGCTT  
 GGCCATGGTGGGGCTCTGGCTCACAGGCATCATCAGGCCACCCATGCCCTCC  
 45 ATCTCTCTCACCTTTCGAGCCACCGATCATCCGCACCTTCTGTGACATCCTGCC  
 AGTACTGAGGCTGGCAAGTGCTGGGAAGCACAGGAGCGAGATCTCGTGATGACAGCCAC  
 CATAGTCITCATTATGATCCCTCTCTGATTGTACCTTACATCCGCATCTGGTG  
 CCATCCTAGCAATGGCCTCACCCAGAGCCGCCAAGGTCTCTCACCTGCTCC  
 50 TCTGCTCGTGGCTCTCTCTTGGAACAGCCAGCATCACCTACATCCGCCGAGGCA  
 GGCTCCTCTGTTACACAGACCGCGCTCAGTCTCTTACACAGTCATCACACCCATGCT  
 CAACCCCATCATCACACCCCTGGAACAGGACGTGAGGAGGGCCCTGCGACACTTGGT  
 GAAGAGGCAGCGCCCTCACCTGA (SEQ ID NO: 450).

**AOLFR241 sequences:**

55 MPQILIFTYLNMFYFFPPLQILAENLTMVTEFLLGFSSLGEIQLALFVVFLFLYLVLVILSGNVTIIS  
 VIHLDKSLHPTMYFFLGLISTSETFYTFVILPKMLINLLSVARTISFNCCALQMFFLFAITNCLL

LGVMGYDRYAAICHPLHYPTLMSWQVCGKLAAACAGGFLASLTVVNLVFSLPFCSANKVNHYFCDISAVILLACTNTDVNEFVIFICGVVLVVPFLFICSYLCILRTILKIPSAEGRRAFKSTCAS  
HLSVVIVHYGCASFYLRPTANYVSNKDRLVTVTYTIVTPLNPMVYSLRNKDVLQAIRKVLGKKGSLKLYN (SEQ ID NO: 451).

5 ATGCCCAAATTCTTATATTACACATACTGAATATGTTTACTCTTCCCCCTTGCAGAT  
CTTGGCAGAAAACCTACCATGGTACCGAATTCTGTTGGGTTTCCAGCCTTGGT  
GAAATTCACTGGCCCTTGTAGTTTCTTCTGTATCTAGTCATTCTAGTGGCAA  
10 TGTCACCAATTACAGTGTACCCACCTGGATAAAAGCCTCACACACCAATGTACTCTCC  
TTGGCATTCTCTAACATCTGAGACCTTCTACACCTTGTCACTTACCCAAGATGCTCATC  
AATCTACTTCTGTGGCCAGGACAATCTCCTCAACTGTTGTCTTCAAATGTTCTTCTT  
CCTTGGTTTGCCTTACCAACTGCCTGCTATTGGGTGTATGGGTTATGATCGCTATGTC  
CCATTGTCACCCCTGCATTACCCACTCTTATGAGCTGGCAGGGTGTGGAAAAGTGGC  
15 AGCTGCCTGTGCAATTGGTGGCTTCTGGCCTCTTACAGTAGTAAATTAGTTTCA  
TCCCTTTGTAGGCCAACAAAGTCAATCATTACTCTGTGACATCTCAGCAGTCATTCTT  
CTGGCTTGTACCAACACAGATGTTAACGAATTGTGATATTCAATTGTGGAGTTCTTGTAC  
TTGTGGTTCCCTTCTGTTATCTGTGTTCTTATCTCTGCATTCTGAGGACTATCCTGAAG  
ATTCCCTCAGCTGAGGGCAGACGAAAGCGTTTCCACCTGCCTCTCACCTCAGTGG  
20 TTATTGTCATTATGGCTGTGCTTCTTACCTGAGGCCTACAGCAAACATGTGTC  
AACAAAGACAGGCTGGTGAAGGTGACATACACGATTGTCACTCCATTACTAAACCCATG  
GTTTATAGCCTCAGAAACAAGGATGTCACCTGCTATCAGAAAAGTGTGGCAAGAAA  
GGTTCTCTAAACTATATAATTGA (SEQ ID NO: 452).

**AOLFR242 sequences:**

25 MNNTLFHPYSFLLGIPGLESMHLWVGFPAVFLTAVLGNITILFVIQTDSSLHHPMFYFLAILS  
SIDPGLSTSTIPKMLGTFWFTLREISFEGCLTQMFFIHLCTGMESAFLVAMAYDCYVAICDPLCY  
TLVLTNKVVSVMALAIFRLRPLVVFVIPFVLFLRPLFCGHQIPIHPTYGEHMGIAIRLSCASIRVNIY  
LCAISILVFDIIAIVISYVQILCAVFLSSHDAKLAFSTCGSHVCVMLTFYMPAFFSFMTHRFRGR  
NIPHFIHILLANFYVVIPALNSVIYGVRTKQIRAQVLKMFN (SEQ ID NO: 453).

30 ATGAATACCACTCTATTCTACCTTACTCTTCTTCTGGAAATTCTGGCTGGAAAG  
TATGCATCTCTGGTTGGTTTCTTCTTGTGTTCTGACAGCTGTCCTTGGAAATA  
TCACCATCCCTTTGTGATTCACTGACAGTAGTCTCCATCATCCATGTTCTACTTCTG  
GCCATTCTGTCACTATTGACCCGGGCTGTCTACATCCACCATCCCTAAATGCTTGGC  
35 CTTCTGGTTACCCCTGAGAGAAATCTCTTGAAGGATGCCCTACCCAGATGTTCTCATCC  
ACCTGTGCACTGGCATGGAATCAGCTGTGCTTGGCCATGCCCTATGATTGCTATGTGGC  
CATCTGTGACCCCTTTGCTACACGTTGGTGTGACAAACAAGGTGGTGTCACTTATGGCA  
CTGGCCATCTTCTGAGACCCTAGTCTTGTCTACCCCTTGTCTATTATCTAAGGCT  
TCCATTGTGGACACCAAATTATCCTCATACTTATGGTGGACATGGCATTGCCGC  
40 CTGTCITGTGCCAGCATCAGGTTAACATCATCTATGGCTATGTGCCATCTATCTGGT  
CTTGTACATCATAGCAATTGTCAATTCTATGTACAGATCTTGTGCTGTATTCTACTCT  
CTTCACATGATGCACGACTCAAGGCATTCAAGCACCCTGTGGCTCTCATGTGTGT  
GACTTCTATATGCCTGCATTCTCATGACCCATAGGTTGGTGGAAATATACCTC  
ACTTATCCACATTCTGGCTAATTCTATGTAGTCATTCCACCTGCTCAACTCTGA  
45 ATTATGGTGTGAGAACCAAACAGATTAGAGCACAAGTGTGAAAATGTTTCAATAAAT  
AA (SEQ ID NO: 454).

**AOLFR243 sequences:**

50 MEQVNKTVVREFVVLGFSSLARLQQLFVFLYLFTLGTNAIIISTIVLDRALHPTMYFLAIL  
SCSEICYTFVIVPKMLVDLSSQKKTISFLGCAIQMFSFLFGSSHFSLLAAMGYDRYMAICNPLR  
YSVLMGHGVCMGLMAAACACGFTVSLVTTSLVFHLPFHSSNQLHHFFCDISPVLKLAQSQHSGF  
SQLVIFMLGVFALVPLLLLILVSYIRIISAILKIPSSVGRYKTFSTCASHLIVVTVHYSCASFYLRPK  
TNYTSSQDTLISVSYTILTPLFNPYIYSLRNKEFKSALRRTIGQTFYPLS (SEQ ID NO: 455).

55 ATGGAGCAAGTCAATAAGACTGTGGTGAAGAGAGTCGTCGTCCTCGGCTCTCATCCCTGG  
CCAGGCTGCAGCTGCTTTGTATCTTCTGCTCCTACCTGTTACTCTGGCACC

5 AATGCAATCATCATTCACCATTGTGCTGGACAGAGCCCTCATACTCCATGTACTTCTT  
 CCTTGCATCCTTCTTGCTCTGAGATTGCTATACCTTGTCTTGTACCCAAGATGCTGG  
 TTGACCTGCTGCTCCAGAAGAACCTTCTTCTGGCTGTGCCATCCAAATGTTTCC  
 TTCCCTCTTCTTGCTCCTCTCACTCCTCTGGCTGGCAGCCATGGCTATGATGCTATAT  
 10 GCCATCTGTAACCCACTGCGCTACTCAGTGTCTGGACATGGGCTATGGGTGTATGGGACTA  
 ATGGCTGCTGCCTGTGCCTGTGGCTTCACTGCTCCCTGGTACCCACCTCCCTAGTATTCA  
 TCTGCCCTCACTCCTCAACCAGCTCCATCACTTCTCTGTGACATCTCCCTGTCCCTA  
 AACTGGCATCTCAGCACTCCGGCTTCAGTCAGCTGGTCATATTGCTTGGTATTTGC  
 CTTGGTCATTCCCTGCTACTTATCCTAGTCTCCTACATCCGCATCATCTGCCATTCTAA  
 15 AAATCCCTTCCCGTTGGAAGATACAAGACCTCTCCACCTGTGCCCTCCATCTCATTGTG  
 GTAACTGTTCACTACAGTGTGCCTTTCATCTACTTAAGGCCAAGACTAATTACACTTC  
 AAGCCAAGACACCCCTAATATCTGTGTACACACCACCTTACCCATTGTTCAATCCAATG  
 ATTTATAGTCTGAGAAATAAGGAATTCAAATCAGCCCTACGAAGAACAAATCGGCCAAACT  
 TTCTATCCTCTAGTTAA (SEQ ID NO: 456).

15 **AOLFR244 sequences:**

MWQEYYFLNVFFPLLKVCCLTINSHVILLPWECYHLIWLPYIGTTVGSMEYNTSSTDFTF  
 MGLFNRKETSGLIFAIISIIFTALMANGVMIFLIQTDRLHTPMYFLLSHSLIDMMYISTIVPKM  
 20 LVNYLLDQRTISFVGCTAQHFLYLTIVGAEFFLLGLMAYDRYVAICNPLRYPVLMRSRVCWMI  
 IAGSWFGGSLDGFLTPITMSFPFCNSREINHFFCEAPAVLKLACADTALYETVMYVCCVLMLL  
 IPFSVVLASYARILTTVQCMSSVEGRKKAFATCSSHMTVVSFLYGAAMYTYMLPHSYHKPAQ  
 DKVLSVFYTLTPMLNPLIYSLRNKDVGTGALKRALGRFKGPQRVSGGVF (SEQ ID NO: 457).

25 ATGTGGCAAGAATACTATTTTAAATGTTTCTTCCCACTTTAAAAGTTGCTGCCAAC  
 AATTAAATTACATGTTTACTGCCCTGGAAATGCTATCATCTTATTGGAAGATAT  
 TACCTTATATCGGCACAACGTAGGATCAATGGAAGAGTACAACACATCCTACAGACTT  
 CACTTCATGGGCTGTTCAACAGAAAGGAAACCTCAGGTCTTATTGCCCACATCTCT  
 ATCATCTTCTCACCGCACTGATGGCAATGGGTTATGATCTCCTGATCCAAACAGATT  
 TGCCTCTACACCCATGTACTTCTCCTCAGCCACCTTCTTAATTGACATGATGTAT  
 30 ATTTCACTATTGCTTAAGATGCTGGTAATTACCTGCTGGATCAAAGGACCATTCCT  
 TGTGGGGTGCACAGCTAACACTTCTCACCTTACCCCTGTGGGAGCTGAATTCTCCTG  
 CTGGGCCTCATGGCCTATGACCGCTATGTGGCCATTGCAACCCCTCTGAGATAACCTGTCC  
 TCATGAGCCGCCGGTCTGGATGATTATAGCAGGTTCTGGTTGGGGCTCTTGG  
 TGGCTTCTCTAAACCCCATCACCATGAGCTTCCCTCTGCAATTCCGGAGATTAAAC  
 35 ACTTCTCTGTGAGGCACCAAGCAGCTCTGAAGTGGCATGTGCAAGACACAGCCCTACGA  
 GACAGTGATGTATGTTGCTGTGTTGATGCTGCTGATTCTCTGCTAGTCCTGCTT  
 CCTATGCCGAATCCTGACTACAGTTCAGTGCATGAGCTCAGTGGAGGGCAGGAAGAAGG  
 CATTGCCACTGCTCATCCACATGACTGTGGTGTCTTGTACGGGCTGCCATGTAC  
 40 ACCTACATGCTGCCACATTCTACCACAAAGCCAGCCAGGACAAAGTCTCTGTGTTT  
 ACACCATTCTCACACCCATGCTGAACCCCTCATCTACAGCCTAGAAACAAGGATGTGAC  
 TGGAGCTCTGAAGAGGGCTTGGGGAGGTTCAAGGGCTCAAAGGGTGTCAAGGAGGT  
 CTTTTGA (SEQ ID NO: 458).

45 **AOLFR245 sequences:**

45 MDLKNGSLVTEFILLGGFGRWELQIFFVTFSIYGATVMGNILIMVTTCRSTLHSPLYFLLGN  
 LSFLDMCLSTATPKMIDLLTDHKTISVWGCVTQMFFMHFFGAEMTLIIMAFDRYVAICKP  
 LHYRTIMSHKLLKGFAILSWIIGFLHSISQIVLTMNLPFCGHNVINNIFCDLPLVIKLACIETYTL  
 LFVIADSGLLSFTCFILLVSYIVILVSVPKKSSHGLSKALSTSAHIVVTLFFGPCIFIYVWPFSSL  
 ASNKTLAVFYTITPLLNPSIYTLRNKKMQEARKLRFQYVSSAQNF (SEQ ID NO: 459).

50 50 ATGGATCTAAAAATGGATCTCTAGTGACCGAGTTATTTACTAGGATTTGGACGAT  
 GGGAACTCAAATTTCTTGTGACATTCTCCCTGATCTACGGTGTACTGTGATGGGA  
 AACATTCTCATTATGGTCACAGTGACATGTTAGGTCAACCCCTCATTCTCCCTGTACTTCT  
 CTTGGAAATCTCTCTTGGACATGTGTCTCTCACTGCCACAACACCCAAGATGATCA  
 55 TAGATTGCTCACTGACCACAAGACCATCTCTGTGTGGGGCTGCGTGACCCAGATGTTCTT  
 CATGCACTCTTGGGGTGCTGAGATGACTCTGATAATCATGGCCTTGACAGGTAT

5 GTAGCCATATGTAACCCCTGCACTATAGGACAATCATGAGCCACAAGCTGCTAAAGGGG  
TTTGCATACTTCATGGATAATTGGTTTTACACTCCATAAGCCAGATAGTTTAACAAT  
GAACCTGCCTTCTGTGGCCACAATGTCATAAACACATATTITGTGATCTCCCTGTGA  
TCAAGCTTGTGCTTGCATTGAAACATACACCCCTGGAATTATTGTGATGCTGACAGGGGCT  
GCTCTTTACACCTGTTCATCCTCTTGCTGTTCTACATTGTCATCCTGGTCAGTGTACC  
AAAAAAATCATCACATGGGCTCTCCAAGGCCTGCCACATTGTCATGCCACATCATTGTC  
GTCACTCTGTTCTTGGACCTGTATTITATCTATGTTGGCCATTCACTAGTAGTTGGCAAG  
CAATAAAACTCTGCCGTATTATACAGTTATCACACCCCTACTGAATCCGAGTATTATA  
CCCTGAGAAAATAAGAAAATGCAAGAGGCCATAAGAAAATTACGGTTCCAATATGTTAGTT  
10 CTGCACAGAATTCTAG (SEQ ID NO: 460).

### AOLFR246 sequences:

15 AOLFR246 sequences:  
MSPENQSSVSEFLLGLPIRPEQQAVFFTLFLGMYLTTVLGNLLIMLLIQLDSHLHTPMYFFLSH  
LALTDISFSSVTVPKMLMDMRTKYKSILYEECISQMYFFIFFTDLSFLITSMAYDRYVAICHPL  
HYTVIMREELCVFLVAWSWILSCASSLSHTLLTRLSFCAANTIPHVFCDLAALLKLSCSDIFLNE  
LVMFTVGVVVITLPFMCLILSYGYIGATILRPSTKGHIKALSTCGSHLSVSVLYGSIFGQYLF  
PTVSSSIDKDVIDVALMYTVVTPMLNPFIYSLRNRDMEALGKLFSRATFFSW (SEQ ID NO:  
461).

20 ATGAGCCCTGAGAACCAAGAGCAGCGTGTCCGAGTTCCCTCTGGGCCTCCCATCCGGC  
 CAGAGCAGCAGGCTGTGTTCTCACCTGTTCTGGGCATGTACCTGACCACGGTGTGGG  
 GAACCTGCTCATCATGCTGCTCATCCAGCTGGACTCTCACCTCACACCCCCATGACTTCT  
 TCCTCAGCCACTTGGCTCTCACTGACATCTCCTTCTCATCTGTCACTGTCCCTAAGATGCTG  
 ATGGACATGCGGACTAAGTACAATCGATCCTCATGAGGAATGCATTCTCAGATGTATT  
 25 TTTTTATAATTTTACTGACCTGGACAGCTCCTTATTACATCAATGGCATATGACCGATAT  
 GTGCCATATGTCACCCCTCCACTACACTGTACATGAGGGAAAGAGCTGTGTCTTCTT  
 AGTGGCTGTATCTGGATTCTGCTTGTGCCAGCTCCCTCTCACACCCCTCTCCTGACCC  
 GGCTGTCTTCTGTGCTGCGAACACCATCCCCATGTCTGTGACCTTGCTGCCCTGCTC  
 AAGCTGTCTGCTCAGATATCTCCTCAATGAGCTGGTATGTTCACAGTAGGGGTGGTGG  
 30 TCATTACCCCTGCCATTATGTTATCTGGTATCATATGGTACATTGGGCCACCATCTG  
 AGGGTCCCTCAACCAAAGGGATCCACAAAGCATTGTCCACATGTGGCTCCATCTCTG  
 TGTTGTCTCTATTATGGTCAATATTGGCCAGTACCTTCTCCGACTGTAAAGCAGTTCT  
 ATTGACAAGGATGTCATTGTGGCTCTCATGTACACGGTGGTACACCCATGTTAAACCCCT  
 TTATCTACAGCCTTAGGAACAGGGACATGAAAGARGCCCTGGAAACTCTCAGTAGAG  
 35 CAACATTCTCCTGGTACATCTGACTTTAAAAAATTAG (SEQ ID NO: 462).

### AQLFR247 sequences:

40 AOLFR247 sequences:  
 MGQHNLTVLTERFILMELTRRPELQIPLFGVFLVIYLITVVGNLTMILTKLDSLHTPMYFSIRHL  
 ASVDLGNSTVICPKVLANFVVDRNTISYYACAAQLAFFLMFIISFFILSAMAYDRYVAICNPLL  
 YYVIMSQRLLCHVLVGIQYLYSTFQALMFTIKIFTLTCFGNSNVISHFYCDDVPLPMLCSNAQEIE  
 LLSILFSVFNLISSFLIVLVSYMILLIAICQMHSAEGRKKAFSTCGSHLTVVVVFYGSLLFMYMQ  
 PNSTHFFDTDKMASVFYTLVIPMLNPLIYSLRNEEVKNAFYKLFEN (SEQ ID NO: 463).

45 ATGGGCCAACACAATCTAACAGTGCTAACTGAATCATTCTGATGGAACTCACAAGGCGGC  
CTGAGCTGCAGATTCCCTTTGGAGTCTCCTCGTCATCTACCTAACAGTGGTGGGC  
AACCTAACTATGATCATTGACCAAACCTGGACTCCCACCTACATACACCTATGACTTTTC  
TATCAGACATTGGCTCTGTTGATCTTGGTAATTCTACTGTCATTGCCCCAAGGTGCTGG  
CAAATTTGGTGTGGATCGAAATACTATTCCATTATGCATGTGCTGCACAGCTGGCATTG  
50 TTCCATTATGTCATTATCAGTGAATTTCATCCTGTCAGCCATGGCCTATGACCGCTATGT  
GGCCATTGTAACCCCTGCTCTATTATGTTATTATGTCAGCGACTGTGTCATGTACTGG  
TGGGCATTCAATATCTACAGCACATTAGGCTCTGATGTTCACTATTAAAGATTTTACA  
TTGACCTTCTGTTGGCTAAATGTCATCAGTCATTAACTGTGATGATGTTCTTGTACCC  
TATGCTTGCTAAATGCACAGGAAATAGAATTGTTGAGCATACTATTCTGTATTAAATT  
55 TGATCTCCTCTTGTGATAGTCAGTGTCTACATGTTGATTGTAGCTATATGTCAA  
ATGCATTCTGCAGAGGGCAGGAAAAAGGCTTCTCCACATGTGGTCCCATTGACAGTGG  
TGGTGTGTTCTATGGGCTCTACTCTCATGTACATGCAGCCAAATTCACTCACTTCTT

GA TACTGATAAAATGGCTCTGTGTTTACACTTAGTAATCCCCATGCTTAACCCTTGAT  
TTACAGCTTAAGAACGAAGAGGTGAAAATGCCTCTATAAGCTTTGAGAATTGA  
(SEQ ID NO: 464).

5   **AOLFR248 sequences:**

MPCMPICALPTGGLLPHQHTMMELANVSSPEVFVLLGFSTRPSLETVLFIVVLSFYMVSLGN  
IILVSHTDVHLHPTMYFFLANLPFLDMSFTTSIVPQLLANLWGPQKTISYGGCVVQFYISHWLG  
ATECVLLATMSYDRYAAICRPLHYTVIMHPQLCLGLALASWLGGLTSMVGSTLMLPLCG  
NNCIDHFFCEMPLIMQLACVDSLNEMEMYLASFVVFVPLGLILVSYGHIAVLKIRSAEGR  
10   RKAFNTCSSHVAVVSLFYGSIIFMYLQPAKSTSHEQGKFIALFYTVVTPALNPLIYTLRNT  
EVKS ALRHMVLENCCGSAGKLAQI (SEQ ID NO: 465).

ATGCCCTGTATGCCCTGTGCTCTCCCACAGTGGCCTTGCACCCCCAGCATA  
15   GATGGAAATAGCCAATGTGAGTTCTCCAGAACGACTTGTCTGGAGTTTACATGGTATCGATCTGG  
CCCTCACTAGAAACTGTCTCTCATAGTTGTCTTGAGTTTACATGGTATCGATCTGG  
CAATGGCATCATCATTCTGGTCTCCACAGATGTGACCTCCACACACCTATGTACTTCT  
TTCTTGCAACCTCCCCTCCTGGACATGAGCTTACCCACAGCTCCTG  
GCTAACCTCTGGGGACCACAGAAAACCATAAGCTATGGAGGGTGTGGTCCAGTTCTAT  
ATCTCCCATTGGCTGGGGCAACCGAGTGTCTGCTGGCCACCATGTCTATGACCGCT  
20   ACGCTGCCATCTGCAGGCCACTCCATTACACTGTATTATGCATCCACAGCTTGCCTTGG  
GCTAGCTTGGCCTCCTGGCTGGGGCTGACCACAGCATGGTGGGCTCCACGCTCACC  
ATGCTCCTACCGCTGTGGAAACAATTGCATCGACCACTTCTTGCAGAGATGCCCTCA  
TTATGCAACTGGCTTGTGGATACCAGCCTCAATGAGATGGAGATGTACCTGGCAGCTT  
25   TGTCTTGTGTCTGCCTCTGGGGCTCATCTGGTCTTACGCCACATTGCCGGCCG  
TGTGAAGATCAGGTCAAGAGGGCGGAGAAAGGCATTCAACACCTGTTCTCCACG  
TGGCTGTGGTCTCTGTTTACGGAGCATCATCTTGTATCTCCAGCCAGCCAAGAG  
CACCTCCATGAGCAGGGCAAGTTCATAGCTCTGTTACACCGTAGTC  
AACCCACTATTACACCTGAGGAACACGGAGGTGAAGAGCGCCCTCCGGCACATGGT  
TTAGAGAACTGCTGTGGCTCTGCAGGCAAGCTGGCGCAAATTAG (SEQ ID NO: 466).

30

**AOLFR249 sequences:**

MKSQIEKSDLKYRAILLQKVTRMFLLFWVLLLVLRSLLVVMGRGNSTEVTEFHLLGFGVQHEF  
QHVLFIQLIYVTSIGNIGMILLIKTDSRLQTPMYFFPQHLAGFVDCYTSAITPKMLQSFT  
35   EN NLITFRGCVIQFLVYATFATSDCYLLAIMAMDCYVAICKPLRYPMIMSQT  
VYIQLVAGSYIIGSI  
NASVHTGFTFSLSFCKSNKINHFFCDGLPILALSCSNIDINII  
LDVVFVGFDFLMFTELVIIFSYIYIM  
VTLKMSSTAGRKKSFSTCASHLTAVTIFYGTL  
50   SYMLQPQSNNSQENMKVASIFYGTVIPMLN  
PLIYSLRNKEGK (SEQ ID NO: 467).

ATGAAAAGTCAAATTGAAAAAGTGA  
40   CTTAAATAGAGCCATTATTGCAAAAGTC  
ACAAGGATGTTCTGCTTCTGGGCTCTCTTGTGATAGACTTTGGTAGTCAT  
GGGTGAGGAAACAGCACTGAAGTGA  
55   ACTGAATTCCATCTCTGGGATTGGTAGTCAACAC  
GAATTTCAGCATGTCCTTTCATTGACTTCTTATCTATGTGACCTCC  
TATTGGAAATGATCTTACTCATCAAGACCGATTCCAGACT  
CACAACATTGGCTTTGTGATATCTGTTACTCTGCTATCA  
AGCTTACAGAAGAAAATAATTGATA  
60   ACATTCTGGGCTGTGATACAATTCTAGTT  
ATGCAACATTGCAACCAGTGA  
55   CTGTTACCTCTAGCTATTATGGCAATGGATTGTTATGT  
TGCCATCTGTAAGCCCCCTCGCTATCC  
50   CATGATCATGTCCAAACAGTCTACATCCA  
TAGCTGGCTCATATAATTAGGCTCA  
CTGTCCTCTGCAAGTCTA  
65   ATAAAAATCAACTCA  
CTTTCTGTGATGGTCTCC  
CCTTCATGCTCCA  
70   ACATTGACATCAACATCATTCTAGATGTTGCTTGTGGATTGACT  
TGATGTTCACTGAGTTGGT  
75   CATCATCTTCTACATCTACATTATGGTC  
ACCATCCTGAAG  
ATGTCTTCACTGCTGGGAGG  
80   AAAAACCTCTCCACATGTG  
TGCTCCACCTGACAGCAG  
TAACCA  
85   TTCTATGGGACACTCTTACATGTACTTACAGC  
CTAGTCTAATAATTCTCAG  
GAGAATATGAAAGTAGC  
90   CTCTATATTATGGCACTGTTATTCC  
ATGTTGAATCCTTAAT  
CTATAGCTTGAGAAATAAGGAAGGAAATAA (SEQ ID NO: 468).

**AOLFR250 sequences:**

5 MENQSSISEFFLRGISAPPEQQQLFGIFLCMYLVTLTGNLLIILAIGSDLHLHHTPMYFFLANLSFV  
 DMGLTSSTVTKMLVNIQTRHTISYTGCLTQMYFFLMFGDLSFFLAAMAYDRYVAICHPLCY  
 10 STVMRPQVCALMLACWVLTNIVALHTFLMARLSFCVTGEIAHFFCDITPVLKLSCSDTHINE  
 15 MMVFVLGGTVLIVPFLCIVTSYIHIVPAILRVRTRGGVGKAFSTCSSHLCVVCVFYGTLSAYLC  
 PPSIASEEKDIAAAAMYTIVPMLNPFYSLRNKDMKGALKRFLSHRSIVSS (SEQ ID NO: 469).

10 ATGGAAAACCAATCCAGCATTTCTGAATTTTCTCCGAGGAATATCAGCGCTCCAGAGC  
 AACAGCAGTCCCTTCGGAATTTCTGTGTATGTATCTGTACCTGACTGGAACCTG  
 CTCATCATCCTGGCCATTGGCTCTGACCTGCACCTCCACACCCCCATGTACTTTTCTTGGC  
 15 CAACCTGTCTTTGTTGACATGGGTTAACGTCTCCACAGTTACCAAGATGCTGGTGAAT  
 ATACAGACTCGGCATCACACCATCTCCTATACGGGTTGCTCACGCAAATGTATTTCTTCT  
 GATGTTGGTATCTAGACAGCTTCTGGCTGCATGGCGTATGACCCTATGCTTGC  
 20 ATTGCCACCCCTCTGCTACTCCACAGTCATGAGGCCAAGTCTGTGCCCTAATGCTTGC  
 ATTGTGCTGGTCTCACCAATATCGTTGCCCTGACTCACAGTCTCATGGCTCGGTTGT  
 CCTTCTGTGACTGGGAAATTGCTCACTTTCTGTGACATCACCTGTCTGAAGCTG  
 TCATGTTCTGACACCCACATCAACGAGATGATGGTTTGTCTGGAGGCACCGTACTCA  
 TCGTCCCCCTTTATGCAATTGTCACCTCCTACATCCACATTGTCAGCTATCTGAGGGTC  
 CGAACCCGTGGTGGGGTGGCAAGGCCTTCCACCTGCAGTTCCACCTCTGCGTTGTT  
 GTGTGTTCTATGGGACCCCTTCAGTGCCTACCTGTGCTCTCCCTCATGCCTCTGAAGAG  
 25 AAGGACATTGCAAGCAGCTGCAATGTACACCATAGTGACTIONCATGTTGAACCCCTTATCT  
 ATAGCCTAAGGAACAAGGACATGAAGGGGCCCTAAAGAGGCTTCAAGTCACAGGAGTA  
 TTGTTCCCTTTAG (SEQ ID NO: 470).

**AOLFR251 sequences:**

25 MEGNKTWITDITLPRFQVGPALIELLCGLFSAFYTLTLLNGNVIFGIICLDCKLHHTPMYFFLSHLA  
 IVDISYASNYVPKMLTNLMNQESTISFFPCIMQTFLYLAFAHVECLILVMSYDRYADICHPLRY  
 NILMSWRVCTVLAVASWVFSFLALVPLVLILRLPFCGPHEINHFCIELSVLKLACADTWLNQV  
 VIFAAVFLVGPLCLVLVSYLRILAIRIQSGEGRRAKAFSTCSSHLCVVGGLFFSAIVTYMAPK  
 30 SRHPEQQKVLSLFYSLFNPMLNPLIYSLRNAEVKGALRALRKERLT (SEQ ID NO: 471).

35 ATGGAAGGCAACAAGACATGGATCACAGACATCACCTGCCGATTCCAGGTTGGTCCA  
 GCACTGGAGATTCTCCTCTGGACTTTCTGCCTCTACACTCACCTGCTGGGAA  
 TGGGGTCATCTTGGGATTATCTGCTGGACTGTAAGCTCACACACCCATGTACTCTTCC  
 TCTCACACCTGGCATTGGACATATCCTATGCTCCAACATGTCCTCCAGATGCTGACG  
 40 AATCTTATGAAACAGGAAAGCACCATCTCCTTTTCATGCATAATGCAGACATTCTGT  
 ATTGGCTTTGCTCACGTAGAGTGTGATTTGGGGTGTGATGTCCTATGTCATGCG  
 GACATCTGCCACCCCTACGTTACAATATCCTATGAGCTGGAGAGTGTGACTGTCC  
 CTGGCTTCTGGGTGTTCAAGCTTCTCTGGCTGGTCCCTTAGTTCTCATCCTGAGG  
 45 CTGCCCTCTGGGCCCTCATGAAATCAACCACTTCTGTGAAATCCTGTGTCCTCAAGTT  
 GGCCTGTGCTGACACCTGGCTAACAGGGTGTATTTGCAAGCTGGCCATCTGAGGA  
 GTGGGGCCACTCTGCTGGTGTGGTCTCTACTTGCCTGCTGGCCATCTGAGGA  
 TCCAGTCTGGGGAGGGCCGAGAAAGGCCCTCTCCACCTGCTCTCCACCTTGCGTGG  
 GGGACTCTTGGCAGGCCATTGTCACGTACATGGCCCCAAGTCCGCCATCTGAG  
 50 GAGCAGCAGAAAGTTCTTCCCTGTTACAGCTTCAATCCAATGCTGAACCCCTGA  
 TATATGCTAAGGAATGCAGAGGTCAAGGGGCCCTGAGGAGGGCACTGAGGAAGGAG  
 AGGCTGACGTGA (SEQ ID NO: 472).

**AOLFR252 sequences:**

55 MRLANQTLGGDFLLGIFSQISHPGRLLCLLISIFLMAVSWNITLILLIHDSSLHHTPMYFFINQLSL  
 IDLTYISVTVPKMLVNLAKDKTISVLGCGTQMYFYLQLGGAECCLLAAMAYDRYVAICHPLR  
 YSVLMSHRVCLLASGCWFVGSDGMLTPLMSFPFCRSHEIQHFFCEVPAVLKLSCSDTSLY  
 KIFMYLCCVIMLLIPVTVISVSYIILTIHKMNSVEGRKKAFSTCSSHITVVSFLFYAAIYNML  
 PSSYQTPEKDMMSFFYTIITPVLNPYIYSLRNKDVTRALKMLSVQKPPY (SEQ ID NO: 473).

ATCGGGCTGGCCAACCAGACCCTGGGTGGTACCTTTCTGTTGGGAATCTCAGCCAGA  
 TCTCACACCCTGGCGCCTGCTGCTTATCTCAGTATATTITGATGGCTGTCTTGG  
 AATATTACATTGATACTTCTGATCCACATTGACTCCTCTGCATACTCCATGTACTTCTT  
 5 TATAAACCAAGCTCTCACTCATAGACTGACATATATTCTGTCAGTCCCCAAATGCTG  
 GTGAACCAGCTGGCAAAGACAAGACCATCTCGGTCTGGGTGGCACCCAGATGTAC  
 TTCTACCTGCAGTTGGGAGGTGCAGAGTGCTGCCTCTAGCCGCATGGCTATGACCGCT  
 ATGTGCTATCTGCCATCCTCTCCGTTACTCTGTGCTATGAGCCATAGGGTATGTCTCCTC  
 CTGGCATCAGGCTGCTGGTTGTGGCTCAGGGATGGCTCATGCTCACTCCATGCCA  
 TGAGCTCCCTCTGCAGATCCCATGAGATTGAGCTTCACTCTGTGAGGTCCCTGCTGTT  
 10 TTGAAGCTCTTGCTCAGACACCTCACTTACAAGATTTCATGTACTTGCTGTGTCAT  
 CATGCTCCTGATACCTGTGACGGTCACTTCAGTGCTTACTACTATATCATCCTCACCATCC  
 ATAAGATGAACTCAGTTGAGGGTGGAAAAAGGCCTCACACCTGCTCCTCCACATTAC  
 AGTGGTCAGCCTCTCATGGAGCTGCTATTACAACATACATGCTCCAGCTCTACCAA  
 ACTCCTGAGAAAGATATGATGTACACCTTTCTACACTATCCTAACACCTGCTTGAATCC  
 15 TATCATTACAGTTCAGGAATAAGGATGTACACAGGGCTTGAAAAAAATGCTGAGCGT  
 GCAGAAACCTCCATATTAA (SEQ ID NO: 474).

**AOLFR253 sequences:**

MTFFSSGGNCEPVMCSGNQTSQNQTASTDFTLTGLFAESKHAALLYTVTFLLFLMALTGNALL  
 20 ILLIHSERLHTPMYFFISQLALMDLMYLCVTVPKMLVGQVTGDDTISPSGCGIQMFFHILLAG  
 AEVFLAAMAYDRYAAVCRPLHYPLLMNQRVCQLLVSACWVLGMVDGLLTPITMSFPFCQS  
 RKILSFFCETPALLKLSCSDVSLYKMLTYLCCILMLTPIMVISSSYTLILHLIHRMNSAAGRKA  
 LATCSSHMIIVLLLFGASFYTYMLRSSYHTAEQDMMVSAFYTIFTPVNLPIYSLRNKDVTRAL  
 RSMMQSRMNQEK (SEQ ID NO: 475).

25 ATGACTTTTTTCCTCAGGGGAAACTGTGAGCCAGTCATGTGCTCAGGGAAATCAGACTT  
 CTCAGAACAAACAGCAAGCACTGATTCACCCCTCACGGGACTCTTGCTGAGAGCAAGCA  
 TGCTGCCCTCTACACCGTGACCTTCTTCTTGATGGCCCTCACTGGGAATGCC  
 30 TCCTCATCCTCCTCATCCACTCAGAGCCCCGCTCCACACCCCCATGTAATTCTCATCAGC  
 CAGCTCGCGCTCATGGATCTCATGTACCTATGCGTACTGTGCCAAGATGTTGTTGGGCC  
 AGGTCACTGGAGATGATACCAATTCCCCGTCAAGGCTGAGGATCCAGATGTTCTTCCACCT  
 GACCTGGCTGGAGCTGAGGTTTCTCTGGCTGCCATGGCTATGACCGATATGCTGCT  
 GTTTGCAGACCTCTCCATTACCCACTGCTGATGAACAGAGGGTGTGCCAGCTCTGGTGT  
 CAGCCTGCTGGTTTGGGAATGGTTGATGGTTGTTGCTCACCCCCATTACCATGAGCTT  
 35 CCCCTTTGCCAGTCTAGGAAAATCCTGAGTTTCTGTGAGACTCCTGCCCTGCTGAAGC  
 TCTCTGCTCTGACGTCTCCCTCTATAAGATGCTACGTACCTGTGCTGCATCCTCATGCTT  
 CTCACCCCCATCATGGTCATCTCCAGCTCATACACCCCTCATCCTGCATCTCATCCACAGGAT  
 GAATTCTGCCCGGCCGAGGAAGGCCCTGGCCACCTGCTCCTCCCACATGATCATAGTG  
 CTGCTGCTCTCGGTGCTTCTTACACCTACATGCTCCGGATTCTACACACAGCTGA  
 40 GCAGGACATGATGGTGTGCTGCCTTACACCATCTCACTCCTGTGCTGAACCCCCCTCATTT  
 ACAGTCTCCGCAACAAAGATGTACCCAGGGCTCTGAGGGAGCATGATGCAAGAATGA  
 ACCAAGAAAAGTAG (SEQ ID NO: 476).

**AOLFR254 sequences:**

45 MTNTSSSDFTLLGVLNSEAAGIVFTVILAVFLGAVTANLVMIFLIQVDSRLHTPMYFLSQLSI  
 MDTLFICITVPKLLADMVSKEIISFVACGIQIFLYLTMIGSEFFLLGLMAYDCYVAVCNPLRYP  
 VLMNRKKCLLAAGAWFGGSLDGFLTPITMNPYCGRSRSINHFFCEIPAVLKLACADTSLYET  
 LMYICCVLMLLIPISIISTSYSLILLTIHRMPSAEGRKKAFTCSSHLTVVSIYGAAFYTYVLPQS  
 FHTPEQDKVVSAYTIVTPMLNPLIYSLRNKDVGAFKKVFACCSAQKVATSDA (SEQ ID NO:  
 50 477).

ATGACGAACACATCATCCTCTGACTTCACCCCTCTGGGGCTCTGGTGAACAGTGAGGCTG  
 CCGGGATTGTATTACAGTGATCCTGCTGTTCTTGGGGCCGTGACTGCAAATTGGT  
 CATGATATTCTGATTCAAGGTGGACTCTGCCTCCACACCCCCATGTAATTCTGCTCAGTC  
 55 AGCTGTCCATCATGGACACCCCTTCTCATCTGTACCACTGTCCTCCAAAACCTCTGGCAGACAT  
 GGTTCTAAAGAGAAGATCATTCCTTGTGGCCTGTGGCATCCAGATCTCCTCTACCTG

WO 01/98526

5           ACCATGATTGGTTCTGAGTTCTCCTCTGGGCCTCATGGCCTATGACTGCTACGTGGCTGT  
 CTGTAACCCCTGAGATAACCAAGTCCTGATGAACCGCAAGAAGTGTCTTGTGGCTGCT  
 GGTGCCTGGTTGGGGCTCCCTCGATGGCTTCTGCTACTCCCACCATGAATGTCC  
 CTTACTGTGGCTCCCAGATCAACCACTTTCTGTGAGATCCCAGCAGTCTGAAACT  
 10          5 GGCCTGTGCAGACACAGTCCTGTATGAAACTCTGATGTACATCTGCTGTGCTCATGTG  
 CTCATCCCCATCTATCATCTCACTCCTACTCCCTCATCTGTTAACCATCCACCGCAT  
 GCCCTCTGCTGAAGGTGCAAAAAGGCCTCACCACTTGTCTCCACTTGACTGTAGTT  
 AGCATCTCTATGGGGCTGCCTCTACACATACGTGCTGCCAGTCTCCACACCCCCG  
 AGCAGGACAAAGTAGTGTCAGCCTCTATACCATGTCACGCCATGCTTAATCCTCTCAT  
 15          10 CTACAGCCTCAGAAAACAAGGACGTCAAGGGCATTTAAAAGGTATTCGATGTTGCTCA  
 TCTGCTCAGAAAGTAGCAACAAGTGTGCTTAG (SEQ ID NO: 478).

**AOLFR255 sequences:**

15          MEQSNYSVYADFILLGLFSNARFPWLLFALILLVFLTSIASNVVKIILIHDSRLHTPMYFLLSQLS  
 LRDILYISTIVPKMLVDQVMSQRAISFAGCTAQHFLYLTLAGAEFFLLGLMSYDRYVAICNPLH  
 YPVLMRSRKICWLIVAAAWLGGSIDGFLTPVTMQFPFCASREINHFFCEVPALLKLSCTDT SAY  
 ETAMYVCCIMLLIPFSVISGSYTRILITVYRMSEAEGRGKAVATCSSHMVVVSLFYGAAMYT  
 20          15 YVLPHSYHTPEQDKAVSAFYTILTPMLNPLIYSLRNKDVTGALQKVVGRCVSSGKVTTF (SEQ  
 ID NO: 479).

20          ATGGAGCAGAGCAATTATCCGTGTATGCCGACTTTATCCTCTGGTTGTCAGCAACG  
 CCCGTTTCCCCTGGCTTCTCTTGCCTCATTCTCTGGCTTTGACCTCCATAGCCAGC  
 AACGTGGTCAAGATCATTCTCATCCACATAGACTCCGCCCTCACACCCCCATGACTCCT  
 GCTCAGCCAGCTCTCCCTCAGGGACATCCTGTATATTCACCATGTCGCCCCAAATGCTG  
 25          25 GTCGACCAGGTGATGAGCCAGAGAGCCATTCTCTGGATGCACTGCCAACACTTCC  
 TCTACTTGACCTTAGCAGGGCTGAGTTCTCTCTAGGACTCATGTCCTATGTCGCTAC  
 GTAGCCATCTGCAACCCTCTGCACTATCCTGCTCTAGGCCAGATCTGCTGGTGA  
 TTGTGGCGCAGCCTGGCTGGAGGGTCTATCGATGGTTCTGCTCACCCCCGTACCAT  
 GCAGTTCCCTCTGTGCTCTCAGGGAGATCAACCACTTCTGCGAGGTGCTGCCCTC  
 30          30 TGAAGCTCTCTGACGGACACATCAGCCTACGAGACAGCCATGTATGTCGCTATT  
 GATGCTCTCATCCCTCTGTCTGTCATCTGGCTCTACACAAGAATTCTCATTACTGTT  
 ATAGGATGAGCGAGGCAGAGGGAGGGAAAGGCTGTCGCCACCTGCTCTCACACATGG  
 35          35 TGGTGTAGCCTCTATGGGGCTGCCATGTACACATACGTGCTGCTCATTCTACCAC  
 ACCCCTGAGCAGGACAAAGCTGTATCTGCTCTACACCATCCTACTCCATGCTCAATC  
 CACTCATTACAGCCTAGGAACAAGGATGTCACAGGGCCCTACAGAAGGTTGTTGGGA  
 GGTGTGTCTCAGGAAAGGTAACCACTTCTAA (SEQ ID NO: 480).

**AOLFR256 sequences:**

40          MGGKQPWVTEFILVGFQVGPALAILCGLFSVFYTLTLLNGVIFGIICLDSLHHTPMYFFLSHL  
 AIIDMSYASNNVPKMLANLMNQKSTISFVPCIMQTFLYLAFAVTECLILVMSYDRYVAICHPF  
 QYTIVMSWRVCTILASTCWIISFLMALVHITHLRRPFCCPQKINHFCQIMSFKLACAGPRLNQ  
 VVLYAGSAFIVEGPLCLELVSNLHILSRHLEDPVMGRAADRLTLPAPSHLCMVGLLFGSTMVM  
 YMAPKSRHPEEQKVLVLSFYSLFNPMLNPLIYSLRNAEVKGALKRVLWKQRSK (SEQ ID NO:  
 481).

45          45 ATGGGAGGCAAGCAGCCCTGGGTACAGAATTCTCTGGTGGATTCCAGGTTGGTCCA  
 GCACCTGGCGATTCTCCTCTGTGGACTCTCTCTGTCTTCTATACACTCACCTGCTGGGAA  
 TGGGGTCATCTTGGGATTATCTGCTGGACTCTAACGCTCACACACCCATGACTCTCC  
 TCTCACACCTGGCATATTGACATGTCTATGCTTCAACAAATGTCCTAACAGTGGC  
 50          50 AACCTAATGAACCAAGAAAAGCACCATTCTCTTGTCCATGCATAATGCAAGACTTTTG  
 TATTGGCTTGTGTTACAGAGTCCTGATTTGGTGGTGTGCTCATGTCATGAGCTGGAGAGTGTG  
 GCCCATCTGCCACCCCTTCCAGTACACTGTCATCATGAGCTGGAGAGTGTG  
 GCCTCAACATGCTGGATAATTAGCTTCTCATGGCTCTGGTCATATAACTCATATTCTGAG  
 GCCGCCTTTGTGGCCACAAAAGATCAACCACTTATCTGCAAATCATGTCCTATTCA  
 55          55 AATTGGCCTGTGCTGCCCTAGGCTCAACCAGGTGGTCTATGCGGTTCTGCTCAT  
 CGTAGAGGGCCGCTCTGCTGGAGCTGCTCCAATTGCAACATCCTGTCGCCATCTT

5 GAGGATCCAGTAATGGGGAGGGCCGCAGACCGACTTACTCTTCTGCTCCTCCACCTT  
 GCATGGTGGACTCCTTTGGCAGCACCATGGTATGTACATGGCCCCAAGTCCGCCA  
 CCCTGAGGAGCAGCAGAAGGTCTTCCCTGTTTACAGCCTTCACAGGATGCTGAAC  
 CCCTGATCTACAGCCTGAGGAACGCAGAGGTCAAGGGTGCCTGAAAAGAGTGTGTGG  
 AAACAGAGATCAAAGTGA (SEQ ID NO: 482).

**AOLFR257 sequences:**

10 MESNQTWITEVILLGFQVDPALELFLFGFFLLFYSLTLMNGIILGLIYLDRLHTPMYVFLSHL  
 AIVDMSYASSTVPKMLANLVMHKVISFAPCILQTFYLAFATECLILVMMCYDRYVAICHPL  
 QYTLIMNWRVCTVLASTCWIFSFLALVHITLILRLPFCGPQKINHFFCQIMSFKLACADTRLN  
 QVVLFAFSAFILVGPLCLVLVSYLHILVAILRIQSGEGRKAFSTCSSHLCVVGFFGSAIVMYM  
 APKSSHSQERRKILSLFYSLFNPLIYSLRNAEVKGALKRVLWKQRSM (SEQ ID NO: 483).

15 ATGGAAAGCAATCAGACCTGGATCACAGAACGTCATCCTGTTGGATTCCAGGTGGACCCA  
 GCTCTGGAGTTGTCCTCTTGGGTTTCTTGTCTATTCTACAGCTTAACCCCTGATGGGAAA  
 TGGGATTATCCTGGGGCTCATCTACTGGACTCTAGACTGCACACACCCATGTATGCTTC  
 CTGTCACACCTGCCATTGTGGACATGTCCTATGCCTCGAGTACTGTCCTAAGATGCTAG  
 CAAATCTTGTGATGCACAAAAAAGTCATCTCCTTGCTCCTTGCAACTTCAGACTTTTG  
 TATTGCGTTGCTATTACAGAGTGTCTGATTTGGTATGATGTGCTATGATCGGTATG  
 20 TGGCAATCTGTCACCCCTGCAATAACACCCCTCATTATGAACTGGAGAGTGTGCACTGTCCT  
 GGCCTCAACTTGTGGATATTAGCTTCTCTGGCTCTGGTCCATTACTCTTATTCTGA  
 GGCTGCCCTTTGTGGCCACAAAAGATCAACCCTTTCTGTCAAATCATGTCGTATT  
 AAATTGGCCTGTGCTGACACTAGGCTCAACCAGGTGGCCTATTGCGGGTCTGCGTTCA  
 TCTTAGTGGGCCGCTGCTGGTCTGCTACTTGACATCCTGGCCATCTTG  
 25 AGGATCCAGTCTGGGGAGGGCCGCAGAAAGGCCTCTACCTGCTCTCCACCTCTGCG  
 TGGTGGGGCTTTCTTGTGGCAGGCCATTGTATGTCATGTCATGGCCCCAAGTCAGCCATT  
 TCAAGAACGGAGGAAGATCCTTCCCTGTTTACAGCCTTCAACCCGATCCTGAACCCC  
 CTCATCTACAGCCTAGGAATGCAAGAGTGAAGGGCTAAAGAGAGTCCTTGGAAA  
 CAGAGATCAATGTGA (SEQ ID NO: 484).

30

**AOLFR259 sequences:**

35 MGDNQSRVTEFILVGFQLSVEMEVLLWIFSLLYLFSLLANGMILGLICLDPLRTPMYFFLSHL  
 AVIDIYYASSNLLNMLENLVKHKKTISFISCIMQMAYLTFAAAVCMILVVMSYDRFVAICHPL  
 HYTVIMNWRVCTVLAITSWACGFSLALINLILLRLPFCGPQEVDHFFGEILSVKLACADTWIN  
 EIFVFAGGVFVLVGPLSLMLISYMRILLAIKIQSKEGRKAFSTCSSHLCVVGLYFGMAMVY  
 LVPDNSQRQKQQKILTLFYSLFNPLLNPLIYSLRNAQVKGALYRALQKKRTM (SEQ ID NO:  
 485).

40 ATGGGGACAACCAATCACGGGTACAGAACGTCATCCTGGTTGGATTCCAGCTCAGTGTG  
 GAGATGGAAGTGTCCCTCTGGATCTCTCCCTGTTATCTCTTCAGCCTGCTGGCAAA  
 TGGCATGATCTGGGCTCATCTGTCGGATCCCAGACTGCGCACCCCCATGTAACCTTCC  
 TGTACACTTGGCGTCATTGACATATACTATGCTTCCAGCAATTGCTCAACATGCTGGA  
 AACACCTAGTGAACACAAAAAAACTATCTGTTCATCTCTGCAATTGCAAGATGGCTTG  
 TATTGACTTTGCTGCTGCAGTGTGCATGATTTGGTGGTATGTCCTATGACAGATTG  
 45 GGCATCTGCCATCCCCCTGCATTACACTGTATCATGAACACTGGAGAGTGTGACAGACTG  
 GCTATTACTCCTGGCATGTGGATTTCCTGGCCCTCATAAATCTAATTCTCTTCTAAG  
 GCTGCCCTCTGTTGGCCCCAGGAGGTGAACCACCTCTCGGTGAAATTCTGTCTGCTCTC  
 AACTGGCCTGTGCAGACACCTGGATTATGAAATTCTGTCTTGTGGGTGTGTTG  
 TCTTAGTCGGGCCCTTCTTGTGATGCTGATCTCTACATGCGCATCCTCTGGCCATCCTG  
 50 AAGATCCAGTCAAAGGAGGGCCGAAAAAAGCCTTCCACCTGCTCTCCACCTCTGTG  
 TGGTGGGCTTACTTGGCATGGCATGGTGGTTACCTGGTCCAGACAAACAGTCACG  
 ACAGAACGAGCAGAAAATTCTCACCTGTTACAGCCTTCAACCCATTGCTGAACCCC  
 CTCATCTACAGCCTGCGGAATGCTCAAGTGAAGGGTGCCTTATACAGAGCACTGCAGAAA  
 AAGAGGACCATGTGA (SEQ ID NO: 486).

55

**AOLFR24B sequences:**

5 MPSINDTHFYPFFLGLPGLDTLHIWISFPFCIVYLIAIVGNMTILFVIKTEHSLHQPMFYFLAM  
 LSMIDLGLSTSTIPKMLGIFWFNLQEISFGGCLLQMFFIHMFETGMETVLLVVMAYDRFVAICNP  
 LQYTMILTNKTISILASVVVGRNLVLVTPFVFLILRLPFCGHNIVPHTYCEHRLAGLACAPIKIN  
 10 IIYGLMVISYIIVDVLIASSYVILRAVFRLPSPDVRLKAFNTCGSHVCVMLCFYTPAFFSFMTH  
 RFGQNIPHYPHILLANLYVVVPPALNPVIYGVRTKQIREQIVKIFVQKE (SEQ ID NO: 487)

15 ATGCCTTCTATCAATGACACCCACTTCTATCCCCCTCTCCTCTGCTAGGAATACCAAGG  
 ACTGGACACTTACATATCTGGATTCTTCCCATCTGTATTGTGTACCTGATTGCCATTG  
 20 TGGGAATATGACCATTCTTGTGATCAAACACTGAACATAGTCTACACCAGCCATGTT  
 CTACTCCTGGCCATGTTGCTATGATTGATCTGGGTCTGTCCACATCCACTATCCCCAAA  
 TGCTAGGAATCTCTGGTCAACCTCAAGAGATCAGCTTGGGGATGCCTCTTCAGAT  
 GTTCTTATTACATGTTACAGGCATGGAGACTGTTCTGGTGGTATGGCTTATGACC  
 GCTTGTGCCATCTGCAACCCCTCTCCAGTACACCATGATCCTCACCAATAAAACCATCAG  
 25 TATCCTAGCTTCTGTGGTTGGAAGAAATTAGTCTGTAAACCCATTGTGTTCTCA  
 TTCTCGCTCTGCCATTCTGGGATAACATCGTACCTCACACATACTGTGAGCACAGGGG  
 TCTGGCCGGGTTGGCCTGTGACCCATTAAGATCAACATAATCTATGGGCTCATGGTATT  
 TCTTATATTATTGTGGATGTGATCTAATTGCTCTTCTATGTGCTTATCCTAGAGCTGT  
 30 TTTTGCCTCCCTCTCAAGATGTCCGACTAAAGGCCTCAATACCTGTGGTCTATGTCT  
 GTGTTATGCTGTGCTTACACACCAGATTTCTTATGACACATCGTTGGCCAA  
 AACATCCCCACTATATCCATATTCTTGGCTAACCTGTATGTGGTGTCCACCTGCCCT  
 TAACCTGTCAATTATGGAGTCAGGACCAAGCAGATCCGAGAGCAAATTGTGAAAATATT  
 GTACAGAAAGAATAA (SEQ ID NO: 488)

**AOLFR33B sequences:**

25 MLHTNNTQFHPSFLVVGVPGLEDVHWIGPFFAVYLTLGNIIILFVIQTEQLHQPMLYFL  
 AMLAGTDLGLSTATIPKMLGIFWFNLGEIAFGACITQMYTIHCTGLESVVLTVTGDYIAICNP  
 LRYSMILTNKVIAILGIVIVRTLVFVTPFTLRLPFCGVRIIPHTYCEHMLAKLACASINVY  
 30 GLIAFSVGYIDISIVGFSYVQILRAVFHLPAWDARKALSTCGSHVCVMLAFYLPALFSMTHRF  
 GHNIPHYPHILLANLYVVVPPALNSVIYGVTKQIREQVLRILNPKSFWHFDPKRIFHNNSVRQ  
 (SEQ ID NO: 489)

35 ATGCTTCATACCAACAATACACAGTTCACCCCTCACCTCTCGTAGTGGGGTCCAG  
 GGCTGGAAGATGTGCATGTATGGATTGGCTCCCTCTTGCCTGTATCTAACAGCCCT  
 TCTAGGGAACATCATTCTCTGTTGTGATACAGACTGAACAGAGCCTCCACCAACCCATG  
 40 TTTTACTTCCTAGCCATGTTGGCCGGCACTGATCTGGCTGTACAGCAACCATCCCC  
 AGATGCTGGAAATTCTGGTTAATCTTGGAGAGATGCTTGGTCTACAGTCACGGCATA  
 GATGTATACCATTCATATGCCTGGCTGGAGTCTGTGGTACTGACAGTCACGGCATA  
 GATCGCTATATTGCCATCTGCAACCCCTGAGATATAGCATGATCCTACCAACAAGGAA  
 45 TAGCCATTCTGGGATAGTCATCATTGTCAAGGACTTGGTATTGTGACTCCATTCACTT  
 CTCACCCCTGAGATTGCCATTCTGTGGTCTGGGATTATCCCTCATACCTATTGTGAACACAT  
 GGGCTGGCAAAGTTAGCTTGTGCCAGTATTAAATGTTATATGGATTGATTGCCCTCTCA  
 GTGGGATACATTGACATTCTGTGATTGGATTCTCTATGTCCAGATCTCCGAGCTGTCTT  
 CCATCTCCAGCCTGGGATGCCCTTAAGGCACTCAGCACATGTGGCTCTACGTCTGT  
 50 GTTATGTTGGCTTCTACCTGCCAGCCCTTTCTCATGACACACCGCTTGGCCACAA  
 CATCCCTCATTACATCCACATTCTCTGCCAATCTGTATGTGGTTTCTCCCTGCTCTTA  
 ACTCTGTTATCTATGGGGTAAACAAAACAGATACAGAGAGCAGGTACTTAGGATACTCA  
 ACCCTAAAAGCTTGGCATTGACCCCAAGAGGATCTTCCACAAACAATTCACTTAGACA  
 ATAA (SEQ ID NO: 490)

50

**AOLFR112B sequences:**

55 MKNKTVLTFILLGLTDVPELQAVFTFLAYLLSILGNLTILITLLDSHLQTPMYFFLRNFSF  
 LEISFTNIFIPRVLISITGNKSISAGCFTQYFAMFLGATEFYLLAAMSYDRYVAICKPLHYTTI  
 MSSRICIQLIFCSWLGGLMAIPTITLMSQQDFCASNRLNHYFCDYEPILLESCSDTSLIEKVVFL  
 VASVTLVVTLVVLVILSYAFIUKTILKLPSAQQRTKAFSTCSSHMIVISLSYGSCKMFYINPSAKEG  
 DTFNKGVALLITSVAPLNPFIYTLRNQQVKQPFKDMVKLLNL (SEQ ID NO: 491)

5 ATGAAAAAATAAAACCGTGTAACTGAGTTATCCTCTGGCTAACAGATGTCCTGAAC  
 TCCAGGTGGCAGTTCACCTTCTTCTGCGTATTTACTCAGCATCCTGGAAATCTG  
 10 GAACTTCTCCCTCTGGAAATTCTTCAACAAACATCTCATCCAAGGGCCTGATTAGCA  
 TCACAAACAGGGAAACAAGAGTATCAGCTTCTGCTGGCTACTCAGTATTCCTGCCAT  
 GTTCCCTGGGCTACAGAGTTACCTTCTGGCTGCCATGTCCTATGACCGCTATGGCC  
 ATCTGCAAACCTCTGCATTACACCACATGAGCAGCAGAACTGCACTCAGCTGATT  
 15 TCTGCTCTGGCTGGGCTAATGGCTATTACCAACAATCACCCTGATGAGTCAGCA  
 GGACTTTGTGCATCCAACAGACTGAATCATTACTCTGTGACTATGAGCCTCTGGAA  
 CTCTCATGTTCAGACACAAGCCTCATAGAGAAGGTTGCTTCTGTGGCATCTGTGACCC  
 TGGTGGTCACTCTGGTCTAGTGAATTCTCTCATGCAATTATCAAGACTATTCTGAAG  
 CTCCCCCTGCCCACAAAGGACAAAAGCCTTCCACATGTTCTCCACATGATTGTCAT  
 CTCCCTCTCTACCGAAGCTGCATGTTATGTACATTAATCCCTCTGCAAAAGAAGGGAT  
 20 ACATTCAACAAGGGAGTAGCTACTCATTACTTCAGTTGCTCCTTGTGAACCCCTTAT  
 TTACACCTAAGGAACCAACAGTAAAACAACCCCTCAAGGATATGGTCAAAAGCTTCT  
 GAATCTTAA (SEQ ID NO: 492)

**AOLFR130B sequences:**

20 MEGKNQTAPSEFIILGFDHLNELQYLLFTIFFLTYICLGGNVFIIVVTIADSHLHTPMYYFLGNL  
 ALIDICYTTNVPQMMVHLSEKKIISYGGCVTQLFAFIFVGSECLLLAAMA YDRYIAICKPLR  
 YSFIMNKALCSWLAASCWTGFLNSVLHTVLTFHLPFCGNNQINYFFCDIPPLLILSCGDTSLNE  
 LALLSIGILISWTPFLCIILSYLYIISTILRIRSSEGRHKAFSTCASHLLIVLYGSAIFTYVRPISSYS  
 LEKDRLISVLYSVVTPMLNPVIYTLRNKDIKEAVKAIGRKWQPPVSSDI (SEQ ID NO: 493)  
 25 ATGGAAGGAAAGAATCAAACAGCTCCATCTGAATTCATCATCTGGGTCGACCACCTGA  
 ATGAATTGCAGTATTTACTCTTACCATCTCTTCTGACCTACATATGCACCTTAGGAGGC  
 AATGTTTTATCATGTGGTACCATAGCTGATTCCACCTACACACACCCATGTATTATT  
 30 CCTAGGAAATCTGCCCTATTGACATCTGCTACACTACTAAATGTCAGGCTGTGACCCAGCTCTTG  
 GTGCATCTCTGTACAGAGAAGAAAATCATTCCTATGGAGGCTGTGACCCAGCTCTTG  
 CATTCACTTCTTGTGGCTCAGAGTGTCTCCTCTGGCAGCAATGGCATATGATCGATAT  
 ATTGCTATCTGTAAGCGTTAAGGTACTCATTATTATGAACAAGGCCCTGTGAGCTGGT  
 TAGCAGCCTCATGCTGGACATGTGGTTCTCAACTCAGTGTGACACCCGTTCTGACCTT  
 35 CCACCTGCCCTCTGTGGTAACAATCAGATCAATTATTCCTGTGACATACCTCCCTTGC  
 TCATCTGTCTGTGGTACACTCCCTCAATGAACCTGGCTTGTGTCATTGGGATCCTC  
 ATAAGCTGGACTCCTTCTGTGCATCATCCTTCACTTACATCATCCACCATCCT  
 GAGGATCCGTTCTCTGAGGGGAGGCACAAAGCCTTCCACCTGTGCCTCCCACCTGCTC  
 ATTGTTATTCTCTATTATGGCAGTGTATCTCACGTATGTGAGGCCATCTCATCTTACTC  
 TCTAGAGAAAGATAGATTGATCTCAGTGTATAGTGTGACACCCATGCTGAATCCT  
 40 GTAATTATACGCTAAGGAATAAGGACATCAAAGAGGCTGTGAAGGCCATAGGGAGAAAG  
 TGGCAGGCCACCAGTTCTTCTGTATATAA (SEQ ID NO: 494)

**AOLFR142B sequences:**

45 MARKDMAHNCTQATEFILVGLTDHQELKMPFLVFLSIYLFTVVGNLGLILLIRADTSNTPM  
 YFFLSNLAFVDFCYSSVTPKMLGNFLYKQNVISFDACATQLGCFITFMISESLLASMAYDRY  
 VAICNPLLYMVVMTPGICQLVAVPYSYSFLMALFHTILFRLSYCHSNIVNFYCDMDPLLRL  
 TCSDTRFKQLWIFACAGIMFISSLIVFVSYMFIISAILRMHSAEGRQKAFSTCGSHMLAVTIFYG  
 TLIFMYLQPSSSHALDKMASVFYTVIIPMLNPLIYSLQNKEVKEALKKIIINKN (SEQ ID NO:  
 495)  
 50 ATGGCCAGAAAAGATATGGCTCACATCAATTGCACCCAGGCACAGAGTTATTCTGTGG  
 GCCTCACAGACCATCAGGAGTTGAAGATGCCCTCTTGTCTATTCTATCCATCTACCTC  
 TTCACAGTGGTAGGCACCTGGTTGATCCTACTCATTAGAGCGGATACAAGTCTCAACA  
 CACCAATGTACTCTTCTAGCAACCTAGCTTGTGGATTCTGTTACTCTCTGTCAATT  
 55 ACACCCAAAATGCTTGGGAATTCTGTACAAACAAATGTTATATCCTTGTGATGCA  
 CTACTCAACTGGCTGCTTCTCACCTCATGATATCAGAATCCTGCTACTGGCTTCCATG

WO 01/98526

5           GCCTATGACCGATATGGCCATTGTAACCTCTATTGTATGGTTGAATGACTCCAG  
 GAATCTGCATTCAACTGTAGCAGTCCTTATAGCTATAGCTTCATAAGGCACATTTCAC  
 ACCATCCTCACCTCCGCTCTCTATTGCCACTCCAACATTGCTCAACCATTCTATTGTGA  
 TGACATGCCTCTCCAGGCTAACATTGCTCAGACACTCGCTCAAACAGCTCTGGATCTT  
 10          GCCTGTGCTGGTATCATGTTATTCCCTCTGTATGCTTGTCTTACATGTTCATC  
 ATTTCTGCCATCCTGAGGATGCATTCAAGCTGAGGAAGACAGAAGGCTTCTGACGTGTG  
 GCTCTCACATGCTGGCAGTCACCATATTCTATGGACCCCTCATTGTACTTACAGCCT  
 AGCTCTAGCCATGCCCTGGACACAGACAAGATGGCCTGTCTTACACAGTGTACATTAC  
 CCATGTTGAATCCCTAACCTATAGCCTCCAGAATAAGGAGGTGAAAGAAGCTCTGAAGA  
 15          AAATCATTATCAATAAAAACAG (SEQ ID NO: 496)

## AOLFR171C sequences:

15          MAEVNIYVTVILKGITNRPQAPCFGVFLVIYLVTVLGNLGLITLIKIDTRLHPTMYYFLSHL  
 AFVDLCYSSAITPKMMVNVERNTIPFHACATQLGCFMFITECFLASMAKYDCYVAICSP  
 HYSTLMSRRVCIQLVAVPYIYFLVALFHTVITFRILTYCGPNLHFCDDLPFLALSCSDTHMK  
 EILIFAFAGFDMISSSIVLTSYIFIAILRIRSTQGQHKAISTCGSHMVTVIFYGTLIFMYLQPKS  
 NHSLDTDKMASVFTVVIPMLNPLIYSLRNKEVKDASKKALDKGCENIQLTFLKIRKLY (SEQ  
 ID NO: 497)

20          ATGGCTGAAGTTAATATCATTTATGTCAGTATTCACTGAAAGGAATTACCAACGGC  
 CAGAGCTCAGGCCCGTCTTGGGTGTTTGTATTCTATCTGGTCACAGTGTGGG  
 CAATCTGGGTGATTACTTAATCAAGATTGACTCGACTCCACACACCTATGTACTATT  
 25          TCCTCAGGCCACCTGGCCTTGTGACCTTGTACTCCTCTGCTATTACACCGAAGATGATG  
 GTGAATTITGTGTGGAACGCAACACCATTCCCTCATGCTTGTGCAACCCAACGGTT  
 GTTTCTCACCTCATGACTGAGTGTCTCTAGCCTCATGGCTTACGATTGCTAT  
 GTCGCCATCTGAGTCCCTGCATTATTCAACACTGATGTCAGAAGAGTCTGCATTCAAC  
 TGGTGGCAGTCCATATATACAGCTTCTGGTGCCTCTCCACACCGTTACCTTC  
 CGTCTGACTTACTGTGGCCAAACTTAATTACCATTTCTATTGTGATGACCTCCCTT  
 AGCTCTGCTCTGCTCAGACACACATGAAGGAAATTCTGATATTGCTTGCCTGGCTT  
 30          GATATGATCTCTCCTCTCCATTGTCTCACCTCCTACATCTTATTATTGCCCTATCCTA  
 AGGATCCGCTCTACTCAGGGCACACAAAGCCATTCCACCTGTGGCTCCATATGGTA  
 CTGTCACTATTCTATGGCACACTGATCTTATGTACTCACGCCAAATCAAATCCTCC  
 TTGGACACAGACAAGATGGCTCTGTATTACACAGTGGTGTACCTGGGATCCCCATGTTAAACCCCC  
 TAATCTATAGCTAAGAACAAAGAAGTGAAGATGCTCAAAGAAAGCCTGGATAAAG  
 35          GTGTGAAAACCTACAGATATTACATTAAACATTAAAAGAAAACTTTATTAA (SEQ ID NO:  
 498)

## AOLFR225B sequences:

40          MKNRTMFGFILLGLTNQPELQVMIFIFLTYMLSILGNLTITLTLDPHLQTPMYFFLRFNSF  
 LEISFTSIFIRFLTSMTGNKVISAGCLTYFFAIFLGADEFYLLASMSYDRYVAICKPHYLTI  
 MSSRCVCIQLVFCSWLGGFLAILPIIILMTQVDFCVSNILHYYCDYGPLVELACSDTSLELMVI  
 LLAVVTLMVTLVLTLSYTYIIRILRIPSAQQRTKAFSTCSSHMIVISLGSMPMYINPSAKE  
 GGAFNKGIAVLITSVTPLLNPFIYTLRNQQVKQAFKDSVKIVKL (SEQ ID NO: 499)

45          ATGAAAAACAGAACCATGTTGGTAGTTATTCACTGGGCCTACAAATCAACCTGAAC  
 TCCAAGTGTGATATTCACTTCTGTCCTCACCTACATGCTAAGTATCCTAGGAAATCTG  
 ACTATTATCACCTCACCTACTAGACCCCCACCTCCAGACCCCCATGTATTCTCTCCG  
 GAATTCTCCTCTAGAAATTCTTCACATCCATTTCAGCTTGTGGTGTGACTCAGTATTCTGACCAGCA  
 TGACAACAGGAATAAAAGTTATCAGCTTGTGGTGTGACTCAGTATTCTGACCAGCA  
 50          ATTCTGGAGCTACCGAGTTTACCTCTGGCCTCATGTTATGATCGTTATGTGGCCA  
 TCTGCAAACCCCTGCATTACCTGACTATTATGAGCAGCAGACTGCTCATACAAGTGT  
 CTGCTCTGGTGGGGATCCTAGCAATCTTACCAACATCCTGATGACCCAGGTA  
 GATTCTGTGTCTAACATTCTGAATCACTATTACTGTGACTATGGGCTCTGGAGCT  
 TGCCTGCTCAGACACAAGCCTTGAAGAAGTGTGACTATGGGCTCTGGAGCT  
 55          ATGGTTACTCTGGTGTGGTACACTTCTACACATATTACAGGACTATTCTGAGGA  
 TCCCTCTGCCAGCAAAGGACAAAGGACAAAGCCTTCCACTTGTCTCCACATGATTGTCATC

TCCCTCTTATGGCAGCTGCATGTTATGTACATTAATCCTCTGCAAAAGAAGGAGGTG  
 CTTCAACAAAGGAATAGCTGTACTCATTACTCGGTACTCCCTACTGAATCCCTCATA  
 TATACTTAAGAAATCAGCAAGTGAACAGCTTCAGGACTCAGTCAAAAGATTGTG  
 AAACITTA (SEQ ID NO: 500)

5

**AOLFR274B sequences:**

MEFVFLAYPSCPHELHLSFLGVSLVYGLITGNILIVVSIHETCLCTSMMYFLGSLSGIEICYTAV  
 VVPHILANTLQSEKTITLLGCATQMAFFIALGSADCFLAAMAYDRYVAICHPLQYPLLMLTTL  
 10 CVHLVVASVISGLFLSQLVAFIFSLPFCQAQGIEHFFCDVPPVMHVVCAQSHIHEQSVLVAAIL  
 AIAVPFFLITTSYTFIVAALLKIHSAGRHRAFSTCSSHLTVVLLQYGCCAFMYLCPSYYNPKQ  
 DRFISLVYTLGTPLLNPLIYALRNSEMKGAVGRVLTRNCLSQNS (SEQ ID NO: 501)

15 ATGGAATTGTGTTCTGGCCTATCCCTCTGCCAGAACACTGCATATTCTGTCCTTCCTGG  
 GGTCAAGCCTGGTTATGGTTGATCATCACTGGAACATTCTCATTGTGGTGTCCATTCA  
 ACAGAAACCTGTCTATGCACATCCATGACTATTCCCTGGCAGCCTTCTGGGATTGAAA  
 TATGCTACACTGCAGTGGTGGGCCATATCCTGGCCAACACCCCTACAGTCAGAGAAC  
 CATCACTCTCCTGGCTGTGCCACCCAGATGGCTTCTCATTGCAGTGGCAGTGTGAT  
 TGCTTCCTCTGGCTGCCATGGCTATGACCGCTATGTGGCCATTGCCACCCGTTGCAGTA  
 20 CCCCTCCTCATGACATTGACTTTGTGTCCACTGGTTGTGGCATCAGTCATCAGTGGTC  
 TGTTCCCTGTCCTACAACGGTGGCCTCATCTCTCTGCACTGCCATTGCCAGGCTCAGGGC  
 ATTGAGCACTCTTGTGATGTGCCACAGTCATGCATGTTGTGCTCAGAGTCACAT  
 TCATGAGCAGTCAGTGTGGCAGCCATACTAGCCATTGCTGTGCCTTCTCCTCATC  
 ACCACCTCCTACACCTCATAGTGGCTGCTGCTCAAGATCCACTCGGCTGCTGGCGCC  
 25 ACCGGGCCTCTCCACCTGCTCTCCCACCTCACTGTGGTGTGCTGCTGAGTATGGCTGCTG  
 GCCTTCATGTACCTGTGCCAGCTCCAGCTACAACCCCAAGCAAGATCGGTTCATCTC  
 TGGTGTACACATTGGAACCCCACTGCTCAACCCACTATCTATGCCCTGAGGAACAGTGA  
 GATGAAAGGGCCGTAGGGAGAGTTCTTACCAAGGAACGCCAGAAGACTGCTTCCCAGAACAGCTAG  
 (SEQ ID NO: 502)

30

**AOLFR276B sequences:**

MGGFTNISSTSFTLTGFPEMKGLEHWLAALLLYAISFLGNILLFIKEEQLHQPMLYFLS  
 LFSVNDLGVSFSTLPTVLAACVCFHAPETTDACLAQMFFHFSWTEFGILLAMSFDHYVAICNP  
 LRYATVLTDRVRAHNGISIVRSFCMVFLPFLKRLPFCKASVVL AHLSYCLHADLIRLPWGDT  
 35 TINSMYGLFIVISAFGVDSLLLSSYVLILHSVLAIASRGERLKTNTCVSHIYAVLIFYVPMVS  
 MVHRFGRHAPEYVHKFMSLCTSNAALPNYLFHQD (SEQ ID NO: 503)

40 ATGGGGGGCTTGGACTAACATCTCAAGTACTACCAGCTTCACTAACAGGCTTCCCTG  
 AGATGAAGGGTCTGGAGCACTGGCTGGCTGCCCTCTGCTGCTGCTTATGCTATTCTT  
 CCTGGCAACATCCTCATCCTCTTATCATAAAAGGAAGAGCAGAGCTGCACCAGCCAATG  
 TACTACTCTGTCTCTTTCTGTTAATGACCTGGGTGTGCTCTTCTACATTGCCCACT  
 GTACTGGCTGCTGTGTTTCTATGCCCAAGAGACAACCTTGTGCTGCCTGGCCAGA  
 TGTTCTCATCCACTTCTGCTGGACAGAGTTGGCATCCTACTGCCATGAGTTTGAC  
 CACTATGTGCCATCTGTAACCCGCTGCGCTATGCCACAGTGCTCACTGATGTCCGTG  
 45 CCCACAATGGCATATCCATTGTCATCCGAGCTCTGCATGGTATTCCCACCTCCCTC  
 CTGAAGAGACTGCCATTCTGTAAGGCCAGTGTGGTACTGCCATTCTACTGTCATG  
 CAGACCTGATTGGCTGCCCTGGGGAGACACTACCATCACAGCATGTATGGCCTGTC  
 TGTCACTCTGCCTTGTGTTAGATTCACTGCTCATCCTCTCCTATGTGCTATTCTAC  
 ATTCTGTGCTGCCATTGCCCTCAGGGGTGAGAGGCTTAAGACACTCACACATGTG  
 50 ACATATCTATGCAGTGTGATCTCTATGTGCTATGGTAGTGTGTCATGGTCATGCT  
 TTGGGAGGGCATGCTCTGAATATGTGCAACAGTCATGTCATTGTACCTCCAATGCT  
 ACCCAATTATCTATTCCATCAAGACTAA (SEQ ID NO: 504)

55

**AOLFR311B sequences:**

MDWENCSSLTDFFLLGITNNPEMKVTLFAVFLAVYIINFSANLGMIVLIRMDYQLHTPMYFFLS  
 HLSFCDCLCYSTATGPKMLVDLLAKNKSIPFYGCALQFLVFCIFADSECLL SVMAFDRYKAIINP  
 LLYTVNMSSRVCYLLTGVYLVGIADALIHMTLAFLRCFCGSNEINHFFCDIPPLLLRSRDTQV

WO 01/98526

NELVLFTVFGFIELSTISGVFISYCYIILSVLEIHSAGRFKALSTCTSHLSAVAIFQGTLLFMYFRP  
 SSSYSLDQDKMTSLFYTLVVPMLNPLIYSLRNKDVEALKLKNKILF (SEQ ID NO: 505)

5 ATGGACTGGAAAATTGCTCCTCATTAACGTATTCTTCTGGAAATTACCAATAACCC  
 AGAGATGAAAGTGAACCTATTGCTGATTCTGGCTGTTATATCATTAAATTCTCAGCAA  
 10 ATCTTGGAAATGATAGTTAACAGAATGGATTACCAACTCACACACCAATGTATTCTT  
 CCTCAGTCATCTGCTTCTGTGATCTGCTATTCTACTGCAACTGGGCCAAGATGCTGG  
 TAGATCTACTTGCCAAGAACAGTCAATACCCCTATGGCTGCTGCAATTCTGGT  
 CTTCTGTATCTTGAGATTCTGAGTGTACTGCTGAGTGTAGCAGAGTGTCTACT  
 AGGCCATCATCAACCCCTGCTATACAGTCAACATGTAGCAGAGTGTCTACT  
 CTTGACTGGGTTATCTGGGAAATAGCAGATGCTTGTAGACATATGACACTGGCCTTC  
 CGCCTATGCTCTGTGGGCTAATGAGATTAATCATTCTGTGATATCCCTCTCTT  
 ATTACTCTCGCTCAGATACACAGGTCATGAGTTAGTGTATTCAACGTCTTGGTTTA  
 TTGAACTAGGTACCATTCAGGAGTTCAAGCTCTCTACATGCACTCCACTATCTG  
 15 GAGATACACTCTGCTGAGGGGAGGTTCAAAGCTCTCTACATGCACTCCACTATCTG  
 CGGTTGCAATTTCAGGAACTCTGCTTTATGTATTCCGGCAAGTCTCCTATTCT  
 CTAGATCAAGATAAAATGACCTCATTGTTACACCCCTGTTCCATGTTGAACCCCT  
 GATTATAGCCTGAGGAACAAGGATGTGAAAGAGGCCCTGAAAAACTGAAAAATAAAAT  
 TTTATTTAA (SEQ ID NO: 506)

20 **AOLFR314 sequences:**  
 MEVKNCMVTEILLGIPHTEGLEMTLFVLFLPFYACTLLGNVSILVAVMSSARLHTPMYFFLG  
 NLSVFDMGSSVTPKMLLYMGLSLISYKDCVQLFFFHLSIECLFTVMAYDRFTAICY  
 PLRYTVIMPRICVALAVGTWLLGCIHSSILTSLTFLPYCPNEVDHFFCDIPALLPLACADTS  
 25 AQRVSFTNVGLISLVCFLLLSYTRITISILSIRTTEGRRRAFSTCSAHLIAILCAYGPIITVYLQPT  
 PNPMLGTVVQILMNLVGPMLNPLIYLRNKEVKTALKTILHRTGHVPES (SEQ ID NO: 507)

30 ATGGAGGTGAAGAACTGCTGCATGGTACAGAGTTACCTTTGGAAATCCACACACA  
 GAGGGGCTGGAGATGACACTTTGTCTTATCTGCCCTCTATGCCCTACTGACTCTACTGGG  
 AAATGTGTCTATCCTGTTGCTGTATGCTCTGCTGCCCTCACACACCTATGTATTCT  
 TCTGGGAAACTGTCTGTTGACATGGGTTCTCCAGTGTCTGCCAAATGCT  
 GCTCTACCTATGGGCTGAGCCGACTCATCCTACAAAGACTGTCTGCCAGCTTCT  
 TCTCCATTCTCGGGAGCATTGAGTGTCTTACGGTGTACGGCTATGACCGCTTC  
 ACTGCCATCTGTTATCCTCGCGATACACAGTCATCATGAACCCAAGGATCTGTGGCC  
 TGGCTGGGCACATGGCTTAGGGTCATTCACTGCTTCTGACCTCCAGCTTCTGAC  
 ACCCTGCCATACTGTGGTCCAACTGAAGTGGTCACTCTCTGACATTCCAGCAGCTT  
 GCCCTTGGCTGTGCTGACACATCCTTAGCCCAGAGGGTGAGCTCACCAACGTTGGCTC  
 ATATCTCTGCTGCTTCTGCTAATTCTTATCTACACTAGAAATCACAATATCTATCTT  
 AAGCATTCTGACAATGAGGCCGTCGCCGCTCCACCTGCAGTGTCACTTCACT  
 35 GCCATCCTCTGCTATGGGCCATCATCACTGTCTACCTGCAAGCCCACACCAACCCCA  
 TGCTGGGACCGTGGTACAAATTCTCATGAATCTGGTAGGACCAATGCTGAACCCCTTGAT  
 CTATACCTTGAGGAATAAGGAAGTAAAAACAGCCCTGAAAACAATTGCACAGGACAGG  
 CCATGTTCTGAGAGTTAG (SEQ ID NO: 508)

40 **AOLFR324B sequences:**  
 MPIANDTQFHTSSFLLGIPGLEDVHIWGFPPFSVYLIAALLGNAIAFFVIQTEQLHEPMYYCLA  
 MLDSDLSLSTATIPKMLGIFWFNIKEISFGYLSQMFFIHFFTVMESIVLVAMAFDRYIAICKPL  
 WYTMILTSKIIISLIAGIAVRLSLYMVIPLVFLRLPFCGHRIPTHYCEHMGIA  
 FGLGSISLLLDVLLIILSHIRILYAVFCPLSWEARLKALNTCGSHIGVILAFSTPAFFSFTHCFGH  
 45 DIPQYIHIFLANLYVVPPTLNPVIYGVRTKHIRETVLRIFFKTDH (SEQ ID NO: 509)

50 ATGCCTATAGCTAACGACACCCAGTCCATCTCTCATTCTACTGCTGGGTATCCAGG  
 GCTAGAAAGATGTGCACATCTGGATTGGATTCCCTTTCTCTGTGATCTTATTGCACTCC  
 TGGGAAATGCTGCTATCTCTTGTGATCCAAACTGAGCAGAGTCTCCATGAGCCCATGTA  
 55 CTACTGCCTGGCATGTGGATTCCATTGACCTGAGCTGCTACGGCCACCACTCCAAA  
 ATGCTGGGATCTCTGGTCAATATCAAGGAAATCTTGGAGGCTACCTTCAGA

5                   TGTCTTCATCCATTCTCACTGTCATGGAGAGCATGTATTGGTGGCATGGCTTGAC  
 CGCTACATTGCCATTGCAAACCTTTGGTACACCATGATCCTCACCAAGAAAATCATCA  
 GCCTCATTGCAGGCATTGCTCTGAGGAGCTGTACATGGTATTCCACTGGTGTCT  
 CCTCTTAAGGTTGCCCTCTGTGGACATCGTATCATCCCTCATACTTACTGTGAGCACATGG  
 10                GCATTGCCGTCTGGCTGTGCCAGCATCAAAGTCAACATTATGTTGGTCTTGGCAGTAT  
 TTCTCTTGTATTGGATGTGCTCCTATTATTCTCTCCATATCAGGATCCTATGCTGT  
 CTTCTGCCCTGCCCTGGAGCTGACTCAAAGCTCTAACACACTGTGGCTCTCACATT  
 GGTGTTATCTTAGCCTTCTACACCAGCATTTCTCTTACACACTGCTTGGCCAT  
 GATATTCCCCAATATATCCACATTCTGGCTAATCTATATGTTGTTCTCCCACCC  
 15                CAATCCTGTAATCTATGGGTAGAACACATATTAGGGAGACAGTGTGAGGATTTC  
 TTCAAGACAGATCACTAA (SEQ ID NO: 510)

**AOLFR328 sequences:**

15                MALGNHSTITEFLLLGLSADPNIRALLFVLFLGIYLLTIMENLMLLVIRADSCLHKPMYFFLSH  
 LSFVDLCFSSVIVPKMLENLLSQRKTISVEGCLAQVFFVFTAGTEACLLSGMAYDRHAAIRP  
 LLYGQIMGKQLYMHLVWGSWGLGFLDALINVLLAVNMVFCEAKIHHYSYEMPSLLPLSCSDI  
 SRSLIVLLCSTLLHGLGNLLVFLSYTRIISTILSISSTSRSKAFSTCSAHLTAVTLYYGSLLRHL  
 MPNSGSPIELFSVQYTVVTPMLNSLIYSLKNKEVKVALKRTLEKYLQYTRR (SEQ ID NO: 511)

20                ATGGCCTGGGAATCACAGCACCATCACCGAGTTCCCTCCCTGGGCTGTCTGCCGACC  
 CCAACATCCGGCTCTGCTCTTGTGCTTCCCTGGGATTACCTCCGACCATATGGAA  
 AACACCTGATGCTGCTGCTCGTGATCAGGGCTGATTCTGTCTCCATAAGCCCATGTATTCT  
 TCCTGAGTCACCTCTCTTGTGATCTCTGCTCTCTCAGTCATTGTGCCAAGATGCTG  
 GAGAACCTCCTGTCACAGAGGAAAACCATTTCAGTAGAGGGCTGCCCTGGCTCAGGTCTTCT  
 25                TTGTGTTGTCACTGCAGGGACTGAAGCCTGCCCTCTCAGGGATGGCCTATGACCGCCA  
 TGCTGCCATCCGCCGCCCACACTTTATGGACAGATCATGGGTAACAGCTGTATATGCAC  
 CTTGTGGGGCTCATGGGACTGGGCTTCTGGACGCCACTCATCAATGTCCTCTAGCTG  
 TAAACATGGCTTTGTGAAGCAAATCATCACCACAGCTATGAGATGCCATCCCT  
 CCTCCCTGTCCTGCTCTGATATCTCCAGAACGCTCATCGTTGCTCTGCTCCACTCTCC  
 30                TACATGGGCTGGGAAACTCCCTTTGGTCTCTTACACCCGTATAATCTTACCATC  
 CTAAGCATCAGCTCACCTCGGGCAGAACAGCAAGGCCTCTCCACCTGCTCTGCCACCTCA  
 CTGCAGTGACACTTACTATGGCTCAGGTTGCTCCGCCATCTCATGCCAAACTCAGGTT  
 CCCCATAGAGTTGATCTCTGTGCACTATGTTAGTCACCTCCATGCTGAATTCCCTCA  
 TCTATAGCCTGAAAAATAAGGAAGTGAAGGTAGCTCTGAAAAGAAACTTTGGAAAAATATT  
 35                TGCAATATACCAAGACGTTGA (SEQ ID NO: 512)

Claims:

1. A method for representing sensory perception of one or more odorants comprising:
  - 5 (a) providing a representative class of n olfactory receptors or ligand-binding domains thereof;
  - (b) measuring values  $X_1$  to  $X_n$  representative of at least one activity of the one or more odorants selected from the group consisting of binding of the one or more odorants to the ligand-binding domain of at least one of the n 10 olfactory receptors, activating at least one of the n olfactory receptors with the one or more odorants, and blocking at least one of the n olfactory receptors with the one or more odorants; and
  - (c) generating a representation of sensory perception from the values  $X_1$  to  $X_n$ ;
- 15 wherein at least one of the n olfactory receptors has an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, SEQ ID NO: 69, SEQ ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 79, SEQ ID NO: 81, SEQ ID NO: 83, SEQ ID NO: 85, SEQ ID NO: 77, SEQ ID NO: 89, SEQ ID NO: 91, SEQ ID NO: 93, SEQ ID NO: 95, SEQ ID NO: 97, SEQ ID NO: 99, SEQ ID NO: 101, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 107, SEQ ID NO: 109, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, SEQ ID NO: 119, SEQ ID NO: 121, SEQ ID NO: 123, SEQ ID NO: 125, SEQ ID NO: 127, SEQ ID NO: 129, SEQ ID NO: 131, SEQ ID NO: 133, SEQ ID NO: 135, SEQ ID NO: 137, SEQ ID NO: 139, SEQ ID NO: 141, SEQ ID NO: 143, SEQ ID NO: 145, SEQ ID NO: 147, SEQ ID NO: 149, SEQ ID NO: 151, SEQ ID NO: 153, SEQ ID NO: 155, SEQ ID NO: 157, SEQ ID NO: 159, SEQ ID NO: 161, SEQ ID NO: 163, SEQ ID NO: 165, SEQ ID NO: 167, SEQ ID NO: 169,

SEQ ID NO: 171, SEQ ID NO: 173, SEQ ID NO: 175, SEQ ID NO: 177, SEQ ID NO: 179, SEQ ID NO: 181, SEQ ID NO: 183, SEQ ID NO: 185, SEQ ID NO: 187, SEQ ID NO: 189, SEQ ID NO: 191, SEQ ID NO: 193, SEQ ID NO: 195, SEQ ID NO: 197, SEQ ID NO: 199, SEQ ID NO: 201, SEQ ID NO: 203, SEQ ID NO: 205, 5 SEQ ID NO: 207, SEQ ID NO: 209, SEQ ID NO: 211, SEQ ID NO: 213, SEQ ID NO: 215, SEQ ID NO: 217, SEQ ID NO: 219, SEQ ID NO: 221, SEQ ID NO: 223, SEQ ID NO: 225, SEQ ID NO: 227, SEQ ID NO: 229, SEQ ID NO: 231, SEQ ID NO: 233, SEQ ID NO: 235, SEQ ID NO: 237, SEQ ID NO: 239, SEQ ID NO: 241, SEQ ID NO: 243, SEQ ID NO: 245, SEQ ID NO: 247, SEQ ID NO: 249, SEQ ID NO: 251, SEQ ID NO: 253, SEQ ID NO: 255, SEQ ID NO: 257, SEQ ID NO: 259, 10 SEQ ID NO: 261, SEQ ID NO: 263, SEQ ID NO: 265, SEQ ID NO: 267, SEQ ID NO: 269, SEQ ID NO: 271, SEQ ID NO: 273, SEQ ID NO: 275, SEQ ID NO: 277, SEQ ID NO: 279, SEQ ID NO: 281, SEQ ID NO: 283, SEQ ID NO: 285, SEQ ID NO: 287, SEQ ID NO: 289, SEQ ID NO: 291, SEQ ID NO: 293, SEQ ID NO: 295, 15 SEQ ID NO: 297, SEQ ID NO: 299, SEQ ID NO: 301, SEQ ID NO: 303, SEQ ID NO: 305, SEQ ID NO: 307, SEQ ID NO: 309, SEQ ID NO: 311, SEQ ID NO: 313, SEQ ID NO: 315, SEQ ID NO: 317, SEQ ID NO: 319, SEQ ID NO: 321, SEQ ID NO: 323, SEQ ID NO: 325, SEQ ID NO: 327, SEQ ID NO: 329, SEQ ID NO: 331, SEQ ID NO: 333, SEQ ID NO: 335, SEQ ID NO: 337, SEQ ID NO: 339, SEQ ID NO: 341, SEQ ID NO: 343, SEQ ID NO: 345, SEQ ID NO: 347, SEQ ID NO: 349, 20 SEQ ID NO: 351, SEQ ID NO: 353, SEQ ID NO: 355, SEQ ID NO: 357, SEQ ID NO: 359, SEQ ID NO: 361, SEQ ID NO: 363, SEQ ID NO: 365, SEQ ID NO: 367, SEQ ID NO: 369, SEQ ID NO: 371, SEQ ID NO: 373, SEQ ID NO: 375, SEQ ID NO: 377, SEQ ID NO: 379, SEQ ID NO: 381, SEQ ID NO: 383, SEQ ID NO: 385, 25 SEQ ID NO: 387, SEQ ID NO: 389, SEQ ID NO: 391, SEQ ID NO: 393, SEQ ID NO: 395, SEQ ID NO: 397, SEQ ID NO: 399, SEQ ID NO: 401, SEQ ID NO: 403, SEQ ID NO: 405, SEQ ID NO: 407, SEQ ID NO: 409, SEQ ID NO: 411, SEQ ID NO: 413, SEQ ID NO: 415, SEQ ID NO: 417, SEQ ID NO: 419, SEQ ID NO: 421, SEQ ID NO: 423, SEQ ID NO: 425, SEQ ID NO: 427, SEQ ID NO: 429, SEQ ID NO: 431, SEQ ID NO: 433, SEQ ID NO: 435, SEQ ID NO: 437, SEQ ID NO: 439, 30 SEQ ID NO: 441, SEQ ID NO: 443, SEQ ID NO: 445, SEQ ID NO: 447, SEQ ID NO: 449, SEQ ID NO: 451, SEQ ID NO: 453, SEQ ID NO: 455, SEQ ID NO: 457, SEQ ID NO: 459, SEQ ID NO: 461, SEQ ID NO: 463, SEQ ID NO: 465, SEQ ID

WO 01/98526

NO: 467, SEQ ID NO: 469, SEQ ID NO: 471, SEQ ID NO: 473, SEQ ID NO: 475,  
SEQ ID NO: 477, SEQ ID NO: 479, SEQ ID NO: 481, SEQ ID NO: 483, SEQ ID  
NO: 485, SEQ ID NO: 487, SEQ ID NO: 489, SEQ ID NO: 491, SEQ ID NO: 493,  
SEQ ID NO: 495, SEQ ID NO: 497, SEQ ID NO: 499, SEQ ID NO: 501, SEQ ID  
NO: 503, SEQ ID NO: 505, SEQ ID NO: 507, SEQ ID NO: 509 and SEQ ID NO:  
5 511.

2. The method of Claim 1, wherein at least one of the olfactory receptors  
specifically recognizes the odorant, and there are between 5 and 350 of the n olfactory  
10 receptors selected from the listed amino acid sequences.

3. The method of Claim 1, wherein at least two different activities are measured  
to provide the values  $X_1$  to  $X_n$ .

15 4. The method of Claim 1, wherein each odorant receptor is expressed in cells,  
and the cells expressing each odorant receptor are located at an identifiable position.

5. The method of Claim 1, wherein at least one olfactory receptor is soluble, and  
binding of odorant to a ligand-binding domain of the soluble olfactory receptor is  
20 measured in solution.

6. The method of Claim 1, wherein at least one olfactory receptor is in solid state,  
and binding of odorant to a ligand-binding domain of the solid-state olfactory receptor  
is measured on a substrate.

25 7. The method of Claim 1, wherein the value measured for binding is above a  
preset limit for specific binding to olfactory receptors.

30 8. The method of Claim 1, wherein the value measured for activating an olfactory  
receptor is derived from a signal selected from the group consisting of intracellular  
 $\text{Ca}^{2+}$ , cAMP, cGMP and IP3.

9. The method of Claim 1, wherein the value measured for activating an olfactory receptor is above a preset limit for specific activation.
10. The method of Claim 1, wherein the value measured for blocking an olfactory receptor is at least a reduction in binding of the odorant or activation by the odorant.
11. The method of Claim 1, wherein the representation of sensory perception is generated with a neural network.
- 10 12. A biosensor comprised of the n ligand-binding domains or olfactory receptors of Claim 1.
13. A method for producing a database of odorant representations comprising:
  - (a) providing one or more known odorants and
  - 15 (b) generating a representation of the one or more known odorants in accordance with the method of Claim 1 to produce the database.
14. A database produced by Claim 13.
- 20 15. A method of identifying an unknown odorant comprising:
  - (a) measuring values  $X_1$  to  $X_n$  representative of at least one activity selected from the group consisting of binding the unknown odorant to a ligand-binding domain of at least one of n olfactory receptors, activating at least one of n olfactory receptors with the unknown odorant, and blocking at least one of n olfactory receptors with the unknown odorant;
  - (b) generating a representation of the unknown odorant from the values  $X_1$  to  $X_n$ ; and
  - (c) comparing the unknown odorant's representation to the database of Claim 14 to identify the known odorant which is most similar in representation.
- 30 16. A method of producing an artificial odorant comprising:

WO 01/98526

(a) measuring values  $X_1$  to  $X_n$  representative of at least one activity selected from the group consisting of binding a desirable odorant to a ligand-binding domain of at least one of  $n$  olfactory receptors, activating at least one of  $n$  olfactory receptors with a desirable odorant, and blocking at least one of  $n$  olfactory receptors with a desirable odorant;

5 (b) generating a representation of the desirable odorant from the values  $X_1$  to  $X_n$ ;

(c) decomposing the desirable odorant's representation into representations of known odorants from the database of Claim 14 or superposing known odorants' representations from the database to reproduce the desirable odorant; and

10 (d) formulating the known odorants to reproduce sensory perception of the desirable odorant and thereby produce the artificial odorant.

15 17. An artificial odorant produced by Claim 16.

18. A method of identifying a primary odorant related to sensory perception

comprising:

(a) providing a representative class of  $n$  olfactory receptors or ligand-binding domains thereof,

20 (b) measuring at least one activity of a odorant selected from the group consisting of binding of the candidate odorant to the ligand-binding domain of at least one of the  $n$  olfactory receptors and activating with the candidate odorant at least one of the  $n$  olfactory receptors, and

(c) identifying the candidate odorant as a primary odorant if only one or less than 10% of the representative class of  $n$  olfactory receptors is bound or activated;

25 wherein at least one of the  $n$  olfactory receptors has an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID

NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, SEQ ID NO: 69, SEQ ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 79, SEQ ID NO: 81, SEQ ID NO: 83, SEQ ID NO: 85, SEQ ID 5 NO: 87, SEQ ID NO: 89, SEQ ID NO: 91, SEQ ID NO: 93, SEQ ID NO: 95, SEQ ID NO: 97, SEQ ID NO: 99, SEQ ID NO: 101, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 107, SEQ ID NO: 109, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, SEQ ID NO: 119, SEQ ID NO: 121, SEQ ID NO: 123, SEQ ID NO: 125, SEQ ID NO: 127, SEQ ID NO: 129, SEQ ID NO: 131, SEQ ID NO: 133, 10 SEQ ID NO: 135, SEQ ID NO: 137, SEQ ID NO: 139, SEQ ID NO: 141, SEQ ID NO: 143, SEQ ID NO: 145, SEQ ID NO: 147, SEQ ID NO: 149, SEQ ID NO: 151, SEQ ID NO: 153, SEQ ID NO: 155, SEQ ID NO: 157, SEQ ID NO: 159, SEQ ID NO: 161, SEQ ID NO: 163, SEQ ID NO: 165, SEQ ID NO: 167, SEQ ID NO: 169, SEQ ID NO: 171, SEQ ID NO: 173, SEQ ID NO: 175, SEQ ID NO: 177, SEQ ID 15 NO: 179, SEQ ID NO: 181, SEQ ID NO: 183, SEQ ID NO: 185, SEQ ID NO: 187, SEQ ID NO: 189, SEQ ID NO: 191, SEQ ID NO: 193, SEQ ID NO: 195, SEQ ID NO: 197, SEQ ID NO: 199, SEQ ID NO: 201, SEQ ID NO: 203, SEQ ID NO: 205, SEQ ID NO: 207, SEQ ID NO: 209, SEQ ID NO: 211, SEQ ID NO: 213, SEQ ID NO: 215, SEQ ID NO: 217, SEQ ID NO: 219, SEQ ID NO: 221, SEQ ID NO: 223, 20 SEQ ID NO: 225, SEQ ID NO: 227, SEQ ID NO: 229, SEQ ID NO: 231, SEQ ID NO: 233, SEQ ID NO: 235, SEQ ID NO: 237, SEQ ID NO: 239, SEQ ID NO: 241, SEQ ID NO: 243, SEQ ID NO: 245, SEQ ID NO: 247, SEQ ID NO: 249, SEQ ID NO: 251, SEQ ID NO: 253, SEQ ID NO: 255, SEQ ID NO: 257, SEQ ID NO: 259, SEQ ID NO: 261, SEQ ID NO: 263, SEQ ID NO: 265, SEQ ID NO: 267, SEQ ID 25 NO: 269, SEQ ID NO: 271, SEQ ID NO: 273, SEQ ID NO: 275, SEQ ID NO: 277, SEQ ID NO: 279, SEQ ID NO: 281, SEQ ID NO: 283, SEQ ID NO: 285, SEQ ID NO: 287, SEQ ID NO: 289, SEQ ID NO: 291, SEQ ID NO: 293, SEQ ID NO: 295, SEQ ID NO: 297, SEQ ID NO: 299, SEQ ID NO: 301, SEQ ID NO: 303, SEQ ID NO: 305, SEQ ID NO: 307, SEQ ID NO: 309, SEQ ID NO: 311, SEQ ID NO: 313, 30 SEQ ID NO: 315, SEQ ID NO: 317, SEQ ID NO: 319, SEQ ID NO: 321, SEQ ID NO: 323, SEQ ID NO: 325, SEQ ID NO: 327, SEQ ID NO: 329, SEQ ID NO: 331, SEQ ID NO: 333, SEQ ID NO: 335, SEQ ID NO: 337, SEQ ID NO: 339, SEQ ID NO: 341, SEQ ID NO: 343, SEQ ID NO: 345, SEQ ID NO: 347, SEQ ID NO: 349,

WO 01/98526

SEQ ID NO: 351, SEQ ID NO: 353, SEQ ID NO: 355, SEQ ID NO: 357, SEQ ID NO: 359, SEQ ID NO: 361, SEQ ID NO: 363, SEQ ID NO: 365, SEQ ID NO: 367, SEQ ID NO: 369, SEQ ID NO: 371, SEQ ID NO: 373, SEQ ID NO: 375, SEQ ID NO: 377, SEQ ID NO: 379, SEQ ID NO: 381, SEQ ID NO: 383, SEQ ID NO: 385, 5 SEQ ID NO: 387, SEQ ID NO: 389, SEQ ID NO: 391, SEQ ID NO: 393, SEQ ID NO: 395, SEQ ID NO: 397, SEQ ID NO: 399, SEQ ID NO: 401, SEQ ID NO: 403, SEQ ID NO: 405, SEQ ID NO: 407, SEQ ID NO: 409, SEQ ID NO: 411, SEQ ID NO: 413, SEQ ID NO: 415, SEQ ID NO: 417, SEQ ID NO: 419, SEQ ID NO: 421, SEQ ID NO: 423, SEQ ID NO: 425, SEQ ID NO: 427, SEQ ID NO: 429, SEQ ID NO: 431, SEQ ID NO: 433, SEQ ID NO: 435, SEQ ID NO: 437, SEQ ID NO: 439, 10 NO: 441, SEQ ID NO: 443, SEQ ID NO: 445, SEQ ID NO: 447, SEQ ID NO: 449, SEQ ID NO: 451, SEQ ID NO: 453, SEQ ID NO: 455, SEQ ID NO: 457, SEQ ID NO: 459, SEQ ID NO: 461, SEQ ID NO: 463, SEQ ID NO: 465, SEQ ID NO: 467, SEQ ID NO: 469, SEQ ID NO: 471, SEQ ID NO: 473, SEQ ID NO: 475, 15 NO: 477, SEQ ID NO: 479, SEQ ID NO: 481, SEQ ID NO: 483, SEQ ID NO: 485, SEQ ID NO: 487, SEQ ID NO: 489, SEQ ID NO: 491, SEQ ID NO: 493, SEQ ID NO: 495, SEQ ID NO: 497, SEQ ID NO: 499, SEQ ID NO: 501, SEQ ID NO: 503, SEQ ID NO: 505, SEQ ID NO: 507, SEQ ID NO: 509 and SEQ ID NO: 511.

20

19. A primary odorant identified by Claim 18.

20. A method of identifying a compound which blocks activation by a odorant of at least one olfactory receptor comprising:

25 (a) producing a structurally-related candidate compound from a ligand of the at least one olfactory receptor,

(b) measuring activation by the odorant of the at least one olfactory receptor with the candidate compound, and

(c) identifying the candidate compound as a compound which blocks activation if activation of the at least one olfactory receptor is reduced or inhibited;

30 wherein at least one of the olfactory receptors has an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID

NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID 5 NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, SEQ ID NO: 69, SEQ ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 79, SEQ ID NO: 81, SEQ ID NO: 83, SEQ ID NO: 85, SEQ ID NO: 87, SEQ ID NO: 89, SEQ ID NO: 91, SEQ ID NO: 93, SEQ ID NO: 95, SEQ ID 10 NO: 97, SEQ ID NO: 99, SEQ ID NO: 101, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 107, SEQ ID NO: 109, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, SEQ ID NO: 119, SEQ ID NO: 121, SEQ ID NO: 123, SEQ ID NO: 125, SEQ ID NO: 127, SEQ ID NO: 129, SEQ ID NO: 131, SEQ ID NO: 133, SEQ ID NO: 135, SEQ ID NO: 137, SEQ ID NO: 139, SEQ ID NO: 141, SEQ ID 15 NO: 143, SEQ ID NO: 145, SEQ ID NO: 147, SEQ ID NO: 149, SEQ ID NO: 151, SEQ ID NO: 153, SEQ ID NO: 155, SEQ ID NO: 157, SEQ ID NO: 159, SEQ ID NO: 161, SEQ ID NO: 163, SEQ ID NO: 165, SEQ ID NO: 167, SEQ ID NO: 169, SEQ ID NO: 171, SEQ ID NO: 173, SEQ ID NO: 175, SEQ ID NO: 177, SEQ ID NO: 179, SEQ ID NO: 181, SEQ ID NO: 183, SEQ ID NO: 185, SEQ ID NO: 187, SEQ ID NO: 189, SEQ ID NO: 191, SEQ ID NO: 193, SEQ ID NO: 195, SEQ ID 20 NO: 197, SEQ ID NO: 199, SEQ ID NO: 201, SEQ ID NO: 203, SEQ ID NO: 205, SEQ ID NO: 207, SEQ ID NO: 209, SEQ ID NO: 211, SEQ ID NO: 213, SEQ ID NO: 215, SEQ ID NO: 217, SEQ ID NO: 219, SEQ ID NO: 221, SEQ ID NO: 223, SEQ ID NO: 225, SEQ ID NO: 227, SEQ ID NO: 229, SEQ ID NO: 231, SEQ ID 25 NO: 233, SEQ ID NO: 235, SEQ ID NO: 237, SEQ ID NO: 239, SEQ ID NO: 241, SEQ ID NO: 243, SEQ ID NO: 245, SEQ ID NO: 247, SEQ ID NO: 249, SEQ ID NO: 251, SEQ ID NO: 253, SEQ ID NO: 255, SEQ ID NO: 257, SEQ ID NO: 259, SEQ ID NO: 261, SEQ ID NO: 263, SEQ ID NO: 265, SEQ ID NO: 267, SEQ ID NO: 269, SEQ ID NO: 271, SEQ ID NO: 273, SEQ ID NO: 275, SEQ ID NO: 277, SEQ ID NO: 279, SEQ ID NO: 281, SEQ ID NO: 283, SEQ ID NO: 285, SEQ ID 30 NO: 287, SEQ ID NO: 289, SEQ ID NO: 291, SEQ ID NO: 293, SEQ ID NO: 295, SEQ ID NO: 297, SEQ ID NO: 299, SEQ ID NO: 301, SEQ ID NO: 303, SEQ ID NO: 305, SEQ ID NO: 307, SEQ ID NO: 309, SEQ ID NO: 311, SEQ ID NO: 313,

WO 01/98526

SEQ ID NO: 315, SEQ ID NO: 317, SEQ ID NO: 319, SEQ ID NO: 321, SEQ ID NO: 323, SEQ ID NO: 325, SEQ ID NO: 327, SEQ ID NO: 329, SEQ ID NO: 331, SEQ ID NO: 333, SEQ ID NO: 335, SEQ ID NO: 337, SEQ ID NO: 339, SEQ ID NO: 341, SEQ ID NO: 343, SEQ ID NO: 345, SEQ ID NO: 347, SEQ ID NO: 349, 5 SEQ ID NO: 351, SEQ ID NO: 353, SEQ ID NO: 355, SEQ ID NO: 357, SEQ ID NO: 359, SEQ ID NO: 361, SEQ ID NO: 363, SEQ ID NO: 365, SEQ ID NO: 367, SEQ ID NO: 369, SEQ ID NO: 371, SEQ ID NO: 373, SEQ ID NO: 375, SEQ ID NO: 377, SEQ ID NO: 379, SEQ ID NO: 381, SEQ ID NO: 383, SEQ ID NO: 385, NO: 377, SEQ ID NO: 379, SEQ ID NO: 381, SEQ ID NO: 383, SEQ ID NO: 385, SEQ ID NO: 387, SEQ ID NO: 389, SEQ ID NO: 391, SEQ ID NO: 393, SEQ ID NO: 395, SEQ ID NO: 397, SEQ ID NO: 399, SEQ ID NO: 401, SEQ ID NO: 403, 10 SEQ ID NO: 405, SEQ ID NO: 407, SEQ ID NO: 409, SEQ ID NO: 411, SEQ ID NO: 413, SEQ ID NO: 415, SEQ ID NO: 417, SEQ ID NO: 419, SEQ ID NO: 421, SEQ ID NO: 423, SEQ ID NO: 425, SEQ ID NO: 427, SEQ ID NO: 429, SEQ ID NO: 431, SEQ ID NO: 433, SEQ ID NO: 435, SEQ ID NO: 437, SEQ ID NO: 439, 15 SEQ ID NO: 441, SEQ ID NO: 443, SEQ ID NO: 445, SEQ ID NO: 447, SEQ ID NO: 449, SEQ ID NO: 451, SEQ ID NO: 453, SEQ ID NO: 455, SEQ ID NO: 457, SEQ ID NO: 459, SEQ ID NO: 461, SEQ ID NO: 463, SEQ ID NO: 465, SEQ ID NO: 467, SEQ ID NO: 469, SEQ ID NO: 471, SEQ ID NO: 473, SEQ ID NO: 475, SEQ ID NO: 477, SEQ ID NO: 479, SEQ ID NO: 481, SEQ ID NO: 483, SEQ ID NO: 485, SEQ ID NO: 487, SEQ ID NO: 489, SEQ ID NO: 491, SEQ ID NO: 493, 20 SEQ ID NO: 495, SEQ ID NO: 497, SEQ ID NO: 499, SEQ ID NO: 501, SEQ ID NO: 503, SEQ ID NO: 505, SEQ ID NO: 507, SEQ ID NO: 509 and SEQ ID NO: 511.

25 21. The method of Claim 20, wherein the ligand is a primary odorant.

22. A compound which blocks activation of an olfactory receptor identified by Claim 20.